EAU19 | BARCELONA
15-19 March 2019
Cutting-edge Science at Europe’s largest Urology Congress
### Joint Session of the European Association of Urology (EAU) and the World Chinese Urologists

**Urology beyond Europe**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday 15</td>
<td>08:45 - 12:15</td>
<td><strong>Welcome and introduction</strong></td>
<td>Green Area, Room 1</td>
<td>J. N'Dow, Aberdeen (GB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y.S. Pu, Taipei (TW)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>L-Q. Zhou, Beijing (CN)</td>
</tr>
<tr>
<td></td>
<td>08:45 - 08:50</td>
<td><strong>Oncology</strong></td>
<td></td>
<td>J. N'Dow, Aberdeen (GB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Y.S. Pu, Taipei (TW)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>L-Q. Zhou, Beijing (CN)</td>
</tr>
<tr>
<td></td>
<td>08:50 - 09:35</td>
<td><strong>Advancing the diagnosis technique for urological cancer to improve treatment outcome</strong></td>
<td></td>
<td>T. Loch, Flensburg (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>T-J. Pan, Wuhan (CN)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>W.J. Wu, Kaohsiung (TW)</td>
</tr>
<tr>
<td></td>
<td>08:50 - 09:05</td>
<td><strong>Chinese Urological Cancer registries</strong></td>
<td></td>
<td>R. Shancheng, Shanghai (CN)</td>
</tr>
<tr>
<td></td>
<td>09:05 - 09:20</td>
<td><strong>The need for patient engagement in urological cancer care</strong></td>
<td></td>
<td>K. Plass, Arnhem (NL)</td>
</tr>
<tr>
<td></td>
<td>09:35 - 10:20</td>
<td><strong>Andrology</strong></td>
<td></td>
<td>W.J. Huang, Taipei (TW)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X. Gao, Guangzhou (CN)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A. Salonia, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td>09:35 - 09:50</td>
<td><strong>Penile augmentation: The role of urologists in Taiwan</strong></td>
<td></td>
<td>Y. Chen, Kaohsiung City (TW)</td>
</tr>
<tr>
<td></td>
<td>09:50 - 10:05</td>
<td><strong>Penile augmentation: The experience in China</strong></td>
<td></td>
<td>S-J. Xia, Shanghai (CN)</td>
</tr>
<tr>
<td></td>
<td>10:05 - 10:20</td>
<td><strong>Penile curvature surgery: European perspectives</strong></td>
<td></td>
<td>S.S. Minhas, London (GB)</td>
</tr>
<tr>
<td></td>
<td>10:20 - 11:05</td>
<td><strong>Laparoscopy/Robotic surgery</strong></td>
<td></td>
<td>C.Y. Huang, Taipei (TW)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>T.B. Lam, Aberdeen (GB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X. Zhang, Wuhan (CN)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20 - 10:35</td>
<td><strong>Robot-assisted radical prostatectomy via only two ports</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C.C. Li, Kaohsiung (TW)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:35 - 10:50</td>
<td><strong>Innovations in prostate cancer imaging</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>X. Gao, Shanghai (CN)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:05</td>
<td><strong>What is new in the Prostate Cancer EAU Guidelines</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N. Mottet, Saint-Étienne (FR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:05 - 11:35</td>
<td><strong>Functional urology</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em> C.H. Chang, Taipei (TW)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Gravas, Larissa (GR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>W. Xu, Harbin (CN)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:05 - 11:15</td>
<td><strong>Potential application of low energy shock wave on functional urology</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Y-C. Chuang, Kaohsiung (TW)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:25</td>
<td><strong>Minimally invasive treatment strategies for LUTS – Chinese experience</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liu, Hangzhou (CN)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:25 - 11:35</td>
<td><strong>Male LUTS - EAU Guidelines Update</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Gravas, Larissa (GR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35 - 12:05</td>
<td><strong>Urolithiasis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em> M.L. Hsieh, Tao-Yuan, Kwei-Shan (TW)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Skolarikos, Athens (GR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.X. Yang, Wuhan (CN)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td><strong>Treatments of urolithiasis in Taiwan</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.K. Huang, Tainan (TW)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45 - 11:55</td>
<td><strong>Stone surgery outcomes in China – Chinese data</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>G.H. Zeng, Guangzhou (CN)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:55 - 12:05</td>
<td><strong>What’s new in the Urolithiasis EAU Guidelines?</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Skolarikos, Athens (GR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:05 - 12:15</td>
<td><strong>Closing remarks</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T. Loch, Flensburg (DE)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>W.J. Wu, Kaohsiung (TW)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>L-Q. Zhou, Beijing (CN)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

**Urology beyond Europe**

**Friday 15 March 08:45 - 12:15**

**Location:** Green Area, Room 11

**Chairs:**
- C.R. Chapple, Sheffield (GB)
- J. Gutierrez, Winston Salem (US)

**Aims and objectives of this session**
The aim of this session is to facilitate an educational channel between urology in Europe and Latin-America. A deep insight in selected topics of current clinical practice in urology will be presented by a group of recognised experts from different countries’ members of the EAU and CAU. Attendees will be able to learn updates on the diagnosis and management of prostate cancer, NMI bladder cancer, urethral trauma, andrology, treatment of renal stones and lower urinary symptoms in female patients. Participants can also pick up tips and tricks on surgical techniques including robotic transplant, surgery for hidden penis and holmium and green light laser prostate enucleation. This session will serve as an outstanding opportunity to exchange concepts and to improve the education of urology.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 08:50</td>
<td>Welcome and introduction</td>
<td>C.R. Chapple, Sheffield (GB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Gutierrez, Winston Salem (US)</td>
</tr>
<tr>
<td>08:50 - 09:10</td>
<td>Does MRI prevent the need of prostate biopsy?</td>
<td>J. Walz, Marseille (FR)</td>
</tr>
<tr>
<td>09:10 - 09:30</td>
<td>Lymphadenectomy for prostate cancer: When and for who?</td>
<td>R. Sanchez-Salas, Paris (FR)</td>
</tr>
<tr>
<td>09:30 - 09:50</td>
<td>Management of BCG refractory NMI bladder cancer</td>
<td>M. Babjuk, Prague (CZ)</td>
</tr>
<tr>
<td>09:50 - 10:10</td>
<td>Robotic renal transplant</td>
<td>A. Breda, Barcelona (ES)</td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td>Surgical treatment of buried penis: Practical hints</td>
<td>R. Virasoro, Virginia Beach (US)</td>
</tr>
<tr>
<td>10:30 - 10:50</td>
<td>Urethral trauma: An update</td>
<td>C.R. Chapple, Sheffield (GB)</td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td>Prostate enucleation: Holmium or green light laser?</td>
<td>F. Gomez Sancha, Madrid (ES)</td>
</tr>
<tr>
<td>11:10 - 11:30</td>
<td>Andrology for urologists: Update 2019</td>
<td>N. Sofikitis, Ioannina (GR)</td>
</tr>
</tbody>
</table>
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:30 - 11:50 | **1 to 2 cm renal stones: What is the best treatment alternative?**  
M.D. Baptistussi, Ribeirao Preto (BR) |
| 11:50 - 12:10 | **Evaluation of lower urinary symptoms in female patients: What is needed and what is not?**  
D.M. Castro Díaz, Santa Cruz de Tenerife (ES) |
| 12:10 - 12:15 | **Closing remarks**  
C.R. Chapple, Sheffield (GB)  
J. Gutierrez, Winston Salem (US) |
The future is bright: Basic research in spinal cord injury
Poster Session 01

Friday 15 March
09:00 - 10:30

Location: Red Area, eURO Auditorium 2
Chairs: L. Birder, Pittsburgh (US)
        To be confirmed
        M.P. Schneider, Steffisburg (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1  Effect of early sacral neuromodulation on bladder function in a rat model of incomplete spinal cord injury due to focal contusion
   1Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea,
   2Kangwon National University School of Medicine, Dept. of Urology, Chuncheon, South Korea

2  Anti-Nogo-A antibodies: Promising treatment for neurogenic lower urinary tract dysfunction after spinal cord injury
   By: Schneider M.P., Sartori M., Schwab E., Kessler M.
   1Inselspital, Dept. of Urology, Bern, Switzerland,
   2University of Zürich, Balgrist University Hospital, Dept. of Neuro-Urology, Spinal Cord Injury Center & Research, Zurich, Switzerland,
   3University of Zürich, Brain Research Institute, Dept. of Health Sciences and Technology, Zurich, Switzerland

* 3  Barrington’s nucleus CRH neurons conditionally drive bladder contraction: A multi-unit optogenetic recording study in mice
   By: Ito H., Sales A., Tench B., Drake M.J., Pickering A.E.
   University of Bristol, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom

4  Therapeutic effects of p38 MAP kinase inhibitor in storage and voiding dysfunction in mice with spinal cord injury (SCI)
   1Kindai University, Dept. of Urology, Faculty of Medicine, Osaka-Sayama, Japan,
   2Hamamatsu University school of Medicine, Dept. of Urology, Hamamatsu, Japan,
   3University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America,
   4Kindai University Nara Hospital, Dept. of Urology, Ikoma, Japan,
   5University of Pittsburgh, Dept.
### Improvement of bladder and urethral dysfunction by the early intervention with anti-BDNF antibody after spinal cord injury in mice

By: Wada N.W. ¹, Suzuki T. ², Tyagi P. ², Tsuchida M. ¹, Banjo H. ¹, Yoshimura N. ², Kakizaki H. ¹

¹Asahikawa Medical University, Dept. of Renal and Urologic Surgery, Asahikawa, Japan, ²University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America

### High field single subject brain mapping of pelvic floor motor control. A 7-Tesla fMRI study

By: Groenendijk I.M. ¹, Luijten S. ¹, Van Der Zwaag W. ², Holstege J.C ³, Scheepe J. ¹, De Zeeuw C. ⁴, Blok B. ¹

¹Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Spinoza Center for Neuroimaging, Dept. of Neuroimaging, Amsterdam, The Netherlands, ³Erasmus Medical Center, Dept. of Neuroscience, Rotterdam, The Netherlands, ⁴Netherlands Institute for Neuroscience, Dept. of Neuroscience, Amsterdam, The Netherlands

### Muscarinic receptor expression in spinal cord transected rats with early anticholinergic treatment

To be confirmed

### Urinary TIMP-2 is significantly associated with poor bladder compliance and upper urinary tract damage in adult patients with spina bifida

By: Peyronnet B. ¹, Richard C. ¹, Bendavid C. ², Naudet F. ³, Hascoet J. ¹, Brochard C. ⁴, Alimi Q. ¹, Khene Z. ¹, Siproudhis L. ⁵, Bouguen G. ⁶, Kerdraon J. ⁷, Manunta A. ¹, Gamé X. ⁸

¹Rennes University Hospital, Dept. of Urology, Rennes, France, ²Rennes University Hospital, Dept. of Biochemistry, Rennes, France, ³University of Rennes, Inserm CIC, Rennes, France, ⁴Rennes University Hospital, Dept. of Gastroenterology, Rennes, France, ⁵Rennes University Hospital, Dept. of Gastroenterology, Rennes, France, ⁶Rennes university Hospital, Dept. of Gastroenterology, Rennes, France, ⁷Centre de Rééducation de Kerpape, Dept. of Rehabilitation, Ploemeur, France, ⁸Toulouse University Hospital, Dept. of Urology, Toulouse, France

### Nerve growth factor-mediated Na+ channel plasticity of bladder afferent neurons in mice with spinal cord injury

By: Gu B. ¹, Ni J.S. ¹, Yoshimura N. ²

¹Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Dept. of Urology, Shanghai, China, ²University of Pittsburgh, School of Medicine, Dept. of Urology, Pittsburgh, United States of America
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15</td>
<td>Physiopathology of neurogenic detrusor overactivity: Role of neurotrophins, inflammation and extracellular matrix according to the neurological disease</td>
<td>Richard C. 1, Bendavid C. 1, Hascoet J. 1, Alimi Q. 1, Khene Z-E. 1, Kerdraon J. 1, Manunta A. 1, Gamé X. 2, Peyronnet B. 1</td>
<td>University of Rennes, Dept. of Urology, Rennes, France, University of Toulouse, Dept. of Urology, Toulouse, France</td>
</tr>
<tr>
<td>11:00</td>
<td>Bladder primary afferent pathways to the spinal cord in mice</td>
<td>Takezawa K. 1, Ueda N. 1, Sekii Y. 1, Inagaki Y. 1, Fukuhara S. 1, Kiuchi H. 1, Kondo M. 2, Shimada S. 2, Nonomura N. 1</td>
<td>Osaka University Medical School, Dept. of Urology, Suita, Japan, Osaka University Medical School, Dept. of Neuroscience and Cell Biology, Suita, Japan</td>
</tr>
<tr>
<td>11:45</td>
<td>Injecting RNA interference lentiviruses targeting the muscarinic 3 receptor gene into the bladder wall inhibits neurogenic detrusor overactivity in rats with spinal cord injury</td>
<td>Shang Z., Ou T.</td>
<td>Xuanwu Hospital Capital Medical University, Dept. of Urology, Beijing, China</td>
</tr>
<tr>
<td>10:15 - 10:22</td>
<td>State-of-the-art lecture The bladder, the spinal cord and the brain</td>
<td>L. Birder, Pittsburgh (US)</td>
<td></td>
</tr>
</tbody>
</table>
# Stones: It is all about endourology

**Poster Session 02**

**Location:** Green Area, Room 2

**Chairs:**
- G. Bozzini, Busto Arsizio (IT)
- To be confirmed
- G.H. Zeng, Guangzhou (CN)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

## 13

**Safety and efficacy of different calyx accesses in percutaneous nephrolithotomy**

By: Değer M., İzol V., Ok F., Sukur I.H., Bayazıt Y., Aridogan I.A.
University of Çukurova, Dept. of Urology, Faculty of Medicine, Adana, Turkey

## 14

**Safety and efficacy of renal access establishment in percutaneous nephrolithotomy by an optical puncture system based on ultra-mini percutaneous nephrolithotomy platform under ultrasound guidance**

By: Lei X., Wu X., Xuan H., Cao Y., Chen Q., Xue W.
Renji Hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China

## 15

**Safety and efficacy of superior calyceal access versus inferior calyceal access for pelvic and lower calyceal stones – prospective observational comparative study**

By: Chawla A.K., Mohan A.
Kasturba Medical College, Manipal University, Dept. of Urology and Renal Transplant, Manipal, India

## 16

**First experience with vacuum-assisted mini percutaneous nephrolithotomy (vmPCNL): Preliminary results**

Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Department of Clinical Sciences and Community Health, University of Milan, Dept. of Urology, Milan, Italy

## 17

**The addition of retrograde flexible ureteroscopy to percutaneous nephrolithotomy improves safety and efficacy of the procedure: Results from 400 consecutive ECIRS (Endoscopic Combined IntraRenal Surgery) in the Galdakao-modified supine Valdivia position**
19 Percutaneous nephrolithotomy in kidneys with impaired renal function: Recoverability assessment using diuretic scintigraphy
By: Harraz A. M. 1, Nabeeh H. 2, Elbaset M. 1, Taha D-E. 2, Fakhreldin I. 1, El-Nahas A. 1, Osman Y. 1
1 Mansoura University, Dept. of Urology, Mansoura, Egypt, 2 Kafr El-Sheikh University, Dept. of Urology, Kafr El-Sheikh, Egypt

20 Trends and predictors of 30 day readmissions following percutaneous nephrolithotomy in kidney stones formers and implications for readmissions-based quality metrics
By: Tully K. 1, Harmouch S.S. 1, Cole A.P. 1, Nguyen D. 1, Ramaswamy A. 1, Lipsitz S.R. 2, Trinh Q-D. 1, Bhojani N. 3
1 Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, 2 Brigham and Women's Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, United States of America, 3 Centre Hospitalier de l'Université de Montréal, faculté de médecine de l'Université de Montréal, Division of Urologic Surgery, Montreal, Canada

21 Development of a simple and practical nomogram for predicting stone-free rate after flexible ureteroscopy or percutaneous nephrolithotomy for solitary medium sized renal stones in adults
By: Micali S. 1, Di Pietro C. 1, Elsherbiny A. 2, Bevilacqua L. 1, Eissa A. 2, Fidanza F. 1, Mofferdin A. 1, Zoeir A. 2, Kaleci S. 3, Puliatti S. 1, Sighinolfi M.C. 1, Bianchi G. 1, Rocco B.M.C. 1
1 University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, 2 Faculty of Medicine, Tanta University, Dept. of Urology, Tanta, Egypt, 3 University of Modena and Reggio Emilia, Dept. of Diagnostic Medicine, Modena, Italy

22 Impact of preoperative ureteral stenting on ureteroscopic findings: A propensity score matching analysis
By: Hamamoto S. 1, Sugino T. 1, Hasebe K. 1, Isogai M. 1, Taguchi K. 1, Ando R. 1, Inoue T. 2, Okada S. 3, Okada A. 1, Matsuda T. 2, Yasui T. 1, SMART Study Group
1 Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, 2 Kansai Medical University Medical Center, Dept. of Urology, Osaka, Japan, 3 Gyotoku general Hospital, Dept. of Urology, Chiba, Japan

23 Impact of previous SWL on ureterorenoscopy outcomes and optimal timing for safe ureterorenoscopy after SWL in proximal ureteral stones: A multi-center study of Society of Urological Surgery-Aegean Study Group
By: Irer B. 1, Sahin M.O. 2, Erbatu O. 3, Yildiz A. 4, Ongun S. 5, Cinar O. 6, Cihan A. 7,
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
</table>
| 24   | **Awareness reduces radiation exposure during flexible ureteroscopy – a prospective multicenter evaluation** | Sahin M. 8, Sen V. 2, Ucer O. 3, Kizilay F. 8, Bozkurt O. 4 | Society of Urological Surgery-Aegean Study Group  
Izmir Metropolitan Municipality Esrefpasa Hospital, Dept. of Urology, Izmir, Turkey  
Manisa State Hospital, Dept. of Urology, Manisa, Turkey  
Celal Bayar University School of Medicine, Dept. of Urology, Manisa, Turkey  
Dokuz Eylul University School of Medicine, Dept. of Urology, Izmir, Turkey  
Balikesir University School of Medicine, Dept. of Urology, Balikesir, Turkey  
Bulent Ecevit University School of Medicine, Dept. of Urology, Zonguldak, Turkey  
Nigde Omer Halisdemir University School of Medicine, Dept. of Urology, Nigde, Turkey  
Ege University School of Medicine, Dept. of Urology, Izmir, Turkey |
| 26   | **Longitudinal assessment of reprocessing effectiveness for flexible ureteroscope after high level disinfection** | Legemate J.D. 1, Kamphuis G.M. 2, Freund J.E. 1, Baard J. 1, Oussoren H. 3 |  
Amsterdam University Medical Centers, Dept. of Urology, Amsterdam, The Netherlands  
Amsterdam University Medical Centers, Dept. of Urology, Amsterdam, The Netherlands  
Amsterdam University Medical Centers, Dept. of Microbiology and Hygiene, Amsterdam, The Netherlands  
Istanbul Medipol University, Dept. of Urology, Istanbul, Turkey |
| 27   | **Withdrawn**                                                         |         |                                                                                                       |
|      | **To be confirmed**                                                  |         |                                                                                                       |
**Evaluation of the proposed update of FDA guidelines on the symptomatic diagnosis of acute uncomplicated cystitis in women**

By: Alidjanov J.F. 1, Naber K.G. 2, Pilatz A. 1, Abdufattaev U.A. 3, Wagenlehner F.M.E. 1

1 Justus-Liebig University, Clinic and Polyclinic for Urology, Pediatric Urology and Andrology, Giessen, Germany, 2 Technical University of Munich, Dept. of Urology, Munich, Germany, 3 State Inst. Republican Specialized Scientific-Practical Medical Center of Urology, Dept. of Radiology, Tashkent, Uzbekistan

**Aims and objectives of this presentation**

**Evaluation of knowledge and perception of antibiotic use, resistance and strategies toward antimicrobial stewardships in urology**


Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain

**Aims and objectives of this presentation**

**Epidemiological features of resistance patterns among uropathogens: Focus on fosfomycin trometamol**

By: Cai T. 1, Caciagli P. 2, Lanzafame P. 3, Palmieri A. 4, Verze P. 4, Arcaniolo D. 5, Mirone V. 4, Malossini G. 1

1 Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, 2 Santa Chiara Regional Hospital, Dept. of Laboratory Medicine, Trento, Italy, 3 Santa Chiara Regional Hospital, Dept. of Microbiology, Trento, Italy, 4 University of Naples, Federico II, Dept. of Urology, Naples, Italy, 5 University of Naples, Vanvitelli, Dept. of Urology, Naples, Italy
Aims and objectives of this presentation
30

### Benefits of nonavalent vaccine in a high risk male population

By: Lopez-Diez E.¹, Castro M.¹, Tortolero Blanco L.J.², Diaz Alvarez J.M.¹, Sanchez J.¹, López S.¹, Perez Schoch M.¹, Montero R.¹, Carballo M.¹, Almuster S.¹, Perez S.³

¹Hospital Alvaro Cunqueiro, Dept. of Urology, Vigo, Spain, ²Hospital Imed Levante, Dept. of Urology, Benidorm, Spain, ³Hospital Alvaro Cunqueiro, Dept. of Microbiology, Vigo, Spain

Aims and objectives of this presentation
31

### Comparative study of 1-day versus multiple-day administration of antimicrobial prophylaxis in radical cystectomy


The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Dept. of Genitourinary Oncology, Tokyo, Japan

Aims and objectives of this presentation
32

### Impact of a long-term antibiotic prophylaxis on the bladder colonisation by E. coli in clean intermittent self-catheterisation patients

By: Vallée M.¹, Mowbray C.¹, Fisher H.², Ming Zhi Tan A.¹, Harding C.³, Hall J.¹, Aldridge P.¹

¹Newcastle University, Institute for Cell & Molecular Bio Sciences, Newcastle upon Tyne, United Kingdom, ²Institute of Health and Society, Dept. of Microbiology Department, Newcastle upon Tyne, United Kingdom, ³Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom

Aims and objectives of this presentation
33

### Acute uncomplicated cystitis: Do we follow guidelines?

By: Kulchavenya E.¹, Neymark A.², Kapsargin F.³, Koves B.⁴, Tenke P.⁵, Naber K.⁶, Tandogdu Z.⁷, Wagenlehner F.M.⁸, Cai T.⁹, Bonkat G.¹⁰, Bjerklund Johansen T.E.¹¹

¹Novosibirsk Research TB Institute, Novosibirsk Medical University, Dept. of Urogenital, Novosibirsk, Russia, ²Altay Medical University, Dept. of Urogenital, Barnaul, Russia, ³Krasnoyarsk Medical University, Dept. of Urogenital, Krasnoyarsk, Russia, ⁴South-Pest Teaching Hospital, Dept of Urology, Budapest, Hungary, ⁵Jahn Ferenc South Pest Theaching Hospital, Dept of Urology, Budapest, Hungary, ⁶Munich Technical University,
Aims and objectives of this presentation

34

Do not use antimicrobial prophylaxis (AMP) before routine transurethral resection of the bladder tumor (TURB)!

By: Verzotti E.¹, Rizzo M.¹, Di Cosmo G.¹, Morreale C.¹, Marchesin A.¹, Pavan N.¹, Cai T.², Cocci A.³, Umar P.⁴, Ussai S.⁵, Liguori G.¹, Trombetta C.¹
¹Università degli Studi di Trieste, Dept. of Urology, Trieste, Italy, ²Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, ³Università degli Studi di Firenze, Dept. of Urology, Florence, Italy, ⁴Università degli Studi del Piemonte Orientale, Dept. of Urology, Novara, Italy, ⁵DG Welfare, Regione Lombardia, Progetti Sanitari Internazionali, Milan, Italy

Aims and objectives of this presentation

35

Prospective randomized controlled trial comparing the effect of fulguration versus fulguration and hydrodistension in Interstitial Cystitis/Bladder Pain Syndrome

By: Son H.S.¹, Yoon H.², Kim J.H.¹
¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Ewha Womans University, College of Medicine, Dept. of Urology, Seoul, South Korea

Aims and objectives of this presentation

36

Clinical pharmacokinetics of beta-lactam and quinolone antibiotics in prostate tissue, and dosing considerations for prostatitis based on site-specific pharmacodynamics

By: Nakamura K.¹, Ikawa K.², Nishikawa G.¹, Kobayashi I.¹, Sugie M.¹, Muramatsu H.¹, Morinaga S.¹, Kajikawa K.¹, Watanabe M.¹, Kanao K.¹, Morikawa N.²
¹Aichi Medical University, School of Medicine, Dept. of Urology, Nagakute, Japan, ²Hiroshima University, Dept. of Clinical Pharmacotherapy, Hiroshima, Japan

Aims and objectives of this presentation

37

Individual, DNA-guided, antibacterial prophylaxis prior to transrectal prostate biopsy based on results of next generation sequencing (NGS) of rectal swabs can be considered as a promising targeted approach to prevent severe urinary tract
infection

By: Mouraviev V. ¹, Dixon M. ², Stefil M. ², Skinner C. ³, Mcdonald M. ⁴, Vourganti S. ⁵, Albala D. ⁶, Wagenlehner F. ⁷, Naber K. ⁸, Bjerklund Johansen T. ⁹, Crawford E. ¹⁰

¹Central Florida Cancer Institute, Dept. of Urology, Davenport, United States of America, ²University of East Anglia, Norwich Medical School, Norwich, United Kingdom, ³University of Central Florida, College of Medicine, Orlando, United States of America, ⁴Florida Hospital Celebration Health, Urology Centre of Central Florida, Celebration, United States of America, ⁵Rush University Medical Center, Division of Urology, Chicago, United States of America, ⁶Associated Medical Professionals of New York, Dept. of Urology, New York City, United States of America, ⁷Justus-Liebig University Giessen, Dept. of Urology, Pediatric Urology, and Andrology, Giessen, Germany, ⁸Technical University of Munich, Medical Faculty, Munich, Germany, ⁹Oslo University Hospital, Dept. of Urology, Oslo, Norway, ¹⁰University of Colorado Anschutz Medical Center, Dept. of Urologic Oncology and Radiation Oncology, Aurora, United States of America

Aims and objectives of this presentation

38

Rectal swab cultures prior to transrectal prostate biopsy: Among Gram-negative isolates, in 42% of samples non-E.coli species are present

By: Hajdinjak T. ¹, Wergner A-N. ², Prammer W. ³, Rigler-Hohenwarter K. ³, Pelzer A.E. ¹

¹Klinikum Wels-Grieskirchen, Dept. of Urology, Wels, Austria, ²Medical University, Graz, Austria, ³Klinikum Wels-Grieskirchen, Dept. of Microbiology and Immunology, Wels, Austria

Aims and objectives of this presentation

39

Urethral swab for STDs diagnosis in men: The reason for not doing it

By: Cai T. ¹, Caciagli P. ², Lanzafame P. ³, Mazzoli S. ⁴, Bartoletti R. ⁵, Malossini G. ¹

¹Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, ²Santa Chiara Regional Hospital, Dept. of Laboratory Medicine, Trento, Italy, ³Santa Chiara Regional Hospital, Dept. of Microbiology, Trento, Italy, ⁴Azienda Sanitaria di Firenze, STDs Centre, Florence, Italy, ⁵University of Pisa, Dept. of Urology, Pisa, Italy

Aims and objectives of this presentation

40

Is urine dipstick testing still useful in evaluating the presence of bacteriuria in a post antibiotic era?

By: Taktak S., Gall Z.J., Dyer J.E.  
Stepping Hill Hospital, Dept. of Urology, Stockport, United Kingdom
Aims and objectives of this presentation
41

42

Diversity of the microbial flora in healthy male genitourinary tract

By: Cao M., Xu H., Hui Z., Li Q.
the Second Chengdu Hospital Affiliated to Chongqing Medical University, Dept. of Urology, Chengdu, China

Aims and objectives of this presentation
42
Novel regulators of cellular events in prostate cancer tissue and stroma

Location: Green Area, Room 5
Chairs: D. Albino, Bellinzona (CH)
M. Puhr, Innsbruck (AT)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

43

The bone microenvironment drives upregulation of the pentose phosphate pathway in prostate cancer, improving antioxidant properties

By: Whitburn J.¹, Rao S.R.¹, Tabata S², Hirayama A.², Soga T.², Hamdy F.C.¹, Edwards C.M.¹
¹University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, ²Keio University, Institute for Advanced Biosciences, Tsuruoka, Japan

Aims and objectives of this presentation

44

Xenobiotic metabolism of abiraterone acetate and glucocorticoids by the gut microbiota

By: Abdur-Rashid K.¹, Nair S.M.², Chanyi R.¹, Chin J.², Burton J.¹
¹University of Western Ontario, Dept. of Microbiology and Immunology, London, Canada, ²London Health Sciences Centre, Division of Urology, London, Canada

Aims and objectives of this presentation

45

A preclinical model to assess the interaction between patient-derived 3D microtumors and tumor infiltrating immune cells in prostate cancer

By: Erne E.¹, Stahl R.¹, Bodenhoefer M.², Anderle N.², Yuez S.², Stenzl A.¹, Schmees C.², Todenhoefer T.¹
¹University Hospital Tuebingen, Dept. of Urology, Tuebingen, Germany, ²Natural and Medical Science Institute, University of Tuebingen, Dept. of Tumorbiology, Reutlingen, Germany

Aims and objectives of this presentation

46

Loss of miR-21 delays Myc-driven prostate cancer progression in the Hi-Myc transgenic mouse model
HSP70/STUB1 complex regulates androgen receptor variants through proteostasis and confers enzalutamide and abiraterone resistance in lethal prostate cancer

University of California Davis, Dept. of Urology, Sacramento, United States of America

Long noncoding RNA CRAT1 inhibits castration-resistance of prostate cancer via inhibiting androgen receptor protein translation

By: Xu C., Peng G., Ruilui X., Ming H., Qianghua Z., Jingtong Z., Jian H., Tianxin L.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China

EphA2 ligand independent activation underpins PTEN related metastatic migration and poor outcome in prostate cancer

1University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, 2The Christie, Dept. of Surgery, Manchester, United Kingdom

The role of SPOP & BRCA-1 in the regulation of estrogenic activity in prostate stem cells

By: Greenwald D., Hu D-P., Hu W-Y., Prins G.S.
University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America

Tumor suppressor REIC/Dkk-3 and its co-chaperone SGTA: Their interaction and role to control castration-resistant prostate cancer by the release from androgen...
independence and malignancy

Okayama University Graduate School of Medicine, Dept. of Urology, Okayama, Japan

Aims and objectives of this presentation

51

miR-424 secreted in extracellular vesicles/exosomes promotes prostate tumorigenesis

By: Albino D., Falcione M., Shinde D.S., Civenni G., Merulla J., Catapano C.V., Carbone G.M.
Institute of Oncology Research (IOR), Dept. of Experimental Therapeutics & Prostate Cancer Biology, Bellinzona, Switzerland

Aims and objectives of this presentation

52

Spliceosome components and splicing factors as novel therapeutic targets for prostate cancer

1Maimonides Institute of Biomedical Research of Cordoba, Dept. of Cell Biology, Physiology and Immunology, Córdoba, Spain, 2Maimonides Institute of Biomedical Research of Cordoba, Dept. of Anatomical Pathology, Córdoba, Spain, 3Maimonides Institute of Biomedical Research of Cordoba, Dept. of Urology, Córdoba, Spain

Aims and objectives of this presentation

53

Follicle-stimulating hormone is responsible for androgen deprivation therapy associated atherosclerosis by exaggerating endothelial inflammation

By: Wang Q., Zhou J., Yao W., Xu T.
1Peking University People’s Hospital, Dept. of Urology, Beijing, China, 2Peking University, Dept. of Physiology and Pathophysiology, Beijing, China

Aims and objectives of this presentation

54

GPRC5A facilitates cell proliferation and bone metastasis of prostate cancer

By: Sawada Y., Kikugawa T., Iio H., Yanagihara Y., Saeki N., Sakakibara I., Győrffy B., Kishida T., Miyagi Y., Saika T., Imai Y.
1Ehime University Graduate School of Medicine, Dept. of Urology, Toon, Japan, 2Ehime University, Division of Laboratory Animal Research, Advanced Research Support Center,
### Scientific Programme - EAU19 Barcelona

Toon, Japan, Ehime University, Division of Integrative Pathophysiology, Proteo-Science Center, Toon, Japan, The University of Tokyo, Research Center for Advanced Science and Technology, Tokyo, Japan, Hungarian Academy of Sciences, MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Budapest, Hungary, Kanagawa Cancer Center, Division of Urology, Kanagawa, Japan, Kanagawa Cancer Center Research Institute, Molecular Pathology and Genetics Division, Kanagawa, Japan

**Aims and objectives of this presentation**

55

<table>
<thead>
<tr>
<th>56</th>
<th><strong>Generation of prostate basal stem cell lines from transgenic mice - proof of principle of inducible ex vivo gene deletion</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Höfner T. 1, Klein C. 2, Medyouf H. 3, Sprick M. 2, Haferkamp A. 1</td>
<td></td>
</tr>
<tr>
<td>1University Hospital Mainz, Dept. of Urology, Mainz, Germany, 2HI-STEM gGmbH, Heidelberg Institute for Stem Cell Research and Experimental Medicine, Heidelberg, Germany, 3Georg-Speyer-Haus, Institute for Tumoriology and Experimental Therapy, Frankfurt, Germany</td>
<td></td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

56

<table>
<thead>
<tr>
<th>57</th>
<th><strong>Fibroblast-secreted exosomes in prostate cancer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Kessler J., Theobald L., Baumgart S., Stöckle M., Junker K., Linxweiler J.</td>
<td></td>
</tr>
<tr>
<td>Saarland University, Dept. of Urology, Homburg, Germany</td>
<td></td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

57
New techniques in functional and reconstructive urology

Video Session 01

Friday 15 March
09:00 - 10:30

Location: Green Area, Room 10

Chairs: C. Introini, Genova (IT)
        B. Peyronnet, Rennes (FR)
        F. Van Der Aa, Leuven (BE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V01

Prone patient positioning for surgical excision of complex female urethral diverticula

By: Mangir N., Osman N.I., Inman R.D., Chapple C.R.
Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom

Aims and objectives of this presentation
V01

V02

First robot-assisted laparoscopic pyeloplasty utilizing the da Vinci SP system

By: Agarwal D.K., Viers B.R., Chow G.K., Frank I., Tollefson M.K., Gettman M.
Mayo Clinic, Dept. of Urology, Rochester, United States of America

Aims and objectives of this presentation
V02

V03

Integral perineal sacrocolpopexy, a whole non invasive technique to restore perineal descent and concomitant pelvic prolapse

Hospital Universitario Ramon y Cajal, Dept. of Urology, Madrid, Spain

Aims and objectives of this presentation
V03

V04

Robot-assisted supratrigonal cystectomy and augmentation cystoplasty (RASCAC) with total intracorporeal reconstruction in neuro-urological patients: Technique description and preliminary results

By: Grilo N., Chartier-Kastler E., Grande P., Rouprêt M., Parra J., Phé V.
Médecine Sorbonne Université, Pitié-Salpêtrière, Academic Hospital, Dept. of Urology, Paris, France

Aims and objectives of this presentation
V04
Scientific Programme - EAU19 Barcelona

**Aims and objectives of this presentation**

**V04**

**Robot-assisted implantation of artificial urinary sphincter in women: A standardized surgical technique**


1 Rennes University Hospital, Dept. of Urology, Rennes, France, 2 Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, 3 Pole Santé Sud, Dept. of Urology, Le Mans, France, 4 Pitié Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, 5 Saint Grégoire Private Hospital, Dept. of Urology, Rennes, France, 6 Foch Hospital, Dept. of Urology, Suresnes, France, 7 Toulouse University Hospital, Dept. of Urology, Toulouse, France, 8 Limoges University Hospital, Dept. of Urology, Limoges, France, 9 Brest University Hospital, Dept. of Urology, Brest, France

**Aims and objectives of this presentation**

**V05**

**Robot-assisted AMS 800™-sphincter implantation around the membranous urethra – a different cuff position**

By: Abo Youssef N., Pannek J., Horton K., Randazzo M., John H.

1 Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland, 2 Swiss Paraplegic Centre Nottwil, Dept. of Neuro Urology, Nottwil, Switzerland

**Aims and objectives of this presentation**

**V06**

**Intraoperative adjustable non obstructive bulbourethral suspension**

By: Wyss Y., Randazzo M., John H.

Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

**Aims and objectives of this presentation**

**V07**

**Superficial transverse perineal muscle interposition for vesicorectal fistula after radical prostatectomy**

By: Rioja Zuazu J.P., Rioja C., Baltanas P., Solano J., Oliva J., Rodriguez-Vela L., Mallen E., Galve V., Corbatón D., Capapé V., Valle J., Blasco B.

1 University Clinic Hospital, Dept. of Urology, Zaragoza, Spain, 2 Montecanal Clinic, Dept. of Urology, Zaragoza, Spain, 3 University Clinic Hospital, Dept. of Anesthesiology, Zaragoza, Spain, 4 Quiron Clinic, Dept. of Surgery, Zaragoza, Spain, 5 Royo Villanova Hospital, Dept. of Urology, Zaragoza, Spain, 6 University Hospital, Dept. of Urology, Zaragoza, Spain, 7 University Hospital, Dept. of Urology, Zaragoza, Spain

**Aims and objectives of this presentation**

**V08**
Aims and objectives of this presentation

V08
Potential for a personalised approach in renal tumours
Poster Session 05

Location: Green Area, Room 12
Chairs: K. Junker, Homburg (DE)
G. Procopio, Milan (IT)
G. Stewart, Cambridge (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma

By: Singla N.¹, Choi J.², Onabolu O.³, Woolford L.³, Stevens C.³, Tcheuyap V.³, McKenzie T.³, Xie Z.⁴, Wang T.⁴, McKay R.³, Christie A.⁵, Kapur P.⁶, Rini B.², Brugarolas J.³
¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America,
²Cleveland Clinic, Dept. of Internal Medicine, Cleveland, United States of America,
³University of Texas Southwestern Medical Center, Dept. of Internal Medicine, Dallas, United States of America,
⁴University of Texas Southwestern Medical Center, Dept. of Bioinformatics, Dallas, United States of America,
⁵University of Texas Southwestern Medical Center, Dept. of Biostatistics, Dallas, United States of America,
⁶University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America

Aims and objectives of this presentation

Comprehensive investigation of the molecular underpinnings of translocation renal cell carcinoma

By: Marcon J.¹, Sanchez A.¹, Gupta S.², Di Natale R.G.¹, Sandhu A.³, Mano R.¹, Silagy A.W.¹, Blum K.A.¹, Nassau D.E.¹, Motzer R.J.⁴, Coleman J.A.¹, Russo P.¹, Reuter V.E.², Hakimi A.A.¹, Reznik E.³
¹Memorial Sloan-Kettering Cancer Center, Dept. of Surgery, Urology Service, New York, United States of America,
²Memorial Sloan-Kettering Cancer Center, Dept. of Pathology, New York, United States of America,
³Memorial Sloan-Kettering Cancer Center, Computational Biology Center, Center for Molecular Oncology, New York, United States of America,
⁴Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, Dept. of Medicine, New York, United States of America

Aims and objectives of this presentation
The concordant analysis of target gene sequencing data showing the tumor heterogeneity in triplet-paired metastatic tumor tissues in metastatic renal cell carcinoma

By: Kim S.H. ¹, Park W.S. ², Kim S-H. ¹, Chung J. ³
¹Center for Prostate Cancer, Research Institute and Hospital of National Cancer Center, Dept. of Urology, Goyang, South Korea, ²Center for Prostate Cancer, Research Institute and Hospital of National Cancer Center, Dept. of Pathology, Goyang, South Korea, ³Center for Prostate Cancer, National Cancer Center, Dept. of Urology, Goyang, South Korea

Aims and objectives of this presentation

Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients

By: Singla N. ¹, Woolford L. ², Stevens C. ², Tcheuyap V. ², Onabolu O. ², Xie Z. ³, McKay R. ², Wang T. ³, Christie A. ⁴, Gahan J. ¹, Bagrodia A. ¹, Raj G. ¹, Sagalowsky A. ¹, Lotan Y. ¹, Cadeddu J. ¹, Margulis V. ¹, Kapur P. ⁵, Brugarolas J. ²
¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ²University of Texas Southwestern Medical Center, Dept. of Internal Medicine, Dallas, United States of America, ³University of Texas Southwestern Medical Center, Dept. of Bioinformatics, Dallas, United States of America, ⁴University of Texas Southwestern Medical Center, Dept. of Biostatistics, Dallas, United States of America, ⁵University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America

Aims and objectives of this presentation

Feasibility of establishing renal cancer patient-specific ‘tumouroids’ as personalised treatment screening tools

By: Stamati K. ¹, Neves J.B. ¹, De Albuquerque Garcia Redondo P. ¹, Presneau N. ², Azimi T. ², Mohammad Hadi L. ¹, Brew-Graves C. ³, Williams N.R. ³, Grierson J. ³, Tran M.G.B. ¹, Cheema U. ⁴, Loizidou M. ¹, Emberton M. ⁵
¹UCL, Research Department of Surgical Biotechnology, Division of Surgery and Interventional Science, London, United Kingdom, ²University of Westminster, Cancer Research Group, London, United Kingdom, ³UCL, Surgical and Interventional Trials Unit, Division of Surgery and Interventional Science, London, United Kingdom, ⁴UCL, Research Department of Orthopaedics and Musculoskeletal Science, Division of Surgery and Interventional Science, London, United Kingdom, ⁵UCL, Faculty of Medical Science, London, United Kingdom

Aims and objectives of this presentation
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>64</td>
<td>Tumor-infiltrating regulatory T lymphocytes orchestrate oncogenic PAK1-conferred immune evasion in clear-cell renal cell carcinoma</td>
<td>Qu Y., Liu L., Bai Q., Xu J., Guo J.</td>
<td>The study by Qu et al. explores the role of tumor-infiltrating regulatory T lymphocytes in oncogenic PAK1-conferred immune evasion in clear-cell renal cell carcinoma.</td>
</tr>
<tr>
<td>65</td>
<td>Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal cell carcinoma patients</td>
<td>Xiong Y., Liu L., Bai Q., Xia Y., Wang J., Guo J.</td>
<td>The study by Xiong et al. investigates the predictive value of an individualized immune-related gene signature for immune status and oncologic outcomes in clear cell renal cell carcinoma patients.</td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

66

Real world data of how next-generation sequencing changes treatment strategy and identify hereditary diseases in urology cancers

By: Wang H-K., Yao Z., Ye D.W.
Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation

67

The UCLA histo-genetic risk classification (U-HGRC) to stratify prognosis of localized clear-cell renal cell carcinoma

1Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, CA - Department of Urology, University Hospital Bicetre, APHP, University Paris-Saclay, Dept. of Urology, Le Kremlin Bicetre, France, 2Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Dept. of Urology, Los Angeles, United States of America, 3David Geffen School of Medicine at UCLA, Dept. of Pathology and Cytogenetic lab, Los Angeles, United States of America, 4David Geffen School of Medicine at UCLA, Dept. of Urology, Los Angeles, United States of America, 5University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, 6Fielding School of Public Health at UCLA, Los Angeles, CA - Department of Radiological Science, David Geffen School of Medicine at University of California, Dept. of Biostatistics, Los Angeles, United States of America, 7David Geffen School of Medicine at UCLA, Dept. of Hematology and Oncology, Los Angeles, United States of America, 8Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Dept. of Hematology and Oncology, Los Angeles, United States of America

Aims and objectives of this presentation

69

Genomic categorization of high-grade unclassified renal cell carcinoma to refine prognostication and therapeutic approach

By: Marcon J.1, Jayakumaran G.2, Di Natale R.1, Ghanaat M.1, Brannon R.3, Al-Ahmadie H.2, Fine S.2, Gopalan A.2, Sirintrapun S.2, Tickoo S.2, Arcila M.2, Motzer R.4, Coleman J.1, Russo P.1, Reuter V.2, Hakimi A.1, Chen Y-B.2
1Memorial Sloan-Kettering Cancer Center, Urology Service, Dept. of Surgery, New York, United States of America, 2Memorial Sloan-Kettering Cancer Center, Dept. of Pathology, New York, United States of America, 3Memorial Sloan-Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States of America, 4Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, Dept. of Medicine, New York, United States of America
Aims and objectives of this presentation
70

Circulating tumor cells in renal cancer

By: Klézl P.¹, Sonsky J.¹, Grill R.¹, Pospisilova E.², Kolostova K.², Bobek V.²
¹University Hospital Kralovske Vinohrady, Dept. of Urology, Prague, Czech Republic,
²University Hospital Kralovske Vinohrady, Dept. of Laboratory Diagnostics, Lab. Genetics,
Prague, Czech Republic

Aims and objectives of this presentation
71
### Joint Session of the European Association of Urology (EAU) and Russian Society of Urology (RSU)

**Urology beyond Europe**

**Friday 15 March**

09:30 - 12:15

**Location:** Green Area, Room 13

**Chairs:** W. Artibani, Verona (IT)  
            I. Korneyev, St. Petersburg (RU)

Simultaneous translation from Russian to English will be provided.

#### Aims and objectives of this session

This session aims to involve Russian urologists into active discussion of hot urological topics with EAU opinion leaders. Current opinion in BPH/LUTS treatment, reconstructive urology and urolithiasis will be presented by both sides followed by interactive discussion of clinical cases and approaches to solve the patients’ problems. The simultaneous translation of both languages will be provided.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 09:30 - 09:35 | Welcome and introduction  
             W. Artibani, Verona (IT)  
             I. Korneyev, St. Petersburg (RU) |
| 09:35 - 10:25 | Current trends in BPH/LUTS treatment  
             Moderators:  
             M.S. Gazimiev, Moscow (RU)  
             M.I. Kogan, Rostov On Don (RU)  
             A.Z. Vinarov, Moscow (RU) |
| 09:35 - 09:50 | Is urodynamic evaluation needed to plan BPO surgery?  
             M. Lazzeri, Milan (IT) |
| 09:50 - 10:05 | A single-centre comparative study on the efficacy of different endoscopic prostatic enucleation techniques  
             D. Enikeev, Moscow (RU) |
| 10:05 - 10:25 | Case presentations  
             R.S. Ismailov, Rostov-on-Don (RU)  
             M. Lazzeri, Milan (IT) |
| 10:25 - 11:15 | Reconstructive urology  
             Moderators:  
             O.B. Loran, Moscow (RU)  
             V.L. Medvedev, Krasnodar (RU)  
             D. Pushkar, Moscow (RU) |
| 10:25 - 10:40 | When and how to use meshes in Pelvic Organ Prolapse (POP) surgery  
             E.C Costantini, Perugia (IT) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:40 - 10:55 | Detailed Pelvic Organ Prolapse (POP) evaluation: Would it improve further treatment results?  
Y.A. Kupriyanov, Moscow (RU) |
| 10:55 - 11:15 | **Case presentations**  
B. Komyakov, St. Petersburg (RU)  
V.A. Ochelenko, St. Petersburg (RU)  
E.C Costantini, Perugia (IT) |
| 11:15 - 12:05 | **Urolithiasis**  
*Moderators:*  
A.G. Martov, Moscow (RU)  
V. Pavlov, Ufa (RU)  
A. Zyrianov, Tyumen (RU) |
| 11:15 - 11:30 | **Technological advances in endourology**  
G. Giusti, Milan (IT) |
| 11:30 - 11:45 | **Urolithiasis: A look at aspects of metaphylaxis**  
V. Pavlov, Ufa (RU)  
A. Pushkarev, Ufa (RU) |
| 11:45 - 12:05 | **Case presentations**  
A.G. Martov, Moscow (RU)  
G. Giusti, Milan (IT) |
| 12:05 - 12:15 | **Closing remarks**  
W. Artibani, Verona (IT)  
I. Korneyev, St. Petersburg (RU) |
Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)

Urology beyond Europe

**Location:** Green Area, Room 3

**Chairs:**
H. Abol-Enein, Mansoura (EG)
J. Palou, Barcelona (ES)

**Aims and objectives of this session**
This session aims to open a channel between European urology and the urologists in the Arab world. The chosen topics include future developments of urinary stone treatment and reconstructive urology and different situations in Urology-oncology and European and Arab approaches to solve these problems. Thus all participants will be able to learn from alternatives from Europe and Arab countries. It is expected to have interaction and exchange of concepts in order to improve urology all over the world.

**09:45 - 09:50**
**Welcome and introduction**
N. Al-Hamdani, Baghdad (IQ)
M. Eissa, Cairo (EG)
Y. Farahat, Dubai (AE)
J. Palou, Barcelona (ES)

**09:50 - 10:25**
**Uro-oncology**

*Moderators:*
R. Azhar, Jeddah (SA)
H. Abol-Enein, Mansoura (EG)
M. Colombel, Lyon (FR)

09:50 - 10:05
Neoadjuvant chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Current status and outcome
J.A. Witjes, Nijmegen (NL)

10:05 - 10:20
Prostate Specific Antigen (PSA) relapse following radical prostatectomy: What and when to do?
M. Bulbul, Riad El Solh - Beirut (LB)

10:20 - 10:25
Discussion

**10:25 - 11:00**
**Stones and endourology**

*Moderators:*
O. Angerri Feu, Barcelona (ES)
H. Kouicem, Sétif (DZ)
M. Mustafa, Nablus (PA)

10:25 - 10:40
Residual stones after Percutaneous nephrolithotomy (PCNL): Significance and outcome
E. Liatsikos, Patras (GR)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40 - 10:55</td>
<td>Complications of Ureteroscopy (URS): How to avoid and tricks of treatment</td>
</tr>
<tr>
<td>Y. Farahat, Dubai (AE)</td>
<td></td>
</tr>
<tr>
<td>10:55 - 11:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:00 - 11:35</td>
<td>Lower urinary tract disorders</td>
</tr>
<tr>
<td>Moderators:</td>
<td>M.S.A. Al-Marhoon, Muscat (OM)</td>
</tr>
<tr>
<td>N. Alfagih, Tripoli (LY)</td>
<td></td>
</tr>
<tr>
<td>T.R.W. Herrmann, Frauenfeld (CH)</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Failure of prostatectomy to cure in Lower Urinary Tract Symptoms (LUTS): Case selection and technique of choice</td>
</tr>
<tr>
<td>E. Chartier-Kastler, Paris (FR)</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Overactive Bladder (OAB): What to do when medical therapy fails</td>
</tr>
<tr>
<td>Y. Nouira, Tunis (TN)</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:35 - 12:10</td>
<td>Reconstructive urology</td>
</tr>
<tr>
<td>Moderators:</td>
<td>A.N. Al Shunaigat, Amman (JO)</td>
</tr>
<tr>
<td>N. Ramadan, Khartoum (SD)</td>
<td></td>
</tr>
<tr>
<td>S. Sarikaya, Ankara (TR)</td>
<td></td>
</tr>
<tr>
<td>11:35 - 11:50</td>
<td>Pyeloplasty: Open, laparoscopic or robotic tricks and outcome</td>
</tr>
<tr>
<td>A. Minervini, Florence (IT)</td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td>Stress urinary incontinence in female: The optimal procedure for the best outcome</td>
</tr>
<tr>
<td>F. Farag, Portstewart (GB)</td>
<td></td>
</tr>
<tr>
<td>12:05 - 12:10</td>
<td>Discussion</td>
</tr>
<tr>
<td>12:10 - 12:15</td>
<td>Closing remarks</td>
</tr>
<tr>
<td>H. Abol-Enein, Mansoura (EG)</td>
<td></td>
</tr>
<tr>
<td>J. Palou, Barcelona (ES)</td>
<td></td>
</tr>
</tbody>
</table>
### Joint Session of the European Association of Urology (EAU) and the Maghreb Union Countries

**Urology beyond Europe**

**Location:** Green Area, Room 20

**Chairs:** M. Harouni, Oran (DZ)  
V.G. Mirone, Naples (IT)

#### Aims and objectives of this session
This session aims to open a channel between European urology and the urologists in the Magreb world. The chosen topics include future developments of urinary stone treatment and different situations in Urology-oncology and European and Magreb approaches to solve these problems. Thus all participants will be able to learn from alternatives from Europe and Magreb countries. It is expected to have interaction and exchange of concepts in order to improve urology all over the world.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:45 - 09:48 | Welcome and introduction  
M. Harouni, Oran (DZ)  
V.G. Mirone, Naples (IT) |
| 09:48 - 10:43 | Bladder cancer  
**Moderators:** S. Braiek, Kairouan (TN)  
M. El Mcherqui, Casablanca (MA)  
M.J. Ribal Caparros, Barcelona (ES) |
| 09:48 - 09:58 | En-bloc resection of bladder tumours: Indications, advantages, pitfalls  
M. Burger, Regensburg (DE) |
| 10:08 - 10:18 | European perspective Management of pT1 high-grade bladder tumours  
S. Shariat, Vienna (AT) |
| 10:18 - 10:38 | Maghreb Union perspective Management of pT1 high-grade bladder tumours  
N. Bekki, Djasr Kassentina (DZ)  
M.M. Atoui, Annaba (DZ)  
M. Fourati, Sfax (TN)  
S.K Kerroumi, Sig (DZ)  
S.M. Moudouni, Marrakech (MA) |
| 10:38 - 10:43 | Discussion |
| 10:43 - 11:23 | Stone management  
**Moderators:** M. Harouni, Oran (DZ)  
M. Lezrek, Meknes (MA)  
E. Liatsikos, Patras (GR) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:43 - 11:13</td>
<td><strong>Maghreb - Complex stones: Which therapeutic approach?</strong></td>
</tr>
<tr>
<td></td>
<td>S. Bouras, Setif (DZ)</td>
</tr>
<tr>
<td></td>
<td>S. Braiek, Kairouan (TN)</td>
</tr>
<tr>
<td></td>
<td>I. Ziouziou, Rabat (MA)</td>
</tr>
<tr>
<td>11:13 - 11:23</td>
<td><strong>The management of large kidney stones: PCNL versus RIRS</strong></td>
</tr>
<tr>
<td></td>
<td>S. Choong, London (GB)</td>
</tr>
<tr>
<td>11:23 - 12:13</td>
<td><strong>Prostate cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong></td>
</tr>
<tr>
<td></td>
<td>Z. Belahnech, Rabat (MA)</td>
</tr>
<tr>
<td></td>
<td>A. Belkacem Nacer, Algiers (DZ)</td>
</tr>
<tr>
<td></td>
<td>V.G. Mirone, Naples (IT)</td>
</tr>
<tr>
<td>11:23 - 11:33</td>
<td><strong>European perspective</strong> The management of locally advanced prostate cancer</td>
</tr>
<tr>
<td></td>
<td>C. Stief, Munich (DE)</td>
</tr>
<tr>
<td>11:33 - 11:48</td>
<td><strong>Maghreb Union perspective</strong> The management of locally advanced prostate cancer</td>
</tr>
<tr>
<td></td>
<td>M. Azli, Algiers (DZ)</td>
</tr>
<tr>
<td></td>
<td>S. Ben Rhouma, ()</td>
</tr>
<tr>
<td>11:48 - 11:58</td>
<td><strong>European perspective</strong> Update on the management of Castration Resistant Prostate Cancer (CRPC)</td>
</tr>
<tr>
<td></td>
<td>P. Verze, Naples (IT)</td>
</tr>
<tr>
<td>11:58 - 12:13</td>
<td><strong>Maghreb Union perspective</strong> Update on the management of Castration Resistant Prostate Cancer (CRPC)</td>
</tr>
<tr>
<td></td>
<td>K. Benakila, Alger (DZ)</td>
</tr>
<tr>
<td></td>
<td>Y. El Harrech, Rabat (MA)</td>
</tr>
<tr>
<td></td>
<td>M. Ghadouane, Rabat (MA)</td>
</tr>
<tr>
<td>12:13 - 12:15</td>
<td><strong>Closing remarks</strong></td>
</tr>
<tr>
<td></td>
<td>M. Harouni, Oran (DZ)</td>
</tr>
<tr>
<td></td>
<td>V.G. Mirone, Naples (IT)</td>
</tr>
</tbody>
</table>
### Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

**Urology beyond Europe**

**Friday 15 March**  
**09:45 - 12:15**

**Location:** Green Area, Room 17  
**Chairs:** C.C.M. Lei, Kuching (MY)  
J. Rassweiler, Heilbronn (DE)

**Aims and objectives of this session**  
This session continues the excellent collaboration between the major countries included in the FAUA and the EAU. Focusing on four important fields in urology, experts from Asia and Europe will present and discuss new developments. There will be a special focus on the Discussion with active participation of the delegates.

**09:45 - 09:50**  
**Welcome and introduction**  
C.C.M. Lei, Kuching (MY)

**09:50 - 10:30**  
**Paediatric urology**

**09:50 - 10:00**  
**DSD, Development Sexual Dysfunction**  
I. Wahyudi, Jakarta (ID)

**10:00 - 10:10**  
**Hypospadias in Indonesia**  
G.W.K. Duarsa, Denpasar (ID)

**10:10 - 10:20**  
**Diagnosis and treatment of testicular torsion: A multicenter clinical study in Thailand**  
P. Mahawong, Chiang Mai (TH)

**10:20 - 10:30**  
**How to avoid complications of circumcision**  
G. Bogaert, Leuven (BE)

**10:30 - 11:10**  
**Reconstructive urology**

**10:30 - 10:40**  
**Urethroplasty in Malaysia: Past, present and future**  
S. Sothilingam, Kuala Lumpur (MY)

**10:40 - 10:50**  
**Challenges in management of penile paraffinoma**  
P. Myint, Yangon Myanmar (MM)

**10:50 - 11:00**  
**Management of uro-genital fistula: Asian perspective**  
T. Lwin, Yangon (MM)

**11:00 - 11:10**  
**How to manage complicated cases of hypospadias**  
M. Fisch, Hamburg (DE)

**11:10 - 11:40**  
**Kidney transplantation**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:10 - 11:20 | **Standardised surgical technique of laparoscopic donor nephrectomy: Experience from a single high-volume center in Asia**  
K Kijvikai, Bangkok (TH) |
| 11:20 - 11:30 | **Laparoscopic right donor nephrectomy: Philippines’ experience and technique**  
E. Gerial Jr., Quezon City (PH) |
| 11:30 - 11:40 | **Robot-assisted kidney transplantation – the new way to go?**  
A. Breda, Barcelona (ES) |
| 11:40 - 12:10 | **Minimally invasive surgery in Asia** |
| 11:40 - 11:50 | **Evolution of Percutaneous nephrolithotomy (PCNL) in the Philippines**  
S.V. Yrastorza, Quezon City (PH) |
| 11:50 - 12:00 | **Robot assisted laparoscopy radical cystectomy – the real world**  
V.L. Chuyen, Ho Chi Minh City (VN) |
| 12:00 - 12:10 | **MRI targeted prostate biopsy**  
H.S.S. Ho, Singapore (SG) |
| 12:10 - 12:15 | **Closing remarks**  
J. Rassweiler, Heilbronn (DE) |
### Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

**Location:** Green Area, Room 18  
**Chairs:** M.S. Agrawal, Agra (IN)  
J.O.R. Sønksen, Herlev (DK)

**Aims and objectives of this session**  
To discuss challenges in urolithiasis and male infertility through case presentations and present newer modalities for treatment of benign prostatic hyperplasia. Key note lectures will include difficult cases and tissue engineering in urethral reconstruction as well as new dimensions of flexible ureteroscopy and miniaturisation in percutaneous endourology. Leading experts from the Urological Society of India and European Association of Urology will give the case presentations and lectures followed by panel discussion led by key opinion leaders.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45 - 09:50</td>
<td><strong>Welcome and introduction</strong></td>
<td>M.S. Agrawal, Agra (IN) J.O.R. Sønksen, Herlev (DK)</td>
</tr>
</tbody>
</table>
| 09:50 - 10:25 | **Panel discussion: Challenges in urolithiasis**                         | T. Knoll, Sindelfingen (DE)  
D.K. Mishra, Agra (IN)  
P. Rao, Dombivli (IN) |
| 09:50 - 09:57 | **Case 1**                                                          | D.K. Mishra, Agra (IN)                                |
| 09:57 - 10:04 | **Case 2**                                                          | P. Maheshwari, Mumbai (IN)                            |
| 10:04 - 10:11 | **Case 3**                                                          | O. Traxer, Paris (FR)                                 |
| 10:11 - 10:18 | **Case 4**                                                          | S.K. Pal, Delhi (IN)                                  |
| 10:18 - 10:25 | **Discussion**                                                        |                                                       |
| 10:25 - 11:00 | **Symposium: Newer modalities for Benign prostatic hyperplasia (BPH)** | A. Elhence, Meerut (IN)  
M.M. Fode, Herlev (DK) |
<p>| 10:25 - 10:32 | <strong>Plasma enucleation</strong>                                                  | M. Chiruvella, Hyderabad (IN)                         |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:32 - 10:39</td>
<td>Uro-Lift</td>
<td>O. Kayes, Leeds (GB)</td>
</tr>
<tr>
<td>10:39 - 10:46</td>
<td>Aquablation</td>
<td>A. Elhence, Meerut (IN)</td>
</tr>
<tr>
<td>10:46 - 10:53</td>
<td>Stents in BPH</td>
<td>R.P. Kulkarni, Chertsey (GB)</td>
</tr>
<tr>
<td>10:53 - 11:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
| 11:00 - 11:35 | Panel discussion: Challenges in male infertility  | Panel: A.K. Chawla, Manipal (IN)  
|               |                                                   | M. Dinkelman-Smit, Rotterdam (NL)  
|               |                                                   | R. Sood, New Delhi (IN)            |
| 11:00 - 11:07 | Case 1: Antioxidant treatment                     | A. Salonia, Milan (IT)     |
| 11:07 - 11:14 | Case 2: Varicoceles                               | R. Kumar, New Delhi (IN)   |
| 11:21 - 11:28 | Case 4: Hypogonadism                              | R. TP, Guwahati (IN)       |
| 11:28 - 11:35 | Discussion                                        |                          |
| 11:35 - 12:10 | Key note lectures                                 | Panel: C.R. Chapple, Sheffield (GB)  
|               |                                                   | A. Seth, New Delhi (IN)            |
| 11:35 - 11:42 | Miniaturisation in percutaneous endourology: How small is small enough | M.S. Agrawal, Agra (IN)     |
| 11:49 - 11:56 | Difficult cases in urethral reconstruction        | S. Kulkarni, Pune (IN)      |
| 11:56 - 12:03 | Tissue engineering in urethral reconstruction: Where are we today? | F. Castiglione, London (GB) |
| 12:03 - 12:10 | Discussion                                        |                          |
| 12:10 - 12:15 | Closing remarks                                   | M.S. Agrawal, Agra (IN)    
|               |                                                   | J.O.R. Sønksen, Herlev (DK)   |
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

10:15 - 10:18

Introduction

F. Liedberg, Malmö (SE)

PT001

Excision and primary anastomosis for strictures at the anastomosis between the fixed and phallic part of the urethra in female-to-male transsexuals

By: Verla W., Hoebek P., Spinoit A-F., Waterloos M., Lumen N.
Ghent University Hospital, Dept. of Urology, Ghent, Belgium

Aims and objectives of this presentation

PT001

PT002

Penile prosthesis insertion after female to male phalloplasty: Our experience

By: Stojanovic B., Bizic M., Kojovic V., Pusica S., Bencic M., Djordjevic M.
School of Medicine, University of Belgrade, Dept. of Urology, Belgrade, Serbia

Aims and objectives of this presentation

PT002

PT003

A single center experience in Peyronie’s disease surgical treatment: Comparison of two different grafting techniques

By: Colombo F.¹, Masetti M.¹, Gentile G.¹, Sadini P.², Piazza P.², Droghetti M.², Bianchi L.², Vagnoni V.¹, Franceschelli A.¹
¹University Hospital S. Orsola, Dept. of Gynecology and Urology, Andrology unit, Bologna, Italy, ²University Hospital S. Orsola, Dept. of Gynecology and Urology, Bologna, Italy

Aims and objectives of this presentation

PT003
### Correction of isolated congenital penile curvature in young adults

**By:** Roizman S.\(^{1}\), Chertin B.\(^{2}\), Zisman A.\(^{3}\), Shenfeld O.Z.\(^{1}\)

\(^{1}\)Shaare Zedek Medical Center, Center for Reconstructive and Functional Urology, Jerusalem, Israel, \(^{2}\)Shaare Zedek Medical Center, Dept. of Urology, Jerusalem, Israel, \(^{3}\)Shamir (Asaf Harofeh) Medical Center, Dept. of Urology, Zerifin, Israel

**Aims and objectives of this presentation**
PT004

### Feasibility of Yachia procedure without degloving for ventral and dorsal penile curvatures: Surgical and functional outcomes

**By:** Dell’Atti L., Tallè M., Polito M., Galosi A.B.

University Hospital, Dept. of Urology, Ancona, Italy

**Aims and objectives of this presentation**
PT005

### Australian trends in urinary diversion over the past 20 years

**By:** Best O.\(^{1}\), Patel M.I.\(^{2}\)

\(^{1}\)Westmead Hospital, Dept. of Surgery, Westmead, Australia, \(^{2}\)Westmead Hospital, Dept. of Urology, Westmead, Australia

**Aims and objectives of this presentation**
PT006

### Fluorescence-enhanced intracorporeal urinary diversion during robotic-assisted radical cystectomy using the Firefly system for mesenteric angiography: A prospective pilot study

**By:** Jeglinschi S., Carlier M., Denimal L., Chevallier D., Tibi B., Durand M., Ahallal Y.

University Hospital of Nice, Dept. of Urology, Nice, France

**Aims and objectives of this presentation**
PT007

### Intracorporeal Studer robotic orthotopic neobladder: 1-year functional results

**By:** Obrecht F., Burkhardt O., Schregel C., Randazzo M., Padevit C., John H.

Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

**Aims and objectives of this presentation**
PT008

### Surgical outcomes of transvaginal neobladder-vaginal fistula repair after radical cystectomy with ileal orthotopic neobladder in women

**By:** Song W.\(^{1}\), Jeong J.Y.\(^{2}\), Kim T.H.\(^{3}\), Yoon H.S.\(^{1}\), Kim K.H.\(^{1}\), Yoon H.\(^{1}\), Chung

**Aims and objectives of this presentation**
PT009
<table>
<thead>
<tr>
<th>Id</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT09</td>
<td>The Turin pouch: A continent cutaneous urinary diversion with very low stoma stenosis rate at long term follow up</td>
<td>Tosco L. ¹, Germinale F. ¹, Collura D. ¹, Kurti M. ¹, Leucci G. ¹, Muto G. ², Giacobbe A. ¹, Berdondini E. ¹, Muto G. ¹</td>
<td>Humanitas Gradenigo, Dept. of Urology, Turin, Italy, Careggi Hospital, Dept. of Urology, Florence, Italy</td>
</tr>
<tr>
<td>PT11</td>
<td>Subject specific bladder morphology and correspondent 3D mold lattice structure for organ reconstruction</td>
<td>Monteiro V. ¹, Gasser C.T. ², Moerman K. ³</td>
<td>MIT, Media Lab, Cambridge, United States of America, The Royal Institute of Technology, Dept. of Solid Mechanics, Stockholm, Sweden, NUI Galway, Galway, Ireland</td>
</tr>
<tr>
<td>PT13</td>
<td>Risk factors of recurrence and de novo incontinence following endoscopic treatment of vesico-urethral anastomotic stenosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

PT014

Depression, anxiety and erectile function after successful urethroplasty: A short-term follow up study

By: Kogan M.I., Mitusov V.V., Amirbekov B.G.
Rostov State Medical University, Dept. of Urology and Human Reproductive Health, Rostov-on-Don, Russia

Aims and objectives of this presentation

PT015

Augmentation urethral reconstruction using tissue-engineered oral mucosa graft MukoCell®

By: Karapanos L., Akbarov I., Zugor V., Eich C., Heidenreich A.
University Hospital of Cologne, Dept. of Urology, Uro-Oncology and robot-assisted Surgery, Cologne, Germany

Aims and objectives of this presentation

PT016

The application of 3D printed poly-L-lactide nanofiber membrane in substitutional urethroplasty

By: Qiang F.
Shanghai 6th Hospital, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation

PT017

Managing difficult catheter placement in complex urethroplasty and lower urinary tract reconstruction with a new urethral catheterisation device

By: Frost A., Bugeja S., Jeffery N., Alkandari M.H.E.A., Lomiteng A., Dragova M., Mundy A.
University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation
The augmented non-transecting anastomotic bulbar urethroplasty

By: Bugeja S., Frost A., Ivaz S., Jeffrey N., Lomiteng A., Dragova M., Andrich D.E., Mundy A.R.
University College London Hospitals NHS Foundation Trust, Dept. of Reconstructive Urology, London, United Kingdom

The outcome of revisional urethroplasty surgery

University College London Hospitals NHS Foundation Trust, Dept. of Reconstructive Urology, London, United Kingdom

Gastro-urethroplasty for salvage of lengthy complex pelvic fracture urethral distraction defect: Long-term follow up

By: Hosseini S.J.¹, Soleimanzadeh F.², Hosseini M.A.³, Mousavi S.R.⁴
¹Shahid Beheshti University of Medical Sciences, Infertility and Reproductive Health Research Center, Tehran, Iran, ²Imam Reza Hospital, Dept. of Urology, Tabriz, Iran, ³Qazvin University of Medical Sciences, Faculty of Medicine, Qazvin, Iran, ⁴Shohada Medical Center, Shahid Beheshti University of medical Sciences, Dept. of Vascular and Reconstructive Microsurgery, Tehran, Iran

Retrospective comparison between thermo-expandable urethral stent and self-expandable polymer coated urethral stent for temporary stent placement in patients with traumatic bulbar urethral stricture

By: Kim S.W., Ahn S.T., Lee D.H., Kim J.W., Oh M.M., Park H.S., Moon D.G.
Korea University, College of Medicine, Dept. of Urology, Seoul, South Korea

The sexual and continence outcome of patients with post anastomotic (end to end) urethroplasty for pelvic fracture posterior urethral distraction defects

By: Abdel-Aziz O.¹, Ghoneima W.¹, Abdel-Rassoul M.¹, Abdelwahab M.¹, Elkady A.
Aims and objectives of this presentation

PT023

**Transvaginal repair of anterior and apical prolapse using OPUR 6-strap mesh: Five years of experience**

By: Snurnitsyna O., Enikeev M., Glybochko P., Rapoport L., Nikitin A., Lobanov M., Abdusalamov A.

1 Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia
2 Spasocucotskogo Hospital, Dept. of Gynecology, Moscow, Russia

Aims and objectives of this presentation

PT024

**The management and outcomes of urethral complications of mid urethral tapes for stress urinary incontinence**

By: Toia B., Sihra N., Mahreen P., Hamid R., Ockrim J., Greenwell T.

University College Hospital London, Dept of Urology, London, United Kingdom

Aims and objectives of this presentation

PT025

**Comparison of surgical outcomes of laparoscopic versus robotic assisted repair of vesicovaginal fistula: Initial experience from northwest China**

By: Zhu G.D., Wu D.P., Song W.B., Yang Z.S., He D.L.

The First Affiliated Hospital of Xi’an Jiaotong University, Dept of Urology, Xi’an, China

Aims and objectives of this presentation

PT026

**Surgical outcomes of vesicovaginal fistula in the radiotherapy field**

By: Toia B., Pakzad M., Hamid R., Greenwell T., Ockrim J.

University College Hospital London, Dept of Urology, London, United Kingdom

Aims and objectives of this presentation

PT027

**Outcomes of recto-urethral fistula repair using a York-Mason procedure – return to full normal continuity of urinary and bowel function**

By: Kowalik U., Sexton S., Inouye B., Gilmore B., Kahokehr A., Peterson A., Mantyh C., Migaly J.

1 Duke University Medical Center, Dept. of Urology, Durham, United States of America,
Aims and objectives of this presentation
PT028

Results of the York Mason procedure with or without concomitant graciloplasty to treat iatrogenic rectourethral fistulas

By: Van Der Doelen M.J. 1, Fransen Van De Putte E.E. 2, Martens F.M.J. 1, Horenblas S. 2, Heesakkers J.P.F.A. 1

1Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, 2The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands

Aims and objectives of this presentation
PT029
Joint Session of the European Association of Urology (EAU) and the Pakistan Association of Urological Surgeons (PAUS)

Urology beyond Europe

Friday 15 March
09:45 - 12:15

Location:  Green Area, Room 14

Chairs:  M. Sheriff, Gillingham (GB)
         P. Van Kerrebroeck, Maastricht (NL)

Aims and objectives of this session
In this session EAU and PAUS will collaboratively endeavor to provide an overview of the latest developments in these two important areas of Urological practice. The aim is to discuss challenges and latest advances in management of clinical Benign Prostatic Hyperplasia (BPH) and vesico-vaginal fistula which pose a considerable health burden but have historically received inadequate attention in Pakistan.

09:45 - 09:55
Welcome and introduction
M. Ahmad, Rawalpindi (PK)
P. Van Kerrebroeck, Maastricht (NL)

09:55 - 10:45
Management of clinical Benign Prostatic Hyperplasia (BPH)

Moderators:  M. Nazir, Lahore (PK)
             M. Speakman, Taunton (GB)

09:55 - 10:10
Developments in treatment of clinical BPH
M. Speakman, Taunton (GB)

10:10 - 10:25
Management of clinical BPH: Current practice patterns in Pakistan
S.E-K. Ansari, Karachi (PK)

10:25 - 10:45
Questions and answers

10:45 - 11:35
Vesicovaginal fistula (VVF)

Moderators:  A. Abdullah, Karachi (PK)
             D.J.M.K. De Ridder, Leuven (BE)

10:45 - 11:00
How to achieve best outcomes in treatment of vesicovaginal fistula
D.J.M.K. De Ridder, Leuven (BE)

11:00 - 11:15
Evolution in surgical management of VVF in Pakistan
M. Lal, Karachi (PK)

11:15 - 11:35
Questions and answers

11:35 - 12:05
EAU-PAUS case discussion

Moderators:  M.S. Khan, London (GB)
             M. Speakman, Taunton (GB)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:35 - 11:50</td>
<td>Male Lower Urinary Tract Symptoms (LUTS)</td>
<td>N. Orakzai, Peshawar (PK)</td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td>VVF</td>
<td>H.N. Mengal, Quetta (PK)</td>
</tr>
<tr>
<td>12:05 - 12:15</td>
<td>Closing remarks</td>
<td>S. Khan, Quetta (PK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Van Kerrebroeck, Maastricht (NL)</td>
</tr>
</tbody>
</table>
Joint Session of the European Association of Urology (EAU) and the Iranian Urological Association (IUA)
Urology beyond Europe

<table>
<thead>
<tr>
<th>Friday 15 March</th>
<th>09:45 - 12:15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location:</strong></td>
<td>Green Area, Room 22</td>
</tr>
</tbody>
</table>
| **Chairs:**     | A. Basiri, Tehran (IR)  
|                 | J.M. Nijman, Groningen (NL) |

Aims and objectives of this session
The objective of this session is to discuss several scenarios regarding common urological problems. Each speaker will present his own worst case scenario (nightmare) in endourology, laparoscopy etc. Following each presentation there will be time to discuss the issues with the presenters.

<table>
<thead>
<tr>
<th>09:45 - 09:50</th>
<th>Welcome and introduction</th>
</tr>
</thead>
</table>
| A. Basiri, Tehran (IR)  
| J.M. Nijman, Groningen (NL) |

<table>
<thead>
<tr>
<th>09:50 - 10:20</th>
<th>Nightmares in endourology</th>
</tr>
</thead>
</table>
| Moderators: A. Skolarikos, Athens (GR)  
| M.A. Zargar Shoushtari, Tehran (IR) |

<table>
<thead>
<tr>
<th>09:50 - 10:05</th>
<th>IUA presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Basiri, Tehran (IR)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:05 - 10:20</th>
<th>EAU presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.J.S. Oster, Fredericia (DK)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:20 - 10:40</th>
<th>Nightmares in laparoscopy</th>
</tr>
</thead>
</table>
| Moderators: M. Asl Zare, Tehran (IR)  
| R. Sosnowski, Warsaw (PL) |

<table>
<thead>
<tr>
<th>10:20 - 10:30</th>
<th>IUA presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>M.H. Radfar, Tehran (IR)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:30 - 10:40</th>
<th>EAU presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Rassweiler, Heilbronn (DE)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:40 - 11:00</th>
<th>Locally advanced prostate cancer</th>
</tr>
</thead>
</table>
| Moderators: M. Sedehi, Tehran (IR)  
| J.P.M. Sedelaar, Nijmegen (NL) |

<table>
<thead>
<tr>
<th>10:40 - 10:55</th>
<th>IUA presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>M.R. Nowroozi, Tehran (IR)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:55 - 11:10</th>
<th>EAU presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>H.G. Van Der Poel, Amsterdam (NL)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:10 - 11:40</td>
<td>Oligo and widespread metastasis in prostate cancer</td>
</tr>
<tr>
<td>11:10 - 11:25</td>
<td>IUA presentation</td>
</tr>
<tr>
<td>11:25 - 11:40</td>
<td>EAU presentation</td>
</tr>
<tr>
<td>11:40 - 12:10</td>
<td>Pediatrics (complicated hypospadiasis)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>11:40 - 11:55</td>
<td>IUA presentation</td>
</tr>
<tr>
<td>11:55 - 12:10</td>
<td>EAU presentation</td>
</tr>
<tr>
<td>12:10 - 12:15</td>
<td>Closing remarks</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Regional meetings session - Best Poster presenters and first prize winners Young Urologist Competition

Friday 15 March 10:00 - 12:00

**Location:** Green Area, Room 21

Poster viewing of 20 minutes. Introduction by the chairs
Poster presentations:
• 2 min. presentation
• 2 min. discussion
Video presentations:
• Max 8 min. video presentation
• 4 min discussion
First prize winners Young Urologist Competition presentation:
• Max 7 min. presentation
• 3 min. discussion

Best posters presented at the time of the 5th Baltic Meeting in conjunction with the EAU

*Chairs:* A. Kotsar, Tartu (EE)
A. Minich, Minsk (BY)
J.L. Vásquez, Copenhagen (DK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20 - 10:30</td>
<td><strong>BALTIC1</strong> Laparoscopic pyeloplasty combined with flexible nephroscopy (video) M. Cerskute, Vilnius (LT)</td>
</tr>
<tr>
<td>10:30 - 10:34</td>
<td><strong>BALTIC2</strong> Blood-circulating androgen receptor variants as markers for progression and response to treatment in prostate cancer patients A. Bakavicius, Vilnius (LT)</td>
</tr>
<tr>
<td>10:34 - 10:38</td>
<td><strong>BALTIC3</strong> Epigenetic markers to overcome limitations in prostate cancer diagnostics A. Bakavicius, Vilnius (LT)</td>
</tr>
<tr>
<td>10:38 - 10:42</td>
<td><strong>BALTIC4</strong> Prostate resection speed in TURP – how determining is this for patients and how appropriate as a measure for assessing trainees? J.F. Donati-Bourne, Birmingham (GB)</td>
</tr>
<tr>
<td>10:42 - 10:52</td>
<td><strong>BALTIC5</strong> Laparoscopic left adrenalectomy. Adrenal ganglioneuroma (video) T. Põdramägi, Tartu (EE)</td>
</tr>
<tr>
<td>10:52 - 10:56</td>
<td><strong>BALTIC6</strong> The influence of specific urinary incontinence type on the quality of life of incontinent women Z. Pilsetniece, Riga (LV)</td>
</tr>
<tr>
<td>10:00 - 12:00</td>
<td>Best posters presented at the time of the 18th EAU Central European Meeting in conjunction with the national congress of the Romanian Association of Urology</td>
</tr>
</tbody>
</table>
### CEM1 Perineal urethrostomy – a last resort in the treatment of difficult urethral conditions
A. Andresanu, Sector 3, Bucuresti (RO)

### CEM2 A novel surgical technique to reduce lymphocele formation following pelvic lymph node dissection
A. Magyar, Budapest (HU)

### CEM3 Cystic tumours of the kidney - our experiences in treatment and diagnostics
T. Pitra, Plzeň (CZ)

### CEM4 Lymphopenia can help to predict response to targeted 1st-line therapy in patients with metastatic renal cell carcinoma
M. Seles, Graz (AT)

### CEM5 Single-use cystoscopy - assessment of quality
A. Ostrowski, Bydgoszcz (PL)

### CEM6 Musculocutaneous latissimus dorsi free flap as an option for phallic reconstruction in transmen
V. Kojovic, Belgrade (RS)

### Best posters presented at the time of the 13th South Eastern European Meeting in conjunction with the EAU

**Chairs:**
- D. Basic, Nis (RS)
- J.L. Vásquez, Copenhagen (DK)
- A. Vuksanovic, Belgrade (RS)

**SEEM1 Low-intensity shockwave therapy (LiST) for erectile dysfunction: A randomized clinical trial assessing the impact of energy flux density (EFD) and frequency of sessions**
I. Mykoniatis, Thessaloniki (GR)

**SEEM2 Late functional and psychosexual complications of primary hypospadias repaired in childhood**
B. Stojanovic, Belgrade (RS)

**SEEM3 Buccal one-stage mucosal graft urethroplasty for urethral stricture: Results of 10 years of experience**
G. Galiqi, Shkoder (AL)

**First prize winners Young Urologist Competition**

**Chairs:**
- J. Gómez Rivas, Madrid (ES)
- J.L. Vásquez, Copenhagen (DK)
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:32 - 11:42</td>
<td>Upper Tract Urothelial Carcinome: Is it possible to save the kidney?</td>
<td>T. Pödramägi, Tartu (EE)</td>
</tr>
<tr>
<td>11:42 - 11:52</td>
<td>Invasive nodal staging in intermediate and high risk cN0 penile cancer. Dynamic sentinel lymph node biopsy or modified lymph node dissection?</td>
<td>I. Trávníček, Plzeň (CZ)</td>
</tr>
<tr>
<td>11:52 - 12:02</td>
<td>The biocompatibility profile of urogynecology synthetic grafts and the underlying mechanism of action</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>
Understanding of LUTS mechanisms: New insights
Poster Session 06

Friday 15 March
10:45 - 12:15

Location: Red Area, eURO Auditorium 2
Chairs: R. Cartwright, London (GB)
F. Cruz, Porto (PT)
T.A.T. Marcelissen, Maastricht (NL)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 72

Parameters for detrusor underactivity in women: Predictive value towards ineffective voiding in a large cohort of women with urinary incontinence

By: Rosier P.
University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands

75

Sensitivity and specificity of neurotrophins as biomarkers of a neurogenic detrusor overactivity in multiple sclerosis patients

By: Philippova E.S. 1, Bazhenov I. 2, Zyryanov A. 2, Bazarny V. 3, Sazonov S. 4, Volkova L. 5
1Ural State Medical University, Dept. of Urology, Ekaterinburg, Russia, 2Ural State Medical University, Dept. of Urology, Ekaterinburg, Russia, 3Ural State Medical University, Dept. of Laboratory Diagnosis, Ekaterinburg, Russia, 4Ural State Medical University, Dept. of Histology, Cytology and Embriology, Ekaterinburg, Russia, 5Ural State Medical University, Dept. of Neurology, Ekaterinburg, Russia

76

Detecting differences with magnetoencephalography (MEG)-urodynamics study of somatosensory processing normal desire to void and maximum desire to void sensation

By: Kitta T. 1, Shiraishi H. 2, Yagyu K. 2, Shimojo A. 2, Egawa K. 2, Kanno Y. 1, Ouchi M. 1, Higuchi M. 1, Togo M. 1, Takahashi Y. 1, Tsukiyama M. 1, Moriya K. 1, Ariga T. 2, Shinohara N. 1
1Hokkaido University, Dept. of Urology, Sapporo, Japan, 2Hokkaido University, Dept. of Pediatrics, Sapporo, Japan

77

Time to change microbiological approach to overactive bladder

By: Perovic S.U. 1, Ksiezarek M. 1, Rocha J. 1, Vale L. 2, Silva C. 2, Dinis P. 2, Antunes Lopes T. 2, Peixe L. 1
1University of Porto, Faculty of Pharmacy, Porto, Portugal, 2Hospital de São João, University of Porto, Dept. of Urology, Faculty of Medicine, Porto, Portugal
Dynamic connectivity in the periaqueductal gray matter measured by 7 Tesla functional MRI during a bladder filling protocol

By: De Rijk M.M. 1, Van Den Hurk J. 2, Rahnama'i M.S. 1, Van Koeveringe G.A. 3
1 Maastricht University, Dept. of Urology, Maastricht, The Netherlands, 2 Scannexus, Maastricht, The Netherlands, 3 Maastricht University, Medical Center, Dept. of Urology, Maastricht, The Netherlands

Possible roles of urethral C-fiber afferents in storage/voiding dysfunction in female patients

By: Ichiyanagi O. 1, Nishimoto K-I. 2, Nagaoka A. 3, Naito S. 4, Yagi M. 4, Ushijima M. 4, Kajinuma A. 1, Kato T. 4, Tsuchiya N. 4
1 Yamagata Prefectural Kahoku Hospital, Dept. of Urology, Kahoku, Japan, 2 Seichokai Fuchu Hospital, Dept. of Urology, Izumi, Japan, 3 Yonezawa City Hospital, Dept. of Urology, Yonezawa, Japan, 4 Yamagata University Faculty of Medicine, Dept. of Urology, Yamagata, Japan

Lower urinary tract symptoms amongst adult patients with genetically-confirmed mitochondrial disease

By: Sachdeva A. 1, Feeney C. 1, Gorman G. 1, Turnbull D.M. 1, Harding C. 2
1 Newcastle University, Wellcome Centre for Mitochondrial Research, Newcastle upon Tyne, United Kingdom, 2 Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom

Therapeutic effects of PDE9 inhibitor on lower urinary tract dysfunction (LUTD) in mice with spinal cord injury (SCI)

1 Kindai University Faculty of Medicine, Dept. of Urology, Osaka-Sayama, Japan, 2 University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America, 3 Kindai University Nara Hospital, Faculty of Medicine, Dept. of Urology, Ikoma, Japan, 4 University of Pittsburgh, Dept. of Medicine, Pittsburgh, United States of America, 5 University of Pittsburgh, Dept. of Pharmacology and Chemical Biology, Pittsburgh, United States of America

Three-dimensional model of MRI prostate in bladder outlet obstruction of male LUTS/BPH patients

By: Xia S., Jie S.
Renji Hospital, Dept. of Urology, Shanghai, China

The role of prostatic apex shape in voiding symptom and urine flow: A development and validation study

Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Title</th>
<th>Speaker, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:04 - 12:09</td>
<td>State-of-the-art lecture</td>
<td>Can imaging differentiate function from dysfunction?</td>
<td>F. Cruz, Porto (PT)</td>
</tr>
</tbody>
</table>
Aims and objectives of this session
ESO Observatories are high-level sessions organised during major international congresses with the aim of providing the audience with updated and unbiased information on a given topic. An ESO Observatory lasts about one hour and concentrates on a forecast given by panel of experts of what it is expected to happen in their own field in the coming 12 months. The Panel includes distinguished clinicians and/or scientists and a patient advocate.

The forecast by each Panel Member is given in the form of concise take-home messages with 8-minute slide presentation followed by 2 minutes of discussion for each topic. The forecast will be discussed by the panel.

10:45 - 10:50
Introduction and looking back at the 2018 predictions
J. Dowling, Dublin (IE)
R.J.A. Van Moorselaar, Amsterdam (NL)

10:50 - 11:00
The urologist's perspective on focal therapy
R. Ganzer, Bad Tölz (DE)

11:00 - 11:10
The urologist's perspective on surgery
M. Graefen, Hamburg (DE)

11:10 - 11:20
The urologist's perspective on active surveillance
R.C.N. Van Den Bergh, Nieuwegein (NL)

11:20 - 11:30
The imaging specialist's perspective on MRI
O. Rouvière, Lyon (FR)

11:30 - 11:40
The pathologist's perspective
F. Algaba, Barcelona (ES)

11:40 - 11:50
The radiation oncologist's perspective
A. Bossi, Villejuif (FR)

11:50 - 12:00
The medical oncologist's perspective
S. Gillessen Sommer, Manchester (GB)

12:00 - 12:10
The andrologist’s perspective
M. Albersen, Leuven (BE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10 - 12:25</td>
<td><strong>The patient's perspective</strong></td>
<td>J. Dowling, Dublin (IE)</td>
</tr>
<tr>
<td>12:25 - 12:30</td>
<td><strong>Discussion and take-home messages</strong></td>
<td>J. Dowling, Dublin (IE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R.J.A. Van Moorselaar, Amsterdam (NL)</td>
</tr>
</tbody>
</table>
**Infectious diseases: Prostate and bladder**

**Poster Session 07**

**Friday 15 March**  
**10:45 - 12:15**

**Location:** Green Area, Room 4

**Chairs:**  
A. Chkhotua, Tbilisi (GE)  
S. Malde, London (GB)  
F.M.E. Wagenlehner, Giessen (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**85**

**Chronological trends of resistant Escherichia coli isolated from community-acquired urinary tract infections**

By: Nasu Y. 1, Kosaka N. 2, Tanaka D. 1, Sugimoto M. 1, Takamoto A. 1  
1Okayama Rosai Hospital, Dept. of Urology, Okayama, Japan, 2Okayama Rosai Hospital, Dept. of Clinical Laboratory, Okayama, Japan

Aims and objectives of this presentation

---

**86**

**Outcomes of an observational protocol to prevent healthcare-associated infections (HAIs) in a urology ward**

By: Medina-Polo J. 1, Justo-Quintas J. 1, Gil-Moradillo J. 1, García-Rojo E. 1, González-Padilla D.A. 1, Abad-López P. 1, González-Díaz A. 1, Santos-De La Blanca R. 1, Hernández-Arroyo M. 1, Peña-Vallejo H. 1, Teigell-Tobar J. 1, López-Medrano F. 2, Tejido-Sánchez A. 1  
1Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, 2Hospital Universitario 12 de Octubre, Dept. of Infectious Diseases, Madrid, Spain

Aims and objectives of this presentation

---

**87**

**The effects of intervention by a dedicated urology team on reduction of catheter associated urinary tract infections, morbidity and mortality in hospitalized patients**

By: Sadeh O. 1, Shabataev V. 1, Ram S. 2, Paul M. 3, Amiel G.E. 1  
1Rambam Health Care Campus, Dept. of Urology, Haifa, Israel, 2Technion- Israel Institute of Technology, Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, 3Rambam Health Care Campus, Dept. of Infectious Diseases, Haifa, Israel

Aims and objectives of this presentation
Intra-vesical gentamicin (IVG) installations improve QoL, reduces the frequency of UTIs and reduce micro-organism resistance in patients with intractable recurrent UTIs

By: Hamed A.H.¹, McPhee S.¹, Jones J.¹, Altmeier U.², Meddings R.N.¹, Bekarma H.¹
¹University Hospital Ayr, Dept. of Urology, Ayr, United Kingdom, ²University Hospital Crosshouse, Dept. of Microbiology, Kilmarnock, United Kingdom

Aims and objectives of this presentation

Efficacy of prophylactic administration of prurifloxacin vs. cefixime in patients undergoing ultrasound guided prostate biopsy: A prospective randomized study

By: Samarinas M.¹, Skriapas K.¹, Karatzas A.², Gravas S.², Tzortzis V.²
¹General Hospital of Larissa, Dept. of Urology, Larissa, Greece, ²University Hospital of Larissa, Dept. of Urology, Larissa, Greece

Aims and objectives of this presentation

Blood stream infections following TRUS prostate biopsy: A 20-year analysis of bacteriology and antibiotic sensitivities

By: Yiu T.W.¹, Rice J.¹, Byers J.², Gordon L.¹, He Y.¹, Al-Sameraii A.¹, Bowden F.³, Chan H.F.¹, Gilbourd D.¹, Hart K.¹, Kahloon M.¹, Collignon P.³, McCredie S.¹, Haxhimolla H.¹
¹ACT Health, Dept. of Urology, Canberra, Australia, ²Australian National University, Medical School, Canberra, Australia, ³ACT Health, Calvary Hospital, Dept. of Infectious Disease, Canberra, Australia

Aims and objectives of this presentation

Is adjuvant amikacin to oral levofloxacine effective for prevention of febrile complications following transrectal prostate biopsy in patients with fluoroquinolone-resistant E. coli in the rectal flora?

By: Nasu Y.¹, Kosaka N.², Tanaka D.¹, Murata T.¹
¹Okayama Rosai Hospital, Dept. of Urology, Okayama, Japan, ²Okayama Rosai Hospital, Dept. of Clinical Laboratory, Okayama, Japan

Aims and objectives of this presentation

Microbiology, histology or radiology – what is better for early diagnosis of prostate tuberculosis?

By: Kulchavenya E., Brizhatyuk E., Potapov V.
Aims and objectives of this presentation
92

The role of next generation sequencing of semen samples in the diagnosis and treatment of chronic bacterial prostatitis

By: Mouraviev V.
CFCI, Dept. of Urology, Davenport, United States of America

Aims and objectives of this presentation
93

Improving the management of recurrent urinary tract infections in women under 30 – does conservative treatment really work?

By: Hamed A.H., Cameron L., McPhee S., Granger L., Bell A., Crombie E., Larkin K., Clark R., Bekarma H.
Health Care - NHS, Dept. of Urology, Ayr, United Kingdom

Aims and objectives of this presentation
94

Minimally invasive combined surgical treatment for postcoital cystitis

By: Snurnitsyna O.¹, Enikeev M.², Rapoport L.¹, Lobanov M.¹, Abdusalamov A.¹, Malinina O.³
¹Sechenov University, Dept. of Urology and Reproductive Health, Moscow, Russia,
²Sechenov University, Dept. of Urology and Reproductive Health, Moscow, Russia,
³29 Bauman Hospital, Dept. of Urology, Moscow, Russia

Aims and objectives of this presentation
95

Prevalence and antibiotic susceptibility of bacterial uropathogens in obstetric patients of Moscow region

By: Lokshin K.¹, Shirshov V.², Popko A.², Demidko Y.³, Luchenkova N.⁴
¹GMS Clinics and Hospitals, Dept. of Urology, Moscow, Russia,
²Clinical Hospital Lapino, Mother and Child Group of Companies, Dept. of Urology, Moscow, Russia,
³Clinic of Urology, Sechenov University, Dept. of Urology, Moscow, Russia,
⁴Clinical Hospital Lapino, Mother and Child Group of Companies, Dept. of Obstetrics, Moscow, Russia

Aims and objectives of this presentation
96

Analysis of mixed growth urine cultures in patients undergoing endoscopic urological procedures at an Australian tertiary hospital

Scientific Programme - EAU19 Barcelona
Aims and objectives of this presentation

97

Is index of suspicion on urogenital tuberculosis high?

By: Kulchavenya E., Shevchenko S.
Novosibirsk Research TB Institute, Novosibirsk Medical University, Dept. of Urogenital, Novosibirsk, Russia

Aims and objectives of this presentation

98

Urine culture test: Is the sample collected satisfactorily?

By: Maheshwari P., Chaurasia A., Okwi N., Mukasa N.V.
1Fortis Hospital Mulund, Dept. of Urology, Mumbai, India, 2Faculty of Health Sciences, Busitema University, Dept. of Surgery, Busitema, Uganda, 3Mulago National Referral Hospital, Dept. of Surgery, Kampala, Uganda

Aims and objectives of this presentation

99
Novel biomarkers to improve prostate cancer predictions: The research continues
Poster Session 08

**Location:** Green Area, Room 5

**Chairs:**
- G. Giannarini, Udine (IT)
- J.A. Schalken, Nijmegen (NL)
- G. Zhu, Beijing (CN)

Friday 15 March
10:45 - 12:15

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

### 100

**Use of the PHI assay as a first line triaging test in an image-guided prostate cancer diagnostic pathway. The PHI in Refining MRI (PRIM) study**

By: Gnanapragasam V.J., Barret T., Starling L., George A., Burling K., Saeb-Parsy K., Kastner C., Lamb B., Kim L.

1. University of Cambridge, Academic Urology Group, Cambridge, United Kingdom
2. University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom
3. University of Cambridge, Dept. of Urology Translational Research and Clinical Trials, Cambridge, United Kingdom
4. University of Cambridge, Dept. of Core Biochemistry and Analytical Laboratory, Cambridge, United Kingdom
5. Cambridge University Hospitals Trust, Dept. of Urology, Cambridge, United Kingdom
6. University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom

### 101

**External validation of SelectMDx (v1) in an opportunistic screening cohort in first TRUS-guided biopsy without MRI imaging**


1. Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain
2. Hospital Miguel Servet, Dept. of Urology, Zaragoza, Spain
3. Escuela Universitaria Politécnica La Almunia, Universidad de Zaragoza, Dept. of Biostatistics, Zaragoza, Spain
4. Instituto Valenciano de Oncología, Dept. of Statistics, Valencia, Spain

### 102

**Percent genome alteration predicts adverse oncologic outcomes after radical prostatectomy in African American men: A profile of cancer genomics by racial ancestry**

By: Faisal F., Tomlins S., Lotan T., Schaeffer E.

1. Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America
2. University of Michigan, Dept. of Urology and Pathology, Ann Arbor, United States of America
3. Johns Hopkins University School of Medicine, Dept. of Urology
Pooled analysis of >1000 patients enrolled in two independent prospective validation studies show consistent performance of a urine exosome gene expression assay to rule-out benign and low-grade prostate cancer at initial biopsy


Identification of clinically significant prostate cancer using a novel multiplexed urine biomarker panel

By: Niknafs Y., Tosoian J., Morgan T., Tomlins S., Chinnaiyan A.M.

Prostate cancer (PCa) incidence and severity in 823 hypogonadal men with and without testosterone therapy (TTh) in a controlled, observational registry study over up to 14 years

By: Haider A., Haider K.S.

Low free testosterone is an independent risk factor for high grade prostate cancer

By: Towe M., Huynh L.M., El-Khatib F.M., Osman M., Yafi F., Ahlering T.

International comparison in the Risk Calculator-based age-standardized incidence rate of prostate cancer between Japan and the Netherlands

109 Clinical significant prostate cancer diagnostic performance of LacdiNAc-prostate-specific antigen glycoisomer assay at initial prostate biopsy: Retrospective multi-institutional study

By: Yoneyama T.¹, Tobisawa Y.², Kaneko T.³, Kaya T.³, Hatakeyama S.², Mitsuzuka K.⁴, Duivenvoorden W.⁵, Pinthus J.⁵, Hashimoto Y.², Ito A.⁴, Koie T.⁶, Suda Y.³, Gardiner R.⁷, Ohyama C.²

¹Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ³Konica Minolta Inc., Corporate R&D Headquarters, Hino, Japan, ⁴Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan, ⁵McMaster University, Dept. of Surgery, Ontario, Canada, ⁶Gifu University Graduate School of Medicine, Dept. of Urology, Gifu, Japan, ⁷University of Queensland, Centre for Clinical Research (UQCCR), Herston, Australia

110 Detection of significant prostate cancer through exhaled-breath analysis with an electronic nose, Aeonose™

By: Waltman C.G., Kolenburg J.W.C. , Marcelissen T.A.T. , Van Roermund J.G.H. Maastricht University Medical Centre, Dept. of Urology, Maastricht, The Netherlands

111 The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study

By: Loubersac T.¹, Nguile-Makao M.², Pouliot F.², Fradet V.², Toren P.²

¹CHU Nantes, Urology Unit, Nantes, France, ²Centre Hospitalier Universitaire (CHU) de Québec Research Centre, Urology Unit, Quebec City, Canada

112 Prognostic significance of serum γ-glutamyltransferase in patients with castration-resistant prostate cancer treated with enzalutamide

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan

12:00 - 12:08 State-of-the-art lecture How to develop a clinically relevant biomarker
J.A. Schalken, Nijmegen (NL)
Novel approaches to stone management

Video Session 02

Friday 15 March 10:45 - 12:15

Location: Green Area, Room 10

Chairs: E. Emiliani, Barcelona (ES)  
J-T. Klein, Ulm (DE)  
Y. Tanidir, Izmit/Kocaeli (TR)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V09

Comprehensive clinical study of SuperPulse™ fiber laser for treatment of stone disease

By: Traxer O. ¹, Dymov A.M. ², Rapoport L.M. ², Enikeev D.V. ², Tsarichenko D.G. ², Sorokin N.I. ², Proskura A.V. ², Akopyan G.N. ², Ali S.K.H. ², Lekarev V.Y. ², Klimov R.E. ², Korolev D.O. ²

¹Tenon Hospital, Dept. of Urology, Paris, France, ²Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

Aims and objectives of this presentation

V09

V10

Prospective transurethral lithotripsy study with SuperPulse™ fiber laser

To be confirmed

Aims and objectives of this presentation

V10

V11

Simultaneous bilateral endoscopic surgery (SBES): A new technique for the treatment of bilateral renal stones

By: Proietti S. ¹, Rodriguez Socarras M.E. ¹, Eisner B. ², Saitta G. ¹, De Coninck V. ¹, Mantica G. ¹, De Marchi D. ¹, Bellinzoni P. ¹, Gaboardi F. ¹, Giusti G. ¹

¹San Raffaele Hospital, Ville Turro Division, Dept. of Urology, Milan, Italy, ²Harvard Medical School, Massachusetts General Hospital, Dept. of Urology, Boston, United States of America

Aims and objectives of this presentation

V11

V12

The management of urinary stones in pediatrics: Overcoming traditional challenges with Moses technology

By: Tasian G.

The Children's Hospital of Philadelphia, Dept. of Urology, Philadelphia, United States of
America

Aims and objectives of this presentation

V12

High-power holmium laser with Moses technology: Our initial experience

Fundació Puigvert, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation

V13

One-surgeon basketing technique in flexible ureteroscopy

By: Okada S., Hamamoto S., Inoue T., Minagawa S., Morikawa H., Matsuda T., Miura H., SMART Study Group
1Gyotoku General Hospital, Dept. of Urology, Ichikawa, Japan, 2Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, 3Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan, 4Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan, 5Hachinohe Koyo Clinic, Dept. of Urology, Hachinohe, Japan

Aims and objectives of this presentation

V14

Non-biological 3D printed simulator for percutaneous nephrolithotripsy

1Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, 2Ludwig-Maximilians University, Dept. of Internal Medicine, Munich, Germany

Aims and objectives of this presentation

V15

Endoscopic renal parenchyma tunnel cauterization for the management of hemorrhage during percutaneous renal surgery

By: Lezrek M., Tazi H., El Yazami O., Alami M., Ammani A.
1Military Hospital Moulay Ismail, Dept. of Urology, Meknes, Morocco, 2Al Ghassani Hospital, Dept. of Urology, Fes, Morocco

Aims and objectives of this presentation

V16
Utility of the modified MAP score for predicting adherent perinephric fat in robot-assisted partial nephrectomy

By: Shiozaki K.¹, Sasaki Y.¹, Nakanishi R.¹, Izaki H.¹, Kanda K.¹, Kawanishi Y.², Yamanaka M.², Izumi K.², Kanayama H.³
¹Tokushima Prefectural Central Hospital, Dept. of Urology, Tokushima, Japan,
²Takamatsu Red Cross Hospital, Dept. of Urology, Tokushima, Japan,
³Tokushima University Hospital, Dept. of Urology, Tokushima, Japan

Aims and objectives of this presentation

113

Association between adherent perinephric fat assessed using MAP score and PnFSD and perioperative outcomes at the time of partial nephrectomy for localized renal mass. A single high-volume referral center experience

By: Di Maida F.¹, Campi R.¹, Tellini R.¹, Sforza S.¹, Cocci A.¹, Corti F.¹, Viola L.¹, Bertelli E.², Lucarini S.², Agostini S.², Siena G.¹, Masieri L.¹, Carini M.¹, Mari A.¹, Minervini A.¹
¹University of Florence, CAREGHI Hospital, Dept. of Urology, Florence, Italy,
²University of Florence, CAREGHI Hospital, Dept. of Radiology, Florence, Italy

Aims and objectives of this presentation

114

The greatest dimension in 3D sphere has stronger predictive power than 2D plane in the prognosis of renal cell carcinoma

By: Sun Z.¹, Zhao X.¹, Jiang B.¹, Kan Y.¹, Zheng J.², Guo X.², Guo H.¹
¹Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical School, Dept. of Urology, Nanjing, China,
²INCOOL Medical Technology Co. Ltd., Dept. of Technology, Hangzhou, China

Aims and objectives of this presentation

115
Aims and objectives of this presentation

* 116

Proposal for tripartite reclassification of cT1 renal cell carcinoma into cT1a (very low risk), cT1b (low risk), and cT1c (intermediate risk) substages

By: Bradshaw A. 1, Capitanio U. 2, Uzzo R. 3, Patil D. 4, Eldefrawy A. 1, Larcher A. 2, Joshi S. 3, Ryan S. 1, Margaret M. 1, Cotta B. 1, Yee A. 1, Wan F. 1, Montorsi F. 2, Master V. 4, Derweesh I. 1
1 UC San Diego Health, Dept. of Urology, La Jolla, United States of America, 2 Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 3 Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, 4 Emory University, Dept. of Urology, Atlanta, United States of America

Aims and objectives of this presentation

116

117

Refining American joint committee on cancer prognostic groups for renal cell carcinoma: A more precise prediction of survival

By: Ning S., Qu Y., Wan F., Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation

117

* 118

Topographic distribution of lymphatic oligometastases in patients with renal cancer

By: Kuusk T. 1, Zondervan P. 2, Lagerveld B. 3, Rosenzweig B. 4, Raman A. 5, Bex A. 1
1 Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, 2 Academic Medical Center, Dept. of Urology, Amsterdam, The Netherlands, 3 OLVG, Dept. of Urology, Amsterdam, The Netherlands, 4 The Chaim Sheba Medical Center, Dept. of Urology, Ramat Gan, Israel, 5 John Hunter Hospital, Dept. of Urology, Newcastle, Australia

Aims and objectives of this presentation

118

119

The role of non-tumour renal biopsy in patients treated with radical nephrectomy

By: Larcher A. 1, Trevisani F. 1, Dell’Antonio G. 2, Di Marco F. 1, Cinque A. 1, Bettiga A. 1, Muttin F. 1, Porrini E. 3, Doglioni C. 2, Salonia A. 1, Bertini R. 1, Montorsi F. 1, Capitanio U. 1
1 Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Experimental Oncology, Milan, Italy, 2 IRCCS San Raffaele Scientific Institute, Dept. of Pathology, Milan, Italy, 3 University of La Laguna, Center for Biomedical Research of the Canary Islands (CIBICAN), Tenerife, Spain
Aims and objectives of this presentation

Clinical utility of the mutational landscape and fragment size of circulating tumor DNA in renal cell carcinoma

By: Uemura M.\textsuperscript{1}, Yamamoto Y.\textsuperscript{1}, Fujita M.\textsuperscript{2}, Maejima K.\textsuperscript{2}, Koh Y.\textsuperscript{1}, Matsushita M.\textsuperscript{1}, Nakano K.\textsuperscript{1}, Hayashi Y.\textsuperscript{1}, Wang C.\textsuperscript{1}, Ishizuya Y.\textsuperscript{1}, Kato T.\textsuperscript{1}, Kawashima A.\textsuperscript{1}, Ujike T.\textsuperscript{1}, Nagahara A.\textsuperscript{1}, Fujita K.\textsuperscript{1}, Nakagawa H.\textsuperscript{2}, Nonomura N.\textsuperscript{1}

\textsuperscript{1}Osaka University, Graduate School of Medicine, Dept. of Urology, Suita, Japan, \textsuperscript{2}RIKEN Center for Integrative Medical Sciences, Laboratory for Genome Sequencing Analysis, Tokyo, Japan

Aims and objectives of this presentation

Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients

By: Xu W.H.\textsuperscript{1}, Qu Y-Y.\textsuperscript{1}, Jun W.\textsuperscript{1}, Wan F.N.\textsuperscript{1}, Zhao J.Y.\textsuperscript{2}, Zhang H.L.\textsuperscript{1}, Ye D.\textsuperscript{1}

\textsuperscript{1}Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, \textsuperscript{2}The Obstetrics & Gynecology Hospital of Fudan University, State Key Lab of Genetic Engineering, School of Life Sciences and Collaborative Center of Genetics & Development, Fudan University, Shanghai, China

Aims and objectives of this presentation

Summary

S. Dabestani, Malmö (SE)
Active surveillance in prostate cancer
Expert-Guided Poster Tour 02

Friday 15 March
11:45 - 13:45

Location: Green Area, Room A
Chairs: C.H. Bangma, Rotterdam (NL)
R. Sanchez-Salas, Paris (FR)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

12:15 - 12:18

Introduction
C.H. Bangma, Rotterdam (NL)
R. Sanchez-Salas, Paris (FR)

PT030
Withdrawn
To be confirmed

Aims and objectives of this presentation
PT030

PT031
NCCN favourable intermediate-risk prostate cancer patients: Do all of them have a good prognosis?

By: Ono A.¹, Hirasawa Y.¹, Matsubara S.¹, Tokuyama N.¹, Hashimoto T.¹, Satake N.¹, Nakagami Y.¹, Namiki K.¹, Nakashima J.², Ohno Y.¹
¹Tokyo Medical University, Dept. of Urology, Tokyo, Japan, ²Sanno Hospital, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation
PT031

PT032
Thirty-year nationwide population-based follow-up of men on active surveillance for prostate cancer: Who benefits the most? A state-transition analysis

By: Ventimiglia E.¹, Van Hemelrijck M.², Lindhagen L.³, Statin P.⁴, Garmo H.²
¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²King’s College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, United Kingdom, ³Uppsala Clinical Research Center, Dept. of Statistics, Uppsala, Sweden, ⁴Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden
Scientific Programme - EAU19 Barcelona

Aims and objectives of this presentation
PT032

PT033
Active surveillance vs. radical prostatectomy in favourable-risk localised prostate cancer

By: Thomsen F.B. ¹, Røder M.A. ¹, Jakobsen H. ², Langkilde N.C. ³, Borre M. ⁴, Jakobsen E.B. ⁵, Frey A. ⁶, Lund L. ⁷, Lunden D. ⁸, Dahl C. ⁵, Brasso K. ¹
¹Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, ²Herlev Hospital, Dept. of Urology, Copenhagen, Denmark, ³Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ⁴Aarhus University Hospital Skejby, Dept. of Urology, Aarhus, Denmark, ⁵Zealand University Hospital, Dept. of Urology, Roskilde, Denmark, ⁶Sydvestjysk Sygehus, Dept. of Urology, Esbjerg, Denmark, ⁷Odense University Hospital, Dept. of Urology, Odense, Denmark, ⁸Hospitalsenhed Midt, Dept. of Urology, Viborg, Denmark

Aims and objectives of this presentation
PT033

PT034
A novel predictor of clinical progression in patients on active surveillance for prostate cancer

University Health Network, Division of Urology, Toronto, Canada

Aims and objectives of this presentation
PT034

PT035
Eight year patient reported outcome data of the first 150 Dutch men on active surveillance in the Prostate cancer Research International Active Surveillance study (PRIAS)

By: Venderbos L.D.F. ¹, Van Den Bergh R.C.N. ², Bangma C.H. ¹, Roobol M.J. ¹
¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²St. Antonius Hospital, Dept. of Urology, Nieuwegein, The Netherlands

Aims and objectives of this presentation
PT035

PT036
Reclassification due to upgrading during active surveillance protocols in low risk prostatic cancer: The role of number of repeat biopsies in the long terms

By: Marenghi C. ¹, Nicolai N. ², Badenchini F. ³, Catanzaro M.A. ², Avuzzi B. ⁴, Macchi A. ², Morlino S. ⁴, Stagni S. ², Torelli T. ², Villa S. ⁴, Colecchia M. ⁵, Massa S. ⁵, Zollo F. ³, Magnani T. ³, Tesone A. ², Salvioni R. ², Valdagni R. ⁶
¹Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Unit, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Prostate Cancer Unit, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Program, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Therapy, Milan, Italy, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Therapy, Milan, Italy, ⁶Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Therapy, Milan, Italy,
Aims and objectives of this presentation
PT036

**Do number of biopsies and PSA doubling time at 3 and 5 years in active surveillance protocols associate with upgrading reclassification?**

By: Nicolai N. ¹, Badenchini F. ¹, Marenghi C. ¹, Rancati T. ², Magnani T. ³, Villa S. ⁴, Avuzzi B. ⁴, Morlino S. ⁴, Noris Chiorda B. ⁴, Catanzaro M.A. ¹, Tesone A. ¹, Stagni S. ¹, Torelli T. ¹, Macchi A. ¹, Salvioni R. ¹, Colecchia M. ⁵, Procopio G. ⁶, Verzoni E. ⁶, Massa S. ⁵, Valdagni R. ⁷

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Pathology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Therapy, Prostate Cancer Unit, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Therapy, Prostate Program, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Pathology, Milan, Italy, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiation Therapy, Milan, Italy, ⁶Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, ⁷Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiation Therapy, Prostate Program, Prostate Cancer Unit, Milan, Italy

Aims and objectives of this presentation
PT037

**Do we really need detailed biopsy assessment of patients with low-risk prostate cancer candidate to active surveillance? A prospective validation of the ISUP recommendations**

By: Bandini M. ¹, Suardi N. ², Scarcella S. ², Nocera L. ², Gandaglia G. ², Fossati N. ², Cucchiara V. ², Zaffuto E. ², Shariat S. ³, Longo N. ⁴, Mirone V. ⁴, Scuderi S. ², Larcher A. ², Robesti D. ², Karakiewicz P. ⁵, Rizzo A. ², Cannoletta D. ², Pellegrino A. ², Barletta F. ², Montorsi F. ², Briganti A. ²

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴University of Naples Federico II, Dept. of Urology, Naples, Italy, ⁵University of Montreal Health Center, Montreal, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada

Aims and objectives of this presentation
PT038

**Active surveillance in men with low to intermediate risk localized prostate cancer: A prospective multiple cohort study**

By: Rakauskas A. ¹, Lucca I. ¹, Burruni R. ¹, Tawadros T. ¹, Herrera F. ², Bourhis J. ², La Rosa S. ³, Meuwly J. ⁴, Jichlinski P. ¹, Berthold D. ⁵, Valerio M. ¹

¹Lausanne University Hospital, Dept. of Urology, Lausanne, Switzerland, ²Lausanne
University Hospital, Dept. of Radiotherapy, Lausanne, Switzerland, \(^3\)Lausanne University Hospital, Inst. of Pathology, Lausanne, Switzerland, \(^4\)Lausanne University Hospital, Dept. of Radiology, Lausanne, Switzerland, \(^5\)Lausanne University Hospital, Dept. of Oncology, Lausanne, Switzerland

**Aims and objectives of this presentation**
PT039

**PT040**

**Examining the limits of eligibility: Validation of a Swedish national prostate cancer register (NPCR) observational study**

By: Chadrasekar T., Leong J.Y., Teplitsky S., Mann M., Trabulsi E., Lallas C., Gomella L., Mark J.R.
Thomas Jefferson University, Sidney Kimmel Cancer Center, Dept. of Urology, Philadelphia, United States of America

**Aims and objectives of this presentation**
PT040

**PT041**

**Does time spent on active surveillance adversely affect the pathologic and oncologic outcomes in patients undergoing delayed radical prostatectomy?**


\(^1\)Princess Margaret Cancer Centre, University Health Network, University of Toronto, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada, \(^2\)Centre Hospitalier Universitaire de Sherbrooke, Centre de Recherche du CHUS, Université de Sherbrooke, Division of Urology, Dept. of Surgery, Sherbrooke, Canada, \(^3\)Hospital De Braga, Faculty of Medicine, University of Coimbra, CUF Dept. of Urology, Braga, Portugal, \(^4\)Princess Margaret Cancer Centre, University Health Network, University of Toronto, Division of Urology, Dept. of Surgery, Toronto, Canada

**Aims and objectives of this presentation**
PT041

**PT042**

**Do small tumor foci at biopsy predict the occurrence of adverse pathology in active surveillance patients?**

By: Al-Kailani Z.T.F., Niklas C., Siemer S., Stöckle M., Saar M.
Universitätsklinikum des Saarlandes, Dept. of Urology, Homburg, Germany

**Aims and objectives of this presentation**
PT042

**PT043**

**Active surveillance of men younger than 60: Assessment of differences in discontinuation and treatment choice in the Movember GAP3 Consortium**

By: Remmers S., Helleman J., Nieboer D., Bangma C.H., Roobol M.J., Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands
Aims and objectives of this presentation
PT043

PT044

Focal cryoablation reduces pathological progression of Gleason 6 prostate cancer compared to active surveillance

By: Ashrafi A.N. ¹, Tafuri A. ¹, Shakir A. ¹, Cacciamani G.E. ¹, Medina L. ¹, Park D. ¹, Bahn D. ², Gill I. ¹, Abreu A. ¹
¹University of Southern California, USC Institute of Urology, Los Angeles, United States of America, ²Community Memorial Hospital, Prostate Institute of America, Los Angeles, United States of America

Aims and objectives of this presentation
PT044

PT045

Comparative analysis of cryoablation, brachytherapy, HIFU and active surveillance: Oncological outcomes in low-risk prostate cancer

By: Taratkin M., Enikeev D., Rapoport L., Amosov A., Chinenov D., Krupinov G., Chernov Y., Glybochko P.
Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

Aims and objectives of this presentation
PT045

PT046

Comparison of oncologic outcomes in active surveillance between two prospective Afro-Caribbean and Caucasian French cohorts

By: Percot M. ¹, Robert G. ², Le Pailh J.P. ², Stempfer G. ¹, Blanchet P. ¹, Eyraud R. ¹
¹University Hospital Center, Dept. of Urology, Pointe à Pitre, France, ²University Hospital Center, Dept. of Urology, Bordeaux, France

Aims and objectives of this presentation
PT046

PT047

Active surveillance for low risk prostate cancer among men with high risk genetic predisposition

By: Halstuch D., Sela S., Ber Y., Kedar D., Daniel J., Margel D.
Rabin Medical Center, Dept. of Urology, Petah-Tikva, Israel

Aims and objectives of this presentation
PT047

PT048

Follow up of mostly Afro-Caribbean patients with prostate cancer under active surveillance

By: Stempfer G., Blanchet P., Brureau L., Gourtaud G., Roux V., Sénéchal C., Moureaux C., Seddik S., Percot M., Eyraud R.
PT050

Magnetic resonance imaging and ultrasound fusion biopsy in follow-up of patients in active surveillance protocol. Can PSA density discriminate patients at higher risk of reclassification?

By: Roscigno M. 1, Stabile A. 2, Lughezzani G. 3, Pepe P. 4, Dell’Atti L. 5, Nicolai M. 1, La Croce G. 1, Manica M. 1, Naselli A. 6, Guazzoni G. 7, Balzarini L. 8, Montorsi F. 9, Briganti A. 10, Sironi S. 11, Da Pozzo L.F. 12

1ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, 2Urological Research Institute, IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, Milan, Italy, 3Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, 4Cannizzaro Hospital, Dept. of Urology, Catania, Italy, 5University Hospital, Dept. of Urology, Ancona, Italy, 6Ospedale San Giuseppe, Gruppo Multimedica, Dept. of Urology, Milan, Italy, 7Humanitas Clinical and Research Center, Humanities University, Dept. of Urology, Rozzano, Italy, 8Humanitas Clinical and Research Center, Dept. of Radiology, Rozzano, Italy, 9Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute University, Unit of Urology/Division of Oncology, Milan, Italy, 10Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute University, Unit of Urology, Division of Oncology, Milan, Italy, 11School of Medicine, University of Milano-Bicocca, H. Papa Giovanni XXIII, Dept. of Radiology, Bergamo, Italy, 12School of Medicine, University of Milano-Bicocca, H. Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy

PT051

Danish nationwide results for active surveillance for localised prostate cancer

By: Thomsen F.B. 1, Jakobsen H. 2, Langkilde N.C. 3, Borre M. 4, Jakobsen E.B. 5, Frey A. 6, Lund L. 7, Lunden D. 8, Dahl C. 5, Helgstrand J.T. 1, Brasso K. 1

1Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, 2Herlev Hospital, Dept. of Urology, Copenhagen, Denmark, 3Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, 4Aarhus University Hospital Skejby, Dept. of Urology, Aarhus, Denmark, 5Zealand University Hospital, Dept. of Urology, Roskilde, Denmark, 6Sydvestjysk Sygehus, Dept. of Urology, Esbjerg, Denmark, 7Odense University Hospital, Dept. of Urology, Odense, Denmark, 8Hospitalshedenh Midt, Dept. of Urology, Viborg, Denmark

PT052

Molecular markers of grade progression in longitudinally tracked prostate cancer foci during active surveillance of low risk disease

By: Tosoian J. 1, Salami S. 1, Nallandhighal S. 1, Jones Jr T. 2, Plouffe K. 3, Elkhoury F. 2, Morgan T. 1, Liu C. 3, Kunju L. 3, Montgomery J. 1, Natarajan S. 2, Sisk Jr A. 4, Tomlins S. 3, Palapattu G. 1, Marks L. 2
Aims and objectives of this presentation
PT052

Magnetic resonance imaging alone should not be considered as a stand-alone test for disease reclassification of men in active surveillance


1ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, 2Urological Research Institute, IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, Milan, Italy, 3Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, 4Cannizzaro Hospital, Dept. of Urology, Catania, Italy, 5Polytechnic University of Marche Region, Dept. of Urology, Ancona, Italy, 6Ospedale San Giuseppe, Gruppo Multimedica, Dept. of Urology, Milan, Italy, 7Humanitas Clinical and Research Center, Dept. of Urology, Milan, Italy, 8Urological Research Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Oncology, Milan, Italy, 9Humanitas Clinical and Research Center, Dept. of Radiology, Rozzano, Italy, 10Urological Research Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Oncology, Milan, Italy, 11School of Medicine, University of Milano-Bicocca, Osp. Papa Giovanni XXIII, Dept. of Radiology, Bergamo, Italy, 12School of Medicine, University of Milano-Bicocca, Osp. Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy

Aims and objectives of this presentation
PT053

Upgrading in men with serial MRIs on active surveillance for low-risk prostate cancer: Are confirmatory biopsies still necessary?


1Erasmus University Medical Center, Dept. of Urology, Dept. of Radiology, Dept. of Nuclear Medicine, Rotterdam, The Netherlands, 2Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, 3Erasmus University Medical Center, Dept. of Radiology, Dept. of Nuclear Medicine, Rotterdam, The Netherlands

Aims and objectives of this presentation
PT054

Incremental utility of mp-MRI performed before confirmatory biopsy in reducing the risk of progression during active surveillance for men with low risk prostate cancer: Is imaging always useful?

By: Bandini M., Nocera L., Scarcella S., Suardi N., Gandaglia G., Fossati N.

1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 3Vienna General Hospital, Unit of Urology, Vienna, Austria, 4University of Naples Federico II, Unit of Urology, Naples, Italy, 5University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montréal, Canada

Aims and objectives of this presentation
PT055

Is a confirmatory biopsy still necessary in men considering active surveillance for low-risk prostate cancer in the multiparametric MRI era?

By: Fishelevitz A., Haskiya H., Kogan T., Buchler A., Keizman D., Dresler H., Leibovitch I., Sternberg I.

1Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, 2Meir Medical Center, Dept. of Radiology, Kfar Saba, Israel, 3Meir Medical Center, Dept. of Pathology, Kfar Saba, Israel, 4Meir Medical Center, Dept. of Oncology, Kfar Saba, Israel

Aims and objectives of this presentation
PT056

Is multiparametric MRI really helpful to predict upgrading and upstaging in active surveillance?

By: Kim H., Pak S., Kim M., Jeong I.G., Song C., Hong J.H., Kim C.S., Ahn H.

Asan Medical Center, Dept. of Urology, Seoul, South Korea

Aims and objectives of this presentation
PT057
**Poster Session 10**

**Friday 15 March**

**12:30 - 14:00**

**Location:** Green Area, Room 1

**Chairs:** To be confirmed
- G.R. Kasyan, Moscow (RU)
- M. Tutolo, Milan (IT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

### 135

**10-year follow-up study on long-term intravesical botulinum toxin A injections efficacy for overactive bladder treatment**

By: **Ragab M.**, Yang B., Guy P., Davies M.
Salisbury District Hospital, Dept. of Urology, Salisbury, United Kingdom

### 125

**In females with overactive bladder, an alternative injection paradigm for onabotulinumtoxinA is associated with low clean intermittent catheterisation use**


1. Alliance Urology Specialists, Dept. of Urology, Greensboro, United States of America,
2. Virginia Urology, Dept. of Urology, Emporia, United States of America,
3. Chesapeake Urology, Dept. of Urology, Owings Mills, United States of America,
4. Eastern Virginia Medical School, Dept. of Urology, Virginia Beach, United States of America,
5. Adult Pediatric Urology, Dept. of Urology, Omaha, United States of America,
6. Center for Pelvic Health, Female Pelvic Medicine & Reconstructive Surgery, Franklin, United States of America,
7. Allergan plc, Dept. of Urology, Irvine, United States of America,
8. Allergan plc, Biostatistics, Madison, United States of America,
9. Allergan plc, Medical Safety, Madison, United States of America,
10. Allergan plc, Medical Affairs (Neurology and Urology), Marlow, United Kingdom

### 126

**Intradetrusor botulinum toxin administration under local anaesthesia: A prospective, randomized trial comparing two different anaesthesia protocols**

By: **Borges Da Ponte C.**, Pereira E. Silva R.M., Pinto Pe Leve P.J., Sousa Guimarães De Castro A., Palma Dos Reis J.M., Matos Lopes T.M.
Centro Hospitalar Lisboa Norte, Dept. of Urology, Lisbon, Portugal

### 127

**Intra-urethral lidocaine gel versus intravesical alkalinized lidocaine as anaesthesia in the ambulatory intradetrusor injection of botulinum toxin (BoNTA): A prospective study**
128 Delivery of intravesical botulinum toxin A using low energy shock waves in treatment of overactive bladder: A phase II self-controlled feasibility study

By: Nageib M., El-Hefnawy A.S., Zahran M.H., El-Tabey N.A., Sheir K.Z., Shokeir A.A. Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt

129 Randomized prospective trial comparing uni- and bilateral sacral neuromodulation tests in the treatment of refractory idiopathic overactive bladder


1 Nimes University Hospital, Dept. of Urology, Nimes, France, 2 Nimes University Hospital, Dept. of Biostatistics, Nimes, France, 3 Nantes University Hospital, Dept. of Urology, Nantes, France, 4 Beausoleil Clinic, Dept. of Urology, Montpellier, France, 5 Toulouse University Hospital, Dept. of Urology, Toulouse, France, 6 Rouen University Hospital, Dept. of Urology, Rouen, France

130 Sacral neuromodulation: A comparison of office test stimulation vs. staged implant

By: Badin Castro J., Abello A., Das A.K.

1 Beth Israel Deaconess Medical Center, Dept. of Surgery and Urology, Boston, United States of America, 2 Yale School of Medicine, Dept. of Urology, New Haven, United States of America

131 InterStim™ Sacral Neuromodulation for intractable urinary voiding dysfunctions (SOUNDS): Results of clinical effectiveness, quality of life, patient-reported outcomes and safety in a French multicenter observational study


1 Academic Hospital Pitié-Salpêtrière Paris, Dept. of Urology, Paris, France, 2 CH Lyon Sud, Dept. of Urology, Lyon, France, 3 CHU de Nantes - Hôtel Dieu, Dept. of Urology, Nantes, France, 4 CHU de Rouen – Hôpital Charles Nicolle, Dept. of Urology, Rouen, France, 5 Medtronic Intl Sàrl, Dept. of Clinical RTG implantable therapies, Tolochenaz, Switzerland

132 Subjective and objective scales assessment after retreatment with anticholinergics post botox-faded effects in refractory idiopathic overactive bladder: A prospective single blinded randomized trial

By: Elbaset M., Taha D., Zahran M., Ezzat O., El-Hefnawy A.S., Elkenawy M., Shokier
Patient satisfaction with sacral neuromodulation therapy for lower urinary tract dysfunction and factors affecting therapy satisfaction: A single-center survey

By: Banakhar M. 1, Hassouna M. 2
1King Abdulaziz University Hospital, Dept. of Urology, Jeddah, Saudi Arabia, 2Toronto Western Hospital, Dept. of Urology, Toronto, Canada

Is botulinum toxin A an effective treatment in patients following radiotherapy?

By: Toia B., Pakzad M., Hamid R., Greenwell T., Ockrim J.
University College Hospital London, Dept. of Urology, London, United Kingdom

Treatment outcomes of patients with overactive bladder with or without uninhibited bladder contraction following selective bladder denervation

By: Brière R. 1, Richard P. 2, Gratton M. 3, Tu L.M 2
1Laval University, Quebec, Canada, 2Sherbrooke University, Dept. of Urology, Sherbrooke, Canada, 3Laval University, Dept. of Urology, Quebec, Canada

A multinational real-world study of onabotulinumtoxinA in patients with overactive bladder demonstrates reduction in urinary symptoms and an improvement in quality of life along with a reduction in reliance on incontinence products

By: Hamid R. 1, Lorenzo-Gomez M-F. 2, Schulte-Baukloh H. 3, Boroujerdi A. 4, Patel A. 5, Farrelly E. 6
1University College London Hospitals, Dept. of Urology, London, United Kingdom, 2University Hospital of Salamanca, Dept. of Urology, Salamanca, Spain, 3St. Hedwig-Krankenhaus, Dept. of Urology, Berlin, Germany, 4Allergan plc, Dept. of Urology, Irvine, CA, United States of America, 5Allergan plc, Dept. of Medical Affairs, Neurology and Urology, Marlow, United Kingdom, 6Södersjukhuset, Stockholm South General Hospital, Dept. of Urology, Stockholm, Sweden

State-of-the-art lecture Botox versus SNM: The verdict

M. Tutolo, Milan (IT)
Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

Urology beyond Europe

Friday 15 March 12:30 - 15:45

Location: Green Area, Room 3

S.K. Hong, Sungnam (KR)
A. Stenzl, Tübingen (DE)

Aims and objectives of this session
With the help of specialists and key opinion leaders an up to date approach to urothelial cancer, benign prostatic enlargement, imaging in prostate cancer, and the role of cytoreductive nephrectomy will be outlined for both regions. Common approaches as well as regional differences will discussed with state of the art lectures, and panel and case based discussions to understand their reasoning.

12:30 - 12:35
Welcome and introduction
K-S. Lee, Seoul (KR)
A. Stenzl, Tübingen (DE)

12:35 - 13:20
Urothelial cancer
Moderators: Y.G. Lee, Seoul (KR)
R. Seiler, Bern (CH)

12:35 - 12:45
Current concept of en-block resection in Muscle Invasive Bladder Cancer (MIBC)
H.K. Seo, Goyang-si, (KR)

12:45 - 12:50
Questions and answers

12:50 - 13:00
Molecular markers: Where is the clinical application?
R. Seiler, Bern (CH)

13:00 - 13:05
Questions and answers

13:05 - 13:15
Is it necessary of ureteroscopy for Upper Tract Urothelial Carcinoma (UTUC)
S.H. Kang, Seoul (KR)

13:15 - 13:20
Questions and answers

13:20 - 13:40
Benign Prostatic Hyperplasia (BPH) - current alternatives
Moderators: S. Gravas, Larissa (GR)
K-S. Lee, Seoul (KR)

13:20 - 13:30
Current EAU guidelines on BPH
S. Gravas, Larissa (GR)
13:30 - 13:35 Questions and answers

13:35 - 13:45 Current practice on BPH in South Korea
D.K. Kim, Daejeon (KR)

13:45 - 13:50 Questions and answers

13:50 - 14:00 Anatomical endoscopic enucleation of prostate
C.M. Scoffone, Turin (IT)

14:00 - 14:05 Questions and answers

14:05 - 14:15 Postoperative management of enucleation procedures of prostate
S.Y. Cho, Seoul (KR)

14:15 - 14:20 Questions and answers

14:20 - 15:05 Imaging in prostate cancer
Moderators: J. Cheon, Seoul (KR)
J. Walz, Marseille (FR)

14:20 - 14:30 Does negative MRI really mean no cancer?
S.K. Hong, Sungnam (KR)

14:30 - 14:35 Questions and answers

14:35 - 14:45 Prostate imaging: Ultra-sensitive ultrasound versus mp MRI
J. Walz, Marseille (FR)

14:45 - 14:50 Questions and answers

14:50 - 15:00 Past, present and future of PI-RADS in prostate cancer
S.H. Choi, Daegu (KR)

15:00 - 15:05 Questions and answers

15:05 - 15:25 Case discussion: MR Fusion biopsy in real practice
Panel: S-S. Byun, Seongnam (KR)
F.K.-H. Chun, Frankfurt (DE)
J.H. Hong, Seoul (KR)
C. Kastner, Cambridge (GB)
D.D. Kwon, Gwangju (KR)
J. Walz, Marseille (FR)
Case presenter: H.K. Ha, Busan (KR)

15:25 - 15:45 Debate: Role of cytoreductive nephrectomy in the era of immunotherapy in Renal Cell Carcinoma (RCC)
Moderators: A. Bex, Amsterdam (NL)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:25 - 15:30</td>
<td>Pro</td>
</tr>
<tr>
<td></td>
<td>A. Bex, Amsterdam (NL)</td>
</tr>
<tr>
<td>15:30 - 15:35</td>
<td>Con</td>
</tr>
<tr>
<td></td>
<td>S.I. Seo, Seoul (KR)</td>
</tr>
<tr>
<td>15:35 - 15:45</td>
<td>Questions and answers</td>
</tr>
</tbody>
</table>

Scientific Programme - EAU19 Barcelona

By: Abufaraj M. ¹, Yang L. ², Waldhoer T. ², Seitz C. ¹, Özsoy M. ¹, D’Andrea D. ¹, Briganti A. ³, Schernhammer E. ⁴, Shariat S. ¹
¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Medical University of Vienna, Dept. of Epidemiology, Vienna, Austria, ³IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁴Harvard T.H Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America

Aims and objectives of this presentation

138

Urinary stone disease in Germany – trends from federal hospital episode statistics

By: Heers H. ¹, Stay D. ², Hofmann R. ¹, Hegele A. ¹, Keil C. ¹, Wiesmann T. ²
¹Philipps-Universität Marburg, Dept. of Urology and Paediatric Urology, Marburg, Germany, ²Philipps-Universität Marburg, Dept. of Anaesthesiology and Intensive Care Medicine, Marburg, Germany

Aims and objectives of this presentation

139

Factors predicting the failure of spontaneous passage by patients of small ureteric stones ≤3 mm

Chungbuk National University, Dept. of Urology, Cheongju, South Korea

Aims and objectives of this presentation

140

Renal colic during pregnancy: Predictors of ureteral stones

By: Lourenco D., Partezani A.D., Amaral B.S., Teles S.B., Barbosa A.R., Kayano P.P., Korkes F.
Aims and objectives of this presentation
141

**Can hyperoxaluria cause kidney damage in women with recurrent pyelonephritis?**

By: Stepanova N., Kolesnyk M., Driianska V., Korol L.
Institute of Nephrology of the National Academy of Medical Sciences, Nephrology and Dialysis, Kyiv, Ukraine

Aims and objectives of this presentation
142

**Reducing delay in care for patients with obstructing stones: Results from an accelerated pathway**

By: Matanhelia M., Simmons L., Jelski J., Albuheissi S., Timoney A., Philip J.
Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom

Aims and objectives of this presentation
143

**Percutaneous nephrostomy vs ureteral stent for hydronephrosis secondary to ureteric calculi: Impact on spontaneous stone passage and health-related quality of life – a prospective study**

By: De Sousa Morais N.A., Pereira J.P., Mota P., Carvalho-Dias E., Torres J.N., Cordeiro A., Anacleto S., Lima E.
¹Hospital de Braga, Dept. of Urology, Braga, Portugal, ²Minho University, School of Medicine, Braga, Portugal

Aims and objectives of this presentation
144

**Efficacy and safety of complete intra-ureteral stent placement versus conventional stent placement in relieving ureteral stent-related symptoms: A randomized, prospective, single-blinded, multicenter clinical trial**

By: Yoshida T., Inoue T., Taguchi M., Matsuzaki T., Murota T., Kinoshita H., Matsuda T.
Kansai medical university, Dept. of Urology, Osaka, Japan

Aims and objectives of this presentation
145

**Randomized clinical trial on urinary pH monitoring and nutraceutical intervention in the prevention of ureteral stent calcification**

By: Fernandez-Concha Schwalb J., Torrecilla Ortiz C., Cansino Alcaide J.R.
Aims and objectives of this presentation

Efficacy of a novel, single-use digital flexible cystoscope for double J removal: A multicentric study

By: Oderda M., Fasolis G., Doizi S., Gontero P.

Città della Salute e della Scienza, Dept. of Urology, Turin, Italy, Alba Hospital, Dept. of Urology, Alba, Italy, Tenon Hospital, Dept. of Urology, Paris, France

Aims and objectives of this presentation

New persistent opioid use after ureteroscopy for stone treatment

By: Tam C., Yan P., Raisky J., Gunaseelan V., Kim T., Leavitt D., Dauw C., Hollingsworth J.M.

University of Michigan Medical School, Dept. of Urology, Ann Arbor, United States of America, Henry Ford Health System, Dept. of Urology, Detroit, United States of America

Aims and objectives of this presentation

Effects of silicone hydrocoated double loop ureteral stent (DJ) on symptoms and quality of life in patients undergoing F-URS for kidney stone: Final results of a prospective randomized multicentre clinical study

By: Traxer O., Letendre J., Cloutier J., Daudon M., Kleinclauss F., Doizi S., Wiseman O.

Sorbonne University, GRC Urolithiasis no.20, Hospital Tenon, Dept. of Urology, Paris, France, Hôpital Maisonneuve-Rosemont Montreal, Dept. of Urology, Montreal, Canada, CHU de Quebec, Dept. of Urology, Quebec, Canada, Tenon Hospital, Dept. of Urology, Paris, France, CHRU Besancon, Dept. of Urology, Besancon, France, Cambridge University Hospitals NHS Trust, Dept. of Urology, Cambridge, United Kingdom

Aims and objectives of this presentation
150  
**Comparison of 4.8 Fr and 6 Fr ureteral stents on stent related symptoms following ureterorenoscopy: A prospective randomized controlled trial**

By: Cubuk A.¹, Yanaral F.², Ozgor F.², Savun M.², Ozdemir H.², Erbin A.², Yuksel B.³, Sarilar O.²  
¹Kartal Dr. Lütfi Kırdar Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ²Haseki Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ³Esenler Maternity and Children Hospital, Obstetrics and Gynecology, Istanbul, Turkey

**Aims and objectives of this presentation**
150

151  
**Development and validation of a disease specific renal stone patient reported outcome measure (PROM)**

By: Ragab M.¹, Collie J.², Baldin N.³, Tran M.⁴, Armitage J.², Al Hayek S.², Wiseman O.²  
¹Salisbury District Hospital, Dept. of Urology, Salisbury, United Kingdom, ²Cambridge University Hospital, Dept. of Urology, Cambridge, United Kingdom, ³University of Cambridge, Dept. of Pure Mathematics and Mathematical Statistics, Cambridge, United Kingdom, ⁴Royal Free Hospital, Dept. of Urology, London, United Kingdom

**Aims and objectives of this presentation**
151

152  
**Effect of payer status and index care setting on 30-day revisit following elective surgery for nephroureterolithiasis**

By: Friedlander D.F., Krimphove M.J., Cole A.P., Marchese M., Ortega G., Trinh Q-D.  
Brigham and Women’s Hospital, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America

**Aims and objectives of this presentation**
152
Individualising prostate cancer treatment decision-making

Poster Session 12

Friday 15 March
12:30 - 14:00

Location: Green Area, Room 5

Chairs: S. Boxler, Bern (CH)
S. Loeb, New York (US)
H.U. Uemura, Osaka (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

Added value of concomitant systematic biopsies in predicting upgrading in patients with localized prostate cancer diagnosed by MRI-targeted biopsy: Implications for treatment selection

By: Gandaglia G. 1, Ploussard G. 2, Valerio M. 3, Mattei A. 4, Fiori C. 5, Fossati N. 1, Stabile A. 1, Beauval J. 6, Malavaud B. 6, Roumigué M. 6, Robesti D. 7, Dell’Oglio P. 1, Dehò F. 1, Capitario U. 1, Moschini M. 4, Zamboni S. 4, Rakauskas A. 3, De Cobelli F. 8, Porpiglia F. 5, Montorsi F. 1, Barletta F. 9, Briganti A. 1

1IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, Milan, Italy, 2Saint Jean Languedoc/La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, 3Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, 4Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 5San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, 6CHU Rangueil, Dept. of Urology, Andrology and Renal Transplantation, Toulouse, France, 7IRCCS Ospedale San Raffaele, Unit of Urology: Division of Oncology, Milan, Italy, 8IRCCS Ospedale San Raffaele, Unit of Clinical Research in Radiology, Experimental Imaging Center, Milan, Italy, 9IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation

---

Impact of introducing pre-biopsy multi-parametric MRI on presenting grade group and prognostic categories of newly diagnosed prostate cancers


1University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, 2Cambridge University Hospitals Trust, Dept. of Urology, Cambridge, United Kingdom, 3Cambridge University Hospitals Trust, Dept. of Radiology, Cambridge, United Kingdom, 4Cambridge University Hospitals Trust, Dept. of Pathology, Cambridge, United Kingdom, 5Oxford University Hospitals NHS Foundation Trust, Dept. of Urology, Oxford, United Kingdom, 6Oxford University Hospitals NHS Foundation Trust, Dept. of Radiology, Oxford, United Kingdom, 7University of Oxford, Nuffield Department of Surgical Sciences, Oxford,
154

**Changes in Gleason score misclassification between diagnostic biopsies and radical prostatectomy specimens – a nationwide analysis**

By: Helgstrand J.T. 1, Røder M.A. 1, Klemann N. 1, Kawa S.M. 1, Toft B.G. 2, Brasso K. 1

1Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, 2Copenhagen University Hospital, Rigshospitalet, Dept. of Pathology, Copenhagen, Denmark

Aims and objectives of this presentation

155

156

**Using machine learning tools to predict prostate cancer upgrading after robotic radical prostatectomy**


1Università degli studi di Trieste, Dept. of Urology, Trieste, Italy, 2Ospedale Sant Andrea, University La Sapienza, Dept. of Urology, Rome, Italy, 3Ospedale di Latina, Dept. of Urology, Rome, Italy, 4Aindo EU, s.r.l.s., Dept. of Urology, Trieste, Italy, 5Sant'Andrea Hospital-, Dept. of Urology, Rome, Italy, 6Queen Elisabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, 7St Antonius Hospital, Urology, Dept. of Urology, Pediatric Urology and Urological Oncology, Gronau, Germany

Aims and objectives of this presentation

156

157

**Hybrid PSMA PET/MRI for primary staging in presumed localised prostate cancer: A contemporary, tertiary hospital series**


1University of Queensland, School of Medicine, Brisbane, Australia, 2Princess Alexandra Hospital, Dept. of Urology, Brisbane, Australia, 3Princess Alexandra Hospital, Dept. of Radiology, Brisbane, Australia

Aims and objectives of this presentation

157

159

**Diagnostic efficacy of 18F-rhPSMA7 positron emission tomography for lymph node staging in patients with high-risk primary prostate cancer**
Aims and objectives of this presentation

159

The AJCC 8th edition no longer substages pT2 prostate cancer: Does extent of tumor involvement not matter?

By: Pompe R.S. 1, Preisser F. 2, Leyh-Bannurah S. 3, Gild P. 3, Salomon G. 1, Graefen M. 1, Fisch M. 3, Huland H. 1, Tilki D. 1

1 University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, 2 University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 3 University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

Aims and objectives of this presentation

161

Rare histological variants of prostate adenocarcinoma (PCa): A National Cancer Database (NCDB) analysis


Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America

Aims and objectives of this presentation

162

Tumor locations in the prostate gland affect the incidence, clinicopathological features and prognosis of prostate cancer

By: Akatsuka J. 1, Kimura G. 1, Obayashi K. 1, Mikami H. 1, Sano M. 1, Yanagi M. 1, Takeda H. 1, Matsuzawa I. 1, Suzuki Y. 1, Hamasaki T. 1, Yamamoto Y. 2, Kondo Y. 1

1 Nippon Medical School Hospital, Dept. of Urology, Tokyo, Japan, 2 RIKEN Center for Advanced Intelligence Project, Pathology Informatics Team, Tokyo, Japan

Aims and objectives of this presentation

163

External validation of the PREDICT Prostate tool for prognostication in non-metastatic prostate cancer: A study in 69,206 men from prostate cancer data base Sweden
Aims and objectives of this presentation

164

Understanding of prognosis in non-metastatic prostate cancer: A randomised comparative study of clinician estimates measured against the PREDICT prostate tool

By: Thurtle D.¹, Jenkins V.², Pharoah P.D.³, Gnanapragasam V.J.¹
¹University of Cambridge, Academic Urology Group, Dept. of Surgery, Cambridge, United Kingdom, ²University of Sussex, Sussex Health Outcomes Research in Cancer, Brighton, United Kingdom, ³University of Cambridge, Dept. of Cancer Epidemiology, Cambridge, United Kingdom

Aims and objectives of this presentation

165

A multilayer perceptron artificial neural network model for predicting survival of patients with prostate cancer according to initial treatment strategy: Development of a web-based clinical decision support system

By: Koo K.C.¹, Min G.R.¹, Kim J.¹, Park J.S.¹, Kim J.W.¹, Ahn H.K.¹, Min M.², Kim J.², Chung B.H.¹
¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Selvas Artificial Intelligence, ML Research Team, Seoul, South Korea

Aims and objectives of this presentation

166

Development and external validation of a novel risk score to predict long-term clinical recurrence after radical prostatectomy

By: Mazzone E.¹, Gandaglia G.², Knipper S.³, Graefen M.³, Tilki D.³, Rosiello G.², Fallara G.², Bandini M.², Stabile A.², Bravi C.A.², Dell'Oglio P.², Fossati N.², Montorsi F.², Briganti A.²
¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology URI, Milan, Italy, ²IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, ³Martini Klinik, University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

Aims and objectives of this presentation

167
Urothelial cancer and bladder reconstruction

Video Session 03

Location: Green Area, Room 10

Chairs: J.W. Collins, Stockholm (SE)
To be confirmed
J.D. Kelly, London (GB)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V17

High resolution micro-ultrasound imaging for bladder cancer: A gender and stage-oriented assessment


1Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy,
2Humanitas San Pio X Hospital, Dept. of Urology, Milan, Italy,
3Humanitas Clinical and Research Center, Dept. of Pathology, Rozzano, Italy

Aims and objectives of this presentation

V18

Total retroperitoneoscopic nephroureterectomy with modified pluck technique: Initial experience

By: Izumi K., Kawanishi Y., Yamanaka M., Kawanishi S., Fukawa T., Kanayama H.

1Takamatsu Red Cross Hospital, Dept. of Urology, Takamatsu, Japan,
2Goshikidai Clinic, Dept. of Psychiatry, Takamatsu, Japan,
3Tokushima University, Dept. of Urology, Tokushima, Japan

Aims and objectives of this presentation

V19

Ten commandments of intracorporeal ileal conduit during robot assisted radical cystectomy

By: Narain T.A., Mavuduru R., Bora G., Tyagi S., Mandal A.K.
Post Graduate Institute of Medical Education and Research, Dept. of Urology, Chandigarh, India

Aims and objectives of this presentation
| V20 | Efficiency of the Firefly® system for mesenteric vessel identification during total intracorporeal urinary diversion following radical cystectomy using the DaVinci Xi robot |
|     | By: Jeglinschi S. , Carlier M. , Denimal L. , Chevallier D. , Tibi B. , Durand M. , Ahallal Y. University Hospital of Nice, Dept. of Urology, Nice, France |
|     | Aims and objectives of this presentation |

| V21 | Sex-sparing vs standard robot-assisted radical cystectomy with intracorporeal Padua ileal neobladder in female: Step-by-step surgical technique, perioperative, oncological and functional outcomes |
|     | By: Tuderti G. , Mastroianni R. , Flammia R.S. , Guaglianone S. , Minisola F. , Anceschi U. , Brassetti A. , Ferriero M. , Gallucci M. , Simone G. Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy |
|     | Aims and objectives of this presentation |

| V22 | Robotic radical cystectomy with “en bloc” extended lymphadenectomy and intracorporeal orthotopic neo bladder: An innovative and reproducible technique |
|     | By: Fakhfakh S. , Hoepffner J.L , Brillac N.B , Piechaud T. , Gaston R.P. Saint Augustin Clinic, Dept. of Urology, Bordeaux, France |
|     | Aims and objectives of this presentation |

| V23 | Robot-assisted radical cystectomy and hybrid neobladder reconstruction with the aid of GelPOINT device: Technical nuances and preliminary results |
|     | ¹AOUC Azienda Ospedaliero-Universitaria Careggi, Dept. of Urology, Florence, Italy, ²Aou Careggi, Dept. of Urology, Florence, Italy |
|     | Aims and objectives of this presentation |
Novel technology and techniques in urothelial cancer diagnosis

**Poster Session 13**

**Friday 15 March**
12:30 - 14:00

**Location:** Green Area, Room 11

**Chairs:**
- Y. Fujii, Tokyo (JP)
- M. Kramer, Lübeck (DE)
- M. Moschini, Luzern (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**168**

**Ex vivo fluorescence confocal microscopy in the assessment of urothelial carcinoma grading in bladder and ureter: Our preliminary experience**

By: Puliatti S.¹, Eissa A.², Bevilacqua L.¹, Pellacani G.³, Sighinolfi M.C.¹, Azzoni P.⁴, Bertoni L.⁴, Reggiani Bonetti L.⁵, Elsherbiny A.², Micali S.⁶, Patel V.⁷, Rocco B.M.C.¹, Bianchi G.¹

¹University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ²Tanta University, Dept. of Urology, Faculty of Medicine, Tanta, Egypt, ³University of Modena and Reggio Emilia, Dept. of Dermatology, Modena, Italy, ⁴University of Modena and Reggio Emilia, Dept. of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, Modena, Italy, ⁵University of Modena and Reggio Emilia, Dept. of Pathology, Modena, Italy, ⁶University of Modena & Reggio Emilia, Dept. of Urology, Modena, Italy, ⁷Global Robotics Institute, Florida Hospital-Celebration Health Celebration, Dept. of Urology, Florida, United States of America

**Aims and objectives of this presentation**

---

**169**

**Stepwise transfer learning in convolutional neural networks for the cystoscopic diagnosis of bladder cancer using gastroscopic images**

By: Ikeda A.¹, Nosato H.², Kojima T.¹, Kawai K.¹, Kochi Y.², Sakanaishi H.², Murakawa M.², Tada T.³, Nishiyama H.¹

¹University of Tsukuba, Dept. of Urology, Faculty of Medicine, Tsukuba, Japan, ²National Institute of Advanced Industrial Science and Technology, Artificial Intelligence Research Center, Tsukuba, Japan, ³Tada Tomohiro Institute of Gastroenterology and Proctology, Dept. of Gastroenterology and Proctology, Saitama, Japan

**Aims and objectives of this presentation**

---

**170**

**IDENTIFY: The Investigation and DEtection of urological Neoplasia in paTients reFerred with suspected urinarY tract cancer: A multicentre analysis**
Aims and objectives of this presentation

Clinical study on circulating tumor cells for diagnosis and prognosis of patients with bladder cancer

The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, Jiangsu, China

Aims and objectives of this presentation

The pathological and clinical response of molecular subtype of muscle-invasive bladder cancer to neoadjuvant chemotherapy

By: Zhang R., Chen H., Huang Y., Xue W., Li C., Zhuang G., Allory Y., Radvanyi F.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China, Institute of Biophysics, Chinese Academy of Sciences, Laboratory Animal Center, Protein Science core facility center, Beijing, China, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Shanghai, China, Hôpitaux Universitaires Henri-Mondor, Dept. of Pathology, Créteil, France, Institut Curie, Centre de Recherche, CNRS, Paris, France

Aims and objectives of this presentation

Predictive value and potentials for co-targeted therapy of STAT1 signaling in gemcitabine/cisplatin resistant bladder cancer

Hiroshima University, Dept. of Urology, Hiroshima, Japan, Vancouver Prostate Centre,
The impact of hormones and reproductive factors on the risk of bladder cancer in women: Results from nurses' health study and nurses' health study II

By: Abufaraj M. 1, Shariat S. 1, Moschini M. 1, Markt S. 2, Zhang H. 3, Schernhammer E. 4, Nurses’ Health Study group (NHS)

1 Medical university of Vienna, Dept. of Urology, Vienna, Austria, 2 Case Western Reserve University School of Medicine, Dept. of Population and Quantitative Health Sciences, Cleveland, United States of America, 3 Harvard Medical School, Channing Division of Network Medicine, Boston, United States of America, 4 Harvard T.H Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America

Survival differences between men and women with bladder cancer depend strongly on time since diagnosis


1 Netherlands Comprehensive Cancer Organisation, Dept. of Research, Utrecht, The Netherlands, 2 Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, 3 Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, 4 Radboud University Medical Center, Dept. for Health Evidence, Dept. of Urology, Nijmegen, The Netherlands, 5 Radboud Institute for Health Sciences, Nijmegen, The Netherlands; Netherlands Comprehensive Cancer Organisation, Dept. of Research, Utrecht, The Netherlands

The pathological diagnostic convenience and accuracy of en-bloc TUR specimen: Analysis of 10 pathologists

By: Yanagiswawa T. 1, Yorozu T. 2, Sano T. 1, Otsuka T. 1, Enei Y. 1, Iwatani K. 1, Kobayashi D. 1, Tanaka S. 1, Obayashi K. 1, Sato S. 2, Kimura T. 3, Takahashi H. 2, Egawa S. 3

1 Jikei University Kashiwa Hospital, Dept. of Urology, Kashiwa, Japan, 2 Jikei University School of Medicine, Dept. of Pathology, Tokyo, Japan, 3 Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan

Multimodal fiber optic spectroscopy can successfully and rapidly discriminate between high and low grade urothelial cancer and provide valid tumor stage
Aims and objectives of this presentation

178

Prediction of muscle invasive bladder cancer using the Vesical Imaging-Reporting and Data System and apparent diffusion coefficient values (VI-RADS/ADC)

By: Sakamoto K., Ito M., Nakanishi Y., Kataoka M., Suzuki H., Takemura K., Tobisu K., Koga F.
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

179

Assessing the proposed confocal laser endomicroscopy criteria for grading of upper tract urothelial carcinoma

1Amsterdam UMC, University of Amsterdam, Dept. of Urology, Amsterdam, The Netherlands, 2Amsterdam UMC, University of Amsterdam, Dept. of Pathology, Amsterdam, The Netherlands, 3Istanbul Medipol University, Dept. of Urology, Istanbul, Turkey, 4Amsterdam UMC, University of Amsterdam, Dept. of Biomedical Engineering & Physics and Dept. of Urology, Amsterdam, The Netherlands

Aims and objectives of this presentation

180

A randomized controlled trial of a modified cystoscopy technique to decrease patient's pain and anxiety

By: Hetou K., Li Gan A.M., Izawa J., Chin J.L., Power N.E.
University of Western Ontario, Dept. of Urology, London, Canada

Aims and objectives of this presentation

181

Development and external validation of the haematuria cancer risk score to identify patient at risk of harbouring cancer

Aims and objectives of this presentation

182
Meeting of the Young Academic Urologists (YAU)

Location: Green Area, Room 12
Chair: M.S. Silay, Istanbul (TR)

Aims and objectives of this session
The Young Academic Urologists (YAU) is a group of talented and already renowned European young urologists. We aim to promote high-quality studies in order to provide strong evidence for the best urological practice. In this session both scientific and educational context will be discussed among the members of YAU and the leaders of European Urology.

12:30 - 13:10
EAU Young Academic Urologists (YAU) and improving science
Moderators: J.P.M. Sedelaar, Nijmegen (NL)
M.S. Silay, Istanbul (TR)
A. Stenzl, Tübingen (DE)

12:30 - 12:40
Young Academic Urologists: Overview of the scientific activities and future perspectives
M.S. Silay, Istanbul (TR)

12:40 - 12:50
Overview of the Non-Oncology groups achievements
B. Haid, Linz (AT)

12:50 - 13:00
Overview of the Oncology and Technology group achievements
D. Veneziano, Reggio Calabria (IT)

13:00 - 13:10
EAU Scientific Office and scientific contribution of YAU members in EAU meetings
A. Stenzl, Tübingen (DE)

13:10 - 13:15
YAU Awards

13:10 - 13:15
Best paper published in 2018 by a YAU group

13:10 - 13:15
Best poster presented at EAU 2019 by a YAU group

13:10 - 13:15
Reviewer of the year from YAU

13:15 - 14:15
Step by step: How do I get funded for my research?
Moderators: A.S. Bjartell, Malmö (SE)
G. Ploussard, Toulouse (FR)
E. Xylinas, Paris (FR)

13:15 - 13:25
How I developed a research which was funded by EAU Research Foundation
M. Albersen, Leuven (BE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:35 - 13:45</td>
<td>Criticism of the research project of YAU-RCC group</td>
<td>A.S. Bjartell, Malmö (SE)</td>
</tr>
<tr>
<td>13:45 - 13:55</td>
<td>Research proposal by YAU-Men’s Health group: Li-SWT for penile rehabilitation after radical prostatectomy: a prospective, multi-center, randomized, sham-controlled study</td>
<td>P. Capogrosso, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Verze, Naples (IT)</td>
</tr>
<tr>
<td>13:55 - 14:05</td>
<td>Criticism of the research project of Men’s Health group</td>
<td>A.S. Bjartell, Malmö (SE)</td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>How to conduct a prospective collaborative research? Examples from BURST</td>
<td>V. Kasivisvanathan, London (GB)</td>
</tr>
<tr>
<td>14:15 - 15:15</td>
<td>Challenge the expert</td>
<td>U. Capitanio, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Verze, Naples (IT)</td>
</tr>
<tr>
<td>14:15 - 14:35</td>
<td>Ejaculation-sparing approaches in LUTS-BPH surgery: from ‘laser’ to ‘water’</td>
<td></td>
</tr>
<tr>
<td>14:35 - 14:55</td>
<td>Slings versus artificial urinary sphincter for urinary incontinence after radical prostatectomy</td>
<td></td>
</tr>
<tr>
<td>14:55 - 15:15</td>
<td>Primary urethral realignment versus suprapubic catheter for posterior urethral (traumatic) injuries</td>
<td></td>
</tr>
<tr>
<td>15:15 - 16:15</td>
<td>Key studies of the year</td>
<td>G. De Naeyer, Aalst (BE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Kallidonis, Patras (GR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T.A.T. Marcelissen, Maastricht (NL)</td>
</tr>
<tr>
<td>15:35 - 15:55</td>
<td>Local treatment in oligometastatic disease (STAMPEDE and HORRAD trials)</td>
<td></td>
</tr>
<tr>
<td>15:55 - 16:15</td>
<td>Development and validation of a risk-prediction nomogram for patients with ureteral calculi associated with urosepsis: A retrospective analysis</td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:20</td>
<td>Introduction YUO Leadership Course</td>
<td>H. Rijksen, Maarsbergen (NL)</td>
</tr>
</tbody>
</table>
**Joint Session of the European Association of Urology (EAU) and the Urological Society of Australia and New Zealand (USANZ)**

**Urology beyond Europe**

**Friday 15 March 12:30 - 15:15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:30 - 12:35 | Welcome and introduction  
P. Heathcote, Sydney (AU)  
M. Wirth, Dresden (DE) |
| 12:35 - 12:50 | Practice patterns of female urologists in Australia and New Zealand: Do we need to know?  
L. Johns Putra, Ballarat (AU) |
| 12:50 - 12:55 | Discussion |
| 12:55 - 13:10 | Female to male gender reassignment surgery Australia: Early experience and outcome  
H. Goossen, Upper Mount Gravatt (AU) |
| 13:10 - 13:15 | Discussion |
| 13:15 - 13:30 | Nightmare of urology: Iatrogenic ureteric fistulas – what is the best management of care?  
S. Propping, Dresden (DE) |
| 13:30 - 13:35 | Discussion |

**Aims and objectives of this session**

In this Joint Session of the European Association of Urology and the Urological Society of Australia and New Zealand Practice patterns in the different regions of the world will be presented and discussed.

The session itself includes different urological topics starting with gender reassignment surgery in Australia and treatment of iatrogenic ureteric fistulas today. LUTS and treatment of benign prostate hyperplasia is another topic which will be currently discussed.

News in medical and surgery treatment modalities will be presented. Modern Stone treatment and the limits of Mini-PNL is another important topic in a country like Australia with a quite hot temperature. The session will be concluded by topics in prostate cancer regarding especially new imaging techniques and diagnosis of the local tumour and in metastasis.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:35 - 13:50| Controversy to Consensus: The development of national Australian guidelines for PSA testing - Early Management of test detected prostate cancer  
P. Heathcote, Sydney (AU) |
| 13:50 - 13:55| Discussion                                                              |
| 13:55 - 14:10| Modern surgical management of benign prostate hyperplasia: Which technique is the best for whom?  
J. Rassweiler, Heilbronn (DE) |
| 14:10 - 14:15| Discussion                                                              |
| 14:15 - 14:30| Mini PNL: It is getting small and tiny - the challenge of minimal invasive approach in modern stone treatment  
T. Knoll, Sindelfingen (DE) |
| 14:30 - 14:35| Discussion                                                              |
| 14:35 - 14:50| Prostate biopsy: Is multiparametric MRI the decision maker?  
A. Briganti, Milan (IT) |
| 14:50 - 14:55| Discussion                                                              |
| 14:55 - 15:10| PSMA PET Imaging has shifted the goalposts of advanced prostate cancer  
D. Murphy, Melbourne (AU) |
| 15:10 - 15:15| Discussion                                                              |
Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

**Urology beyond Europe**

**Friday 15 March**

12:30 - 15:00

**Location:** Green Area, Room 20

**Chairs:**
- F. Montorsi, Milan (IT)
- Y. Tomita, Niigata (JP)

**Aims and objectives of this session**
The aim of this session is to provide the audience a deep insight on specific topics of current clinical practice in urology. The selected themes are renal cell cancer, reconstructive surgery and prostate cancer. For each topic, the discussion will follow two pathways: on one hand a synthesis of the most recent scientific evidence will be examined, on the other hand, complex surgical scenarios will be discussed by top-class experts. The audience will learn how to face complex clinical decision-making in case of metastatic or locally advanced kidney cancer, challenging scenarios of congenital hydronephrosis and reconstructive surgery and local and systemic management of metastatic prostate cancer.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 - 12:35</td>
<td>Welcome and introduction</td>
<td>F. Montorsi, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Y. Tomita, Niigata (JP)</td>
</tr>
<tr>
<td>12:35 - 13:20</td>
<td>Renal cell cancer</td>
<td>G. De Naeyer, Aalst (BE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Y. Tomita, Niigata (JP)</td>
</tr>
<tr>
<td>12:35 - 12:45</td>
<td>Upfront nephrectomy for M1 disease</td>
<td>R. Kato, Morioka (JP)</td>
</tr>
<tr>
<td>12:45 - 12:55</td>
<td>Robot-assisted radical nephrectomy with IVC thrombosis</td>
<td>M. Gallucci, Rome (IT)</td>
</tr>
<tr>
<td>12:55 - 13:20</td>
<td>Panel discussion on renal cell cancer</td>
<td></td>
</tr>
<tr>
<td>13:20 - 14:05</td>
<td>Congenital hydronephrosis/reconstructive surgery</td>
<td>N. Fossati, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Kawauchi, Otsu (JP)</td>
</tr>
<tr>
<td>13:30 - 13:40</td>
<td>Complex robot-assisted pyeloplasty</td>
<td>A. De La Taille, Créteil (FR)</td>
</tr>
<tr>
<td>13:40 - 14:05</td>
<td>Panel discussion on congenital hydronephrosis: How to manage this situation?</td>
<td></td>
</tr>
<tr>
<td>14:05 - 14:50</td>
<td>Prostate cancer</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
<td>Speaker/Location</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>Local therapy for patients with oligo-metastasis</td>
<td>A. Mattei, Luzern (CH)</td>
</tr>
<tr>
<td>14:15 - 14:25</td>
<td>Differential management of drug therapy in specific clinical situation</td>
<td>S. Akamatsu, Kyoto (JP)</td>
</tr>
<tr>
<td>14:25 - 14:50</td>
<td>Panel discussion on prostate cancer: What is your choice of treatment?</td>
<td></td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>Closing remarks</td>
<td>M. Fujisawa, Kobe (JP)</td>
</tr>
</tbody>
</table>
### Joint Session of the European Association of Urology (EAU) and the Société Internationale d’Urologie (SIU)

**Urology beyond Europe**

**Friday 15 March**

**12:30 - 15:00**

**Location:** Green Area, Room 17

**Chairs:**
- S. Tanguay, Montreal (CA)
- H.P.A.M. Van Poppel, Leuven (BE)

**Aims and objectives of this session**
- Attendees will be able to develop an understanding of the key controversial issues in urologic oncology.
- Attendees will be able to identify and utilise best practices and current technology and methods of management of complex urologic problems.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:30 - 12:35 | **Welcome and introduction**  
S. Tanguay, Montreal (CA)  
H.P.A.M. Van Poppel, Leuven (BE) |
| 12:35 - 13:40 | **Prostate cancer**  
**Moderators:** L.H. Klotz, Toronto (CA)  
H.P.A.M. Van Poppel, Leuven (BE) |
| 12:35 - 12:45 | **Debate** Prostate cancer diagnosis after mpMRI: Only target biopsies should be performed  
C. Moore, London (GB) |
| 12:45 - 12:55 | **Debate** Prostate cancer diagnosis after mpMRI: Random and target biopsies should be performed  
M.V. Khochikar, Miraj (IN) |
| 12:55 - 13:10 | **Is active surveillance appropriate for Gleason 7 prostate cancer?**  
L.H. Klotz, Toronto (CA) |
| 13:10 - 13:25 | **Optimal management of castration sensitive metastatic prostate cancer**  
N. Mottet, Saint-Étienne (FR) |
| 13:25 - 13:40 | **Castration resistant prostate cancer: How to select optimal initial treatment**  
F. Saad, Montréal (CA) |
| 13:40 - 14:10 | **Renal cancer**  
**Moderators:** A. Bex, Amsterdam (NL)  
S. Tanguay, Montreal (CA) |
| 13:40 - 13:55 | **Is there a role for cytoreductive nephrectomy in 2019?**  
A. Bex, Amsterdam (NL) |
| 13:55 - 14:10 | **Optimal use of check point inhibition in metastatic Renal Cell Carcinoma (RCC)**  
J.J. Ischia, Heidelberg (AU) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:10 - 14:55</td>
<td><strong>Urothelial carcinoma</strong></td>
<td>S. Tanguay, Montreal (CA)</td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em> S. Tanguay, Montreal (CA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>H.P.A.M. Van Poppel, Leuven (BE)</td>
</tr>
<tr>
<td>14:10 - 14:25</td>
<td><strong>Check point inhibition in the treatment of non-invasive bladder cancer</strong></td>
<td>A. Necchi, Milan (IT)</td>
</tr>
<tr>
<td>14:25 - 14:40</td>
<td><strong>Robotic cystectomy: Surgical tips and prevention of complications</strong></td>
<td>N.P. Wiklund, Stockholm (SE)</td>
</tr>
<tr>
<td>14:40 - 14:55</td>
<td><strong>Optimal timing of peri-operative chemotherapy in Urinary Tract urothelial Carcinoma (UTUC)</strong></td>
<td>S. Osanto, Leiden (NL)</td>
</tr>
<tr>
<td>14:55 - 15:00</td>
<td><strong>Closing remarks</strong></td>
<td>S. Tanguay, Montreal (CA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H.P.A.M. Van Poppel, Leuven (BE)</td>
</tr>
</tbody>
</table>
### Joint Meeting of the European Association of Urology (EAU) and the Caucasian/Central Asian countries

#### Urology beyond Europe

**Friday 15 March**  
**12:30 - 15:45**

| Location: | Green Area, Room 18 |
| Chairs: | D. Nikoleishvili, Tbilisi (GE)  
J.P.M. Sedelaar, Nijmegen (NL) |

#### Aims and objectives of this session

This session aims to integrate the urological societies of the Caucasus and Central Asia under the EAU umbrella. Meet up-and-coming urologists from this region and learn more about the EAU’s activities. The session will also serve to spread EAU and international standards in urological care through these regional associations.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 - 12:35</td>
<td><strong>Welcome and introduction</strong></td>
</tr>
<tr>
<td></td>
<td>D. Nikoleishvili, Tbilisi (GE)</td>
</tr>
<tr>
<td></td>
<td>J.P.M. Sedelaar, Nijmegen (NL)</td>
</tr>
<tr>
<td>12:35 - 13:35</td>
<td><strong>Bladder cancer: Radical cystectomy</strong></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em> S. Mukhtarov, Tashkent (UZ)</td>
</tr>
<tr>
<td></td>
<td>F. Guliyev, Baku (AZ)</td>
</tr>
<tr>
<td></td>
<td>E. Xylinas, Paris (FR)</td>
</tr>
<tr>
<td>12:35 - 12:45</td>
<td><strong>Immediate radical cystectomy for high-risk non-muscle invasive bladder cancer</strong></td>
</tr>
<tr>
<td></td>
<td>E. Xylinas, Paris (FR)</td>
</tr>
<tr>
<td>12:45 - 12:50</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td><strong>Development of the surgical treatment of invasive bladder cancer in Georgia</strong></td>
</tr>
<tr>
<td></td>
<td>A. Chkhotua, Tbilisi (GE)</td>
</tr>
<tr>
<td>13:00 - 13:05</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:05 - 13:15</td>
<td><strong>10 years of experience of radical cystectomy with orthotopic diversion in Azerbaijan</strong></td>
</tr>
<tr>
<td></td>
<td>T. Musayev, Baku (AZ)</td>
</tr>
<tr>
<td>13:15 - 13:20</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td><strong>Extraperitoneal radical cystectomy with and without the extraperitonealization of the orthotopic neobladder: A retrospective study</strong></td>
</tr>
<tr>
<td></td>
<td>K. Kiknavelidze, Kutaisi (GE)</td>
</tr>
<tr>
<td>13:30 - 13:35</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:35 - 14:35</td>
<td><strong>Endo-urology: Part 1</strong></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em> Z. Khakimkhodzaev, Bishkek (KG)*</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>13:35 - 13:45</td>
<td><strong>Optimal treatment of lower pole 1-2 cm renal stones</strong>&lt;br/&gt;E. Emiliani, Barcelona (ES)</td>
</tr>
<tr>
<td>13:45 - 13:50</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td><strong>Urolithiasis: Experience from the National Hospital in Kyrgyzstan</strong>&lt;br/&gt;N. Monolov, Bishkek (KG)</td>
</tr>
<tr>
<td>14:00 - 14:05</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td><strong>Multiple and staghorn stones – difficulties of endoscopic approach</strong>&lt;br/&gt;S. Mukhtarov, Tashkent (UZ)</td>
</tr>
<tr>
<td>14:15 - 14:20</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:20 - 14:30</td>
<td><strong>Survival and quality of life of patients following radical cystectomy</strong>&lt;br/&gt;A. Tsaturyan, Yerevan (AM)</td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:35 - 15:35</td>
<td><strong>Endo-urology: Part 2</strong>&lt;br/&gt;Moderators: S.V. Fanarjyan, Yerevan (AM)&lt;br/&gt;P. Kallidonis, Patras (GR)&lt;br/&gt;D. Nikoleishvili, Tbilisi (GE)</td>
</tr>
<tr>
<td>14:35 - 14:45</td>
<td><strong>Papillary approach for percutaneous nephrolithotomy. Is it a dogma?</strong>&lt;br/&gt;P. Kallidonis, Patras (GR)</td>
</tr>
<tr>
<td>14:45 - 14:50</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td><strong>Evaluation of complication during laparoscopic surgery in urology</strong>&lt;br/&gt;B. Ayubov, Tashkent (UZ)</td>
</tr>
<tr>
<td>15:00 - 15:05</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>15:05 - 15:15</td>
<td><strong>Case from practice: Augmentation - dorsal urethroplasty using buccal mucosa graft into the female patient with distal urethral stricture</strong>&lt;br/&gt;B. Kassymov, Astana (KZ)</td>
</tr>
<tr>
<td>15:15 - 15:20</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>15:20 - 15:30</td>
<td><strong>Features of the methods of reconstruction of post-traumatic stricture of the posterior urethra</strong>&lt;br/&gt;I. Rofiev, Dushanbe (TJ)</td>
</tr>
<tr>
<td>15:30 - 15:35</td>
<td><strong>Discussion</strong></td>
</tr>
</tbody>
</table>
| 15:35 - 15:45 | **Closing remarks**  
|              | D. Nikoleishvili, Tbilisi (GE) |
EUA History Office: Spanish contributions to urology

Specialty Session

Friday 15 March
12:30 - 15:00

Location: Green Area, Room 14

Chairs: L.A. Fariña-Pérez, Vigo (ES)
P. Van Kerrebroeck, Maastricht (NL)

Aims and objectives of this session
Each European country has made unique contributions to the field of urology, be it through early technical breakthroughs, medical insights or by visionary surgeons who pushed the boundaries of their field. The EAU History Office has prepared a programme featuring four prominent speakers who each highlight a different facet of uniquely Spanish urology. We go back to the 16th century for the earliest developments in Spanish urology, to the former Spanish Empire for a profile of one of Cuba’s most celebrated urologists and his time in Spain, and we examine a key Spanish-language publication and the development of ureteroscopy in the modern treatment of stones.

12:30 - 12:35  
Welcome and introduction  
P. Van Kerrebroeck, Maastricht (NL)

12:35 - 13:05  
The birth of urology in renaissance Europe (XVI century): The Hispanic contribution  
R. Vela Navarrete, Madrid (ES)

13:05 - 13:10  
Discussion

13:10 - 13:40  
Joaquín María Albarrán (1860-1912): The Spanish influence in his life, work and professional links  
J. Angulo Cuesta, Getafe (ES)

13:40 - 13:45  
Discussion

13:45 - 14:15  
Salvador Gil Vernet’s “Patologia Urogenital” (1944) and medical illustration in urology  
J.M. Gil-Vernet Sedo, Barcelona (ES)

14:15 - 14:20  
Discussion

14:20 - 14:50  
The beginnings of ureteroscopy (URS)  
E. Perez-Castro Ellendt, Madrid (ES)

14:50 - 14:55  
Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:55 - 15:00</td>
<td>Closing remarks</td>
<td>P. Van Kerrebroeck, Maastricht (NL)</td>
</tr>
</tbody>
</table>
## Common problems in muscle-invasive and advanced bladder cancer: Evidence based debates

### Specialty Session

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday 15 March</td>
<td>12:45 - 15:45</td>
<td>Welcome and introduction</td>
<td>A.M. Kamat, Houston (US)</td>
<td>Green Area, Room 2</td>
</tr>
<tr>
<td></td>
<td>12:48 - 13:10</td>
<td>Case-based debate: Role of radical cystectomy in metastatic disease, (N+ and/or M+)</td>
<td>B.A. Inman, Durham (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:48 - 13:10</td>
<td>Case presenter</td>
<td>B.A. Inman, Durham (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:50 - 13:00</td>
<td>Discussants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:00 - 13:03</td>
<td>Summary</td>
<td>A.M. Kamat, Houston (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:03 - 13:10</td>
<td>Questions and answers</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:10 - 13:32</td>
<td>Case-based debate: Can I avoid radical cystectomy in a patient who is cT0 after neoadjuvant chemotherapy?</td>
<td>A.M. Kamat, Houston (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:10 - 13:12</td>
<td>Case presenter</td>
<td>A.M. Kamat, Houston (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:12 - 13:22</td>
<td>Discussants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:22 - 13:25</td>
<td>Summary</td>
<td>A.M. Kamat, Houston (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:25 - 13:32</td>
<td>Questions and answers</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:32 - 13:54</td>
<td>Case-based debate: Ileal conduit or continent diversion: Which is a better choice for most patients?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Aims and objectives of this session
- Using case based discussions, allow the presenters an opportunity to discuss nuances of common dilemmas facing urologic oncology patients and providers
- Use evidence based debates to provide clear, rationale guidance on the management of difficult situations in bladder cancer

**Location:** Green Area, Room 2

**Chairs:**
- A.M. Kamat, Houston (US)
- A. Stenzl, Tübingen (DE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:34 - 13:39</td>
<td>Discussant - Conduit</td>
<td>J. Taylor</td>
<td>Kansas City (US)</td>
</tr>
<tr>
<td>13:47 - 13:54</td>
<td>Questions and answers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:54 - 13:56</td>
<td>Case-based debate: Who lives better - quality of life after bladder-preserving therapy (Trimodal Therapy) versus radical cystectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:54 - 13:58</td>
<td>Case presenter</td>
<td>A. Stenzl</td>
<td>Tübingen (DE)</td>
</tr>
<tr>
<td>13:56 - 14:01</td>
<td>Discussant - Radical cystectomy</td>
<td>J.W.F. Catto</td>
<td>Sheffield (GB)</td>
</tr>
<tr>
<td>14:01 - 14:06</td>
<td>Discussant - Trimodal therapy</td>
<td>A. Birtle</td>
<td>Preston (GB)</td>
</tr>
<tr>
<td>14:06 - 14:09</td>
<td>Summary</td>
<td>A. Stenzl</td>
<td>Tübingen (DE)</td>
</tr>
<tr>
<td>14:09 - 14:16</td>
<td>Questions and answers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:16 - 14:16</td>
<td>Case-based debate: In a patient who is pure UC, T2 disease; good GFR, should I go straight to radical cystectomy without neoadjuvant chemotherapy?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:16 - 14:18</td>
<td>Case presenter</td>
<td>M. Babjuk</td>
<td>Prague (CZ)</td>
</tr>
<tr>
<td>14:18 - 14:23</td>
<td>Discussant - Yes (no NAC)</td>
<td>W. Kassouf</td>
<td>Montreal (CA)</td>
</tr>
<tr>
<td>14:23 - 14:28</td>
<td>Discussant - No (NAC)</td>
<td>P. Grivas</td>
<td>Seattle (US)</td>
</tr>
<tr>
<td>14:28 - 14:31</td>
<td>Summary</td>
<td>M. Babjuk</td>
<td>Prague (CZ)</td>
</tr>
<tr>
<td>14:31 - 14:38</td>
<td>Questions and answers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:38 - 15:00</td>
<td>Case-based debate: 1 year after cystectomy, a patient develops a 2 cm PET avid lung nodule, only site of disease. The best management is: (what if lone site: liver or RP node?)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:38 - 14:40</td>
<td><strong>Case presenters</strong>&lt;br&gt;J.W.F. Catto, Sheffield (GB)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:40 - 14:45</td>
<td><strong>Discussant - Systemic therapy</strong>&lt;br&gt;F.C. Maluf, Criciúma - SC (BR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45 - 14:50</td>
<td><strong>Discussant - Metastasectomy</strong>&lt;br&gt;B.A. Inman, Durham (US)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:50 - 14:53</td>
<td><strong>Summary</strong>&lt;br&gt;J.W.F. Catto, Sheffield (GB)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:53 - 15:00</td>
<td><strong>Questions and answers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:22</td>
<td><strong>Case based debate:</strong> Healthy male patient wants radical cystectomy, undecided on diversion. Open or robotic?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:02</td>
<td><strong>Case presenters</strong>&lt;br&gt;J. Palou, Barcelona (ES)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:02 - 15:07</td>
<td><strong>Discussant - Open RC better</strong>&lt;br&gt;S. Lerner, Houston (US)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:07 - 15:12</td>
<td><strong>Discussant - Robot RC better</strong>&lt;br&gt;P. Agarwal, Bethesda (US)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:12 - 15:15</td>
<td><strong>Summary</strong>&lt;br&gt;J. Palou, Barcelona (ES)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:22</td>
<td><strong>Questions and answers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:22 - 15:44</td>
<td><strong>Case based debate:</strong> In a PDL1 + ve patient, good PS and renal function, with lung metastases, should I use IO (anti PDL1 therapy) as initial therapy instead of chemotherapy?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:22 - 15:24</td>
<td><strong>Case presenter</strong>&lt;br&gt;W. Kassouf, Montreal (CA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:24 - 15:29</td>
<td><strong>Discussant - No, chemotherapy first</strong>&lt;br&gt;J. Bedke, Tübingen (DE)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:29 - 15:34</td>
<td><strong>Discussant - Yes, IO first</strong>&lt;br&gt;P. Grivas, Seattle (US)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:34 - 15:37</td>
<td><strong>Summary</strong>&lt;br&gt;W. Kassouf, Montreal (CA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:37 - 15:44</td>
<td><strong>Questions and answers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:44 - 15:45</td>
<td><strong>Closing remarks</strong>&lt;br&gt;A. Stenzl, Tübingen (DE)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Scientific Programme - EAU19 Barcelona
New technologies
Expert-Guided Poster Tour 03

Location: Green Area, Room A
Chairs: A.R. Azzouzi, Angers (FR)
        K. Touijer, New York (US)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

14:15 - 14:18
Introduction
A.R. Azzouzi, Angers (FR)
K. Touijer, New York (US)

PT058 Novel modalities for real-time optical imaging in urological neoplasm: A systematic review

By: Brunckhorst O.1, Ong Q.J.1, Elson D.2, Mayer E.1
1St Mary's Hospital Campus, Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, 2Imperial College London, Hamlyn Centre for Robotic Surgery, Institute of Global Health Innovation, London, United Kingdom

PT059 Utilizing semantic segmentation method with convolutional neural net to model a partial nephrectomy simulator for 3D printing

By: Kyung Y.S.1, Lim B.2, Choi S.Y.2, Han J.H.2, Lee W.2, Jeong I.G.2, Kim N.3, Kim C-S.2
1Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Health Screening and Promotion Center, Seoul, South Korea, 2Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, South Korea, 3Asan Medical Center, University of Ulsan College of Medicine, Dept. of Convergence Medicine, Seoul, South Korea

PT060 Safety, feasibility and oncologic efficacy of treatment for small renal masses using an innovative liquid nitrogen-based cryogenic device

By: Shprits S.1, Sachner R.2, Croitoru S.2, Dorfman K.2, Avitan O.1, Bahouth Z.1, Zisman A.3, Nativ O.1
1Bnai Zion Medical Center, Dept. of Urology, Haifa, Israel, 2Bnai Zion Medical Center, Dept. of Radiology, Haifa, Israel, 3Assaf Harofeh Medical Center, Dept. of Urology, Be’er Ya’akov, Israel
PT061  An experimental study of the use of sodium fumarate as a nephroprotective method under warm ischemia of the kidney

By: Popov S., Guseinov R., Orlov I., Katunin A.
City Hospital Saint Luka, Dept. of Urology, Saint Petersburg, Russia

PT062  NephroCheck™ and kinetic GFR as promising markers for the early detection of acute kidney injury after partial nephrectomy: Preliminary results from a single-centre prospective study

1University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, 2Renal and dialysis Unit, Careggi University Hospital, University of Florence, Dept. of Biomedical Experimental and Clinical Sciences 'Mario Serio', Florence, Italy, 3University of Florence, Dept. of Biomedical Experimental and Clinical Sciences 'Mario Serio', Florence, Italy, 4University of Florence, Dept. of Urology, Florence, Italy, 5Careggi University Hospital, Renal and dialysis Unit, Florence, Italy, 6AOU Careggi, University of Florence, Laboratory analysis, Florence, Italy, 7AOU Careggi, University of Florence, Dept. of Oncologic Anesthesia and Intensive Care, Florence, Italy

PT063  Obtaining a personalised 3D model of renal cell cancer with venous thrombus extension to aid in surgical planning and simulation

1Virgen del Rocio University Hospital, Dept. of Uro-Nephrology, Seville, Spain, 2Ramón y Cajal University Hospital, Dept. of Urology, Madrid, Spain, 3Virgen del Rocio University Hospital, Dept. of Radiology, Seville, Spain, 4Ramón y Cajal University Hospital, Dept. of Radiology, Madrid, Spain, 5Virgen del Rocio University Hospital, Dept. of Urology, Seville, Spain

PT064  Efficacy and safety of ultrasonic longitudinal-axis vibration for the reduction of ureteral access sheath insertion force: A randomized controlled trial in a porcine model

1Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, 2Yonsei University College of Medicine, Dept. of Pathology, Seoul, South Korea, 3Yonsei University College of Medicine, School of Mechanical Engineering, Seoul, South Korea

PT065  Extracorporeal acoustic impact for prevention ureteral stent’s encrustation

By: Ahmetov D., Tsukanov A., Blesman A., Rogachev E., Novikov A., Negrov D.
1Omsk State Medical University, Dept. of Surgical diseases and Urology, Omsk, Russia,
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT066</td>
<td>Impact of SuperPulse Thulium Fiber Laser settings and curve diameter on optical fiber fracture during intracorporeal lithotripsy</td>
<td>Chiron P.H.L. 1, Doizi S. 2, De Coninck V. 2, Keller E.X. 2, Berthe L. 3, Traxer O. 2 1HIA Bégin, Dept. of Urology, Saint-Mandé, France, 2Tenon Hospital, Dept. of Urology, Paris, France, 3Ecole Nationale Supérieure des Arts et Métiers, PIMM Laboratory, Paris, France</td>
</tr>
<tr>
<td>PT067</td>
<td>Dusting efficiency comparison between Moses technology of Ho: YAG laser and superpulse thulium fiber laser</td>
<td>De Coninck V.M.J. 1, Keller E.X. 2, Kovalenko A. 3, Vinnichenko V. 3, Traxer O. 2 1AZ Klina, Dept. of Urology, Brasschaat, Belgium, 2Tenon Hospital, Assistance-Publique Hôpitaux de Paris. Pierre et Marie Curie University, Dept. of Urology, Paris, France, 3National Research Nuclear University MEPHI, Dept. of Engineering, Moscow, Russia</td>
</tr>
<tr>
<td>PT068</td>
<td>Effect of fiber tip to tissue distance on resulting damage pattern: An in vitro study of four laser systems</td>
<td>Taratkin M. 1, Enikeev D. 1, Glybochko P. 1, Netsch C. 2, Becker B. 2, Gross A.J. 2, Rapoport L. 1 1Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, 2Asklepios Hospital Barmbek, Dept. of Urology, Hamburg, Germany</td>
</tr>
<tr>
<td>PT069</td>
<td>Methylene blue-conjugated gold nanoparticles enhanced photoimmunotherapy for bladder cancer in T24 cell line</td>
<td>Hsu C-W. 1, Chiu Y-C. 1, Cheng N-C. 2, Liao M-Y. 3, Huang C-C. 2 1Division of Urology, Department of Surgery, Zhongxiao Branch Taipei City Hospital, Dept. of Surgery, Taipei, Taiwan, 2Center for Micro/Nano Science and Technology and Advanced Optoelectronic Technology Center, National Cheng Kung University, Dept. of Photonics, Tainan, Taiwan, 3National Pingtung University, Dept. of Applied Chemistry, Pingtung, Taiwan</td>
</tr>
<tr>
<td>PT070</td>
<td>Directed differentiation of feeder-free human induced pluripotent stem cells into stratified bladder urothelium</td>
<td>Suzuki K. 1, Koyanagi-Aoi M.K-A 2, Uehara K.U. 3, Hinata N.H. 1, Fujisawa M.F. 1, Aoi T.A. 2 1Kobe University Graduate school of Medicine, Division of Urology, Kobe, Japan, 2Kobe University Graduate School of Science, Technology and Innovation, Division of Advanced Medical Science, Kobe, Japan, 3Kobe University Graduate school of Medicine, Division of Pathology, Kobe, Japan</td>
</tr>
</tbody>
</table>
Reducing perioperative anxiety in patients undergoing transurethral resection of bladder tumor by acupuncture treatment: A prospective randomized controlled study

By: Shprits S.\(^1\), Meyer G.\(^1\), Halachmi S.\(^1\), Stoppelman N.\(^1\), Avshalomov D.\(^1\), Biton K.\(^1\), Attias S.\(^2\), Schiff E.\(^2\), Nativ O.\(^1\)

\(^1\)Bnai Zion Medical Center, Dept. of Urology, Haifa, Israel, \(^2\)Bnai Zion Medical Center, Dept. of Internal Medicine, Haifa, Israel

ACSS-eDiary to self-monitor symptomatic episodes and therapeutic outcome of uncomplicated cystitis

By: Abdufattaev U.\(^1\), Alidjanov J.F.\(^2\), Basitkhanov B.T.\(^3\), Naber K.G.\(^4\), Pilatz A.\(^2\), Wagenlehner F.M.\(^2\)

\(^1\)State Inst. Republican Specialized Scientific-Practical Medical Center of Urology, Dept. of Radiology, Tashkent, Uzbekistan, \(^2\)Justus-Liebig-University, UKGM, Dept. of Urology, Pediatric Urology and Andrology, Giessen, Germany, \(^3\)State Investment Committee of the Republic of Uzbekistan, Dept. of Energy and Chemical Industry, Tashkent, Uzbekistan, \(^4\)Technical University of Munich, Dept. of Urology, Munich, Germany

Developing a future-proof database for the European Randomized study of Screening for Prostate Cancer (ERSPC)

By: Hulsen T.\(^1\), Van Der Linden W.\(^1\), De Jonge C.\(^2\), Hugosson J.\(^3\), Auvinen A.\(^4\), Roobol M.\(^5\), ERSPC Consortium

\(^1\)Philips Research, Dept. of Professional Health Solutions & Services, Eindhoven, The Netherlands, \(^2\)Philips Research, Dept. of Digital Platform Solutions, Eindhoven, The Netherlands, \(^3\)University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, \(^4\)University of Tampere, Dept. of Epidemiology, Tampere, Finland, \(^5\)Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

A prospective randomized trial of paper versus digital PROMS follow-up in prostate cancer patients after radiation therapy: Acceptance of digital follow-up by patients

By: Myllykangas M.\(^1\), Bergroth R.H.J.\(^2\), Tenhunen H.\(^3\), Hiltunen A.\(^3\), Silander K.\(^3\), Kouri M.\(^1\), Rannikko A.\(^4\)

\(^1\)Helsinki University Hospital, Dept. of Oncology, Helsinki, Finland, \(^2\)Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, \(^3\)Aalto University, Dept. of Industrial Engineering and Management, Espoo, Finland, \(^4\)University of Helsinki, Dept. of Urology, Helsinki, Finland

A tethered laparoscopic gamma probe for radioguided surgery in prostate cancer – usability and technical feasibility evaluation in a pelvic phantom and porcine model

By: Adshead J.\(^1\), Oldfield F.\(^2\), Hadaschik B.\(^3\), Everaets W.\(^4\), Mestre-Fusco A.\(^5\), Newbery M.\(^6\), Elson D.\(^7\), Grootendorst M.\(^8\), Vyas K.\(^2\), Fumado L.\(^9\), Harke N.N.\(^3\)

\(^1\)The Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, \(^2\)Lightpoint Medical Ltd., Dept of. Product Development, Chesham, United Kingdom, \(^3\)University Hospital Essen, Dept. of Urology, Essen, Germany, \(^4\)KU Leuven, Dept. of Urology, Leuven,
PT076  
**GMP-verification processes of the final product in a clinical stem cell trial to treat stress urinary incontinence**

By: Prange J.A.¹, Mohr-Haralampieva D.¹, Alves De Sousa R.A.¹, Schmid F.², Eberli D.²  
¹University Zurich, Dept. of Urology, Zurich, Switzerland, ²UniversitätsSpital Zürich, Dept. of Urology, Zurich, Switzerland

PT077  
**Organ culture of seminiferous tubules using a modified soft agar culture system**

By: Pourmand G.¹, Gholami K.², Koruji M.³, Ashouri S.², Abbasi M.²  
¹Tehran University of Medical Sciences, Urology Research Center, Tehran, Iran, ²Tehran University of Medical Sciences, Dept. of Anatomy, School of Medicine, Tehran, Iran, ³Iran University of Medical Sciences, Cellular and Molecular Research Center & Department of Anatomical Sciences, Tehran, Iran

PT078  
**PET/CT tracking of human muscle precursor cells and neo-vascularization for tissue engineering of skeletal muscles**

By: Mohr-Haralampieva D., Salemi S., Eberli D.  
University of Zurich, Dept. of Urology, Zurich, Switzerland

PT079  
**A novel machine-learning augmented audio-uroflowmetry – comparison with standard uroflowmetry**

By: Aslim E.J.¹, T B B.², Ng Y.S.L.¹, Kuo T.L.C.¹, Chen J.S.², Chen J.², Ng L.G.¹  
¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²Singapore University of Technology and Design, Information Systems Technology and Design, Singapore, Singapore

PT081  
**New biomaterials alternative to small intestinal submucosa (SIS) for urethral stricture repair**

By: Vulpì M.¹, Gallo N.², Salvatore L.², Vitarelli A.¹, Sallustio F.³, Curci C.³, Divella C.³, Gallone A.³, Gervaso F.⁴, Ditonno P.¹, Sannino A.²  
¹University of Bari, Dept. of Urology and Andrology Unit, Department of Emergency and Organ Transplantation, Bari, Italy, ²University of Salento, Dept. of Engineering for Innovation, Lecce, Italy, ³University of Bari, Dept. of Basic Medical Sciences, Neuroscience and Sense Organs, Bari, Italy, ⁴CNR Nanotech, Institute of Nanotechnology, Lecce, Italy

PT082  
**A new urethral catheterisation device for safe urethral catheterisation in difficult cases**
A novel urinary catheter for use in haematuria

By: Kesavan A. ¹, Pha M.T.N. ²
¹National University Health System, Dept. of Urology, Singapore, Singapore, ²National University of Singapore, Dept. of Industrial Design, Singapore, Singapore

The screening of deep venous thrombosis in patients undergoing urological surgery

By: Tatarano S., Enokida H., Yonemori M., Eura R., Yoshino H., Nishimura H., Yamada Y., Nakagawa M.
Kagoshima University, Dept. of Urology, Kagoshima, Japan

A simple novel surgical technique for penile elongation: Compensation for tunical plication in Peyronie’s disease

By: Lee D.H., Kim S.W., Ahn S.T., Kim J.W., Moon D.G.
Korea University, College of Medicine, Dept. of Urology, Seoul, South Korea

Transgender and adolescence: Is online information accurate or misleading?

By: Dunford C., Gresty H., Takhar M., Morley R., Rashid T.
Imperial College Healthcare NHS Trust, Dept. of Urology, London, United Kingdom
New insights in LUTS/BPH pathophysiology and medical treatment
Poster Session 14

Location: Green Area, Room 1
Chairs: G.I. Russo, Catania (IT)
M. Speakman, Taunton (GB)
T. Tammela, Tampere (FI)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

**183**

5α-Reductase inhibitors and risk of prostate cancer death

By: **Bonde Miranda T.**¹, Garmo H.², Stattin P.³, Robinson D.¹
¹Ryhon Hospital, Dept. of Urology, Jonkoping, Sweden,
²Uppsala University Hospital, Regional Cancer Centre, Uppsala, Sweden,
³Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

Aims and objectives of this presentation

**184**

Dutasteride may change renal morphology?

By: **Da Silva M.**¹, **Sampaio F.**², **De Souza D.**³
¹Rio de Janeiro State University, Urogenital Research Unit, Rio de Janeiro, Brazil

Aims and objectives of this presentation

**185**

Neuroactive steroid levels in cerebrospinal fluid of patients treated with dutasteride: A case-control study

By: **Favilla V.**¹, **Cimino S.**¹, **Alessio P.**¹, **Li Volti G.**², **Russo G.I.**¹, **Trovato F.**¹, **Morgia G.**¹
¹University of Catania, Dept. of Urology, Catania, Italy,
²University of Catania, Dept. of Biomedical and Biotechnological Sciences, Catania, Italy

Aims and objectives of this presentation

**187**

Long-term effects of tadalafil on storage and voiding function for male patients with detrusor underactivity induced by benign prostatic hyperplasia

By: **Matsukawa Y.**¹, **Takai S.**², **Kanada Y.**³, **Ishida S.**⁴, **Majima T.**⁵, **Funahashi Y.**⁶, **Yamamoto T.**⁷, **Gotoh M.**
¹Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
²Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
³Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
⁴Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
⁵Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
⁶Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
⁷Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of overactive bladder associated with benign prostatic hyperplasia (CONTACT Study)

By: Yamanishi T. 1, Kaga K. 2, Sakata K. 3, Yokoyama T. 4, Fuse M. 2, Kaga M. 2, Tokunaga S. 5
1Dokkyo University School of Medicine, Dept. of Urology, Mibu, Japan, 2Continence Centre, Dokkyo Medical University, Dept. of Urology, Tochigi, Japan, 3Imaichi Hospital, Dept. of Urology, Imaichi, Japan, 4Yokoyama Urological Clinic, Dept. of Urology, Okayama, Japan, 5Kyushu University Hospital, Medical Information Center, Fukuoka, Japan

Mild-to-moderate benign prostatic hyperplasia symptoms: Filling the gap. Efficacy and safety of Afalaza in men with benign prostatic hyperplasia at risk of progression: A multicenter, double-blind, placebo-controlled, randomized clinical trial

By: Vinarov A.Z. 1, Pushkar D. 2, Spivak L. 1
1Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, 2Moscow State University of Medicine and Dentistry, Clinic of Urology, Moscow, Russia

Correlation of alpha blocker with dementia in patients with benign prostate hyperplasia: A nationwide population-based study using the National Health Insurance Service database

By: Tae B.S. 1, Jeon B.J. 1, Choi H. 1, Park J.Y. 1, Cheon J. 2, Lee J.G. 2, Bae J.H. 1
1Korea University Ansan Hospital, Dep. of Urology, Ansan, South Korea, 2Korea University Ansan Hospital, Dep. of Urology, Seoul, South Korea

Urinary NGF and MMP-1 levels are associated with persistence of detrusor hyperactivity in patients with benign prostatic hyperplasia

By: Barbosa J.A., Sajovic De Conti P., Reis S., Viana N., Nunes M., Nahas W.C., Srougi M., Antunes A.A.
University of Sao Paulo Medical School, Dept. of Urology, Sao Paulo, Brazil
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>191</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>192</strong> Ghrelin-mediated promotion of prostate growth and prostate smooth muscle contraction: Evidence from functional, in vivo, and genomic approaches</td>
<td></td>
</tr>
<tr>
<td>By: Wang X.¹, Wang Y.¹, Gratzke C.¹, Li B.¹, Yu Q.¹, Strittmatter F.¹, Stief C.¹, Liu C.², Hennenberg M.¹</td>
<td></td>
</tr>
<tr>
<td>¹Ludwig-Maximilians University, Dept. of Urology, Munich, Germany, ²Southern Medical University, Dept. of Urology, Guangzhou, China</td>
<td></td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>192</td>
</tr>
<tr>
<td><strong>193</strong> Inhibition of prostate smooth muscle contraction by NAV2729: Evidence for a role of ADP ribosylation factor 6 (ARF6) for prostate smooth muscle contraction</td>
<td></td>
</tr>
<tr>
<td>Ludwig-Maximilians University, Dept. of Urology, Munich, Germany</td>
<td></td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>193</td>
</tr>
<tr>
<td><strong>194</strong> Withdrawn</td>
<td></td>
</tr>
<tr>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>194</td>
</tr>
<tr>
<td><strong>195</strong> Autophagy-mediated myofibroblast phenotype and proliferation during the progression of benign prostatic hyperplasia</td>
<td></td>
</tr>
<tr>
<td>By: Song J., Peng X., Jindong S., Yang Y., Shuai H., Jie J.</td>
<td></td>
</tr>
<tr>
<td>Peking University First Hospital, Dept. of Urology, Beijing, China</td>
<td></td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>195</td>
</tr>
<tr>
<td><strong>196</strong> Estrogen receptor alpha (ERα) antagonist improves benign prostatic hyperplasia (BPH) in high fat induced obesity rat model</td>
<td></td>
</tr>
<tr>
<td>By: Yamanaka N., Mori K., Mizoguchi S., Shin T., Mimata H.</td>
<td></td>
</tr>
<tr>
<td>Oita University, Dept. of Urology, Oita, Japan</td>
<td></td>
</tr>
</tbody>
</table>
### Stones: Research and metabolics

**Poster Session 15**

**Friday 15 March**

**14:15 - 15:45**

**Location:** Green Area, Room 4

**Chairs:**
- P. M. Ferraro, Rome (IT)
- M.S. Agrawal, Agra (IN)
- K. Taguchi, Nagoya (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

<table>
<thead>
<tr>
<th>Presentation Number</th>
<th>Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>198</td>
<td><strong>Withdrawn</strong>&lt;br&gt;<strong>To be confirmed</strong></td>
<td></td>
</tr>
<tr>
<td>199</td>
<td><strong>β3 Stimulant contributes to the prevention of renal crystal formation via differentiation of beige adipocytes</strong></td>
<td>By: Sugino T.¹, Okada A.¹, Tanaka Y.¹, Unno R.¹, Taguchi K.¹, Hamamoto S.¹, Ando R.¹, Mogami T.², Kohri K.¹, Yamashita H.³, Yasui T.¹&lt;br&gt;¹Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, ²JA Mie Komono Kosei Hospital, Dept. of Urology, Komono, Japan, ³College of Life and Health Sciences, Chubu University, Dept. of Biomedical Sciences, Kasugai, Japan</td>
</tr>
<tr>
<td>200</td>
<td><strong>Estrogen can reduce incidence of kidney stones by enhancing intestinal excretion of oxalate</strong></td>
<td>By: Gong J.¹, Jiang H.², Gao X.², Liu J.²&lt;br&gt;¹Tongji Hospital, Dept. of Urology, Wuhan, China, ²Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China</td>
</tr>
<tr>
<td>201</td>
<td><strong>Withdrawn</strong>&lt;br&gt;<strong>To be confirmed</strong></td>
<td></td>
</tr>
</tbody>
</table>
Identification of aberrant glycosylation of osteopontin in urinary stone former patients as a urolithiasis biomarker


1Tohoku Medical and Pharmaceutical University, Dept. of Urology, Sendai, Japan, 2Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, 3Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 4Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan

Aims and objectives of this presentation

Discovery of fatty acid binding protein 4 as an essential molecule for the development of kidney stones: A new understanding of the relationship between obesity and nephrolithiasis


1University of California, Dept. of Urology, San Francisco, United States of America, 2Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, 3Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan

Aims and objectives of this presentation

Association between metabolic syndrome (MetS) and kidney stone disease recurrence: Outcomes from a retrospective cohort study with a mean follow-up of 18-years

By: Geraghty R., Cook P., Somani B.

1University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom, 2University Hospital Southampton, Dept. of Chemical Pathology, Southampton, United Kingdom

Aims and objectives of this presentation

High concentration of calcium promotes mineralization and apoptosis via an NADPH oxidase/Nox4-MAPK pathway-dependent mechanism


Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of urology, Hubei Wuhan, China

Aims and objectives of this presentation
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>206</td>
<td><strong>Withdrawn</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To be confirmed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>207</td>
<td><strong>Low bone mineral density is associated with the onset of symptoms during follow-up: The relationship between bone mineral density and clinical outcomes in urolithiasis patients</strong></td>
<td>Taguchi K., Sugino T., Okada A., Hamamoto S., Tanaka Y., Unno R., Ando R., Tozawa K., Kohri K., Yasui T. Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan</td>
<td></td>
</tr>
<tr>
<td>208</td>
<td><strong>The role of gut microbiome and short chain fatty acids in renal calcium oxalate stones formation</strong></td>
<td>Liu Y., Chen Z., Jiang Q., Cheng L., Zhou L., Li Y., Sun Q., Wang K., Li H. West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China, University of Michigan, Dept. of Kidney Epidemiology and Cost Center, School of Public Health, Ann Arbor, United States of America, Sichuan University, Dept. of Life Sciences, Chengdu, China</td>
<td></td>
</tr>
<tr>
<td>209</td>
<td><strong>Methodological basis for the prevention of pathological crystallogenesis</strong></td>
<td>Gorbachev M., Emanuel V.L., Al-Shukri S.H., Fedorov D.A., Mosoyan M.S. Almazov National Medical Research Centre, Dept. of Urology and Robotic surgery, Saint Petersburg, Russia, Pavlov First State Medical University, Laboratory Diagnostics, Saint Petersburg, Russia, Pavlov First State Medical University, Dept. of Urology, Saint Petersburg, Russia</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td><strong>A new approach to the dietary stereotypes study in urolithiasis patients</strong></td>
<td>Anokhin N.A., Prosiannikov M., Konstantinova O., Voytko D., Golovanov S., Apolihin O., Sivkov A. N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre of the Ministry of Health of Russian Federation, Dept. of Uro lithiasis, Moscow, Russia, N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre of the Ministry of Health of Russian Federation, Dept. of Uro lithiasis, Moscow, Russia</td>
<td></td>
</tr>
</tbody>
</table>
Nephrolithiasis predicts ischemic stroke: A longitudinal follow-up study using a national sample cohort

By: Bang W.¹, Ko K.T.², Shim M.S.¹, Oh C.Y.¹, Lee Y.S.¹, Cho J.S.¹
¹Hallym Sacred Heart Hospital, Dept. of Urology, Anyang, South Korea, ²Kangdong Sacred Heart Hospital, Dept. of Urology, Seoul, South Korea

Aims and objectives of this presentation
210
**Improving outcomes from radical prostatectomy: The influence of big data**

**Poster Session 16**

**Location:** Green Area, Room 5

**Chairs:** M. Alvarez-Maestro, Madrid (ES)
G. Carrieri, Bari (IT)
X. Cathelineau, Paris (FR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 213

18-year prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer

By: Herlemann A., Cowan J.E., Washington 3rd S.L., Broering J.M., Carroll P.R., Cooperberg M.R.
University of California, Dept. of Urology, San Francisco, United States of America

* 214

Long-term mortality in patients with positive lymph nodes at radical prostatectomy

Technische Universität Dresden, Dept. of Urology, Dresden, Germany, Technische Universität Dresden, Dept. of Pathology, Dresden, Germany

215

Oncologic outcomes after radical prostatectomy for high risk prostate cancer: Impact of various definitions on cancer-specific and overall mortality

By: Knipper S., Karakiewicz P., Steuber T., Huland H., Graefen M., Tilki D.
Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montréal, Germany

216

Which patients with clinically node positive prostate cancer should be considered as candidates for radical prostatectomy as part of a multimodal treatment? The impact of nodal burden

IRCCS Ospedale San Raffaele, Division of Oncology Unit of Urology URI, Milan, Italy, Mayo Clinic, Dept. of Urology, Rochester (MN), United States of America, University
| 217 | Impact of bilateral neurovascular bundle preservation on oncological outcomes in non-organ confined prostate cancer patients |
| 218 | Oncologic outcomes of patients with incidental prostate cancer who underwent robot-assisted radical cystectomy: A comparison between nerve sparing and non-nerve sparing approach |
| 219 | Dehydrated human amnion/chorion membrane accelerates the return to continence and potency recovery after a nerve-sparing robotic-assisted radical prostatectomy |
| 220 | The impact of surgical experience on the risk of surgical margins and biochemical recurrence after robot-assisted radical prostatectomy: A learning-curve study |
| 221 | Gleason pattern 4 or 5 at a positive surgical margin predicts early biochemical recurrence (<12 months) after robotic radical prostatectomy |
Variation in positive surgical margin status following radical prostatectomy for pT2 prostate cancer

By: Tan W.S.¹, Krimphove M.², Cole A.², Berg S.², Marchese M.², Lipsitz S.³, Loppenberg B.⁴, Nabi J.², Abdollah F.⁵, Choueiri T.⁶, Kibel A.², Sooriakumaran P.⁷, Trinh Q-D.²
¹Imperial College Healthcare, Dept. of Urology, London, United Kingdom, ²Brigham and Women’s Hospital, Dept. of Urology, Boston, United States of America, ³Brigham and Women’s Hospital, Center for Surgery and Public Health, Boston, United States of America, ⁴Marien Hospital Herne, Dept. of Urology, Herne, Germany, ⁵Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, ⁶Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, United States of America, ⁷University College London Hospitals, Dept. of Urology, London, United Kingdom

Atlas of ex vivo prostate tissue and cancer images using confocal laser endomicroscopy: A project for intraoperative positive surgical margins detection during radical prostatectomy

By: Panarello D.¹, Compérat E.², Seyde O.², Colau A.¹, Terrone C.³, Guillonneau B.¹
¹Diaconesses -Croix St Simon Hospital, Sorbonne University, Dept. of Urology, Paris, France, ²Tenon Hospital, HUEP, Dept. of Pathology, Paris, France, ³San Martino Hospital, Dept. of Urology, Genova, Italy

Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence

By: Preisser F.¹, Busto Castanon L.², Haese A.², Pompe R.S.³, Graefen M.², Tilki D.²
¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²University Hospital Hamburg-Eppendorf, Martini-Klinik, Hamburg, Germany, ³University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

Inductive androgen deprivation and radical prostatectomy in T4 prostate cancer: Consecutive assessment of perioperative outcomes and long-term follow up

By: Saar M.¹, Niklas C.¹, Hajili T.¹, Ohlmann C-H.², Linxweiler J.¹, Siemer S.¹, Stöckle M.¹
¹Saarland University, Dept. of Urology, Homburg/Saar, Germany, ²Saarland University, Malteser Hospital Bonn/Rhein-Sieg, Dept. of Urology, Homburg/Saar, Bonn, Germany

Comparison of outcomes in salvage robot-assisted laparoscopic prostatectomy for post-primary radiation vs. ablation therapies

By: Önol F.F.¹, Bhat S.¹, Rogers T.¹, Ganapathi H.¹, Jenson C.¹, Rocco B.M.C.², Patel V.¹
¹Florida Hospital Global Robotics Institute, Dept. of Urology, Celebration, United States of America, ²University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy
Complex kidney and adrenal surgery

Video Session 04

Friday 15 March
14:15 - 15:45

Location: Green Area, Room 10

Chairs: K. Decaestecker, Ghent (BE)
M. Musquera Felip, Barcelona (ES)
P-T. Piéchaud, Bordeaux (FR)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V24

Removal of the tumor thrombus from the right atrium without extracorporeal circulation: Emphasis on the displacement of the tumor apex

By: Shchukin D.¹, Lesovoy V.¹, Khareba G.¹, Harahatyi A.¹, Polyakov M.¹, Stetsyshyn R.², Mozghakov P.¹
¹Kharkiv National Medical University, Dept. of Urology, Nephrology and Andrology, Kharkiv, Ukraine,
²Kharkiv Medical Academy of Postgraduate Education, Dept. of General, Pediatric and Oncological Urology, Kharkiv, Ukraine

Aims and objectives of this presentation

V25

En bloc removal of left renal cell carcinoma and cavo-atrial thrombosis with an intra-abdominal approach using liver transplantation techniques

By: Urbani L.¹, Roffi N.¹, Baldesi R.², Tesi L.², Signori S.¹, Selli C.²
¹Pisa Hospitals, Dept. of Surgery, Section of Liver Metastasis Parenchyma-Sparing Surgery, Pisa, Italy,
²University of Pisa, Dept. of Translational Research, Section of Urology, Pisa, Italy

Aims and objectives of this presentation

V26

Indocyanine green guided robot assisted radical nephrectomy and level III inferior vena cava tumor thrombectomy

Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation

V27

Latrogenic complications during robotic surgery: Lessons learnt
Scientific Programme - EAU19 Barcelona

By: Mandal A.K. 1, Mavuduru R.S. 1, Bora G.S. 1, Jain V. 2, Singh S.K. 1
1PGIMER Chandigarh, Dept. of Urology, Chandigarh, India, 2PGIMER Chandigarh, Dept. of Gynaecology, Chandigarh, India

Aims and objectives of this presentation
V27

V28

3D laparoscopic cavoraphy solutions for controlling vena cava during the surgical treatment of T3b renal tumors

By: Petrut B. 1, Bujoreanu E.C. 1, Hardo V.V. 1, Maris C.V. 1, Munteanu V.C. 1, Schitcu V.H. 1, Maghiar T. 2
1“Prof. Dr. Ion Chiricuta” Institute of Oncology, Dept. of Urology, Cluj Napoca, Romania, 2Pelican Hospital, Dept. of Urology, Oradea, Romania

Aims and objectives of this presentation
V28

V29

Robot-assisted retroperitoneal lymphadenectomy in patients with type 1 papillary renal cancer recurrence after 5 years of follow-up

By: Al Salhi Y. 1, Pastore A.L. 1, Fuschi A. 1, Velotti G. 1, Capone L. 1, Martoccia A. 1, Artibani W. 2, Carbone A. 1
1Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Latina, Italy, 2University of Verona, Dept. of Urology, Verona, Italy

Aims and objectives of this presentation
V29

V30

Robot-assisted laparoscopic adrenalectomy – utility and feasibility in a tertiary setup

By: Srivathsan R.
Kokilaben Dhirubhai Ambani Hospital, Dept. of Robotic Urooncology, Mumbai, India

Aims and objectives of this presentation
V30
Urine, serum and tissue diagnostic innovations in urothelial cancer

**Location:** Green Area, Room 11

**Chairs:**
- R. T. Bryan, Birmingham (GB)
- To be confirmed
- M. Rink, Hamburg (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**227**

**Mix methods approach to determine patients’ perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy for bladder cancer surveillance**


1. University College London, Dept. of Urology, London, United Kingdom,
2. University of Malaya, Dept. of Primary Care Medicine, Kuala Lumpur, Malaysia,
3. University College London, Health Behaviour Research Centre, Department of Epidemiology and Public Health, London, United Kingdom

**Aims and objectives of this presentation**

---

**228**

**A urine assay to triage patients with haematuria for cystoscopy**


1. Erasmus University Medical Center, Dept. of Pathology, Rotterdam, The Netherlands,
2. Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands,
3. Haga Teaching Hospital, Dept. of Urology, The Hague, The Netherlands,
4. Harbour Hospital, Dept. of Urology, Rotterdam, The Netherlands,
5. Franciscus Hospital, Dept. of Urology, Rotterdam, The Netherlands,
6. Amphia Hospital, Dept. of Urology, Breda, The Netherlands,
7. IJssel Hospital, Dept. of Urology, Rotterdam, The Netherlands,
8. MDxHealth, Dept. of R&D, Irvine, United States of America,
9. Erasmus University Medical Center, Dept. of Public Health, Rotterdam, The Netherlands,
10. University of Ghent, Faculty of Biosciences, Ghent, Belgium

**Aims and objectives of this presentation**

---

**229**

**Prediction of tumor recurrence in patients in follow up for bladder cancer with suspicious urinary cytology using molecular and cytogenetic approaches**
**Aims and objectives of this presentation**

229

**Xpert bladder cancer monitor in the follow up of patients affected by non muscle invasive bladder cancer (NMIBC): An update**


**1**Central Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, **2**Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, **3**Central Hospital of Bolzano, Dept. of Pathology, Bolzano, Italy

**Aims and objectives of this presentation**

230

**TOF-MS based urine DNA methylation classifier: A fast and effective technique for non-invasive diagnosis and monitoring of bladder cancer**


**1**Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China, **2**AnchorDx Medical Co., Ltd., Guangzhou, China, **3**Agena Bioscience, Inc., San Diego, United States of America, **4**Southern Medical University, School of Basic Medical Sciences, Guangzhou, China, **5**Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China

**Aims and objectives of this presentation**

231

**Performance of FDA/EMA approved PD-L1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab**


**1**University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Pathology, Erlangen, Germany, **2**Ruprecht-Karls-Universität Heidelberg, Dept. of Urology, Medical Faculty Mannheim, Mannheim, Germany, **3**Ruprecht-Karls-Universität Heidelberg, Institute of Pathology, Medical Faculty Mannheim, Mannheim, Germany, **4**STRATIFYER Molecular Pathology, Cologne, Germany, **5**University Hospital, Friedrich-Alexander Universität Erlangen-Nürnberg, Dept. of Urology and Paediatric Urology, Erlangen,
Germany, 6University Hospital, University of Regensburg, Dept. of Urology, Regensburg, Germany, 7TU Munich, Institute of Pathology, Munich, Germany, 8University Hospital, University of Ulm, Dept. of Urology, Ulm, Germany

Aims and objectives of this presentation
232

High diagnostic efficacy of 5-aminolevulinic acid induced fluorescence urine cytology for urothelial carcinoma

By: Yamamichi G. 1, Nakata W. 1, Tani M. 1, Tsujimura G. 1, Tsujimoto Y. 1, Nin M. 1, Mimura A. 2, Miwa H. 3, Tsujihata M. 1
1Osaka Rosai Hospital, Dept. of Urology, Sakai, Japan, 2Osaka Rosai Hospital, Laboratory Medicine, Sakai, Japan, 3Osaka Rosai Hospital, Dept. of Pathology, Sakai, Japan

Aims and objectives of this presentation
233

mRNAs detection in urinary extracellular vesicles as diagnostic markers of non-muscle invasive bladder cancer

By: Minami K. 1, Hiroshi H. 2, Takahiro O. 3, Hiroshi T. 1, Toshimori S. 1
1Sapporo City General Hospital, Dept. of Urology, Sapporo, Japan, 2Sapporo City General Hospital, Dept. of Kidney Transplant Surgery and Urology, Sapporo, Japan, 3Hokkaido University Hospital, Dept. of Urology, Sapporo, Japan

Aims and objectives of this presentation
234

Low coverage copy number profiling of urinary sediments DNAs for bladder cancer molecular diagnostics

By: Liu H. 1, Chen X. 1, Huang M. 1, Ouyang N. 2, Xu K. 1, Han J. 1, Wang J. 3, Hu C. 3, Lu S. 3, Lin T. 1, Huang J. 1
1Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China, 2Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Cellular & Molecular Diagnostics Center, Guangzhou, China, 3Yikon Genomics, Dept. of Clinical Research, Shanghai, China

Aims and objectives of this presentation
235

A non-invasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade

Aims and objectives of this presentation
236

Photonic sensor-based detection of urinary volatile organic compounds (VOCs) bladder cancer biomarkers: A prospective study

By: Zhu S., Nabi G.
University of Dundee, School of Medicine, Dundee, United Kingdom

Knowledge of bladder cancer in the French population: Results of the EDIFICE 6 survey

By: Rouprêt M. 1, Morère J.-F. 2, Viguier J. 3, Touboul C. 4, Lhomel C. 5, Greillier L. 6, Couraud S. 7, Eisinger F. 8, De La Motte Rouge T. 9
1 Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, Dept. of Urology, Paris, France, 2 Hôpital Paul Brousse, Dept. of Medical Oncology, Villejuif, France, 3 Hôpital Bretonneau, Dept. of Medical Oncology, Tours, France, 4 Kantar Health, Statistics, Paris, France, 5 Roche, Medical Operations, Boulogne-Billancourt, France, 6 Assistance Publique - Hôpitaux de Marseille, Dept. of Multidisciplinary Oncology and Therapeutic Innovations, Marseille, France, 7 Centre Hospitalier Lyon Sud, Dept. of Respiratory Diseases and Thoracic Oncology, Pierre Bénite, France, 8 Institut Paoli Calmette, Dept. of Anticipation et de Suivi du Cancer (DASC), Marseille, France, 9 Centre
Aims and objectives of this presentation
240

Androgen receptor mRNA expression in urothelial carcinoma of the bladder: A retrospective analysis of two independent cohorts

By: Sikic D.¹, Wirtz R.M.², Wach S.¹, Dyrekjøt L.³, Erben P.⁴, Bolenz C.⁵, Breyer J.⁶, Otto W.⁶, Hoadley K.A.⁷, Lerner S.P.⁸, Eckstein M.⁹, Hartmann A.⁹, Keck B.¹

¹Friedrich-Alexander University Erlangen-Nürnberg, Dept. of Urology and Pediatric Urology, Erlangen, Germany, ²STRATIFYER Molecular Pathology GmbH, Dept. of Molecular Pathology, Cologne, Germany, ³Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, ⁴Medical Faculty Mannheim, University of Heidelberg, Dept. of Urology, Mannheim, Germany, ⁵University Hospital Ulm, Dept. of Urology and Pediatric Urology, Ulm, Germany, ⁶University of Regensburg, Dept. of Urology, Regensburg, Germany, ⁷Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Dept. of Genetics, Chapel Hill, United States of America, ⁸Baylor College of Medicine, Dept. of Urology, Houston, United States of America, ⁹Friedrich-Alexander University Erlangen-Nürnberg, Dept. of Pathology, Erlangen, Germany

Aims and objectives of this presentation
241
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00 - 18:05</td>
<td>Opening address</td>
</tr>
<tr>
<td>18:05 - 18:20</td>
<td>Announcement of the new EAU Honorary Members</td>
</tr>
<tr>
<td>18:20 - 18:30</td>
<td>Presentation of the EAU Willy Gregoir Medal 2019</td>
</tr>
<tr>
<td>18:30 - 18:40</td>
<td>Presentation of the EAU Frans Debruyne Life Time Achievement Award 2019</td>
</tr>
<tr>
<td>18:40 - 18:50</td>
<td>Presentation of the EAU Crystal Matula Award 2019</td>
</tr>
<tr>
<td>18:50 - 19:00</td>
<td>Presentation of the EAU Hans Marberger Award 2019</td>
</tr>
<tr>
<td>19:00 - 19:10</td>
<td>EAU Innovators in Urology Award</td>
</tr>
<tr>
<td>19:10 - 19:20</td>
<td>EAU Ernest Desnos Prize 2019</td>
</tr>
<tr>
<td>19:20 - 19:30</td>
<td>Presentation of the EAU Prostate Cancer Research Award 2019</td>
</tr>
</tbody>
</table>
Networking Reception

Location: Red Area, eURO Auditorium 1

Friday 15 March
19:30 - 21:00
<table>
<thead>
<tr>
<th>Time</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 - 08:15</td>
<td>Welcome by the EAU Secretary General</td>
</tr>
<tr>
<td>07:15 - 08:15</td>
<td>Approval minutes General Assembly of 17 March 2018, Copenhagen, Denmark</td>
</tr>
<tr>
<td>07:15 - 08:15</td>
<td>General report by the EAU Secretary General</td>
</tr>
<tr>
<td>C.R. Chapple, Sheffield (GB)</td>
<td></td>
</tr>
<tr>
<td>07:15 - 08:15</td>
<td>Report by the EAU Treasurer</td>
</tr>
<tr>
<td>M. Wirth, Dresden (DE)</td>
<td></td>
</tr>
<tr>
<td>07:15 - 08:15</td>
<td>Specific reports on the EAU Offices by the EAU Executive</td>
</tr>
<tr>
<td>-</td>
<td>Elections and Nominations for EAU Executive and EAU Office Chair positions</td>
</tr>
<tr>
<td>-</td>
<td>• Re-election / 2nd term of the EAU Secretary General</td>
</tr>
<tr>
<td>-</td>
<td>• Election of the Adjunct Secretary General – Science</td>
</tr>
<tr>
<td>-</td>
<td>• Approval Nominations Chair and Vice-Chair of the Membership office</td>
</tr>
<tr>
<td>-</td>
<td>Report by the Secretary General on the EAU Membership</td>
</tr>
<tr>
<td>-</td>
<td>• Approval new EAU members</td>
</tr>
<tr>
<td>-</td>
<td>• Approval new Honorary members</td>
</tr>
<tr>
<td>07:15 - 08:15</td>
<td>Other business: Report of the chairman of the EAU Research Foundation (EAURF)</td>
</tr>
<tr>
<td>A.S. Bjartell, Malmö (SE)</td>
<td></td>
</tr>
<tr>
<td>07:15 - 08:15</td>
<td>Announcement of the 35th Annual EAU Congress in Amsterdam, 20-24 March 2020</td>
</tr>
</tbody>
</table>
Bladder cancer in the young patient: Unique aspects
Plenary Session 1
Saturday 16 March
08:15 - 10:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 - 08:40</td>
<td>Fertility in the young female patient with bladder cancer</td>
</tr>
</tbody>
</table>
| 08:15 - 08:20 | Setting the stage  
F.C. Burkhard, Bern (CH)                          |
| 08:20 - 08:30 | Surgical aspects  
J. Cresswell, Middlesbrough (GB)           |
| 08:30 - 08:40 | Pregnancy and delivery: What do you need to know  
E. Chartier-Kastler, Paris (FR)         |
| 08:40 - 09:10 | Immunotherapy in localised disease                                                      |
| 08:40 - 08:55 | Beyond BCG in non-muscle invasive bladder cancer  
A.M. Kamat, Houston (US)                   |
| 08:55 - 09:10 | Perioperative systemic immunotherapy in Muscle Invasive Bladder Cancer (MIBC): Where are we heading?  
A. Necchi, Milan (IT)         |
| 09:10 - 09:25 | Molecular aspects in young patients  
R. Seiler, Bern (CH)                         |
| 09:25 - 10:00 | Case-based debate  
No evidence of disease after neoadjuvant chemotherapy for MIBC: What next?  
Moderator: M. Brausi, Modena (IT)      |
| 09:25 - 09:30 | Case presentation  
M. Brausi, Modena (IT)                     |
| 09:30 - 09:38 | Cystectomy  
V. Hernández Cañas, Madrid (ES)           |

**Aims and objectives of this session**
In young patients with bladder cancer the physician is faced with unique aspects associated with younger age. This session focuses on special challenges such as preserving fertility and the problems of pregnancy and delivery after urinary diversion and also addresses the role of developing diagnostic and therapeutic options in the younger patient. Specific molecular aspects and pathways and perspectives in the use of systemic immunotherapy in that setting will also be discussed extensively.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:38 - 09:46</td>
<td>Chemoradiation</td>
<td>J. Efstathiou, Boston (US)</td>
<td></td>
</tr>
<tr>
<td>09:46 - 09:54</td>
<td>Active surveillance</td>
<td>E. Solsona, Valencia (ES)</td>
<td></td>
</tr>
<tr>
<td>09:54 - 09:59</td>
<td>What can we expect from imaging?</td>
<td>V. Panebianco, Rome (IT)</td>
<td></td>
</tr>
<tr>
<td>09:59 - 10:00</td>
<td>Summary</td>
<td>M. Brausi, Modena (IT)</td>
<td></td>
</tr>
</tbody>
</table>
## Nightmare session: Stones

**Location:** Red Area, eURO Auditorium 2  
**Chairs:**  
T. Knoll, Sindelfingen (DE)  
T.S. O'Brien, London (GB)

### Aims and objectives of this session
Stones are everywhere. No urology unit can afford not to treat stones. Treatment has become a minimally-invasive daily business with low morbidity. However, pitfalls are everywhere and complications where nobody expects them are disappointing for urologists and patients. We will discuss some routine procedures leading to significant issues to identify risk factors and preventive strategies.

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 - 08:50</td>
<td>Case-based debate</td>
<td>The forgotten stent</td>
</tr>
<tr>
<td>08:15 - 08:20</td>
<td>Case presentation</td>
<td>K. Davidoff, Sofia (BG)</td>
</tr>
<tr>
<td>08:20 - 08:30</td>
<td>Evidence</td>
<td>P.J.S. Osther, Fredericia (DK)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>Cross examination</td>
<td>B. Leigh, London (GB)</td>
</tr>
<tr>
<td>08:45 - 08:50</td>
<td>Case solution</td>
<td>K. Davidoff, Sofia (BG)</td>
</tr>
<tr>
<td>08:50 - 09:25</td>
<td>Case-based debate</td>
<td>Severe sepsis following ureteroscopy</td>
</tr>
<tr>
<td>08:50 - 08:55</td>
<td>Case presentation</td>
<td>M. Fiedler, Heilbronn (DE)</td>
</tr>
<tr>
<td>08:55 - 09:05</td>
<td>Evidence</td>
<td>J. Denstedt, London (CA)</td>
</tr>
<tr>
<td>09:05 - 09:20</td>
<td>Cross examination</td>
<td>B. Leigh, London (GB)</td>
</tr>
<tr>
<td>09:20 - 09:25</td>
<td>Case solution</td>
<td>M. Fiedler, Heilbronn (DE)</td>
</tr>
<tr>
<td>09:25 - 10:00</td>
<td>Case-based debate</td>
<td>Bowel injury following percutaneous nephrolithotomy</td>
</tr>
<tr>
<td>09:25 - 09:30</td>
<td>Case presentation</td>
<td>L.B. Dragoş, Timisoara (RO)</td>
</tr>
<tr>
<td>09:30 - 09:40</td>
<td>Evidence</td>
<td>C.C. Seitz, Vienna (AT)</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>09:40 - 09:55</td>
<td>Cross examination</td>
<td>B. Leigh, London (GB)</td>
</tr>
<tr>
<td>09:55 - 10:00</td>
<td>Case solution</td>
<td>L.B. Dragoş, Timisoara (RO)</td>
</tr>
</tbody>
</table>
### Aims and objectives of this session

The ESU Course on testicular cancer will cover all important issues in the diagnosis and treatment of patients with germ cell cancer. There will be time for discussion during and after the presentations. Case reports will be discussed to highlight special situations of controversy. In addition, short video clips will be presented to demonstrate surgical techniques in retroperitoneal residual tumour resection.

In brief, following items will be presented and discussed:
- EAU Guideline recommended staging procedures classifications like IGCCCG.
- Stage-by-stage treatment of low stage disease including TIN.
- Chemotherapy and indication of post chemotherapy surgery according to EAU guidelines.
- Recommended follow-up investigations, long-term toxicities, 2nd malignancies.

### Testicular cancer - Early stages

N.W. Clarke, Manchester (GB)

### Testicular cancer - Case discussion

N.W. Clarke, Manchester (GB)

### Testicular cancer - Advanced stages

P. Albers, Düsseldorf (DE)

### Testicular cancer - Case discussion

P. Albers, Düsseldorf (DE)
Treatment of small renal masses
ESU Course 03

Location: Green Area, Room 14
Chair: P. Gontero, Turin (IT)

Aims and objectives of this session
- The course aims to address the multiplicity of treatment options for small renal masses (SRM).
- Essential concepts to guide the clinical decision making process will be interactively discussed with the help of clinical cases.
- Practical tips for a safe and effective treatment delivery will be provided on the current standard of ablative therapies and minimally invasive surgery.
- Attendees should become familiar on when and how to propose active surveillance in their daily clinical practice.

Introduction
P. Gontero, Turin (IT)

Active surveillance and ablative therapies: When and how
P. Gontero, Turin (IT)

Minimally invasive surgery: Tips and tricks
F. Keeley, Bristol (GB)

How to choose the best treatment for SRM: A clinical case based approach
P. Gontero, Turin (IT)
F. Keeley, Bristol (GB)
Renal transplantation: Technical aspects, diagnosis and management of early and late urological complications
ESU Course 02

Saturday 16 March
08:30 - 10:30

Location: Green Area, Room 15
Chair: F.J. Burgos Revilla, Madrid (ES)

Aims and objectives of this session
Renal transplant is an essential part of urology. The aims of the course are:
• To show surgical techniques of organ procurement in deceased and living donation settings.
• To establish the basic principles for evaluation of candidates to donation and recipients of kidney graft.
• To show the different approaches and surgical details of kidney transplant in conventional and complex recipients.
• To review the algorithms for diagnosis and treatment of medical and surgical complications after kidney transplantation.

Selection and urological preparation of transplant recipients. Surgical aspects of deceased donor nephrectomy
A.J. Figueiredo, Coimbra (PT)

Living donor nephrectomy: Technical alternatives and controversies
F.J. Burgos Revilla, Madrid (ES)

Renal transplantation. Surgical options: Tips and tricks
A.J. Figueiredo, Coimbra (PT)

How to diagnose and manage postoperative and long-term complications following renal transplantation
F.J. Burgos Revilla, Madrid (ES)
How to write the introduction and methods
ESU Course 01

Location: Green Area, Room 16
Chair: J.W.F. Catto, Sheffield (GB)

Aims and objectives of this session
Understand how to construct a well written introduction and methods section for your manuscript. Learn how to work through examples of good and bad practices, and understand key points when writing. Obtain insight from editors on what they expect to see.

• To understand what makes good introduction.
• To understand what makes a good methods section.
• To understand about systematic reviews and meta-analysis.
• To learn from experienced editors.

Welcome
J.W.F. Catto, Sheffield (GB)

Writing the introduction
M.R. Cooperberg, San Francisco (US)

How to write the methods section
M. Albersen, Leuven (BE)

Key features for a systematic review
G. Novara, Padova (IT)

What to look for in the statistics section
D. Sjoberg, New York (US)
Aims and objectives of this session

Urolithiasis is an increasingly prevalent worldwide disease with recurrence rates up to 50% over 5 years. Metabolic assessment to identify predisposing factors and prevention therefore play an important role in patient management. This course will address common findings on dietary and metabolic workup and highlight medical and non-medical treatment options for these metabolic abnormalities in the prevention of stone recurrence.

The goal of the course is for participants to be able to
• Identify patients that would benefit from metabolic workup.
• Interpret standard metabolic workup, including dietary and medical history and biochemical analyses.
• Understand what the guidelines say on targeted medical treatment for prevention of urinary stone disease.
• Understand the influence of dietary changes on metabolic urinary values and provide dietary counseling.

Who needs a metabolic evaluation and why should this be done
T. Tailly, Ghent (BE)

How to do a metabolic evaluation, step by step
O. Wiseman, Cambridge (GB)

Common stone types: What abnormalities might we find on investigation?
T. Tailly, Ghent (BE)

Stone and diet: What advice should we give?
O. Wiseman, Cambridge (GB)

Medical treatment for stones: What works?
T. Tailly, Ghent (BE)

Case discussions
T. Tailly, Ghent (BE)
O. Wiseman, Cambridge (GB)
Aims and objectives of this session
An increasing number of urological surgeons are developing a surgical practice which involves prosthetic surgery. This course will aim to cover the key areas of prosthetic surgery in urology with the aid of a video based platform. The course is aimed at urological trainees as well as established urologists wishing to develop a practice or gain an update and surgical tips in this area.

Surgical techniques with the aid of semi-live surgery will be a key focus of this course. At the end of the course participants should have a good understanding of:

- Minimising the risk of prosthesis infection and understand the role of biofilms.
- Theatre preparation and set up for prosthetic surgery.
- Patient selection and prosthetic surgery for male and female urinary incontinence including artificial urinary sphincters and sacral neuromodulation.
- Penile prosthesis surgery – surgical techniques, avoiding complications and revision surgery.

Introduction to biofilms and prosthetic infections
A. Muneer, London (GB)

Theatre set up and preparation of patients
A. Muneer, London (GB)

Prosthetic surgery for male urinary incontinence - Male slings and AUS
S. Malde, London (GB)

Prosthetic surgery for female urinary incontinence
S. Malde, London (GB)

Penile prosthesis surgery – Surgical technique and avoiding complications
A. Muneer, London (GB)

Dealing with intraoperative complications and penile prosthesis revision surgery
A. Muneer, London (GB)
Prostate biopsy - Tips and tricks
ESU Course 07

Location: Green Area, Room 23
Chair: P. Hammerer, Braunschweig (DE)

Aims and objectives of this session
• Provide an update on recent imaging techniques like TRUS, Elastography, Histoscanning, multiparametric magnetic resonance imaging (mpMRI) and nuclear imaging techniques for prostate cancer diagnosis.
• Explain standard reporting systems for ultrasound and mpMRI like PI-RADS.
• Discuss different prostate biopsy techniques.
• Tips and Tricks to reduce morbidity of prostate biopsies.

Indications for TRUS and biopsy
P. Hammerer, Braunschweig (DE)

Practical aspects of TRUS and TRUS-guided biopsies
P. Hammerer, Braunschweig (DE)

Indications for rebiopsy
C. Moore, London (GB)

Update on new technical developments
C. Moore, London (GB)
ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone treatment - step 1
Sponsored by KARL STORZ

Saturday 16 March
09:30 - 10:30

Location: Green Area, Room 6

Tutors: A. Ploumidis, Athens (GR)
K. Ahmed, London (GB)
S. Proietti, Milan (IT)
N. Macchione, Milan (IT)
J.P. Caballero Romeu, Alicante (ES)
M. Cepeda, Valladolid (ES)

Chair: B. Somani, Southampton (GB)

Aims and objectives of this session
In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

• At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
• The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.
Aims and objectives of this session
Subtitle: Interpretation of invasive urodynamic tests
Course: Expert Urodynamic test interpretation; cystometry and pressure flow.
Audience: Urologists, medical doctors nurses and technicians looking to improve their knowledge and expertise in the evaluation of urodynamic test results.
Keywords: ICS standard, Good Urodynamic Practice, Quality UDS, Artefacts/Pitfalls, Technique, Reporting, Urodynamic diagnosis.
Goal: At the end of the course, the participants have increased their knowledge to evaluate and improve the quality of their urodynamic procedures following the ICS standards. We will discuss how different types of artefacts are recognizable. We will also discuss prevention and correction of various types of errors and artifacts. A structured way of reporting a urodynamic test results and urodynamic diagnosis will be explained.
YUORDay19 - EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU)

**Specialty Session**

**Location:** Green Area, Room 2

**Chairs:** J. Gómez Rivas, Madrid (ES)  
J.P.M. Sedelaar, Nijmegen (NL)

**Aims and objectives of this session**
In this session we introduce the European Society of Residents in Urology (ESRU) and the Young Urology Office (YUO). The main aim of this session is to offer talks tailored to residents' educational needs. We present the traditional surgical tips and tricks with all you need to know about certain surgical procedures. Furthermore, we show what residents need to know on the most recent oncological studies. Modern surgical practice requires technical and non-technical skills. As a new feature this year, we present the “soft skills session” together with the Young Endourological society. We will finish with the great finale of the EAU Guidelines Cup, a competition between the three finalists of the Cup and also the audience.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
</table>
| 10:00 - 10:10 | Welcome and introduction                            | J. Gómez Rivas, Madrid (ES)  
J.P.M. Sedelaar, Nijmegen (NL) |
| 10:10 - 10:55 | European Urology Scholarship Programme (EUSP)       | F. Esperto, Sheffield (GB)  
V.G. Mirone, Naples (IT) |
<p>| 10:10 - 10:20 | EUSP Programme; does it deserve your attention?        | M.J. Ribal Caparros, Barcelona (ES)              |
| 10:20 - 10:28 | EUSP Scholarship: Science in practice              | J.A. Schalken, Nijmegen (NL)                      |
| 10:28 - 10:36 | EUSP Scholarship: Practice makes perfection       | G. Patruno, Rome (IT)                              |
| 10:36 - 10:41 | Why it is worth to have a visiting Professor in your centre? | T.A. Borkowski, Warsaw (PL)                       |
| 10:41 - 10:45 | Announcing the Best Scholar award winners          | V.G. Mirone, Naples (IT)                           |
| 10:45 - 10:48 | Presentation Best Scholar award winner clinical research | V.M.J. De Coninck, Paris (FR)                   |
| 10:48 - 10:51 | Presentation Best Scholar award winner basic research | M.D. Vartolomei, Targu Mures (RO)                |
| 10:51 - 10:55 | Questions and answers                             |                                                 |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Moderators</th>
</tr>
</thead>
</table>
| 10:55 - 11:15 | EAU session                                                          | S. Nikles, Zagreb (HR)  
                        |                                      | J.L. Vásquez, Herlev (DK)            |
| 10:55 - 11:05 | What can the EAU do for you?                                         | J.P.M. Sedelaar, Nijmegen (NL)           |
| 11:05 - 11:15 | European Board of Urology                                            | A.J. Figueiredo, Coimbra (PT)            |
| 11:15 - 11:15 | Introduction YUO Leadership Course                                  | J.P.M. Sedelaar, Nijmegen (NL)           |
| 11:15 - 12:15 | What do the residents need to know about...                         | P.B. Østergren, Herlev (DK)              
                        |                                      | J. Gómez Rivas, Madrid (ES)         |
| 11:15 - 11:30 | CPRC M0. Prosper and Spartan trials                                  | M. Rouprêt, Paris (FR)                   |
| 11:30 - 11:45 | M+ Renal carcinoma. CARMENA trial                                     | U. Capitanio, Milan (IT)                 |
| 11:45 - 12:00 | MRI in prostate cancer. PRECISION trial                             | V. Kasivisvanathan, London (GB)          |
| 12:00 - 12:15 | Upper Tract Carcinoma. POUT trial                                    | S. Shariat, Vienna (AT)                  |
| 12:15 - 12:30 | Surgery tips and tricks                                              | A. Cebulla, Ulm (DE)                     
                        |                                      | T. Ucar, Istanbul (TR)                 |
| 12:15 - 12:30 | Basic penile surgery                                                 | M. Fisch, Hamburg (DE)                   |
| 12:30 - 12:45 | Prepubic approach to urethrectomy                                    | H.P.A.M. Van Poppel, Leuven (BE)         |
| 12:45 - 13:00 | TURBT                                                                | T.S. O'Brien, London (GB)                |
| 13:00 - 13:15 | Urgent urinary diversions                                            | S. Proietti, Milan (IT)                  |
| 13:15 - 13:25 | The European School of Urology                                       | J. Palou, Barcelona (ES)                 |
| 13:25 - 14:20 | Joint session with the young endourological society                  | M.E. Rodríguez Socarrás, Milan (IT)  
<pre><code>                    |                                      | T. Tailly, Ghent (BE)                  |
</code></pre>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 13:40</td>
<td>Organising urological research by the young academic network: YAU</td>
</tr>
<tr>
<td></td>
<td>E. Xylinas, Paris (FR)</td>
</tr>
<tr>
<td>13:40 - 13:50</td>
<td>“The Endo Society”, where do we come from and where are we going? Serving our mutual benefit</td>
</tr>
<tr>
<td></td>
<td>J. Denstedt, London (CA)</td>
</tr>
<tr>
<td>13:50 - 14:05</td>
<td>Fellowship: The perfect transition from resident to an academic position</td>
</tr>
<tr>
<td></td>
<td>P. Kallidonis, Patras (GR)</td>
</tr>
<tr>
<td>14:05 - 14:20</td>
<td>Dealing with stress starting your career: Stay cool and work smart</td>
</tr>
<tr>
<td></td>
<td>J. Gómez Rivas, Madrid (ES)</td>
</tr>
<tr>
<td>14:20 - 15:00</td>
<td>Challenging clinical cases</td>
</tr>
<tr>
<td></td>
<td>Moderators: G. Mantica, Genoa (IT)</td>
</tr>
<tr>
<td></td>
<td>M. Taskovska, Ljubljana (SI)</td>
</tr>
<tr>
<td>14:20 - 14:40</td>
<td>Penile trauma</td>
</tr>
<tr>
<td></td>
<td>A. Van Der Merwe, Cape Town (ZA)</td>
</tr>
<tr>
<td>14:40 - 15:00</td>
<td>Urinary fistulas</td>
</tr>
<tr>
<td></td>
<td>N.I. Osman, Sheffield (GB)</td>
</tr>
<tr>
<td>15:00 - 15:45</td>
<td>New paradigms in urology</td>
</tr>
<tr>
<td></td>
<td>Moderators: D.M. Carrion, Madrid (ES)</td>
</tr>
<tr>
<td></td>
<td>D. Karsza, Budapest (HU)</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>New diagnostic imaging in Upper Tract Urothelial Carcinoma (UTUC)</td>
</tr>
<tr>
<td></td>
<td>J. Baard, Amsterdam (NL)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Robotic renal transplant</td>
</tr>
<tr>
<td></td>
<td>A. Territo, Barcelona (ES)</td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td>New robots</td>
</tr>
<tr>
<td></td>
<td>D. Veneziano, Reggio Calabria (IT)</td>
</tr>
<tr>
<td>15:45 - 16:45</td>
<td>Guidelines cup</td>
</tr>
<tr>
<td></td>
<td>Moderators: G. Dosin, Bruxelles (BE)</td>
</tr>
<tr>
<td></td>
<td>J.L. Vásquez, Herlev (DK)</td>
</tr>
<tr>
<td>15:45 - 16:45</td>
<td>Guideline masters</td>
</tr>
<tr>
<td></td>
<td>M. Albersen, Leuven (BE)</td>
</tr>
<tr>
<td></td>
<td>T.A.T. Marcelissen, Maastricht (NL)</td>
</tr>
<tr>
<td></td>
<td>M.J. Ribal Caparros, Barcelona (ES)</td>
</tr>
<tr>
<td>16:45 - 16:55</td>
<td>Prices and awards</td>
</tr>
<tr>
<td></td>
<td>J. Gómez Rivas, Madrid (ES)</td>
</tr>
<tr>
<td></td>
<td>J.P.M. Sedelaar, Nijmegen (NL)</td>
</tr>
</tbody>
</table>
New medical and surgical options in andrological treatment: From molecular biology to surgery and from philosophy to ethics
Meeting of the EAU Section of Andrological Urology (ESAU)

Saturday 16 March 10:00 - 14:00

Location: Green Area, Room 3
Chair: N. Sofikitis, Ioannina (GR)

Aims and objectives of this session
The main objective of the meeting of the EAU Section of the European Section of Andrological Urology is to provide the latest information on several controversial issues and unanswered questions in the fields of male infertility, male endocrinology, and sexual medicine. Video presentations will assist the participants to pick up the tips and tricks of several surgical procedures in the male genital tract as take home-messages. Time-lapse cinematography of embryological development will raise an important role for the male gamete-DNA beyond fertilisation susceptible to philosophical considerations. Emphasis will be given to the molecular biology- basis of several andrological pathophysiologies. Novel surgical techniques, ethical barriers, and physiological consequences of disputable and criticised procedures such as penile elongation/penile enlargement and gender reassignment surgery will be discussed. The role of the andrologist in the oncological clinics will be promoted. In addition this meeting will provide compelling evidence for the unique role of testosterone as a source of youth for the male. Discussion of interesting case reports will give the opportunity for an active interaction between the faculty members and the participants.

10:00 - 10:01
Welcome and introduction
N. Sofikitis, Ioannina (GR)

10:01 - 10:10
State-of-the-art lecture Penile rehabilitation after radical prostatectomy: Where we are today?
Moderators: J.I. Martínez Salamanca, Majadahonda (ES)
J. Rassweiler, Heilbronn (DE)
Speaker: F. Montorsi, Milan (IT)

10:10 - 10:28
Debate Penile elongation and enlargement surgery: Should we do it?
Moderators: O. Apolikhin, Moscow (RU)
M.M. Fode, Herlev (DK)
Pro: D.J. Ralph, London (GB)
Con: C. Bettocchi, Bari (IT)

10:28 - 10:55
Challenges in andrology
Moderators: S. Pahernik, Nuremberg (DE)
J.O.R. Sønksen, Herlev (DK)

10:28 - 10:37
Early or delayed penile implant insertion in low flow priapism
P.A.S. Vendeira, Matosinhos (PT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:37 - 10:46</td>
<td>Can male infertility serve as an indicator of male health status?</td>
<td>A. Salonia, Milan (IT)</td>
</tr>
<tr>
<td>10:46 - 10:55</td>
<td>Asymptomatic infections in the male reproductive tract: Consequences on male fertility</td>
<td>S. Kliesch, Münster (DE)</td>
</tr>
<tr>
<td>10:55 - 11:16</td>
<td>Surgery in motion: Sexual medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderators: O. Apolikhin, Moscow (RU)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M.F. Usta, Antalya (TR)</td>
<td></td>
</tr>
<tr>
<td>10:55 - 11:03</td>
<td>Prevention and treatment of the infected penile prosthesis</td>
<td>E. Ruiz-Castañé, Barcelona (ES)</td>
</tr>
<tr>
<td>11:03 - 11:11</td>
<td>Advances in reconstructive surgery in Peyronie’s disease</td>
<td>A. Kadioglu, Istanbul (TR)</td>
</tr>
<tr>
<td>11:11 - 11:16</td>
<td>The difficult penile implant</td>
<td>P. Egydio, Sao Paulo (BR)</td>
</tr>
<tr>
<td>10:55 - 11:16</td>
<td>Surgery in motion: Sexual medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderators: A. Muneer, London (GB)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Takenaka, Yonago (JP)</td>
<td></td>
</tr>
<tr>
<td>11:16 - 11:36</td>
<td>Urethral reconstruction and sexual function</td>
<td>A. Muneer, London (GB)</td>
</tr>
<tr>
<td>11:26 - 11:36</td>
<td>Stem cell therapies in erectile dysfunction: Is it too early or too risky?</td>
<td>M. Albersen, Leuven (BE)</td>
</tr>
<tr>
<td>11:36 - 11:54</td>
<td>Testosterone as a source of youth for the male</td>
<td>E. Ruiz-Castañé, Barcelona (ES)</td>
</tr>
<tr>
<td></td>
<td>Moderators: A. Takenaka, Yonago (JP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>P. Verze, Naples (IT)</td>
<td></td>
</tr>
<tr>
<td>11:36 - 11:45</td>
<td>Controversies of the effects of testosterone treatment on cardiovascular events</td>
<td>A. Giwercman, Malmö (SE)</td>
</tr>
<tr>
<td>11:45 - 11:54</td>
<td>How much evidence is available for the treatment of late-onset male hypogonadism?</td>
<td>G.R. Dohle, Rotterdam (NL)</td>
</tr>
<tr>
<td>11:54 - 12:30</td>
<td>Surgery of the testis and male infertility</td>
<td>C-C. Abbou, Créteil (FR)</td>
</tr>
<tr>
<td></td>
<td>Moderators: S.S. Minhas, London (GB)</td>
<td></td>
</tr>
<tr>
<td>11:54 - 12:03</td>
<td>Do we need robotic surgery in andrology?</td>
<td>T. Diemer, Giessen (DE)</td>
</tr>
<tr>
<td>12:03 - 12:12</td>
<td>Are there any indications for varicocele repair beyond the EAU Guidelines?</td>
<td>S.S. Minhas, London (GB)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>12:12 - 12:21</td>
<td>Is there a role for salvage testicular sperm extraction in the setting of a negative sperm retrieval?</td>
<td>M. Dinkelman-Smit, Rotterdam (NL)</td>
</tr>
<tr>
<td>12:21 - 12:30</td>
<td>Onco-testicular sperm extraction (onco-TESE): Indications, outcomes, and effects on testicular endocrine function</td>
<td>F. Fusco, Naples (IT)</td>
</tr>
<tr>
<td>12:30 - 12:48</td>
<td>Surgery in motion: Male infertility</td>
<td>Moderators: T. Diemer, Giessen (DE) F. Dimitriadis, Kalamaria, Thessaloniki (GR)</td>
</tr>
<tr>
<td>12:30 - 12:38</td>
<td>Video presentation Microdissection TESE, TESA, and MESA: How do I do it?</td>
<td>W.J. Huang, Taipei (TW)</td>
</tr>
<tr>
<td>12:38 - 12:43</td>
<td>Video presentation Real-time observation of varicocele-induced effects on early embryonic development by lapse cinematography</td>
<td>N. Sofikitis, Ioannina (GR)</td>
</tr>
<tr>
<td>12:43 - 12:48</td>
<td>Video presentation Tips and tricks in the identification of the testicular artery during varicocele repair</td>
<td>S. Çayan, Mersin (TR)</td>
</tr>
<tr>
<td>13:06 - 13:15</td>
<td>Vaginoplasty: Tips and tricks for aesthetic outcome</td>
<td>F. Fusco, Naples (IT)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Presenter</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>13:42 - 13:45</td>
<td><strong>Case presentation 1</strong></td>
<td>P.A.S. Vendeira</td>
</tr>
<tr>
<td>13:45 - 13:48</td>
<td><strong>Case presentation 2</strong></td>
<td>M.F. Usta</td>
</tr>
<tr>
<td>13:48 - 13:51</td>
<td><strong>Case presentation 3</strong></td>
<td>P. Egydio</td>
</tr>
<tr>
<td>13:51 - 13:59</td>
<td><strong>Panel discussion</strong></td>
<td></td>
</tr>
<tr>
<td>13:59 - 14:00</td>
<td><strong>Closing remarks</strong></td>
<td>N. Sofikitis</td>
</tr>
</tbody>
</table>
Aims and objectives of this session
Treatment concepts in the contemporary management of stone disease have considerably changed in the last two decades in the light of the remarkable technological advances, coupled with increased experience in both adults and children. Clinical introduction of new treatment methods along with the effective use of disposable instruments led us to change our existing treatment policies in order to ease the procedures with acceptable “stone free” rates and limited or no complications. Management of stones in certain patient populations requiring special expertise will be demonstrated and discussed during semi-live video presentations by experienced surgeons. Thus, in this EULIS session we will take a close look at the recent developments, particularly new minimally invasive stone treatment procedures in complex cases. Additionally, we will try to focus on the importance of experience with tips and tricks from the experts to increase stone-free rates and limit well-known complications. The possible introduction of new treatment concepts and/or new future treatment modalities that can further minimize the invasiveness and increase patient acceptance will also be discussed in detail.

10:00 - 10:03  Welcome and introduction
K. Sarica, Istanbul (TR)

10:03 - 10:43  Pathophysiology and non-surgical management of stones: What’s new?
*Moderators:* G. Gambaro, Rome (IT)  
J.P. Haymann, Paris (FR)  
D.J. Kok, Oegstgeest (NL)  
C.A. Wagner, Zurich (CH)

10:03 - 10:13  The renal papilla and kidney stone formation: Where are we in 2019?
D. Lange, Vancouver (CA)

10:13 - 10:23  Urolithiasis as a systemic disorder: What are the hypotheses?
K. Sarica, Istanbul (TR)

10:23 - 10:33  Dietary management of urinary stones: Tips and tricks based on stone composition
P. M. Ferraro, Rome (IT)

10:33 - 10:43  Herbal treatments for renal stones: Myth or fact
S. Al-Hayek, Cambridge (GB)

10:43 - 11:31  Video session 1: Percutaneous management of 1-2 cm renal stones – How I do it
*Moderators:* M. Cepeda, Valladolid (ES)  
P.A. Geavlete, Bucharest (RO)  
A. Papatsoris, Athens (GR)  
A. Szendröi, Budapest (HU)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:43 - 10:55 | Video presentation: **Mini-PNL**  
|              | S. Lahme, Pforzheim (DE)                                              |
| 10:55 - 11:07 | Video presentation: **Ultra-mini PNL**  
|              | U. Nagele, Hall in Tirol (AT)                                        |
| 11:07 - 11:19 | Video presentation: **Super-mini PNL**  
|              | G.H. Zeng, Guangzhou (CN)                                            |
| 11:19 - 11:31 | Video presentation: **Flexible URS**  
|              | T. Knoll, Sindelfingen (DE)                                          |
| 11:31 - 11:41 | **Late breaking news**  
|              | **TISU: A randomised trial of ESWL vs URS**  
|              | S. McClinton, Aberdeen (GB)                                          |
| 11:41 - 12:01 | **Lasers for stones: What is new?**  
|              | **Moderators:** E. Cicerello, Treviso (IT)  
|              | C.C. Seitz, Vienna (AT)                                              
|              | S.P. Zanetti, Milan (IT)                                             |
| 11:41 - 11:51 | **Impact of laser settings on lithotripsy performance**  
|              | A. Miernik, Freiburg (DE)                                            |
| 11:51 - 12:01 | **New lasers for stone treatment in 2020: What can we expect?**  
|              | O. Traxer, Paris (FR)                                                |
| 12:01 - 12:49 | Video session 2: **Management of complex renal stones – How I do it**  
|              | **Moderators:** P. Kallidonis, Patras (GR)  
|              | M. Özsoy, Vienna (AT)                                                
|              | I. Saltirov, Sofia (BG)                                               
|              | A. Skolarikos, Athens (GR)                                           |
| 12:01 - 12:13 | Video presentation: **Paediatric lower calyceal stone – Micro PNL**  
|              | M. Straub, Munich (DE)                                               |
| 12:13 - 12:25 | Video presentation **Large and complex renal stone: Upper pole approach in supine position**  
|              | M.I. Gökce, Ankara (TR)                                              |
| 12:25 - 12:37 | Video presentation **Large renal pelvic stone (>20 mm): FURS without access sheath**  
|              | R. Cansino, Madrid (ES)                                              |
| 12:37 - 12:49 | Video presentation **Pediatric large renal stone (>15 mm): Standard PNL**  
|              | B. Önal, Istanbul (TR)                                               |
| 12:49 - 13:09 | **Sepsis after endourologic management of stones: How to minimise the risk**  
|              | **Moderators:** J.P. Caballero Romeu, Alicante (ES)  
|              | D. Prezioso, Naples (IT)                                             
|              | L. Villa, Milan (IT)                                                |
| 12:49 - 12:59 | **Pre-, intra- and post-op work-up in infections in stones**  
<p>|              | E. Montanari, Milan (IT)                                             |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
A. Hoznek, Creteil (FR) |
*Moderators:*  
J. Galán-Llopis, Alicante (ES)  
F. Sanguedolce, Barcelona (ES)  
C. Türk, Vienna (AT)  
G. Wendt-Nordahl, Sindelfingen (DE) |
| 13:09 - 13:19 | **Disposable URS: Suitable for stones?**  
A. Budía Alba, Valencia (ES) |
| 13:19 - 13:29 | **Which role plays anatomy for PNL?**  
A. Bourdoumis, Manchester (GB) |
| 13:29 - 13:39 | **A unique tool in order to intraoperatively tailor the best procedure on the patient with stone disease for a maximally safe and effective treatment**  
C.M. Scoffone, Turin (IT) |
S. Hruby, Zell am See (AT) |
| 13:49 - 13:59 | **Development of a training curriculum for percutaneous renal surgery**  
K. Ahmed, London (GB) |
| 13:59 - 14:00 | **Closing remarks**  
K. Sarica, Istanbul (TR) |
Prepare for the future: Prevent, detect, strike back!
Joint meeting of the EAU Section of Infections in Urology (ESIU) and the EAU Section of Urological Imaging (ESUI)

Saturday 16 March
10:00 - 14:00

Location: Green Area, Room 10
Chairs: G. Salomon, Hamburg (DE)  
F.M.E. Wagenlehner, Giessen (DE)

Aims and objectives of this session
Get prepared for the future: This joined session of ESIU and ESUI will handle the dilemma of increasing antibiotic resistance, what to expect and what to do. The impact of increasing antibiotic resistance on infectious complications after prostatic biopsies will be highlighted. If or how imaging can help to avoid prostatic biopsies, and if imaging can in any way help in chronic systemic infections. In addition the hottest topics in imaging (PIRADS v3 and radioguided surgery)

10:00 - 10:05
Welcome and introduction
G. Salomon, Hamburg (DE)  
F.M.E. Wagenlehner, Giessen (DE)

10:05 - 10:50
The dilemma of increasing antibiotic resistance in the prostate
Moderators: T.E. Bjerklund Johansen, Oslo (NO)  
V. Scattoni, Milan (IT)

10:05 - 10:20
Increasing prevalence of biopsy-related complications and increasing incidence of antibiotic resistance
Z. Tandoğdu, Edinburgh (GB)

10:20 - 10:35
Rectal preparations: Evidence and clinical practice
A. Pilatz, Giessen (DE)

10:35 - 10:50
Targeted prophylaxis: What you need to know
T. Cai, Trento (IT)

10:50 - 12:20
Decreasing the risk of biopsy-related complications by imaging
Moderators: M. Ritter, Mannheim (DE)  
A. Villers, Lille (FR)

10:50 - 11:05
Does the mpMRI help avoid unnecessary biopsies?
A. Villers, Lille (FR)

11:05 - 11:20
Will sophisticated ultrasound be the future?
J. Walz, Marseille (FR)

11:20 - 11:35
Better go transperineal?
V. Mouraviev, Davenport (US)

11:35 - 11:50
Time for transrectal biopsy is NOT over!
V. Scattoni, Milan (IT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:50 - 12:05| Better be prepared! Standards and recommendations for antibiotic prophylaxis in transrectal prostate biopsy  
G. Bonkat, Basel (CH) |
| 12:05 - 12:20| What to do if acute systemic infection results after prostate biopsy?  
F. Bruyere, Tours (FR) |
| 12:20 - 12:50| ESUI Hot topics  
*Moderators:*  
L. Budäus, Hamburg (DE)  
M.C. Kriegmair, Mannheim (DE) |
J.J. Futterer, Nijmegen (NL) |
| 12:35 - 12:50| Will radio-guided surgery will become state of the art?  
T. Maurer, Hamburg (DE) |
| 12:50 - 13:05| ESUI Vision Award  
*Moderators:*  
G. Salomon, Hamburg (DE)  
M. Mischi, Eindhoven (NL) |
| 12:50 - 13:00| A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies  
G. Gandaglia, Milan (IT) |
| 13:00 - 13:05| Award |
*Moderators:*  
T. Perepanova, Moscow (RU)  
B. Wullt, Helsingborg (SE) |
| 13:05 - 13:20| How to reduce antibiotic administrations  
R. Bartoletti, Pisa (IT) |
| 13:20 - 13:35| Non-antibiotic treatment in Urinary Tract Infection (UTI)  
J. Kranz, Eschweiler (DE) |
| 13:35 - 13:55| The difficulties in chronic infections/inflammations of the male genital organs  
*Moderators:*  
J.J. Futterer, Nijmegen (NL)  
E. Kulchavenya, Novosibirsk (RU) |
| 13:35 - 13:45| Does imaging help in any way?  
P. Martino, Bari (IT) |
| 13:45 - 13:55| What is the best management  
J. Medina-Polo, Madrid (ES) |
| 13:55 - 14:00| Closing remarks  
G. Salomon, Hamburg (DE)  
F.M.E. Wagenlehner, Giessen (DE) |
New modalities in diagnosis and treatment in oncology
Joint meeting of the EAU Section of Oncological Urology (ESOU), the EAU Robotic Urology Section (ERUS), the EAU Section of Uro-Technology (ESUT) and with the ECCO, EORTC GUCG, ESMO, ESSO, ESTRO and EUOG

Saturday 16 March
10:15 - 15:00

Location: Red Area, eURO Auditorium 2
Chairs: M. Brausi, Modena (IT)
        E. Liatsikos, Patras (GR)
        H.G. Van Der Poel, Amsterdam (NL)

Aims and objectives of this session
To give an update on diagnosis and treatment of urological malignancies. The importance of new technologies and training facilities for young European urologists will be illustrated together. Basic science advancements in oncurology will be also presented and discussed with the audience.

10:15 - 10:20
Welcome and introduction
M. Brausi, Modena (IT)
E. Liatsikos, Patras (GR)
H.G. Van Der Poel, Amsterdam (NL)

10:20 - 10:35
The European Uro-Oncology Group (EUOG)

10:20 - 10:30
Genetics in bladder cancer
S. Osanto, Leiden (NL)

10:30 - 10:35
Discussion

10:35 - 10:50
The European Cancer Organisation (ECCO)

10:35 - 10:45
The essential requirements of quality cancer care
I. Banks, Spa (IE)

10:45 - 10:50
Discussion

10:50 - 11:05
The European Society for Radiotherapy & Oncology (ESTRO)

10:50 - 11:00
Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
P. Hoskin, Northwood (GB)

11:00 - 11:05
Discussion

11:05 - 11:20
The European Society for Medical Oncology (ESMO)
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05 - 11:15</td>
<td>Neo-adjuvant chemotherapy and checkpoint inhibitors in muscle-invasive bladder cancer</td>
<td>A. Bamias, Athens (GR)</td>
</tr>
<tr>
<td>11:15 - 11:20</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:30</td>
<td>New therapeutic strategies in the treatment of renal cancer</td>
<td>A. Bex, Amsterdam (NL)</td>
</tr>
<tr>
<td>11:30 - 11:35</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:35 - 11:50</td>
<td>The European Society of Surgical Oncology (ESSO)</td>
<td></td>
</tr>
<tr>
<td>11:35 - 11:45</td>
<td>Multidisciplinary surgical team (GS, U, Gy, RO, VS) in advanced pelvic tumours</td>
<td>D. Lorente Garcia, Barcelona (ES)</td>
</tr>
<tr>
<td>11:45 - 11:50</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:50 - 11:50</td>
<td>ESOU-ESUR-ESUT: Advances in diagnosis and treatment of cancer</td>
<td></td>
</tr>
<tr>
<td>12:05 - 12:10</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:10 - 12:25</td>
<td>The role of mpMRI in prostate cancer patients eligible for active surveillance</td>
<td>C. Moore, London (GB)</td>
</tr>
<tr>
<td>12:25 - 12:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:30 - 12:55</td>
<td>Debate Focal therapy in intermediate risk patients</td>
<td></td>
</tr>
<tr>
<td>12:30 - 12:40</td>
<td>Pro</td>
<td>M. Emberton, London (GB)</td>
</tr>
<tr>
<td>12:40 - 12:50</td>
<td>Con</td>
<td>A. Alcaraz, Barcelona (ES)</td>
</tr>
<tr>
<td>12:50 - 12:55</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:55 - 13:05</td>
<td>Radical prostatectomy (open vs robotic) in oligometastatic prostate cancer</td>
<td>F. Montorsi, Milan (IT)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>13:05 - 13:10</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>13:10 - 13:20</td>
<td>Robotic radical cystectomy with intracorporeal diversion: Really the standard or only for a few?</td>
<td>H.G. Van Der Poel, Amsterdam (NL)</td>
</tr>
<tr>
<td>13:20 - 13:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>13:25 - 13:35</td>
<td>Robotic radical nephrectomy for locally-advanced renal cancer</td>
<td></td>
</tr>
<tr>
<td>13:35 - 13:40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>13:40 - 13:45</td>
<td>Debate</td>
<td>Radiotherapy and bladder preservation in muscle-invasive bladder cancer</td>
</tr>
<tr>
<td>13:40 - 13:50</td>
<td>Pro</td>
<td></td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Con</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:05 - 14:10</td>
<td>Debate</td>
<td>Renal-sparing surgery for T2 Renal Cell Carcinoma (RCC): Always indicated?</td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>14:15 - 14:25</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>14:25 - 14:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td>Debate</td>
<td>Conservative treatment of MI Upper urinary tract tumours: Any role?</td>
</tr>
<tr>
<td>14:30 - 14:40</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>14:40 - 14:50</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>14:50 - 14:55</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:55 - 15:00</td>
<td>Closing remarks</td>
<td></td>
</tr>
</tbody>
</table>
### Innovative surgical procedures in functional urology

**Meeting of the EAU Section of Female and Functional Urology (ESFFU)**

**Saturday 16 March**

**Location:** Green Area, Room 1

**Chair:** F. Cruz, Porto (PT)

#### Aims and objectives of this session

Functional urology requires expertise in a large number of complex surgeries on the lower urinary tract. Along the years, many of these surgeries incorporated numerous technical advances initially applied in other fields of urology or the result of the search for minimally-invasive procedures. The main objective of this session is to review some of the surgical innovations introduced in functional urology and discuss some of the present controversies related to the minimally-invasive treatment of female stress urinary incontinence.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 - 10:20</td>
<td><strong>Welcome and introduction</strong></td>
<td>F. Cruz, Porto (PT)</td>
</tr>
</tbody>
</table>
| 10:20 - 11:20 | **Robotics is arriving to functional urology** | F.C. Burkhard, Bern (CH)  
E. Chartier-Kastler, Paris (FR) |
| 10:20 - 10:32 | **Colposuspension**              | P. Dasgupta, London (GB)          |
| 10:32 - 10:35 | **Discussion**                   |                                   |
| 10:35 - 10:47 | **Sacrocolpopexy and Pelvic Organ Prolapse (POP)** | E.C Costantini, Perugia (IT)     |
| 10:47 - 10:50 | **Discussion**                   |                                   |
| 10:50 - 11:02 | **Laparoscopic repair of vesico-vaginal fistula** | C. Kouriefs, Limassol (CY)       |
| 11:02 - 11:05 | **Discussion**                   |                                   |
| 11:05 - 11:17 | **Benign Prostatic Hyperplasia (BPH) prostatectomy** | H. John, Winterthur (CH)         |
| 11:17 - 11:20 | **Discussion**                   |                                   |
| 11:20 - 12:20 | **Minimally-invasive surgery in prostate** | H. Hashim, Bristol (GB)  
F. Van Der Aa, Leuven (BE) |

**Scientific Programme - EAU19 Barcelona**

176
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 - 11:32</td>
<td>I prefer uro-lift K-D. Sievert, Detmold (DE)</td>
</tr>
<tr>
<td>11:32 - 11:35</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:35 - 11:47</td>
<td>I prefer prostate embolisation D. Abt, St. Gallen (CH)</td>
</tr>
<tr>
<td>11:47 - 11:50</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:50 - 12:02</td>
<td>I prefer aquablation N. Barber, Camberley (GB)</td>
</tr>
<tr>
<td>12:02 - 12:05</td>
<td>Discussion</td>
</tr>
<tr>
<td>12:05 - 12:17</td>
<td>I prefer aquablation N. Barber, Camberley (GB)</td>
</tr>
<tr>
<td>12:17 - 12:20</td>
<td>Discussion</td>
</tr>
<tr>
<td>12:20 - 12:35</td>
<td>ESFFU meets with other societies</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> R. Hamid, London (GB) T.M. Kessler, Zurich (CH)</td>
</tr>
<tr>
<td>12:35 - 12:50</td>
<td>International Continence Society (ICS) lecture: Are synthetic slings for female Stress Urinary Incontinence (SUI) coming to an end? D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)</td>
</tr>
<tr>
<td>12:50 - 13:05</td>
<td>Research news from the 7th International Neuro-Urology Meeting U. Mehnert, Zurich (CH)</td>
</tr>
<tr>
<td>13:32 - 13:35</td>
<td>Discussion</td>
</tr>
<tr>
<td>13:35 - 13:50</td>
<td>Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC)</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> S. Charalampous, Limassol (CY) M. Drake, Bristol (GB)</td>
</tr>
<tr>
<td>13:50 - 13:52</td>
<td>Why phenotyping patients may be so important in BPS/IC D.S. Engeler, St. Gallen (CH)</td>
</tr>
<tr>
<td>13:52 - 13:55</td>
<td>Discussion</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>13:47 - 13:50</td>
<td>Discussion</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>

F. Cruz, Porto (PT)
**Current aspects of advanced tumour therapy: From bedside to bench**

Joint meeting of the EAU Section of Uropathology (ESUP) and the EAU Section of Urological Research (ESUR)

**Saturday 16 March**

**10:15 - 14:00**

**Location:** Green Area, Room 4

**Chairs:** K. Junker, Homburg (DE)
R. Montironi, Ancona (IT)

**Aims and objectives of this session**

Treatment options in metastatic patients are currently changing. More effective systemic therapies are available for prostate, bladder and kidney tumour patients. In this regard, the role of primary tumour surgery in the metastatic situation has to be discussed based on new clinical data. On the other hand, the impact of primary tumour on formation and therapy response of metastases has to be considered. In the first part of the session clinicians and researcher will present the current knowledge in this field and will also discuss the rationale of primary tumour surgery in metastatic patients. In the second part, challenges and prerequisites of immune checkpoint inhibition will be discussed including development of predictive markers.

---

<table>
<thead>
<tr>
<th>10:15 - 10:20</th>
<th>Welcome and introduction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K. Junker, Homburg (DE)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:20 - 12:20</th>
<th>The role of the primary tumour for metastatic disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Moderators:</strong></td>
<td>K. Junker, Homburg (DE)</td>
</tr>
<tr>
<td></td>
<td>I. Heidegger, Innsbruck (AT)</td>
</tr>
<tr>
<td></td>
<td>R. Montironi, Ancona (IT)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:20 - 10:35</th>
<th>Cytoreductive primary tumour surgery in metastatic disease - Prostate cancer: In?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M. Stöckle, Homburg (DE)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:35 - 10:50</th>
<th>Cytoreductive primary tumour surgery in metastatic disease - Kidney cancer: Out?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Mejean, Paris (FR)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:50 - 11:05</th>
<th>Cytoreductive primary tumour surgery in metastatic disease - Bladder cancer: Never ever?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>G.N. Thalmann, Bern (CH)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11:05 - 11:25</th>
<th>Crosstalk between primary tumour and metastasis and the role of exosomes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K. Junker, Homburg (DE)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11:25 - 11:45</th>
<th>Reasonability of inductive therapy in urologic metastatic patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Necchi, Milan (IT)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11:45 - 12:15</th>
<th>Panel discussion</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>12:15 - 12:20</th>
<th>Discussion</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>12:20 - 13:20</th>
<th>Checkpoint inhibitors: The best for all patients?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Moderators:</strong></td>
<td>M. Colecchia, Milan (IT)</td>
</tr>
</tbody>
</table>

179
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20 - 12:35</td>
<td><strong>Do we understand checkpoint inhibition?</strong></td>
</tr>
<tr>
<td></td>
<td>E. Nossner, Munich (DE)</td>
</tr>
<tr>
<td>12:35 - 12:40</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>12:40 - 12:55</td>
<td><strong>The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1</strong></td>
</tr>
<tr>
<td></td>
<td>L. Derosa, Villejuif (FR)</td>
</tr>
<tr>
<td>12:55 - 13:00</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:00 - 13:15</td>
<td><strong>PD-1, PD-L1…: What are the best predictive markers? Standardisation of marker analysis</strong></td>
</tr>
<tr>
<td></td>
<td>T. Gevaert, Leuven (BE)</td>
</tr>
<tr>
<td>13:15 - 13:20</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:25 - 13:50</td>
<td><strong>A translational approach to prostate cancer</strong></td>
</tr>
<tr>
<td></td>
<td>A.S. Bjartell, Malmö (SE)</td>
</tr>
<tr>
<td>13:20 - 13:50</td>
<td><strong>Chopin award session</strong></td>
</tr>
<tr>
<td>13:20 - 13:25</td>
<td><strong>Dominique Chopin award</strong></td>
</tr>
<tr>
<td></td>
<td>K. Junker, Homburg (DE)</td>
</tr>
<tr>
<td>13:50 - 14:00</td>
<td><strong>Closing remarks</strong></td>
</tr>
<tr>
<td></td>
<td>R. Montironi, Ancona (IT)</td>
</tr>
</tbody>
</table>
Genito-urinary reconstruction in 2019
Meeting of the EAU Section of Genito-Urinary Reconstructive Surgeons (ESGURS)

**Location:** Green Area, Room 11

**Chair:** R. Djinovic, Belgrade (RS)

**Aims and objectives of this session**
Again another comprehensive programme of genitourinary reconstruction designed to give both the general urologist and the reconstructive surgeon an update on the management of common and complex pathologies. The first session is on urethral stricture disease: From basic urethrotomy to simple and then complex urethroplasty with the final session on BXO. An update on penile augmentation, penile cancer and revascularisation is followed by a session on female reconstruction and surgery for male incontinence. Peyronie's disease will be fully covered with new insights into its' medical and surgical management. The programme is completed with talks on urinary diversion and bladder reconstruction. This is a state of the art programme which will be informative to all.

**10:15 - 10:20**
Welcome and introduction
R. Djinovic, Belgrade (RS)

**10:20 - 11:15**
Urethral reconstruction - I

*Moderators:* M. Fisch, Hamburg (DE)  
A. Mundy, London (GB)

- **10:20 - 10:30**  
Spongiosum-sparing bulbar urethroplasty techniques: Single graft, double graft, TT muco-mucosa  
E. Palminteri, Arezzo (IT)

- **10:30 - 10:40**  
Early urethral reconstruction after urethral trauma: When and for whom?  
N. Lumen, Ghent (BE)

- **10:40 - 10:50**  
Primary versus redo-urethroplasty: What are the differences?  
W. Verla, Ghent (BE)

- **10:50 - 11:00**  
Spiral preputial graft for very long, non-BXO urethroplasties modification of technique  
P. Anderson, Dudley (GB)

- **11:00 - 11:15**  
Complex posterior urethroplasty  
S. Kulkarni, Pune (IN)

**11:15 - 12:00**
Urethral reconstruction - II

*Moderators:* E. Lledó García, Madrid (ES)  
A. Zhivov, Moscow (RU)

**11:15 - 11:30**  
Reconstructive urology in the European reference networks: Workstream 2 of eUROGEN  
M. Fisch, Hamburg (DE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:35</td>
<td>The role of internal urethrotomy in selected urethral strictures</td>
<td>S. Sansalone, Rome (IT)</td>
</tr>
<tr>
<td>11:35 - 11:42</td>
<td>BXO: Diagnosis and medical treatment</td>
<td>J.I. Martínez Salamanca, Majadahonda (ES)</td>
</tr>
<tr>
<td>11:42 - 11:50</td>
<td>BXO: Surgical management of glans disease</td>
<td>J. Romero Otero, Madrid (ES)</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>BXO: Surgical management of pendular and pan-urethral disease</td>
<td>D.E. Andrich, London (GB)</td>
</tr>
<tr>
<td>12:00 - 12:40</td>
<td>Penile and Sex Reassignment Surgery (SRS)</td>
<td>R. Djinovic, Belgrade (RS)</td>
</tr>
<tr>
<td>12:00 - 12:10</td>
<td>Penis enlargement surgery</td>
<td>F. Colombo, Bologna (IT)</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Video presentation: Microsurgical penile revascularisation</td>
<td>C. Trombetta, Trieste (IT)</td>
</tr>
<tr>
<td>12:30 - 12:40</td>
<td>Video presentation: Vaginoplasty; when skin is not enough (alternatives to penile inversion skin flaps)</td>
<td>E. Kocjancic, Chicago (US)</td>
</tr>
<tr>
<td>12:40 - 13:10</td>
<td>Female reconstruction</td>
<td>R. Djinovic, Belgrade (RS)</td>
</tr>
<tr>
<td>12:40 - 12:50</td>
<td>Female urethroplasty options</td>
<td>Shah, Paldi, Ahmedabad (IN)</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>The use of buccal mucosa in vaginal reconstruction</td>
<td>D.N. Wood, London (GB)</td>
</tr>
<tr>
<td>13:00 - 13:10</td>
<td>Urethral diverticulum in women</td>
<td>T.J. Greenwell, London (GB)</td>
</tr>
<tr>
<td>13:10 - 13:50</td>
<td>Peyronie's disease in the era of Clostridium Histolyticum (CH)</td>
<td>D.J. Ralph, London (GB)</td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td>Results of Peyronie treatment with CH</td>
<td>J. Romero Otero, Madrid (ES)</td>
</tr>
<tr>
<td>13:30 - 13:40</td>
<td>Differences in the protocol of CH</td>
<td>A. Cocci, Calenzano (IT)</td>
</tr>
</tbody>
</table>

Scientific Programme - EAU19 Barcelona
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40 - 13:50</td>
<td>Do I find differences when operating?</td>
<td>I. Moncada Iribarren, Madrid (ES)</td>
</tr>
<tr>
<td>13:50 - 14:35</td>
<td>Penile implant and Peyronie's surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> C. Bettocchi, Bari (IT)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>R. Olianas, Luneburg (DE)</td>
</tr>
<tr>
<td>13:50 - 14:05</td>
<td>Diverse using of penile implant: Peyronie's disease, penile enlargement, neofallus..</td>
<td>J. Romero Otero, Madrid (ES)</td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>SIS-Corporoplasty: Long term results</td>
<td>A. Soave, Hamburg (DE)</td>
</tr>
<tr>
<td>14:25 - 14:35</td>
<td>Tips and tricks in Peyronie's IPP surgery</td>
<td>P. Egydio, Sao Paulo (BR)</td>
</tr>
<tr>
<td>14:35 - 14:55</td>
<td>Incontinence surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> E. Kocjancic, Chicago (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>V. Pansadoro, Rome (IT)</td>
</tr>
<tr>
<td>14:35 - 14:45</td>
<td>De novo incontinence after sphincter or sling</td>
<td>O. Shenfeld, Jerusalem (IL)</td>
</tr>
<tr>
<td>14:45 - 14:55</td>
<td>Expertise and complications arising and evaluations in Artificial Urinary Sphincter (AUS) surgery and what is new?</td>
<td>O.R. Sedigh, Turin (IT)</td>
</tr>
<tr>
<td>14:55 - 15:35</td>
<td>Upper tract reconstruction: Tips and tricks</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> M. Alvarez-Maestro, Madrid (ES)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Deger, Ostfildern (DE)</td>
</tr>
<tr>
<td>14:55 - 15:05</td>
<td>Different kinds of urinary diversion in adult patients after ureterosigmostomy in childhood</td>
<td>S. Darenkov, Moscow (RU)</td>
</tr>
<tr>
<td>15:05 - 15:15</td>
<td>Video presentation: The serous-lined continent outlet</td>
<td>H. Abol-Enein, Mansoura (EG)</td>
</tr>
<tr>
<td>15:15 - 15:25</td>
<td>Complications after Mitrofanoff procedure and their treatment</td>
<td>C. Konstantinidis, Ilion (GR)</td>
</tr>
<tr>
<td>15:25 - 15:35</td>
<td>The Tübinger i-Pouch in modification</td>
<td>K-D. Sievert, Detmold (DE)</td>
</tr>
<tr>
<td>15:35 - 15:45</td>
<td>Summary and closing remarks</td>
<td>R. Djinovic, Belgrade (RS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D.J. Ralph, London (GB)</td>
</tr>
</tbody>
</table>
Uro-genital infections: What is important in the urologic office?
Joint Meeting of the EAU Section of Infections in Urology (ESIU) and of the EAU Section of Urologists in Office (ESUO)

Aims and objectives of this session
This joint meeting of the EAU sections for Urologists in Office (ESUO) and Infections in Urology (ESIU) will deal with the topic of treatment of Urinary Tract Infections (UTI) in the urologic office. Diagnostics and treatment of these infections are a core task in everyday urologic practice. Guided by cases and supported by an interactive discussion with the audience, ESUO members will present characteristic cases and elucidate their way of treatment regarding the infrastructure of urologic office. ESIU members will present scientific information about diagnostics and treatment of UTI in general, but also related to the cases presented. Key information will be given about the diagnostics necessary and the rational selection of antibiotics according to the extent of disease, the situation of antibiotic resistances in different European countries, the demands of antibiotic stewardship, and the decision which patients should be treated in the urologic office and which in hospital. The audience will learn in a systematic way what to consider when treating patients for UTI in the urologic office and make wise decisions.

10:15 - 10:20  
Welcome and introduction  
H. Haas, Heppenheim (DE)

10:20 - 10:35  
Case presentation and keynote speech  
S.M. Haensel, Rotterdam (NL)

10:35 - 10:55  
What can we learn from science?  
Z. Tandoğdu, Edinburgh (GB)

10:55 - 11:05  
Discussion

11:05 - 11:20  
HPV vaccination in men: To whom and when?  
F. Dimitriadis, Kalamaria, Thessaloniki (GR)  
H.M. Çek, Edirne (TR)

11:20 - 11:35  
Case presentation and keynote speech  
L.P. Zapala, Warsaw (PL)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 - 11:40</td>
<td><strong>What do we learn from science</strong></td>
</tr>
<tr>
<td></td>
<td>T. Cai, Trento (IT)</td>
</tr>
<tr>
<td>11:40 - 11:50</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>11:50 - 12:35</td>
<td><strong>When to treat a UTI: The differences between asymptomatic bacteriuria and symptomatic UTI. Treatment in patients with urinary diversion</strong></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em> S.M. Haensel, Rotterdam (NL)</td>
</tr>
<tr>
<td></td>
<td>K. Naber, Straubing (DE)</td>
</tr>
<tr>
<td>11:50 - 12:05</td>
<td><strong>Case presentation and keynote speech</strong></td>
</tr>
<tr>
<td></td>
<td>F. Dimitriadis, Kalamaria, Thessaloniki (GR)</td>
</tr>
<tr>
<td>12:05 - 12:25</td>
<td><strong>What do we learn from science</strong></td>
</tr>
<tr>
<td></td>
<td>B. Wullt, Lund (SE)</td>
</tr>
<tr>
<td>12:25 - 12:35</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>12:35 - 13:20</td>
<td><strong>Urogenital tuberculosis and BCGitis: How to diagnose, how to manage</strong></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em> T.E. Bjerklund Johansen, Oslo (NO)</td>
</tr>
<tr>
<td></td>
<td>A. Zachariou, Volos (GR)</td>
</tr>
<tr>
<td>12:35 - 12:50</td>
<td><strong>Case presentation and keynote speech</strong></td>
</tr>
<tr>
<td></td>
<td>H. Brenneis, Pirmasens (DE)</td>
</tr>
<tr>
<td>12:50 - 13:10</td>
<td><strong>What do we learn from science</strong></td>
</tr>
<tr>
<td></td>
<td>E. Kulchavenya, Novosibirsk (RU)</td>
</tr>
<tr>
<td>13:10 - 13:20</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:20 - 13:55</td>
<td><strong>Recent developments of new antibiotics</strong></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em> H. Haas, Heppenheim (DE)</td>
</tr>
<tr>
<td></td>
<td>P. Tenke, Budapest (HU)</td>
</tr>
<tr>
<td>13:20 - 13:30</td>
<td><strong>Case presentation and keynote speech</strong></td>
</tr>
<tr>
<td></td>
<td>T.H. Kuru, Köln (DE)</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td><strong>What do we learn from science</strong></td>
</tr>
<tr>
<td></td>
<td>K. Naber, Straubing (DE)</td>
</tr>
<tr>
<td>13:45 - 13:55</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>13:55 - 14:00</td>
<td><strong>Closing remarks</strong></td>
</tr>
<tr>
<td></td>
<td>H. Haas, Heppenheim (DE)</td>
</tr>
</tbody>
</table>
ERN eUROGEN
Specialty Session

Saturday 16 March
10:15 - 11:45

Location: Green Area, Room 19

Chairs: M. Battye, Sheffield (GB)
W.F.J. Feitz, Nijmegen (NL)

Aims and objectives of this session
The ERN eUROGEN session will update you on the recent largest health care innovation in Europe involving 30 million patients with rare or complex conditions.
This program on urogenital rare diseases and complex conditions involves the whole spectrum from congenital anomalies to lifelong care and complex functional and rare urogenital tumours. Patients care and interaction, guidelines, training and education and research programs are interacting for the improvement of the care for your patients. Additional information is available on www.eurogen-ern.eu.

10:15 - 10:30
EUProtect and future expectations from ERN eUROGEN
W.F.J. Feitz, Nijmegen (NL)

10:30 - 10:45
Monitoring and assessment of ERN’s and new partnerships
M. Battye, Sheffield (GB)

10:45 - 11:00
Collaborative research within eUROGEN - creating the way forward for rare diseases
V. Sangar, Manchester (GB)

11:00 - 11:15
A CPMS case: A complicated cases with multidisciplinary involvement, suggestions and outcome
G. Mosiello, Rome (IT)

11:15 - 11:30
ePAG representation and actions from EURORDIS
R.S. Bartezzati, Rome (IT)

11:30 - 11:45
ERNs and non-financial conflicts of interest – views from surgeons and patient representatives
E. Schmiedeke, Bremen (DE)
# Sexual dysfunction and andrological issues in end stage renal disease and kidney transplant patients

Joint meeting of the EAU Section of Transplantation Urology (ESTU) and the EAU Section of Andrological Urology (ESAU)

## Saturday 16 March 10:15 - 14:00

**Location:** Green Area, Room 20

**Chairs:**
- E. Lledó García, Madrid (ES)
- N. Sofikitis, Ioannina (GR)

### Aims and objectives of this session

The main objective of the joint meeting of the EAU Section of Transplantation Urology and the EAU Section of Andrological Urology is to elucidate the molecular, biochemical, hormonal, and cytological alterations in men with end-stage renal disease resulting in testicular deficiency and sexual dysfunction, as well. Pharmaceutical treatment of defects in testicular function, low sexual desire, and erectile dysfunction will be discussed. The role of penile surgery for obtaining adequate erections in men with end-stage renal disease will be emphasized.

### Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15</td>
<td>Welcome and introduction</td>
<td>E. Lledó García, Madrid (ES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N. Sofikitis, Ioannina (GR)</td>
</tr>
<tr>
<td>10:20</td>
<td>Effects of End-Stage Renal Disease (ESRD) and KT on testicular testosterone production. The role of supplementation.</td>
<td>T. Diemer, Giessen (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. García-Cruz, Barcelona (ES)</td>
</tr>
<tr>
<td>10:20</td>
<td>Physiopathology</td>
<td>A. Giwercman, Malmö (SE)</td>
</tr>
<tr>
<td>10:35</td>
<td>Treatment</td>
<td>R. Boissier, Marseille (FR)</td>
</tr>
<tr>
<td>10:50</td>
<td>Physiopathological effect of ESRD, kidney transplant and immunosupressors on spermathogenesis: Therapeutical possibilities</td>
<td>C. Balmori Boticario, Madrid (ES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.S. Minhas, London (GB)</td>
</tr>
<tr>
<td>11:20</td>
<td>Round table discussion on sexual dysfunction and ESRD: Therapeutic options and effects of kidney transplantation - libido, erection and ejaculatory disorders</td>
<td>Z. Kopa, Budapest (HU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N. Sofikitis, Ioannina (GR)</td>
</tr>
<tr>
<td>11:20</td>
<td>Therapeutics before transplantation: PDE5I</td>
<td>V. Tugcu, Istanbul (TR)</td>
</tr>
</tbody>
</table>

Scientific Programme - EAU19 Barcelona
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:40</td>
<td>Therapeutics before transplantation: Others</td>
<td>A. Salonia, Milan (IT)</td>
</tr>
<tr>
<td>11:40 - 11:50</td>
<td>Therapeutics after the transplant: Surgical</td>
<td>J.I. Martínez Salamanca, Majadahonda (ES)</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>Therapeutics after the transplant: Pharmacological</td>
<td>A. Kadioglu, Istanbul (TR)</td>
</tr>
</tbody>
</table>
| 12:00 - 12:40 | Round table discussion: Lower Urinary Tract Symptoms (LUTS) in patients before and after the transplant. When and how to treat. Pharmaceutical approaches and surgical options. | Moderators: F.J. González Garcia, Madrid (ES)  
C. Hernández Fernández, Madrid (ES) |
| 12:00 - 12:20 | Before                                                                 | J.D.J.M. Branchereau, Nantes (FR)                                      |
| 12:20 - 12:40 | After                                                                  | R.H. Zakri, London (GB)                                                |
| 12:40 - 12:55 | Rene Küss Award 2019                                                   | F.J. Burgos Revilla, Madrid (ES)                                       |
|               |                                                                        | A.J. Figueiredo, Coimbra (PT)                                          |
|               |                                                                        | E. Lledó García, Madrid (ES)                                           |
| 12:40 - 12:55 | Management of end-stage renal disease patients diagnosed with active surveillance-eligible prostate cancer during pre-transplantation work-up: A decision analysis | M.S. Wettstein, Zürich (CH)                                           |
| 12:55 - 13:10 | Presentation of results: ESTU research project 2018                   | V. Gomez Dos Santos, Madrid (ES)                                       |
|               |                                                                        | F. Regis, Italy (IT)                                                  |
| 13:10 - 13:25 | Presentation of 2019 awarded research project                          | E. Lledó García, Madrid (ES)                                           |
|               |                                                                        | R. Boissier, Marseille (FR)                                            |
| 13:25 - 14:00 | Robotic-assisted Artificial Urinary Sphincter (AUS) in females: Current state of the art. Indications and results. | L. Peri Cusi, Barcelona (ES)                                           |
|               |                                                                        | D. Subirá Rios, Madrid (ES)                                            |
|               |                                                                        | K. Decaestecker, Ghent (BE)                                            |
|               |                                                                        | K. Everaert, Ghent (BE)                                                |
| 13:50 - 14:00 | Closing remarks                                                         | E. Lledó García, Madrid (ES)                                           |
|               |                                                                        | R. Boissier, Marseille (FR)                                            |
Technology development never ends!
Meeting of the EAU Section of Uro-Technology (ESUT), in cooperation with the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS)

Saturday 16 March
10:30 - 18:00

Location: Red Area, eURO Auditorium 1
Chair: E. Liatsikos, Patras (GR)

Aims and objectives of this session
Following a more than 10-year tradition of live-surgery sessions, the EAU Section of Uro-Technology (ESUT) presents an ambitious programme focusing on novel techniques and technologies in endourological, laparoscopic and robotic-assisted procedures. This year, we want to focus on novel technology improving the performance of video-assisted surgery and diagnostics in all fields of Endourology. This session is conducted in collaboration with the the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS).

In the laparoscopic and robot-assisted cases, we will focus on the developments of imaging as well as on new instruments and devices that improve its ergonomics. The latest digital developments for flexible endoscopy of the upper urinary tract for diagnosis and treatment of tumours and calculi will also be demonstrated. ESUT faculty consists of internationally well-known experts serving as surgeons and moderators. The different surgical procedures will be transmitted from Fundacio Puigvert Hospital, Barcelona in high definition and 3D quality. Traditionally, the format of ESUT Live Surgery will allow all delegates to directly communicate with the surgeons to ask questions and to discuss every aspect of the procedure. In addition, the ESUT session will also be available online.

- Live broadcasts from Fundacio Puigvert Hospital, Barcelona (ES)
- Coordinators in the eURO Auditorium
- Coordinator at the Fundacio Puigvert hospital, Barcelona (ES)

10:30 - 18:00
Patient advocates
J.M. Gaya Sopena, Barcelona (ES)
O. Rodriguez Faba, Barcelona (ES)
F. Sanguedolce, Barcelona (ES)
A. Territo, Barcelona (ES)

10:30 - 10:35
Welcome and introduction
E. Liatsikos, Patras (GR)

10:35 - 10:40
Ethics of Live-Surgery – Cases from last year
B. Kromann-Andersen, Herlev (DK)

10:40 - 12:33
Live surgery - Part I
Moderators: F. Gomez Sancha, Madrid (ES)
P. Kallidonis, Patras (GR)
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40</td>
<td>3D Laparoscopic partial nephrectomy</td>
<td>A. Alcaraz, Barcelona (ES)</td>
</tr>
<tr>
<td>11:10</td>
<td>Prone percutaneous nephrolithotripsy</td>
<td>J-T. Klein, Ulm (DE)</td>
</tr>
<tr>
<td>11:29</td>
<td>Mini Percutaneous Nephrolithotripsy utilising the MOSES Technology</td>
<td>O. Angerri Feu, Barcelona (ES)</td>
</tr>
<tr>
<td>11:47</td>
<td>Complex robot-assisted partial nephrectomy</td>
<td>A. Mottrie, Aalst (BE)</td>
</tr>
<tr>
<td>12:17</td>
<td>Pre-recorded video GreenLight XPS™ - GreenLEP</td>
<td>E. Rijo, Barcelona (ES)</td>
</tr>
<tr>
<td>12:25</td>
<td>Pre-recorded video TOOKAD Vascular focal therapy with non-thermal L-light for unilateral low-risk prostate cancer</td>
<td>F. Montorsi, Milan (IT)</td>
</tr>
<tr>
<td>12:33</td>
<td>Live surgery - Part II</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Bachmann, Vienna (AT)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E. Barret, Paris (FR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>O.R. Durutovic, Belgrade (RS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Netsch, Hamburg (DE)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>I.Y. Ozgok, Ankara (TR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R. Sanchez-Salas, Paris (FR)</td>
<td></td>
</tr>
<tr>
<td>12:33</td>
<td>Pre-recorded video Robot-assisted radical cystectomy</td>
<td>J.M. Gaya Sopena, Barcelona (ES)</td>
</tr>
<tr>
<td>12:43</td>
<td>Pre-recorded video MOSES Laser enucleation (MOLEP)</td>
<td>K. Lehrich, Berlin (DE)</td>
</tr>
<tr>
<td>12:51</td>
<td>Supine endoscopic combined intrarenal surgery</td>
<td>A. Celia, Bassano Del Grappa (IT)</td>
</tr>
<tr>
<td></td>
<td>C.M. Scoffone, Turin (IT)</td>
<td></td>
</tr>
<tr>
<td>13:21</td>
<td>4K Laparoscopic radical prostatectomy</td>
<td>J-U. Stolzenburg, Leipzig (DE)</td>
</tr>
<tr>
<td>13:51</td>
<td>LithoVue™ Single Use Ureteroscopic Lithotripsy with MOSES Technology</td>
<td>E. Emiliani, Barcelona (ES)</td>
</tr>
<tr>
<td>14:04</td>
<td>Pre-recorded video Bipolar enucleation of prostate</td>
<td>J.U. Kempter, Leipzig (DE)</td>
</tr>
<tr>
<td>14:12</td>
<td>Flexible ureteroscopic lithotripsy</td>
<td>M. Straub, Munich (DE)</td>
</tr>
</tbody>
</table>
14:24 - 14:32  Pre-recorded video Holmium prostate enucleation
A. Miernik, Freiburg (DE)

14:32 - 16:23  Live surgery - Part III
Moderators: D. Enikeev, Moscow (RU)
L. Lusuardi, Salzburg (AT)
U. Nagele, Hall in Tirol (AT)
A. Papatsoris, Athens (GR)
F. Porpiglia, Turin (IT)

14:32 - 15:02  Prone endoscopic combined intrarenal surgery
L. Ajayi, London (GB)
E. Liatsikos, Patras (GR)

15:02 - 15:15  Flexible Ureteroscopic Lithotripsy
O. Traxer, Paris (FR)

15:15 - 15:23  Pre-recorded video MOSES Lithotripsy of Bladder Stone Lithotripsy
M. Lipkin, Durham (US)

15:23 - 15:31  Pre-recorded video NBI-assisted resection of bladder tumour
B. Malavaud, Toulouse (FR)

15:31 - 15:39  Pre-recorded video Pulsed thulium en bloc anatomic enucleation of prostate with early apex release
J.B. Roche, Bordeaux (FR)

15:39 - 15:47  Pre-recorded video Bipolar Enucleation of the prostate
T.R.W. Herrmann, Frauenfeld (CH)

15:47 - 16:05  MIP L with Calculase III
T. Knoll, Sindelfingen (DE)

16:05 - 16:23  En bloc bipolar bladder tumour resection
A. Breda, Barcelona (ES)

16:23 - 18:00  Live surgery - Part IV
Moderators: B. Petrut, Cluj Napoca (RO)
E.A. Rodrigues De Lima, Braga (PT)
L. Tunc, Ankara (TR)
I. Varkarakis, Athens (GR)
D. Veneziano, Reggio Calabria (IT)
P.J. Zondervan, Amsterdam (NL)

16:23 - 16:31  Pre-recorded video Rezum™ Water Vapor Therapy for BPH
R.G. Hindley, Hook (GB)

16:31 - 16:39  Pre-recorded video Aquablation
T. Bach, Hamburg (DE)

16:39 - 16:52  Flexible single-use ureteroscopic lithotripsy
B. Somani, Southampton (GB)

16:52 - 17:00  Pre-recorded video UTUC ablation – Comparison of Thulium and Holmium
G. Giusti, Milan (IT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 17:12</td>
<td>Flexible ureteroscopic lithotripsy</td>
<td>T. Tailly, Ghent (BE)</td>
</tr>
<tr>
<td>17:12 - 17:30</td>
<td>Percutaneous Nephrolithotripsy</td>
<td>D.A. Pérez Fentes, Santiago de Compostela (ES)</td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td>Robot-assisted radical prostatectomy with nerve sparing</td>
<td>M. Graefen, Hamburg (DE)</td>
</tr>
</tbody>
</table>
**Adrenals for urologists**  
ESU Course 09

**Location:** Green Area, Room 15  
**Chair:** A.S. Gözen, Heilbronn (DE)

**Aims and objectives of this session**  
To teach all about the adrenal gland minimal invasive approach; starting with the correct indications for surgery and preoperative medical preparation. The different approaches and new equipment will be shown including special instructions. The operations will be given step by step in high quality videos in detail with tips and tricks. The complication videos and intraoperative management will be discussed interactively with the experts.

---

**Introduction**  
A.S. Gözen, Heilbronn (DE)

**Indications and patient preparation (medical and surgical)**  
J.F. Langenhuijsen, Nijmegen (NL)

**Surgical anatomy of adrenals**  
F. Porpiglia, Turin (IT)

**How I do it; step by step operative procedure, technical tips and tricks**

- **Transperitoneal**  
  J.F. Langenhuijsen, Nijmegen (NL)

- **Retroperitoneal and prone**  
  A.S. Gözen, Heilbronn (DE)

- **Mini-laparoscopic**  
  F. Porpiglia, Turin (IT)

**Partial adrenalectomy and challenging cases in adrenalectomy**  
J.F. Langenhuijsen, Nijmegen (NL)

**Complications and management**  
A.S. Gözen, Heilbronn (DE)

**Discussion and interaction**  
A.S. Gözen, Heilbronn (DE)  
J.F. Langenhuijsen, Nijmegen (NL)  
F. Porpiglia, Turin (IT)
**Aims and objectives of this session**

The course objective is to explain the surgical technique of radical prostatectomy performed through robotic-assisted laparoscopy for the treatment of prostatic carcinoma. The outline of this course will give a detailed reminder of anatomical basic principles of radical prostatectomy. General principles regarding ports placement will be also reminded considering the different possible options and the different types of robotic systems used. Then each teacher will make a presentation of his surgical technique using a video of 20 minutes explaining all the steps of the surgery in details. Other options of anatomical approach will be also introduced (posterior approach, lateral approach). Finally, the course will present the possible intraoperative risks of complications and the functional and oncological results of this surgery.

**Scientific Programme - EAU19 Barcelona**

<table>
<thead>
<tr>
<th>Location:</th>
<th>Green Area, Room 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair:</td>
<td>P-T. Piéchaud, Bordeaux (FR)</td>
</tr>
</tbody>
</table>

### Introduction

P-T. Piéchaud, Bordeaux (FR)

### General principles of robotic radical prostatectomy, patient position, ports placement, ways of access

W. Artibani, Verona (IT)
P. Dasgupta, London (GB)

### Anatomical and oncological supports of radical prostatectomy:

- **Bladder neck preservation: Useful? Dangerous?**  
P-T. Piéchaud, Bordeaux (FR)

- **Neurovascular bundle dissection: Anatomical reminders of the peri-prostatic fascia and space of dissection**  
P. Dasgupta, London (GB)

### Step by step operative procedure: How I do it?

W. Artibani, Verona (IT)  
P. Dasgupta, London (GB)  
P-T. Piéchaud, Bordeaux (FR)

### Technical alternatives:

- **Posterior approach: Bocciardi technique**  
  W. Artibani, Verona (IT)

- **Lateral approach: Gaston technique**  
  P-T. Piéchaud, Bordeaux (FR)
<table>
<thead>
<tr>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphadenectomy: Technical principles</td>
<td>W. Artibani</td>
<td>Verona (IT)</td>
</tr>
<tr>
<td>Operative and postoperative complications</td>
<td>P. Dasgupta</td>
<td>London (GB)</td>
</tr>
<tr>
<td>Oncological and functional results</td>
<td>W. Artibani</td>
<td>Verona (IT)</td>
</tr>
<tr>
<td>Conclusion</td>
<td>P-T. Piéchaud</td>
<td>Bordeaux (FR)</td>
</tr>
</tbody>
</table>
Paediatric urology for the adult urologist. Congenital disorders of the external genitalia, DSD and longterm outcome

ESU Course 10

Saturday 16 March 11:00 - 14:00

Location: Green Area, Room 14

Chair: G. Bogaert, Leuven (BE)

Aims and objectives of this session

Congenital anomalies of the external genitalia are an important topic for the urologist and paediatric urologist. A child born with a disorder of sexual differentiation is a physical and psychological emergency. It requires the knowledge of the pathophysiology of the most frequent causes and the subsequent diagnostic and treatment decision tree. Together with a team of paediatricians, psychologists, geneticists, the (paediatric) urologist must be able to explain the condition to the parents in a way that they can choose the best option for their child. The external genitalia of a child will evolve from a social and voiding tool to an erotic and reproduction tool during puberty and adolescence. Again, the (paediatric) urologist should be aware of possible problems and accompany the child and their parents during that process.

After this course, the attendant will be able:
• To identify the most common causes of sexual differentiation (DSD) and know how to handle in the neonatal period.
• To diagnose and how to treat the most common congenital and acquired problems of the external genitalia.
• The normal development of the sexual function and fertility during puberty and adolescence, as well as possible problems due to congenital or acquired pathology.

Disorders of sex development
C. Radmayr, Innsbruck (AT)

Congenital malformations of the external genitalia: What do we need to know regarding sexual function and fertility in adolescence and adulthood?
G. Bogaert, Leuven (BE)

Congenital and acquired pathology of the external genitalia
B. Burgu, Ankara (TR)

Discussion
Aims and objectives of this session

Within this interactive session, we will explore the evidence base underpinning three controversial treatment recommendations in the EAU Non-muscle-invasive Bladder cancer, Urolithiasis and Upper Tract Urothelial Cancer Guidelines. In each case, the evidence for and against each recommendation will be presented and then reviewed by an external discussant. What is your opinion on these topics? To have your say, attend this session and vote to let us know.

The aim of this session is thus to acquaint attendees with recent work of the EAU Guidelines Panels by presenting how the evidence base is used to provide support for and against three controversial guidelines topics.

The EAU Guidelines Office oversees the development of clinical practice guidelines from some 20 different EAU guidelines panels. Guideline recommendations are underpinned, whenever possible, by systematic reviews and meta-analyses of randomised controlled trials. The validity of the results of a systematic review depends on the quality of the individual studies and their clinical and methodological heterogeneity. In many cases, however, only lower levels of evidence exist because randomisation is not feasible, or a systematic review has not been done.

Guideline controversies arise when a recommendation is based on evidence that is not robust. Disagreements can occur, even between members of the same panel, if, for example, the results of a new randomised controlled trial differ from those found in a previous meta-analysis or if the results across different series of randomised and/or non-randomised studies vary from one to another. Such discrepancies are more often than not related to study differences relating to patient selection, treatment, outcome evaluation, and risk of bias.

So come to this session to let us know if you agree with experts and if not, then why not!

11:00 - 11:10

Welcome and introduction

J. N'Dow, Aberdeen (GB)
R.J. Sylvester, Brussels (BE)

11:10 - 12:10

Non-muscle-invasive bladder cancer: Should a TUR be done in all bladder tumours?

Moderator: M. Babjuk, Prague (CZ)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10 - 11:15</td>
<td>Introduction</td>
<td>M. Babjuk, Prague (CZ)</td>
</tr>
<tr>
<td>11:15 - 11:25</td>
<td>TURB is a grotesque procedure</td>
<td>J.W.F. Catto, Sheffield (GB)</td>
</tr>
<tr>
<td>11:25 - 11:30</td>
<td>Voting</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:40</td>
<td>Pro: We need to do TURB in any clinical situation as is specified in guidelines</td>
<td>M. Burger, Regensburg (DE)</td>
</tr>
<tr>
<td>11:40 - 11:50</td>
<td>Con: In some situations TURB is not necessary</td>
<td>P. Gontero, Turin (IT)</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>External discussant</td>
<td>A.M. Kamat, Houston (US)</td>
</tr>
<tr>
<td>12:00 - 12:05</td>
<td>Revoting</td>
<td></td>
</tr>
<tr>
<td>12:05 - 12:10</td>
<td>Conclusion</td>
<td>M. Babjuk, Prague (CZ)</td>
</tr>
<tr>
<td>12:10 - 13:00</td>
<td>Urolithiasis – PCNL: Does the instrument size matter?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: C. Türk, Vienna (AT)</td>
<td></td>
</tr>
<tr>
<td>12:10 - 12:13</td>
<td>Introduction</td>
<td>C. Türk, Vienna (AT)</td>
</tr>
<tr>
<td>12:13 - 12:15</td>
<td>Voting</td>
<td></td>
</tr>
<tr>
<td>12:15 - 12:25</td>
<td>Pro: Miniperc, or smaller, should be the gold standard</td>
<td>C.C. Seitz, Vienna (AT)</td>
</tr>
<tr>
<td>12:25 - 12:35</td>
<td>Con: Standard PCNL suits them all</td>
<td>A. Skolarikos, Athens (GR)</td>
</tr>
<tr>
<td>12:35 - 12:55</td>
<td>External discussant</td>
<td>A. Neisius, Trier (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Petřík, Ceske Budejovice (CZ)</td>
</tr>
<tr>
<td>12:55 - 12:57</td>
<td>Revoting</td>
<td></td>
</tr>
<tr>
<td>12:57 - 13:00</td>
<td>Conclusion</td>
<td>C. Türk, Vienna (AT)</td>
</tr>
<tr>
<td>13:00 - 13:05</td>
<td>Introduction</td>
<td>M. Rouprêt, Paris (FR)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>13:05 - 13:10</td>
<td>Voting</td>
<td></td>
</tr>
</tbody>
</table>
| 13:10 - 13:20 | **Pro:** Peri operative chemotherapy will become the new standard  
S. Shariat, Vienna (AT) |
| 13:20 - 13:30 | **Con:** Radical nephroureterectomy will remain the gold standard  
A. Masson-Lecomte, Paris (FR) |
| 13:30 - 13:40 | **External discussant**  
R. Jones, Glasgow (GB) |
| 13:40 - 13:45 | Revoting                                    |
| 13:45 - 13:50 | **Conclusion**  
M. Rouprêt, Paris (FR) |
| 13:50 - 14:00 | **Closing remarks**  
J. N'Dow, Aberdeen (GB)  
R.J. Sylvester, Brussels (BE) |
Guideline updates and controversies: Incontinence, bladder / paediatric stones and male LUTS
ESU Course 12

Saturday 16 March 11:00 - 14:00

Location: Green Area, Room 22

Chair: A.K. Nambiar, Newcastle-upon-Tyne (GB)

Aims and objectives of this session
This course will focus on 3 non-oncology guidelines (Urinary Incontinence, Non-Neurogenic Male LUTS and Urolithiasis).
There will be a brief review of the EAU guidelines methodology and process of guideline development.
The course will then involve an interactive discussion of the main new changes to these guidelines, challenges in development, areas of inconsistency and opportunities for further research.

Welcome and introduction
A.K. Nambiar, Newcastle-upon-Tyne (GB)

The EAU guidelines development process and methodology
A.K. Nambiar, Newcastle-upon-Tyne (GB)

Urolithiasis guideline: Changes, challenges, areas of uncertainty
J. Donaldson, Aberdeen (GB)

Non-neurogenic male LUTS guideline: Changes, challenges, areas of uncertainty
J-N.L. Cornu, Rouen (FR)

Urinary incontinence guideline: Changes, challenges, areas of uncertainty
A.K. Nambiar, Newcastle-upon-Tyne (GB)
## ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone treatment - step 1

*Sponsored by KARL STORZ*

<table>
<thead>
<tr>
<th><strong>Saturday 16 March</strong></th>
<th><strong>11:00 - 12:00</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location:</strong></td>
<td>Green Area, Room 6</td>
</tr>
<tr>
<td><strong>Chair:</strong></td>
<td>B. Somani, Southampton (GB)</td>
</tr>
<tr>
<td><strong>Tutors:</strong></td>
<td>J.P. Caballero Romeu, Alicante (ES)</td>
</tr>
<tr>
<td></td>
<td>A. Ploumidis, Athens (GR)</td>
</tr>
<tr>
<td></td>
<td>S. Proietti, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td>K. Ahmed, London (GB)</td>
</tr>
<tr>
<td></td>
<td>N. Macchione, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td>M. Talso, Milan (IT)</td>
</tr>
</tbody>
</table>

### Aims and objectives of this session

In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models.
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.
# EBU Session: European standards for assessment, accreditation and certification

**Specialty Session**

**Location:** Green Area, Room 19  
**Chairs:** A.J. Figueiredo, Coimbra (PT)  
R.J.A. Van Moorselaar, Amsterdam (NL)

**Aims and objectives of this session**
The common purpose of all urologists is the best care for the patient. The EBU in collaboration with the EAU and national urological organisations is concerned with the standards of training and education for urologists of the present and the future. The aim of this session is to explore current and future needs.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 12:05</td>
<td>Welcome and introduction</td>
<td>A.J. Figueiredo, Coimbra (PT)</td>
</tr>
<tr>
<td>12:05 - 12:15</td>
<td>CME/CPD in Europe</td>
<td>K.A. German, Birkirkara (MT)</td>
</tr>
<tr>
<td>12:15 - 12:25</td>
<td>EBU exams</td>
<td>S. Tekgül, Ankara (TR)</td>
</tr>
<tr>
<td>12:25 - 12:35</td>
<td>Medbook PRO</td>
<td>K.A. German, Birkirkara (MT)</td>
</tr>
<tr>
<td>12:35 - 12:55</td>
<td>Do we need certification for onco-urology?</td>
<td></td>
</tr>
<tr>
<td>12:35 - 12:45</td>
<td>EBU perspective</td>
<td>A.J. Figueiredo, Coimbra (PT)</td>
</tr>
<tr>
<td>12:45 - 12:55</td>
<td>EAU perspective</td>
<td>M. Rouprêt, Paris (FR)</td>
</tr>
<tr>
<td>12:55 - 13:00</td>
<td>Closing remarks</td>
<td>A.J. Figueiredo, Coimbra (PT)</td>
</tr>
</tbody>
</table>
How to write results and discussion
ESU Course 08

Location: Green Area, Room 16
Chair: J.W.F. Catto, Sheffield (GB)

Aims and objectives of this session
Learn the best way to draft the results and discussion section of a scientific paper. Understand how to work through examples of good and bad practices, to find the key points of the manuscript. Obtain insight from editors on what they expect to see.

• To understand what makes good results section and how best to present your data.
• To understand what makes a good discussion.
• To learn from experienced editors.

Welcome
J.W.F. Catto, Sheffield (GB)

Choosing and presenting your statistical analysis
D. Sjoberg, New York (US)

How to write the results section
R. Lee, New York (US)

Writing the discussion section
P.L. Nguyen, Boston (US)

What the editor looks for when reviewing the results and discussion
L. Albiges, Villejuif (FR)
ESU/ESUT/EULIS Hands-on Training Course in Endoscopic stone
treatment - step 1
Sponsored by KARL STORZ

Saturday 16 March
12:30 - 13:30

Location: Green Area, Room 6

Tutors: A. Papatsoris, Athens (GR)
M. Goossens, Haaltert (BE)
Pereira, Lisboa (PT)
L.B. Dragoş, Timișoara (RO)
M. Talso, Milan (IT)
S. Ferretti, Parma (IT)

Chair: D. Veneziano, Reggio Calabria (IT)

Aims and objectives of this session
In this course, basic endoscopic skills can be acquired and learned. Skills associated with cystoscopy, rigid and flexible ureteroscopy are trained by the validated exercises of the Endoscopic stone treatment (EST s1). Experienced Endourologists will guide you to master navigation skills needed with hand-eye-coordination for cystoscopy, rigid ureteroscopy in a model, placement of access sheath and flexible ureteroscopy in the K-Box. The course can be used as an additional training to prepare for the EST S1 examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

• At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
• The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.
Aims and objectives of this session
Subtitle: Interpretation of invasive urodynamic tests
Course: Expert Urodynamic test interpretation; cystometry and pressure flow.
Audience: Urologists, medical doctors nurses and technicians looking to improve their knowledge and expertise in the evaluation of urodynamic test results.
Keywords: ICS standard, Good Urodynamic Practice, Quality UDS, Artefacts/Pitfalls, Technique, Reporting, Urodynamic diagnosis.
Goal: At the end of the course, the participants have increased their knowledge to evaluate and improve the quality of their urodynamic procedures following the ICS standards. We will discuss how different types of artefacts are recognizable. We will also discuss prevention and correction of various types of errors and artifacts. A structured way of reporting a urodynamic test results and urodynamic diagnosis will be explained.

Expert Urodynamic test interpretation; cystometry and pressure flow.
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

13:30 - 13:33
Introduction
M.R. Cooperberg, San Francisco (US)
M. Valerio, Lausanne (CH)

PT087
Classification of prostate cancer based on clinical and omic data using neural networks techniques to improve prognostic power

By: Marin L., Racoceanu D., Casado F.
Pontifical Catholic University of Peru, Engineering Department, Lima, Peru

Aims and objectives of this presentation
PT087

PT088
Trends in prostate biopsy criteria and outcomes from 2010 to present: The Columbia experience

By: Haas C.R. 1, Caputo J.M. 2, Sebesta E.M. 1, Wang V. 1, Siddiqui S. 1, Hyams E. 1, Wenske S. 1
1 New York-Presbyterian Columbia University Medical Center, Dept. of Urology, New York, United States of America,
2 NewYork-Presbyterian Columbia University Medical Center, Dept. of Urology, New York, United States of America

Aims and objectives of this presentation
PT088

PT089
Which cancers are still diagnosed by standard prostate biopsy without an upfront multiparametric MRI? Results from a tertiary care, high volume centre

By: Stabile A. 1, Dell'Oglio P. 1, Zaffuto E. 1, De Cobelli F. 2, Gandaglia G. 1, Rosiello G. 1, Fossali N. 1, Galosi A.B. 3, Scarcella S. 1, Scattoni V. 1, Gallina A. 1, Suardi N. 1, Roupret M. 4, Esposito A. 2, Montorsi F. 1, Briganti A. 1
1 IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy,
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT089</td>
<td>Identification of the index lesion and contralateral significant cancer in men undergoing transperineal mapping biopsy</td>
<td>Crawford E.D., Stone N., Skouteris V., Lucia M.S., La Rosa F., Werahera P., Skouters M., Metsinis M.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. The University of Colorado Anschutz Cancer Center, Dept. of Urology, Aurora, United States of America, 2. The Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, 3. Hygeia Brachytherapy Center, Dept. of Urology, Athens, Greece, 4. University of Colorado Anschutz Medical Center, Dept. of Urology, Aurora, United States of America</td>
</tr>
<tr>
<td>PT090</td>
<td>Role of PI-RADS version 2 for prediction of incidental prostate cancer after radical cystoprostatectomy</td>
<td>Song W., Jeong J.Y., Kim T.H., Yoon H.S., Kim K.H., Yoon H., Chung W.S., Sim B.S., Lee D.H.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. Ewha Womans University School of Medicine, Dept. of Urology, Seoul, South Korea, 2. Kangbuk Samsung Hospital, Dept. of Urology, Seoul, South Korea, 3. CHA Bundang Medical Center, Dept. of Urology, Seongnam, South Korea</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. Pusan National University Hospital, Dept. of Urology, Busan, South Korea, 2. Pusan National University Hospital, Dept. of Pathology, Busan, South Korea, 3. Pusan National University Hospital, Dept. of Radiology, Busan, South Korea</td>
</tr>
<tr>
<td>PT092</td>
<td>Quantitative analysis between multiparametric MRI parameters and prostate cancer Gleason score with whole-mount histopathology</td>
<td>Gao J., Zhang Q., Zhang C., Guo H.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. Pusan National University Hospital, Dept. of Urology, Busan, South Korea, 2. Pusan National University Hospital, Dept. of Pathology, Busan, South Korea, 3. Pusan National University Hospital, Dept. of Radiology, Busan, South Korea</td>
</tr>
<tr>
<td>PT093</td>
<td></td>
<td>1. Pusan National University Hospital, Dept. of Urology, Busan, South Korea, 2. Pusan National University Hospital, Dept. of Pathology, Busan, South Korea, 3. Pusan National University Hospital, Dept. of Radiology, Busan, South Korea</td>
</tr>
</tbody>
</table>
### Aims and objectives of this presentation

#### PT093
**Periprocedural and diagnostic outcomes of transrectal versus transperineal US/MRI guided fusion prostate biopsy: Multi-institutional propensity score matched pair analysis**

By: Ferriero M.C.\(^1\), Flammia R.S.\(^1\), Oderda M.\(^2\), Forte V.\(^3\), Peltier A.\(^4\), Kumar P.\(^5\), Giacobbe A.\(^6\), Mastroianni R.\(^1\), Tuderti G.\(^1\), Anceschi U.\(^1\), Brassetti A.\(^1\), Guaglianone S.\(^1\), Rouprêt M.\(^7\), Piechaud T.\(^6\), Roche J.\(^8\), Cicciariello M.\(^3\), Mozer P.\(^7\), Gontero P.\(^2\), Muto G.\(^6\), Gallucci M.\(^1\), Simone G.\(^1\)

\(^1\)Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, \(^2\)University of Turin, Dept. of Surgical Sciences, Urology, Turin, Italy, \(^3\)Sapienza University, Dept. of Radiological, Oncological and Anatomo-Pathological Sciences, Rome, Italy, \(^4\)Institut Jules Bordet, Universite Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, \(^5\)Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, \(^6\)Humanitas Gradenigo Hospital, Dept. of Urology, Turin, Italy, \(^7\)Pitie Salpetriere Hospital, Assistance Publique - Hopitaux de Paris, Universites Paris Sorbonne, Dept. of Urology, Paris, France, \(^8\)Clinique Saint Augustin, Dept. of Urology, Bordeaux, France

#### PT094
**How to prevent patients with a false positive overall score of PI-RADS 4**

By: Von Beyme Cortés C.\(^1\), Ullrich T.\(^2\), Quentin M.\(^2\), Laqua N.\(^2\), Rabenalt R.\(^1\), Antoch G.\(^2\), Schimmöller L.\(^2\), Albers P.\(^1\), Arsov C.\(^1\)

\(^1\)University of Dusseldorf, Dept. of Urology, Dusseldorf, Germany, \(^2\)University of Dusseldorf, Dept. of Diagnostic and Interventional Radiology, Dusseldorf, Germany

#### PT095
**Prostate cancer risk prediction using 5 different strategies: Independent validation in a Belgian cohort**


AZ Groeninge, Dept. of Urology, Courtrai, Belgium

#### PT096
**Does size matter? A comparison of Gleason score concordance rate between 23 Belgian centres**

By: Soenens C.\(^1\), Dekuyper P.\(^1\), Van Cleynenbreugel B.\(^2\), Quackels T.\(^3\),
Aims and objectives of this presentation

PT097

Differences in contemporary biopsy Gleason score distribution in men diagnosed with prostate cancer from China and Canada

By: Dong L. 1, Woon D. 2, Kuk C. 3, Erlich A. 3, Ma Z. 1, Shi O. 4, Dong B. 1, Nesbitt M. 2, Carlsson S. 5, Kulkarni G. 2, Hamilton R. 2, Finelli A. 2, Fleshner N. 2, Van Der Kwast T. 6, Xue W. 1, Zlotta A. 3

1Renji Hospital, Dept. of Urology, Shanghai, China, 2University Health Network, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada, 3Sinai Health System, Dept. of Surgery, Division of Urology, Toronto, Toronto, Canada, 4Shenzhen Second People's Hospital, Dept. of Neurology, Shenzhen, China, 5Memorial Sloan Kettering Cancer Center, Dept. of Surgery and Epidemiology & Biostatistics, New York, United States of America, 6University Health Network, Dept. of Pathology, Toronto, Canada

Aims and objectives of this presentation

PT098

Is one targeted biopsy core of the index lesion sufficient to accurately detect clinically significant prostate cancer across all PI-RADS scores?

By: Dell'Oglio P. 1, Stabile A. 1, Boeri L. 2, Soligo M. 2, Rosiello G. 1, Grande P. 3, Esposito A. 4, Fossati N. 1, Gandaglia G. 1, Cucchiara V. 1, Bravi C. 1, Nocera L. 1, De Cobelli F. 4, Karnes J. 2, Montorsi F. 1, Briganti A. 1

1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Groupe Hospitalier Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, University Paris Sorbonne, Dept. of Urology, Paris, France, 4IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy

Aims and objectives of this presentation

PT099

Fusion US/MRI prostate biopsy using a computer aided diagnostic (CAD) system

By: Ferriero M.C. 1, Flammia R.S. 1, Zeccolini G. 2, De Concilio B. 2, Tuderti G. 1, Anceschi U. 1, Brassetti A. 1, Mastroianni R. 1, Celia A. 2, Gallucci M. 1, Simone G. 1

1Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2San Bassiano Hospital, Dept. of Urology, Bassano del Grappa, Italy

Aims and objectives of this presentation

PT100
<table>
<thead>
<tr>
<th>PT101</th>
<th>Predictors of adverse pathology on radical prostatectomy: Development of a prognostic nomogram incorporating transperineal biopsy and mpMRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Kalapara A. 1, Sathianathen N. 2, Frydenberg M. 1, Grummet J.P. 1</td>
</tr>
<tr>
<td>1Monash University, Dept. of Surgery, Melbourne, Australia, 2University of Minnesota, Dept. of Urology, Minneapolis, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT101

<table>
<thead>
<tr>
<th>PT102</th>
<th>Clinical impact of male BRCA2 germline pathogenic mutation: Preliminary results from a National Clinical Research Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Buffi N. 1, Saita A. 2, Zuradelli M. 2, Casale P. 2, Hurle R. 2, Lughezzani G. 2, Pasini L. 2, Fasulo V. 2, Paciotti M. 2, Domanico L. 2, Bevilacqua G. 2, Barile M. 3, Ripamonti C.B. 3, Lazzeri M. 2, Guazzoni G. 1</td>
</tr>
<tr>
<td>1Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Humanitas University, Dept. of Urology, Rozzano, Italy, 2Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, 3Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Laboratory Unit, Rozzano, Italy</td>
<td></td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT102

<table>
<thead>
<tr>
<th>PT103</th>
<th>Descriptive analysis of BRCA-associated cancer family history among Japanese prostate cancer patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Ishiyama Y. 1, Shimbo M. 2, Deshpande G. 3, Iizuka J. 1, Tanabe K. 1, Hattori K. 2</td>
</tr>
<tr>
<td>1Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan, 2St. Luke's International Hospital, Dept. of Urology, Tokyo, Japan, 3St. Luke's International Hospital, Dept. of General Internal Medicine, Tokyo, Japan</td>
<td></td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT103

<table>
<thead>
<tr>
<th>PT104</th>
<th>Genetic testing for hereditary prostate cancer among men in Israel</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Golan S. 1, Sela S. 1, Frumer M. 1, Kedar I. 2, Ber Y. 1, Kedar D. 1, Margel D. 1</td>
</tr>
<tr>
<td>1Rabin Medical Center, Dept. of Urology, Petah-Tikva, Israel, 2Rabin Medical Center, Dept of Genetics, Petah-Tikva, Israel</td>
<td></td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT104

<table>
<thead>
<tr>
<th>PT105</th>
<th>Bioelectric impedance analysis (BIA) for non-invasive prostate carcinoma (PCa) diagnosis using a novel “finger” probe tool: Results from a cross-sectional, hospital-based study</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Bartoletti R. 1, Neri G. 1, Greco A. 2, Di Vico T. 1, Durante J. 1, Tognarelli A. 1</td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT105
Talluri T. ³, Valenza G. ²

¹University of Pisa, Dept. of Translational Research and New Technologies, Pisa, Italy,
²University of Pisa, Dept. of Information Engineering & Bioengineering and Robotics Research Center, Pisa, Italy,
³Akern Srl, Dept. of Development and Research, Pontassieve, Italy

Aims and objectives of this presentation
PT105

**PT106**

**Prognostic value of prostate specific antigen in primary neuroendocrine prostate cancer**

By: Wang J., Zhu Y., Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation
PT106

**PT107**

**Circulating tumor cells may improve PSA ability to predict positive prostate biopsy in patients with total serum prostate-specific antigen levels of 4–10 ng/mL**

By: Wang B., Ma L.
Peking University Third Hospital, Dept. of Urology, Beijing, China

Aims and objectives of this presentation
PT107

**PT108**

**Effects of metabolic syndrome on the prevalence of prostate cancer: Historical cohort study using the national health insurance service database**

By: Park J. ¹, Yoo S. ¹, Cho S.Y. ¹, Cho M.C. ¹, Paick J-S. ², Son H. ¹, Jeong H. ¹
¹Boramae Medical Center, Dept. of Urology, Seoul, South Korea,
²Mediplex Sejong Hospital, Dept. of Urology, Incheon, South Korea

Aims and objectives of this presentation
PT108

**PT109**

**The effect of lifestyle changes on serum PSA levels in a cohort of asymptomatic men with PSA between 2-10 ng/ml and normal DRE**

By: Zlotta A.R. ¹, Mari A. ², Erlich A. ¹, Kuk C. ¹, Misurka J. ³, Marzario S. ¹, Zisman A. ³,
Nesbit M. ³, Carlsson S. ⁴, Perlis N. ³, Hamilton R. ³, Finelli A. ³, Fleshter N. ³
¹Sinai Health System, Dept. of Surgery, Division of Urology, Toronto, Canada,
²University of Florence, Dept. of Urology, Florence, Italy,
³University Health Network, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada,
⁴Memorial Sloan Kettering Cancer Center, Dept. of Surgery and Epidemiology & Biostatistics, New York, United States of America

Aims and objectives of this presentation
PT109
Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort

By: Siltari A. 1, Murtola T.J. 1, Talala K. 2, Taari K. 3, Tammela T.L.J. 1, Auvinen A. 4

1University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland, 2Finnish Cancer Registry, Finnish Cancer Registry, Helsinki, Finland, 3Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 4University of Tampere, School of Health Sciences, Tampere, Finland

Aims and objectives of this presentation

Association between chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer

By: Beckmann K. 1, Russell B. 1, Josephs D. 2, Garmo H. 1, Haggstrom C. 3, Holmberg L. 1, Stattin P. 4, Van Hemelrijck M. 1, Aldofsson J. 5

1Kings College London, School of Cancer and Pharmaceutical Studies, London, United Kingdom, 2Guy's and St Thomas' NHS Foundation Trust, Dept. of Oncology, London, United Kingdom, 3Umea, Dept. of Biobanking Research, Umea, Sweden, 4Uppsala University Hospital, Regional Cancer Centre Uppsala, Uppsala, Sweden, 5Karolinska Institute, CLINTEC-Department, Stockholm, Sweden

Aims and objectives of this presentation

Negative predictive value of multi-parametric MRI in detection of clinically significant prostate cancer: A systematic review and meta-analysis


1University of Minnesota, Dept. of Urology, Minneapolis, United States of America, 2University of Oxford, Dept. of Surgical Sciences, Oxford, United Kingdom, 3University College London Hospital, Dept. of Urology, London, United Kingdom, 4Cambridge University Hospitals NHS Foundation Trust, CamPARI Clinic, Cambridge, United Kingdom, 5Utrecht Medical Centre, Dept. of Urology, Utrecht, The Netherlands, 6University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia

Aims and objectives of this presentation

Robot-assisted radical prostatectomy (RARP) versus volumetric modulated arc therapy (VMAT) in cT1-4N0M0 prostate cancer

By: Taguchi S. 1, Shiraishi K. 2, Fujimura T. 3, Naito A. 4, Kawai T. 4, Nakagawa K. 5, Igawa Y. 4, Abe O. 5, Kume H. 4, Fukuhara H. 1

1Kyorin University Faculty of Medicine, Dept. of Urology, Tokyo, Japan, 2Teikyo University School of Medicine, Dept. of Radiology, Tokyo, Japan, 3Jichi Medical University, Dept. of
| PT145 | Withdrawn | To be confirmed | Aims and objectives of this presentation | PT115 |
Trials in progress
Expert-Guided Poster Tour 05

Saturday 16 March
13:30 - 15:30

Location: Green Area, Room B
Chairs: A.S. Bjartell, Malmö (SE)
M. De Santis, Berlin (DE)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

13:30 - 13:33
Introduction
A.S. Bjartell, Malmö (SE)
M. De Santis, Berlin (DE)

PT116
Baseline features and treatment-decision making in patients with prostate cancer enrolled in the United in Fight against prOstate (UFO) cancer registry

¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²Kindai University Faculty of Medicine, Dept. of Urology, Osaka, Japan, ³West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China, ⁴National University Hospital, National University Health System, Dept. of Urology, Singapore, Singapore, ⁵Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki University, Japan, ⁶Chulalongkorn University, Dept. of Surgery, Bangkok, Thailand, ⁷Institute Urology and Nephrology, Hospital Kuala Lumpur, Dept. of Urology, Kuala Lumpur, Malaysia, ⁸Gangnam Severance Hospital, Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea, ⁹Rajeev Gandhi Cancer Institutes & Research Centre, Uro Oncology Services, New Delhi, India, ¹⁰National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, ¹¹National Cancer Centre, Division of Medical Oncology, Singapore, Singapore, ¹²Faculty of Medicine, University of Malaya, Dept. of Surgery, Kuala Lumpur, Malaysia, ¹³Faculty of Medicine, Prince of Songkla University, Dept. of Surgery, Songkhla, Thailand, ¹⁴Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, South Korea, ¹⁵Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ¹⁶Janssen Research & Development, LLC, Epidemiology, Raritan, United States of America, ¹⁷Janssen (China) Research & Development Center, SDS China Dept, Shanghai, China, ¹⁸Janssen, GCDO-MAO, Selangor, Malaysia, ¹⁹Janssen Asia-Pacific, Medical Affairs, Sydney, Australia, ²⁰Janssen Research & Development, Epidemiology, Singapore, Singapore
Aims and objectives of this presentation

**PT116**

**PROPEL: A randomized phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)**


1 The Christie and Salford Royal Hospitals, Dept. of Surgery, Salford, United Kingdom, 2 Duke Cancer Institute, Duke Prostate and Urologic Cancer Center, Durham, United States of America, 3 CHU Besançon, CU-PH Medical Oncology, Besançon, France, 4 Keio University, Dept. of Urology, Tokyo, Japan, 5 Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, 6 Vall d’Hebron Institute of Oncology, Prostate Cancer Translational Research Group, Barcelona, Spain, 7 AstraZeneca, Global Medicines Development, Gaithersburg, United States of America, 8 Centre Hospitalier de l’Université de Montréal, Dept. of Surgery, Montréal, Canada

Aims and objectives of this presentation

**PT117**

**Design of phase 1b/2 study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration and androgen blocking agent resistant prostate cancer**

By: Getzenberg R., Markowski M.C., Eisenberger M.A., Antonarakis E.S., Yu E.Y., Barnette G., Rodriguez D., Steiner M.S.

1 Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, FL, United States of America, 2 Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States of America, 3 University of Washington, Dept. of Oncology, Seattle, WA, United States of America, 4 Veru Inc, Miami, FL, United States of America

Aims and objectives of this presentation

**PT118**

**A phase 2, dose finding, placebo-controlled, study of zuclomiphene citrate to alleviate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer**

By: Getzenberg R., Rodriguez D., Hancock M., Fisch H., Steiner M.

1 Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, FL, United States of America, 2 Veru Inc, Clinical Operations, Miami, FL, United States of America, 3 Hancock Consulting, Biostatistics, Memphis, TN, United States of America

Aims and objectives of this presentation

**PT119**
**PT120**

Comparing HIFU versus radical prostatectomy in low and intermediate risks prostate cancer: The early data of the HiFi study

By: Rischmann P. 1, Gelet A. 2, Villers A. 3, Coloby P. 4, Crouzet S. 2

1 Hôpital Rangueil CHU, Dept. of Urology, Andrology and Renal Transplant, Toulouse, France, 2 Hôpital Edouard Herriot, Dept. of Urology and Transplantation Surgery, Lyon, France, 3 Hôpital Huriez, Dept. of Urology, Lille, France, 4 Hôpital Pontoise, Dept. of Urology, Pontoise, France

Aims and objectives of this presentation

PT120

**PT121**

Novel and feasible methodology to obtain LE1 evidence for BPS treatment. Implementing the combined N-of-1 trial design

By: Janssen D.A.W. 1, Hoogenboom T. 2, Heesakkers J.P.F.A. 1

1 Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 2 Radboudumc, IQhealthcare, Nijmegen, The Netherlands

Aims and objectives of this presentation

PT121

**PT122**

Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (SOAP) surgery for benign prostate obstruction: A multicentre randomized controlled trial


1 Clinique Pasteur, Dept. of Urology, Toulouse, France, 2 University Hospital Tours, Dept. of Urology, Tours, France, 3 University Hospital Rennes, Dept. of Urology, Rennes, France, 4 University Hospital Grenoble, Dept. of Urology, Grenoble, France, 5 University Hospital Limoges, Dept. of Urology, Limoges, France, 6 Cochin Hospital, Dept. of Urology, Paris, France, 7 Private Hospital of Cotes d’Armor, Dept. of Urology, Plerin, France, 8 Conception Hospital, Dept. of Urology, Marseille, France, 9 Private Hospital of Louviere, Dept. of Urology, Lille, France, 10 University Hospital Angers, Dept. of Urology, Angers, France, 11 University Hospital Brest, Dept. of Urology, Brest, France, 12 Clinique Pasteur, Dept. of Cardiovascular Medicine, Toulouse, France, 13 University Grenoble-Alpes, University Hospital, Dept. of Anesthesiology and Intensive Care Medicine, Grenoble, France, 14 Assistance Publique-Hôpitaux de Paris, Cochin University Hospital, Dept. of Anaesthesiology and Intensive Care, Paris, France, 15 University Hospital of Toulouse Rangueil, Dept. of Haematology, Toulouse, France, 16 Clinique Pasteur, Dept. of Anaesthesiology and Intensive Care, Toulouse, France

Aims and objectives of this presentation

PT122
**The effects of sequential mitomycin and bacillus Calmette-Guérin treatment versus bacillus Calmette-Guérin monotherapy in patients with high risk non-muscle invasive bladder cancer: Mito-bcg (EudraCT-2017-004540-37)**

By: De Nunzio C.¹, Nacchia A.¹, Simone G.², Leonardo C.³, Gallucci M.², Tubaro A.¹

¹Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ²IFO, Istituto Nazionale Tumori Regina Elena Hospital, Dept. of Urology, Rome, Italy, ³Sapienza University of Rome, Umberto I Hospital, Dept. of Urology, Rome, Italy

**Aims and objectives of this presentation**

**A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT**


¹Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, ²Technical University of Munich, Dept. of Urology, Munich, Germany, ³Fundació Puigvert, Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, ⁴University of California, San Francisco, Dept. of Urology, San Francisco, United States of America, ⁵Vanderbilt University School of Medicine, Dept. of Urologic Surgery, Nashville, United States of America, ⁶Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁷University of Minnesota, Dept. of Urology, Minneapolis, United States of America, ⁸The University of Chicago Medicine, Dept. of Surgery, Chicago, United States of America, ⁹University of Tsukuba, Dept. of Urology, Tsukuba, Japan, ¹⁰University of Kansas Medical Center, Dept. of Urology, Kansas City, United States of America, ¹¹Bristol-Myers Squibb, Princeton, United States of America, ¹²Bristol-Myers Squibb, Dept. of Clinical Biostatistics, Princeton, United States of America, ¹³Bristol-Myers Squibb, Dept. of Clinical Pharmacology and Pharmcometrics, Princeton, United States of America, ¹⁴Bristol-Myers Squibb, Dept. of Translational Medicine, Princeton, United States of America, ¹⁵Bristol-Myers Squibb, Dept. of Clinical Protocol, Princeton, United States of America, ¹⁶Bristol-Myers Squibb, Dept. of Clinical Operations, Princeton, United States of America, ¹⁷Bristol-Myers Squibb, Dept. of Clinical Trials, Bladder Cancer Program, Princeton, United States of America, ¹⁸Bristol-Myers Squibb, Dept. of Clinical Trials, Princeton, United States of America, ¹⁹Bristol-Myers Squibb, Dept. of Development, Princeton, United States of America, ²⁰Johns Hopkins University School of Medicine, Departments of Oncology and Urology, Baltimore, United States of America

**Aims and objectives of this presentation**

**PURE-02: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (Pembro), preceding radical nephroureterectomy (RNU), for**

---

**Scientific Programme - EAU19 Barcelona**

---

PT123

The effects of sequential mitomycin and bacillus Calmette-Guérin treatment versus bacillus Calmette-Guérin monotherapy in patients with high risk non-muscle invasive bladder cancer: Mito-bcg (EudraCT-2017-004540-37)

By: De Nunzio C.¹, Nacchia A.¹, Simone G.², Leonardo C.³, Gallucci M.², Tubaro A.¹

¹Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ²IFO, Istituto Nazionale Tumori Regina Elena Hospital, Dept. of Urology, Rome, Italy, ³Sapienza University of Rome, Umberto I Hospital, Dept. of Urology, Rome, Italy

**Aims and objectives of this presentation**

---

PT124

A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT


¹Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, ²Technical University of Munich, Dept. of Urology, Munich, Germany, ³Fundació Puigvert, Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, ⁴University of California, San Francisco, Dept. of Urology, San Francisco, United States of America, ⁵Vanderbilt University School of Medicine, Dept. of Urologic Surgery, Nashville, United States of America, ⁶Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁷University of Minnesota, Dept. of Urology, Minneapolis, United States of America, ⁸The University of Chicago Medicine, Dept. of Surgery, Chicago, United States of America, ⁹University of Tsukuba, Dept. of Urology, Tsukuba, Japan, ¹⁰University of Kansas Medical Center, Dept. of Urology, Kansas City, United States of America, ¹¹Bristol-Myers Squibb, Princeton, United States of America, ¹²Bristol-Myers Squibb, Dept. of Clinical Biostatistics, Princeton, United States of America, ¹³Bristol-Myers Squibb, Dept. of Clinical Pharmacology and Pharmcometrics, Princeton, United States of America, ¹⁴Bristol-Myers Squibb, Dept. of Translational Medicine, Princeton, United States of America, ¹⁵Bristol-Myers Squibb, Dept. of Clinical Protocol, Princeton, United States of America, ¹⁶Bristol-Myers Squibb, Dept. of Clinical Operations, Princeton, United States of America, ¹⁷Bristol-Myers Squibb, Dept. of Clinical Trials, Bladder Cancer Program, Princeton, United States of America, ¹⁸Bristol-Myers Squibb, Dept. of Clinical Trials, Princeton, United States of America, ¹⁹Bristol-Myers Squibb, Dept. of Development, Princeton, United States of America, ²⁰Johns Hopkins University School of Medicine, Departments of Oncology and Urology, Baltimore, United States of America

**Aims and objectives of this presentation**

---

PT125

PURE-02: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (Pembro), preceding radical nephroureterectomy (RNU), for
patients with localized high-risk urothelial carcinoma of the upper urinary tract (UTUC)

By: Necchi A. 1, Raggi D. 1, Gust K. 2, D’Andrea D. 2, Briganti A. 3, Capitanio U. 3, Colecchia M. 1, Chung J. 4, Ali S. 4, Ross J. 4, Montorsi F. 3, Shariat S. 2

1 Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2 Medical University of Vienna, Dept. of Urology, Vienna, Austria, 3 Vita Salute San Raffaele University, Urological Research Institute (URI), Milan, Italy, 4 Foundation Medicine, Foundation Medicine, Cambridge, United States of America

Aims and objectives of this presentation

PT125

A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress

By: Petrylak D. 1, Rosenberg J. 2, Duran I. 3, Loriot Y. 4, Sonpavde G. 5, Wu C. 6, Gartner E. 7, Melhem-Bertrandt A. 8, Powles T. 9

1 Yale University School of Medicine, Dept. of Medical Oncology and Urology, New Haven, United States of America, 2 Memorial Sloan Kettering Cancer Center, Dept. of Genitourinary Oncology Service, New York City, United States of America, 3 Hospital Universitario Marqués de Valdecilla, Dept. of Medical Oncology, Santander, Spain, 4 Institut Gustave Roussy, Dept. of Medical Oncology, Paris, France, 5 Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 6 Astellas Pharma US, Inc., Dept. of Biostatistics, Northbrook, United States of America, 7 Seattle Genetics, Inc., Dept. of Clinical Research, Bothell, United States of America, 8 Astellas Pharma US, Inc., Development Medical Sciences, Oncology, Northbrook, United States of America, 9 Queen Mary University of London, Barts Cancer Institute, London, United Kingdom

Aims and objectives of this presentation

PT126

ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma


1 Hospital Del Mar, Dept. of Genitourinary Cancer Unit, Barcelona, Spain, 2 Studienpraxis Urologie, Dept. of Urologic Oncology, Nurtingen, Germany, 3 Gustave Roussy Cancer Campus, Dept. of Cancer Medicine, Villejuif, France, 4 Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 5 Huntsman Cancer Institute, University of Utah, Dept. of Genitourinary Oncology Program, Salt Lake City, United States of America, 6 Guy’s and St. Thomas’ NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, 7 Stanford University School of Medicine, Dept. of Urologic Oncology Clinic, Stanford, United States of America, 8 University of Iowa and Holden Comprehensive Cancer Center, Dept. of Division of Hematology, Iowa City, United States of America, 9 Clovis Oncology, Inc., Dept. of Clinical Science, Boulder,
United States of America, \textsuperscript{10} Clovis Oncology, Inc., Dept. of Biostatistics, Boulder, United States of America, \textsuperscript{11} Clovis Oncology, Inc., Dept. of Clinical Operations, Boulder, United States of America, \textsuperscript{12} Clovis Oncology, Inc., Dept. of Translational Medicine, Boulder, United States of America, \textsuperscript{13} University of Washington, Dept. of Medicine, Division of Oncology, Seattle, United States of America, \textsuperscript{14} Guy’s and St Thomas’ NHS Foundation Trust and Sarah Cannon Research Institute, Dept. of Medical Oncology, London, United Kingdom

**Aims and objectives of this presentation**

PT127

**PT128**

**Post-nephrectomy adjuvant therapy for localized renal cell carcinoma (RCC): The phase III randomized, placebo-controlled CheckMate 914 study of nivolumab plus ipilimumab in patients at high risk of relapse**

By: Bex A. \textsuperscript{1}, Russo P. \textsuperscript{2}, Tomita Y. \textsuperscript{3}, Grunwald V. \textsuperscript{4}, Ramirez L.M. \textsuperscript{5}, McHenry M.B. \textsuperscript{6}, Motzer R.J. \textsuperscript{7}

\textsuperscript{1} Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, \textsuperscript{2} Memorial Sloan Kettering Cancer Center, Dept. of Surgery, New York, United States of America, \textsuperscript{3} Niigata University Graduate School of Medical and Dental Sciences, Dept. of Molecular Oncology, Niigata, Japan, \textsuperscript{4} Hannover Medical School, Dept. of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover, Germany, \textsuperscript{5} Bristol-Myers Squibb, Dept. of Research & Development Oncology, Princeton, United States of America, \textsuperscript{6} Bristol-Myers Squibb, Dept. of Global Biometric Sciences, Princeton, United States of America, \textsuperscript{7} Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America

**Aims and objectives of this presentation**

PT128

**PT129**

**Real world evidence in renal cell carcinoma: A national, prospective, non-interventional study of nivolumab in patients with advanced renal cell carcinoma after prior therapy (NORA)**

By: Grimm M-O. \textsuperscript{1}, Grünwald V. \textsuperscript{2}, Müller-Huesmann H. \textsuperscript{3}, Schostak M. \textsuperscript{4}, Schultze-Seemann W. \textsuperscript{5}, Bedke J. \textsuperscript{6}

\textsuperscript{1} Jena University Hospital, Dept. of Urology, Jena, Germany, \textsuperscript{2} University Hospital Essen, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Essen, Germany, \textsuperscript{3} Brüderkrankenhaus St. Josef, Dept. of Internal Medicine, Hematology and Oncology, Paderborn, Germany, \textsuperscript{4} University Hospital Magdeburg, Dept. of Urology and Pediatric Urology, Magdeburg, Germany, \textsuperscript{5} University of Freiburg, Faculty of Medicine, Dept. of Urology, Freiburg, Germany, \textsuperscript{6} Eberhard Karls University, Dept. of Urology, Tübingen, Germany

**Aims and objectives of this presentation**

PT129

**PT130**

**Pilot results from the laparoscopic entry technique in renal surgery: A randomised controlled trial comparing open (Hasson) versus closed (Veress) techniques**

Scientific Programme - EAU19 Barcelona
Aims and objectives of this presentation

PT130

The iROC trial: An RCT comparing intracorporeal robot-assisted vs open radical cystectomy for bladder cancer


1University College London, Dept. of Urology, London, United Kingdom, 2University College London, Surgical and Interventional Trials Unit, London, United Kingdom, 3University College London, Dept. of Statistical Science, London, United Kingdom, 4Guy's Hospital, Dept. of Urology, London, United Kingdom, 5University College London Hospital, Dept. of Anaesthetics, London, United Kingdom, 6University College London, Division of Surgical & Interventional Sciences, London, United Kingdom, 7University of Sheffield, Dept. of Health Economics and Decision Science, Sheffield, United Kingdom, 8Lister Hospital, Stevenage, Dept. of Urology, Stevenage, United Kingdom, 9University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, 10Royal Devonshire and Exeter NHS Trust, Dept. of Urology, Exeter, United Kingdom, 11Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, 12North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, 13University College London Hospital, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation

PT131

Solutions towards implementing a multisystem cell therapy for improvement of urinary continence

By: Mohr-Haralampieva D., Prange J., Sousa R., Schmid F., Eberli D.
University of Zurich, Dept. of Urology, Zurich, Switzerland

Aims and objectives of this presentation

PT132

NeuroSAFE PROOF: A multi-centre feasibility study to evaluate the ability to randomize men with prostate cancer into an RCT comparing NeuroSAFE robotic-assisted radical prostatectomy (RARP) to standard RARP

By: Dinneen E. 1, Haider A. 2, Allen C. 3, Briggs T. 4, Nathan S. 4, Brew-Graves C. 1, Freeman A. 2, Oakley N. 5, Rowe E. 6, Persad R. 6, Shaw G. 1

Aims and objectives of this presentation

PT133
Aims and objectives of this presentation
PT133

PT134

Neo-adjUvant veRsus AdjuvaNt chemotherapy in upper tract Urothelial carcinoma: A feaSibility phase II randomized clinical trial (“URANUS”)

By: Palou J.¹, Maroto P.², Osanto S.³, Bellmunt J.⁴, Beisland C.⁵, Roupret M.⁶, European Uro-Oncology Group (EUOG)
¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Hospital de Sant Pau, Dept. of Urology, Barcelona, Spain, ³Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, ⁴Hospital del Mar, Dept. of Urology, Barcelona, Spain, ⁵Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ⁶CHU la Pitié-Salpetriere, Dept. of Urology, Paris, France

Aims and objectives of this presentation
PT134
**Aims and objectives of this session**

The Endoscopic Stone Treatment (EST) training curriculum has the goal to provide the clinician with proficiency skills in the treatment of urinary stones with endoscopic techniques. This protocol has been designed following a very strict process, in order to mitigate the risks of complications related to the learning curve process. Moving along the different tasks 336 Programme Book EAU Education and training steps, the participant will learn how to use the different instruments and technologies that can be functional to stone fragmentation and extraction.

The EST s1 (Endoscopic Stone Treatment step 1) is the first step of this training and assessment curriculum. To aid in the training of these skills and to prepare for this ESTs1 exam, the exercises to be performed can be found in the instructional videos at uroweb.org.
**ESU/ESUT/ESUI Hands-on Training Course in Fusion biopsy**
Sponsored by EIGEN, PHILIPS, KOELIS, MEDCOM, HITACHI, EXACT IMAGING, BK MEDICAL

**Saturday 16 March**
**14:00 - 16:00**

**Location:** Green Area, Room 8

**Chair:** L. Budäus, Hamburg (DE)

**Tutors:**
- A. Borkowetz, Dresden (DE)
- J.P. Radtke, Essen (DE)
- C. Kastner, Cambridge (GB)
- E. Baco, Oslo (NO)
- S. Boxler, Bern (CH)
- H. Cash, Berlin (DE)

**Aims and objectives of this session**
MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow.

The course will provide an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. During the second half of the course, the participants are able to try out 7 different Fusion biopsy machines in small groups, changing every 10 min.

At the end of the course, the participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.

**14:00 - 16:00**

**Introduction to Exact Imaging**
L. Budäus, Hamburg (DE)
Aims and objectives of this session
Within this interactive session, we will explore the evidence base underpinning three controversial treatment recommendations in the Prostate Cancer, Renal Cell Cancer and Sexual and Reproductive Health Guidelines. In each case, the evidence for and against recommendations will be presented and then reviewed by an external discussant. What is your opinion on these topics? To have your say, attend this session and vote to let us know.

The aim of this session is thus to acquaint attendees with recent work of the EAU Guidelines Panels by presenting how the evidence base is used to provide support for and against three controversial guidelines topics.

The EAU Guidelines Office oversees the development of clinical practice guidelines from some 20 different EAU guidelines panels. Guideline recommendations are underpinned, whenever possible, by systematic reviews and meta-analyses of randomised controlled trials. The validity of the results of a systematic review depends on the quality of the individual studies and their clinical and methodological heterogeneity. In many cases, however, only lower levels of evidence exist because randomisation is not feasible, or a systematic review has not been done.

Guideline controversies arise when a recommendation is based on evidence that is not robust. Disagreements can occur, even between members of the same panel, if, for example, the results of a new randomised controlled trial differ from those found in a previous meta-analysis or if the results across different series of randomised and/or non-randomised studies vary from one to another. Such discrepancies are more often than not related to study differences relating to patient selection, treatment, outcome evaluation, and risk of bias.

So come to this session to let us know if you agree with experts and if not, then why not!

14:15 - 14:30
Welcome and introduction
J. N'Dow, Aberdeen (GB)
R.J. Sylvester, Brussels (BE)

14:30 - 15:20
Prostate Cancer: No biopsy in case of a normal MRI
Moderator: N. Mottet, Saint-Étienne (FR)

14:30 - 14:35
Introduction
N. Mottet, Saint-Étienne (FR)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:35 - 14:40</td>
<td>Voting</td>
<td></td>
</tr>
<tr>
<td>14:40 - 14:50</td>
<td>Pro</td>
<td>C. Moore, London (GB)</td>
</tr>
<tr>
<td>14:50 - 15:00</td>
<td>Con</td>
<td>S. Carlsson, New York (US)</td>
</tr>
<tr>
<td>15:00 - 15:10</td>
<td>Discussant</td>
<td>O. Rouvière, Lyon (FR)</td>
</tr>
<tr>
<td>15:10 - 15:15</td>
<td>Revoting</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:20</td>
<td>Conclusion</td>
<td>N. Mottet, Saint-Étienne (FR)</td>
</tr>
<tr>
<td>15:20 - 16:10</td>
<td>Renal Cell Carcinoma (RCC): Should we be doing cytoreductive nephrectomies in M1 patients requiring targeted therapy?</td>
<td>Moderator: B. Ljungberg, Umeå (SE)</td>
</tr>
<tr>
<td>15:20 - 15:25</td>
<td>Introduction</td>
<td>B. Ljungberg, Umeå (SE)</td>
</tr>
<tr>
<td>15:25 - 15:30</td>
<td>Voting</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:40</td>
<td>Pro</td>
<td>M. Staehler, Munich (DE)</td>
</tr>
<tr>
<td>15:40 - 15:50</td>
<td>Con</td>
<td>A. Bex, Amsterdam (NL)</td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td>Discussant</td>
<td>L. Lund, Odense (DK)</td>
</tr>
<tr>
<td>16:00 - 16:05</td>
<td>Revoting</td>
<td></td>
</tr>
<tr>
<td>16:05 - 16:10</td>
<td>Conclusion</td>
<td>B. Ljungberg, Umeå (SE)</td>
</tr>
<tr>
<td>16:10 - 17:00</td>
<td>Male sexual health - Focal therapy vs. Robotic surgery for prostate cancer: Reported sexual function outcomes are misleading and require standardisation in guidelines</td>
<td>Moderator: A. Salonia, Milan (IT)</td>
</tr>
<tr>
<td>16:10 - 16:15</td>
<td>Introduction</td>
<td>A. Salonia, Milan (IT)</td>
</tr>
<tr>
<td>16:15 - 16:20</td>
<td>Voting</td>
<td></td>
</tr>
<tr>
<td>16:20 - 16:30</td>
<td>Pro</td>
<td>S.S. Minhas, London (GB)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speakers</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------</td>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td>Con</td>
<td>V. Ficarra, Messina (IT)</td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td>Discussant</td>
<td>F. Montorsi, Milan (IT)</td>
</tr>
<tr>
<td>16:50 - 16:55</td>
<td>Revoting</td>
<td></td>
</tr>
<tr>
<td>16:55 - 17:00</td>
<td>Conclusion</td>
<td>A. Salonia, Milan (IT)</td>
</tr>
<tr>
<td>17:00 - 17:15</td>
<td>Closing remarks</td>
<td>J. N'Dow, Aberdeen (GB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R.J. Sylvester, Brussels (BE)</td>
</tr>
</tbody>
</table>
Male infertility and reproductive health: Translating new techniques into clinical application
Poster Session 18

Location: Green Area, Room 3
Chairs: M. Dinkelman-Smit, Rotterdam (NL)
        S.S. Minhas, London (GB)
        E. Ventimiglia, Milan (IT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

242 Platelet-rich plasma therapy for spermatogenesis recovery in rats with Busulfan-induced azoospermia

By: Epifanova M.\(^1\), Gvasalia B.\(^2\), Artemenko S.\(^3\), Durashov M.\(^3\)
\(^1\)RUDN University, Clinical Andrology, Moscow, Russia, \(^2\)FGBU, Reconstructive Urology and Andrology, Moscow, Russia, \(^3\)Sechenov university, N/A, Moscow, Russia

Aims and objectives of this presentation
242

243 Autophagy controls the homeostatic environment in the male accessory organs which is essential for fertility

By: Jaulim A.\(^1\), Cassidy L.D.\(^1\), Young A.R.J\(^1\), Lan G.\(^1\), Taylor A.\(^2\), Arlt W.\(^2\), Pacey S.\(^1\), Narita M.\(^1\)
\(^1\)CRUK Cambridge Institute, University of Cambridge, Dept. of Urology, Cambridge, United Kingdom, \(^2\)University of Birmingham, Dept. of Metabolism and Systems Research, Birmingham, United Kingdom

Aims and objectives of this presentation
243

* 244 Impact of human papilloma virus infection on the success of ART in infertile couples: A prospective cohort study

By: Monforte M.\(^1\), Sotto A.\(^2\), Rougié-Maillard N.\(^3\), Hamamah S.\(^4\), Huberlant S.\(^5\), Boule N.\(^6\), Anahory T.\(^7\), Fabbro-Perray P.\(^8\), Costa P.\(^9\), Droupy S.\(^9\)
\(^1\)CHU de Montpellier, Dept. of Gynaecology and Reproductive Medicine, Montpellier, France, \(^2\)CHU de Nimes, Dept. of Infectiology, Nimes, France, \(^3\)CHU de Nimes, Dept. of Reproductive Medicine, Nimes, France, \(^4\)CHU de Montpellier, Dept. of Reproductive Medicine, Montpellier, France, \(^5\)CHU de Nimes, Dept. of Gynaecology, Nimes, France, \(^6\)CHU de Montpellier, Dept. of Infectiology, Montpellier, France, \(^7\)CHU de Montpellier,
Dept. of Gynecology and Reproductive Medicine, Montpellier, France, 8CHU de Nimes, Dept. of Methodology, Nimes, France, 9CHU de Nimes, Dept. of Urology and Andrology, Nimes, France

Aims and objectives of this presentation

244

High-risk human papillomavirus in semen is associated with poor sperm progressive motility and a high sperm DNA fragmentation index in infertile men

By: Boeri L. 1, Capogrosso P. 1, Ventimiglia E. 1, Cazzaniga W. 1, Pederzoli F. 1, Chierigo F. 1, Pozzi E. 1, Gaboardi F. 1, Montanari E. 2, Montorsi F. 1, Salonia A. 1
1IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology, Milan, Italy, 2IRCCS Fondazione Ca’ Granda - Maggiore Policlinico Hospital, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation

245

Prevalence of positive semen cultures in infertile men without leukocytospermia: A cross sectional study

By: Cazzaniga W. 1, Capogrosso P. 2, Ventimiglia E. 2, Boeri L. 3, Pozzi E. 1, Chierigo F. 1, Schifano N. 1, Belladelli F. 1, Zuabi R. 1, Abbate C. 1, Dehò F. 1, Mirone V. 4, Gaboardi F. 1, Montorsi F. 1, Salonia A. 1
1IRCCS Ospedale San Raffaele, Dept. of Urology, Division of Experimental Oncology, Milan, Italy, 2Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy, 3IRCCS Fondazione Ca’ Granda – Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, 4University of Naples “Federico II”, Dept. of Urology, Dept. of Neurosciences, Sciences of Reproduction and Odontostomatology, Naples, Italy

Aims and objectives of this presentation

246

Evidence that testicular sperm in infertile men has improved DNA integrity compared to ejaculated sperm

By: Vyas L. 1, Lewis S. 2, Tharakan T. 1, Jayasena C. 1, Minhas S. 1, Ramsay J. 1
1Imperial University Hospitals trust, Dept. of Urology, London, United Kingdom, 2Examen labs, Dept. of Pathology, London, United Kingdom

Aims and objectives of this presentation

247

Outcome of microdissection testicular sperm extraction in hypogonadotropic hypogonadal azoospermia after failure of gonadotropin therapy

By: Chen Y.K., Chen W.J., Huang E.Y., Huang W.J.
Aims and objectives of this presentation

248

Serum albumin levels are associated with sex steroids hormones and sperm concentration impairment in primary infertile men – results of a cross-sectional study

By: Boeri L.\textsuperscript{1}, Capogrosso P.\textsuperscript{2}, Ventimiglia E.\textsuperscript{2}, Cazzaniga W.\textsuperscript{2}, Pozzi E.\textsuperscript{3}, Schifano N.\textsuperscript{2}, Chierigo F.\textsuperscript{3}, Abbate C.\textsuperscript{2}, Dehò F.\textsuperscript{2}, Mirone V.\textsuperscript{4}, Gaboridi F.\textsuperscript{2}, Montanari E.\textsuperscript{1}, Montorsi F.\textsuperscript{2}, Salonia A.\textsuperscript{2}
\textsuperscript{1}IRCCS Fondazione Ca’ Granda – Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, \textsuperscript{2}IRCCS Ospedale San Raffaele, Unit of Urology, URI, Milan, Italy, \textsuperscript{3}Università Vita-Salute San Raffaele, Dept. of Urology, Urological Research Institute (URI), Milan, Italy, \textsuperscript{4}Department of Neurosciences, Sciences of Reproduction and Odontostomatologia, Urology Unit, University of Naples “Federico II”, Dept. of Urology, Naples, Italy

Aims and objectives of this presentation

249

More prevalent prescription of testosterone in men from couples undergoing intracytoplasmic sperm injection (ICSI)

By: Elenkov A., Al-Jebari Y., Lundberg Giwercman Y., Giwercman A.
Lund University, Dept. of Translational Medicine, Malmo, Sweden

Aims and objectives of this presentation

250

Success rate of bilateral onco-testicular semen extraction (oncoTESE) in azoospermic men with testicular germ cell tumor (TGCT)

By: Van Moolenbroek G.\textsuperscript{1}, Boellaard W.\textsuperscript{2}, Dinkelman-Smit M.\textsuperscript{2}
\textsuperscript{1}Erasmus MC, University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, \textsuperscript{2}Erasmus MC, University Medical Center, Dept. of Urology, Rotterdam, The Netherlands

Aims and objectives of this presentation

251

Predictors of success for onco-TESE in testis containing tumour at time of radical orchiectomy in azoospermic men

By: Tracey J.\textsuperscript{1}, Sujenthiran A.\textsuperscript{1}, Dajani Y.\textsuperscript{2}, Capon S.\textsuperscript{1}, Kopeika Y.\textsuperscript{2}, Yap T.\textsuperscript{1}, Shabbir M.\textsuperscript{1}
\textsuperscript{1}Guys and St Thomas NHS Trust, Dept. of Urology, London, United Kingdom, \textsuperscript{2}Guys and St Thomas NHS Trust, Assisted Contraception Unit, London, United Kingdom

Aims and objectives of this presentation

252
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>252</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>253</strong> Randomized, single-blind, controlled clinical trial to evaluate the effect of intra- operative flushing of vas deferens with sterile water and nitrofurazone on the semen of post-vasectomy control</td>
<td></td>
</tr>
<tr>
<td>Hospital Universitario Puerta del Mar, Dept. of Urology, Cadiz, Spain</td>
<td></td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>253</td>
</tr>
<tr>
<td><strong>254</strong> Post vasectomy semen analysis can be performed at 8 weeks without compromising clearance rates: A single centre retrospective study</td>
<td></td>
</tr>
<tr>
<td>Forth Valley Royal Hospital, Dept. of Urology, Larbert, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>254</td>
</tr>
<tr>
<td><strong>255</strong> Epididymovasostomy: Patency, pregnancy rate and predictive factors for success in 109 patients over a decade</td>
<td></td>
</tr>
<tr>
<td>By: Chiriacò G., Modgil V., Assiri H.M, Blecher G.A., Alnajjar H., Sangster P., Ralph D.J.</td>
<td></td>
</tr>
<tr>
<td>University College London Hospital (UCLH), Dept. of Andrology, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>255</td>
</tr>
</tbody>
</table>
Usefulness of novel tumour models in studies on oncogenes and tumour suppressors
Poster Session 19

Saturday 16 March
14:15 - 15:45

Location: Green Area, Room 4
Chairs: J. Ceraline, Illkirch (FR)
S.K. Hong, Sungnam (KR)
M. Nevalainen, Milwaukee (US)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

256
Luteolin regulates AR-V7 expression via miRNA recruitment in castration-resistant prostate cancer

By: Naiki T. ¹, Naiki-Ito A. ², Etani T. ¹, Iida K. ¹, Ando R. ¹, Nagai T. ¹, Kawai N. ¹, Takahashi S. ², Yasui T. ¹
¹Nagoya City University Graduate School of Medicine, Dept. of Nephro-Urology, Nagoya City, Japan, ²Nagoya City University Graduate School of Medicine, Dept. of Experimental Pathology and Tumor Biology, Nagoya City, Japan

259
The role of fibroblasts in local progression and metastatic spread of prostate cancer: Examinations in an orthotopic xenograft model

By: Linxweiler J. ¹, Körbel C. ², Stöckle M. ¹, Menger M.D. ², Junker K. ¹, Saar M. ¹
¹Saarland University, Dept. of Urology, Homburg Saar, Germany, ²Saarland University, Institute for Clinical-Experimental Surgery, Homburg Saar, Germany

260
PCDH9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients

By: Sekino Y. ¹, Goto K. ¹, Sakamoto N. ¹, Oue N. ², Sentani K. ², Hayashi T. ¹, Teishima J. ¹, Yasui A. ², Matsubara A. ¹
¹Hiroshima University Graduate School of Biomedical and Health Sciences, Dept. of Urology, Hiroshima, Japan, ²Hiroshima University Graduate School of Biomedical and Health Sciences, Dept. of Molecular Pathology, Hiroshima, Japan

261
Profiling of the immune microenvironment in prostate cancer at single cell level

By: Lazzeri M. ¹, Saita A. ¹, Casale P. ¹, Buffi N.M. ², Hurle R. ¹, Lughezzani G. ¹, Fasulo V. ¹, Paciotti M. ¹, Maffei D. ¹, Domanico L. ¹, Bevilacqua G. ¹, Colombo P. ³, Elefant G.M. ³, Peano C. ⁴, Kunderfranco P. ⁴, Cibella J. ⁴, Guazzoni G. ¹, Di Mitri D. ⁵
¹Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, ²Istituto Clinico Humanitas IRCCS, Humanitas University, Dept. of
Molecular research on localized prostate cancer needs to take inter-focal heterogeneity into account

By: Axcrona E.J.K.¹, Løvf M.², Totland Carm K.², Johanessen B.², Bakken A.C.², Hoff A.², Axcrona U.³, Lothe R.², Skotheim R.²
¹Akershus University Hospital, Dept. of Urology, Lørenskog, Norway, ²Oslo University Hospital, Molecular Oncology, Institute Cancer Research, Oslo, Norway, ³Oslo University Hospital, Dept. of Pathology, Oslo, Norway

Activation of IRAK1 by uropathogenic E.coli and its overexpression in prostate cancer is regulated by DNA methylation

By: Breiding V., Loose M., Steger K., Luedecke G., Wagenlehner F., Schagdarsurengin U., Dansranjavin T.
Justus Liebig University, Clinic of Urology, Pediatric Urology and Andrology, Giessen, Germany

Investigation of TRPM4 and store-operated calcium entry in prostate cancer cell systems and a primary prostate cancer stem cell model

By: Borgstroem A.¹, Kiener M.², Kappel S.¹, Hauert B.¹, Delalande C.³, Zoni E.², Reymond J.³, Thalmann G.N.⁴, Peinelt C.¹, Kruithof-De Julio M.²
¹University of Bern, Institute of Biochemistry and Molecular Medicine, Bern, Switzerland, ²University of Bern, Dept. of Urology and BioMedical Research, Bern, Switzerland, ³University of Bern, Dept. of Biochemistry and Chemistry, Bern, Switzerland, ⁴University Hospital of Bern, Dept. of Urology, Bern, Switzerland

Cancer-associated fibroblasts induce epithelial-mesenchymal transition in prostate cancer cells through HGF/Met/Fra1/SOX9 signaling

By: Qin H., Qiu X., Jiang B., Chen W., Diao W., Zhao X., Guo H.
Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Nanjing, China

Role of ER-generated redox and calcium signals in the modulation of prostate cancer progression

By: Cornelius J.¹, Pozzi E.², Anelli T.³, Cavarretta I.⁴, Tempio T.⁵, Montorsi F.⁴, Mattei A.¹, Sitia R.⁵, Salonia A.⁴
¹Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ²Università Vita- Salute San Raffaele, Urological Research Institute (URI), Dept. of Urology, Milan, Italy, ³Università Vita-Salute San Raffaele, Istituto di Ricovero e Cura a Carattere Scientifico, Protein Transport and Secretion Unit, Division of Genetics and Cell Biology, Milan, Italy,
<table>
<thead>
<tr>
<th>267</th>
<th>PrLZ stabilizes LAMP2A to promote chaperone-mediated autophagy and tumor growth of prostate cancer cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Fan Y. 1, Hou T. 2, Liu T. 2, Zeng J. 2, Li L. 2</td>
</tr>
<tr>
<td></td>
<td>1Xi'an jiaotong University, Dept. of Urology, Xi'an, China, 2Xi'an Jiaotong University, Dept. of Urology, Xi'an, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>268</th>
<th>The tumor suppressor ESE3/EHF acts as a gatekeeper in TMPRSS2-ERG positive tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Institute of Oncology Research (IOR), Dept. of Experimental Therapeutics and Prostate Cancer Biology, Bellinzona, Switzerland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>269</th>
<th>Development and characterisation of a spontaneously metastatic patient-derived xenograft (PDX) model of human prostate cancer (PCa)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Lange T. 1, Oh-Hohenhorst S.J. 2, Joosse S. 3, Hahn O. 4, Gosau T. 1, Feldhaus S. 1, Maar H. 1, Gehrcke R. 1, Kluth M. 5, Simon R. 5, Schlomm T. 2, Huland H. 2, Schumacher U. 1</td>
</tr>
<tr>
<td></td>
<td>1University Medical Center Hamburg-Eppendorf, Institute of Anatomy and Experimental Morphology, Hamburg, Germany, 2University Medical Center Hamburg-Eppendorf, Martini Clinic, Prostate Cancer Center, Hamburg, Germany, 3University Medical Center Hamburg-Eppendorf, Institute of Tumor Biology, Hamburg, Germany, 4University Medical Center Goettingen, Dept. of Urology, Goettingen, Germany, 5University Medical Center Hamburg-Eppendorf, Institute of Pathology, Hamburg, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>270</th>
<th>The phenotype of tumor infiltrating T cells and the expression of PD1, PD-L1 and B7-H4 in prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Wei Z. 1, Hao Y. 2, Wang T. 1, Liu J. 1</td>
</tr>
<tr>
<td></td>
<td>1Tongji Hospital, Dept. of Urology, Wuhan, China, 2School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Pathogen Biology, Wuhan, China</td>
</tr>
</tbody>
</table>
Stones: Extracorporeal shock wave lithotripsy

**Location:** Green Area, Room 5

**Chairs:**
- M. Hanna, London (GB)
- A. Hernandez Porras, Tijuana (MX)
- A. Petřík, Ceske Budejovice (CZ)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**271**

**Predictive model for one-session success rate of shock wave lithotripsy using variation coefficient of stone density ratio**

By: Lee J.Y. 1, Kim J.W. 1, Kang D.H. 2, Jung H.D. 1, Cho K.S. 1, Choi Y.D. 1

1Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, South Korea,
2Inha University School of Medicine, Dept. of Urology, Incheon, South Korea

---

**272**

**Evaluation of a neural network model with machine learning for predicting optimal shockwave lithotripsy treatment protocols: Alignment with known successful treatments**

By: Seltzer R. 1, Hamilton B.D. 2, Klett D.E. 2, Chen Z. 3, Nakada S.Y. 4, Gerber G.S. 5

1Translational Analytics and Statistics, Dept. of Research, Tucson, United States of America,
2University of Utah, Dept. of Urology, Salt Lake City, United States of America,
3University of Arizona, Dept. of Statistics, Tucson, United States of America,
4University of Wisconsin, Dept. of Urology, Madison, United States of America,
5University of Chicago, Dept. of Urology, Chicago, United States of America

---

**273**

**Algorithm-based tools to improve shockwave lithotripsy outcomes in urology practice: Results of implementing interactive, real-time tools**

By: Hamilton B.D. 1, Seltz R.G.N. 2, Klett D.E. 1, Chen Z. 3, Nakada S.Y. 4, Gerber G.S. 5

1University of Utah, Dept. of Urology, Salt Lake City, United States of America,
2Translational Analytics and Statistics, Dept. of Research, Tucson, United States of America,
3University of Arizona, Dept. of Statistics, Tucson, United States of America,
4University of Wisconsin, Dept. of Urology, Madison, United States of America,
5University of Chicago, Dept. of Urology, Chicago, United States of America

---

**274**

**Ureteral wall volume at ureteral stone site is a critical predictor for shock wave lithotripsy outcome: Comparison with ureteral wall thickness and area**

By: Yamashita S., Kohjimoto Y., Higuchi M., Iguchi T., Nishizawa S., Kikkawa K., Hara
A clinical observational study of a solid conductive interface for improving treatment efficacy in extracorporeal shock wave lithotripsy

By: Chen W-C. 1, Liou W-C 2, Yang Y-H 2, Lin Y. 3, Cheng K-T. 4
1St. Joseph Hospital, Dept. of Urology, Kaohsiung, Taiwan, 2St. Joseph Hospital, Medicine, Kaohsiung, Taiwan, 3National Kaohsiung Normal University, Grad. Inst. Human Res. and Knowledge Management, Kaohsiung, Taiwan, 4CleanWave Medical Co., LTD, Research and Development, Kaohsiung, Taiwan

The effect of focus size on stone fragmentation in SWL

By: Veser J., Jahrreis V., Seitz C., Özsoy M.
Medical University Vienna, Dept. of Urology, Vienna, Austria

To investigate the effect of voltage escalation on treatment outcome in extracorporeal shockwave lithotripsy of renal calculi – final analysis

By: Ng C.F. 1, Yee C.H. 1, Teoh J.Y.C. 1, Leung S.C.H. 1, Lau B. 1, Wong K.T. 2, Chu W.C.W. 2
1The Chinese University of Hong Kong, SH Ho Urology Centre, Hong Kong, Hong Kong, 2The Chinese University of Hong Kong, Dept. of Imaging and Interventional Radiology, Hong Kong, Hong Kong

Emergency extracorporeal shockwave lithotripsy: Reducing morbidity and enhancing stone free rates for obstructing ureteric stones

By: Matanhelia M., Lee S-M., Timoney A., Philip J.
Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom

KIM-1: A novel serum & urinary biomarker to predict acute/tubular injury following ESWL

By: Ilyas R., Young J.G., Chow K.
Central Manchester NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom

What's the role of extracorporeal shockwave lithotripsy (ESWL) in endoscopic era? The retrospective review of ESWL for urinary tract calculi in the past thirty years

By: Li X.
First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China

Optimal non-invasive treatment of 1-2.5 cm radiolucent renal stones: Oral dissolution therapy (ODT), shock wave lithotripsy (SWL) or combined treatment: A randomized controlled trial

By: Elbaset M., Hashem A., Eraky A., Ezzat O., Sharaf M., El-Assmy A.
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>282</td>
<td>The effect of shock wave lithotripsy and retrograde intrarenal surgery on health-related quality of life in 10-20mm renal stones: A prospective randomized study</td>
<td>Culpan M., Atis G., Sendogan F., Ucar T., Yildirim A., Caskurlu T.</td>
<td>Silopi State Hospital, Dept. of Urology, Sirnak, Turkey, Istanbul Medeniyet University Goztepe Training and Research Hospital, Dept. of Urology, Istanbul, Turkey</td>
</tr>
<tr>
<td>284</td>
<td>Shockwave lithotripsy and ureteroscopy for the treatment of lower pole stones: Results from a statewide clinical registry</td>
<td>Ghani K., Stockall E., Swarna K., Telang J., Kim T., Hollingsworth J., Dauw C.</td>
<td>University of Michigan, Dept. of Urology, Ann Arbor, MI, United States of America, Capital Urology Associates, Dept. of Urology, Lansing, MI, United States of America</td>
</tr>
</tbody>
</table>
### What is new in Percutaneous Nephrolithotomy (PCNL)?

**Video Session 05**

<table>
<thead>
<tr>
<th>Saturday 16 March 14:15 - 15:45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location: Green Area, Room 10</td>
</tr>
<tr>
<td>Chairs: F.J. Burgos Revilla, Madrid (ES) M. Lezrek, Meknes (MA) To be confirmed</td>
</tr>
</tbody>
</table>

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

**V31**

**Miniperc: Yes, please!**

Ospedale San Raffaele, Turro, Dept. of Urology, Milan, Italy

**Aims and objectives of this presentation**

**V32**

**Semi-closed circuit vacuum-assisted mini-percutaneous nephrolithotomy with holmium laser lithotripsy**

Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

**Aims and objectives of this presentation**

**V33**

**NAID: A novel percutaneous navigation system**

By: **Patena Forte J.P.**, Baltazar P.M., Fernandes F., Falcão G., Campos-Pinheiro L.  
Centro Hospitalar e Universitário de Lisboa Central, Dept. of Urology, Lisbon, Portugal

**Aims and objectives of this presentation**

**V34**

**Miniaturized percutaneous nephrolithotomy with Moses laser lithotripsy**

By: Knoll T., Dlugosch J., Wundt-Nordahl G., **Atassi N.**  
Klinikum Sindelfingen-Boeblingen, Dept. of Urology, Sindelfingen, Germany

**Aims and objectives of this presentation**
Techniques for fluoroscopic access in PNL: An ESUT educational video

By: Berdempes M. 1, Kyriazis I. 2, Lazarou L. 1, Markopolos T. 1, Kallidonis P. 2, Liatsikos E. 2, Skolarikos A. 1
1Sismanoglio General Hospital, Dept. of Urology, Athens, Greece, 2General University Hospital of Patras, Dept. of Urology, Patras, Greece

Aims and objectives of this presentation

Thulium SuperPulse Fiber Laser (TSPFL) for micro-PCNL

By: Martov A.G. 1, Andronov A. 1, Dutov S. 2, Traxer O. 3
1Federal Medical-Biological Agency of Russian Federation State Institute of Continuous Medical Education, Dept. of Urology, Moscow, Russia, 2Pletnev’s Clinical Hospital, Dept. of Urology, Moscow, Russia, 3Sorbonne Université, GRC n°20, Hôpital Tenon, Dept. of Urology, Paris, France

Aims and objectives of this presentation

Homemade on the spot improvised baskets for PCNL

By: Lezrek M. 1, Tazi H. 2, Mawfik H. 2, El Yazami O. 2, Slimani A. 1, Alami M. 1, Ammani A. 1
1Military Hospital Moulay Ismail, Dept. of Urology, Meknes, Morocco, 2Al Ghassani Hospital, Dept. of Urology, Fes, Morocco

Aims and objectives of this presentation
Infectious diseases: New basic insights

Poster Session 21

Saturday 16 March 14:15 - 15:45

Location: Green Area, Room 12
Chairs: G. Bonkat, Basel (CH)
T. Cai, Trento (IT)
A.H. Pourmand, Tehran (IR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

286

Long-term efficacy of antibiotics prophylaxis for preventing recurrent uncomplicated urinary tract infections: A systematic review and network meta-analysis

By: Salahia S.¹, Riffai M.¹, Shehata M.², Salahia H.¹, Dall’Antonia M.³, Hammadeh M.⁴
¹Ain Shams University, Faculty of Medicine, Cairo, Egypt, ²Zagazig University, Faculty of Medicine, Zagazig, Egypt, ³Queen Elizabeth Hospital, Consultant Microbiologist, Department of Microbiology, London, United Kingdom, ⁴Queen Elizabeth Hospital, Consultant Urological Surgeon & Honorary Senior Lecturer, London, United Kingdom

Aims and objectives of this presentation

287

Identifying barriers for non-adherence to guidelines on urinary tract infections

By: Schneidewind L.¹, Schlager D.², Mühlstädt S.³, Kranz J.⁴
¹University Medicine Greifswald, Dept. of Haematology/Oncology, Greifswald, Germany, ²University of Freiburg Medical Center, Dept. of Urology, Freiburg, Germany, ³University of Halle (Saale) Medical Center, Dept. of Urology, Halle/Saale, Germany, ⁴St.-Antonius-Hospital Eschweiler, Dept. Of Urology and Paediatric Urology, Eschweiler, Germany

Aims and objectives of this presentation

288

The age is an important factor to predict the resistance rate against fosfomycin trometamol among uropathogens

By: Cai T.¹, Caciagli P.², Lanzafame P.³, Palmieri A.⁴, Verze P.⁴, Arcaniolo D.⁵, Malossini G.¹, Mirone V.⁴
¹Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, ²Santa Chiara Regional Hospital, Dept. of Laboratory Medicine, Trento, Italy, ³Santa Chiara Regional Hospital, Dept. of Microbiology, Trento, Italy, ⁴University of Naples, Federico II, Dept. of Urology, Naples, Italy, ⁵University of Naples, Vanvitelli,, Dept. of Urology, Naples, Italy
Adapted bacteriophages for treating urinary tract infections

By: Leitner L. 1, Ujmajuridze A. 2, Chanishvili N. 3, Goderdzishvili M. 3, Mehnert U. 1, Chkhouta A. 2, Sybesma W. 1, Kessler T.M. 1

1University Hospital Balgrist, Dept. of Neuro-Urology, Zürich, Switzerland, 2The Alexander Tsulukidze National Center of Urology, Dept. of Urology, Tbilisi, Georgia, 3The George Eliava Institute of Bacteriophage, Dept. of Microbiology and Virology, Tbilisi, Georgia

Aims and objectives of this presentation

289

Anti-virulence treatment: The solution to antimicrobial resistance?

By: Magistro G. 1, Stief C.G. 1, Schubert S. 2

1Ludwig-Maximilians-University of Munich, Dept. of Urology, Munich, Germany, 2Ludwig-Maximilians-University of Munich, Max von Pettenkofer-Institute for Hygiene and Medical Microbiology, Munich, Germany

Aims and objectives of this presentation

290

Prevalence of recurrent extended-spectrum beta-lactamase (ESBL) urinary tract infections (UTIs) in patients within a urology service. Introducing the concept of faecal Microbiota transplantation (FMT) as a treatment modality

By: Ghani R. 1, Gan C. 2, Mullish B. 3, Vaishali F. 2, Davies F. 1, Thursz M. 3, Marchesi J. 4, Dasgupta R. 2, Minhas S. 2

1Imperial College Healthcare NHS Trust, Dept. of Microbiology, London, United Kingdom, 2Imperial College Healthcare NHS Trust, Dept. of Urology, London, United Kingdom, 3Imperial College Healthcare NHS Trust, Dept. of Gastroenterology, London, United Kingdom, 4Imperial College London, Dept. of Digestive Diseases, London, United Kingdom

Aims and objectives of this presentation

291

A new bacterial resistant polymer catheter coating to reduce catheter associated urinary tract infection (CAUTI): A first-in-man pilot study

By: Jeffery N. 1, Kalenderski K. 2, Dubern J. 2, Lomiteng A. 1, Dragova M. 1, Frost A. 1, Macrae B. 3, Mundy A. 1, Alexander M. 4, Williams P. 2, Andrich D. 1

1University College London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 2University Nottingham, Centre for Biomolecular Sciences & School of Life Sciences, Nottingham, United Kingdom, 3University College London NHS Foundation Trust, Dept. of Microbiology, London, United Kingdom, 4University Nottingham, School of
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>292</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comparative value of chronic urinary tract infection (UTI) diagnosis between standard culture sensitivity and next generation sequence (NGS) in urine samples</strong></td>
<td>293</td>
</tr>
<tr>
<td>By: Dixon M.¹, Stefan M.¹, Skinner C.², Coba G.³, Zaman S.³, Koo T.³, Ni L.⁴, McDonald M.⁵, Mouraviev V.⁶</td>
<td></td>
</tr>
<tr>
<td>¹University of East Anglia, Norwich Medical School, Norwich, United Kingdom, ²University of Central Florida, College of Medicine, Orlando, United States of America, ³University of South Florida, Morsani College of Medicine, Tampa, United States of America, ⁴University of Central Florida, Dept. of Statistics, Orlando, United States of America, ⁵Florida Hospital Celebration Health, Urology Centre of Central Florida, Celebration, United States of America, ⁶Central Florida Cancer Institute, Dept. Of Urology, Davenport, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>293</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rapid detection of extended-spectrum β-lactamases in uropathogenic Escherichia coli in urinary tract infections: A new alternative for empirical treatment</strong></td>
<td>294</td>
</tr>
<tr>
<td>By: Ortega M.¹, Hernandez R.², Martinez C.¹, Cantellano M.¹, Morales G.¹, Fernandez G.¹, Cortes P.¹, Hernandez A.¹, Calvo I.¹, Pacheco C.¹</td>
<td></td>
</tr>
<tr>
<td>¹Hospital General Dr. Manuel Gea Gonzalez, Dept. of Urology, Mexico City, Mexico, ²Hospital General Dr. Manuel Gea Gonzalez, Dept. of Research, Mexico City, Mexico</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>294</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeting IL-11 in the treatment of BK virus associated hemorrhagic cystitis – a promising new approach</strong></td>
<td>295</td>
</tr>
<tr>
<td>By: Schneidewind L.¹, Neumann T.¹, Weigel M.¹, Plis A.¹, Brückmann S.², Krüger W.¹, Schmidt C.A.¹</td>
<td></td>
</tr>
<tr>
<td>¹University Medicine Greifswald, Dept. of Haematology and Oncology, Greifswald, Germany, ²University Medicine Greifswald, Dept. of Pathology, Greifswald, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>295</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacteriological diagnosis with volatile organic compounds – first experiences with an electronic nose</strong></td>
<td>296</td>
</tr>
<tr>
<td>By: Heers H.¹, Heinig J.¹, Von Stauffenberg F.¹, Hegele A.¹, Hofmann R.¹, Böselt T.², Koczulla A.R.²</td>
<td></td>
</tr>
<tr>
<td>¹Philipps-Universität Marburg, Dept. of Urology and Paediatric Urology, Marburg,</td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

296

Can E. coli $10^3$ CFU/ml cause the development of acute bacterial prostatitis? Experimental study

By: Kogan M.I. 1, Naboka Y.L. 2, Pasechnik D.G. 1, Ismailov R.S. 1, Popov I.V. 1, Slyusarenko N.V. 1
1 Rostov State Medical University, Dept. of Urology and Human Reproductive Health, Rostov-on-Don, Russia, 2 Rostov State Medical University, Dept. of Microbiology and Virology, Rostov-on-Don, Russia

Aims and objectives of this presentation
297

Evaluating Aerococcus urinae infection of the urinary tract in a mouse model

By: Gilbert N. 1, Hilt E. 2, Wolfe A. 2, Lewis A.L.L. 3
1 Washington University School of Medicine, Obstetrics and Gynaecology, Saint Louis, United States of America, 2 Loyola University Chicago, Microbiology and Immunology, Chicago, United States of America, 3 Washington University School of Medicine, Molecular Microbiology, Saint Louis, United States of America

Aims and objectives of this presentation
298

Phosphorylation of CREB in dorsal root ganglia after uropathogenic Escherichia coli infection in rat urinary bladder

By: Taesoo C., Lee D-G., Jeon S.H., Lee H-L.
Kyung Hee University School of Medicine, Dept. of Urology, Seoul, South Korea

Aims and objectives of this presentation
299

Aortic calcification is the risk factor of severe acute kidney injury development in patients with urological sepsis

By: Fujita N. 1, Momota M. 1, Tobisawa Y. 1, Yoneyama T. 1, Yamamoto H. 1, Imai A. 1, Hatakeyama S. 1, Ito H. 2, Yoneyama T. 1, Hashimoto Y. 1, Yoshikawa K. 3, Ohyama C. 1
1 Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2 Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, 3 Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

Aims and objectives of this presentation
300
A safety and efficacy study of lumasiran, an investigational RNA interference (RNAi) therapeutic, in adult and pediatric patients with primary hyperoxaluria type 1

By: Frishberg Y. ¹, Deschenes G. ², Cochat P. ³, Magen D. ⁴, Grothoff J. ⁵, Hulton S.A. ⁶, Harambat J. ⁷, Van’t Hoff W. ⁸, Hoppe B. ⁹, Lieske J.C. ¹⁰, McGregor T.L. ¹¹, Tamimi N. ¹¹, Haslett P. ¹¹, Talamudupula S. ¹², Erbe D.V. ¹³, Milliner D.S. ¹⁰

¹Shaare Zedek Medical Center, Dept. of Pediatric Nephrology, Jerusalem, Israel,
²Hospital Robert Debre, Dept. of Pediatric Nephrology, Paris, France,
³Université ClaudeBernard, Dept. of Pediatrics, Lyon, France,
⁴Rambam Health Care Campus, Dept. of Pediatric Nephrology, Haifa, Israel,
⁵Academic Medical Center, Dept. of Pediatrics, Amsterdam, The Netherlands,
⁶Birmingham Childrens’ Hospital, Dept. of Pediatric Nephrology, Birmingham, United Kingdom,
⁷Bordeaux University Hospital, Dept. of Pediatrics, Bordeaux, France,
⁸Great Ormond Street Hospital, Dept. of Nephrology, London, United Kingdom,
⁹University Hospital Bonn, Dept. of Pediatrics, Division of Pediatric Nephrology, Bonn, Germany,
¹⁰Mayo Clinic, Dept. of Nephrology and Hypertension, Rochester, United States of America,
¹¹Alynam Pharmaceuticals, Dept. of Clinical Research, Cambridge, United States of America,
¹²Alynam Pharmaceuticals, Dept. of Clinical Operations, Cambridge, United States of America

Is vitamin B6 supplementation needed for cystinuric patients taking penicillamine?

By: Farrah N. ¹, Ross L. ², Wells H. ², Game D. ³, Thomas K. ¹, Bultitude M. ¹

¹Guy’s and St. Thomas’ NHS Foundation Trust, Urology Centre, London, United Kingdom,
²Guy’s and St. Thomas’ NHS Foundation Trust, Dept. of Pharmacy, London, United Kingdom,
³Guy’s and St. Thomas’ NHS Foundation Trust, Dept. of Nephrology, London, United Kingdom

Assessment of health-related quality of life in a UK cystinuric population

By: Shahrjerdi P. ¹, Vijay A. ¹, Game D. ², Thomas K. ¹, Bultitude M. ¹

¹Guy’s and St. Thomas’ NHS Foundation Trust, Urology Centre, London, United Kingdom,
²Guy’s and St. Thomas’ NHS Foundation Trust, Dept. of Nephrology, London, United Kingdom
304 Neodymium/YAG-laser coagulation of urinary tract haemangiomas causing macroscopic haematuria, 5 to 10-years follow-up

By: Brehmer M., Hasan M.
Karolinska Institutet Danderyd Hospital (KI DS), Dept. of Clinical Sciences, Stockholm, Sweden

305 Identification of novel susceptibility loci for tuberous sclerosis complex (TSC) in the Japanese population

By: Uemura M. 1, Yamamoto Y. 1, Ishizuya Y. 1, Katayama K. 2, Yamaguchi R. 3, Miyano S. 3, Kaneda M. 4, Matsuda K. 5, Inagaki Y. 1, Fukuhara S. 1, Fiujita K. 1, Imamura R. 1, Nonomura N. 1
1Osaka University, Graduate School of Medicine, Dept. of Urology, Suita, Japan, 2The University of Tokyo, The institute of of medical science, Human genome center, Laboratory of Sequence analysis, Tokyo, Japan, 3The University of Tokyo, The Institute of of medical science, Human genome Center, Laboratory of DNA information analysis, Tokyo, Japan, 4Osaka University, Graduate School of Medicine, Dept. of Dermatology, Suita, Japan, 5The University of Tokyo, The Institute of of medical science, Human genome center, Dept. of Computational Biology and Medical Sciences, Laboratory of Clinical Genome Sequencing, Tokyo, Japan

306 Presurgical targeted therapy with Everolimus for angiomyolipoma associated with tuberous sclerosis complex

By: Guo G., Xu Z.
The PLA General Hospital, Dept. of Urology, Beijing, China

307 Prognostic analysis of extramammary Paget's disease in scrotum

By: Xiao W., Zhu Y., Qu Y., Zhu Y., Su H., Wang J., Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

308 Prognosis of early stage small cell bladder cancer is not always dismal

By: Lim J.H., Al-Izzi S., Santhanam S.
Nottingham University Hospitals NHS Trust, Dept. of Clinical Oncology, Nottingham, United Kingdom

309 Fifteen years of experience in emphysematous cystitis: Findings in a rare disease

Ramon y Cajal Hospital, IRYCIS Institute, University of Alcalá, Dept. of Urology, Madrid, Spain

310 Differential expression of PD-L1 between sporadic and VHL-associated hereditary clear cell renal cell carcinoma and its correlation with clinicopathological features
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>311</td>
<td>Intra-familial phenotypic heterogeneity in von Hippel-Lindau disease: Implications for personalized surveillance plan</td>
<td>By: Hong B., Ma K.F., Zhou J., Zhang J., Xie H., Zhang K., Li L., Gong K. Peking University First Hospital, Dept. of Urology, Beijing, China</td>
</tr>
<tr>
<td>312</td>
<td>Follow-up of MiT family translocation RCC in young adults</td>
<td>By: Wang J.Y., Gong K. Institute Of Urology, Peking University, Peking University First Hospital, Dept. of Urology, Beijing, China</td>
</tr>
<tr>
<td>313</td>
<td>Sexuality and pregnancy education among transitional spina bifida women: A patient-based survey</td>
<td>By: Bujons Tur A., Lang Motta G., Garat J.M., Palou J. Fundació Puigvert, Dept. of Urology, Barcelona, Spain</td>
</tr>
<tr>
<td>314</td>
<td>A review of the trends and management of renal trauma in England &amp; Wales from 1991-2015</td>
<td>By: Brenton T.¹, Sharma D. ², Moran C. ³ ¹St Georges Hospital, Dept. of Urology, London, United Kingdom, ²St Georges Hospital, Dept. of Urology, London, United Kingdom, ³Trauma Audit Research Network, Salford, United Kingdom</td>
</tr>
<tr>
<td>315</td>
<td>Sperm retrieval rates in non-mosaic Klinefelter patients undergoing microsurgical testicular sperm extraction: What expectations do we have in the real-life setting?</td>
<td>By: Boeri L.¹, Preto M. ², Sibona M. ², Palmisano F. ¹, Capogrosso P. ³, Ventimiglia E. ³, Lo Russo V. ¹, Serrago M. ¹, Falcone M. ², Timpano M. ², Ceruti C. ², Gadda F. ¹, Salonia A. ³, Rolle L. ², Gontero P. ², Montanari E. ¹ ¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ²A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Dept. of Urology, Turin, Italy, ³IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology; URI, Milan, Italy</td>
</tr>
</tbody>
</table>
**Paediatric urology: Upper urinary tract**  
Poster Session 23

| Location: | Green Area, Room 20 |
| Chairs: | B. Burgu, Ankara (TR)  
M. Eissa, Cairo (EG)  
B. Haid, Linz (AT) |

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

**316**  
*Anatomical aspects of the kidney surface in human fetuses during the second gestational trimester*

By: Lobo M.L.P., Favorito L.A., Sampaio F.  
State University of Rio de Janeiro, Urogenital Research Unit, Rio de Janeiro, Brazil

**317**  
*Isolated bilateral low grade antenatal hydronephrosis: Clinical outcome*

1Prince Sultan Military Medical City, Dept. of Urology, Riyadh, Saudi Arabia, 2King Fahad Specialist Hospital, Dept. of Urology, Dammam, Saudi Arabia

**318**  
*Complex renal cysts: Examining the applicability of modified Bosniak classification for children*

By: Frumer M., Shenhar C., Konen O., Shpira-Rootman M., Livne P.M., Ben Meir D.  
1Schneider Childrens Medical Center of Israel, Dept. of Urology, Petach Tikva, Israel, 2Schneider Childrens Medical Center of Israel, Dept. of Paediatric Radiology, Petach Tikva, Israel, 3Schneider Childrens Medical Center of Israel, Dept. of Paediatric Radiology, Petach Tikva, Israel, 4Schneider Childrens Medical Center of Israel, Dept. of Paediatric Radiology, Petach Tikva, Israel, 5Schneider Childrens Medical Center of Israel, Dept. of Paediatric Radiology, Petach Tikva, Israel, 6Schneider Childrens Medical Center of Israel, Dept. of Paediatric Radiology, Petach Tikva, Israel, 7Schneider Childrens Medical Center of Israel, Dept. of Paediatric Radiology, Petach Tikva, Israel

**319**  
*Laparoscopic and robotic-assisted repair of retrocaval ureter in children: A multi-institutional comparative study with open repair*

By: Esposito C., Masieri L., Valla J., Lopez P.J., Tokar B., Mushtaq I., Sforza S., Venturini S., Escolino M.  
1Federico II University of Naples, Dept. of Pediatric Surgery, Naples, Italy, 2University of Florence, Dept. of Urology, Florence, Italy, 3CHU Lenval, Dept. of Pediatric Urology, Nice, France, 4Hospital Exequiel Gonzalez Cortes & Clinica Alemana, Dept. of Pediatric Urology, Santiago, Chile, 5Eskisehir Osmangazi University, Dept. of Pediatric Urology,
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| 320          | Robot-assisted laparoscopic pyeloplasty (RALP) in children with horseshoe kidneys: Results of a multicentric study | By: Esposito C. 1, Masieri L. 2, Blanc T. 3, Manzoni G. 4, Silay S. 5, Cerulo M. 1, Venturini S. 2, Escolino M. 1  
Federico II University of Naples, Dept. of Pediatric Urology, Naples, Italy,  
University of Florence, Meyer Children's Hospital, Dept. of Pediatric Urology, Florence, Italy,  
Hopital Necker-Enfants Malades, Dept. of Pediatric Urology, Paris, France,  
Ospedale Maggiore Policlinico, Dept. of Pediatric Urology, Milan, Italy,  
Istanbul Medeniyet University, Dept. of Pediatric Urology, Istanbul, Turkey |
University of Florence, Dept. of Urology, Florence, Italy |
Kasr Alainy Hospital, Cairo University, Dept. of Urology, Cairo, Egypt |
Habib Thameur Hospital, Dept. of pediatric surgery, Tunis, Tunisia |
| 324          | Surgical outcome of robot-assisted laparoscopy pyeloplasty in children with no drainage placement for ureteropelvic junction obstruction | By: Venturini S., Cini C., Longo M., Cito G., Morselli S., Minervini A., Carini M., Masieri L.  
University of Florence, Dept. of Urology, Florence, Italy |
| 325          | Correlation of renal scarring to urinary tract infections and vesicoureteral reflux in children | By: Aboutaleb H. 1, Ali T.A. 2, El-Hagrasi H. 3, El Gohary M.A. 4  
Burjeel Hospital, Dept. of Urology, Abu Dhabi, United Arab Emirates,  
Al-Azhar University Hospital, Dept. of Urology, Cairo, Egypt,  
Suez Canal University, Dept. of Pediatrics, Ismailia, Egypt,  
Burjeel Hospital, Dept. of Pediatric Surgery, Abu Dhabi, United Arab Emirates |
<table>
<thead>
<tr>
<th>328</th>
<th>Ureterocele size predicts surgical management and outcome: Data from 20 years experience with long follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Haid B.¹, Kerling M. ², Stredele R. ², Oswald J. ¹, Waidelich R. ², Riccabona M. ²</td>
</tr>
<tr>
<td></td>
<td>¹Hospital of the Sisiters of Charity, Dept. of Pediatric Urology, Linz, Austria, ²Ludwig Maximilians University, Dept. of Urology, Munich, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>329</th>
<th>Mini-laparotomy in-situ pyeloplasty for repair of the uretroplevic junction obstruction: Outcome of 150 cases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: El-Moghazy H.¹, Eissa M. ²</td>
</tr>
<tr>
<td></td>
<td>¹Sohag university, Dept. of Urology, Sohag, Egypt, ²Cairo University, Dept. of Urology, Cairo, Egypt</td>
</tr>
</tbody>
</table>
Urinary tract and genital trauma
ESU Course 16

Location: Green Area, Room 13
Chair: N. Kitrey, Ramat Gan (IL)

Aims and objectives of this session
Trauma is a leading cause of death and morbidity in civilian populations. All urologists will have to manage trauma patients and need to understand basic principles. The EAU Guidelines Group prepare guidelines in order to assist in the management of urological trauma and these principles will be followed for the specific organ systems and in the context of polytrauma.

- Urological trauma is usually associated with other injuries. The role of the urologist in polytrauma is important to understand.
- Modern diagnostic imaging and interventional radiology techniques has resulted in a greater understanding of organ injury and treatment.
- Increasing use is made of non-operative or delayed surgical intervention with a resulting higher rate of organ preservation.
- Minimising long term morbidity is an important role for injuries that are usually not life threatening.

Introduction and trauma management principles
N. Kitrey, Ramat Gan (IL)

Renal trauma
D.M. Sharma, London (GB)

Renal trauma case
N. Kitrey, Ramat Gan (IL)
N. Lumen, Ghent (BE)
D.M. Sharma, London (GB)

Ureteral trauma
N. Lumen, Ghent (BE)

Bladder trauma
N. Kitrey, Ramat Gan (IL)

Urethral trauma
N. Lumen, Ghent (BE)

Urethral trauma case
N. Kitrey, Ramat Gan (IL)
N. Lumen, Ghent (BE)

Genital trauma
D.M. Sharma, London (GB)
Dealing with the challenge of infection in urology
ESU Course 15

Location: Green Area, Room 14
Chair: F.M.E. Wagenlehner, Giessen (DE)

Aims and objectives of this session
This ESU course on infection diseases provides a broad, up to date coverage of the most important and recent problems of infectious diseases in urology. Antimicrobial resistance is one of the biggest worldwide challenges in medicine and gains increasing importance in urology. The management of infections in general and of urogenital tract infections especially, has been compromised by this rapid and continuous increase of antimicrobial resistance. Basic biologic principles and strategies to treat urogenital tract infections from benign infections to life threatening infections will be discussed in this course:

• Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis.
• Diagnosis, treatment and prophylaxis strategies of urogenital tract infections.
• Uncomplicated and recurrent cystitis.
• Complicated urinary tract infections.
• Urosepsis and Fournier gangrene.
• Male genital tract infections.

Introduction
F.M.E. Wagenlehner, Giessen (DE)

Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis
Z. Tandoğdu, Edinburgh (GB)

Low grade and recurrent UTI
F.M.E. Wagenlehner, Giessen (DE)

Male genital infections: Prostatitis, epididymitis and urethritis
B. Köves, Budapest (HU)

Hospital acquired UTI and antibiotic resistance
Z. Tandoğdu, Edinburgh (GB)

Perioperative prophylaxis with special focus on prostate biopsies, stone surgery and prosthesis implantation
B. Köves, Budapest (HU)

Sepsis and Fournier’s gangrene
F.M.E. Wagenlehner, Giessen (DE)
Paediatric urology for the adult urologist. Congenital problems of the urinary tract: Obstruction and reflux and longterm outcome
ESU Course 14

Location: Green Area, Room 15
Chair: J.M. Nijman, Groningen (NL)

Aims and objectives of this session
Many children with congenital anomalies will present to the adult urologist with long-term sequellae. It is important to know what has been done in terms of surgical procedures so that the adult urologist knows what he can do in the future. It is also important to know how the urological follow-up of these patients should be done. The most common paediatric conditions will be reviewed, while long-term complications will be explored by short interactive case presentations.

• Many children born with hydronephrosis may not require surgical intervention, but need close follow-up until after puberty.
• Penile and urethral reconstruction, such as hypospadias may have serious implications for transurethral procedures in the future.
• The clinical presentation of congenital anomalies of the urinary tract is changing but some of these may still present in the adult patient.
• Obstructive uropathy and VUR are not always surgical anomalies, but may be functional in nature: The treatment modalities and long-term outcomes depend on the pathophysiology.

Prenatal hydronephrosis / prenatal intervention and postnatal management
J.M. Nijman, Groningen (NL)

Vesico-ureteral reflux: Longterm outcome and complications
S. Tekgül, Ankara (TR)

Obstructive uropathy: Megaureter, posterior urethral valves and the valve bladder. A life-long dilemma
D.N. Wood, London (GB)

Discussion
Aims and objectives of this session

• Prostate cancer is a global public health concern. While large randomized trials have shown a reduction in prostate cancer mortality with regular prostate-specific antigen (PSA) screening, there is potential for negative effects from over-diagnosis and treatment, making screening a controversial topic. This course will provide an overview of the evidence of both benefits and harm from the randomized trials as well as data from epidemiological studies illustrating the global incidence and mortality trends.

• Today’s challenges include the age when to start screening, screening intervals and the optimal use of “smarter screening”. This course will cover the EAU-ESTRO-SIOG guidelines and other risk-stratified approaches to screening based on age, health and PSA-values, family history, ethnicity and genetic risk.

• Active surveillance (AS) is now widely accepted as a management strategy for low risk prostate cancer with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Several AS studies have consistently shown a low rate of progression to metastatic disease or death from prostate cancer with AS, with the majority of patients remaining free from definitive therapy for many years.

• Clinical and pathological factors influencing the risk of disease progression in patients with low risk prostate cancer under AS, surveillance strategy, role of repeat biopsy, inclusion criteria, and the use of MRI will be discussed.

• The course will be interactive and include illustrative and practical clinical case discussions.

Who, when, and how often to screen and when to stop? An illustrated risk-adapted strategy
S. Carlsson, New York (US)

Active surveillance
A.R. Zlotta, Toronto (CA)
Retropubic radical prostatectomy – Tips, tricks and pitfalls
ESU Course 17

Location: Green Area, Room 21
Chair: O. Hakenberg, Rostock (DE)

Aims and objectives of this session
In many parts of Europe, open retropubic radical prostatectomy is still the gold standard for treating localised prostate cancer. The competition with radiotherapy and novel techniques like cryosurgery and HIFU, should encourage urologists to optimally perform the surgical resection. This teaching course is a must for the elder resident and the younger urologist but well trained urologists who do not treat many patients with localised prostate cancer, will benefit.

Introduction
O. Hakenberg, Rostock (DE)

Surgical anatomy
O. Hakenberg, Rostock (DE)

Step by step radical retropubic prostatectomy
G.N. Thalmann, Bern (CH)

Tips, tricks and pitfalls
O. Hakenberg, Rostock (DE)

Treatment of complications
G.N. Thalmann, Bern (CH)

Discussion and interaction
Practical management of non-muscle-invasive bladder cancer (NMIBC)
ESU Course 18

Saturday 16 March
14:30 - 17:30

Location: Green Area, Room 22
Chair: J.A. Witjes, Nijmegen (NL)

Aims and objectives of this session
Our main objective is to not only enrich what you know about NMIBC, but to also equip you with frontline strategies when dealing with common and complex patient cases.

This course will commence with discussions on NMIBC diagnostic opportunities then proceed to the best practices and the pitfalls to avoid in transurethral resection (TUR). Get to know the techniques, tips and tricks, potential problems/complications, TUR with enhanced imaging, en-bloc resection and more through videos and lively discussions with key opinion leaders.

Further into the course, you will familiarise yourself with the new modalities and the limitations of recommendations on additional risk-adapted intravesical treatment. These will be followed by deliberations on typical problems encountered, complications during and after intravesical therapy, and strategies on how you can prevent them.

Another course highlight you can look forward to is how you can deal with abnormal cytology including locations outside the bladder.

Introduction
J.A. Witjes, Nijmegen (NL)

Diagnosis, markers and innovations, no video’s on PDD, NBI etc.
J. Palou, Barcelona (ES)

TUR technique: Tips and tricks; problems; En bloc resection; TUR and the location, including diverticula, ureteral meatus; Re-TUR; PDD, SPIES, NBI etc.: With several cases and video’s
M. Babjuk, Prague (CZ)

Complications during surgery and what to do: Obturator nerve contraction, intra and extraperitoneal perforation, bleeding etc.
J. Palou, Barcelona (ES)

Risk groups and guideline treatment: What is clearly established
J.A. Witjes, Nijmegen (NL)

Comments on guideline treatment including BCG shortage and new treatment modalities
M. Babjuk, Prague (CZ)

Complications of intravesical therapy, including case
J.A. Witjes, Nijmegen (NL)
How to deal with abnormal cytology including locations outside the bladder (UUT and urethra) and its limitations

J. Palou, Barcelona (ES)
Lymphadenectomy in urological malignancies
ESU Course 19

Location: Green Area, Room 23
Chair: A. Mattei, Luzern (CH)

Aims and objectives of this session
Mostly, in case of tumour surgery, a loco-regional lymph node (LND) dissection is also indicated.
With the introduction of minimal invasive surgery the LND often seems to have lost the attention of the surgeons and has been practiced in less cases and/or less extensively.
Throughout our presentation we will corroborate the indications when a LND has to be performed, the templates, the techniques using different approaches and the oncological as well as functional outcomes.

After attending this course, participants should be able to:
• Know the indication when to perform LND during surgery for urological malignancies.
• Apply the most modern imaging concepts for the preoperative lymph node staging.
• Have solid knowledge about the templates that have to be removed.
• Be informed concerning the oncological and functional results of lymph node dissection as well as complications.

Renal cancer
U. Capitanio, Milan (IT)

Urothelial cancer
A. Mattei, Luzern (CH)

Prostate cancer
A. Mattei, Luzern (CH)

Testicular cancer
J. Sheinfeld, New York (US)

Penile cancer
U. Capitanio, Milan (IT)
Aims and objectives of this session
The Endoscopic Stone Treatment (EST) training curriculum has the goal to provide the clinician with proficiency skills in the treatment of urinary stones with endoscopic techniques. This protocol has been designed following a very strict process, in order to mitigate the risks of complications related to the learning curve process. Moving along the different tasks 336 Programme Book EAU Education and training steps, the participant will learn how to use the different instruments and technologies that can be functional to stone fragmentation and extraction.

The EST s1 (Endoscopic Stone Treatment step 1) is the first step of this training and assessment curriculum. To aid in the training of these skills and to prepare for this ESTs1 exam, the exercises to be performed can be found in the instructional videos at uroweb.org.
Aims and objectives of this session
The Endoscopic Stone Treatment (EST) training curriculum has the goal to provide the clinician with proficiency skills in the treatment of urinary stones with endoscopic techniques. This protocol has been designed following a very strict process, in order to mitigate the risks of complications related to the learning curve process. Moving along the different tasks 336 Programme Book EAU Education and training steps, the participant will learn how to use the different instruments and technologies that can be functional to stone fragmentation and extraction.

The ESTs1 (Endoscopic Stone Treatment step 1) is the first step of this training and assessment curriculum. To aid in the training of these skills and to prepare for this ESTs1 exam, the exercises to be performed can be found in the instructional videos at uroweb.org.
Prostate cancer imaging from diagnosis to monitoring
Expert-Guided Poster Tour 06

Saturday 16 March
15:30 - 17:30

Location:  Green Area, Room A
Chairs:  J. Rubio Briones, Valencia (ES)
A. Villers, Lille (FR)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to
provide an interactive platform
informing delegates on the real essentials and providing in-depth information on
the different research
projects. Poster viewing of 30 minutes after which two experts, will ask
questions to individuals and groups
of poster presenters.

16:00 - 16:03
Introduction
J. Rubio Briones, Valencia (ES)
A. Villers, Lille (FR)

PT135
MRI-guided transurethral ultrasound ablation in patients with localized prostate
cancer: 4-year outcomes of a prospective phase I trial

By:  Chin J. ¹, Hatiboglu G. ², Relle M. ³, Dewar M. ¹, Hetou K. ¹, Kuru T. ⁴, Popeneciu
I.V. ², Hafron J. ³, Roethke M. ⁴, Mueller-Wolf M. ⁴, Kassam Z. ⁵, Staruch R. ⁶,
Burtnyk M. ⁶, Bonekamp D. ⁴, Schlemmer H-P. ⁴, Pahernik S. ²
¹Western University, London Health Sciences Centre, Dept. of Urology, London, Canada,
²University Hospital Heidelberg, German Cancer Research Center (DKFZ), Dept. of
Urology, Heidelberg, Germany, ³Beaumont Health System, Dept. of Urology, Royal Oak,
United States of America, ⁴University Hospital Heidelberg, German Cancer Research
Center (DKFZ), Dept. of Radiology, Heidelberg, Germany, ⁵Western University, London
Health Sciences Centre, Dept. of Radiology, London, Canada, ⁶Profound Medical, Dept.
of Clinical Science, Mississauga, Canada

PT136
Does cancer grade impact MRI accuracy in estimating lesion size for prostate focal
therapy?

By:  Aslim E.J. ¹, Law T.Y.X. ¹, Chen K. ¹, Lee L.S. ¹, Ho H.S.S. ¹, Lau W.K.O. ¹, Yuen
J.S.P. ¹, Cheng C.W.S. ¹, Ngo N. ², Law Y.M. ³, Tay K.J. ¹
¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, Singapore
²Singapore General Hospital, Dept. of Anatomical Pathology, Singapore, Singapore, Singapore
³Singapore General Hospital, Dept. of Diagnostic Radiology, Singapore, Singapore

PT137
Diagnostic accuracy of multiparametric magnetic resonance imaging to detect
residual prostate cancer following focal therapy with irreversible electroporation

By:  Blazevski A. ¹, Scheltema M.J. ², Yuen B. ¹, Masand N. ², Cusick T. ², Haynes A. ²
PT138

The role of MRI in the diagnosis of prostate cancer recurrence after thermal ablation

By: Aboyan I.A. 1, Badyan K.I. 2, Redkin V.A. 3
1KDC Zdorovie, Dept. of Urology, Rostov-on-Don, Russia, 2KDC, Dept. of Urology, Rostov-on-Don, Russia, 3KDC Zdovorie, Dept. of Radiology, Rostov-on-Don, Russia

PT139

Evaluating the predictive role of automated bone scan index in selecting newly diagnosed metastatic prostate cancer patients for prostate radiotherapy: A STAMPEDE trial exploratory analysis

By: Ali A. 1, Hoyle A.P. 1, Parker C.C. 2, James N.D. 3, Brawley C.C. 4, Parmar M.K. 4, Sydes M.R. 4, Clarke N.W. 1
1University of Manchester, Genito-Urinary Cancer Research Group, Manchester, United Kingdom, 2Royal Marsden Hospital, Dept. of Academic Urology, London, United Kingdom, 3University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, 4University College London, Medical Research Council - Clinical Trials Unit, London, United Kingdom

PT140

Clinical utility of prebiopsy PSMA PET CT in patients suspected of carcinoma prostate

By: Jain H., Sood R., Goel H.K., Sharma U., Kumar A.
PGIMER & Dr RML Hospital, Dept. of Urology & Renal Transplant, New Delhi, India

PT141

Potentials of 68Ga-prostate specific membrane antigen PET/CT for primary diagnosis of prostate cancer

By: Lopci E. 1, Saita A. 2, Lughezzani G. 2, Castello A. 1, Colombo P. 3, Buffi N. 2, Hurle R. 2, Marzo K. 1, Leonardi L. 1, Benetti A. 2, Casale P. 2, Fasulo V. 2, Paciotti M. 2, Domanico L. 2, Maffei D. 2, Bevilacqua G. 2, Balzarini L. 4, Chiti A. 1, Guazzoni G. 2, Lazzeri M. 2
1Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Nuclear-Medicine, Rozzano, Italy, 2Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, 3Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Pathology, Rozzano, Italy, 4Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Radiology, Rozzano, Italy

PT142

The effect of androgen deprivation therapy on PSMA expression evaluated with 68Ga-PSMA-11 PET/ MRI - a prospective, registered clinical trial

By: Ettala O. 1, Malaspina S. 2, Tuokkola T. 2, Boström P.J. 1, Kemppainen J. 3
1Turku University Hospital, Dept. of Urology, Turku, Finland, 2University of Turku, Turku PET Centre, Turku, Finland, 3Turku University Hospital, Dept. of Clinical Physiology and Nuclear Medicine, Turku, Finland
<table>
<thead>
<tr>
<th>PT143</th>
<th>Apparent diffusion coefficient ratio between tumor and nontumor as a potential imaging biomarker for prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Matsuoka Y. 1, Tanaka H. 2, Kimura T. 2, Moriyama S. 1, Uehara S. 1, Yasuda Y. 1, Kijima T. 1, Yoshida S. 1, Yokoyama M. 1, Ishioka J. 1, Saito K. 1, Fujiy Y. 1</td>
<td></td>
</tr>
<tr>
<td>1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT144</th>
<th>Quantitative analysis between apparent diffusion coefficients on MRI and cellularity metrics of prostate cancer with whole-mount pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Gao J., Zhang Q., Zhang C., Guo H.</td>
<td></td>
</tr>
<tr>
<td>Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT145</th>
<th>Clinical evaluation of dispersion MRI for prostate cancer localization: A multicenter study</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Turco S. 1, Lavini C. 2, Heijmink S. 3, Barentsz J. 4, Wijkstra H. 5, Mischi M. 1</td>
<td></td>
</tr>
<tr>
<td>1Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, The Netherlands, 2Amsterdam UMC/AMC, Dept. of Radiology and Nuclear Medicine, Amsterdam, The Netherlands, 3Nederlands Cancer Institute, Dept. of Radiology, Amsterdam, The Netherlands, 4Radboudumc, Dept. of Radiology and Nuclear Medicine, Nijmegen, The Netherlands, 5Amsterdam UMC/AMC, Dept. of Urology, Amsterdam, The Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT146</th>
<th>Likert vs. PI-RADS v2: A comparison of two radiological scoring systems for detection of clinically significant prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, 2Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, 3Imperial College Healthcare NHS Trust,, Dept. of Imperial Urology, London, United Kingdom, 4Imperial College Healthcare NHS Trust,, Dept. of Imperial Urology, London, United Kingdom, 5Imperial College London, Dept. of Imperial Epidemiology and Biostatistics, London, United Kingdom, 6Imperial College Healthcare NHS Trust, Dept. of Imperial Radiology, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT147</th>
<th>Risk stratification of high-risk prostate cancer based on MR prostate imaging for clinical practice and implementation in computer-aided software systems</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Guberina N. 1, Fehr J-L. 2, Wetter A. 1, Porcellini B. 3, Bauer S. 2, Baumgartner M. 2, Seiler D. 2, Blattner W. 2, Hadaschik B. 4, Patak M.A. 3, Spahn M. 2</td>
<td></td>
</tr>
<tr>
<td>1University Hospital Essen, Dept. of Diagnostic and Interventional Radiology and Neuroradiology, Essen, Germany, 2Hirslanden Klinik Zürich, Dept. of Urology, Prostata Cancer Center Hirslanden, Zürich, Switzerland, 3Klinik Hirslanden Zürich, Dept. of</td>
<td></td>
</tr>
</tbody>
</table>
PT148

Should we rely on multiparametric MRI of the prostate performed at non-academic centres? Implications for optimized target biopsy approaches

By: Stabile A. 1, Barletta F. 1, Dell’Oglio P. 1, De Cobelli F. 2, Esposito A. 2, Brembilla G. 2, Gandaglia G. 1, Fossati N. 1, Zaffuto E. 1, Deho’ F. 1, Capitanio U. 1, Suardi N. 1, Del Maschio A. 2, Montorsi F. 1, Briganti A. 1

1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy

---

PT149

Improved interdisciplinary communication – the impact of structured reporting of prostate magnetic resonance imaging

By: Wetterauer C. 1, Winkel D.J 2, Federer-Gsponer J. 1, Halla A. 1, Subotic S. 1, Deckart A. 1, Seifert H.H 1, Boll D. 2, Ebbing J. 1

1University Hospital Basel, Dept. of Urology, Basel, Switzerland, 2University Hospital Basel, Clinic of Radiology and Nuclear Medicine, Basel, Switzerland

---

PT150

3D multiparametric contrast ultrasound predicts the histopathological outcome of systematic biopsy

By: Wildeboer R.R. 1, Van Sloun R.J.G. 1, Huang P. 2, Wijkstra H. 3, Mischi M. 1

1Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, The Netherlands, 2Second Affiliated Hospital of Zhejiang University, Ultrasound, Hangzhou, China, 3Amsterdam UMC/AMC, Dept. of Urology, Amsterdam, The Netherlands

---

PT151

A biparametric MRI based risk model for improved risk stratification and selection of biopsy-naïve men for prostate biopsies

By: Boesen L. 1, Thomsen F.B. 1, Nørgaard N. 1, Løgager V. 2, Balslev I. 3, Bisbjerg R. 1, Thomsen H.S. 2, Jakobsen H. 1

1Herlev Gentofte University Hospital, Dept. of Urology, Herlev, Denmark, 2Herlev Gentofte University Hospital, Dept. of Radiology, Herlev, Denmark, 3Herlev Gentofte University Hospital, Dept. of Pathology, Herlev, Denmark

---

PT152

Do the performance characteristics of pre-biopsy mpMRI in detecting “clinically significant” prostate cancer vary according to age?

By: Bryant R.J. 1, Brewster S.F. 1, Hobbs C.P. 1, Eyre K.S. 1, Davies L.C. 2, Sullivan M.E. 1, Shields W. 1, Sooriakumaran P. 3, Verrill C.L. 4, El-Sheikha J. 5, Hamdy F.C. 1, Macpherson R. 5, Gleeson F.V. 5

1Oxford University Hospitals NHS Foundation Trust, Dept. of Urology, Oxford, United Kingdom, 2University of Oxford, Nuffield Dept. of Population Health, Oxford, United Kingdom, 3University College London Hospital NHS Foundation Trust, Dept. of Uro-Oncology, London, United Kingdom, 4Oxford University Hospitals NHS Foundation Trust, Dept. of Pathology, Oxford, United Kingdom, 5Oxford University Hospitals NHS Foundation Trust, Dept. of Radiology, Oxford, United Kingdom
PT153  
**Analysis of clinical and oncological follow-up after negative MRI-TRUS fusion biopsy of the prostate**

By: **Von Landenberg N.,** Noldus J., Hanske J., Berg S., Brock M.
Marien Hospital Herne, Ruhr University Bochum, Dept. of Urology, Herne, Germany

PT154  
**Men with a pre-biopsy positive multiparametric MRI of the prostate undergoing targeted biopsy: Are additional systematic biopsies of clinical relevance?**

1Amsterdam University Medical Centers, University of Amsterdam, Dept. of Urology, Amsterdam, The Netherlands, 2Jeroen Bosch Hospital, Dept. of Urology, ’s Hertogenbosch, The Netherlands, 3Amsterdam University Medical Centers, University of Amsterdam, Dept. of Radiology, Amsterdam, The Netherlands, 4Jeroen Bosch Hospital, Dept. of Radiology, ’s Hertogenbosch, The Netherlands

PT155  
**Can we rely on a negative multiparametric MRI to exclude significant prostate cancer at biopsy? Results from a regional cancer centre**

By: **Lobo N.,** Petrides N., Stanowski M., Morrison I., Thomas M., Kommu S., Streeter E., Eddy B.
1Frimley Health NHS Foundation Trust, Dept. of Urology, Frimley, United Kingdom, 2Canterbury Centre for Robotic Urological Surgery, Dept. of Urology, Canterbury, United Kingdom, 3Canterbury Centre for Robotic Urological Surgery, Dept. of Radiology, Canterbury, United Kingdom

PT156  
**Who benefits from multiparametric magnetic resonance imaging after the suspicion of prostate cancer?**

By: **Cuadras Sole M.,** Celma A., Regis L., Salazar A., Miret E., Roche S., De Torres I.M., Mast R., Semidey M.E., Planas J., Morote J.
1Hospital Vall d'Hebron, Dept. of Urology, Barcelona, Spain, 2Hospital Vall d'Hebron, Dept. of Radiology, Barcelona, Spain, 3Hospital Vall d'Hebron, Dept. of Pathology, Barcelona, Spain

PT157  
**How important are prostate MRI reading skills to urologists?**

By: **Sternberg I.,** Fishelevitz A., Kogan T., Sagy I., Buchler A., Keizman D., Dresler H., Leibovitch I.
1Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, 2Meir Medical Center, Dept. of Pathology, Kfar Saba, Israel, 3Meir Medical Center, Dept. of Oncology, Kfar Saba, Israel

PT159  
**Automatic segmentation of the prostate in transrectal ultrasound images using deep learning for application in MRI-TRUS fusion**

By: **Van Sloun R.J.G.,** Wildeboer R.R., Postema A.W., Gayet M., Mannaerts C.K., Beerlage H., Salomon G., Wijkstra H., Mischi M.
1Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, The
PT160
Multivariable retrospective lesion based analyses of number of MRI ultrasound fusion targeted biopsy cores needed for prostate cancer detection in patients treated with radical prostatectomy

By: Leyh-Bannurah S-R., Kachanov M., Beyersdorff D., Pompe R., Preisser F., Tian Z., Karakiewicz P., Fisch M., Maurer T., Graefen M., Budäus L.

1University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2Martini-Klinik Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3University Medical Center Hamburg-Eppendorf, Dept. of Radiology, Hamburg, Germany, 4University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany, 5University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada

PT161
Assessing the diagnostic accuracy of micro-ultrasound for the detection of clinically significant prostate cancer: Results from a single-institutional experience


1Humanitas Clinical and Research Hospital, Dept. of Urology, Milan, Italy, 2Humanitas Clinical and Research Center, Dept. of Pathology, Milan, Italy

PT162
Multiparametric ultrasound for the diagnosis of prostate cancer: Greyscale, shearwave elastography and contrast-enhanced imaging in comparison with radical prostatectomy specimens


1Amsterdam University Medical Centers, University of Amsterdam, Dept. of Urology, Amsterdam, The Netherlands, 2Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, The Netherlands, 3Jeroen Bosch Hospital, Dept. of Urology, ’s-Hertogenbosch, The Netherlands, 4Martini Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

PT163
Who gains additional benefits from systematic biopsy concurrently performed with MRI-ultrasound fusion targeted biopsy in the detection of significant prostate cancer?


1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

**16:00 - 16:03**

**Introduction**

S.M. Haensel, Rotterdam (NL)

**PT164**

**Benign prostatic hyperplasia increases the risk of colon cancer: A population-based study**

By: Lai B.C.H.\(^1\), Shih H-J.\(^1\), Huang C-J.\(^2\)

\(^1\)Wan Fang Hospital, Dept. of Urology, Taipei, Taiwan, \(^2\)Wan Fang Hospital, Dept. of Anesthesiology, Taipei, Taiwan

**Aims and objectives of this presentation**

PT164

**PT165**

**Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to severe symptoms: Results from clinical trial simulations using individual IPSS trajectories**

By: Della Pasqua O.\(^1\), D'Agate S.\(^2\), Adalig B.\(^3\), Wilson T.\(^4\), Chavan C.\(^5\), Manyak M.\(^6\), Palacios-Moreno J.M.\(^7\), Oelke M.\(^8\), Roehrborn C.\(^9\)

\(^1\)GlaxoSmithKline, Dept. of Urology, London, United Kingdom, \(^2\)University College London, Clinical Pharmacology and Therapeutics Group, London, United Kingdom, \(^3\)GlaxoSmithKline, Dept. of Urology, Istanbul, Turkey, \(^4\)PAREXEL International, Dept. of Statistics, Durham, United States of America, \(^5\)GlaxoSmithKline, Dept. of Urology, Mumbai, India, \(^6\)GlaxoSmithKline, Dept. of Urology, Washington, United States of America, \(^7\)GlaxoSmithKline, Dept. of Urology, Madrid, Spain, \(^8\)St. Antonius Hospital, Dept. of Urology, Gronau, Germany, \(^9\)University of Texas Southwestern Medical Center, Dept. of Urology, Texas, United States of America

**Aims and objectives of this presentation**

PT165
Management of urinary retention in patients with benign prostatic obstruction: A systematic review and meta-analysis


1 Athens Medical Center, Dept. of Minimally Invasive Urology, Athens, Greece, 2 University of Patras, Dept. of Urology, Patras, Greece, 3 University of Aberdeen, Academic Urology Unit, Aberdeen, Scotland, United Kingdom, 4 School of Health Sciences, University of Thessaly, Dept. of Urology, Faculty of Medicine, Larissa, Greece, 5 Charles-Nicolle University Hospital, Dept. of Urology, Rouen Cedex, France, 6 Bristol Medical School, University of Bristol and Bristol Urological Institute, Translational Health Sciences, Bristol, United Kingdom, 7 University of Florence AOUC- Careggi Hospital, Minimally Invasive and Robotic Surgery, and Kidney Transplantation, Florence, Italy, 8 Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 9 Spital Thurgau AG, Urology Clinic, Frauenfeld, Switzerland, 10 Kaiser-Franz-Josef-Spital, Dept. of Urology, Vienna, Austria, 11 University Basel, Alta Uro AG, Basel, Switzerland, 12 Taunton and Somerset Hospital, Dept. of Urology, Taunton, United Kingdom, 13 University of Helsinki and Helsinki University Hospital, Dept. of Urology and Public Health, Helsinki, Finland, 14 Health Sciences Centre, McMaster University, Division of Gastroenterology and Cochrane UGPD Group, Dept. of Medicine, Hamilton, Canada, 15 University General Hospital of Heraklion, University of Crete Medical School, Dept. of Urology, Heraklion, Crete, Greece

Aims and objectives of this presentation

PT166

Detrusor wall thickness does not predict a successful trial without catheter after acute urinary retention in patients on medical treatment for benign prostatic hyperplasia

By: De Nunzio C. 1, Tema G. 1, Cindolo L. 2, Bada M. 2, Lombardo R. 1, Cicione A. 1, Nacchia A. 1, Cancrini F. 1, Schips L. 2, Gacci M. 3, Milanese M. 3, Cito G. 3, Serni S. 3, Tubaro A. 1

1 Sapienza University of Rome, Sant’Andrea Hospital, Dept. of Urology, Rome, Italy, 2 S.Pio da Pietrelcina Hospital, Dept. of Urology, Vasto, Italy, 3 University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy

Aims and objectives of this presentation

PT167

The outcomes of male patients with acute urinary retention with concomitant post-obstructive diuresis

By: Fishelevitz A., Leibovitch I., Vainrib M.
Meir Medical Center, Dept. of Urology, Kfar Saba, Israel

Aims and objectives of this presentation

PT168
Is it clinically useful to screen all patients with LUTS for erectile dysfunction?

By: Capogrosso P.¹, Ventimiglia E.¹, Boeri L.¹, Pozzi E.², Schifano N.¹, Chierigo F.¹, Belladelli F.², Cazzaniga W.¹, Abbate C.¹, Dehò F.¹, Mirone V.³, Gaboardi F.⁴, Montorsi F.¹, Salonia A.¹

¹IRCCS Ospedale San Raffaele, Unit of Urology, URI, Milan, Italy, ²Università Vita-Salute San Raffaele, Unit of Urology, URI, Milan, Italy, ³University of Naples “Federico II”, Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, Naples, Italy, ⁴IRCCS Ospedale San Raffaele Turro, Unit of Urology, URI, Milan, Italy

Aims and objectives of this presentation

PT169

Validation of a clinical decision-making Markov model applied to optimization of benign prostatic enlargement treatment

By: Ferrari R.¹, Schiavina R.¹, Borghesi M.¹, Bianchi L.¹, Chessa F.¹, Brunocilla E.¹, Crivellaro S.²

¹University of Bologna, Dept. of Urology, Bologna, Italy, ²University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America

Aims and objectives of this presentation

PT170

A high preoperative PSA level is not accurate to predict incidental prostate cancer detection in patient underwent endoscopic enucleation of the prostate for large glands

By: Misrai V.¹, Peyronnet B.², Pradere B.³, Bordier B.¹, Guillotreau J.¹, Gryn A.¹, Zorn K.C.⁴

¹Clinique Pasteur, Dept. of Urology, Toulouse, France, ²Rennes University, Dept. of Urology, Rennes, France, ³University of Tours, Dept. of Urology, Tours, France, ⁴CHUM university, Dept. of Urology, Montréal, Canada

Aims and objectives of this presentation

PT171

Postoperative PSA levels after holmium laser enucleation of the prostate: Enucleation ratio matters rather than preoperative prostate volume

By: Kimura S., Ohara E., Aoki H., Ishidoya S.
Sendai City Hospital, Dept. of Urology, Sendai, Japan

Aims and objectives of this presentation

PT172

Diagnosing incidental prostate cancer (pT1a/b): Is the game worth the candle in times of changing health economics?

Aims and objectives of this presentation

PT173
Aims and objectives of this presentation

PT173

How should we screen out prostate cancer from benign prostate hyperplasia patients? Analysis of 764 cases treated with Holmium laser enucleation of the prostate in a tertiary institution

By: Kimura S., Ohara E., Aoki H., Shibuya R., Naganuma H., Ishidoya S.
Sendai City Hospital, Dept. of Urology, Sendai, Japan,
Sendai City Hospital, Dept. of Pathology, Sendai, Japan

Aims and objectives of this presentation

PT174

Preoperative pelvic floor muscle exercise for early continence after holmium laser enucleation of the prostate: A randomized controlled study

By: Anan G., Iwamura H., Ito J., Kaiho Y., Sato M.
Tohoku Medical and Pharmaceutical University, Dept. of Urology, Sendai, Japan

Aims and objectives of this presentation

PT175

Holmium laser enucleation of the prostate (HoLEP): Evaluation of the first thousand patients

Vall d'Hebron University Hospital, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation

PT176

Track and teach: Simplified endoscope tracking in prostate enucleation reveals differing motion patterns dependent on surgeon experience

By: Dressler F.F., Gratzke C., Miernik A., Schöb D.S.
University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany

Aims and objectives of this presentation

PT177

Partially versus totally en-bloc no-touch low-power HoLEP: Comparable safety and efficacy, improved post-operative dysuria

By: Cracco C.M., Scoffone C.M.
Cottolengo Hospital, Dept. of Urology, Turin, Italy

Aims and objectives of this presentation
PT178

PT179

Holmium laser transurethral enucleation of the prostate 100 W vs 120 W: 12-month retrospective data from a single surgeon experience

By: Franco M. 1, Sanchez Macias J. 1, Mercader C. 1, Pardo A. 2, Camacho Rovira D. 1, Calaf O. 3, D'Anna M. 1, Alcaraz A. 1
1Hospital Clinic, Dept. of Urology, Barcelona, Spain, 2Laseralia, C.E.O., Barcelona, Spain, 3Hospital Germans Trias, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation
PT179

PT180

The influences of preoperative acute urinary retention to holmium laser enucleation of prostate: Multicenter analysis

By: Bae S. 1, Park B.H. 1, Chung H. 2, Lee Y.S. 1, Kim H.S. 2, Kang S.H. 1, Song K.H. 3, Chang Y.S. 4, Han C.H. 1
1The Catholic University of Korea, Uijeongbu St.Mary's Hospital, Dept. of Urology, Gyeonggi-do, South Korea, 2Konkuk University Chungju Hospital, Dept. of Urology, Chungcheongbuk-do, South Korea, 3Chungnam National University Hospital, Dept. of Urology, School of Medicine, Daejeon, South Korea, 4Konyang University College of Medicine, Dept. of Urology, Daejeon, South Korea

Aims and objectives of this presentation
PT180

PT181

Thulium laser enucleation (ThULEP) versus Holmium laser enucleation of the prostate (HolEP): A two institution trial to compare intra and early postoperative outcomes

By: Bozzini G. 1, Roche J.B 2, Besana U. 1, Romero Otero J. 3, Gastaldi C. 1, Calori A. 1, Buizza C. 1
1ASST Valle Olona, Dept. of Urology, Busto Arsizio, Italy, 2Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, 3Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain

Aims and objectives of this presentation
PT181

PT182

Initial results of a prospective randomized trial on the learning curve of three endoscopic enucleation techniques (HoLEP, ThuFLEP and MEP) for BPH

By: Taratkin M., Enikeev D., Rapoport L., Enikeev M., Glybochko P.
Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

Aims and objectives of this presentation
PT182
<table>
<thead>
<tr>
<th>PT183</th>
<th>Vaporesection of the prostate with Tm:YAG laser: The Oyster technique</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Patras, Dept. of Urology, Patras, Greece</td>
<td></td>
</tr>
<tr>
<td><strong>Aims and objectives of this presentation</strong> PT183</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT184</th>
<th>Energy impact on voiding symptoms after thulium enucleation of prostate: A large multi institutional analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, 2Istituti Clinici Zucchi, Dept. of Urology, Monza, Italy, 3Istituti Clinici Zucchi, Dept. of Urology, Milan, Italy</td>
<td></td>
</tr>
<tr>
<td><strong>Aims and objectives of this presentation</strong> PT184</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT185</th>
<th>Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia: A single centre 3-year comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Sapienza University of Roma, Dept. of Urology, Rome, Italy, 2Nuova Villa Claudia, Dept. of Urology, Rome, Italy</td>
<td></td>
</tr>
<tr>
<td><strong>Aims and objectives of this presentation</strong> PT185</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT186</th>
<th>Aquablation for treating benign prostatic obstruction in small to medium-size glands: 6 months-outcomes of the first French registry</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Misrai V., Barry Delongchamps N., Descazeaud A.</td>
<td></td>
</tr>
<tr>
<td>1Clinique Pasteur, Dept. of Urology, Toulouse, France, 2Cochin Hospital, Dept. of Urology, Paris, France, 3Dupuytren Hospital, Dept. of Urology, Limoges, France</td>
<td></td>
</tr>
<tr>
<td><strong>Aims and objectives of this presentation</strong> PT186</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT187</th>
<th>Aquablation of the prostate. Real-life data from 180 consecutive patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Bach T., Giannakis I., Karimi M., Rijo E.</td>
<td></td>
</tr>
<tr>
<td>1Asklepios Hospital Harburg, Dept. of Urology, Hamburg, Germany, 2Kantonspital Frauenfeld, Dept. of Urology, Frauenfeld, Switzerland, 3Hospital Quirón Barcelona, Dept. of Urology, Hamburg, Germany</td>
<td></td>
</tr>
<tr>
<td><strong>Aims and objectives of this presentation</strong> PT187</td>
<td></td>
</tr>
</tbody>
</table>
Venous thromboembolism (VTE) prophylaxis following transurethral resection of the prostate (TURP): A national audit of practice in Scotland

By: Small R., Leask J., McPhee A.S., Bhatt J.R.
Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom

Aims and objectives of this presentation
PT188

Inferior tissue ablation after 120W greenlight laser vaporization does not result into inferior clinical outcome compared to conventional TURP: Update of a prospective 3D ultrasound volumetry study after 5 years

By: Kranzbühler B., Gross O., Fankhauser C., Wettstein M., Grossmann N., Keller E., Eberli D., Sulser T., Poyet C., Hermanns T.
University Hospital Zürich, Dept. of Urology, Zurich, Switzerland

Aims and objectives of this presentation
PT189

Anticoagulants continued during PVP does not impact the risk of postoperative hemorrhagic complications: A multicentric prospective study

By: Pradere B.1, Naspro R.2, Peyronnet B.3, Guillotreau J.4, Bordier B.4, Misrai V.4
1CHRU Tours, Dept. of Urology, Tours, France, 2ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, France, 3CHU Rennes, Dept. of Urology, Rennes, France, 4Clinique Pasteur, Dept. of Urology, Toulouse, France

Aims and objectives of this presentation
PT190

Clinical comparison of holmium laser enucleation of the prostate (HoLEP) and bipolar transurethral enucleation of the prostate (BTUEP) in patients under either anticoagulation or antiplatelet therapy

By: Boeri L.1, Capogrosso P.1, Ventimiglia E.1, Fontana M.2, Sampogna G.2, Zanetti S.P.2, Pozzi E.1, Schifano N.1, Zuabi R.1, Chierigo F.1, Scatoni V.1, Longo F.2, Gadda F.2, Dell’Orto P.G.2, Montorsi F.1, Montanari E.2, Salonia A.1
1IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology; URI, Milan, Italy, 2IRCCS Fondazione Ca’ Granda - Maggiore Policlinico Hospital, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation
PT191

A prospective, randomized controlled trial (RCT) regarding antimicrobial prophylaxis in transurethral resection of the prostate (TURP): An interim analysis of the prophylaxis001-trial

By: Baten E.1, Arijs I.2, Goethuys H.3, Vandecandelaere M.4, Cartuyvels R.5, Van...
Aims and objectives of this presentation
PT192
Nephron sparing surgery: What can be achieved?

Poster Session 24

Saturday 16 March
16:00 - 17:30

Location: Red Area, eURO Auditorium 2

Chairs: P. Heathcote, Sydney (AU)
F. Jankevicius, Vilnius (LT)
T. Klatte, Bournemouth (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

A prospective multicenter evaluation of predictive factors for positive surgical margins after partial nephrectomy for renal cell carcinoma: The RECORD2 project

By: Mari A. 1, Di Maida F. 1, Schiavina R. 2, Amparore D. 3, Antonelli A. 4, Barale M. 5, Borghesi M. 2, Bove P. 6, Brunocilla E. 2, Capitanio U. 7, Da Pozzo L. 8, Gontero P. 5, Larcher A. 7, Longo N. 9, Montanari E. 10, Porpiglia F. 3, Serni S. 1, Simeone C. 4, Siracusano S. 11, Trombetta C. 12, Volpe A. 13, Ficarra V. 14, Carini M. 1, Minervini A. 1

1University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy,
2University of Bologna, Dept. of Urology, Bologna, Italy,
3San Luigi Gonzaga Hospital, Dept. of Oncology, Division of Urology, Orbassano, Italy,
4University of Brescia, Spedali Civili Hospital, Dept. of Urology, Brescia, Italy,
5University of Studies of Torino, San Giovanni Battista Hospital, Dept. of Surgical Sciences, Turin, Italy,
6University Hospital of Tor Vergata, Dept. of Urology, Rome, Italy,
7URI-Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy,
8Papa Giovanni XXIII Hospital, Dept. of Urology, Bergamo, Italy,
9University Federico II of Naples, Dept. of Urology, Naples, Italy,
10Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Policlinico, University of Milan, Dept. of Urology, Milan, Italy,
11Azienda Ospedaliera Universitaria Integrata (A.O.U.I.) of Verona, Dept. of Urology, Verona, Italy,
12University of Trieste, Dept. of Urology, Trieste, Italy,
13Maggiore della Carità Hospital, Dept. of Urology, Novara, Italy,
14University of Messina, Dept. of Human and Paediatric Pathology Gaetano Barresi, Urologic Section, Messina, Italy

Aims and objectives of this presentation

330

Predictors of positive surgical margins after partial nephrectomy for localized renal masses: Results of a prospective multicentre study (Surface-Intermediate-Base Project)

Aims and objectives of this presentation

## 332

### Negative impact of positive margins in partial nephrectomy in stage 1 renal cell carcinoma: A multicenter analysis

By: Bradshaw A.¹, Eldefrawy A.¹, Uzzo R.², Capitanio U.³, Patil D.⁴, Joshi S.², Larcher A.³, Ryan S.¹, Meagher M.¹, Cotta B.¹, Wan F.¹, Montorsi F.³, Master V.⁴, Derweesh I.¹

¹UC San Diego Health, Dept. of Urology, San Diego, United States of America, ²Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ³Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ⁴Emory University, Dept. of Urology, Atlanta, United States of America

Aims and objectives of this presentation

## 333

### Recurrence after nephron-sparing therapy in Sweden, a register based data study

By: Ljungberg B.¹, Pernilla S.², Magnus F.³, Benny H.⁴, Peter E.⁵

¹Umeå University, Surgical and perioperative sciences, Umeå, Sweden, ²Örebro University Hospital, Dept. of Urology, Örebro, Sweden, ³Sahlgrenska University Hospital, Dept of Urology, Gothenburg, Sweden, ⁴Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden, ⁵Malmö University Hospital, Dept. of Urology, Malmö, Sweden

Aims and objectives of this presentation
Assessment of clinicopathological predictors of local recurrence on tumor resection bed in patients treated with partial nephrectomy for localized renal cell carcinoma (the RECORd 1 project)

By: Mari A.1, Tellini R.1, Amparore D.2, Antonelli A.3, Bianchi G.4, Fiori C.5, Furlan M.6, Longo N.7, Mirone V.7, Morgia G.8, Novara G.9, Porpiglia F.10, Schiavina R.11, Di Maida F.1, Campi R.1, Presutti M.1, Simeone C.6, Terrone C.12, Carini M.1, Minervini A.1

1University of Florence, Dept. of Urology, University of Florence, Careggi Hospital, Florence, Italy, Florence, Italy, 2Università di Torino, Divisione di Urologia, Ospedale San Luigi Gonzaga, Orbassano, Torino, Orbassano, Turin, Italy, 3Azienda AO Spedali Civili di Brescia, Unità Operativa di Urologia, Brescia, Italy, 4Università di Modena, Clinica Urologica, Policlinico di Modena, Modena, Italy, 5Università di Torino, Ospedale San Luigi Gonzaga, Orbassano, Torino, Orbassano, Turin, Italy, 6Azienda AO Spedali Civili di Brescia, Unità Operativa di Urologia Dipartimento di NefroUrologia, Brescia, Italy, 7Università di Napoli, Policlinico Federico II, Naples, Italy, 8University of Catania, Dept. of Urology, Catania, Italy, 9Università di Padova, Clinica Urologica, Orbassano, Turin, Italy, 10Università di Torino, Ospedale San Luigi Gonzaga, Orbassano, Torino, Orbassano, Torino, Italy, 11Università di Bologna, Dipartimento di Urologia, Bologna, Italy, 12Azienda Ospedaliera Maggiore della Carità, Dipartimento di Urologia, Novara, Italy

Aims and objectives of this presentation

Patterns and predictors of late recurrence (beyond 5 years) after partial nephrectomy for renal cell carcinoma

By: Abu-Ghanem Y., Dotan Z., Kaver I., Zilberman D.E., Ramon J. Tel Hashomer, Dept. of Urology, Ramat Gan, Israel

Aims and objectives of this presentation

A novel trifecta to simplify the assessment of perioperative outcomes after robot assisted partial nephrectomy for cT1 renal masses: Results of a multicenter series

By: Anceschi U.1, Bertolo R.2, Brassetti A.1, Tuderti G.1, Guaglianone S.1, Garisto J.3, Kaouk J.2, Mottrie A.4, Dell'oglio P.4, Veccia A.5, Antonelli A.5, Capitanio U.6, Montorsi F.6, Larcher A.6, Minervini A.7, Porpiglia F.8, Aron M.9, Ithaar D.10, Autorino R.11, Swaely N.11, Eun D.12, Ferriero M.1, Gallucci M.1

1Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, 3Cleveland Clinic, Dept. of Urology, Rome, Italy, 4OLV Aalst, Dept. of Urology, Aalst, France, 5University of Brescia, Dept. of Urology, Brescia, Italy, 6San Raffaele, Dept. of Urology, Rome, Italy, 7University of Florence, Dept. of Urology, Florence, Italy, 8San Luigi Orbassano, Dept. of Urology, Orbassano, Italy, 9University of Southern California, Dept. of Urology, Los Angeles, United States of America, 10UCSD, Dept. of Urology, San Diego, United States of America, 11VCU, Dept. of Urology, Richmond, United States of America, 12Temple University, Dept. of Urology, Philadelphia, United States of America
Aims and objectives of this presentation

336

337

A preoperative nomogram to predict major complications after robot assisted partial nephrectomy

By: Khene Z-E. 1, Peyronnet B. 1, Bernhard J. 2, Kocher N. 3, Vaessen C. 4, Doumerc N. 5, Pradere B. 6, Seisen T. 4, Beauval J. 5, Verhoest G. 1, Roumigué M. 5, De La Taille A. 7, Bruyere F. 6, Roupret M. 4, Méjean A. 8, Mathieu R. 1, Shariat S. 9, Raman J. 3, Bensalah K. 1

1University of Rennes, Dept. of Urology, Rennes, France, 2University of Bordeaux, Dept. of Urology, Bordeaux, France, 3Penn State Health Milton S. Hershey Medical Center, Dept. of Urology, Hershey, United States of America, 4La Pitie Salpêtrière Hospital, Dept. of Urology, Paris, France, 5University of Toulouse, Dept. of Urology, Toulouse, France, 6University of Tours, Dept. of Urology, Tours, France, 7Mondor Hospital, Dept. of Urology, Créteil, France, 8University of Paris Descartes, Dept. of Urology, Paris, France, 9Medical University Vienna, Dept. of Urology, Vienna, Austria

338

Aims and objectives of this presentation

Propensity score matched comparison of minimally invasive partial and radical nephrectomy for clinical T2a renal mass: Analysis of the robotic surgery for large renal mass (ROSULA) group


1UC San Diego Health, Dept. of Urology, La Jolla, United States of America, 2VCU Health, Dept. of Urology, Richmond, United States of America, 3IFO Rome, Dept. of Urology, Rome, Italy, 4Changhai Hospital, Dept. of Urology, Shanghai, China, 5Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, 6Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, 7Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, 8Swedish Urology Group, Dept. of Urology, Seattle, United States of America, 9University of Florence, Dept. of Urology, Florence, Italy, 10Temple University, Dept. of Urology, Philadelphia, United States of America, 11City of Hope, Dept. of Urology, Los Angeles, United States of America, 12Yonsei University, Dept. of Urology, Seoul, South Korea, 13OLV, ORSI, Aalst, Belgium, 14University of Chieti-Pescara, Dept. of Urology, Chieti and Pescara, Italy, 15Guy's Hospital, Dept. of Urology, London, United Kingdom, 16Indiana University, Dept. of Urology, Indianapolis, United States of America, 17IVO, Dept. of Urology, Valencia, Spain, 18San Luigi Turin, Dept. of Urology, Turin, Italy, 19University of Southern California, Dept. of Urology, Los Angeles, United States of America

Aims and objectives of this presentation

338
Clinicopathologic factors that influence the occurrence of symptomatic pseudoaneurysm after partial nephrectomy and the influence of selective arterial embolization on postoperative renal function

By: Lee C.H. 1, Seo W.I. 1, Ku J.Y. 2, Chung J.I. 1, Park Y.J. 3, Ha H.K. 2, Choi S.H. 4
1Inje University Busan Paik Hospital, Dept. of Urology, Busan, South Korea, 2Pusan National University Hospital, Dept. of Urology, Busan, South Korea, 3Pusan National University Hospital, Dept. of Internal Medicine, Busan, South Korea, 4Kyungpook National University Hospital, Dept. of Urology, Daegu, South Korea

Aims and objectives of this presentation

Clinical and surgical predictors of medical and surgical postoperative complications in patients with limited life expectancy treated with partial nephrectomy for renal tumors: Insight from the RECORD2 project

By: Mari A. 1, Tellini R. 1, Gontero P. 2, Amparore D. 3, Antonelli A. 4, Barale M. 5, Bertini R. 6, Bove P. 7, Brunocilla E. 8, Capitanio U. 6, Da Pozzo L. 9, Mirono V. 10, Montanari E. 11, Pisano F. 12, Porpiglia F. 13, Schiavina R. 8, Seri S. 14, Simeone C. 4, Trombetta C. 15, Volpe A. 16, Artibani W. 17, Ficarra V. 18, Carini M. 1, Minervini A. 1
1University of Florence, Dept. of Urology, University of Florence, Careggi Hospital, Florence, Italy, Florence, Italy, 2University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, San Giovanni Battista Hospital, Turin, Italy, 3San Luigi Gonzaga Hospital, Division of Urology, San Luigi Gonzaga Hospital, School of Medicine, Orbassano, Turin, Italy, 4University of Brescia, Dept. of Urology, Spedali Civili Hospital, Brescia, Italy, 5University of Turin, Division of Urology, Dept. of Surgical Sciences, San Giovanni Battista Hospital, Turin, Italy, 6Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Unit of Urology, Division of Experimental Oncology, URI-Urological Research Institute, Milan, Italy, 7University Hospital of Tor Vergata, Dept. of Urology, Rome, Italy, 8University of Bologna, Dept. of Urology, Bologna, Italy, 9Papa Giovanni XXIII Hospital, Dept. of Urology, Bergamo, Italy, 10University Federico II of Naples, Dept. of Urology, Naples, Italy, 11University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, 12San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Dept. f Surgical Sciences, Turin, Italy, 13San Luigi Gonzaga Hospital, School of Medicine, Division of Urology, Dept. of Oncology, Orbassano, Turin, Italy, 14University of Florence, Dept. of Urology, Unit of urological minimally invasive robotic surgery and renal transplantation, Careggi Hospital, Florence, Italy, 15University of Trieste, Dept. of Urology, Trieste, Italy, 16Maggiore della Carità Hospital, Dept. of Urology, Novara, Italy, 17Azienda Ospedaliera Universitaria Integrata (A.O.U.I.), Verona, Dept. of Urology, Verona, Italy, 18University of Messina, Dept. of Human and Paediatric Pathology, Gaetano Barresi, Urologic Section, Messina, Italy

Aims and objectives of this presentation

Retrospective comparative study between robot-assisted partial nephrectomy and open partial nephrectomy for the treatment of highly complex renal tumors with
RENAL nephrometry score ≥8

By: Kim J.J., Lee D.H., Hong S.K., Byun S-S.
Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea

Aims and objectives of this presentation

341

Perioperative complications after partial nephrectomy for complex (PADUA score ≥ 10) renal tumors: A prospective multicenter observational study (the RECORD2 Project)

By: Mari A.1, Tellini R.1, Campi R.1, Amparore D.2, Antonelli A.3, Barale M.4, Bove P.5, Brunocilla E.6, Capitanio U.7, Da Pozzo L.8, Gontero P.9, Mirone V.10, Montanari E.11, Montorsi F.12, Pompiglia F.2, Schiavina R.6, Serni S.1, Simeone C.3, Trombetta C.13, Volpe A.14, Artibani W.15, Ficarra V.16, Carini M.1, Minervini A.1
1University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, 2San Luigi Gonzaga Hospital, School of Medicine, Division of Urology, Dept. of Oncology, Orbassano, Italy, 3Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, 4San Giovanni Battista University Hospital, University of Studies of Torino, Division of Urology, Dept. of Oncology, Turin, Italy, 5University Hospital of Tor Vergata, Dept. of Urology, Rome, Italy, 6University of Bologna, Dept. of Urology, Bologna, Italy, 7Vita- Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Division of Urology, Dept. of Oncology, Milan, Italy, 8Papa Giovanni XXIII Hospital, Dept. of Urology, Bergamo, Italy, 9San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Turin, Italy, 10University Federico II of Naples, Dept. of Urology, Naples, Italy, 11Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Policlinico, University of Milan, Dept. of Urology, Milan, Italy, 12Vita- Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Unit of Urology, Division of Experimental Oncology, Milan, Italy, 13University of Trieste, Dept. of Urology, Trieste, Italy, 14Maggiore della Carità Hospital, Dept. of Urology, Novara, Italy, 15Azienda Ospedaliera Universitaria Integrata (A.O.U.I.), Dept. of Urology, Verona, Italy, 16University of Messina, Dept. of Urology, Messina, Italy

Aims and objectives of this presentation

342

Perioperative morbidity of open, laparoscopic and robotic partial nephrectomy: A prospective multicenter observational study (RECORD 2)

By: Bravi C.A.1, Larcher A.1, Capitanio U.1, Montorsi F.1, Antonelli A.2, Barale M.3, Bertini R.1, Bove P.4, Brunocilla E.5, Da Pozzo L.6, Di Maida F.7, Gontero P.3, Li Marzi V.8, Longo N.9, Montanari E.10, Pompiglia F.11, Schiavina R.12, Simeone C.2, Siracusano S.13, Volpe A.14, Ficarra V.15, Carini M.11, Mari A.11, Minervini A.11
1Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Experimental Oncology, Milan, Italy, 2Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, 3Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Turin, Italy, 4University Hospital of Tor Vergata, Dept. of...
Aims and objectives of this presentation

Head to head impact of MIC vs a novel TRIFECTA score on oncologic and functional outcomes after robotic assisted partial nephrectomy: Results of a multicentric series


Aims and objectives of this presentation
Novel insights and perspectives in penile implant surgery
Poster Session 25

**Saturday 16 March**
**16:00 - 17:30**

**Location:** Green Area, Room 3

**Chairs:**
- P. Egydio, Sao Paulo (BR)
- G. Hatzichristodoulou, Würzburg (DE)
- J. Romero Otero, Madrid (ES)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

### 345

**Postoperative vacuum therapy following AMS™ LGX 700® inflatable penile prosthesis placement: Penile dimension outcomes and overall satisfaction**

By: Antonini G.¹, Busetto G.M.¹, Del Giudice F.¹, Gross M.S.², Perito P.E.³, De Berardinis E.¹

¹Sapienza Rome University Policlinico Umberto I, Dept. of Urology, Rome, Italy,
²Dartmouth-Hitchcock Medical Center, Dept. of Urology, Lebanon, United States of America,
³Coral Gables Hospital, Dept. of Urology, Coral Gables, United States of America

**Aims and objectives of this presentation**

### 346

**Adherence to the AUA penile prosthesis antibiotic prophylaxis guidelines in diabetic patients is associated with significantly higher risks of device infection**

By: Towe M., Osman M., Huynh L., El-Khatib F.M., Diabetes and Infection Prosthesis Group D., Yafi F., DIPS (Diabetes and Infection Prosthesis Study)

University of California, Irvine, Dept. of Urology, Orange, United States of America

**Aims and objectives of this presentation**

### 347

**Which patient may benefit the most from penile prosthesis implantation?**

By: Deho F.¹, Capogrosso P.², Bettocchi C.³, Colombo F.⁴, Liguori G.⁴, Fiordelise S.³, Vitarelli A.³, Silvani M.³, Mondaini N.⁴, Paradiso M.⁴, Ceruti C.³, Utizi L.⁴,
Varvello F.⁴, Palumbo F.⁴, Avolio A.³, Antonini G.⁴, Pozza D.⁴, Franco G.³, Bitelli M.³, Conti E.⁴, Caraceni E.⁴, Pescatori E.⁴, Palmieri A.⁴

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy,
²IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy,
³Societa' Italiana di Andrologia SIA, Dept. of Urology Andrology, Rome, Italy,
⁴Societa' Italiana di Andrologia SIA, Dept. of Urology Andrology, Rome, Italy
Aims and objectives of this presentation
347

Outcomes of 764 inflatable penile prostheses in 547 female-to-male transsexuals undergoing phalloplasty

By: Christopher A.N., Garaffa G., Ralph D.J
University College London Hospital, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation
348

Larger malleable rod diameter is associated with more complications and less patient satisfaction

By: Habous M.E., Teloken P., Abdelwahab O., Tealab A., Kamil U., Mulhall J., Betocchi C., Ralph D.
1 Elaj Medical Centers, Dept. of Urology, Jedda, Saudi Arabia, 2 Gold Cost University Hospital, Dept. of Urology, Queensland, Australia, 3 MSKCC, Dept. of Sexual Medicine and Infertility, New York, United States of America, 4 Bari university, Dept. of Urology, Bari, Italy, 5 UCLH, Dept. of Andrology, London, United Kingdom

Aims and objectives of this presentation
349

Comparison of long term results and couples' satisfaction with penile implant types and brands: Lessons learned from 883 patients with erectile dysfunction who underwent penile prosthesis implantation

By: Çayan S., Aşcı R., Efesoy O., Bolat M.S., Akbay E., Yaman Ö.
1 University of Mersin, School of Medicine, Dept. of Urology, Mersin, Turkey, 2 Ondokuz Mayis University, School of Medicine, Dept. of Urology, Samsun, Turkey, 3 Ankara University, School of Medicine, Dept. of Urology, Ankara, Turkey

Aims and objectives of this presentation
350

Predictors of 30-day revisit and associated costs following penile prosthesis surgery

By: Friedlander D.F., Pucheril D.T., Berger A.J., Trinh Q-D.
Brigham and Women’s Hospital, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America

Aims and objectives of this presentation
351

Immediate preoperative blood glucose and Hemoglobin A1c levels are not predictive of post-operative infections in diabetic men undergoing penile prosthesis implantation

By: Ralph D., Garaffa G., Christopher A.N.
University College London Hospital, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation
352
Aims and objectives of this presentation

352

**An overview on pain management and patients’ recovery after inflatable penile prosthesis implantation: Preliminary results from a single-center prospective cohort study**

By: Ceruti C.¹, Falcone M.², Timpano M.¹, Sedigh O.¹, Bertolino L.¹, Preto M.¹, Gontero P.¹

¹University of Turin, Città della Salute e della Scienza, Dept. of Urology, Turin, Italy, ²University of Turin

Aims and objectives of this presentation

353

**Fasting blood sugar at the time of penile prosthesis surgery is not correlated with the outcome of surgery**

By: Habous M.E.¹, Teloken P.², Binsaleh S.³, Mulhall J.⁴, Abdelwahab O.⁵, Ralph D.⁶

¹Elaj medical center, Dept. of Urology, Jedda, Saudi Arabia, ²Gold Cost University Hospital, Dept. of Urology, Queensland, Australia, ³King Saud University, Dept. of Urology, Riyadh, Saudi Arabia, ⁴MSKCC, Dept. of Sexual Medicine and Infertility, New York, United States of America, ⁵Benha university, Dept. of Urology, Benha, Egypt, ⁶St. Peter Institute of Andrology, UCLH, Dept. of Andrology, London, United Kingdom

Aims and objectives of this presentation

354

**20-Year follow-up after penile prosthesis implantation – functional and quality of life outcomes**

By: Chierigo F.¹, Capogrosso P.¹, Dehò F.¹, Ventimiglia E.¹, Cazzaniga W.¹, Boeri L.², Pozzi E.³, Schifano N.¹, Zuabi R.³, Miron V.⁴, Montorsi F.¹, Salonia A.¹

¹IRCCS Ospedale San Raffaele, Unit of Urology; URI, Milan, Italy, ²IRCCS Fondazione Ca’ Granda – Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, ³Università Vita-Salute San Raffaele, Unit of Urology; URI, Milan, Italy, ⁴Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples “Federico II”, Naples, Italy, Dept. of Urology, Naples, Italy

Aims and objectives of this presentation

355
Neurogenic bladder is an independent risk factor for complications associated with inflatable penile prosthesis placement

By: Dave C., Khalaf A., Trock B., Burnett A.
Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America

Aims and objectives of this presentation

The use of implantable penile prosthesis data from the hospital episode statistics database 2014-2017 to inform future National Health Service commissioning in England

By: Bates A.¹, Terry T.²
¹NHS Highland, Dept. of Urology, Inverness, United Kingdom, ²Nottingham City Hospital, Dept. of Urology, Nottingham, United Kingdom

Aims and objectives of this presentation

State-of-the-art lecture How can we optimise the penile implant surgery?
P. Egydio, Sao Paulo (BR)
Genomic biomarkers for diagnosis and prognosis of prostate cancer

Poster Session 26

Saturday 16 March
16:00 - 17:30

Location: Green Area, Room 4

Chairs: R. Flanigan, Maywood (US)
        G. Jenster, Rotterdam (NL)
        K.A. Tasken, Oslo (NO)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

358

Molecular phenotypes in DNA repair deficiency correlate with specific clinical outcomes subtypes and genetic background

By: Cussenot O.¹, Perrot E.², Brureau L.², Blanchet P.², Diedhiou A.³, Comperat E.¹, Iliev D.⁴, Pruss D.⁴, Timms K.M.⁴, Cancel-Tassin G.⁵

¹Sorbonne Universite, GRC n°5, ONCOTYPE-URO, AP-HP, Tenon Hospital, Paris, France, ²CHU Pointe-a-Pitre/Abymes, Dept. of Urology, Pointe a Pitre, Guadeloupe, ³CHU Pointe-a-Pitre/Abymes, Dept. of Pathology, Pointe a Pitre, Guadeloupe, ⁴Myriad Genetics Inc, Salt Lake City, United States of America, ⁵CeRePP, Paris, France

Aims and objectives of this presentation
358

359

Mitochondrial dysfunction correlates directly with progression and poor long-term prognosis in prostate cancer

By: Sachdeva A.¹, Hart C.A.², Carey C.³, Lawless C.¹, Brown M.D.², Greaves L.¹, Heer R.⁴, Turnbull D.M.¹, Clarke N.W.²

¹Newcastle University, Wellcome Centre for Mitochondrial Research, Newcastle-upon-Tyne, United Kingdom, ²University of Manchester, Genito-Urinary Cancer Research Group, Manchester, United Kingdom, ³Newcastle University, Dept. of Molecular Pathology Node, Newcastle-upon-Tyne, United Kingdom, ⁴Newcastle University, Northern Institute for Cancer Research, Newcastle-upon-Tyne, United Kingdom

Aims and objectives of this presentation
359

360

INSM1 expression discriminates neuroendocrine differentiation from Paneth cell-like change in prostate cancer and predicts castration-resistance progression

By: Xin Z, Zhu Y, Pan J, Dong B, Xue W.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation
360
Aims and objectives of this presentation

361

5hmC levels predict biochemical failure following radical prostatectomy in prostate cancer patients with ERG negative tumors

By: Kristensen G.¹, Strand S.H.², Røder M.A.¹, Berg K.D.¹, Toft B.G.³, Høyer S.⁴, Borre M.⁵, Sørensen K.D.², Brasso K.¹
¹Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen, Denmark, ²Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, ³Copenhagen University Hospital, Rigshospitalet, Dept. of Pathology, Copenhagen, Denmark, ⁴Aarhus University Hospital, Dept. of Pathology, Aarhus, Denmark, ⁵Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark

Aims and objectives of this presentation

361

Genomic profiling of patients with metastatic castration-resistant prostate cancer (mCRPC) for the evaluation of rucaparib: Next-generation sequencing (NGS) of tumour tissue and cell-free DNA (cfDNA)

¹Instituto Catalan de Oncologia, Dept. of Medical Oncology, Barcelona, Spain, ²Memorial Sloan Kettering Cancer Center, Dept. of Genitourinary Oncology, New York, United States of America, ³Adelaide and Meath Hospital (Incorporating the National Children's Hospital), Dept. of Genito-Urinary Oncology, Dublin, Ireland, ⁴Cabrini Hospital, Dept. of Medical Oncology, Malvern, Australia, ⁵Mount Vernon Cancer Centre, Dept. of Clinical Oncology, Northwood, United Kingdom, ⁶The Ottawa Hospital Cancer Centre, Dept. of Medical Oncology, Ottawa, Canada, ⁷Vejle Sygehus, Dept. of Oncology, Vejle, Denmark, ⁸Royal Hobart Hospital, Dept. of Medical Oncology, Hobart, Australia, ⁹University of Maryland Greenebaum Cancer Center, Dept. of Medicine, Baltimore, United States of America, ¹⁰Urology Associates Clinical Research, Dept. of Oncology, Nashville, United States of America, ¹¹University Hospital Geelong (Barwon Health), Dept. of Medical Oncology, Geelong, Australia, ¹²Rocky Mountain Cancer Centers – USOR, Dept. of Medical Oncology, Hematology, Aurora, United States of America, ¹³Centre Eugène Marquis, Dept. of Medical Oncology, Rennes, France, ¹⁴Royal Marsden Hospital, Dept. of Medical Oncology, London, United Kingdom, ¹⁵Clinique Victor Hugo Centre Jean Bernard, Dept. of Medical Oncology, Le Mans, France, ¹⁶Centre Hospitalier Universitaire Dr-Georges-L.-Dumont, Dept. of Medical Oncology, Moncton, Canada, ¹⁷Centre d’Oncologie de Gentilly, Dept. of Medical Oncology, Nancy, France, ¹⁸Premier Medical Group of the Hudson Valley, Dept. of Urology, Poughkeepsie, United States of America, ¹⁹Frimley Health NHS Foundation Trust, Dept. of Medical Oncology, Slough, United Kingdom, ²⁰Clovis Oncology, Inc., Dept. of Translational Medicine, Boulder, United States of America, ²¹Clovis Oncology, Inc., Clinical Development, Boulder, United States of America,
22Clovis Oncology, Inc., Clinical Science, Boulder, United States of America, 23University of Minnesota, Dept. of Medicine, Minneapolis, United States of America, 24Guy’s Hospital and Sarah Cannon Research Institute, Dept. of Medical Oncology, London, United Kingdom

Aims and objectives of this presentation

362

Ductal adenocarcinoma of the prostate: Exploring its genetic landscape

By: Chow K.1, Wong L-M.2, Bedo J.3, Papenfuss A.T.3, Peters J.S.4, Costello A.J.4, Hovens C.M.1, Corcoran N.M.1
1University of Melbourne, Dept. of Surgery, Melbourne, Australia, 2St Vincent's Hospital, Dept. of Urology, Melbourne, Australia, 3Walter and Eliza Hall Institute of Medical Research, Bioinformatics Division, Melbourne, Australia, 4Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia

Aims and objectives of this presentation

363

Tumor-metastasis crosstalk in prostate cancer: Examining the effects of cytoreductive primary tumor removal in an orthotopic xenograft model

By: Linxweiler J.1, Hajili T.1, Körbel C.2, Zeuschner P.1, Menger M.D.2, Stöckle M.1, Junker K.1, Saar M.1
1Saarland University, Dept. of Urology, Homburg Saar, Germany, 2Saarland University, Institute for Clinical-Experimental Surgery, Homburg Saar, Germany

Aims and objectives of this presentation

364

The cluster of differentiation 44 variant 8-10 messenger RNA contained in exosomes is a potential marker for docetaxel resistance among prostate cancer patients

By: Kato T.1, Mizutani K.1, Horie K.1, Kawakami K.2, Fujita Y.2, Ito M.2, Koie T.1
1Gifu University Graduate School of Medicine, Dept. of Urology, Gifu, Japan, 2Tokyo Metropolitan Institute of Gerontology, Research Team for Mechanism of Aging, Tokyo, Japan

Aims and objectives of this presentation

365

Natural killer cell activity: An innovative biomarker predicting prostate cancer severity

By: Kuo M-C.1, Huang C-Y.1, Kung H-N.2, Lu Y-C.1
1National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan, 2National Taiwan University, Dept. of Anatomy and Cell Biology, Taipei City, Taiwan
<table>
<thead>
<tr>
<th>Page</th>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>366</td>
<td>Capturing circulating tumor cells from a large blood volume: A pilot study using diagnostic leukapheresis</td>
</tr>
</tbody>
</table>

| 367  | Circulating tumor DNA targeted sequencing predicts the prognosis of mCRPC patients |
| By: Dong B., Fan L., Yang B., Wu K., Zhang F., Chen W., Huihua C., Pan J., Zhu Y., Luo C., Yang Y., Zhao G., Wang C., Li L., Yao X., Wei X. Renji hospital, Dept. of Urology, Shanghai, China, Shanghai Tenth People's Hospital affiliated to Tongji University, Dept. of Urology, Shanghai, China, The First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China, Beijing Friendship Hospital affiliated to Capital Medical University, Dept. of Urology, Shanghai, China, The First Affiliated Hospital of Wenzhou Medical University, Dept. of Urology, Wenzhou, China, Fuzhou General Hospital, Dept. of Oncology, Fuzhou, China, Shanghai Rendong Clinical Laboratory, Clinical Laboratory, Shanghai, China, The First Affiliated hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China |

| 368  | Tissue specific NKX3.1 positive circulating tumor cells isolated by ISET in prostatic cancer patients |
| By: Monterisi S., Colombo P., Duga S., Saita A., Elefante M.G., Casale P., Buffi N.M., Hurle R., Lunghezzani G., Guazzoni G., Veronesi G., Lazzeri M. Humanitas Clinical and Research Center, Lab. Medical Genetics and RNA Biology, Rozzano, Italy, Humanitas Clinical and Research Center, Dept. of Pathology, Rozzano, Italy, Humanitas Clinical and Research Center, Dept. of Biomedical Sciences, Rozzano, Italy, Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, Humanitas Clinical and Research Center, Division of Thoracic and General Surgery, Rozzano, Italy |

| 369  | A modified bioinformatics approach of detecting low-frequency mutations in cell-free DNA to achieve precision medicine for advanced prostate cancer |
| By: Mizuno K., Fujimoto A., Sumiyoshi T., Goto T., Kobayashi T., Yamasaki T., Inoue T., Ogawa O., Akamatsu S., Nakagawa H. |

*Scientific Programme - EAU19 Barcelona*
Aims and objectives of this presentation

370

MiR Scientific Sentinel Scores - a new platform technology for identification of clinically significant prostate cancer using miRNA and snoRNA expression signatures

By: Klotz L.H.\(^1\), Tenniswood M.\(^2\), Tilki D.\(^3\), Dirienzo A.\(^2\), Wang W-L.\(^2\)
\(^1\)Sunnybrook Health Sciences Centre, Dept. of Surgery (urology), Toronto, Canada, \(^2\)miR Scientific LLC, Research and Development, New York, United States of America, \(^3\)Martini Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

Aims and objectives of this presentation

371

Comparative proteome analysis identified NAMPT as a potential serum marker for the prediction of docetaxel-resistance in prostate cancer

By: Keresztes D.\(^1\), Módos O.\(^1\), Szűcs M.\(^1\), Hüttl A.\(^1\), Csizmarik A.\(^1\), Nagy N.\(^1\), Kretz V.\(^1\), Bracht T.\(^2\), Sitek B.\(^2\), Witzke K.\(^2\), Puhr M.\(^3\), Sevcenko S.\(^4\), Kramer G.\(^5\), Shariat S.\(^5\), Nyirády P.\(^1\), Szarvas T.\(^1\)
\(^1\)Semmelweis University, Dept. of Urology, Budapest, Hungary, \(^2\)Ruhr University Bochum, Medizinisches Proteom-Center, Bochum, Germany, \(^3\)Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, \(^4\)Donauspital, Dept. of Urology, Vienna, Austria, \(^5\)Medical University of Vienna, Dept. of Urology, Vienna, Austria

Aims and objectives of this presentation

372

17:23 - 17:23 Conclusion
Stones: Is it all about lasers?

Poster Session 27

Saturday 16 March
16:00 - 17:30

Location: Green Area, Room 5
Chairs: D. Abt, St. Gallen (CH)  
K. Ghani, Ann Arbor (US)  
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

373

The impact of millimetric residual stones after endourological procedures for treatment of kidney calculi: A retrospective analysis

By: De Sousa Morais N.A.¹, Ribeiro C.², Mota P.², Torres J.¹, Anacleto S.¹, Rodrigues R.¹, Carvalho-Dias E.², Oliveira C.¹, Alves M.¹, Lima E.¹

¹Hospital de Braga, Dept. of Urology, Braga, Portugal, ²University of Minho, School of Medicine, Braga, Portugal

Aims and objectives of this presentation

374

What is the exact definition of stone dust? An in vitro evaluation

By: Keller E.X.¹, De Coninck V.², Doizi S.³, Daudon M.⁴, Traxer O.³

¹University Hospital Zurich, University of Zurich, Dept. of Urology, Zurich, Switzerland, ²AZ Klina, Dept. of Urology, Brasschaat, Belgium, ³Sorbonne Université, Hôpital Tenon, Dept. of Urology, Paris, France, ⁴Sorbonne Université, Hôpital Tenon, CRISTAL Laboratory, Paris, France

Aims and objectives of this presentation

375

High frequency for dusting during holmium laser lithotripsy: Does it matter?

By: Black K.M.¹, Aldoukhi A.¹, Hall T.², Roberts W.¹, Ghani K.¹

¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Engineering, Ann Arbor, United States of America

Aims and objectives of this presentation

376

Impact of variable pulse width and pulse modulation on dusting effect for holmium laser lithotripsy: In vitro evaluation with calcium oxalate monohydrate stones

By: Black K.M.¹, Aldoukhi A.H., Roberts W.W., Ghani K.R.
Aims and objectives of this presentation

376

Prospective randomized study of fixed laser settings vs variable laser settings for a better stone free rate

By: Vaddi C.M. 1, Siddalingaswamy P. 1, Ramakrishna P. 1, Manoj Kumar Y. 1, Gopi P. 1, Roopa P. 1, Agarwal M. 2, Panda A. 3
1Preeti Urology and Kidney Hospital, Dept. of Urology, Hyderabad, India, 2Ramesh Hospital, Dept. of Urology, Guntur, India, 3KIMS Hospital, Dept. of Urology, Hyderabad, India

Aims and objectives of this presentation

377

Ho:YAG laser lithotripsy in non-contact mode: Optimization of fiber to stone working distance to improve ablation efficiency

By: De Coninck V.M.J. 1, Keller E. 2, Chiron P. 2, Dragos L. 3, Doizi S. 4, Berthe L. 5, Traxer O. 2
1AZ Klina, Dept. of Urology, Brasschaat, Belgium, 2Tenon Hospital, Assistance-Publique Hôpitaux de Paris. Pierre et Marie Curie University, Dept. of Urology, Paris, France, 3University of Medicine and Pharmacy “Victor Babes” Timișoara, Dept. of Urology, Timisoara, Romania, 4Tenon Hospital, Assistance-Publique Hôpitaux de Paris. Pierre et Marie Curie University, Dept. of Urology, Paris, France, 5Laboratoire PIMM, Dept. of Engineering, Paris, France

Aims and objectives of this presentation

378

High power laser machines – a game changer in the field of endourology? The impact of stone density on laser time using Lumenis laser p120 compared to standard 20w laser

By: Mekayten M. 1, Lorber A. 1, Katafigiotis I. 1, Leotsakos I. 1, Sfouggaristos S. 1, Heifetz E.M. 2, Abu Sbeih B. 1, Yutkin V. 1, Latke A. 1, Gofrit O.N. 1, Duvdevani M.D. 1
1Hadassah Hebrew University Medical Center, Dept. of Urology, Jerusalem, Israel, 2Jerusalem College of Technology, Dept. of Health Informatics, Jerusalem, Israel

Aims and objectives of this presentation

379

“VaporTunnel” ureteroscopic holmium laser lithotripsy: Intraoperativa and early postoperative outcomes

By: Bozzini G. 1, Roche J.B. 2, Romero Otero J. 3, Besana U. 1, Salvatore G. 4, Buizza C. 1
1
Aims and objectives of this presentation

380

Does the working channel position have a role on the efficacy of Ho:YAG laser lithotripsy? Results from a laboratory test

By: Villa L.¹, Ventimiglia E.¹, Doizi S.², Salonia A.³, Montorsi F.³, Traxer O.²
¹IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology; URI, Milan, Italy, ²Hôpital Tenon, Sorbonne Université, GRC n°20 Lithiase Renale, AP-HP, Paris, France, ³IRCCS Ospedale San Raffaele, Division of Experimental Oncology/Unit of Urology; URI, Milan, Italy

Aims and objectives of this presentation

381

Does the change of the environmental fluid modify the Holmium laser effect on kidney tissue?

By: Dragoş L.B.¹, Somani B.K.², Comperat E.M.³, Keller E.X.⁴, De Coninck V.M.J.⁴, Doizi S.⁵, Wiseman O.J.¹, Cumpanas A.A.⁶, Daminescu L.C.⁶, Martis S.M.⁶, Buttice S.⁷, Traxer O.⁵
¹Cambridge University Hospital NHS Foundation Trust, Addenbrooke’s Hospital, Dept. of Urology, Cambridge, United Kingdom, ²University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ³Tenon Hospital, Sorbonne University, Dept. of Pathology, Paris, France, ⁴Tenon Hospital, Dept. of Urology, Paris, France, ⁵Tenon Hospital, Sorbonne University, Dept. of Urology, Paris, France, ⁶Clinical Emergency County Hospital Timisoara, Dept. of Urology, Timisoara, Romania, ⁷Giovanni di Dio Hospital, Dept. of Urology, Agrigento, Italy

Aims and objectives of this presentation

382

Prospective clinical study on superpulse thulium fiber laser: Initial analysis of optimal laser settings

Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

Aims and objectives of this presentation

383

Thermal effects of Ho: YAG laser lithotripsy – real-time evaluation in an ex vivo porcine kidney model

By: Mario De Biasio, Alessandro Ferretti, Marco Iafisco, Gabriele Rassenti, Luigi Picca, Enrico Traverso, Giovanni D’Amico, Giuseppe Quarti, Silvano De Santis, Maurizio N. Carini, Massimo Dell’Aquila, Ennio M. Montorsi, Francesc Fuster, David Traxer, Olivier Traxer, Ettore Vezzetti
IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology; URI, Milan, Italy, Hôpital Tenon, Sorbonne Université, GRC n°20 Lithiase Renale, AP-HP, Paris, France, IRCCS Ospedale San Raffaele, Division of Experimental Oncology/Unit of Urology; URI, Milan, Italy

Aims and objectives of this presentation

385
Aims and objectives of this presentation

385

Super-pulse thulium fiber versus high power holmium lasers. What about temperature?

By: Dragoș L.B.¹, Somani B.², Keller E.³, De Coninck V.³, Doizi S.³, Wiseman O.¹, Sener E.⁴, Martis S.⁵, Cumpanas A.⁵, Botoca M.⁵, Minciu R.⁵, Traxer O.⁶
¹Cambridge University Hospital NHS Foundation Trust, Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, ²University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ³Tenon Hospital, Dept. of Urology, Paris, France, ⁴Marmara University, Dept. of Urology, Istanbul, Turkey, ⁵Clinical Emergency County Hospital Timisoara, Dept. of Urology, Timisoara, Romania, ⁶Tenon Hospital, Sorbonne University, Dept. of Urology, Paris, France

Aims and objectives of this presentation

386

Comparison of three different energy modalities in the treatment of large bladder calculi over 3cm

By: Choi J.Y., Ko Y.H., Song P.H., Moon K.H., Jung H.C.
Yeungnam University Medical Center, Dept. of Urology, Daegu, South Korea

Aims and objectives of this presentation

387
Innovative solutions in urological surgery

Video Session 06

Saturday 16 March
16:00 - 17:30

Location: Green Area, Room 10

Chairs: Y. Ahallal, Meknes (MA)
A. Carbone, Latina (IT)
To be confirmed

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V38

Office-based, ultrasound-guided renal mass biopsy: Technique and results

By: Jefferson F., Okhunov Z., Sung J., Cottone C., Patel R., Landman J.
University of California, Irvine, Dept. of Urology, Orange, United States of America

Aims and objectives of this presentation
V38

V39

Feasibility of virtual partial nephrectomy imaging for T1b and complex T1a tumors

By: Izumi K. 1, Kawanishi Y. 1, Yamanak M. 2, Kawanishi S. 2, Fukawa T. 3, Kanayama H. 3
1 Takamatsu Red Cross Hospital, Dept. of Urology, Takamatsu, Japan, 2 Goshikidai, Clinic, Takamatsu, Japan, 3 Tokushima University, Dept. of Urology, Tokushima, Japan

Aims and objectives of this presentation
V39

V40

Needle in a haystack: Prevention and management of needle loss during robotic surgery

Medanta, The Medcity, Dept. of Urology and Robotic Surgery, Gurugram, India

Aims and objectives of this presentation
V40

V41

Communication in robotic-assisted procedures: The unvoiced stress between bedside and console surgeon

By: Zecha H. 1, Beyer B. 2, Martinschek A. 3
1 Albertinen Krankenhaus, Dept. of Urology and Urooncology, Hamburg, Germany, 2 Martini Klinik, Dept. of Urology and Urooncology, Hamburg, Germany, 3 Bundeswehrkrankenhaus Ulm, Dept. of Urology and Urooncology, Ulm, Germany
Aims and objectives of this presentation

V42

New technologies for old procedures: When Firefly improves robotic bladder diverticulectomy

By: Vedovo F.\(^1\), De Concilio B.\(^2\), Zeccolini G.\(^2\), Celia A.\(^2\)
\(^1\)Azienda Sanitaria Universitaria Integrata di Trieste, Dept. of Urology, Trieste, Italy, \(^2\)San Bassiano Hospital, ULSS 7 Pedemontana, Dept. of Urology, Bassano del Grappa, Italy

V43

Robot-assisted embryological remnant resection in a 1 year old boy with a difference of sexual development

By: Waterschoot M.\(^1\), De Groote R.\(^1\), De Bleser E.\(^1\), Cools M.\(^2\), Van Laecke E.\(^1\), Hoebeke P.\(^1\), Spinoit A-F.\(^1\)
\(^1\)Ghent University Hospital, Dept. of Pediatric Urology, Ghent, Belgium, \(^2\)Ghent University Hospital, Dept. of Pediatric Endocrinology, Ghent, Belgium

V44

Robot-assisted kidney transplantation from deceased donors: Step-by-step technique

By: Vignolini G.\(^1\), Campi R.\(^1\), Sessa F.\(^1\), Greco I.\(^1\), Larti A.\(^2\), Giancane S.\(^1\), Sebastianelli A.\(^1\), Gacci M.\(^1\), Peris A.\(^3\), Li Marzi V.\(^1\), Breda A.\(^4\), Siena G.\(^1\), Serni S.\(^1\)
\(^1\)University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, \(^2\)University of Florence, Careggi Hospital, Dept. of Nephrology, Florence, Italy, \(^3\)University of Florence, Careggi Hospital, Intensive Care Unit and Regional ECMO Referral Centre, Florence, Italy, \(^4\)Fundación Puigvert, University Autonoma of Barcelona, Dept. of Urology, Barcelona, Spain

V45

Robot-assisted laparoscopic retroperitoneal lymph node dissection with concomitant IVC thrombectomy for metastatic mixed testicular germ cell cancer

By: Zhu G., Zhang K., Portillo F.J.M., Li H.
Beijing United Family Hospital, Dept. of Urology, Beijing, China
Reconstruction of the urethra and external genitalia
Poster Session 28

Saturday 16 March 16:00 - 17:30
Location: Green Area, Room 11
Chairs: H. Abol-Enein, Mansoura (EG)
J.L.H.R. Bosch, Utrecht (NL)
D. Eberli, Zürich (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

Total phallic reconstruction in the genetic male: A single centre analysis

By: Ralph D.J. ¹, Falcone M. ², Anfosso M. ², Gontero P. ², Christopher A.N. ¹, Chiriacò G. ³, Ralph O. ¹
¹St Peter's Andrology Centre and UCLH, Dept. of Urology, London, United Kingdom,
²University of Turin, Dept. of Urology - Città della Salute e della Scienza, Turin, Italy,
³Azienda Ospedaliero Universitaria di Trieste, Dept. of Urology, Triest, Italy

Aims and objectives of this presentation

Patient reported outcomes from a 6 year prospective study on satisfaction following penile curvature surgery

By: Akiboye R.D., Patel P., Campbell A.A.E., Watkin N.
Epsom & St Helier University Hospitals NHS Trust, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation

Development and content validation of the Urethroplasty Training and Assessment Tools (UTAT)

By: Jasionowska S. ¹, Shabbir M. ², Brunckhorst O. ², Khan M. ², Manzoor H. ³, Dasgupta P. ², Anderson P. ⁴, Barbagli G. ⁵, Ahmed K. ²
¹Kings College London, Dept. of Urology, London, United Kingdom, ²Kings College Hospital, Dept. of Urology, London, United Kingdom, ³Sindh Institute of Urology and Transplantation, Dept. of Urology, Karachi, Pakistan, ⁴Russells Hall Hospital, Dept. of Urology, Dudley, United Kingdom, ⁵Centro Chirurgico Toscano, Dept. of Urology, Arezzo, Italy
Aims and objectives of this presentation
390

The effect of annual hospital volume on perioperative outcomes after urethroplasty

By: Bandini M. 1, Djinovic R. 2, Montorsi F. 1, Sekulovic S. 2, Spiridonescu B. 3, Dangi A.D. 4, Krishnappa P. 5, Stanojevic N. 2, Pesic V. 2, Slavkovic M. 2, Sansalone S. 6, Salonia A. 1, Briganti A. 1, Karakiewicz P. 7
1Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, 2Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, 3Fundeni Clinical Institute, Center for Uronephrology and Renal Transplant, Bucharest, Romania, 4Christian Medical College and Hospital, Dept. of Urology, Vellore, India, 5NU Hospitals, Dept. of Urology, Bangalore, India, 6University of Tor Vergata, Dept. of Experimental Medicine and Surgery, Rome, Italy, 7Centre Hospitalier de l’Université de Montréal (CHUM), Centre de recherche (CR), Montréal, Canada

Aims and objectives of this presentation
391

Bacterial prostatitis is a significant finding in patients with symptomatic urethral stricture disease

By: Toomey D. 1, Harrison J. 2, Adimonye A. 2, Bendig J. 3, Patel P. 3, Watkin N. 1
1St. George's University NHS Trust, Dept. of Urology, London, United Kingdom, 2St. George's University NHS Trust, Dept. of Urology, London, United Kingdom, 3Epsom and St Helier University Hospitals NHS Trust, Dept. of Urology, Surrey, United Kingdom

Aims and objectives of this presentation
392

Incidence and patterns of catheter associated UTIs (CAUTIs) post urethroplasty

By: Lee H.J. 1, Watkin N.A. 1, Sharma D. 1, Patel P. 2, Bendig J. 2
1St. George's Hospital, Dept. of Urology, London, United Kingdom, 2Epsom and St Helier Hospital, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation
393

Stricture etiology, characteristics, recurrence, and patient-reported outcomes after penile one-stage dorsal inlay buccal mucosal graft urethroplasty according to Asopa

By: Zumstein V. 1, Dahlem R. 1, Rosenbaum C. 1, Maurer V. 1, Kluth L. 2, Fisch M. 1, Vetterlein M.W. 1
1University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2University Medical Center Frankfurt, Dept. of Urology, Frankfurt (Main), Germany

Aims and objectives of this presentation
394
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>394</td>
</tr>
<tr>
<td><strong>Independent risk factors for failure after anterior urethroplasty: A prospective, multivariate analysis</strong></td>
</tr>
<tr>
<td>By: Verla W., Waterloos M., Spinoit A-F., Oosterlinck W., Lumen N. Ghent University Hospital, Dept. of Urology, Ghent, Belgium</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>395</td>
</tr>
<tr>
<td><strong>Seven-year analysis of an on-line national audit of male reconstructive urethral surgery (2): Contemporary surgical management of urethral disease in the United Kingdom</strong></td>
</tr>
<tr>
<td>By: Mundy A., Payne R., Fowler S. 1University College London NHS Foundation Trust, Trust Headquarters, London, United Kingdom, 2British Association of Urological Surgeons, Dept. of Urology, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>396</td>
</tr>
<tr>
<td><strong>The reasonable procedure for pelvic fracture urethral distraction defects: Transperineal end-to-end anastomosis</strong></td>
</tr>
<tr>
<td>By: Sa S., Chongrui J., Yuemin X., Sanbao J., Qiang F. Shanghai JiaoTong University Affiliated Sixth People’s Hospital, Dept. of Urology, Shanghai, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>397</td>
</tr>
<tr>
<td><strong>Augmented anastomotic urethroplasty for ultra-short pendulous urethral stricture: Short-term outcome</strong></td>
</tr>
<tr>
<td>By: Reyad A.M., Elkassaby A. 1Sohag University Hospital, Dept. of Urology, Sohag, Egypt, 2Ain Shams University Hospital, Dept. of Urology, Cairo, Egypt</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>398</td>
</tr>
<tr>
<td><strong>Surgical treatment for recurrent bulbar urethral stricture: A randomised open label superiority trial of open urethroplasty versus endoscopic urethrotomy (The OPEN Trial)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>399</td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

Comparative analysis of successful outcome after substitution urethroplasty with “Buccal Mucosa Graft versus Inner Preputial Skin Graft” for anterior urethral stricture disease

By: Parmar K., Tyagi S., Singh S.K., Kumar S., Mete U., Mohan R., Dewana S., Bora G., Sharma A.
PGIMER, Dept. of Urology, Chandigarh, India

Aims and objectives of this presentation

Does the presence of leak on the peri-catheter urethrogram affect the short term outcomes of urethroplasty?

By: Mangir N., Osman N., Inman R., Chapple C.
Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom

Aims and objectives of this presentation
Infectious diseases: Upper urinary tract infections and sepsis
Poster Session 29

Saturday 16 March
16:00 - 17:30

Location: Green Area, Room 12
Chairs: R. Bartoletti, Pisa (IT)
       T.E. Bjerkland Johansen, Oslo (NO)
       T.W. Khor, Kluang (MY)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

402
Perioperative infectious risk in urology: Management of preoperative polymicrobial urine culture - a systematic review

By: Vallée M.¹, Cattoir V.², Malavaud S.³, Sotto A.⁴, Cariou G.⁵, Arnaud P.⁶, Bugel H.⁷, Coloby P.⁸, Chartier-Kastler E.⁹, Bruyère F.¹⁰
¹Nantes Hôtel Dieu University Hospital, Dept. of Urology, Nantes, France,
²Rennes University Hospital, Dept. of Microbiology, Rennes, France,
³Toulouse-Rangueil University Hospital, Dept. of Epidemiology, Toulouse, France,
⁴Nîmes University Hospital, Dept. of Infectious disease, Nîmes, France,
⁵Cabinet office, Dept. of Urology, Paris, France,
⁶Notre-Dame de la Miséricorde Hospital, Dept. of Urology, Ajaccio, France,
⁷Charles-Nicole University Hospital, Dept. of Urology, Rouen, France,
⁸René-Dubos Hospital, Dept. of Urology, Cergy Pontoise, France,
⁹Academic Hospital Pitîé-Salpêtrière, Assistance Publique-Hôpitaux, Dept. of Urology, Paris, France,
¹⁰Bretonneau University Hospital, Dept. of Urology, Tours, France

Aims and objectives of this presentation

403
The impact of acute kidney injury on cardiovascular disease and renal impairment in patients with urological sepsis

By: Fujita N.¹, Momota M.¹, Tobisawa Y.¹, Yoneyama T.¹, Yamamoto H.¹, Imai A.¹, Hatakeyama S.¹, Ito H.², Yoneyama T.¹, Hashimoto Y.¹, Yoshikawa K.³, Ohyama C.¹
¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,
²Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan,
³Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

Aims and objectives of this presentation

404
Evaluation of the impact of seric procalcitonin in the management of obstructive acute pyelonephritis
Aix-Marseille University, La Conception Academic Hospital, Dept. of Urology, APHM, Marseille, France

Aims and objectives of this presentation
404

405
Fever in patients with upper ureteral stone: How many days of antibiotic treatment are sufficient to proceed with URSL?

By: Cheng P-Y., Wu W.C, Chung S.D
Far Eastern Memorial Hospital, Dept. of Surgery, New Taipei City, Taiwan

Aims and objectives of this presentation
405

406
Can gram staining of urine from initial renal pelvis puncture during percutaneous nephrolithotomy be better than preoperative voiding urine culture for predicting urinary infection?

By: Yucetas U.¹, Karsiyakali N.¹, Karatas A.², Erkan E.¹
¹University Of Health Sciences, Istanbul Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ²University Of Health Sciences, Istanbul Training and Research Hospital, Dept. of Microbiology, Istanbul, Turkey

Aims and objectives of this presentation
406

407
Comparing pre-operative and intra-operative bacteriuria during ureteroscopy with laser lithotripsy: A prospective cohort study

By: Churchill J., Yao J., Wines M.
Royal North Shore Hospital, Dept. of Urology, St Leonards, Australia

Aims and objectives of this presentation
407

408
The significance of intraoperative renal pelvic urine and stone culture for patients at high risk of post-ureteroscopy systemic inflammatory response syndrome

By: Yoshida S., Takazawa R., Waseda Y., Tsuji T.
Tokyo Metropolitan Ohtsuka Hospital, Kidney Stone Center, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation
408

409
Clinical and microbiological characteristics in men with non-obstructive acute pyelonephritis
Aims and objectives of this presentation

409

**Urine culture vs. lithiasis culture: Which is the best?**


Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain

Aims and objectives of this presentation

410

**How many pathogens in stone patients are misidentified without an intraoperative stone culture?**


1Foundation IRCCS Ca’ Granda Ospedale Maggiore Polyclinico Department of Clinical Sciences and Community Health, University of Milan, Dept. of Urology, Milan, Italy,

2Foundation IRCCS Ca’ Granda Ospedale Maggiore Polyclinico, Dept. of Microbiology and Virology, Milan, Italy,

3Foundation IRCCS Ca’ Granda Ospedale Maggiore Polyclinico, Dept. of Microbiology and Virology, Milan, Italy

Aims and objectives of this presentation

411

**Cross-resistance and the mechanisms of cephalosporine-resistant urinary tract infection (UTI)-causative bacteria isolated in Indonesia**

By: Shigemura K., Kitagawa K., Shirakawa T., Fujisawa M.

Kobe University, Dept. of Urology, Kobe, Japan

Aims and objectives of this presentation

412

**Genetic analysis of extended spectrum beta-lactamase (ESBL)-producing Klebsiella pneumonia isolated urinary tract infection (UTI) patients in Indonesia**

By: Shigemura K., Yamasaki S., Osawa K., Fujisawa M.
Aims and objectives of this presentation

414

Impact of Lactobacillus probiotics on biofilm formed by Pseudomonas aeruginosa

By: Matsuo S., Wada K., Sadahira T., Mitsuhashi R., Yamamoto M., Ishii A., Kariyama R., Watanabe T., Nasu Y.
Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan

Aims and objectives of this presentation

414

Comparison of molecular characteristics of carbapenem-resistant urinary tract infection-causing pathogens between Japan, Taiwan and Indonesia

By: Shigemura K.1, Nishimoto K.2, Osawa K.2, Kuntaman K.3, Sung S.4, Chen K.5, Kitagawa K.1, Huang T.6, Shirakawa T.1, Fujisawa M.1
1Kobe University, Dept. of Urology, Kobe, Japan, 2Kobe University, Dept. of Health Science, Kobe, Japan, 3Airlangga University, Dept. of Microbiology, Surabaya, Indonesia, 4Taipei Medical University, The Ph.D. Program for Translational Medicine, Taipei, Taiwan, 5Taipei Medical University, Dept. of Urology, Taipei, Taiwan, 6Taipei Medical University, Dept. of Microbiology, Taipei, Taiwan

Aims and objectives of this presentation

415

Surgical hand hygiene does not influence the onset of surgical site infection in an endourological surgery

Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan

Aims and objectives of this presentation

416
Paediatric urology: Complex urological conditions
Poster Session 30

Location: Green Area, Room 19
Chairs: A. Abdel Aziz Elderwy, Assiut (EG)  
       G. Bogaert, Leuven (BE)  
       S.J. Hosseini, Tehran (IR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

417
Do EAU/ESPU guidelines recommendations fit to patients? Results of a survey on awareness of spina bifida patients
By: Dogan H.S. ¹, Stein R. ², 't Hoen L.A. ³, Bogaert G. ⁴, Nijman R.J.M. ⁵, Tekgul S. ¹, Quaedackers J. ⁶, Silay M.S. ⁷, Radmayr C. ⁸
¹Hacettepe University Faculty of Medicine, Dept. of Urology, Ankara, Turkey, ²Universitätsmedizin Mannheim, Dept. of Urology, Mannheim, Germany, ³Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ⁴University Hospitals of the KU Leuven, Dept. of Urology, Leuven, Belgium, ⁵Rijks Universiteit Groningen, Dept. of Urology, Groningen, The Netherlands, ⁶Universiteit Groningen, Dept. of Urology, Groningen, The Netherlands, ⁷Istanbul Medeniyet University, Dept. of Urology, Istanbul, Turkey, ⁸Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria

418
Clinical and urodynamic outcomes of secondary untethering in spina bifida patients
By: Bañuelos Marco B. ¹, Ciesla L. ², Schneider J. ³, Thomale U. ⁴, Lingnau A. ⁵
¹Universitätsmedizin Berlin, Dept. of Paediatric Urology, Charité, Berlin, Germany, ²Universitätsmedizin Berlin, Klinik für Pädiatrie m.S. Neurologie, Charité, Berlin, Germany, ³Universitätsmedizin Berlin, Institut für Zell- und Neurobiologie, Charité, Berlin, Germany, ⁴Universitätsmedizin Berlin, Klinik für pädiatrische Neurochirurgie, Charité, Berlin, Germany, ⁵Universitätsmedizin Berlin, Paediatric Urology Charité, Berlin, Germany

419
Repeated detrusor injection of botulinum toxin A for neurogenic bladder overactivity in children: A long term option?
To be confirmed

420
Bladder augmentations in patients with spina bifida using terminal ileum or sigmoid colon yield comparable urodynamic results
By: Moldovan D.E. ¹, Bañuelos Marco B. ², Trojan K.C. ³, Schneider J. ⁴, Lingnau A. ²
¹Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Dept. of Paediatric Urology, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Dept. of Paediatric and Neurology, Berlin, Germany
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>421</td>
<td>Urologic status and sexuality in a transitional spina bifida population: A patient-based survey</td>
<td>Bujons Tur A., Lang Motta G., Garat J.M., Palou J. Fundació Puigvert, Dept. of Urology, Barcelona, Spain</td>
</tr>
<tr>
<td>424</td>
<td>Virilized females with congenital adrenal hyperplasia and persistent urogenital sinus, early versus delayed intervention, single center experience</td>
<td>Al Otay A., El Helaly A.A., Al Ghanbar M.S., Al Harbi F., Al Hagbani F., Nakshabandi Z.M., Sarhan O.M. Prince Sultan Military Medical City, Dept. of Urology, Riyadh, Saudi Arabia, King Fahad Specialist Hospital, Dept. of Urology, Dammam, Saudi Arabia</td>
</tr>
<tr>
<td>425</td>
<td>Sigmoid vaginoplasty in patients with vaginal agenesis: Technique and outcomes</td>
<td>Bizic M., Stojanovic B., Bencic M., Korac G., Djordjevic M. School of Medicine, University of Belgrade, Dept. of Urology, Belgrade, Serbia, School of Medicine, University of Belgrade, Dept. of Anesthesiology, Belgrade, Serbia</td>
</tr>
<tr>
<td>429</td>
<td>Abdominal leak point pressure - a simple way to predict urinary incontinence following surgical treatment of unilateral ectopic ureter in girls</td>
<td>Mani A., Yadav P., Ansari M.S.</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>430</td>
<td>A new evaluation method for children with bladder bowel dysfunction: Pelvic floor muscle activity (PFMA)</td>
<td>By: Pekbay Y.¹, Topuz B.², Sarikaya S.², Irkilata Y.³, Irkilata H.C.⁴, Dayanc M.M.¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Prof. Dr. Murat Dayanc Private Pediatric Urology Clinic, Dept. of Pediatric Urology, Ankara, Turkey, ²Gulhane Research and Training Hospital, Dept. of Urology, Ankara, Turkey, ³Prof.Dr.Murat Dayanc Private Pediatric Urology Clinic, Dept. of Pediatric Urology, Ankara, Turkey, ⁴Private Davraz Yasam Hospital, Dept. of Urology, Isparta, Turkey</td>
</tr>
<tr>
<td>431</td>
<td>Fate of micropenis and constitutional small penis: Does it grow to be normal after puberty?</td>
<td>By: Han J.H.¹, Lee J.², Jun J.B.², Song S.H.², Kim K.S.²</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Asan Medical Center, Dept. of Urology, Seoul, South Korea</td>
</tr>
</tbody>
</table>
**Paediatric urology: Stone management in children**

**Poster Session 31**

**Saturday 16 March**

**16:00 - 17:30**

**Location:** Green Area, Room 20

**Chairs:**
- D. Perovic, Podgorica (ME)
- M.S. Silay, Istanbul (TR)
- A-F. Spinoit, Ghent (BE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**External validation of a nomogram for prediction of outcome of pediatric shock-wave lithotripsy**

By: Cetin S.¹, Koparal M.Y.², Bulut E.C.³, Gurocak S.⁴, Tan O.⁴

¹Viransehir State Hospital, Dept. of Urology, Sanliurfa, Turkey,
²Recep Tayyip Erdogan Training and Research Hospital, Dept. of Urology, Rize, Turkey,
³Van Training and Research Hospital, Dept. of Urology, Van, Turkey,
⁴Gazi University, Dept. of Urology, Ankara, Turkey

---

**Optimization of the parameters of extracorporeal shock-wave lithotripsy (ESWL) in pediatrics**

By: Olovets M.¹, Shevchuk A.O.¹, Yurakh A.O.¹, Stepanenko N.A.², Mazurets V.O.¹

¹Institute of Urology NAMS of Ukraine, Dept. of EndoUrology, Kiev, Ukraine,
²Institute of Urology NAMS of Ukraine, Dept. of Computer Tomography, Kiev, Ukraine

---

**Predicting ESWL success on pelvic stones by determination of Hounsfield unit on non-contrast CT is clinically irrelevant in children?**

By: Hajiyev P.¹, Akinci A.², Akpinar C.², Babayigit M.², Baklaci U.², Karaburun M.²

¹Ankara University School of Medicine, Dept. of Pediatric Urology, Ankara, Turkey,
²Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey

---

**Single centre experience of paediatric mini and ultra-mini percutaneous nephrolithotomy**

By: La Touche S.¹, Lloyd J.², Miller S.¹, Bodiwala D.¹, Ratan H.¹, Scriven S.¹

¹Nottingham City Hospital, Dept. of Urology, Nottingham, United Kingdom,
²Nottingham City Hospital, Dept. of Radiology, Nottingham, United Kingdom

---

**Modified tubeless minimally invasive percutaneous nephrolithotomy for management of renal stones in children**
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>438</td>
<td>Results of mini-PNL: Converting from prone to supine approach in a stone referral center</td>
<td>By: Mani A., Yadav P., Sureka S., Ansari M.</td>
<td>Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dept. of Urology and Renal Transplantation, Lucknow, India</td>
</tr>
<tr>
<td>439</td>
<td>Closed-circuit vacuum-assisted miniperc system for kidney stones in children: Our initial experience</td>
<td>By: Sampognia G., Zanetti S.P., Berrettini A., Gnech M., Manzoni G., Montanari E.</td>
<td>Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Dept. of Pediatric Urology, Milan, Italy</td>
</tr>
<tr>
<td>440</td>
<td>Comparing micro-percutaneous nephrolithotomy and flexible ureteroscopic lithotripsy in treating 1-2 cm solitary renal stones in infants</td>
<td>By: Wenying W., Li J.</td>
<td>Beijing Friendship Hospital, Capital Medical University, Dept. of Urology, Beijing, China</td>
</tr>
<tr>
<td>441</td>
<td>Retrograde intrarenal surgery in cystinuric child patients</td>
<td>By: Llorens De Knecht E., Bujons A., Badenes Gallardo A., Palou J.</td>
<td>Fundacio Puigvert, Dept. of Pediatric Urology, Barcelona, Spain</td>
</tr>
<tr>
<td>442</td>
<td>Outcomes of ureteroscopy (URS) for stone disease in the paediatric population: Results of over 100 URS procedures from a UK tertiary centre</td>
<td>By: Jones P., Rob S., Griffin S., Somani B.</td>
<td>University Hospital Southampton NHS Foundation trust, Dept. of Urology, Southampton, United Kingdom, University Hospital Southampton NHS Foundation trust, Dept. of Urology, Southampton, United Kingdom</td>
</tr>
</tbody>
</table>
Treatment of bladder stones in children: A systematic review on behalf of the EAU Urolithiasis Guideline Panel

By: Donaldson J. 1, Ruhayel Y. 2, MacLennan S. 3, Yuan C. 4, Shepherd R. 5, Thomas K. 6, Skolarikos A. 7, Seitz C. 8, Petrik A. 9, Türk C. 10, Neisius A. 11
1 Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, 2 Skåne University Hospital, Dept. of Urology, Malmö, Sweden, 3 University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 4 McMaster University, Hamilton, Division of Gastroenterology & Cochrane Ugpd Group, Department of Medicine, Health Sciences Centre, Hamilton, Canada, 5 European Association of Urology, Guidelines Office, Arnhem, The Netherlands, 6 Guy’s Hospital, Dept. of Urology, London, United Kingdom, 7 Sismanoglio Hospital, Athens Medical School, Second Dept. of Urology, Athens, Greece, 8 Medical University of Vienna, General Hospital of Vienna, Dept. of Urology, Vienna, Austria, 9 Region Hospital, Dept. of Urology, České Budějovice, Czech Republic, 10 Hospital of the Sisters of Charity; Urologische Praxis mit Steinzentrum, Dept. of Urology, Vienna, Austria, 11 Hospital of the Brothers of Mercy Trier, Johannes Gutenberg University Mainz, Dept. of Urology, Trier, Germany

Mutational analysis of HOGA1 in Chinese pediatric patients with primary hyperoxaluria type 3

By: Wenying W. 1, Li J. 2
1 Beijing Friendship Hospital, Capital Medical University, Dept. of Urology, Beijing, China, 2 Beijing Friendship Hospital, Capital Medical University, Dept. of urology, Beijing, China

Brushite calculi: Review of a pediatric cohort

By: Vila Reyes H., Llorens De Knecht E., Quiroz Madariaga Y., Lang Motta G., Kanashiro K., Bujons Tur A., Palou Redorta J.
Fundacio Puigvert, Dept. of Urology, Barcelona, Spain
ESU/ESUT/ESUI Hands-on Training Course in Fusion biopsy
HOT 10

Location: Green Area, Room 8
Chair: L. Budäus, Hamburg (DE)
Tutors: A. Borkowitz, Dresden (DE)
J.P. Radtke, Essen (DE)
C. Kastner, Cambridge (GB)
E. Baco, Oslo (NO)
S. Boxler, Bern (CH)
H. Cash, Berlin (DE)

Aims and objectives of this session
MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow.
The course will provide an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. During the second half of the course, the participants are able to try out 7 different Fusion biopsy machines in small groups, changing every 10 min.

At the end of the course, the participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.
Breaking news session
Plenary Session 3 BN

Sunday 17 March
07:30 - 08:00

Location: Red Area, eURO Auditorium 1
Chairs: F. Montorsi, Milan (IT)
        J. Walz, Marseille (FR)

07:30 - 07:38
Breaking news Darolutamide elicits a strong PSA response in men with nonmetastatic castrationresistant prostate cancer (nmCRPC): Results from the ARAMIS study
T. Tammela, Tampere (FI)

07:38 - 07:45
Discussant
P. Albers, Düsseldorf (DE)

07:45 - 07:53
Breaking news The role of (fast) bi-parametric MRI versus multi-parametric MRI and TRUS-biopsy for detecting clinically significant prostate cancer in biopsy naïve men with elevated PSA
J. Barentsz, Nijmegen (NL)

07:53 - 08:00
Discussant
A. Briganti, Milan (IT)
# Imaging in prostate cancer: Is it time to change paradigms?

**Plenary Session 3**

**Sunday 17 March**
**08:00 - 10:23**

**Location:** Red Area, eURO Auditorium 1

**Chairs:** F. Montorsi, Milan (IT)
J. Walz, Marseille (FR)

**Aims and objectives of this session**
The aim of this session is to discuss recent changes in the diagnostic pathway of clinically localized prostate cancer. In particular, the role of novel imaging techniques and biopsy approaches such as multiparametric MRI and MRI-targeted biopsy for the diagnosis of prostate cancer will be assessed. In addition, the impact of imaging-directed therapies both in the primary and salvage setting will be critically evaluated and discussed. Finally, the European Association of Nuclear Medicine (EANM) lecture will be focused on the role of theranostics in the future of functional imaging.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td><strong>Debate</strong></td>
<td><strong>Is MRI-targeted biopsy enough?</strong></td>
</tr>
<tr>
<td>08:00 - 08:05</td>
<td><strong>Setting the stage / voting</strong></td>
<td>A. Alberts, Rotterdam (NL)</td>
</tr>
<tr>
<td>08:05 - 08:10</td>
<td><strong>Pro I</strong></td>
<td>V. Kasivisvanathan, London (GB)</td>
</tr>
<tr>
<td>08:10 - 08:15</td>
<td><strong>Con I</strong></td>
<td>G. Ploussard, Toulouse (FR)</td>
</tr>
<tr>
<td>08:15 - 08:20</td>
<td><strong>Pro II</strong></td>
<td>F. Porpiglia, Turin (IT)</td>
</tr>
<tr>
<td>08:20 - 08:25</td>
<td><strong>Con II</strong></td>
<td>C. Arsov, Düsseldorf (DE)</td>
</tr>
<tr>
<td>08:25 - 08:30</td>
<td><strong>Conclusion / voting</strong></td>
<td></td>
</tr>
<tr>
<td>08:30 - 08:55</td>
<td><strong>Debate</strong></td>
<td><strong>Critical assessment of image-guided therapy of prostate cancer</strong></td>
</tr>
<tr>
<td>08:30 - 08:35</td>
<td><strong>Setting the stage / voting</strong></td>
<td>C. Surcel, Bucharest (RO)</td>
</tr>
<tr>
<td>08:35 - 08:42</td>
<td><strong>Pro focal therapy</strong></td>
<td>R. Sanchez-Salas, Paris (FR)</td>
</tr>
<tr>
<td>08:42 - 08:49</td>
<td><strong>Con focal therapy</strong></td>
<td>D. Murphy, Melbourne (AU)</td>
</tr>
<tr>
<td>08:49 - 08:55</td>
<td><strong>Discussion / voting</strong></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker (City, Country)</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>08:55 - 09:10</td>
<td>Urological Association of Asia (UAA) lecture The future of prostate fusion biopsies</td>
<td>R. Kumar, New Delhi (IN)</td>
</tr>
<tr>
<td>09:10 - 09:25</td>
<td>Fusion biopsy devices: A true improvement or only marketing?</td>
<td>H. Van Melick, Nieuwegein (NL)</td>
</tr>
<tr>
<td>09:25 - 10:08</td>
<td>Debate PET imaging in prostate cancer: Improvement or waste of money?</td>
<td>Moderator: H.G. Van Der Poel, Amsterdam (NL)</td>
</tr>
<tr>
<td>09:25 - 09:30</td>
<td>Setting the stage</td>
<td>H.G. Van Der Poel, Amsterdam (NL)</td>
</tr>
<tr>
<td>09:30 - 09:37</td>
<td>Pro initial regional staging</td>
<td>T. Maurer, Hamburg (DE)</td>
</tr>
<tr>
<td>09:37 - 09:44</td>
<td>Con initial regional staging</td>
<td>S. Joniau, Leuven (BE)</td>
</tr>
<tr>
<td>09:44 - 09:49</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:49 - 09:56</td>
<td>Pro recurrent disease</td>
<td>P. Ost, Ghent (BE)</td>
</tr>
<tr>
<td>09:56 - 10:03</td>
<td>Con recurrent disease</td>
<td>N. Suardi, Milan (IT)</td>
</tr>
<tr>
<td>10:03 - 10:08</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10:08 - 10:23</td>
<td>European Association of Nuclear Medicine (EANM) lecture Theranostics: The future of functional imaging</td>
<td>S. Fanti, Bologna (IT)</td>
</tr>
</tbody>
</table>
Renal Cell Carcinoma (RCC)

Plenary Session 4

Sunday 17 March
08:00 - 10:15

Location: Red Area, eURO Auditorium 2
Chairs: M-O. Grimm, Jena (DE)
        H.P.A.M. Van Poppel, Leuven (BE)

Aims and objectives of this session
The majority of renal tumours are nowadays diagnosed as small renal mass. During this session the pros and cons of various surgical approaches and alternative treatments will be discussed by distinguished experts. In locally advanced and metastatic RCC the timing and role of tumour nephrectomy is under debate. This session will summarise recent data and ongoing clinical trials and discuss their impact on current treatment algorithms.

08:00 - 08:30
Minimally-invasive partial nephrectomy

08:00 - 08:15
An operation without limits?
A. Mottrie, Aalst (BE)

08:15 - 08:30
There are limits
M. Kuczyk, Hanover (DE)

08:30 - 09:10
Case-based debate Small renal mass in the young and obese: Knife, needle or nothing?
Moderator: P.F.A. Mulders, Nijmegen (NL)

08:30 - 08:35
Case presentation
P.F.A. Mulders, Nijmegen (NL)

08:35 - 08:45
Partial
C.K. Bensalah, Rennes (FR)

08:45 - 08:55
Needle
U. Capitanio, Milan (IT)

08:55 - 09:05
Surveillance
A. Finelli, Toronto (CA)

09:05 - 09:10
Discussion

09:10 - 09:25
Neoadjuvant therapy in localised disease - who is going to benefit?
M.C. Mir Maresma, Valencia (ES)

09:25 - 10:00
Debate Cytoreductive nephrectomy: Does CARMENA change everything?
Moderator: M. Kuczyk, Hanover (DE)

09:25 - 09:35
Yes
A. Mejean, Paris (FR)
<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:35 - 09:40</td>
<td>Rebuttal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:40 - 09:50</td>
<td>Maybe</td>
<td>A. Bex, Amsterdam (NL)</td>
<td></td>
</tr>
<tr>
<td>09:50 - 09:55</td>
<td>Rebuttal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:55 - 10:00</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Update on systemic therapy</td>
<td>J. Bedke, Tübingen (DE)</td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this session
Minimally invasive surgery has steadily improved over the last years. Today one can approach with confidence new, difficult and challenging situations. The course is structured to evaluate and explore the increasing indications and possible complications of laparoscopic and robotic kidney surgery. This course will focus upon common and uncommon complications and how to manage and prevent them. In addition, special situations such as single port inguinal approach, zero ischemia time, cava thrombus, accidental splenectomy and living donor nephrectomy will be presented.

Introduction
R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

Transperitoneal approach
V. Pansadoro, Rome (IT)

Retroperitoneal approach
R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

Single port inguinal approach
R. Bollens, Lomme (FR)

Intraoperative complications
R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

Difficult nephrectomies
R. Bollens, Lomme (FR)

Partial nephrectomy
R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

Special cases
R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)
Metastatic prostate cancer
ESU Course 22

Location: Green Area, Room 14
Chair: K. Pummer, Graz (AT)

Aims and objectives of this session
The three lectures of ESU course 22 will provide comprehensive state-of-the-art information about currently available therapies for hormone-naïve and castration resistant prostate cancer, such as various forms of primary androgen deprivation, immunotherapy, chemotherapy, and therapies approved for CRPC. After the course, attendees should be able to adequately treat patients with metastatic prostate cancer at all disease stages.

Treatment of castration-sensitive metastatic prostate cancer
C.P. Evans, Sacramento (US)

What is the role of chemotherapy and immunotherapy in patients with CRPC?
G. Mickisch, Bremen (DE)

Treatment of mCRPC – Sequence or combination?
K. Pummer, Graz (AT)

Case discussion
G. Mickisch, Bremen (DE)
C.P. Evans, Sacramento (US)
K. Pummer, Graz (AT)
# Update on stone disease

**ESU Course 21**

**Sunday 17 March**

**08:30 - 11:30**

**Location:** Green Area, Room 15

**Chair:** A. Patel, London (GB)

## Aims and objectives of this session

The previously devastating burden of urinary tract urolithiasis has been reduced by modern stone therapy. Complex branched stones are rare, and therapy has moved largely to the outpatient setting. Nevertheless, successful management requires competence in all aspects of stone management. After a brief review of new developments in present treatment strategies, these will be further explored by interactive case presentations.

- Stone disease aetiology is multi-factorial, relating in large part to genetics, diet (salt, calorie and protein intake), hydration status factors and ageing.
- The clinical presentation is changing with a growing base of elderly and obese patient cohorts in developed nations.
- Today’s challenge is employing the ideal initial and salvage approaches for specific situations - individuals, including judicious selection of prevention strategies.
- Patients should be given choices and counselled about the risk benefits and potential outcomes of all appropriate reasonable approaches.

## Introduction

A. Patel, London (GB)

## Medical aspects of urinary stones

M. Straub, Munich (DE)

## SWL

M. Straub, Munich (DE)

## Uretero-Renoscopy

E.K. Bres-Niewada, Warsaw (PL)

## Percutaneous nephrolithotomy and questions and answers

A. Patel, London (GB)

## Interactive case discussion

A. Patel, London (GB)
Aims and objectives of this session
Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is to employ scientific principles, published information and clinical experience to describe and position newly developed techniques in current management of urinary incontinence. Special attention will be given to new techniques that use synthetics tapes in SUI surgery. This course will also cover the management of complications of surgery for stress incontinence and mesh complications. Treatment of recurrent urinary incontinence and incontinence with mixed symptoms also will be under discussion. Management of vesicovaginal fistulae, urethral diverticula and some rare conditions will be shown both during podium and video presentations. An interactive course means active participation by the audience and participants are encouraged to prepare and present interesting and challenging clinical cases for consultation by the faculty. After this course, participants should know how to apply the newest technique in patients with stress incontinence, urethral loss and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those who are just starting their careers and for advanced surgeons.

Introduction: Female Urology – Improving functional outcome
D. Pushkar, Moscow (RU)

Stress urinary incontinence – Approaching patients' expectations
T.J. Greenwell, London (GB)

Obstructive slings: What to do?
D. Pushkar, Moscow (RU)
K-D. Sievert, Detmold (DE)

Autologous sling in 2018
T.J. Greenwell, London (GB)

Management of mesh complications
T.J. Greenwell, London (GB)
D. Pushkar, Moscow (RU)
K-D. Sievert, Detmold (DE)

Urethral diverticulae surgery – Tips and tricks
T.J. Greenwell, London (GB)

Urethral loss in females
D. Pushkar, Moscow (RU)
Scientific Programme - EAU19 Barcelona

Vesico-vaginal fistulae repair from simple to complicated
D. Pushkar, Moscow (RU)

New slings for SUI – Do you need one?
T.J. Greenwell, London (GB)
K-D. Sievert, Detmold (DE)

Conclusions
### Aims and objectives of this session

This course will summarize the decision process and indications for patients with localized and locally advanced disease and will help to select the optimal treatment including active surveillance based on most recent oncological and functional data.

After this course participants have updated their knowledge on:

- Surgical and radiotherapeutic treatment modalities.
- The optimal indication for which treatment option.
- Oncological and functional results.
- New options for adjuvant treatment.

### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 11:30</td>
<td><strong>Introduction</strong>&lt;br&gt;R.J.A. Van Moorselaar, Amsterdam (NL)</td>
</tr>
<tr>
<td></td>
<td><strong>Localised prostate cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Treatment options in localised prostate cancer</strong>&lt;br&gt;J.P.M. Sedelaar, Nijmegen (NL)</td>
</tr>
<tr>
<td></td>
<td><strong>Oncological and functional results of radiation therapy</strong>&lt;br&gt;A. Bossi, Villejuif (FR)</td>
</tr>
<tr>
<td></td>
<td><strong>Oncological and functional results of radical prostatectomy</strong>&lt;br&gt;R.J.A. Van Moorselaar, Amsterdam (NL)</td>
</tr>
<tr>
<td></td>
<td><strong>Advanced prostate cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Radiotherapy with or without hormonal treatment in advanced PCA</strong>&lt;br&gt;A. Bossi, Villejuif (FR)</td>
</tr>
<tr>
<td></td>
<td><strong>Adjuvant therapies following radical prostatectomy</strong>&lt;br&gt;R.J.A. Van Moorselaar, Amsterdam (NL)</td>
</tr>
<tr>
<td></td>
<td><strong>Results of radical prostatectomy for T3 disease</strong>&lt;br&gt;J.P.M. Sedelaar, Nijmegen (NL)</td>
</tr>
<tr>
<td>08:30 - 11:30</td>
<td><strong>Take home messages</strong></td>
</tr>
</tbody>
</table>
Chronic pelvic pain in men and women
ESU Course 25

Location: Green Area, Room 22
Chair: E.J. Messelink, Groningen (NL)

Voting will be available via the EAU19 App or via www.qna.at/eau

Aims and objectives of this session
The urologist is often dealing with patients having Chronic Pelvic Pain. This course will offer the urologist practical guidance in treating these patients. In the case discussion the participants will have the opportunity to help outlining the problem. In the lectures theoretical knowledge will be translated into daily guidelines for diagnostics and treatment of patients with pelvic pain. At the end of this course the participant will:
  • Know the basic principles of treating patients with chronic pelvic pain.
  • Know how to rule out well known causes.
  • Have knowledge of the myofascial and psychological aspects.
  • Be able to refer patients at the right time to the right team.

Chronic pelvic pain, the basics: Mechanisms and terminology
E.J. Messelink, Groningen (NL)

Chronic pelvic pain in men: Case presentation and discussion
D.S. Engeler, St. Gallen (CH)

Chronic pelvic pain in men: Practical guidelines on diagnostics and treatment
D.S. Engeler, St. Gallen (CH)

Chronic pelvic pain in women: Case presentation and discussion
E.J. Messelink, Groningen (NL)

Chronic pelvic pain in women: Practical guidelines on diagnostics and treatment
E.J. Messelink, Groningen (NL)

The interdisciplinary approach: Team members and organisation
D.S. Engeler, St. Gallen (CH)
Aims and objectives of this session
This course addresses comprehensively important anatomical considerations for minimally invasive pelvic surgery. Based on the anatomy key technical aspects of laparoscopic and robotic-assisted radical prostatectomy and radical cystectomy such access, port placement, robotic docking and each step of the procedures will be discussed. Additionally different techniques of nerve-sparing surgery such as interfascial and intrafascial will be discussed and intensively explained by video presentations.

Introduction
J-U. Stolzenburg, Leipzig (DE)

Pelvic and surgical anatomy for laparoscopic/robotic radical prostatectomy (RPE)
H.A.R. Qazi, London (GB)
J-U. Stolzenburg, Leipzig (DE)

Surgical anatomy for laparoscopic/robotic assisted radical cystectomy
J. Cresswell, Middlesbrough (GB)

Port placement and robot docking-principles for pelvic laparoscopy
J. Cresswell, Middlesbrough (GB)
H.A.R. Qazi, London (GB)
J-U. Stolzenburg, Leipzig (DE)

Prostate, bladder and urethral sphincter anatomy. How to preserve urinary continence
H.A.R. Qazi, London (GB)
J-U. Stolzenburg, Leipzig (DE)

Surgical anatomy for nerve sparing surgery. How to perform nerve sparing surgery
J-U. Stolzenburg, Leipzig (DE)

Boundaries and technique of pelvic lymph node dissection for radical prostatectomy (standard, extended PLNA, risk stratified access) and radical cystectomy
J. Cresswell, Middlesbrough (GB)
H.A.R. Qazi, London (GB)

Summary and take home messages
J. Cresswell, Middlesbrough (GB)
Quiz
J. Cresswell, Middlesbrough (GB)
H.A.R. Qazi, London (GB)
J-U. Stolzenburg, Leipzig (DE)
ESU/ESUT Hands-on Training Course in Basic laparoscopy
Sponsored by KARL STORZ

Sunday 17 March
09:00 - 10:00

Location: Green Area, Room 6

Tutors: M. Arslan, Izmir (TR)
L.B. Dragoş, Timisoara (RO)
J. Gómez Rivas, Madrid (ES)
A.S. Gözen, Heilbronn (DE)
P. Kallidonis, Patras (GR)
To be confirmed
J-T. Klein, Ulm (DE)
D. Veneziano, Reggio Calabria (IT)

Aims and objectives of this session
In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

• You will improve your laparoscopic skills such as depth perception and bimanual dexterity
Aims and objectives of this session

This course aims to provide a practical course offering an interactive “hands-on” environment for doctors, nurses and technicians to improve their skills in urodynamics, with an emphasis on practical aspects including equipment used, interpretation of traces, quality control and trouble-shooting. The use of recorded tests, access to equipment and small groups means that individual problems can be addressed. All the speakers are involved in similar “hands-on” courses, which have ran successfully in the United Kingdom and abroad in major international conferences. The small group format has been shown to work well in addressing individual needs. Access to teaching aids and equipment will simulate the clinical scenario as much as possible within the constraints of the conference setting.

The aim is to teach and emphasise good Urodynamics practice using accepted international standards.

At the end of the workshop delegates should feel more confident in their practice of urodynamics.
Aims and objectives of this session

Ultrasonography is an essential instrument in the management of urological patients, both in the diagnostic phase and during follow-up after treatment. It is an evolving technology with increasing performance. Since it is becoming cheaper and user friendly, it is more available in every urological office. The knowledge and the use of this method should be part of the standard background and armamentarium of each urologist.

This hands-on course aims to provide urologists with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. It will provide basic information by short and concise lectures followed by extensive practical exercise.

Aim and objectives

• At the end of the course, the participants understand the advantages, handling and limitations of ultrasound in the urological practice.

Target audience: urologists, interested in the diagnostic ability of urological ultrasound
### Novel treatment strategies in Benign Prostatic Obstruction (BPO): A video-based course on the procedural essentials

**Specialty Session - European Urology**

**Sunday 17 March**  
10:30 - 12:30

**Location:** Red Area, eURO Auditorium 2

**Chairs:** A. Bachmann, Vienna (AT)  
J.W.F. Catto, Sheffield (GB)  
A. Mottrie, Aalst (BE)  
P. Schatteman, Aalst (BE)

**Aims and objectives of this session**
The Surgery-in-Motion session is dedicated to novel treatment strategies in BPO. Experts in the field will provide explanations and video demonstrations of various surgical techniques and discuss why they do it “their way”. Questions from the audience are welcome.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:40</td>
<td>Welcome and introduction</td>
<td>A. Bachmann, Vienna (AT) J.W.F. Catto, Sheffield (GB) A. Mottrie, Aalst (BE) P. Schatteman, Aalst (BE)</td>
</tr>
<tr>
<td>10:40 - 10:48</td>
<td>Natural history of Benign Prostatic Hyperplasia (BPH) and prostate conditions for surgery</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td>10:48 - 11:28</td>
<td>Enucleation techniques</td>
<td>Moderator: A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td>10:48 - 10:58</td>
<td>HoLEP</td>
<td>P. Schatteman, Aalst (BE)</td>
</tr>
<tr>
<td>10:58 - 11:08</td>
<td>ThuLEP</td>
<td>A.J. Gross, Hamburg (DE)</td>
</tr>
<tr>
<td>11:08 - 11:18</td>
<td>Green-LEP</td>
<td>F. Gomez Sancha, Madrid (ES)</td>
</tr>
<tr>
<td>11:18 - 11:28</td>
<td>Bipolar enucleation</td>
<td>T.R.W. Herrmann, Frauenfeld (CH)</td>
</tr>
<tr>
<td>11:28 - 11:52</td>
<td>Vaporisation techniques</td>
<td>Moderator: P. Schatteman, Aalst (BE)</td>
</tr>
<tr>
<td>11:28 - 11:36</td>
<td>Greenlight Laser</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td>11:36 - 11:44</td>
<td>REZUM</td>
<td>A. Bachmann, Vienna (AT)</td>
</tr>
<tr>
<td>Time</td>
<td>Lecture</td>
<td>Speaker/Location</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>11:44 - 11:52</td>
<td>Bipolar plasmavaporisation ('Button' or Mushroom)</td>
<td>B. Geavlete, Bucharest (RO)</td>
</tr>
</tbody>
</table>
| 11:52 - 12:00 | New immediate ablative techniques: Aqua-ablation                                             | Moderator: P. Schatteman, Aalst (BE)  
                      |                                               | Speaker: T. Bach, Hamburg (DE)          |
| 12:00 - 12:16 | Mechanically deobstructing techniques and others                                             | Moderator: A. Bachmann, Vienna (AT)          |
| 12:00 - 12:08 | Urolift                                                                                        | To be confirmed                    |
| 12:08 - 12:16 | Temporary implantable Nitinol Device (iTIND)                                                  | F. Porpiglia, Turin (IT)            |
| 12:16 - 12:21 | Closing remarks                                                                                | A. Bachmann, Vienna (AT)           
                      |                                               | J.W.F. Catto, Sheffield (GB)            
                      |                                               | A. Mottrie, Aalst (BE)                   
                      |                                               | P. Schatteman, Aalst (BE)                |
### Immunotherapy in genitourinary (GU) oncology

**Thematic Session 01**

- **Location:** Green Area, Room 1
- **Chairs:** Z. Culig, Innsbruck (AT)
  M. De Santis, Berlin (DE)

**Aims and objectives of this session**

Immunotherapy has become a standard of care for the treatment of urothelial and renal cell cancer. The field is rapidly evolving and includes research on biomarkers, the tumour microenvironment, tumour mutational burden and genetic alterations. Clinical trials are evaluating combination therapies, sequencing of treatments and new indications like prostate cancer.

Also we need to learn how to best manage patients on immune checkpoint inhibitors and how to deal with specific side effects. This session will cover these major aspects of immunotherapy in GU cancers and summarise research and tips and tricks for daily practice.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Immunotherapy in prostate cancer - review and outlook</td>
<td>N. Shore, Myrtle Beach (US)</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>What is behind the microbiota?</td>
<td>L. Albiges, Villejuif (FR)</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Immunotherapy and genomics</td>
<td>M.S. Van Der Heijden, Amsterdam (NL)</td>
</tr>
<tr>
<td>11:15 - 11:40</td>
<td>Case-based debate Checkpoint inhibitors: Safety and management in daily practice</td>
<td>M. Retz, Munich (DE)</td>
</tr>
<tr>
<td></td>
<td><em>Case presenter:</em> M. Retz, Munich (DE)</td>
<td>L. Albiges, Villejuif (FR)</td>
</tr>
<tr>
<td></td>
<td><em>Panel:</em> L. Albiges, Villejuif (FR)</td>
<td>N. Shore, Myrtle Beach (US)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M.S. Van Der Heijden, Amsterdam (NL)</td>
</tr>
<tr>
<td>11:40 - 12:00</td>
<td>Urothelial and renal cell cancer - is monotherapy out?</td>
<td>I. Duran, Santander (ES)</td>
</tr>
</tbody>
</table>
Limited pelvic lymph node involvement in otherwise localised disease
Thematic Session 03

Sunday 17 March
10:30 - 12:00

Location: Green Area, Room 2
Chairs: T. Bivalacqua, Baltimore (US)
        T.S. O’Brien, London (GB)

Aims and objectives of this session
To address controversies in the management of lymph nodes in pelvic cancer.
Develop a clearer understanding of the value (if any) of different modalities of treatment and how radical that treatment needs to be.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Biology of lymphatic dissemination</td>
<td>G. Palapattu, Ann Arbor (US)</td>
</tr>
</tbody>
</table>
| 10:45 - 10:53 | Late breaking news  
Comparison between limited and extended lymph node dissection for prostate cancer: results from a large, clinically-integrated, randomized trial | K. Touijer, New York (US) |
| 10:53 - 11:00 | Discussant                                        | T. Bivalacqua, Baltimore (US) |
| 11:00 - 11:30 | Case 1  
PCa cN1 cM0                                        |                            |
| 11:00 - 11:05 | Clinical case presentation                        | M. Moschini, Luzern (CH)   |
| 11:05 - 11:15 | Additional local therapy                         | P. Nyirády, Budapest (HU)  |
| 11:15 - 11:25 | Systemic therapy only                            | N. Mottet, Saint-Étienne (FR) |
| 11:25 - 11:30 | Summary                                           | M. Moschini, Luzern (CH)   |
| 11:30 - 12:00 | Case 2  
MIBC cN1 cM0                                     |                            |
| 11:30 - 11:35 | Clinical case presentation                        | A. Masson-Lecomte, Paris (FR) |
| 11:35 - 11:45 | Induction chemotherapy                            | S. Bracarda, Terni (IT)    |
| 11:45 - 11:55 | Upfront radical cystectomy                        | J.E. Gschwend, Munich (DE) |
| 11:55 - 12:00 | Summary                                           | A. Masson-Lecomte, Paris (FR) |
Aims and objectives of this session
This session on focal therapy for intermediate-risk prostate cancer addresses the methods for selection, treating and monitoring in the developing field of imaging and targeted biopsies. The background for the setting will be presented, including guidelines and available oncological and functional outcomes.

À la carte selection of type of energies according to tumour characteristics, location and results are highlighted. Afterwards, the session participants will be able to make a decision when and how to include the individual patient with intermediate risk cancer in focal therapy.
**Thematic Session 04**

**Sunday 17 March**

**10:30 - 12:00**

**Location:** Green Area, Room 4  
**Chairs:** M. Albersen, Leuven (BE)  
A. Muneer, London (GB)

**Aims and objectives of this session**

In the Western world, penile cancer is diagnosed in only 1/100,000-1,000,000 men, which makes it a rare cancer. The rarity of the disease, especially in countries where routine circumcision has been adopted, makes it a challenging diagnosis for many urologists. In this session we will discuss controversies and new developments in penile cancer: should we vaccinate boys against HPV? How to diagnose and manage premalignant diseases? What is the best staging for high risk patients without palpable lymph nodes, and what will the future look like in terms of novel systemic agents? Last, the role of the European Reference Network eUROGEN in penile cancer treatment will be highlighted.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>The role of HPV in penile cancer pathogenesis: An opportunity to start vaccination in boys?</td>
<td>M. Burger, Regensburg (DE)</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Premalignant lesions: What should the urologist know?</td>
<td>C. Bunker, London (GB)</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td><strong>Case-based debate</strong> High-risk cN0 patient</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:05</td>
<td>Case presentation</td>
<td>C. Protzel, Schwerin (DE)</td>
</tr>
<tr>
<td>11:05 - 11:15</td>
<td>DSNB is still the way to go for staging of high-risk N0 disease</td>
<td>N. Watkin, London (GB)</td>
</tr>
<tr>
<td>11:15 - 11:25</td>
<td>Robot-assisted and/or video-endoscopic inguinal management is the future in high-risk cN0 staging</td>
<td>C.A. Pettaway, Houston (US)</td>
</tr>
<tr>
<td>11:25 - 11:30</td>
<td>Concluding remarks</td>
<td>C. Protzel, Schwerin (DE)</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Novel targeted therapies on the horizon?</td>
<td>P. Spiess, Tampa (US)</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Centralisation of penile cancer care and eUROGEN: Are we improving outcomes?</td>
<td>V. Sangar, Manchester (GB)</td>
</tr>
</tbody>
</table>
### Aims and objectives of this session

The mainstay of OAB treatment is medical management. Since decades a search is going on to find the ideal drug for OAB treatment. A drug should be effective, should not have many and severe side events and should be safe. So far the ideal drug has not been found. This implies that other options like the combination of drugs, also qualify for treatment. This session explores the feasibility of drug combination for OAB.

### OAB drugs: What's new from the bench?

10:30 - 10:45
M.C. Michel, Mainz (DE)

### Role of drug combination therapy for OAB management

10:45 - 11:00
F. Van Der Aa, Leuven (BE)

### Case presentation faculty:

11:00 - 11:00
- S. Charalampous, Limassol (CY)
- E. Finazzi Agrò, Rome (IT)
- T.A.T. Marcelissen, Maastricht (NL)
- M.I.A. Wyndaele, Utrecht (NL)

### Case 1

Woman, 50 years old, with mixed incontinence an predominant OAB

11:00 - 11:15

### Case presentation

11:00 - 11:03

### Prefers an anticholinergic

S. Charalampous, Limassol (CY)

11:03 - 11:06

### Prefers mirabegron

E. Finazzi Agrò, Rome (IT)

11:06 - 11:09

### No drugs - prefers PTNS

T.A.T. Marcelissen, Maastricht (NL)

11:09 - 11:12

### Something else

M.I.A. Wyndaele, Utrecht (NL)

11:12 - 11:15

### Case 2

Man, 50 years old, with OAB after Benign Prostatic Obstruction (BPO) relief

11:15 - 11:30

### Case presentation

11:15 - 11:18
11:18 - 11:21  
Prefers an anticholinergic
M.I.A. Wyndaele, Utrecht (NL)

11:21 - 11:24  
Prefers mirabegron
T.A.T. Marcelissen, Maastricht (NL)

11:24 - 11:27  
No drugs - prefers PTNS
E. Finazzi Agrò, Rome (IT)

11:27 - 11:30  
Something else
S. Charalampous, Limassol (CY)

11:30 - 11:45  
Case 3  Man, 60 years old, Parkinson disease, presenting with OAB

11:30 - 11:33  
Case presentation

11:33 - 11:36  
Prefers an anticholinergic
E. Finazzi Agrò, Rome (IT)

11:36 - 11:39  
Prefers mirabegron
M.I.A. Wyndaele, Utrecht (NL)

11:39 - 11:42  
No drugs - prefers PTNS
S. Charalampous, Limassol (CY)

11:42 - 11:45  
Something else
T.A.T. Marcelissen, Maastricht (NL)

11:45 - 12:00  
Associated abstract presentations

125  
In females with overactive bladder, an alternative injection paradigm for onabotulinumtoxinA is associated with low clean intermittent catheterisation use

By: Macdiarmid S. 1, Glazier D. 2, Shapiro A. 3, McCammon K. 4, McCrery R. 5, Jarnagin B. 6, Boroujerdi A. 7, Bai Z. 8, Gao G. 9, Patel A. 10

1Alliance Urology Specialists, Dept. of Urology, Greensboro, United States of America, 2Virginia Urology, Dept. of Urology, Emporia, United States of America, 3Chesapeake Urology, Dept. of Urology, Owings Mills, United States of America, 4Eastern Virginia Medical School, Dept. of Urology, Virginia Beach, United States of America, 5Adult Pediatric Urology, Dept. of Urology, Omaha, United States of America, 6Center for Pelvic Health, Female Pelvic Medicine & Reconstructive Surgery, Franklin, United States of America, 7Allergan plc, Dept. of Urology, Irvine, United States of America, 8Allergan plc, Biostatistics, Madison, United States of America, 9Allergan plc, Medical Safety, Madison, United States of America, 10Allergan plc, Medical Affairs (Neurology and Urology), Marlow, United Kingdom

PT235  
Exploration of litoxetine (LTX): A potential novel treatment for mixed urinary incontinence (MUI)

By: Haab F.
Hopital Tenon, Dept. of Urology, Paris, France
Semi-live surgery: Percutaneous stone removal
Thematic Session 08

Sunday 17 March
10:30 - 12:00

Location: Green Area, Room 10

Chairs: E. Liatsikos, Patras (GR)
        M. Monga, Chagrin Falls (US)

Panel: M.S. Michel, Mannheim (DE)
       E. Montanari, Milan (IT)
       M. Sofer, Tel-Aviv (IL)

10:30 - 10:45 Surgical video presentation *Percutaneous nephrolitholapaxy in difficult cases*
        M.R. Desai, Naidad (IN)

10:45 - 11:00 Panel discussion

11:00 - 11:15 Surgical video presentation *Combined percutaneous and transureteral stone removal*
        M. Özsoy, Vienna (AT)

11:15 - 11:30 Panel discussion

11:30 - 11:45 Surgical video presentation *Complications of percutaneous stone removal - dislocation, perforation, bleeding*
        T. Tailly, Ghent (BE)

11:45 - 12:00 Panel discussion
Aims and objectives of this session
Even in the era of robotics, laparoscopy represents a very important technique which has to be mastered by all urologic surgeons. In this context, the management of the main complications of this procedure is of utmost importance. We are happy to present a distinguished faculty with extraordinary experience with laparoscopy and retroperitoneoscopy. The audience is invited to actively participate during discussion of the different complications, their management and prevention.

10:30 - 10:45
Prevention of complications during laparoscopic access and exit
B. Petrut, Cluj Napoca (RO)

10:45 - 11:00
Intraoperative management of: Vascular and nerve injuries
M. Georgiev, Sofia (BG)

11:00 - 11:15
Intraoperative management of: Bowel injuries
P.L. Chlosta, Cracow (PL)

11:15 - 11:30
Intraoperative management of: Ureter injuries
A.S. Gözen, Heilbronn (DE)

11:30 - 11:45
Decision-making on early re-exploration
R. Autorino, Richmond (US)

11:45 - 12:00
Management and prevention of lymphoceles
J-U. Stolzenburg, Leipzig (DE)
How much do you know about modern imaging: Test yourself!

Thematic Session 07

Sunday 17 March
10:30 - 12:00

Location: Green Area, Room 12

Chair: J. Walz, Marseille (FR)
Panel: J.W.F. Catto, Sheffield (GB)
       N. Fossati, Milan (IT)
       S. Fanti, Bologna (IT)
       S. Shariat, Vienna (AT)
       G. Villeirs, Ghent (BE)

10:30 - 10:49
Case 1 UPJ obstruction with limited renal function

10:30 - 10:35
Case presentation
J. Walz, Marseille (FR)

10:35 - 10:49
Interactive test and discussion

10:49 - 11:08
Case 2 PET in prostate cancer initial/relapse staging and treatment

10:49 - 10:54
Case presentation
J. Walz, Marseille (FR)

10:54 - 11:08
Interactive test and discussion

11:08 - 11:27
Case 3 The use of FDG-PET in newly-diagnosed bladder cancer

11:08 - 11:13
Case presentation
J. Walz, Marseille (FR)

11:13 - 11:27
Interactive test and discussion

11:27 - 11:46
Case 4 The use of mpMRI in newly-diagnosed bladder cancer

11:27 - 11:32
Case presentation
J. Walz, Marseille (FR)

11:32 - 11:46
Interactive test and discussion
Aims and objectives of this session
This session aims to provide you with the latest information and state of the art of different aspects for the care of your pediatric patients with a congenital urogenital anomaly or urological problem and long term outcome related to daily practice. The objectives are to inform urologists, residents in urology, researchers in pediatric urology and pediatric urologists and all interested in the recent developments on different subjects in the field of pediatric urology and the consequences for lifelong urological care.

10:30 - 10:45
Long-term follow-up and quality of life of Spina Bifida patients
A. Bujons Tur, Barcelona (ES)

10:45 - 11:00
Complicated stones in children and safe solutions
M.S. Silay, Istanbul (TR)

11:00 - 11:15
Management of vesico-ureteral reflux and complication solutions
B. Haid, Linz (AT)

11:15 - 11:30
Testicular development and adolescent varicocele: Diagnosis, treatment and outcome
G. De Win, Antwerpen (BE)

11:30 - 11:45
Bladder extrophy care into adulthood
A. Baird, Liverpool (GB)

11:45 - 12:00
Regenerative medicine technologies in the urinary tract
G. Pellegrini, Modena (IT)
Testis cancer: Surgery is back again
Thematic Session 09

Sunday 17 March
10:30 - 12:00

Location: Green Area, Room 20

Chairs: P. Albers, Düsseldorf (DE)
J.L. Boormans, Rotterdam (NL)

Aims and objectives of this session
This session will provide you with up-to-date knowledge on the pathogenesis of germ cell tumors followed by a debate on a still controversial issue of primary RPLND for staging and treatment in patients with high risk clinical stage I non-seminoma. In a state-of-the-art latest data on one of the most dangerous histological transformations will be presented: Somatic malignancies in teratoma. The session will conclude with evidence-based recommendations for follow-up and two of the best abstracts on epidemiology and quality of care in testicular cancer.

10:30 - 10:42 The cause of everything: The testicular dysgenesis syndrome
P. Albers, Düsseldorf (DE)

10:42 - 10:45 Discussion

10:45 - 11:15 Debate Surgery for non-seminoma clinical stage I "high risk"

10:45 - 10:57 Pro surgery
S. Daneshmand, Los Angeles (US)

10:57 - 11:09 Con surgery
D. Nicol, London (GB)

11:09 - 11:15 Discussion

11:15 - 11:27 Surgical management for Somatic Malignant-transformed teratoma (SM)
N.W. Clarke, Manchester (GB)

11:27 - 11:30 Discussion

11:30 - 11:42 Challenging the guidelines Risk-based follow-up schedules for testis cancer
R. Cathomas, Chur (CH)

11:42 - 11:45 Discussion

11:45 - 11:59 Associated abstract presentations
1239  Non-guideline concordant treatment of testicular cancer patients is associated with a significantly reduced event-free survival

By: Paffenholz P., Osterholt T., Nestler T., Pfister D., Heidenreich A.
University Hospital Cologne, Dept. of Urology, Cologne, Germany

1240  Contemporary assessment of survival rates in stage I testicular seminoma: A population-based comparison between surveillance and active treatment after initial orchiectomy

By: Mistretta F.A., 1 Mazzone E., 1 Palumbo C., 1 Knipper S., 1 Tian Z., 1 Nazzani S., 1 Lattouf J-B., 2 Musi G., 3 Perrotte P., 2 Montanari E., 4 Shariat S.F., 5 Montorsi F., 6 Saad F., 7 De Cobelli O., 3 Karakiewicz P.I. 1

1University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 2University of Montreal Health Center, Dept. of Urology, Montreal, Canada, 3European Institute of Oncology, Dept. of Urology, Milan, Italy, 4IRCCS Fondazione Ca’ Granda-Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, 5Medical University of Vienna, Dept. of Urology, Vienna, Austria, 6IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Dept. of Oncology, Unit of Urology, URI, Milan, Italy, 7University of Montreal Hospital Center, Dept. of Urology, Montreal, Canada
Aims and objectives of this session
In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

• You will improve your laparoscopic skills such as depth perception and bimanual dexterity
ESU/ESUI Hands-on Training Course in Urological ultrasound
Sponsored by BK MEDICAL

Sunday 17 March
11:30 - 13:00

Location: Green Area, Room 8

Chairs: P. Martino, Bari (IT)
V. Scattoni, Milan (IT)

Tutors: To be confirmed
C.B. Maccagnano, Galatina (IT)
M. Ritter, Mannheim (DE)
D. Yakar, ()

Aims and objectives of this session
Ultrasonography is an essential instrument in the management of urological patients, both in the diagnostic phase and during follow-up after treatment. It is an evolving technology with increasing performance. Since it is becoming cheaper and user friendly, it is more available in every urological office. The knowledge and the use of this method should be part of the standard background and armamentarium of each urologist.

This hands-on-course aims to provide urologists with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. It will provide basic information by short and concise lectures followed by extensive practical exercise.

Aim and objectives
• At the end of the course, the participants understand the advantages, handling and limitations of ultrasound in the urological practice.

Target audience: urologists, interested in the diagnostic ability of urological ultrasound
Aims and objectives of this session
The course is designed to introduce the application of basic surgical knowledge and principles for the 1st and 2nd year residents. The course will provide the learners with basic knowledge and skills in developing a safe and methodological approach to their initial application of surgical knowledge. The course includes case discussions and learner activity.

Intended learning outcomes.
After this course you will be able to:
• Discuss the basic principles, indications and techniques in basic urological surgery of the scrotum and penis and basic endourology.
• Reason and plan for basic urological procedures based on the anatomy and the individual previous medical history.
• Choose the most appropriate surgical technique in common basic urological conditions.
• Discuss and understand the most common surgical risks in basic urological surgery and endoscopy.

Physical examination of the genitourinary tract
C.S. Biyani, Leeds (GB)
R. Sanchez-Salas, Paris (FR)

Penile surgery
C.S. Biyani, Leeds (GB)
R. Sanchez-Salas, Paris (FR)

Scrotal surgery
C.S. Biyani, Leeds (GB)
R. Sanchez-Salas, Paris (FR)

Basic endoscopic procedures (urethral catheterization, cystoscopy, nephrostomy)
C.S. Biyani, Leeds (GB)
R. Sanchez-Salas, Paris (FR)
Aims and objectives of this session

With the large widespread of mini-invasive surgery, improving knowledge of practical aspects of laparoscopy is mandatory. Knowledge of:

- Indications and contra-indications of laparoscopic approach.
- How to choose and use the instrumentation, in order to optimize the procedure and minimize adverse effects.
- Air insufflations parameters and optimal access in laparoscopic urology.
- How to prevent, recognize and manage complications.

This course aims to provide all this knowledge in an interactive and practical way (video clip, open discussion), in order to assist beginners in laparoscopy shortening their learning curve and optimizing the success of their laparoscopic procedures.

- Laparoscopic surgery: For which patients and which procedures?
- Masterize the armentarium.
- Tips and tricks to optimize the procedure.
- New potential and future evolutions.

Indications for laparoscopy

B.S.E.P. Van Cleynenbreugel, Leuven (BE)

Instrumentation and haemostatis

X. Cathelineau, Paris (FR)

Peritoneal access and effects of pneumoperitoneum

B.S.E.P. Van Cleynenbreugel, Leuven (BE)

Avoiding complications

X. Cathelineau, Paris (FR)
New perspectives in the management of upper tract tumours
ESU Course 28

Sunday 17 March
12:00 - 14:00

Location: Green Area, Room 15
Chair: S. Shariat, Vienna (AT)

Aims and objectives of this session
This course will address contemporary concepts and controversies in UTUC such as:
• Accurate staging and its role in clinical decision making/risk stratification.
• Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery.
• Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy.
• Systemic therapy for high-risk and metastatic patients.

Epidemiology, diagnosis, evaluation
M. Rouprêt, Paris (FR)

Prognostic and predictive factors, pathology
S. Shariat, Vienna (AT)

Treatment of low risk cancer (high grade Ta, T1 and CIS)
M. Rouprêt, Paris (FR)

Treatment of localized high risk (invasive) and metastatic cancer
S. Shariat, Vienna (AT)
Oligometastatic prostate cancer
ESU Course 27

Location: Green Area, Room 16
Chair: A. Briganti, Milan (IT)

Aims and objectives of this session
• Provide an introduction to working definition(s), background, and biology of oligometastatic prostate cancer.
• Update the current molecular imaging to provide such a diagnosis.
• Review the potential roles of surgery and/or radiation as metastasis directed therapy.
• Understand opportunities and challenges in individualizing care of the oligometastatic prostate cancer patient.

Introductions; Oligometastatic prostate cancer as a diagnosis
S. Joniau, Leuven (BE)

Surgery for recurrent nodal metastasis with updates on molecular/PET imaging
A. Briganti, Milan (IT)

Radiation in oligometastatic prostate cancer (primary and recurrent) and clinical trial updates
P. Ost, Ghent (BE)

Surgery of primary oligometastatic prostate cancer (N1/M1)
S. Joniau, Leuven (BE)

Further cases (case illustrations throughout)
A. Briganti, Milan (IT)
S. Joniau, Leuven (BE)
P. Ost, Ghent (BE)

Questions audience
Aims and objectives of this session
The course aims to introduce the basic principles of the diagnostic work-up and management of the common micturition dysfunctions in neurological disease. The early introduction of correct management contributes to the patient’s quality of life and prevents potential complications for neurological patients.

The main aims are:
• To refresh the pathophysiology and the key points of the management of neurogenic bladder dysfunction.
• To apply those principles in specific cases which illustrate the most common problems seen in the clinical practice.
• To discuss with the help of real life clinical cases pharmacological and surgical options available for the management of neuro-urological patients.

Introduction
F. Cruz, Porto (PT)

Pathophysiology and key points of the investigation of neurogenic bladder dysfunction
M. Drake, Bristol (GB)

Management of neurogenic bladder dysfunction: Key principles
F. Cruz, Porto (PT)

Patient with cerebral vascular accident
M. Drake, Bristol (GB)

Conclusion
F. Cruz, Porto (PT)
M. Drake, Bristol (GB)
### Management and outcome in invasive and locally advanced bladder cancer

**ESU Course 32**

**Sunday 17 March**  
**12:00 - 14:00**

**Location:** Green Area, Room 22  
**Chair:** B. Malavaud, Toulouse (FR)

#### Aims and objectives of this session

MIBC is a multifaceted entity where one size no longer fits all, supporting the development of personalized and, in selected cases, organ-preserving strategies.

Are the advances in imaging, molecular biology, conservative surgery; medical oncology and radiotherapy strong enough to shift the current pre-eminence of the ablative approach toward a more integrated and conservative perspective?

If yes, what are the ideal candidates?

- One size does not fit all and urologists are central to the development of personalized treatment in MIBC.
- Patients selection is critical and based on advances in imaging, resection techniques and pathology.
- Organ preservation is feasible in a significant proportion of patients.
- Radical cystectomy and pre-emptive chemotherapy are essential to optimize results in aggressive conditions.

#### Introduction

B. Malavaud, Toulouse (FR)

#### Cystectomy in the management of bladder invasive and locally-advanced bladder cancer

M. Burger, Regensburg (DE)

#### Elements for a multidimensional approach to MIBC

B. Malavaud, Toulouse (FR)

#### Bladder-sparing approaches to muscle invasive bladder cancer

M. Burger, Regensburg (DE)

#### Overview of systemic treatments in metastatic bladder cancer

B. Malavaud, Toulouse (FR)

#### Concluding remarks

B. Malavaud, Toulouse (FR)
Prostate cancer update: 2018-2019
ESU Course 33

Sunday 17 March 12:00 - 14:00
Location: Green Area, Room 23
Chair: F. Montorsi, Milan (IT)

Aims and objectives of this session
This course is aimed at critically reviewing key manuscripts published during the previous 12 months and devoted to the management of prostate cancer patients with a particular focus on basic research, screening, diagnosis, staging, and local and systemic therapies. Practice-changing manuscripts published in peer-reviewed journals between April 2018 and March 2019 will be identified and discussed for each topic. For every paper a clear take home message applicable to the every-day clinical practice will be identified and discussed. The main objective of the course is to inform participants on the latest and most significant novelties related to the contemporary management of prostate cancer patients.

Clinical implications of basic research
F. Montorsi, Milan (IT)

Screening: Novel biomarkers
M. Graefen, Hamburg (DE)

Diagnosis: Multiparametric magnetic resonance imaging (mpMRI) and MRI-targeted biopsies
F. Montorsi, Milan (IT)

Staging: Imaging and predictive models
M. Graefen, Hamburg (DE)

Treatment of localized prostate cancer: Active surveillance
F. Montorsi, Milan (IT)

Treatment of localized prostate cancer: Radical prostatectomy
M. Graefen, Hamburg (DE)

Treatment of localized prostate cancer: External beam radiotherapy and brachytherapy
M. Graefen, Hamburg (DE)

Treatment of localized prostate cancer: Focal therapy
F. Montorsi, Milan (IT)

Management of recurrence after treatment with curative intent
F. Montorsi, Milan (IT)
<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management of hormone sensitive metastatic prostate cancer</td>
<td>F. Montorsi</td>
<td>Milan (IT)</td>
</tr>
<tr>
<td>Management of castration-resistant prostate cancer</td>
<td>M. Graefen</td>
<td>Hamburg (DE)</td>
</tr>
</tbody>
</table>
ESU/ESUT Hands-on Training Course in Basic laparoscopy
Sponsored by KARL STORZ

Sunday 17 March
12:00 - 13:00

**Location:** Green Area, Room 6

**Tutors:**
- S. Barmoshe, Brussels (BE)
- J. Gómez Rivas, Madrid (ES)
- K. Ahmed, London (GB)
- L. Osório, Porto (PT)
- G. Pini, Milano (IT)
- O. Rodriguez Faba, Barcelona (ES)
- T.M. Ribeiro De Oliveira, ()
- P.J. Zondervan, Amsterdam (NL)

**Aims and objectives of this session**
In this course, basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme. Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

• You will improve your laparoscopic skills such as depth perception and bimanual dexterity
Updates on partial nephrectomy techniques
Video Session 07

Sunday 17 March
12:15 - 13:45

Location: Red Area, eURO Auditorium 1
Chairs: C-C. Abbou, Vincennes (FR)
A. Minervini, Florence (IT)
A. Mottrie, Aalst (BE)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V46
Laparoscopic resection of intraparenchymal kidney neoplasm in condition of warm ischemia
By: Popov S., Guseinov R., Orlov I., Katunin A.
City Hospital Saint Luka, Dept. of Urology, Saint Petersburg, Russia

Aims and objectives of this presentation
V46

V47
Bilateral kidney tumor: Management and feasibility
University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy

Aims and objectives of this presentation
V47

V48
Robot-assisted partial nephrectomy: Techniques and outcomes from the Transatlantic Robotic Nephron-sparing Surgery (TRoNeS) study group
1Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, MI, Italy, 2Onze-Lieve-Vrouw Hospital, Dept. of Urology, Aalst, Belgium, 3Swedish Medical Center, Dept. of Urology, Seattle, WA, United States of America

Aims and objectives of this presentation
V48

V49
Non-ischemic partial nephrectomy with the hydrojet resection technique
By: Gakis G., Schubert T., Hassan F., Sokolakis I., Ölschläger M., Hatzichristodoulou G., Kübler H.
Aims and objectives of this presentation
V49

Image-guided robot-assisted partial nephrectomy (IGRAPN): Combining 3 imaging techniques to perform an anatomical zero ischemia hemi-nephrectomy

By: Gury L., Grande P., Bernhard J-C.
CHU Pellegrin, Dept. of Urology, Bordeaux, France

Aims and objectives of this presentation
V50

Robot-assisted partial nephrectomy for complex (PADUA score ≥10) tumors: Results from a multicenter experience at four high-volume centers

By: Buffi N.1, Lughezzani G.1, Maffei D.1, Dell'Oglio P.2, Casale P.1, Saita A.1, Guazzoni G.F.1, Porter J.3, Porpiglia F.4, Fiori C.4, Amparore D.5, Motttrie A.2
1Humanitas Clinical and Research Center, Dept. of Urology, Milan, Italy, 2Onze-Lieve-Vrouw Hospital, Dept. of Urology, Aalst, Belgium, 3Swedish Urology Group, Dept. of Urology, Seattle, United States of America, 4San Luigi Gonzaga Hospital, Division of Urology, Dept. of Oncology, Turin, Italy, 5San Luigi Gonzaga Hospital, Division of Urology, Department of Oncology, Turin, Italy

Aims and objectives of this presentation
V51

Robot-assisted partial nephrectomy in a patient with multiple tumor lesions in an S-shaped kidney: Superselective arterial clamping guided by the use of 3D images generated by a dedicated software
To be confirmed

Aims and objectives of this presentation
V52
Preclinical immunotherapy approaches in urothelium cancer

Poster Session 32

Sunday 17 March
12:15 - 13:45

Location: Green Area, Room 1

Chairs: K.W. Mouw, Boston (US)
        G. Pignot, Montreuil (FR)
        T.W. Todenhöfer, Tübingen (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 447

Mitomycin C triggers immunogenic cell death in bladder cancer cells

By: Oresta B. 1, Pozzi C. 1, Hurle R. 2, Lazzeri M. 2, Faccani C. 1, Colombo P. 3, Elefante G. 3, Casale P. 2, Guazzoni G. 4, Rescigno M. 5

1Humanitas Clinical and Research Center, Laboratory of Mucosal Immunology and Microbiota, Rozzano, Italy, 2Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, 3Humanitas Clinical and Research Center, Dept. of Pathology, Rozzano, Italy, 4Humanitas Clinical and Research Center, Humanitas University, Dept. of Urology, Rozzano, Italy, 5Humanitas Clinical and Research Center, Humanitas University, Laboratory of Mucosal Immunology and Microbiota, Rozzano, Italy

448

Cytotoxic T cell related gene expression signature predicts improved outcome in muscle-invasive urothelial bladder cancer patients following radical cystectomy and adjuvant chemotherapy

By: Eckstein M. 1, Wirtz R. 2, Strissel P. 3, Pfannstiel C. 1, Wullweber A. 1, Lange F. 1, Erben P. 4, Stoehr R. 1, Bertz S. 1, Geppert C. 1, Fuhrich N. 1, Weyerer V. 1, Taubert H. 5, Ermel M. 6, Breyer J. 7, Otto W. 7, Keck B. 5, Wach S. 5, Kunath F. 5, Strick R. 3, Hartmann A. 1, Wullich B. 5, Sikic D. 5, BRIDGE-Consortium Germany

1University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Pathology, Erlangen, Germany, 2STRATIFYER Molecular Pathology, STRATIFYER Molecular Pathology, Cologne, Germany, 3University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Dept. of Gynecology and Obstetrics, Erlangen, Germany, 4Medical Faculty Mannheim, Ruprecht-Karls-Universität Heidelberg, Dept. of Urology Mannheim, Mannheim, Germany, 5University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Dept. of Urology and Pediatric Urology, Erlangen, Germany, 6TU Munich, Institute of Pathology, Munich, Germany, 7University Hospital, University of Regensburg, Dept. of Urology, Regensburg, Germany

449

The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 overcomes cisplatin resistance in cisplatin-resistant bladder cancer cells
The genomic landscape of muscle-invasive bladder cancer enables a personalized in silico drug discovery

By: Krentel A.F.¹, Singer F.², Gibb E.³, Yang L.³, Davicioni E.³, Kruithof-De Julio M.¹, Seiler R.¹
¹University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²ETH Zürich, Clinical Bioinformatics Unit, Zurich, Switzerland, ³GenomeDX Biosciences, R&D, Vancouver, Canada

Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment

By: Umezu D.¹, Okada N.², Sakoda Y.², Adachi K.², Eto M.¹, Tamada K.²
¹Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan, ²Graduate School of Medicine, Yamaguchi University, Dept. of Immunology, Ube, Japan

Targeting PHGDH exerts anti-oncogenic effects in bladder cancer

By: Yoshino H., Osako Y., Yonemori M., Tatarano S., Enokida H., Nakagawa M.
Graduate School of Medical, Kagoshima University, Dept. of Urology, Kagoshima, Japan

Next-gen STING-agonist like BCG confers enhanced immunogenicity and antitumor efficacy in vitro and in vivo

By: Bivalacqua T.¹, Singh A.², Praharaj M.², Joice G.³, Yoshida T.³, Kates M.³, Mcconkey D.³, Bishai W.²
¹Johns Hopkins University, School Of Medicine, Dept. Of Urology, Baltimore, United States of America, ²Johns Hopkins Medical Institutions, School of Medicine, Baltimore, United States of America, ³Johns Hopkins Medical Institutions, Brady Urological Institute, Baltimore, United States of America

Standard anticancer agents increase the sensitivity of human Vy9Vδ2T cell mediated cytotoxicity through NKG2D ligands in urinary bladder cancer

By: Shimizu T.¹, Miyashita M.², Fujihara A.², Hongo F.², Ukimura O.², Ashihara E.³
¹Matsushita Memorial Hospital, Dept. of Urology, Osaka, Japan, ²Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, ³Kyoto Pharmaceutical University, Dept. of Clinical and Translational Physiology, Kyoto, Japan

Cobicistat, a potent CYP3A4 inhibitor, acts synergistically with oprozomib to cause endoplasmic reticulum stress in bladder cancer cells

By: Sato A., Asano T., Isono M., Okubo K.
National Defense Medical College, Dept. of Urology, Tokorozawa, Japan
| 457 | **Tumor targeting hyaluronic acid nanoparticles with combined phototherapy and hypoxia-activated chemotherapy for bladder preservation in MIBC**  
By: Lin T. 1, Qin H. 2  
1Nanjing Drum Tower Hospital, Medical school of Nanjing University, Dept. of Urology, Nanjing, China, 2Nanjing Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Nanjing, China |
| 458 | **Systematic chemical screening identifies disulfiram as a repositionable drug that enhances sensitivity to cisplatin in bladder cancer: A summary of preclinical studies**  
By: Kita Y. 1, Kobayashi T. 1, Teramoto Y. 2, Tanaka R. 3, Hamada A. 1, Matsumoto K. 1, Murakami K. 1, Saito R. 1, Nakayama K. 1, Takano K. 4, Akamatsu S. 1, Yamasaki T. 1, Inoue T. 1, Tabata Y. 3, Okuno Y. 5, Ogawa O. 1  
1Kyoto University, Dept. of Urology, Kyoto, Japan, 2Kyoto University, Dept. of Clinical Pathology, Kyoto, Japan, 3Kyoto University, Dept. of Regeneration Science and Engineering, Kyoto, Japan, 4Hokkaido Institute of Public Health, Dept. of Environmental and Health Sciences, Hokkaido, Japan, 5Kyoto University, Dept. of Clinical System Onco-Informatics, Kyoto, Japan |
| 459 | **Aberrant error-prone DNA damage repair as a potential therapeutic target for chemo-radiation resistant urothelial carcinoma**  
By: Komura K., Inamoto T., Uehara H., Ibuki N., Minami K., Tsujino T., Azuma H. Osaka Medical College, Dept. of Urology, Takatsuki city, Japan |
| 13:34 - 13:41 | **Summary**  
K.W. Mouw, Boston (US) |
**Active surveillance versus focal therapy in prostate cancer?**

**Poster Session 33**

**Sunday 17 March**

**12:15 - 13:45**

**Location:** Green Area, Room 2

**Chairs:**
- V.J. Gnanapragasam, Cambridge (GB)
- P. Rischmann, Toulouse (FR)
- F. Saad, Montréal (CA)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**460**

**Discontinuation of active surveillance of men with GG2 PCa: Assessment of 14 centres in 8 countries in the Movember GAP3 consortium**


Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

---

**462**

**Using prognosis to guide inclusion criteria, stratify follow up and define standardized end-points in active surveillance for prostate cancer**

By: Gnanapragasam V.J., Barret T., Thankapannair V., Bratt O., Stattin P., Muir K., Lophatananon A.

1. University of Cambridge, Academic Urology Group, Cambridge, United Kingdom
2. University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom
3. Cambridge University Hospitals Trust, Dept. of Urology, Cambridge, United Kingdom
4. Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Gothenburg, Sweden
5. Uppsala University Hospital, Surgical Sciences, Uppsala, Sweden
6. University of Manchester, Dept. of Population Health, Manchester, United Kingdom

---

**463**

**Multiparametric magnetic resonance of the prostate during active surveillance for low-risk prostate cancer: Time to reduce the number of follow-up biopsies?**


1. IEO, European Institute of Oncology, Dept of Urology, Milan, Italy
2. IEO, European Institute of Oncology, Dept of Radiology, Milan, Italy

---

**464**

**Natural history of prostate cancer on active surveillance: Stratification by MRI using the PRECISE recommendations in a UK cohort over 11 years**

Young men with low risk prostate cancer can be safely candidate to active surveillance regardless of the extent of biopsy involvement: Results from a single center series with pathological confirmation

By: Bandini M.\textsuperscript{1}, Scarcella S.\textsuperscript{2}, Suardi N.\textsuperscript{1}, Nocera L.\textsuperscript{1}, Gandaglia G.\textsuperscript{1}, Fossati N.\textsuperscript{1}, Stabile A.\textsuperscript{1}, Dell’Oglio P.\textsuperscript{1}, Shariat S.\textsuperscript{3}, Longo N.\textsuperscript{4}, Mirone V.\textsuperscript{4}, Scuderi S.\textsuperscript{1}, Karakiewicz P.\textsuperscript{5}, Robesti D.\textsuperscript{1}, Rizzo A.\textsuperscript{1}, Cannoletta D.\textsuperscript{1}, Barletta F.\textsuperscript{1}, Pellegrino A.\textsuperscript{1}, Montorsi F.\textsuperscript{1}, Briganti A.\textsuperscript{1}

\textsuperscript{1}IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, \textsuperscript{2}IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, \textsuperscript{3}Vienna General Hospital, Dept. of Urology, Vienna, Austria, \textsuperscript{4}University of Naples Federico II, Dept. of Urology, Naples, Italy, \textsuperscript{5}University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada

Development of novel criteria for active surveillance based on multiparametric MRI alone in men with Gleason 3+4 prostate cancer: Use of imaging to safely expand the eligibility for active surveillance

By: Gandaglia G.\textsuperscript{1}, Ploussard G.\textsuperscript{2}, Valerio M.\textsuperscript{3}, Mattei A.\textsuperscript{4}, Fiori C.\textsuperscript{5}, Fossati N.\textsuperscript{6}, Stabile A.\textsuperscript{6}, Beauval J.\textsuperscript{7}, Malavaud B.\textsuperscript{7}, Roumigué M.\textsuperscript{7}, Dell’Oglio P.\textsuperscript{6}, Suardi N.\textsuperscript{6}, Moschini M.\textsuperscript{4}, Zamboni S.\textsuperscript{4}, Rakauskas A.\textsuperscript{3}, Mirone V.\textsuperscript{8}, De Cobelli F.\textsuperscript{9}, Porpiglia F.\textsuperscript{5}, Montorsi F.\textsuperscript{6}, Briganti A.\textsuperscript{6}

\textsuperscript{1}IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, \textsuperscript{2}Saint Jean Languedoc, La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, \textsuperscript{3}Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, \textsuperscript{4}Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, \textsuperscript{5}San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, \textsuperscript{6}IRCCS Ospedale San Raffaele, Dept. of Urology, Division of Oncology, URI, Milan, Italy, \textsuperscript{7}CHU Rangueil, Dept. of Urology, Andrology and Renal Transplantation, Toulouse, France, \textsuperscript{8}University of Naples Federico II, Dept. of Urology, Naples, Italy, \textsuperscript{9}IRCCS Ospedale San Raffaele, Unit of Clinical Research in Radiology, Experimental Imaging Center, Milan, Italy

A longitudinal study of patients undergoing active surveillance for low grade prostate cancer diagnosed at Transperineal Template Prostate Mapping

Nottingham City Hospital, Dept. of Urology, Nottingham, United Kingdom

Multiparametric MRI can exclude prostate cancer progression in patients under active surveillance
469 Update on 12-month biopsy proven oncological and functional outcomes of primary irreversible electroporation for localised prostate cancer

By: Blazevski A.1, Scheltema M.2, Yuen B.1, Masand N.2, Cusick T.2, Haynes A.2, Stricker P.1
1St. Vincent's Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, 2Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Sydney, Australia

470 10-Year experience of primary cryotherapy for localized prostate cancer treatment: Oncologic and functional outcomes

By: Mercader Barrull C.1, Musquera M.1, Roldán F.L.1, Franco A.1, Fernández C.2, Alcaraz A.1, Ribal M.J.1
1Clinic Hospital, Dept. of Urology, Barcelona, Spain, 2Sant Joan de Déu Hospital, Dept. of Urology, Manresa, Spain

471 Medium term oncological outcomes in a large cohort of men treated with either focal- or hemi-ablation with HIFU for primary localized prostate cancer

1IRCCS Ospedale San Raffaele, Dept. of Urology, Division of Experimental Oncology, Milan, Italy, 2University College London Hospitals, Dept. of Urology, London, United Kingdom, 3University College London, Dept. of Surgery & Interventional Science, London, United Kingdom, 4University College London Hospitals, Dept. of Radiology, London, United Kingdom, 5University College London Hospitals, Dept. of Pathology, London, United Kingdom, 6IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 7Charing Cross Hospital, Imperial College Healthcare NHS Trust, Dept. of Urology, London, United Kingdom

472 Pivotal study of MRI-guided transurethral ultrasound ablation in men with localized prostate cancer: Preliminary results

1Sunnybrook Health Sciences Centre, Dept. of Urology, Toronto, Canada, 2University Hospital Heidelberg, German Cancer Research Center, Dept. of Urology, Heidelberg, Germany, 3Radboud University Medical Center, Dept. of Radiology, Nijmegen, The Netherlands, 4University of Cologne, Dept. of Radiology, Cologne, Germany, 5ResoFus Alomar, Hospital Universitari De Bellvitge, Dept. of Urology, Barcelona, Spain, 6Indiana
Menon-precision prostatectomy (MPP): An idea, development, exploration, assessment, long-term follow-up (IDEAL) stage 1 study

By: Abdollah F., Jeong W., Dalela D., Palma-Zamora I., Sood A., Menon M.
Henry Ford Hospital, Vattikuti Urology Institue, Detroit, United States of America

Sexual function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment

By: Chelly S., Maulaz P., Bigot P., Azzouzi A.R., Lebdai S.
University Hospital Center of Angers, Dept. of Urology, Angers, France
**Staging bladder urothelial cancer in the era of molecular imaging and pathology**

**Poster Session 34**

**Sunday 17 March 12:15 - 13:45**

**Location:** Green Area, Room 3

**Chairs:**
- L-M. Krabbe, Münster (DE)
- P. Mariappan, Edinburgh (GB)
- T. Seisen, Boston (US)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**475**

**Prognostic value of the 1973 and 2004/2016 WHO grading systems in primary Ta/T1 non-muscle invasive urothelial carcinoma of the bladder: A multicenter EAU NMIBC guidelines panel study**

By: Van Rhijn B.W.G. 1, Burger M. 2, Comperat E. 3, Babjuk M. 4, Sylvester R. 5, EAU NMIBC Guideline Panel

1Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Surgical Oncology (Urology), Amsterdam, The Netherlands, 2Caritas St Joseph Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, 3Hôpital Tenon, Sorbonne University, Dept. of Pathology, Paris, France, 4Hospital Motol, Second Faculty of Medicine - Charles University, Dept. of Urology, Prague, Czech Republic, 5European Association of Urology Guidelines Office, Dept. of Statistics, Brussels, Belgium

**Aims and objectives of this presentation**

475

---

**476**

**Vesical imaging-reporting and data system (VI-RADS) for bladder cancer staging with multiparametric MRI**

By: Yoshida S. 1, Tanaka H. 2, Kijima T. 1, Yokoyama M. 1, Ishioka J. 1, Matsuoka Y. 1, Saito K. 1, Fuji Y. 1

1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan

**Aims and objectives of this presentation**

476

---

**477**

**Molecular characterization of neuroendocrine-like bladder cancer**

Aims and objectives of this presentation

477

Co-expression of stem cell and epithelial mesenchymal transition markers in circulating tumor cells of bladder cancer patients

By: Zhang R., Chen H., Huang Y., Xue W.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation

478

Independent multicenter validation of the prognostic significance of histopathologic tumor regression grade after neoadjuvant chemotherapy in bladder cancer

By: Voskuilen C.S.
1, Oo H.Z.
2, Genitsch V.
3, Smit L.A.
4, Vidal A.
5, Meneses M.
6, Necchi A.
7, Xylinas E.
8, Fontugne J.
9, Sibony M.
9, Rouprêt M.
10, Lenfant L.
10, Côté J.
11, Daugaard M.
12, Buser L.
12, Black P.C.
2, Van Rhijn B.W.G.
13, Hendrickx K.
13, Poyet C.
14, Seiler R.
15, Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology

1Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Urology,
Amsterdam, The Netherlands, 2Vancouver Prostate Centre - University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 3University of Bern, Dept. of Pathology, Bern, Switzerland, 4Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Pathology, Amsterdam, The Netherlands, 5Instituto Oncológico FALP, Dept. of Urology, Santiago, Chile, 6Instituto Oncológico FALP, Dept. of Pathology, Santiago, Chile, 7Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 8Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 9Cochin Hospital, Paris Descartes University, Dept. of Pathology, Paris, France, 10Sorbonne Université, Hôpital Pitié-Salpêtrière, Dept. of Urology, Paris, France, 11Sorbonne Université, Hôpital Pitié-Salpêtrière, Dept. of Pathology, Paris, France, 12University Hospital Zurich, Institute of Pathology and Molecular Pathology, Zurich, Switzerland, 13Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 14University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, 15University of Bern, Dept. of Urology, Bern, Switzerland

Aims and objectives of this presentation

Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy


1University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3GenomeDx Inc., Clinical Development, Vancouver, Canada, 4John Hopkins Medical Institute, Dept. of Urology, Baltimore, United States of America, 5University of California San Francisco, Dept. of Urology, San Francisco, United States of America, 6Baylor College of Medicine Medical Center, Dept. of Urology, Houston, United States of America, 7Baylor College of Medicine Medical Center, Dept. of Pathology and Immunology, Houston, United States of America, 8University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America, 9GenomeDX, R&D, San Diego, United States of America, 10University of Texas Health San Antonio, Dept. of Urology, San Antonio, United States of America, 11University of British Columbia, Dept. of Urological Sciences, Vancouver, Canada, 12GenomeDx Inc., R&D, Vancouver, Canada

Aims and objectives of this presentation

Associations between genetic pathways and radiomic metrics in muscle-invasive bladder cancer

By: Lerner S. 1, Duddalwar V. 2, Huang E. 3, Varghese B. 2, King K.G. 2, Cen S.Y. 4, Hwang D. 2, Altun E. 5, Bathala T. 6, Kennish S. 7, Ibarra J. 1, Lucchesi F. 8, Muglia V.F. 9, Thomas S. 10, Vikram R. 6, Kirby J. 11, Jaffe C. 12, Freymann J. 11

1Baylor College of Medicine, Dept. of Urology, Houston, United States of America, 2Keck School of Medicine of USC, Dept. of Radiology, Los Angeles, United States of America,
Aims and objectives of this presentation

481

Prognostic significance of controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients

By: Suzuki H., Takemura K., Ito M., Nakanishi Y., Kataoka M., Sakamoto K., Tobisu K., Koga F.
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

482

Histological characterization of lymph nodes metastasis in mixed urothelial-squamous histological variant at radical cystectomy

ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy

Aims and objectives of this presentation

483

Mixed urothelial-squamous histological variant and its percentage on survival outcomes after radical cystectomy for bladder cancer in patients with lymph node invasion

ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy

Aims and objectives of this presentation

484

Prognosis of rare pathological primary urethral carcinoma

Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
Aims and objectives of this presentation

485

486

Expert pathology review and the impact on clinical management in high-risk bladder cancer patients

By: van Doeveren T. 1, Berendsen S.A. 1, Van Leenders G.J.L.H. 2, Boormans J.L. 1

1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands

Aims and objectives of this presentation

486
Penile cancer: Has quality of care already improved through regionalisation?

**Poster Session 35**

**Sunday 17 March**

12:15 - 13:45

**Location:** Green Area, Room 4

**Chairs:** A. Kadioglu, Istanbul (TR)

C. Protzel, Schwerin (DE)

V. Sangar, Manchester (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

1. **Outcomes of penile cancer patients with micro-metastases in dynamic sentinel lymph node biopsy specimens: An eUROGEN collaboration**

By: Khaw R.A.1, Van Thoor J.2, Albersen M.2, Oliveira P.3, Elliott T.3, Sangar V.3, Lau M.3, Parnham A.3

1University of Manchester, Faculty of Biology, Medicine and Health, Manchester, United Kingdom, 2Universitair Ziekenhuis Leuven, Dept. of Urology, Leuven, Belgium, 3The Christie Foundation NHS Trust, Dept. of Urology, Manchester, United Kingdom

---

2. **Radiotherapy plus chemotherapy versus chemotherapy alone in penile cancer patients with extracapsular nodal extension after inguinal lymph node surgery: A multi-institutional study**

By: Li Z.1, Zhou F.2, Han H.2, Wang B.3, Tang Y.4, Liu N.5, Chen P.6, Liao H.7, Li X.8, Ornellas A.A.9, Mi Q.10

1Shenzhen People’s Hospital, Dept. of Urology, Shenzhen, China, 2Sun Yat-sen University Cancer Cente, Dept. of Urology, Guangzhou, China, 3Cancer Center of Guangzhou Medical University, Dept. of Urology, Guangzhou, China, 4Tumor Hospital of GuangXi Medical College, Dept. of Urology, Nanning, China, 5ChongQing Cancer Hospital & Institute, Dept. of Urology, ChongQing, China, 6Affiliated Tumor Hospital of Xinjiang Medical University, Dept. of Urology, Urumchi, China, 7SiChuang Cancer Hospital & Institute, Dept. of Urology, ChengDu, China, 8West China Hospital, Dept. of Urology, Chengdu, China, 9Brazilian National Cancer Institute, Dept. of Urology, Rio de Janeiro, Brazil, 10Dong Guan People’s Hospital, Dept. of Urology, Dongguan, China

---

3. **Treatment outcomes of penile intraepithelial neoplasia (PeIN) related to P16 status**

By: Ashley S.1, Cleaveland P.1, Oliveira P.1, Clarke N.1, Parr N.2, Lucky M.3, Lau M.1, Parnham A.1, Sangar V.1

1The Christie NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, 2Wirral University Hospitals NHS Foundation Trust, Dept. of Urology, Wirral, United Kingdom
Predicting overall survival (OS) in patients (pts) with penile squamous cell carcinoma (PSCC) undergoing regional lymph node dissection (LND) ± multimodal therapy

By: Necchi A.¹, Mariani L.¹, Zhu Y.², Ye D-W.³, Ornellas A.⁴, Watkin N.⁵, Ager M.⁵, Lo Vullo S.¹, Hakenberg O.⁶, Heidenreich A.⁷, Raggi D.¹, Catanzaro M.¹, Salvioni R.¹, Chipollini J.⁸, Azizi M.⁸, Spiess P.⁸
¹Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ³Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ⁴Hospital Mário Kröeff and Brazilian Cancer Institute, Dept. of Urology, Rio de Janeiro, Brazil, ⁵St. George’s University Hospitals, Dept. of Urology, London, United Kingdom, ⁶University Hospital Rostock, Dept. of Urology, Rostock, Germany, ⁷Universitätsklinikum Köln, Dept. of Urology, Cologne, Germany, ⁸Moffitt Cancer Center and Research Institute, Dept. of Urology, Tampa, United States of America

Results of a 10 year multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis (SCCP)

By: Ager M.¹, Njoku K.², Serra M.³, Pickering L.⁴, Afshar M.⁴, Beesley S.⁵, Robinson A.⁶, Crellin P.⁷, Vyas L.⁸, Kayes O.⁸, El mamoun M.⁸, Eardley I.⁹, Ayres B.¹, Henry A.², Tree A.³, Watkin N.¹
¹St George’s University Hospital NHS Trust, Dept. of Urology, London, United Kingdom, ²Leeds Teaching Hospital NHS Trust, Dept. of Oncology, Leeds, United Kingdom, ³Royal Marsden NHS Trust, Dept. of Oncology, London, United Kingdom, ⁴St George’s University Hospital NHS Trust, Dept. of Oncology, London, United Kingdom, ⁵Maidstone and Tunbridge Well NHS Trust, Dept. of Oncology, Maidstone, United Kingdom, ⁶Brighton and Sussex University Hospital NHS Trust, Dept. of Oncology, Brighton, United Kingdom, ⁷Poole NHS Foundation Trust, Dept. of Oncology, Poole, United Kingdom, ⁸Leeds Teaching Hospital NHS Trust, Dept. of Urology, Leeds, United Kingdom, ⁹Leeds Teaching Hospital NHS TrustTeaching Hospital NHS Trust, Dept. of Urology, Leeds, United Kingdom

International multi-center analysis of factors predicting the presence of non-sentinel node inguinal metastases in penile cancer patients undergoing completion inguinal lymph node dissection following positive sentinel node biopsy

By: Nowers J.¹, Afshar M.¹, Ottenhof S.², Djajadiningrat R.², English C.¹, Lam W.³, Ayres B.¹, Horenblas S.², Watkin N.¹
¹St George’s Hospital, Dept. of Urology, London, United Kingdom, ²The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital , Dept. of Urology, Amsterdam, The Netherlands, ³Hong Kong University, Dept. of Urology, Hong Kong, Hong Kong

The SentiPen trial from eUROGEN & The NCRI (UK): Concordance of Sienna+/Sentimag with Standard 99mTc labeled nanocolliod technique for the detection of inguinal sentinel lymph nodes in patients with cN0 penile cancer
Trends in surgical treatment for penile cancer in Germany from 2006 to 2015: Rising case numbers and moderate centralization

By: Groeben C.¹, Koch R.², Baunacke M.¹, Borkowitz A.¹, Thomas C.¹, Huber J.¹
¹Medical Faculty Carl Gustav Carus, TU Dresden, Dept. of Urology, Dresden, Germany,
²Medical Faculty Carl Gustav Carus, TU Dresden, Dept. of Medical Statistics and Biometry, Dresden, Germany

Surveillance algorithm for node positive squamous cell carcinoma of the penis

By: Ager M.¹, Manjunath A.¹, Yan S.¹, Corbishley C.², Tinwell B.², Afshar M.³, Tree A.⁴, Ayres B.¹, Watkin N.¹
¹St George's University Hospital NHS Trust, Dept. of Urology, London, United Kingdom,
²St George's University Hospital NHS Trust, Dept. of Pathology, London, United Kingdom,
³St George's University Hospital NHS Trust, Dept. of Clinical Oncology, London, United Kingdom,
⁴Royal Marsden NHS Trust, Dept. of Clinical Oncology, London, United Kingdom

Chemoradiation in the treatment of loco-regionally advanced penile cancer

By: Ottenhof S.R.¹, Doodeman B.², Vrijenhoek G.L.², Djajadiningrat R.S.³, Horenblas S.¹, Pos F.J.²
¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands,
²Netherlands Cancer Institute, Dept. of Radiotherapy, Amsterdam, The Netherlands,
³Leids Universitair Medisch Centrum, Dept. of Urology, Leiden, The Netherlands

Summary

V. Sangar, Manchester (GB)
# How technology will change your practice in the next decade - the appealing image of new experimental technologies

**Poster Session 36**

**Sunday 17 March**

**12:15 - 13:45**

**Location:** Green Area, Room 5

**Chairs:**
- P.M. Kronenberg, Lisbon (PT)
- U. Nagele, Hall in Tirol (AT)
- E. Nemr, Beirut (LB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

### 498

**The changing face of urologic oncologic surgery from 2000-2018 (63 141 patients) - impact of robotics**

By: Gill I.S., Cacciamani G.E.
University of Southern California, Dept. of Urology, Los Angeles, United States of America

### 499

**Transcription and protein phenotyping with 3D pathology: Light-sheet microscopy overlooks cellular malignancy of intact tumour volumes**

By: Tanaka N., Kanatani S., Kaczynska D., Louhivuori L., Oya M., Miyakawa A., Uhlén P.

1. Keio University School of Medicine, Dept. of Urology, Tokyo, Japan
2. Karolinska Institutet, Dept. of Medical Biochemistry and Biophysics, Stockholm, Sweden
3. Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden

### 500

**Characterization of bladder organoid cultures from healthy and cancer tissues**

By: Patard P.M., Rubio A., Tostivint V., Rouget C., Lluel P., Vergnolle N., Gamé X.

1. Rangueil University Hospital, Dept. of Urology, Andrology and Kidney Transplantation, Toulouse, France
2. Inserm, Institut de Recherche en Santé Digestive, Inserm, U1220, Toulouse, France
3. University of Toulouse, CHU Rangueil, Dept. of Urology, Andrology and Kidney Transplantation, Toulouse, France
4. Urosphere, Dept. of Urology, Andrology and Kidney Transplantation, Toulouse, France

### 501

**Holographic surgical planning of partial nephrectomy using a wearable mixed reality computer**

By: Yoshida S., Fukuda S., Moriyama S., Yokoyama M., Taniguchi N., Shinjo K., Sugimoto M., Saito K., Fujii Y.

1. Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan
2. Holoeyes Inc., Dept. of Urology, Tokyo, Japan

---

**Scientific Programme - EAU19 Barcelona**

---
| 502 | **Biodistribution and toxicity of gold nanoparticle-based photo-immuno-nanotherapy for bladder cancer**  
By: Barton G.¹, Liu Y.², Maccarini P.², Palmer G.³, Etienne W.¹, Tan W.P¹, Vo-Dinh T.², Inman B.¹  
¹Duke University Medical Center, Dept. of Urology, Durham, United States of America,  
²Duke University Medical Center, Dept. of Biomedical Engineering, Durham, United States of America,  
³Duke University Medical Center, Dept. of Radiation Oncology, Durham, United States of America |
| 503 | **Remarkable difference between 3D and 2D cultures of bladder cancer cells in response to drugs: A concrete example for importance of 3D culture**  
By: Yoshida T.¹, Kates M.², Liu X.², Joice G.², Sopko N.², McConkey D.², Bivalacqua T.²  
¹Hyogo Prefectural Nishinomiya Hospital, Dept. of Urology, Nishinomiya, Japan,  
²The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America |
| 504 | **One year follow up of use of chitosan membranes after nerve-sparing radical prostatectomy: Results of a comparative study**  
By: Porpiglia F., Manfredi M., Checcucci E., Garrou D., Cattaneo G., Amparore D., De Cillis S., Volpi G., Piramide F., Piana A., Ragni F., Fion F.  
AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy |
| 506 | **Cerenkov luminescence imaging for intraoperative specimen analysis: A pre-clinical evaluation**  
By: Olde Heuvel J.¹, De Wit-Van Der Veen L.¹, Stokkel M.P.M.¹, Van Der Poel H.G.², Tuch D.S.³, Grootendorst M.R.³, Vyas K.N.³, Slump C.H.⁴  
¹Netherlands Cancer Institute, Antoni van Leeuwenhoek, Dept. of Nuclear Medicine, Amsterdam, The Netherlands,  
²Netherlands Cancer Institute, Antoni van Leeuwenhoek, Dept. of Urology, Amsterdam, The Netherlands,  
³Lightpoint Medical Ltd, Chesham, United Kingdom,  
⁴University of Twente, MIRA Institute for Biomedical Technology and Technical Medicine, Enschede, The Netherlands |
| 507 | **Implementation of grayscale values of hypoechoic lesions in transrectal ultrasound-guided biopsy for predicting prostate cancer and clinically significant prostate cancer: A validating confirmatory study**  
By: Park J.S., Koo K.C., Chung B.H., Lee K.S.  
Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea |
| 508 | **Real-time high resolution diagnostic imaging for prostatic tissue with ex vivo fluorescence confocal microscopy: Our preliminary experience**  
By: Puliatti S.¹, Bertoni L.², Pirola G.M.¹, Azzoni P.², Bevilacqua L.¹, Eissa A.³, Elsherbiny A.³, Sighinolfi M.C.¹, Chester J.², Rocco B.M.C.¹, Micali S.¹, Bagni I.⁴ |
<table>
<thead>
<tr>
<th>509</th>
<th>Early experience on IR technology for kidney graft re-perfusion assessment. An ESUT-YAUWP project</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Veneziano D.¹, Basile G.¹, Sgrò E.¹, Sergi F.¹, Sicuro O.¹, Carbone L.¹, Bevacqua M.¹, Rivas J.G.², Cacciamani G.³, Okhunov Z.⁴, Socarras M.⁵, Dourado A.⁶, Breda A.⁷, Cozzupoli P.¹</td>
</tr>
<tr>
<td>¹</td>
<td>Grande Ospedale Metropolitano BMM, Dept. of Urology and Kidney Transplant, Reggio Calabria, Italy, ²Hospital Universitario la Paz, Dept. of Urology, Madrid, Spain, ³University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁴University of California Irvine, Dept. of Urology, Los Angeles, United States of America, ⁵Camargo Cancer center, Dept. of Urology, Sao Paulo, Brazil, ⁶Hospital São Marcos, Dept. of Urology, Teresina, Brazil, ⁷Fundacio Puigvert, Dept. of Urology, Barcelona, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>510</th>
<th>Utilisation of the HoloLens mixed-reality device in minimally invasive surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Al Janabi H.F.¹, Aydin A.¹, Palaneer S.¹, Macchione N.², Al-Jabir A.¹, Khan M.S³, Dasgupta P.³, Ahmed K.³</td>
</tr>
<tr>
<td>¹</td>
<td>King's College London, MRC Centre for Transplantation, London, United Kingdom, ²Università degli Studi di Milano, ASST Santi Paolo e Carlo, Milan, Italy, ³Guy’s and St. Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>511</th>
<th>Electrophysiological differences between typical and dense benign prostatic hyperplasia tissues retrieved after holmium laser enucleation of the prostate</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Kim H.W.¹, Shin D.G.¹, Lee J.Z.¹, Yoon C.S.², Choi S.³, Cho W.Y.⁴, Min K.S.⁵, Oh T.H.⁶, Lee W.⁷, Lee J.H.⁸</td>
</tr>
<tr>
<td>¹</td>
<td>Pusan National University Hospital, Dept. of Urology, Busan, South Korea, ²BHS Hanseo Hospital, Dept. of Urology, Busan, South Korea, ³Kosin University College of Medicine, Dept. of Urology, Busan, South Korea, ⁴Dong-A University Hospital, Dept. of Urology, Busan, South Korea, ⁵Inje University Busan Paik Hospital, Dept. of Urology, Busan, South Korea, ⁶Samsung Changwon Hospital, Dept. of Urology, Changwon, South Korea, ⁷Ulsan-jeil Hospital, Dept. of Urology, Ulsan, South Korea, ⁸Gwangju Institute of Science and Technology, Biomedical Science and Engineering, Gwangju, South Korea</td>
</tr>
</tbody>
</table>

| 512 | Electric stimulation hyperthermia relieves inflammation via toll-like receptor 4 (TLR-4) suppressor of cytokine signaling (SOCS) pathway in chronic prostatitis/ |
chronic pelvic pain syndrome

Seoul St. Mary's Hospital, Catholic University of Korea, Dept. of Urology, Seoul, South Korea
New modalities for staging of recurrent prostate cancer
Poster Session 37

Sunday 17 March
12:15 - 13:45

Location: Green Area, Room 10

Chairs: G.P. Haas, Syracuse (US)
W.C. Loidl, Linz (AT)
N. Suardi, Milan (IT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

513

Follow-up after robot-assisted radical prostatectomy with sentinel node biopsy and lymph node dissection: Analysis of biochemical recurrences with PSMA-PET/CT

By: Brouwer O.R. 1, Wit E. 1, Van Leeuwen P.J. 1, Van Leeuwen F.W.B. 2, Van Der Poel H.G. 1
1The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands,
2Leiden University Medical Center, Dept. of Interventional Molecular Imaging, Leiden, The Netherlands

Aims and objectives of this presentation

514

18F-rhPSMA7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy

By: Maurer T. 1, Kroenke M. 2, Wurzer A. 3, Ulrich L. 2, Jooß L. 2, Horn T. 4, Haller B. 5
, Weber W. 2, Wester H-J. 3, Eiber M. 2
1Martini-Klinik, Dept. of Urology, UKE, Hamburg, Germany,
2TUM, Dept. of Nuclear Medicine, Munich, Germany,
3TUM, Dept. of Radiochemistry, Munich, Germany,
4TUM, Dept. of Urology, Munich, Germany,
5TUM, Dept. of Medical Statistics and Epidemiology, Munich, Germany

Aims and objectives of this presentation

515

How does 68Ga-PSMA PET/CT impact the treatment management in patients with prostate cancer recurrence after surgery?

By: Bianchi L. 1, Borghesi M. 1, Barbaresi U. 1, Mineo Bianchi F. 1, Castellucci P. 2, Ceci F. 2, Chessa F. 1, Casablanca C. 1, Beretta C. 1, Pultrone C.V. 1, Dababneh H. 1, Nanni C. 2, Schiavina R. 1, Fanti S. 2, Brunocilla E. 1
1S.Orsola-Malpighi University Hospital, University of Bologna, Dept. of Urology, Bologna, Italy,
2S.Orsola-Malpighi University Hospital, University of Bologna, Dept. of Metropolitan Nuclear Medicine, Bologna, Italy
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>515</th>
</tr>
</thead>
<tbody>
<tr>
<td>Validation of strategies for selective bone scan staging in Australian men with newly diagnosed prostate cancer</td>
<td>516</td>
</tr>
<tr>
<td>By: Hiwase M. 1, Vincent A. 2, O'Callaghan M. 3, South Australian-Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC)</td>
<td></td>
</tr>
<tr>
<td>1University of Adelaide, Adelaide Medical School, Adelaide, Australia, 2University of Adelaide, Freemasons Centre for Men’s Health, Adelaide, Australia, 3Flinders Medical Centre, Dept. of Urology, Adelaide, Australia</td>
<td></td>
</tr>
<tr>
<td>Pitfalls of PSMA imaging for nodal recurrences after radical prostatectomy: Comparison of PET/CT results with histopathology and PSMA immunostaining</td>
<td>517</td>
</tr>
<tr>
<td>By: Linxweiler J. 1, Sprenk J. 1, Hölters S. 1, Pryanukhin A. 2, Ezziddin S. 3, Bohle R.M. 4, Ohlmann C.H. 5, Stückle M. 1, Saar M. 1, Junker K. 1</td>
<td></td>
</tr>
<tr>
<td>1Saarland University, Dept. of Urology, Homburg Saar, Germany, 2Bonn University, Dept. of Pathology, Bonn, Germany, 3Saarland University, Dept. of Nuclear Medicine, Homburg Saar, Germany, 4Saarland University, Dept. of Pathology, Homburg Saar, Germany, 5Saarland University, Malteser Hospital Bonn, Dept. of Urology, Homburg Saar, Germany</td>
<td></td>
</tr>
<tr>
<td>68Ga-PSMA-11 PET/CT in recurrent prostate cancer: Efficacy in different clinical stages of PSA failure</td>
<td>518</td>
</tr>
<tr>
<td>By: Ceci F. 1, Castellucci P. 1, Graziani T. 1, Farolfi A. 1, Fonti C. 1, Lodi F. 1, Bianchi L. 2, Borghesi M. 2, Pultrone C.V. 2, Schiavina R. 2, Brunocilla E. 3, Fanti S. 1</td>
<td></td>
</tr>
<tr>
<td>1S.Orsola-Malpighi Hospital, University of Bologna, Dept. of Nuclear Medicine, Bologna, Italy, 2S.Orsola-Malpighi Hospital, University of Bologna, Dept. of Urology, Bologna, Italy, 3S.Orsola-Malpighi Hospital, University of Bologna, Dept. of Urology, Bologna, Italy</td>
<td></td>
</tr>
<tr>
<td>The value of 99mTc-PSMA SPECT/CT guided surgery for recurrent prostate cancer patients</td>
<td>519</td>
</tr>
<tr>
<td>By: Su H., Ye D., Zhu Y.</td>
<td></td>
</tr>
<tr>
<td>Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China</td>
<td></td>
</tr>
</tbody>
</table>
Clinical impact of "true whole-body" Ga-68-PSMA I&T PET/CT: Lesion frequency and added benefit in lower extremities

By: Stolzenbach L.F. 1, Maurer T. 1, Budäus L. 1, Steuber T. 1, Graefen M. 1, Sauer M. 2, Kobayashi Y. 2, Apostolova I. 2, Berliner C. 2

1University Medical Center Hamburg-Eppendorf, Martini Klinik, Hamburg, Hamburg, Germany, 2University Medical Center Hamburg-Eppendorf, Department for Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg, Hamburg, Germany

Aims and objectives of this presentation

520

Quantitative whole-body magnetic resonance imaging to predict prognosis in patients with metastatic prostate cancer: A prospective study

By: Iwamura H. 1, Kaiho Y. 1, Ito J. 1, Anan G. 1, Sato M. 2

1Tohoku Medical and Pharmaceutical University, Dept. of Urology, Sendai, Japan, 2Tohoku Medical and Pharmaceutical University Hospital, Dept. of Urology, Sendai, Japan

Aims and objectives of this presentation

521

Raman spectral signature of serum for prostate cancer bone metastases screening

Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation

522

Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging


1University of Duisburg-Essen and German Cancer Consortium (DKTK), partner site University Hospital Essen, Dept. of Urology, Essen, Germany, 2University of Duisburg-Essen and German Cancer Consortium (DKTK), partner site University Hospital Essen, Dept. of Nuclear Medicine, Essen, Germany, 3Peter MacCallum Cancer Centre, Dept. of Cancer Imaging, Melbourne, Australia, 4University of California Los Angeles, Dept. of Molecular and Medical Pharmacology, Los Angeles, United States of America, 5LMU, Dept. of Nuclear Medicine, Munich, Germany, 6Université de Montréal, Centre Hospitalier de l'Université de Montréal, Montréal, Canada, 7University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America, 8Massachusetts General Hospital Cancer Center and Harvard Medical School,
Aims and objectives of this presentation

523

Metastasis-directed therapy for oligoprogressive castration refractory prostate cancer

By: Berghen C. 1, Joniau S. 2, Ost P. 3, Poels K. 1, Everaerts W. 2, Haustermans K. 1, De Meerleer G. 1
1UZLeuven, Dept. of Radiation Oncology, Leuven, Belgium, 2UZLeuven, Dept. of Urology, Leuven, Belgium, 3UZ Ghent, Dept. of Radiation Oncology, Ghent, Belgium

Aims and objectives of this presentation

524

Loco-regional radiotherapy targeting oligo-progressive lesions in castration-resistant prostate cancer patients: Intra-pelvic localized progressive lesions are the good targets

By: Yoshida S. 1, Takahara T. 2, Ishii C. 3, Nakagawa K. 4, Toda K. 4, Arita Y. 5, Kijima T. 1, Yokoyama M. 1, Ishioka J. 1, Matsuoka Y. 1, Saito K. 1, Yoshimura R. 4, Fujii Y. 1
1Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, 2Tokai University School of Engineering, Dept. of Biomedical Engineering, Kanagawa, Japan, 3AIC Yaesu Clinic, Dept. of Radiology, Tokyo, Japan, 4Tokyo Medical and Dental University Graduate School, Dept. of Radiation Therapeutics and Oncology, Tokyo, Japan, 5Keio University School of Medicine, Dept. of Diagnostic Radiology, Tokyo, Japan

Aims and objectives of this presentation

525

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration resistant prostate cancer

By: Grubmüller B. 1, Senn D. 2, Kramer G. 1, Baltzer P. 3, D’Andrea D. 1, Eidherr H. 2, Haug A. 2, Wadsak W. 2, Pfaff S. 2, Hacker M. 2, Shariat S.F 1, Hartenbach M. 2
1Medical University of Vienna, Dept. of Urology, Vienna, Austria, 2Medical University of Vienna, Dept. of Biomedical Imaging and Image guided Therapy, Division of Nuclear Medicine, Vienna, Austria, 3Medical University of Vienna, Dept. of Biomedical Imaging and Image guided Therapy, Division of General and Pediatric Radiology, Vienna, Austria

Aims and objectives of this presentation

526
<table>
<thead>
<tr>
<th>13:34 - 13:41</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N. Suardi, Milan (IT)</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
</tr>
<tr>
<td>527</td>
<td>Urothelial ATP is implicated in the appearance of detrusor underactivity (DU) early after bladder outlet obstruction (BOO) and in the recovery of detrusor function after obstruction relief</td>
</tr>
<tr>
<td>528</td>
<td>Reduced apoptosis of bladder cells for the improved bladder underactivity after transplantation of HGF over-expressing mesenchymal stem cell</td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

530

The nicotine-induced alterations in oxidative stress parameters in the rat bladder

By: Tsounapi P. 1, Honda M. 1, Teraoka S. 1, Kimura Y. 1, Hikita K. 1, Zachariou A. 2, Sofikitis N. 2, Saito M. 3, Takenaka A. 1

1Tottori University Faculty of Medicine, Dept. of Urology, Yonago, Japan, 2University of Ioannina School of Medicine, Dept. of Urology, Ioannina, Greece, 3Kochi Medical School, Dept. of Pharmacology, Nankoku-shi, Japan

Aims and objectives of this presentation

531

Role of corticotropin-releasing factor on bladder function in rats with psychological stress

By: Seki M., Zha X-M., Ito H., Aoki Y., Matsuta Y., Taga M., Inamura S., Yokoyama O.

School of Medical Science, University of Fukui, Dept. of Urology, Fukui, Japan

Aims and objectives of this presentation

532

MicroRNA-126 transferred by extracellular vesicles of human adipose-derived stem cells enhances regenerated bladder angiogenesis via SDF-1α/CXCR4 pathway

By: Xiao D., Lu M., Yan H., Lv X.G., Zhang M.

Shanghai Renji Hospital, Dept. of Urology and Andrology, Shanghai, China

Aims and objectives of this presentation

533

Inhibition of detrusor contractions by the LIM kinase inhibitors, SR7826 and LIMKi3: A new anti-contractile strategy and implications for a role of LIM kinases in the control of detrusor muscle

By: Yu Q. 1, Hennenberg M. 2, Wang R. 2, Wang X. 2, Li B. 2, Duan X. 1, Zeng G. 1

1The First Affiliated Hospital Of Guangzhou Medical University, Dept. of Urology, Guangzhou, China, 2Ludwig Maximilian University of Munich, Dept. of Urology, Munich, Germany

Aims and objectives of this presentation

534

Dysregulation of phospholamban and beta 3-adrenergic receptor expression might lead to bladder detrusor overactivity via SERCA inhibition

By: Monastyrskaya K. 1, Besic M. 1, Hashemi Gheinani A. 1, Burkhard F.C. 2
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>534</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large-conductance voltage- and calcium-activated potassium channels regulate contraction function of human bladder smooth muscle cells under hydrostatic pressure</td>
<td>535</td>
</tr>
<tr>
<td>By: Wang K.J., He Q., Luo D., Ai J., Jin X., Gong L., Xiao K., Hong L. West China Hospital, Sichuan University, Dept. of Urology, Laboratory of Reconstructive Urology, Chengdu, China</td>
<td>535</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>536</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial inhibition of activin receptor-like kinase 4 alleviates bladder fibrosis caused by bladder outlet obstruction</td>
<td>536</td>
</tr>
<tr>
<td>By: Wang N., Shen H., Qi J. Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China</td>
<td>536</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>537</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibitory effect of tibial nerve stimulation on the micturition reflex in the rat</td>
<td>537</td>
</tr>
<tr>
<td>By: Jianwen Z., Jiang C., Li W., Liao J. The Sixth Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, QingYuan, China</td>
<td>537</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>538</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinary miRNA profiles discriminate between BPO patients and healthy controls</td>
<td>538</td>
</tr>
<tr>
<td>By: Kueffer M., Besic M., Hashemi Gheinani A., Vassella E., Schneider M., Burkhard F.C., Monastyrskaya K. 1 University of Bern, Dept. of BioMedical Research, Bern, Switzerland, 2 University of Bern, Institute of Pathology, Bern, Switzerland, 3 University Hospital, Dept. of Urology, Bern, Switzerland</td>
<td>538</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>539</th>
</tr>
</thead>
<tbody>
<tr>
<td>The circadian rhythm of bladder clock genes in spontaneously hypertensive rat</td>
<td>539</td>
</tr>
<tr>
<td>By: Kimura Y., Honda M., Sasaki R., Panagiota T., Morizane S., Hikita K.</td>
<td>539</td>
</tr>
</tbody>
</table>
Osaki M. ², Okada F. ², Takenaka A. ¹
¹Tottori University, Division of Urology, Faculty of Medicine, Yonago, Japan, ²Tottori University, Division of Pathological Biochemistry, Yonago, Japan

Aims and objectives of this presentation
539

540

Molecular characterization of bladder pain syndrome identifies functional mRNA-microRNA regulatory modules

By: Hashemi Gheinani A. ¹, Burkhard F. ², Rehrauer H. ³, Aquino Fournier C. ³, Rémi B. ⁴, Monastyrska Y. ¹
¹University of Bern, Urology Research Laboratory, Dept. of BioMedical Research, Bern, Switzerland, ²University Hospital, Dept. of Urology, Bern, Switzerland, ³ETH Zurich, Functional Genomics Center, Zurich, Switzerland, ⁴University Hospital, Interfaculty Bioinformatics Unit, Bern, Switzerland

Aims and objectives of this presentation
540

541

What factors affect both urethral and rectal function in a female rat model?

By: Kitta T., Ouchi M., Kanno Y., Higuchi M., Togo M., Takahashi Y., Moriya K., Shinohara N.
Hokkaido University, Dept. of Urology, Sapporo, Japan

Aims and objectives of this presentation
541
**Is mp MRI enough (IMRIE) in prostate cancer diagnosis?**


¹King’s College Hospital, Dept. of Urology, London, United Kingdom, ²Guy’s Hospital, Dept. of Urology, London, United Kingdom, ³Canterbury Centre for Robotic Urological Surgery, Dept. of Urology, Eastbourne, United Kingdom, ⁴Glasgow Royal Infirmary, Dept. of Urology, Glasgow, United Kingdom, ⁵Southmead Hospital, Dept. of Urology, Bristol, United Kingdom, ⁶Brighton and Sussex University Hospital, Dept. of Urology, Brighton, United Kingdom, ⁷Ashford and St. Peter’s Hospital, Dept. of Urology, Ashford, United Kingdom, ⁸Princess Alexandra Hospital, Dept. of Urology, Harlow, United Kingdom, ⁹Imperial College London, Dept. of Urology, London, United Kingdom, ¹⁰University College London Hospitals (UCLH), Dept. of Urology, London, United Kingdom

**Aims and objectives of this presentation**

542

---

**Do performance characteristics of multi-parametric MRI of the prostate change according to patient age? Clinical implications for age-tailored biopsy approaches**

By: Stabile A.¹, Dell’Oglio P.¹, Soligo M.², De Cobelli F.³, Gandaglia G.¹, Zaffuto E.¹, Fallara G.¹, Fossati N.¹, Boeri L.², Scuderi S.¹, Deho’ F.¹, Esposito A.³, Del Maschio A.³, Karnes J.², Montorsi F.¹, Briganti A.¹

¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy

**Aims and objectives of this presentation**

543
Artificial Intelligence for automated Gleason Grading in prostate cancer biopsies

By: Marginean F-E.¹, Krzyzanowska A.¹, Arvidsson I.², Simoulis A.³, Sjöblom E.⁴, Lundström C.⁴, Overgaard N.C.², Ehmström R.³, Åström K.⁵, Heyden A.², Bjartell A.¹

¹Lund University, Faculty of Medicine, Division of Urological Cancers, Malmö, Sweden, ²Lund University, Centre for Mathematical Sciences, Lund, Sweden, ³Skåne University Hospital, Dept. of Pathology, Malmö, Sweden, ⁴Sectra, Linköping, Linköping, Sweden, ⁵Lund University, Centre for Mathematical Sciences, Lund, Sweden

Aims and objectives of this presentation

544

External validation and comparison of multivariable prostate cancer risk calculators incorporating multiparametric magnetic resonance imaging

By: Saba K.¹, Wettstein M.S.¹, Lieger L.¹, Märzendorfer O.¹, Hötker A.M.², Donati O.F.², Poyet C.¹, Sulser T.¹, Eberli D.¹, Mortezavi A.¹

¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital Zurich, Institute of Diagnostic and Interventional Radiology, Zurich, Switzerland

Aims and objectives of this presentation

545

Radiogenomic characterization of multifocal prostate cancer

By: Salami S.¹, Kaplan J.², Nallandhighal S.¹, Takhar M.³, Tosioan J.¹, Lee M.¹, Yoon J.⁴, Hovelson D.⁵, Plouffe K.², Kaffenberger S.¹, George A.¹, Montgomery J.¹, Davenport M.⁶, You S.⁴, Tomlins S.², Curci N.⁶, Kim H.⁷, Spratt D.⁸, Udager A.², Palapattu G.¹

¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³GenomeDx Biosciences Inc., Clinical Laboratory, San Diego, United States of America, ⁴Cedars-Sinai Medical Center, Dept. of Biomedical Sciences, Los Angeles, United States of America, ⁵Strata Oncology, Clinical Laboratory, Ann Arbor, United States of America, ⁶University of Michigan, Dept. of Radiology, Ann Arbor, United States of America, ⁷Cedars-Sinai Medical Center, Dept. of Surgery, Los Angeles, United States of America, ⁸University of Michigan, Dept. of Radiation Oncology, Ann Arbor, United States of America

Aims and objectives of this presentation

546

Prostate MRI, with or without targeted biopsy and standard biopsy for detecting prostate cancer: A Cochrane systematic review and meta-analysis

By: Drost F.J.¹, Osses D.F.¹, Nieboer D.², Bangma C.H.², Steyerberg E.W.³, Roobol M.J.², Schoots I.G.⁴

¹Erasmus University Medical Center, Dept. of Radiology & Nuclear Medicine and Dept. of
Scientific Programme - EAU19 Barcelona

Urology, Rotterdam, The Netherlands, 2Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, 3Erasmus MC University Medical Center, Dept. of Public Health, Rotterdam, The Netherlands, 4Erasmus University Medical Center, Dept. of Radiology & Nuclear Medicine, Rotterdam, The Netherlands

Aims and objectives of this presentation
547

Pathological findings at radical prostatectomy of biopsy naïve men submitted to MRI-targeted biopsy alone without standard systematic sampling

By: Luzzago S. 1, Catellani M. 1, Mistretta F.A. 1, Conti A. 1, Di Trapani E. 1, Brescia A. 1, Pricolo P. 2, Alessi S. 2, Verweij F. 1, Ferro M. 1, Matei D. 1, Renne G. 3, Petralia G. 2, Musi G. 1, De Cobelli O. 1
1IEO, European Institute of Oncology, Dept. of Urology, Milan, Italy, 2IEO, European Institute of Oncology, Dept. of Radiology, Milan, Italy, 3IEO, European Institute of Oncology, Dept. of Pathology, Milan, Italy

Aims and objectives of this presentation
548

Diagnostic accuracy of targeted prostate biopsies: Results from a prospective trial comparing micro-ultrasound with multiparametric MRI for the detection of prostate cancer

By: Maffei D. 1, Paciotti M. 1, Lazzeri M. 1, Colombo P. 2, Fasulo V. 1, Domanico L. 1, Casale P. 1, Saita A. 1, Hurle R. 1, Buffi N. 1, Guazzoni G.F. 1, Lughezzani G. 1
1Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, 2Humanitas Clinical and Research Center, Dept. of Pathology, Rozzano, Italy

Aims and objectives of this presentation
549

There is no way to avoid concomitant systematic prostate biopsies in addition to mp-MRI targeted sampling in men with positive imaging

By: Dell’Oglio P. 1, Stabile A. 1, Soligo M. 2, Zaffuto E. 1, Boeri L. 2, De Cobelli F. 3, Brembilla G. 3, Cannoletta D. 1, Gandaglia G. 1, Fossati N. 1, Esposito A. 3, Del Maschio A. 3, Suardi N. 1, Karnes J. 2, Montorsi F. 1, Briganti A. 1
1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy

Aims and objectives of this presentation
550

Fusion biopsy improves prostate cancer detection in the first set biopsy:
Development of a clinical nomogram

551
By: De Nunzio C. 1, Simone G. 2, Ferriero M. 2, Papalia R. 3, Ludovico G.M. 4, Giacobbe A. 5, Oderda M. 5, Muto G. 5, Gallucci M. 2, Sica A. 1, Scarcia M. 6, Lombardo R. 1, Tubaro A. 1

1 Sapienza University of Rome, Sant’Andrea Hospital, Dept. of Urology, Rome, Italy, 2 IFO, Istututo Nazionale Tumori Regina Elena Hospital, Dept. of Urology, Rome, Italy, 3 Campus Bio-Medico University Hospital, Dept. of Urology, Rome, Italy, 4 Ospedale F. Miulli, Dept. of Urology, Acquaviva delle Fonti, Italy, 5 Humanitas Gradenigo, Dept. of Urology, Gradenigo, Italy, 6 Humanitas Gradenigo, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation

551

Outcomes of transperineal prostate biopsy using local anesthesia by trainee urologists during learning curve: Comparison with those of senior urologists

By: Ito M., Madoka K., Takemura K., Suzuki H., Sakamoto K., Nakanishi Y., Tobisu K., Koga F.
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

552

A multi-institutional randomized controlled trial comparing novel first generation high-resolution micro-ultrasound with conventional frequency ultrasound for transrectal prostate biopsy

By: Pavlovich C. 1, Hyndman M.E. 2, Eure G. 3, Ghai S. 4, Fradet V. 5
1 Johns Hopkins University Brady Urological Institute, Dept. of Urology, Baltimore, United States of America, 2 University of Calgary, Prostate Centre Calgary, Calgary, Canada, 3 Urology Of Virginia, Dept. of Urology, Virginia Beach, United States of America, 4 University Health Network, University of Toronto, Joint Dept. of Medical Imaging, Toronto, Canada, 5 CHU de Québec-Laval University, Dept. of Surgery, Quebec, Canada

Aims and objectives of this presentation

553

Could 68Ga-PSMA PET/CT play a role in primary prostate cancer localisation? A single institution comparative analysis of 68Ga PSMA PET/CT, multiparametric MRI and prostate biopsy

Royal Brisbane and Women’s Hospital, Dept. of Urology, Brisbane, Australia

Aims and objectives of this presentation

554

Contrast enhanced ultrasound for the localization of prostate cancer – correlation with radical prostatectomy specimens

Aims and objectives of this presentation

555
By: Gayet M.¹, Postema A.², Van Sloun R.³, Wildeboer R.³, Schalk S.³, Mannaerts C.², Beerlage H.², Mischi M.³, Wijkstra H.³
¹Jeroen Bosch Hospital, Dept. of Urology, 's-Hertogenbosch, The Netherlands,
²Amsterdam University Medical Centers, Dept. of Urology, Amsterdam, The Netherlands,
³Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, The Netherlands

Aims and objectives of this presentation

V90

Associated video presentation Transperineal systematic prostate biopsy under local anaesthesia using brachytherapy grid with accurate localization of biopsy cores on 3D ultrasound mapping

By: Chiu P.K.¹, Teoh J.Y.¹, Yee C.H.¹, Li S.Y.¹, Kwok S.W.¹, Chan C.K.¹, Hou S.M.¹, Ng C.F.²
¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong,
²SH Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong

Aims and objectives of this presentation

V90
Paediatric urology: Penile and hypospadias reconstruction
Poster Session 40

Sunday 17 March
12:15 - 13:45

Location: Green Area, Room 19
Chairs: A. Bujons Tur, Barcelona (ES)
To be confirmed
D.J. Summerton, Leicester (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

556
Hypospadias complexity score (HCS): A new tool for predicting operating time and complications in hypospadias surgery

By: Bandini M.¹, Sekulovic S.², Stanojevic N.², Slavkovic M.², Spiridonescu B.³, Dangi A.D⁴, Krishnappa P.⁵, Petic V.², Briganti A.¹, Salonia A.¹, Montorsi F.¹, Djinovic R.²
¹Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, ²Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, ³Fundeni Clinical Institute, Center for Uronephrology and Renal Transplantation, Bucharest, Romania, ⁴Christian Medical College and Hospital, Dept. of Urology, Vellore, Tamil Nadu, India, ⁵NU Hospitals, Dept. of Urology, Bangalore, India

557
Genetic variants related to sex hormone biosynthesis, genital tubercle, and urethral development as a predictive marker for hypospadias

By: Han J.H., Song S.H., Choi J., Kim K.S.
Asan Medical Center, Dept. of Urology, Seoul, South Korea

558
High-throughput gene sequencing to investigate the methylation of the androgen gene in patients with hypospadias

By: Liu Y., Lv X., Ye W., Wu M., Huang Y.
Renji Hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China

559
How to make the best choice of hypospadias repair: A 10-year data analysis

By: Jiang X., Ye W.
Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Dept. of Urology, Shanghai, China

561
Proximal hypospadias repair with the Koyanagi urethroplasty: Results as a two-stage procedure and complications easily managed

To be confirmed
562 Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in proximal hypospadias: A feasibility, safety and protocol compliance assessment study

By: Bandini M.1, Sekulovic S.2, Spiridonescu B.3, Dangi A.D.4, Krishnappa P.5, Stanojevic N.2, Pesic V.2, Slavkovic M.2, Briganti A.1, Salonia A.1, Montorsi F.1, Djinovic R.2

1Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, 2Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, 3Fundeni Clinical Institute, Center for Uronephrology and Renal Transplantation, Bucharest, Romania, 4Christian Medical College and Hospital, Dept. of Urology, Vellore, India, 5NU Hospitals, Dept. of Urology, Bangalore, India

563 Montage procedure: One-stage repair using an inner preputial graft with prepuce flap for penoscrotal hypospadias with severe chordee

By: Ye W., Jiang X.
Renji Hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China

564 Covering the skin tube and urethral anastomosis by spongiosum to prevent fistula at the anastomotic site in inner prepuce flap repair

By: Bhat A.L.1, Bhat M.2, Khandelwal N.3, Bhat A.3
1Jaipur National University institute for medical Sciences and Research Centre, Dept. of Urology, Jaipur, India, 2NIIMS, Dept. of Urology, Jaipur, India, 3S.P. Medical College Bikaner, Dept. of Surgery, Bikaner, India

565 Real prevalence and severity of penile curvature in different types of hypospadias

By: Sekulović S.1, Bandini M.2, Spiridonescu B.3, Stanojevic N.1, Slavkovic M.4, Deep Dangi A.5, Krishnappa P.6, Pesic V.7, Montorsi F.2, Djinovic R.1

1Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, 2San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Urological Research Institute (URI), Milan, Italy, 3Fundeni Clinical Institute, Center for Uronephrology and Renal Transplantation, Bucharest, Romania, 4University Children's Hospital Tirsova, Dept. of Urology, Belgrade, Serbia, 5Christian Medical College and Hospital, Dept. of Urology, Vellore, India, 6NU Hospitals, Dept. of Urology, Bangalore, India, 7Clinical Center Dr Dragisa Misovic-Dedinje, Dept. of Urology, Belgrade, Serbia

566 Corporeal penile curvature (CPC) and surgical complications in hypospadias repairs: Associations and outcomes

By: Bandini M.1, Sekulović S.2, Dangi A.D.3, Krishnappa P.4, Stanojevic N.2, Pesic V.2, Slavkovic M.2, Spiridonescu B.5, Briganti A.1, Salonia A.1, Montorsi F.1, Djinovic R.2

1Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy, 2Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Belgrade, Serbia, 3Fundeni Clinical Institute, Center for Uronephrology and Renal Transplantation, Bucharest, Romania, 4Christian Medical College and Hospital, Dept. of Urology, Vellore, India, 5NU Hospitals, Dept. of Urology, Bangalore, India, 6NU Hospitals, Dept. of Urology, Bangalore, India, 7Clinical Center Dr Dragisa Misovic-Dedinje, Dept. of Urology, Belgrade, Serbia
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>567</td>
<td>Risk factors of concomitant undescended testis in patients with hypospadias</td>
<td>Hirata Y., Moriya K., Nakamura M., Kon M., Nishimura Y., Shinohara N.</td>
<td>Hokkaido University Graduate School of Medicine, Dept. of Renal and Genitourinary Surgery, Sapporo, Japan</td>
</tr>
<tr>
<td>568</td>
<td>Prevalence and surgical management of pubic hypertrophy in hypospadias patients: Results from a high-volume surgeon</td>
<td>Bandini M., Sekulović S., Stanojevic N., Spiridonescu B., Dangi A.D., Krishnappa P., Pesic V., Slavkovic M., Briganti A., Salonia A., Montorsi F., Djinovic R.</td>
<td>Urological Research Institute (URI), San Raffaele Hospital, Vita-Salute San Raffaele University, Unit of Urology, Milan, Italy; Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Unit of Genito-Urinary Reconstructive Surgery, Belgrade, Serbia; Sava Perovic Foundation, Center for Genito-Urinary Reconstructive Surgery, Unit of Genito-Urinary Reconstructive Surgery, Belgrade, Serbia; Fundeni Clinical Institute, Center for Uronephrology and Renal Transplantation, Bucharest, Romania; Christian Medical College and Hospital and Hospital, Dept. of Urology, Tamil Nadu, India; NU Hospitals, Dept. of Urology, Bangalore, India</td>
</tr>
<tr>
<td>569</td>
<td>Cowper's gland syringoceles: A multicentre analysis</td>
<td>Waterschoot M., Floyd Jr M.S., Hermans B., Ackaert K., Goeman L., Joniau S.</td>
<td>University of Leuven, Dept. of Urology, Leuven, Belgium; AZ Turnhout, Dept. of Urology, Turnhout, Belgium; AZ Delta, Dept. of Urology, Roeselare, Belgium</td>
</tr>
<tr>
<td>570</td>
<td>Urethral reconstruction for pelvic fracture urethral distraction defects in boys: A 10-year experience</td>
<td>Sa S., Lin W., Chongrui J.</td>
<td>Shanghai Jiaotong University Affiliated Sixth People's Hospital, Dept. of Urology, Shanghai, China; Shanghai Children's Hospital, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China</td>
</tr>
</tbody>
</table>
Modern management of non-muscle invasive bladder cancer: Towards precision medicine and immunotherapy

Location: Green Area, Room 20
Chairs: P.S-K. Chu, Hong Kong (HK)
        L. Izquierdo Reyes, Barcelona (ES)
        Y. Neuzillet, Suresnes (FR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*571

**Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study**

By: Boormans J.L.¹, Balar A.V.², De Wit R.¹, Kamat A.³, Uchio E.⁴, Mourey L.⁵, Krieger L.⁶, Singer E.A.⁷, Bajorin D.⁸, Grivas P.⁹, Seo H.K.¹⁰, Nishiyama H.¹¹, Konety B.¹², Nam K.¹³, Kapadia E.¹⁴, Frenkl T.¹⁴, Kulkarini G.S.¹⁵

¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Perlmutter Cancer Center at NYU Langone Health, Genitorurinary Medical Oncology, New York, United States of America, ³The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁴UC Irvine Health, Dept. of Urology, Orange, United States of America, ⁵University Institute Cancer Toulouse Oncopole, Dept. of Medical Oncology, Toulouse, France, ⁶Royal North Shore Hospital, Northern Cancer Institute, St. Leonards, Australia, ⁷Rutgers Cancer Institute of New Jersey, Dept. of Urologic Oncology, New Brunswick, United States of America, ⁸Memorial Sloan Kettering Cancer Center, Dept. of Medical Oncology, New York, United States of America, ⁹University of Washington, Dept. of Medical Oncology, Seattle, United States of America, ¹⁰National Cancer Center, Dept. of Urology, Goyang, South Korea, ¹¹University of Tsukuba, Dept. of Urology, Tsukuba, Japan, ¹²University of Minnesota, Dept. of Urology, Minneapolis, United States of America, ¹³Merck & Co., Inc., Dept. of Medical Oncology, Kenilworth, United States of America, ¹⁴Merck & Co., Inc., Dept. of Medical Oncology, Kenilworth, United States of America, ¹⁵University of Toronto, UHN Princess Margaret Cancer Center, Toronto, Canada

**Aims and objectives of this presentation**

571

572

**Reducing recurrence in non-muscle invasive bladder cancer by systematically implementing guideline-based recommendations: Outcome of a prospective intervention effort in primary bladder cancer patients**

By: Sörenby A.K.¹, Baseckas G.¹, Bendahl P-O.², Brändstedt J.¹, Håkansson U.¹
Aims and objectives of this presentation

574

**Bipolar en bloc tumor resection versus standard monopolar TURBT in non-muscle invasive bladder cancer – a medium-term, prospective, randomized-controlled comparison**

By: Geavlete B., Multescu R., Georgescu D., Moldoveanu C., Ene C., Bulai C., Balan G., Ene A., Geavlete P.
Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania

575

**12 month results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk (LR) non-muscle invasive bladder cancer (NMIBC)**

Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, Institute of Cancer Research, ICR-CTSU, London, United Kingdom, James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom, University Hospitals of Leicester NHS Trust, Clinical Sciences Unit, Leicester, United Kingdom, University College London Hospital, Dept. of Oncology, London, United Kingdom, University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, Gloucestershire Hospitals NHS Foundation Trust, Dept. of Urology, Cheltenham, United Kingdom, Royal Devon and Exeter NHS Foundation Trust, Exeter Surgical Health Services Research Unit, Exeter, United Kingdom, The Royal Wolverhampton Hospitals NHS Trust, Dept. of Urology, Wolverhampton, United Kingdom, Medway NHS Trust, Dept. of Urology, Gillingham, United Kingdom, University College London, UCL Cancer Institute, London, United Kingdom, St James’s University Hospital, Leeds Institute of Cancer and Pathology, Leeds, United Kingdom, Patient Representative, Hampshire, United Kingdom

576

**The use of selenium and vitamin E supplementation to prevent recurrence of non-muscle-invasive bladder cancer: results of the SELENIB trial**

Aims and objectives of this presentation

576

Development and validation of a simulator-based test in transurethral resection of bladder tumors (TURB) establishing pass/fail standards

By: Bube S.H. 1, Hansen R.B. 2, Dahl C. 1, Konge L. 3, Azawi N. 1
1Zealand University Hospital, Dept. of Urology, Roskilde, Denmark, 2Herlev/Gentofte Hospital, Dept. of Urology, Herlev, Denmark, 3Rigshospitalet, Copenhagen Academy for Medical Education and Simulation, Copenhagen, Denmark

Aims and objectives of this presentation

577

HIVEC HR: Chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a randomized controlled trial

By: González Padilla D.A. 1, González Díaz A. 1, Miranda-Utrera N. 1, De La Rosa Kehrmann F. 1, Villacampa-Aubá F. 2, Guerrero-Ramos F. 1
1Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain, 2Clínica Universidad de Navarra, Dept. of Urology, Madrid, Spain

Aims and objectives of this presentation

578

A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC)

By: Purshouse K. 1, Woodcock V.K. 1, Butcher C. 2, Haddon C. 1, Verrall G. 3, Elhussein L. 4, Salio M. 5, Middleton M.R. 1, Cerundolo V. 6, Kwok J. 1, Blagden S. 1, Protheroe A.S. 1, Yassin M. 7, Crew J. 3
1University of Oxford, Dept. of Oncology, Oxford, United Kingdom, 2Oncology Clinical Trials Office, Dept. of Oncology, Oxford, United Kingdom, 3Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, 4Centre for Statistics in Medicine, Dept. of Statistics,
Aims and objectives of this presentation

579

A prospective, randomized controlled trial regarding antimicrobial prophylaxis in transurethral resection of the bladder tumor (TURB): An interim analysis of the prophylaxis001-trial

By: Baten E., Arijs I., Goethuys H., Vandecandelaere M., Cartuyvels R., Van Der Aa F., Van Renterghem K.

1 UZLeuven, Dept. of Urology, Leuven, Belgium, 2 UHasselt, Dept. of Biomedical Sciences, Hasselt, Belgium, 3 ZOL Genk, Dept. of Urology, Genk, Belgium, 4 KULeuven, Dept. of Educational Sciences, Leuven, Belgium, 5 Jessa Ziekenhuis, Dept. of Microbiology, Hasselt, Belgium, 6 Jessa Ziekenhuis, Dept. of Urology, Leuven, Belgium

Aims and objectives of this presentation

580

Comparing prognosis of photodynamic diagnosis with 5-aminolaevulinic acid or hexylaminolevulinate and narrow band imaging versus white light cystoscopy for non-muscle invasive bladder cancer

By: Chen C., Jian H., Yue Z., Hao H.

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

Aims and objectives of this presentation

581

What advantage does the re-TUR offer in non-muscle invasive bladder cancer, when is it really necessary and can PDD help us with these questions?

By: Sailer E., Krause S., Graf S., Tauber V.

Kepler Universtitätsklinikum Linz Med Campus III., Dept. of Urology, Linz, Austria

Aims and objectives of this presentation

582

Neoadjuvant short-term intensive chemoresection vs. standard adjuvant intravesical instillations in NMIBC: Preliminary results on tolerability and adverse events

By: Skydt Lindgren M., Dyrskjøt Andersen L., Bue P., Bjerregaard Jensen J.

1 Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, 2 Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, 3 Regional Hospital West Jutland, Dept. of Urology, Holstebro, Denmark
Aims and objectives of this presentation
583

Predictive factors for the absence of residual disease at repeated TURBT: Can we avoid a repeat TURBT in selected patients?

By: Soria F. 1, D'Andrea D. 2, Moschini M. 3, Hurle R. 4, Colombo R. 3, Altieri V. 5, Gust K.M. 2, Shariat S.F. 2, Gontero P. 1

1AOU Città della Salute e della Scienza di Torino, Presidio Molinette, Dept. of Urology, Turin, Italy, 2Medical University of Vienna, Vienna General Hospital, Dept. of Urology and Comprehensive Cancer Center, Vienna, Austria, 3Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, 4Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Dept. of Urology, Milan, Italy, 5University of Salerno, Dept. of Urology, Salerno, Italy

Aims and objectives of this presentation
584
**ESU/ESFFU Hands-on Training Course in Sacral Neuromodulation**

*Location: Green Area, Room 7*

**Chair:** H. Hashim, Bristol (GB)

**Tutors:**
- K. Everaert, Ghent (BE)
- E. Chartier-Kastler, Paris (FR)
- D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)
- S. Musco, Florence (IT)
- S. Arlandis Guzman, Valencia (ES)
- L. Thomas, Bristol (GB)
- P. Van Kerrebroeck, Maastricht (NL)

**Aims and objectives of this session**

A practical hands-on workshop that will allow the participants to practise on models the different steps of performing sacral neuromodulation including primary percutaneous nerve evaluation, tined lead and battery implantation and programming and also troubleshooting.

- Understand the indications for SNM
- Be able to perform the different steps of the procedure in a standardised format
- Be able to troubleshoot problems with SNM

**13:00 - 15:00**

H. Hashim, Bristol (GB)
ESU/ESUT/ESUI Hands-on Training Course in Prostate MRI reading for urologists

HOT 22

Sunday 17 March
13:00 - 16:30

Location: Green Area, Room 9

Chair: C. Moore, London (GB)

Tutors: V. Panebianco, Rome (IT)
        C. Allen, London (GB)
        L. Boesen, Vedbaek (DK)

Aims and objectives of this session
This course will provide interactive teaching from expert Faculty in prostate MRI reading and interpretation and help Urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS and Likert scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their own laptops followed by a reference reading provided by expert radiologists and pathological verification.
**Imaging in urology**
Expert-Guided Poster Tour 08

**Sunday 17 March**
**13:15 - 15:15**

**Location:** Green Area, Room A

**Chairs:**
T. Loch, Flensburg (DE)
R. Schiavina, Bologna (IT)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

---

13:45 - 13:48

**Introduction**
T. Loch, Flensburg (DE)
R. Schiavina, Bologna (IT)

---

**PT193**

**Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusion-weighted MRI**

By: Kaneko K.¹, Yoshida S. ¹, Arita Y. ², Yamamoto K. ³, Kijima T. ¹, Yokoyama M. ¹, Ishioka J. ¹, Matsuoka Y. ¹, Saito K. ¹, Fujii Y. ¹
¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Keio University, Dept. of Diagnostic Radiology, Tokyo, Japan, ³Tokyo Medical and Dental University, Dept. of Pathology, Tokyo, Japan

**Aims and objectives of this presentation**
PT193

---

**PT194**

**Characterization of complex renal cystic masses: Comparison among CT, MRI and CEUS in the same series of patients**

By: Verzotti E.¹, Sachs C. ², Campo I. ², Boltri M. ¹, Currò I. ², Cavallaro M. ², Cova M.A. ², Bertolotto M. ², Liguori G. ¹, Trombetta C. ¹
¹Università degli Studi di Trieste, Dept. of Urology, Trieste, Italy, ²Università degli Studi di Trieste, Dept. of Radiology, Trieste, Italy

**Aims and objectives of this presentation**
PT194

---

**PT195**

**Usefulness of numerical imaging analysis for distinguishing pathologic features in small renal masses: A development and validation study**

### Aims and objectives of this presentation

**PT195**

**Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT**

By: Meyer A.R.¹, Rowe S.², Carducci M.³, Denmeade S.³, Markowski M.³, Pomper M.², Allaf M.¹, Gorin M.¹

¹Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, ²Johns Hopkins University School of Medicine, Dept. of Radiology, Baltimore, United States of America, ³Johns Hopkins University School of Medicine, Dept. of Oncology, Baltimore, United States of America

**Aims and objectives of this presentation**

**PT196**

**Anatomical accuracy of 3D-printed patient-specific kidney models used for robot-assisted-partial nephrectomy pre-operative planning (UroCCR study N° 39 : 3D-PRINT)**

By: Michiels C.¹, Jambon E.², Sarrazin J.³, Faessel M.³, Latxague C.¹, Boulenger De Hauteclouque A.¹, Capon G.¹, Bensadoun H.¹, Robert G.¹, Ferrière J-M.¹, Bos F.³, Grenier N.², Bernhard J-C.¹

¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²Bordeaux University Hospital, Dept. of Radiology, Bordeaux, France, ³Bordeaux University Technology Institute, Additive Fabrication Engineering, Bordeaux, France

**Aims and objectives of this presentation**

**PT197**

**Could computed tomography volumetric scanning-split renal volume of the live-donor affects donor side selection?**

By: Zahran M.H.¹, Galal A.¹, Refaie H.², Fakhreldin I.¹, Harraz A.¹, Osman Y.¹, Ali-El-Dein B.¹

¹Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt, ²Urology and Nephrology Center, Mansoura University, Dept. of Radiology, Mansoura, Egypt

**Aims and objectives of this presentation**

**PT198**

**Evaluation of renal volume and adipose tissue distribution as predictors of renal function after radical nephrectomy**

By: Olivero A.¹, Basso L.², Barabino E.², Milintenda P.¹, Testino N.¹, Pacchetti A.¹, Neumaier C.E.³, Terrone C.¹

**Aims and objectives of this presentation**

**PT199**
Aims and objectives of this presentation
PT200

Diagnostic and staging performance of mpMRI-US fusion prostate biopsy: Prospective analysis on consecutive radical prostatectomy specimens from a multicentre series

By: Ferriero M.C. 1, Flammia R.S. 1, Tuderti G. 1, Anceschi U. 1, Brassetti A. 1, Oderda M. 2, Peltier A. 3, Kumar P. 4, Roche J. 5, Piechaud T. 5, Descotes J.L. 6, Mastroianni R. 1, Giacobbe A. 7, Puglisi M. 8, Malossini G. 8, Papalia R. 9, Guaglianone S. 1, Muto G. 7, Gontero P. 2, Gallucci M. 1, Simone G. 1

1Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2University of Turin, Dept. of Surgical Sciences, Urology, Turin, Italy, 3Institut Jules Bordet, Universite Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, 4Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, 5Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, 6Centre Hospitalier Universitaire de Grenoble, Dept. of Urology, Grenoble, France, 7Humanitas Gradenigo Hospital, Dept. of Urology, Turin, Italy, 8Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, 9Campus Bio Medico University, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation
PT200

Can pre biopsy mpMRI accurately predict the pathological stage at robotic assisted radical prostatectomy? A case series of 1421 mpMRIs

By: Stanowski M. 1, Quraishi M.K. 1, Kommu S. 1, Morrison I. 2, Streeter E. 1, Eddy B. 1

1Kent and Canterbury Hospital, East Kent Hospitals University NHS Foundation Trust, Dept. of Urology, Canterbury, United Kingdom, 2Kent and Canterbury Hospital, East Kent Hospitals University NHS Foundation Trust, Dept. of Radiology, Canterbury, United Kingdom

Aims and objectives of this presentation
PT201

Added value of mpMRI, MRI-targeted and systematic biopsy in the prediction of adverse pathologic features in contemporary prostate cancer patients undergoing radical prostatectomy

By: Gandaglia G. 1, Ploussard G. 2, Valerio M. 3, Mattei A. 4, Fiori C. 5, Fossati N. 1, Stabile A. 1, Beauval J. 6, Malavaud B. 6, Roumiguie M. 6, Robesti D. 1, Dell'Oglio P. 1, Moschini M. 4, Zamboni S. 4, Rakauskas A. 3, Dehò F. 1, Gallina A. 1, De Cobelli F. 7, Porpiglia F. 5, Montorsi F. 1, Scuderi S. 8, Briganti A. 1
<table>
<thead>
<tr>
<th>PT202</th>
<th>Extracapsular extension on multiparametric MRI better predicts pT3 disease at radical prostatectomy compared to perineural Invasion on biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Griffiths L., Kotamarti S., Mikhail D., Villani R., Vira M., Hall S., Schwarz M., Richstone L.</td>
</tr>
<tr>
<td></td>
<td>Arthur Smith Institute for Urology at Northwell Health, Dept. of Urology, New Hyde Park, United States of America</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT203</th>
<th>Multiparametric MRI outperforms the Partin tables, Memorial Sloan Kettering Cancer Center nomogram, and CAPRA score in predicting extraprostatic cancer in patients undergoing radical prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Giannarini G., Girometti R., Crestani A., Rossanese M., Calandriello M., Zuiani C., Valotto C., Ficarra V.</td>
</tr>
<tr>
<td></td>
<td>¹Academic Medical Centre Santa Maria della Misericordia, Dept. of Urology, Udine, Italy, ²University of Udine, Dept. of Medicine, Urology Unit, Udine, Italy, ³University of Messina, Dept. of Human and Paediatric Pathology “Gaetano Barresi”, Urology Section, Messina, Italy, ⁴University of Udine, Dept. of Medicine, Radiology Unit, Udine, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT204</th>
<th>Contrast media kinetics in multiparametric MRI before radical prostatectomy predicts probability of postoperative incontinence</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Schmid F.A., Wettstein M.S., Kessler T.M., Boss A., Eberli D.</td>
</tr>
<tr>
<td></td>
<td>¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²Balgrist University Hospital, Dept. of Neuro-Urology, Zurich, Switzerland, ³University Hospital Zurich, Dept. of Radiology, Zurich, Switzerland</td>
</tr>
</tbody>
</table>
Validation of Gallium-68 PSMA-PET/CT for primary lymph node staging in prostate cancer patients

By: Van Kalmthout L. 1, Van Melick H. 2, Lavalaie J. 3, Kooistra A. 4, De Klerk J. 5, Meijer R 6, De Keizer B. 7, Lam M. 7

1 UMC Utrecht, Nuclear Medicine, Dept. of Urology, Utrecht, The Netherlands, 2 St. Antonius Ziekenhuis, Dept. of Urology, Nieuwegein, The Netherlands, 3 St. Antonius Ziekenhuis, Nuclear Medicine, Nieuwegein, The Netherlands, 4 Meander Medisch Centrum, Dept. of Urology, Amersfoort, The Netherlands, 5 Meander Medisch Centrum, Nuclear Medicine, Amersfoort, The Netherlands, 6 UMC Utrecht, Dept. of Urology, Utrecht, The Netherlands, 7 UMC Utrecht, Nuclear Medicine, Utrecht, The Netherlands

Aims and objectives of this presentation

PT206

Impact of 18F-DCFPyL PET scanning in patients undergoing post prostatectomy radiotherapy (IMPPORT) – preliminary results of a prospective multi-site trial

By: Koschel S. 1, Sutherland T. 2, Wong L. 1, Taubman K. 3, Yap K. 3, Schlicht S. 3, Ng M. 4

1 St Vincent's Hospital Melbourne, Dept. of Urology, Melbourne, Australia, 2 St Vincent's Hospital Melbourne, Medical Imaging, Melbourne, Australia, 3 St Vincent's Hospital Melbourne, Nuclear Medicine, Melbourne, Australia, 4 Genesis Care St Vincent's Melbourne, Radiation Oncology, Melbourne, Australia

Aims and objectives of this presentation

PT207

Radioactive tracer guided metastasectomy of 68Ga-PSMA-PET/CT positive lesions in patients with rising prostatic-specific antigen after definitive treatment of prostate cancer

By: Rahnama'i M.S. 1, Von Mallek D. 2, Lehnhardt M. 1, Heinzel A. 2, Mottaghy F. 2, Heinzel A. 2, Bach C. 1

1 Uniklinik RWTH Aachen, Dept. of Urology, Aachen, Germany, 2 Uniklinik RWTH Aachen, Dept. of Nuclear Medicine, Aachen, Germany

Aims and objectives of this presentation

PT208

External validation of the CHAARTED and LATITUDE criteria in patients with hormone-naive metastatic prostate cancer: A multi-institutional study in Japan


1 Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2 Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan, 3 Akita
### Aims and objectives of this presentation

**PT209**

Impact of patient’s real-time visualization of flexible cystoscopy finding on pain in a randomized controlled trial

By: Prasanchaimontri P., Tritipwanit S., Prachapinyo T.
Ratchaburi Hospital, Dept. of Surgery, Ratchaburi, Thailand

### Aims and objectives of this presentation

**PT210**

Application of narrow-band imaging flexible ureteroscopy in the treatment of upper urinary tract transitional carcinomas

By: Hao Y.
Peking University Third Hospital, Dept. of Urology, Beijing, China

### Aims and objectives of this presentation

**PT211**

Narrow band imaging reduces persistence of cancer in patients with pT1 high grade bladder cancer

By: Mirabile G. ¹, Lombardo R. ², Tariciotti P. ¹, Gentile B.C. ¹, Tema G. ¹, Alanesi L. ¹, Mavilla L. ¹, Aloisi P. ¹, Rizzo G. ¹, Bellangino M. ¹, Lopes Mendes A.L. ¹, Giulianelli R. ¹

¹Nuova Villa Claudia, Dept. of Urology, Rome, Italy, ²Sapienza University of Roma, Dept. of Urology, Rome, Italy

### Aims and objectives of this presentation

**PT212**

Development of a rodent model for preclinical evaluation of multiple contrast agents and real-time multispectral imaging in bladder cancer

By: Günes C. ¹, Meessen S. ¹, Rother J. ², Kriegmair M.C. ³, Zheng X. ¹, Hernandez D. ², Grychtol B. ², Deliolanis N. ², Bolenz C. ¹

¹University of Ulm, Dept. of Urology, Ulm, Germany, ²University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany, ³University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany
<table>
<thead>
<tr>
<th>Presentation Code</th>
<th>Title</th>
<th>Authors and Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT213</td>
<td>Aims and objectives of this presentation</td>
<td></td>
</tr>
<tr>
<td>PT214</td>
<td>Diagnostic accuracy of image technique based transurethral resection for non-muscle invasive bladder cancer</td>
<td>Chen C., Hao H., Tianxin L., Jian H. Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China</td>
</tr>
<tr>
<td>PT215</td>
<td>Preoperative FDG-PET/CT predicts non-organ-confined disease and disease recurrence in patients with upper urinary tract urothelial carcinoma</td>
<td>Asai S., Nishida K., Watanabe R., Koyama K., Sawada Y., Noda T., Fukumoto T., Miura N., Yanagihara Y., Miyauchi Y., Miyagawa M., Kikugawa T., Saika T. Ehime Prefectural Central Hospital, Dept. of Urology, Matsuyama, Japan, Ehime University School of Medicine, Dept. of Urology, Toon, Japan, Ehime University School of Medicine, Dept. of Radiology, Toon, Japan</td>
</tr>
<tr>
<td>PT216</td>
<td>Defining better cut-off value for peak systolic velocity and resistance index under Penile Doppler ultrasound for patient with erectile dysfunction in correlation with computed tomography, pelvic angiography and angioplasty</td>
<td>Tung S-Y., Chang Y-K., Chang H-C., Wang T-D., Lee W-J., Liu S-P., Hsieh J-T. National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, National Taiwan University Hospital, Dept. of Cardiology, Taipei, Taiwan, National Taiwan University Hospital, Dept. of Radiology, Taipei, Taiwan</td>
</tr>
<tr>
<td>PT217</td>
<td>Color-coded contrast enhanced voiding urosonography (CE-VUS/ADI): Implementation into pediatric urologic routine by non-radiologists</td>
<td>Steinkellner L., Haid B., Oswald J. Hospital of the Sisters of Charity, Dept. of Pediatric Urology, Linz, Austria, Hospital of the Sisters of Charity, Dept. of Urology, Linz, Austria, Hospital of the Sisters of Charity, Dept. of Pediatric Urology, Linz, Austria</td>
</tr>
<tr>
<td>PT218</td>
<td>Level of knowledge on radiation and compliance to protective equipment: Where do urologists stand? An ESUT/EULIS survey</td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

PT218

Fluoroscopy-use during ureterorenoscopy: Are urologists concerned about radiation exposure?

By: Henderickx M.M.E.L., Baard J., Beerlage H.P., Kamphuis G.M. Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands

Aims and objectives of this presentation

PT219
Overactive bladder, nocturia, bladder pain and other bothersome lower urinary tract symptoms

Expert-Guided Poster Tour 09

Sunday 17 March
13:15 - 15:15

Location: Green Area, Room B

Chairs: F.C. Burkhard, Bern (CH)
        A.G. Giannantoni, Perugia (IT)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

13:45 - 13:48
Introduction
F.C. Burkhard, Bern (CH)
A.G. Giannantoni, Perugia (IT)

PT220
Longitudinal intravital imaging of transplanted mesenchymal stem cells elucidates their functional integration and therapeutic potency in an animal model of interstitial cystitis/bladder pain syndrome

By: Ryu C-M. ¹, Shin J.H. ¹, Yu H.Y. ¹, Lee J. ¹, Shin D-M. ², Choo M-S. ¹
¹Asan Medical Center, Dept. of Urology, Seoul, South Korea,
²Asan Medical Center, Dept. of Biomedical Sciences, Seoul, South Korea

PT221
Bladder pain induced by chronic stress is mediated by a systemic increase of nerve growth factor involving the activation of adrenoceptors

By: Dias B. ¹, Cruz F. ¹, Charrua A. ²
¹Faculty of Medicine of University of Porto, Dept. of Urology, Porto, Portugal,
²Faculty of Medicine of University of Porto, Dept. of Biomedicine, Porto, Portugal

PT222
Anti-inflammatory mechanism of indoleamine 2,3-dioxygenase inhibition in the chronic prostatic inflammation

By: Ohira S. ¹, Nishishita N. ², Tone S. ³, Hara R. ¹, Fujii T. ¹, Miyaji Y. ¹, Nagai A. ¹
¹Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan,
²Graduate School of Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan,
³Graduate School of Tokyo Denki University, Dept. of Life Science and Engineering, Hiki-gun, Saitama, Japan

PT223
The role of GM-CSF in a mouse model of experimental autoimmune prostatitis
### PT224

**Palmitoylethanolamide/polydatin as add-on therapy in pain resistant patients with interstitial cystitis/bladder painful syndrome**

By: Gubbiotti M., Illiano E., Costantini E., Giannantoni A.  
1 Istituto Serafico di Assisi, University of Perugia, Dept. of Biomedical and Surgical Sciences, Perugia, Italy, 2 University of Perugia, Dept. of Biomedical and Surgical Sciences, Andrological and Urogynaecological Clinic, Perugia, Italy, 3 University of Siena, Dept. of Medical and Surgical Sciences and Neurosciences, Siena, Italy

### PT225

**Intravesical therapy for interstitial cystitis/bladder pain syndrome: A systematic review and network meta-analysis**

By: Yeh T-C., Chen P-C., Chang H-C., Tu Y-K.  
1 National Taiwan University Hospital Hsin-Chu Branch, Dept. of Urology, Hsinchu City, Taiwan, 2 En Chu Kong Hospital, Dept. of Urology, New Taipei City, Taiwan, 3 National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan, 4 National Taiwan University, Institute of Epidemiology and Preventive Medicine, Taipei City, Taiwan

### PT226

**Factors affecting the period between the first and second hydrodistension in females with painful bladder syndrome and interstitial cystitis**

1 Pusan National University Hospital, Dept. of Urology, Busan, South Korea, 2 BHS Hane-seo Hospital, Dept. of Urology, Busan, South Korea, 3 Kosin University College of Medicine, Dept. of Urology, Busan, South Korea, 4 Dong-A University Hospital, Dept. of Urology, Busan, South Korea, 5 Inje University Busan Paik Hospital, Dept. of Urology, Busan, South Korea, 6 Samsung Changwon Hospital, Dept. of Urology, Busan, South Korea, 7 Ulsan-Jeil Hospital, Dept. of Urology, Ulsan, South Korea, 8 Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan, South Korea

### PT227

**Botulin toxin type A injections during chronic pelvic pain syndrome**

By: Khelaia A.  
National Center of Urology, Dept. of Urology, Tbilisi, Georgia

### PT228

**Long-term follow-up after cystectomy for bladder pain syndrome: Pain status, sexual function and quality of life**

By: Mateu Arrom L., Gutierrez Ruiz C., Mayordomo O., Martínez V., Palou J., Errando C.  
1 Fundació Puigvert, Dept. of Functional Urology and Urodynamics, Barcelona, Spain, 2 Fundació Puigvert, Dept. of Urology, Barcelona, Spain

### PT229

**Therapeutic effect of tadalafil in the chronic prostatitis**
### Assessment of AV002 by age and gender for the treatment of patients with nocturia: A pooled analysis of two phase 3 trials

**By:** Nishishita N., Ohira S., Tone S., Hara R., Fujii T., Uehara S., Miyaji Y., Nagai A.

1Graduate School of Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan,
2Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan,
3Graduate School of Tokyo Denki University, Dept. of Life Science and Engineering, Hiki-gun, Saitama, Japan

#### PT231

Improvement in first uninterrupted sleep period and quality of life after treatment with AV002, an emulsified microdose desmopressin nasal spray, in patients with overactive bladder and nocturnal polyuria

To be confirmed

#### PT232

Effect of salt reduction on nocturia persistent after administration of mirabegron for overactive bladder

**By:** Tomohiro M., Miyata Y., Tsutomu Y., Araki K., Nakamura Y., Sagara Y., Ohba K., Sakai H.
Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan

#### PT233

Efficacy of the novel β3 adrenergic receptor agonist vibegron for the treatment of nocturia in patients with overactive bladder: A post hoc analysis of phase 3 study

**By:** Yoshida M., Takeda M., Goto M., Yokoyama O., Kakizaki H., Takahashi S., Masumori N., Nagai S., Hashimoto K., Minemura K.
1National Center for Geriatrics and Gerontology, Dept. of Urology, Obu, Japan,
2University of Yamanashi, Dept. of Urology, Kofu, Japan,
3Nagoya University, Dept. of Urology, Nagoya, Japan,
4University of Fukui, Dept. of Urology, Fukui, Japan,
5Asahikawa Medical University, Dept. of Urology, Asahikawa, Jarvis Island,
6Nihon University, Dept. of Urology, Tokyo, Japan,
7Sapporo Medical University, Dept. of Urology, Sapporo, Japan,
8Kyorin Pharmaceutical Co., Dept. of Medical Affairs, Tokyo, Japan

#### PT234

Salt intake reduction as a treatment option for overactive bladder

**By:** Tomohiro M., Miyata Y., Yuno T., Araki K., Nakamura Y., Sagara Y., Ohba K., Sakai H.
Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan

#### PT235

Exploration of litoxetine (LTX): A potential novel treatment for mixed urinary incontinence (MUI)

**By:** Haab F.
Hopital Tenon, Dept. of Urology, Paris, France
PT236
Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in Caucasian patients with overactive bladder

By: Kasyan G.R., Kolontarev K.B., Pushkar D.Y.
Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia

PT237
Chance of OAB patients to become symptom-free upon anti-muscarinic treatment depends on age and gender

By: Michel M.C., Murgas S., Oelke M., Schneider T.
1 Johannes Gutenberg University, Dept. of Pharmacology, Mainz, Germany, 2 Apoepha Arzneimittel GmbH, Dept. of Medicine, Dresden, Germany, 3 St. Antonius Hospital, Dept. of Urology, Gronau, Germany, 4 Praxis-Klinik Rhein-Ruhr, Dept. of Urology, Mülheim, Germany

PT238
Combination of alpha blocker and phosphodiesterase 5 inhibitors versus alpha blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: A systematic review and meta-analysis

By: Chen P-C., Yeh T-C.
1 En Chu Kong Hospital, Dept. of Urology, New Taipei City, Taiwan, 2 National Taiwan University Hospital Hsin-Chu Branch, Dept. of Urology, Hsin-Chu, Taiwan

PT239
Is the combination of alpha-blocker and phosphodiesterase-5 inhibitor better in improving the lower urinary tract symptoms and erectile dysfunction in comparison to monotherapy? A systematic review and meta-analysis

By: Adamou C., Kallidonis P., Kotsiris D., Ntasiotis P., Verze P.
1 University hospital of Patras, Dept. of Urology, Patra, Greece, 2 University of Naples, Dept. of Urology, Naples, Italy

PT240
Benefit-risk evaluation of approved pharmacotherapies for the treatment of overactive bladder: A sensitivity analysis of benefits versus safety for individual OAB symptoms using multi-criteria decision analysis modelling

1 University of Sheffield, Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, 2 London School of Economics, Dept. of Management, London, United Kingdom, 3 Universidad de la Laguna, Dept. of Urology, Santa Cruz de Tenerife, Spain, 4 Sorbonne Université, Dept. of Urology, Paris, France, 5 Leuven University, Dept. of Development and Regeneration, Leuven, Belgium, 6 Medical University of Vienna, Dept. of Obstetrics and Gynaecology, Vienna, Italy, 7 Gothenburg University, Dept. of Obstetrics and Gynaecology, Gothenburg, Sweden, 8 Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, 9 Sapienza University, Dept. of Urology, Rome, Italy, 10 University of Alberta, Dept. of Medicine, Alberta, Canada
### PT241

**Multi-criteria decision analysis modelling to help physicians optimise treatment in patients diagnosed with overactive bladder**

By: Mironska E.¹, Phillips L. ², Castro-Diaz D. ³, Chartier-Kastler E. ⁴, De Ridder D. ⁵, Kölbl H. ⁶, Milsom I. ⁷, Pushkar D. ⁸, Tubaro A. ⁹, Wagg A. ¹⁰, Chapple C. ¹

¹University of Sheffield, Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, ²London School of Economics, Dept. of Management, London, United Kingdom, ³Universidad de la Laguna, Dept. of Urology, Santa Cruz de Tenerife, Spain, ⁴Sorbonne Université, Dept. of Urology, Paris, France, ⁵Leuven University, Dept. of Development and Regeneration, Leuven, Belgium, ⁶Medical University of Vienna, Dept. of Obstetrics and Gynaecology, Vienna, Italy, ⁷Gothenburg University, Dept. of Obstetrics and Gynaecology, Gothenburg, Sweden, ⁸Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, ⁹Sapienza University, Dept. of Urology, Rome, Italy, ¹⁰University of Alberta, Dept. of Medicine, Alberta, Canada

---

### PT242

**Urinary function improves in hypogonadal men receiving long-term treatment with testosterone compared to a hypogonadal control group: 6471 Patient-years of clinical experience**

By: Haider K.S. ¹, Haider A. ¹, Doros G. ², Traish A. ³

¹Praxis Dr. Haider, Dept. of Urology, Bremerhaven, Germany, ²Boston University School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America, ³Boston University School of Medicine, Dept. of Biochemistry and Dept. of Urology, Boston, United States of America

---

### PT243

**Different types of catheters for intermittent self-catheterization: A systematic review and network meta-analysis**

By: Ye D., Chen Y.T., Jian Z.Y., Li H., Wang K.J.

West China Hospital, Sichuan University, Dept. of Urology, Laboratory of Reconstructive Urology, Chengdu, China

---

### PT244

**Patients with severe benign prostatic hyperplasia have lower levels of plasmatic serotonin**

By: Oliveira Da Mota P. ¹, Fernandes C. ¹, De Sousa Morais N.A. ¹, Moura R. ², Lima E. ¹, Correia-Pinto J. ¹, Dias E. ¹

¹University of Minho, School of Medicine, Braga, Portugal, ²University of Minho, Life and Health Sciences Research Institute, Braga, Portugal

---

### PT245

**PTNS: Still going strong or an ever ending story?**

By: Te Dorsthorst M., Van Balken M.R.

Rijnstate, Dept. of Urology, Arnhem, The Netherlands

---

### PT246

**Percutaneous tibial nerve stimulation is effective in the treatment of neurogenic overactive bladder in multiple sclerosis patients: A controlled study**

By: Pacini P. ¹, Iacovelli V. ¹, Petta F. ¹, D'Ippolito G. ¹, Ragaglini R. ², Pletto S. ¹,
Carilli M.¹, Finazzi Agrò E.¹
¹Policlinico Tor Vergata Roma, Dept. of Urology, Rome, Italy, ²Fondazione Santa Lucia, Dept. of Neuro-Urology, Rome, Italy
E-BLUS Exam
Sponsored by KARL STORZ

Location: Green Area, Room 6
Tutors: S. Barmoshe, Brussels (BE)
A.S. Gözen, Heilbronn (DE)
J.F. Langenhuijsen, Nijmegen (NL)
J-T. Klein, Ulm (DE)
L. Osório, Porto (PT)
G. Pini, Milano (IT)
D. Rengifo Abbad, Majadahonda (ES)
C. Wagner, Gronau (DE)

Aims and objectives of this session
One of the main goals of the EAU is to establish and introduce common standards for training and European urological practice in order to improve patient care. The E-BLUS exam certifies a basic level of laparoscopic urological skills. The exercises addresses bimanual dexterity, depth perception, suturing and cutting skills. Clinical application is found in such procedures as partial nephrectomy, total nephrectomy, pyeloplasty and radical prostatectomy. To aid in the training of these skills and to prepare for this E-BLUS exam the online theoretical course is mandatory http://uroweb.org/education/online-education/surgical-education/laparoscopy/theoretical-course/

The course will start with E-BLUS training to further develop your laparoscopic skills and to benefit from the knowledge and expertise of international laparoscopy experts. After the training your skill are tested in the E-BLUS exam. Make sure you are prepared for the exam because training time onsite will be limited and without previous training you will most likely not pass the exam. The exercises to be performed can be found in the instructional videos at http://uroweb.org/education/online-education/surgical-education/laparoscopy/
Innovations and awards
Video Session 08

Sunday 17 March
14:00 - 15:30

Location: Red Area, eURO Auditorium 1
Chairs: A.Y. Alzahrani, Riyadh (SA)
        A. Messas, Paris (FR)
        B.M.C. Rocco, Modena (IT)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V53

3D digital reconstruction of renal model to improve preoperative planning of robot-assisted partial nephrectomy

By: Schiavina R.¹, Bianchi L.¹, Angiolini A.¹, Barbaresi U.¹, Bortolani B.², Cercenelli L.³, Borghesi M.¹, Chessa F.¹, Gaudiano C.⁴, Sessagesimi E.⁴, Molinaroli E.¹, D'Agostino S.¹, Marcelli E.³, Brunocilla E.¹

¹Sant'Orsola-Malpighi Hospital, University of Bologna, Dept. of Urology, Bologna, Italy,
²Sant'Orsola-Malpighi Hospital, University of Bologna, Dept. of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy,
³Sant'Orsola-Malpighi Hospital, University of Bologna, Dept. of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy,
⁴Sant'Orsola-Malpighi Hospital, University of Bologna, Dept. of Radiology, Bologna, Italy

Aims and objectives of this presentation

V53

V54

The crush carving technique using a soft coagulation device - a simple method for successful laparoscopic hemi-nephrectomy without hilar clamping

Cancer Institute Hospital of Japanese Foundation for Cancer Research, Dept. of Genitourinary Oncology, Tokyo, Japan

Aims and objectives of this presentation

V54

V55

The use and applications of near infrared fluorescence using Indocyanine Green in robotic urology

By: Ahallal Y.¹, Jeglinschi S.¹, Chevallier D.¹, Tibi B.¹, Durand M.¹, Messas A.²
¹CHU Nice, Dept. of Urology, Nice, France,
²Turin Urology Hospital, Dept. of Urology, Paris, France

Aims and objectives of this presentation

V55
**The development of a 3D navigation system for robot-assisted partial nephrectomy using augmented reality technology**

By: Sawada A. 1, Hamada A. 1, Sengiku A. 2, Koeda M. 3, Onishi K. 3, Ogawa O. 1

1 Kyoto University Graduate school of Medicine, Dept. of Urology, Kyoto, Japan, 2 Sengiku Clinic, Dept. of Urology, Moriyama, Japan, 3 Osaka Electro-Communication University, Dept. of Biomedical Engineering, Osaka, Japan

**Aims and objectives of this presentation**

V56

---

**Exploring the parameters affecting stone retropulsion in holmium laser lithotripsy: A video analysis**

By: Black K.M. 1, Aldoukhi A.H. 1, Roberts W.W. 1, Hall T. 2, Ghani K.R. 1

1 University of Michigan, Dept. of Urology, Ann Arbor, United States of America, 2 University of Michigan, Dept. of Engineering, Ann Arbor, United States of America

**Aims and objectives of this presentation**

V57

---

**Renal cell carcinoma with inferior vena cava thrombus: 3D laparoscopic approach**

By: Martos Calvo R., Peri L., D'Anna M., Ribal M.J., Alcaraz A.

Hospital Clínica, Dept. of Urology, Barcelona, Spain

**Aims and objectives of this presentation**

V58

---

**3D elastic augmented reality robot-assisted partial nephrectomy for central and posterior renal masses: A new tool for a better resection of the tumor**

By: Porpiglia F., Checcucci E., Amparore D., Piramide F., Piazzolla P., Bellin A., Fiori C.

AOU San Luigi Gonzaga, Dept. of Urology, Turin, Italy

**Aims and objectives of this presentation**

V59
## Robotic education, innovation and surgery session

**Specialty session - Live surgery**

**Sunday 17 March**
**14:00 - 17:00**

**Location:** Red Area, eURO Auditorium 2

**Chairs:**
- A. Mottrie, Aalst (BE)
- H.G. Van Der Poel, Amsterdam (NL)

### Aims and objectives of this session

During the session robot surgical procedures will be performed and broadcasted. The audience can interact with the surgeons performing a robot assisted partial nephrectomy and robot assisted radical prostatectomy with extended lymph node dissection. Aim of the session is to show and teach surgical options and interact with the surgeons.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 17:00</td>
<td><strong>Complex RAPN</strong></td>
<td>A. Breda, Barcelona (ES)</td>
<td></td>
</tr>
<tr>
<td>14:00 - 17:00</td>
<td><strong>RARP with extensive pelvic lymph node</strong></td>
<td>A. Briganti, Milan (IT)</td>
<td></td>
</tr>
</tbody>
</table>
## EAU Patient Information Session

**Location:** Green Area, Room 1

**Chairs:**
- A. Cardone, Brussels (BE)
- H.P.A.M. Van Poppel, Leuven (BE)

### Aims and objectives of this session

Male genitourinary cancers and patient advocates' perspective

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:05</td>
<td>Welcome and introduction</td>
<td>H.P.A.M. Van Poppel, Leuven (BE)</td>
</tr>
<tr>
<td>14:05 - 14:10</td>
<td>We had a dream: Seven years of EAU Patient Information</td>
<td>T. Bach, Hamburg (DE)</td>
</tr>
<tr>
<td>14:10 - 14:20</td>
<td>Latest developments in EAU Patient Information</td>
<td>M.A. Behrendt, Amsterdam (NL)</td>
</tr>
<tr>
<td>14:20 - 14:35</td>
<td>European Cancer Patient Coalition (ECPC) Update</td>
<td>A. Cardone, Brussels (BE)</td>
</tr>
<tr>
<td>14:35 - 15:20</td>
<td>Male genitourinary cancers</td>
<td></td>
</tr>
<tr>
<td>14:35 - 14:50</td>
<td>Reporting on PSA screening session in European parliament</td>
<td>H.P.A.M. Van Poppel, Leuven (BE)</td>
</tr>
<tr>
<td>14:50 - 15:05</td>
<td>Europa Uomo’s perspective</td>
<td>J. Dowling, Dublin (IE)</td>
</tr>
<tr>
<td>15:05 - 15:20</td>
<td>How to proceed with penile and testicular cancer</td>
<td>E-G. Carl, Gehrden (DE)</td>
</tr>
<tr>
<td>15:20 - 15:35</td>
<td>Prostate cancer Guidelines update</td>
<td>N. Mottet, Saint-Étienne (FR)</td>
</tr>
<tr>
<td>15:35 - 16:05</td>
<td>Bladder cancer</td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:05</td>
<td></td>
<td>L. Makaroff, Chinnor (GB)</td>
</tr>
<tr>
<td>16:05 - 16:35</td>
<td>Kidney cancer</td>
<td></td>
</tr>
<tr>
<td>16:05 - 16:20</td>
<td>Kidney Cancer Guidelines update</td>
<td>L. Serra De Oliveira Marconi, Coimbra (PT)</td>
</tr>
</tbody>
</table>
16:20 - 16:35  Kidney Cancer Guidelines update  
R.H. Giles, Utrecht (NL)

16:35 - 16:50  Rare genitourinary cancers: How ERN works  
M. Battye, Sheffield (GB)

16:50 - 17:00  Radiotherapy: How to improve efficacy and decrease toxicity  
M. Buckley, ()
Improving outcome from radical prostatectomy: Imaging and different approaches

Poster Session 42

Location: Green Area, Room 2
Chairs: N. Fossati, Milan (IT)
        S. Joniau, Leuven (BE)
        R. Shiroki, Aichi (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

585
Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI

By: Chung D.Y. ¹, Han H.H. ¹, Cho I.R. ², Kim Y.S. ³, Lee J.S. ⁴, Lim D.H. ⁵, Goh H.J. ¹, Kim J. ¹, Choi Y.D. ¹
¹Yonsei University College of Medicine, Urological Science Institute, Dept. of Urology, Seoul, South Korea, ²Inje University College of Medicine, Dept. of Urology, Gimhae, South Korea, ³National Health Insurance Corporation Ilsan Hospital, Dept. of Urology, Goyang, South Korea, ⁴Cheil General Hospital, Women's Healthcare Center, Dept. of Urology, Seoul, South Korea, ⁵Chosun University College of Medicine, Dept. of Urology, Gwangju, South Korea

Aims and objectives of this presentation
585

586
PI-RADSv2 score <5 associates with a very low risk of pelvic lymph node invasion in prostate cancer, even among high-risk population

By: Song G., Huang C.
Peking University First Hospital, Dept. of Urology, Beijing, China

Aims and objectives of this presentation
586

587
Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer

By: Chung D.Y. ¹, Cho I.R. ², Kim Y.S. ³, Lee J.S. ⁴, Lim D.H. ⁵, Kim J. ¹, Goh H.J. ¹, Heo J.E. ¹, Jang W.S. ¹, Choi Y.D. ¹
¹Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea, ²Inje University College of Medicine, Dept. of Urology, Gimhae, South Korea, ³National Health Insurance Corporation Ilsan Hospital, Dept. of Urology,
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>587</td>
<td>Use of intraoperative 68Gallium-PSMA Cerenkov luminescence imaging for surgical margins in radical prostatectomy – a feasibility study</td>
<td>By: Darr C. 1, Hadaschik B.A. 1, Grootendorst M. 2, Herrmann K. 3, Binse I. 3, Fragoso Costa P. 3, Harke N. 1</td>
<td>1University Hospital Essen, Dept. of Urology and Urological Oncology, Essen, Germany, 2Lightpoint Medical Ltd., Clinical Research, Chesham, United Kingdom, 3University Hospital Essen, Dept. of Nuclear Medicine, Essen, Germany</td>
</tr>
<tr>
<td>588</td>
<td>Which positive surgical margins features impact on the risk of prostate cancer specific mortality? A disease-tailored, competing-risk, long-term analysis</td>
<td>By: Suardi N. 1, Gandaglia G. 1, Robesti D. 1, Scuderi S. 1, Barletta F. 1, Dell'Oglio P. 1, Mazzone E. 1, Bandini M. 1, Freschi M. 2, Stabile A. 1, Zaffuto E. 1, Mirone V. 3, Longo N. 3, Shariat S.F. 4, Soria F. 4, D'Andrea D. 4, Luciano R. 5, Capitanio U. 1, Fossati N. 1, Montorsi F. 1, Briganti A. 1</td>
<td>1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology URI, Milan, Italy, 2IRCCS Ospedale San Raffaele, Unit of Pathology, Milan, Italy, 3University of Naples Federico II, Dept. of Urology, Naples, Italy, 4Medical University of Vienna, Dept. of Urology, Vienna, Austria, 5IRCCS Ospedale San Raffaele, Division of Pathology, Milan, Italy</td>
</tr>
<tr>
<td>589</td>
<td>Combination of prebiopsy magnetic resonance imaging and systematic biopsy can efficiently predict ipsilateral negative lymph-node metastasis in prostate cancer treated with radical prostatectomy and extended pelvic lymph node dissection</td>
<td>By: Ishikawa Y., Numao N., Yasuoka S., Fujiwara R., Inatsu H., Ogawa M., Komai Y., Yuasa T., Yamamoto S., Fukui I., Yonese J.</td>
<td>The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Dept. of Genitourinary Oncology, Tokyo, Japan</td>
</tr>
<tr>
<td>591</td>
<td>Sentinel lymph node biopsy in prostate cancer patients: Results from a modified injection technique targeting the index lesion in the prostate gland</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation
592

Implication of missed posterolateral tumour on mpMRI for nerve-sparing during radical prostatectomy

By: Kalapara A., Pan H., Frydenberg M., Grummet J. P.
Monash University, Dept. of Surgery, Melbourne, Australia

Aims and objectives of this presentation
593

Predictive factors of postoperative quality of life, erectile function and continence after robot-assisted radical prostatectomy: A multicentre study

By: Devlies W., De Coster G., Van Damme N., Roumeguère T., Quackels T., Van Cleynenbreugel B., Dekuyper P., Ameye F., Everaerts W., Joniau S., BE-RALP: the Belgian RALP consortium
KU Leuven, University of Leuven, Dept. of Urology, Leuven, Belgium, Belgian Cancer Registry, Belgian Cancer Registry, Brussels, Belgium, Université Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, Maria Middelares Hospital, Dept. of Urology, Ghent, Belgium

Aims and objectives of this presentation
594

Are we improving functional outcomes of prostate cancer patients treated with robot-assisted radical prostatectomy? A 10-year analysis in men treated at two high volume, tertiary referral centers

IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, URI, Milan, Italy, University Hospital Hamburg-Eppendorf, Dept. of Urology, Martini Klinik, Hamburg, Germany

Aims and objectives of this presentation
595

Pelvic anatomical features after Retzius-sparing robotic-assisted radical prostatectomy intended for early recovery of urinary continence

Scientific Programme - EAU19 Barcelona
Superiority of Retzius-sparing robot assisted radical prostatectomy in continence result compared to conventional method: Single surgeon experience with propensity score matching total of 1218 patients


1Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, South Korea, 2Tanta University College of Medicine, Dept. of Urology, Tanta, Egypt, 3Yonsei University Wonju College of Medicine, Dept. of Urology, Wonju, South Korea

Retzius-sparing radical prostatectomy for surgeons in the learning curve: A propensity score-matching analysis


1San Martino Policlinico Hospital, IRCCS for Oncology, Dept. of Urology, Genoa, Italy, 2Niguarda Hospital, Dept. of Urology, Milan, Italy
Improving the oncological outcomes of cystectomy

Poster Session 43

Sunday 17 March
14:00 - 15:30

Location: Green Area, Room 3

Chairs: P. Gontero, Turin (IT)
Y. Lotan, Dallas (US)
M.S. Michel, Mannheim (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

600

The natural history of untreated muscle-invasive bladder cancer

By: Martini A.¹, Renström-Koskela L.², MortezaI A.², Hosseini A.², Mehrazin R.¹, Galsky M.¹, Sfakianos J.¹, Steineck G.³, Wiklund N.¹
¹Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ²Karolinska Institutet, Dept. of Molecular Medicine and Surgery, section of Urology, Stockholm, Sweden, ³University of Göteborg, Sahlgrenska Academy Clinical Sciences, Stockholm, Sweden

Aims and objectives of this presentation
600

601

Withdrawn
To be confirmed

Aims and objectives of this presentation
601

602

Survival outcomes and salvage treatments for local bladder cancer recurrences following radical cystectomy

By: Soligo M.¹, Colicchia M.¹, Morlacco A.¹, Boeri L.², Sharma V.², Frank I.², Boorjian S.², Karnes R.J.²
¹University of Padua, Dept. of Urology, Padua, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America

Aims and objectives of this presentation
602

603

Risk factors of urethral recurrence in men after radical cystectomy with orthotopic urinary diversion for urothelial carcinoma

By: Song W.¹, Jeong J.Y.², Kim T.H.³, Yoon H.S.¹, Kim K.H.¹, Yoon H.¹, Chung W.S.¹, Sim B.S.¹, Lee D.H.¹
¹Ewha Womans University School of Medicine, Dept. of Urology, Seoul, South Korea,
Aims and objectives of this presentation

604

Clinical outcomes of tetra-modality bladder sparing therapy incorporating consolidative partial cystectomy in muscle-invasive bladder cancer patients with hydronephrosis

Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

605

A novel nomogram to identify patients with lymph node metastases in the extended lymph node dissection area at radical cystectomy

IRCCS Ospedale San Raffaele; URI, Unit of Urology, Division of Oncology, Milan, Italy, Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, Medical University of Vienna, Dept. of Urology, Vienna, Austria

Aims and objectives of this presentation

606

Standard vs extended pelvic lymph node dissection: Peri-operative complications and survival outcomes following radical cystectomy

By: Soligo M., Morlacco A., Colicchia M., Boeri L., Sharma V., Frank I., Boorjian S., Karnes R.J.
University of Padua, Dept. of Urology, Padua, Italy, Mayo Clinic, Dept. of Urology, Rochester, United States of America

Aims and objectives of this presentation

607

Attributable fraction for the risk of death in patients with clinically localized muscle-invasive bladder cancer

By: Audenet F., Ferket B.S., Waingankar N., Jia R., Galsky M.D., Sfakianos J.P.
Hôpital Européen Georges Pompidou, Dept. of Urology, Paris, France, Icahn School of Medicine at Mount Sinai, Institute for Healthcare Delivery Science, Dept. of Population Health Science and Policy, New York, United States of America, Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, Icahn School of Medicine at Mount Sinai, New York, United States of America

Aims and objectives of this presentation
School of Medicine at Mount Sinai, Tisch Cancer Institute, Division of Hematology, Oncology, Dept. of Medicine, New York, United States of America

Aims and objectives of this presentation

607

Conservative management following non-invasive down-staging with neoadjuvant chemotherapy for muscle-invasive bladder cancer patients refusing radical cystectomy

By: Onishi T., Sekito S., Terabe T., Shibahara T.
Ise Red cross hospital, Dept. of Urology, Ise, Japan

Aims and objectives of this presentation

608

Incidence and impact of histological variants on survival in candidates for radical cystectomy: Results from a multicenter collaboration

By: Moschini M.¹, Zamboni S.¹, Karnes J.R.², Roghmann F.³, Sargos P.⁴, Montorsi F.⁵, Briganti A.⁵, Colombo R.⁵, Gallina A.⁵, Mattei A.¹, Baumeister P.¹, Rink M.⁶, Poyet C.⁷, Saba K.⁸, Di Trapani E.⁹, De Cobelli O.⁹, Antonelli A.¹⁰, Simeone C.¹⁰, Boeri L.², Soligo M.¹¹, Simone G.¹², Gallucci M.¹², Aziz A.¹³, Xylinas E.¹⁴, Shariat S.F.¹⁵, On behalf of the European Association of Urology - Young Accademia Urologists (EAU-YAU), Utothelial carcinoma working group and of the EAU Research Foundation
¹Luzerner Kantonsstipal, Dept. of Urology, Lucerne, Switzerland, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Ruhr-University Bochum, Marien Hospital, Dept. of Urology, Herne, Germany, ⁴Institut Bergonié, Dept. of Radiation Therapy, Bordeaux, France, ⁵Urological Research Institute, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁶University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁷University Hospital Zürich, University of Zürich, Dept. of Urology, Zurich, Switzerland, ⁸University Hospital Zürich, University of Zürich, Dept. of Urology, Zurich, Switzerland, ⁹European Institute of Oncology, Dept. of Urology, Milan, Italy, ¹⁰Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, ¹¹Mayo Clinic, Dept. of Urology, Rochester, United States of America, ¹²IRCCS, Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹³University Medical Center Rostock, Dept. of Urology, Rostock, Germany, ¹⁴Bichat Hospital, Paris Descartes University, Dept. of Urology, Paris, France, ¹⁵Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

Aims and objectives of this presentation

609

Comparison of different treatment modalities outcomes in clinically node-positive bladder cancer; analysis of a population-based cancer registry.

By: Staník M.¹, Poprach A.², Malúšková D.³, Zapletalová M.³, Macík D.¹, Čapák I.¹, Jarkovský J.³, Lakomý R.², Doležel J.¹
¹Masaryk Memorial Cancer Institute, Dept. of Urologic Oncology, Brno, Czech Republic,
Aims and objectives of this presentation

610

Minimal invasive surgery and brachytherapy as bladder preserving multimodality treatment in selected solitary MIBC

By: Smits G.A.H.J. 1, Van Der Steen-Banasik E. 2, Oosterveld B. 2, Weijerman P.C. 1, Kroon B. 1, Haverkort D. 2, Wijburg C.J. 1
1Rijnstate Hospital Arnhem, Dept. of Urology, Arnhem, The Netherlands, 2RadioTherapieGroep, Dept. of Radiotherapy, Arnhem, The Netherlands

Aims and objectives of this presentation

611

Global assessment of outcomes of robot-assisted radical cystectomy with orthotopic neobladder: Trifecta vs pentafecta

By: Simone G., Guaglianone S., Gallucci M., Tuderti G., Anceschi U., Misuraca L., Ferriero M., Brassetti A., Minisola F., Flammia R.S., Mastroianni R.
Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation

612

Impact of lymph node dissection in radical cystectomy for bladder cancer: How many vs how far?

Asan Medical Center, Dept. of Urology, Seoul, South Korea

Aims and objectives of this presentation

613

Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study

1The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Urology, Amsterdam, The Netherlands, 2Caritas St Joseph Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, 3University of Turku,
Aims and objectives of this presentation

614
**Testis cancer: Complex problems - here are the solutions!**

**Poster Session 44**

**Sunday 17 March**
**14:00 - 15:30**

**Location:** Green Area, Room 4

**Chairs:** M. Jewett, Toronto (CA)  
J. Oldenburg, Lørenskog (NO)  
D. Pfister, Cologne (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**615**

**Comparison of testis cancer-specific survival: An analysis of National Cancer Registry Data from the United States, United Kingdom, and Germany**

By: Withington J.¹, Cole A.P.², Meyer C.³, Seisen T.⁴, Schmid M.⁵, Lipsitz S.⁶, Dasgupta P.², Sweeney C.⁷, Trinh Q-D.²

¹NIHR Biomedical Research Centre, King’s College, MRC Centre for Transplantation, London, United Kingdom, ²Brigham and Women’s Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, ³University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁴Pierre et Marie Curie University, Pitié Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France, ⁵University Medical Center Goettingen, Dept. of Urology, Goettingen, Germany, ⁶Brigham and Women’s Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, ⁷Dana Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, Massachusetts, United States of America

**Aims and objectives of this presentation**

615

---

**616**

**Comprehensive analysis of metastatic seminoma germ cell tumors shows divergent expression of immune-related pathways**

By: Nestler T.¹, Haidl F.¹, Wittersheim M.², Dalvi P.², Paffenholz P.¹, Wagener-Ryczek S.², Pfister D.¹, Hellmich M.³, Büttner R.², Odenthal M.², Heidenreich A.¹

¹University Hospital of Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany, ²University Hospital of Cologne, Institute of Pathology, Cologne, Germany, ³University of Cologne, Institute of Medical Statistics and Computational Biology, Cologne, Germany

**Aims and objectives of this presentation**

616

---

**617**

**Change in body composition following systemic chemotherapy in patients with testicular germ cell tumor**
Aims and objectives of this presentation

Primary retroperitoneal lymph-node dissection (RPLND) in stage IIA/IIB germ-cell tumours (GCT) of the testis: Is it an effective and safe approach in modern setting?

By: Nicolai N.₁, Tesone A.₁, Biasoni D.₁, Catanzaro M.A.₁, Stagni S.₁, Torelli T.₁, Macchi A.₁, Piva L.₁, Necchi A.₂, Raggi D.₂, Giannatempo P.₂, Faré E.₂, Colecchia M.₃, Lanocita R.₄, Cascella T.₄, Salvioni R.₁

₁Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Testis Surgery Unit, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Pathology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiology, Milan, Italy

Aims and objectives of this presentation

Template versus bilateral postchemotherapy retroperitoneal lymph node dissection in patients with testicular cancer

University of Düsseldorf, Dept. of Urology, Medical Faculty, Düsseldorf, Germany

Aims and objectives of this presentation

Independent validation of two models to predict necrosis/fibrosis in post chemotherapy residual retroperitoneal masses of patients with advanced testicular cancer

By: Paffenholz P.₁, Nestler T.₁, Hoier S.₁, Pfister D.₁, Hellmich M.₂, Heidenreich A.₁

₁University Hospital Cologne, Dept. of Urology, Cologne, Germany, ²University of Cologne, Dept. of Medical Statistics and Computational Biology, Cologne, Germany

Aims and objectives of this presentation

Higher frequency of adjunctive surgery after salvage chemotherapy in patients with testicular cancer

Universitätsklinikum Düsseldorf, Dept. of Urology, Düsseldorf, Germany

Aims and objectives of this presentation
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>622</td>
<td>Non-pulmonary visceral metastases are associated with poor survival in post-chemotherapy retroperitoneal lymph node dissection (RPLND) for non-seminomatous germ cell tumours (NSGCT) of the testis</td>
<td>By: Dosanjh A. ¹, Baldwin S. ¹, Evison F. ¹, Gallier S. ¹, Wallace M. ², Patel P. ³</td>
<td>¹University Hospitals Birmingham NHS Foundation Trust, Health Informatics, Birmingham, United Kingdom, ²University Hospitals Birmingham NHS Foundation Trust, Dept. of Urology, Birmingham, United Kingdom, ³University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom</td>
<td>622</td>
</tr>
<tr>
<td>624</td>
<td>Laparoscopic residual mass resection as an alternative to template-based postchemotherapy retroperitoneal lymph node dissection</td>
<td>By: Blok J.M. ¹, Meijer R. ¹, Van Der Poel H. ², Bex A. ², Bosch R. ¹, Horenblas S. ²</td>
<td>¹University Medical Center Utrecht, Dept. of Oncological and Urology, Utrecht, The Netherlands, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands</td>
<td>624</td>
</tr>
<tr>
<td>625</td>
<td>LncRNA H19 promotes cisplatin resistance by sequestering miRNA-106b-5p in seminoma cells</td>
<td>By: Tang Y. ¹, Wei J. ², Gan Y. ³, Peng D. ², Zhou J. ², Li Z. ², Yin Y. ², Zhang W. ², Peng J. ², Chen H. ², Yang J. ², Dai Y. ¹</td>
<td>¹The Fifth Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Zhuhai, China, ²The Third Xiangya Hospital of Central South University, Dept. of Urology, Changsha, China, ³Xiangya Hospital of Central South University, Dept. of Urology, Changsha, China</td>
<td>625</td>
</tr>
<tr>
<td>626</td>
<td>Seminomatous germ cell tumors are heterogenic and metastasis can be predicted based on a gene signature of the tumor invasive front</td>
<td>By: Nestler T. ¹, Haidl F. ¹, Wittersheim M. ², Dalvi P. ², Paffenholz P. ¹, Wagener-Ryczek S. ², Pfister D. ¹, Hellmich M. ³, Böttner R. ², Odenthal M. ², Heidenreich A. ¹</td>
<td>¹University Hospital of Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany, ²University Hospital of Cologne, Institute of Pathology, Cologne, Germany, ³University of Cologne, Institute of Medical Statistics and Computational Biology, Cologne, Germany</td>
<td>626</td>
</tr>
</tbody>
</table>
627

Newly identified regulation mechanism in EBV positive seminoma

By: von Brandenstein M.1, Paffenholz P.1, Thönnissen J.1, Salem J.1, Köditz B.1, Nestler T.1, Fries J.W.U.2, Göbel H.2, Heidenreich A.1
1University Hospital of Cologne, Dept. of Urology, Cologne, Germany, 2University Hospital of Cologne, Institute of Pathology, Cologne, Germany

Aims and objectives of this presentation
627

628

Impact of adjuvant treatment and patient factors on long-term quality of life of testicular cancer survivors

By: Van Hoorn R.1, Siva S.2, Tran B.3, Ngo T.1, Koschel S.4, Wong L-M.1
1St Vincent's Hospital Melbourne, Dept. of Urology and Surgery, Melbourne, Australia, 2Peter MacCallum Cancer Centre, Dept. of Radiation Oncology, Melbourne, Australia, 3The Royal Melbourne Hospital, Dept. of Medical Oncology, Melbourne, Australia, 4University of Melbourne, Dept. of Surgery, Melbourne, Australia

Aims and objectives of this presentation
628

629

Non-Leydig cell-stromal-tumors of the testis: Systematic literature review and meta-analysis of treatment outcomes in 745 patients

By: Grogg J.1, Schneider K.1, Bode P-K.2, Wettstein M.S1, Eberli D.1, Sulser T.1, Beyer J.3, Hermanns T.1, Fankhauser C.D1
1University Hospital, University of Zurich, Dept. of Urology, Zurich, Switzerland, 2University Hospital, University of Zurich, Dept. of Pathology of Molecular Pathology, Zurich, Switzerland, 3University Hospital, University of Bern, Dept. of Oncology, Zurich, Switzerland

Aims and objectives of this presentation
629
Deep learning computer vision algorithm for detecting kidney stone composition: Towards an automated future

By: Black K.M.¹, Law H.², Aldoukhi A.H.¹, Roberts W.W.¹, Deng J.², Ghani K.R.¹
¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²Princeton University, Dept. of Computer Science, Princeton, United States of America

Aims and objectives of this presentation

How to choose the therapy you need when you find it difficult to read?

By: Schlatmann F.W.M., Van Balken M.R.
Rijnstate Hospital, Dept. of Urology, Arnhem, The Netherlands

Aims and objectives of this presentation

Impact of health literacy on decision-making for prostate-specific antigen screening in the United States

By: Nguyen D-D.¹, Trinh Q-D.¹, Tully K.¹, Krimphove M.J.¹, Nguyen P.², Sammon J.³
¹Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, ²Brigham and Women's Hospital, Harvard Medical School, Dept. of Radiation Oncology, Boston, Massachusetts, United States of America, ³Maine Medical Center, Division of Urology and Center for Outcomes Research and Evaluation, Portland, Maine, United States of America

Aims and objectives of this presentation
Social media coverage of scientific articles immediately after publication predicts subsequent citations: #SoMe_Impact Score

By: Sathianathen N. 1, Lane R. 1, Murphy D.G. 2, Loeb S. 3, Bakker C. 1, Lamb A.D. 4, Weight C.J. 1

1University of Minnesota, Dept. of Urology, Minneapolis, United States of America, 2Peter MacCallum Cancer Centre, Dept. of Surgical Oncology, Melbourne, Australia, 3New York University, Dept. of Urology, New York, United States of America, 4University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom

Aims and objectives of this presentation

Worldwide public interest over time in minimally invasive surgery: Evidence from “big data” trends analysis

By: Cacciamani G.E. 1, Gill I. 1, Tafuri A. 1, Sebben M. 2, Artibani W. 2

1University of Southern California, USC Institute of Urology, Los Angeles, United States of America, 2University of Verona, Dept. of Urology, Verona, Italy

Aims and objectives of this presentation

Prostate Cancer Canada electronic-library for Improved Function (eLIFT): The construction of the platform and initial analysis for patients' satisfaction

By: Hetou K. 1, Tangen-Steffins K. 2, Nair S. 1, Siddiqui K. 1, Chan G. 1, Leong H. 1, Leong N. 2, Goulart J. 2, Chin J.L. 1

1University of Western Ontario, Dept. of Urology, London, Canada, 2BC Cancer, Victoria Centre, Dept. of Radiation Oncology, Victoria, Canada

Aims and objectives of this presentation

Systematic review on digital dissemination strategies for clinical practice guidelines and the @Uroweb #eauguidelines experience

By: Borgmann H. 1, Roupret M. 2, Loeb S. 3, Van Oort I. 4, N'dow J. 5, Esperto F. 6, Pradere B. 7, Czarniecki S. 8, Giannarini G. 9, Ribal M.J. 10

1University Medicine Johannes Gutenberg-University Mainz, Dept. of Urology, Mainz, Germany, 2La Pitié-Salpêtrière Hospital, Assistance-Publique Hôpitaux de Paris, Academic Dept. of Urology, Paris, France, 3New York University, New York, NY, USA; Manhattan Veterans Affairs Medical Center, Dept. of Urology and Population Health, New York, United States of America, 4Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, 5University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 6Ospedale Sant'Andrea, University La Sapienza, Dept. of Urology, Rome, Italy, 7Rennes University Hospital, Dept. of Urology, Rennes, France, 8Independent Public Specialist John Paul II Western Hospital, Grodzisk Mazowiecki, Dept. of Urology, Warsaw, Poland, 9Academic Medical Centre , Urology Unit, Udine, Italy,
Aims and objectives of this presentation

635

An interactive application for hospitalized patients providing real-time feedback to caregivers

By: Nativ O., Abbadi S., Hassadieh B., Zisman A., Amiel G.
Rambam Health Center, Dept. of Urology, Haifa, Israel

Aims and objectives of this presentation

636

Informed consent (IC), randomized controlled trial digital vs conventional IC

By: Galve La Hoz, V., Rioja, J., Salas, E., Enguita, L., Sanz Del Pozo, M., Corbatón, D., Gareta, C., Ezquerro, S., Muñoz, M., Cabañez, T., Gil, P., Gil M.J.

1University Hospital Miguel Servet, Dept. of Urology, Zaragoza, Spain, 2University Clinic Hospital, Dept. of Urology, Zaragoza, Spain

Aims and objectives of this presentation

637

The view of patients and urologists on an online decision aid for patients with non-metastatic prostate cancer: A nationwide project with over 6,000 users in two years


1TU Dresden, Dept. of Urology, Dresden, Germany, 2University of Heidelberg, Dept. of General Internal Medicine and Psychosomatic, Heidelberg, Germany, 3TU Dresden, Dept. of Radiation Oncology, Dresden, Germany, 4University of Zurich, Dept. of Clinical Ethics, Zurich, Switzerland, 5ASD Concepts GmbH&Co. KG, CEO, Reinheim, Germany, 6University of Muenster, Centre of Andrology and Reproductive Medicine, Muenster, Germany, 7Asklepios Hospital Altona, Dept. of Urology, Hamburg, Germany

Aims and objectives of this presentation

638

A smartphone-based mobile health app to address the adverse effects of androgen deprivation therapy in men with prostate cancer


1Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, 2Dana Farber Cancer Institute, Harvard Medical School, Lank Center for Genitourinary Oncology, Boston, United States of America, 3Dana Farber Cancer Institute, Harvard Medical School
Aims and objectives of this presentation

Deep learning model to predict urinary continence after robot-assisted radical prostatectomy

1 Keck School of Medicine, University of Southern California, USC Institute of Urology, Center for Robotic Simulation & Education, Los Angeles, United States of America,
2 Peking University, School of Electronics Engineering and Computer Science, Beijing, China,
3 University of Maryland, Dept. of Information Systems, Baltimore, United States of America,
4 Viterbi School of Engineering, University of Southern California, Computer Science Department, Los Angeles, United States of America

Implementation of a ureteric colic phone consult clinic reduces unnecessary outpatient urology consults

By: Lu J., Ong C.S.H., Tan L.
National University Hospital, Dept. of Urology, Singapore, Singapore

State-of-the-art lecture Social media in urology; fake news or reality?
P. Dasgupta, London (GB)

Summary
P. Dasgupta, London (GB)
How to improve predictions and outcomes of recurrent prostate cancer
Poster Session 46

Sunday 17 March
14:00 - 15:30

Location: Green Area, Room 10
Chairs: G. De Meerleer, Ghent (BE)
        G. Gandaglia, Milan (IT)
        A. Mendoza-Valdes, Mexico City (MX)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

643

Prospective randomized trial of gene expression classifier utility in men at high risk of recurrence following radical prostatectomy (G-MINOR)

By: Morgan T.¹, Okoth L.¹, Feng F.², Johnson A.¹, Lane B.³, Linsell S.¹, Khurdish G.¹, Montie J.¹, Fishbane N.⁴, Marti T.⁵, Du Plessis M.⁶, Mehra R.⁷, Davicioni E.⁸, Maatman T.⁹, Wojno K.¹⁰, Burks F.¹¹, Rodriguez P.¹², Liu N.¹³, Sarle R.¹⁴, Miller D.¹, Cher M.¹⁵

¹University of Michigan, Michigan Medicine, Dept. of Urology, Ann Arbor, United States of America, ²University of California, Dept. of Radiation Oncology, San Francisco, United States of America, ³Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, United States of America, ⁴GenomeDx Biosciences, Biostatistics, Vancouver, Canada, ⁵GenomeDx Biosciences, Clinical Research, Vancouver, Canada, ⁶GenomeDx Biosciences, Clinical Research, Vancouver, Canada, ⁷University of Michigan, Michigan Medicine, Dept. of Pathology, Ann Arbor, United States of America, ⁸GenomeDx Biosciences, Vancouver, Canada, ⁹Michigan Urological Clinic, Dept. of Urology, Grand Rapids, United States of America, ¹⁰Comprehensive Urology, Dept. of Pathology, Royal Oak, United States of America, ¹¹Comprehensive Urology, Dept. of Urology, Royal Oak, United States of America, ¹²Urology Associates of Grand Rapids P.C, Dept. of Urology, Grand Rapids, United States of America, ¹³IHU Urology, Dept. of Urology, Ypsilanti, United States of America, ¹⁴Michigan Institute of Urology, Dept. of Urology, Troy, United States of America, ¹⁵Wayne State University, Dept. of Urology, Detroit, United States of America

Aims and objectives of this presentation

644

Multi-scale tissue architecture analysis of prostate cancer biopsies: A new imaging tissue biomarker of biochemical recurrence?

By: Pukl M.¹, Carraro A.², Korbelic J.², Harisson A.², Zhaoyang C.², Palcic B.², Macaulay C.², Guillaud M.², Volavsek M.³

¹GH Celje, Dept. of Urology, Celje, Slovenia, ²British Columbia Cancer Research Centre, Dept. of Integrative Oncology, Vancouver, Canada, ³Faculty of Medicine, University of Ljubljana, Dept. of Pathology, Ljubljana, Slovenia
Identifying the optimal definition for early biochemical recurrence after radical prostatectomy: A risk-stratified approach to optimize postoperative follow-up and the use of timely salvage therapies

By: Mazzone E.1, Gandaglia G.1, Knipper S.2, Graefen M.2, Gallina A.1, Tilki D.2, Suardi N.1, Bandini M.1, Cucchiara V.1, Stabile A.1, Dell'Oglio P.1, Fossati N.1, Montorsi F.1, Briganti A.1
1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, URI, Milan, Italy, 2University Hospital Hamburg-Eppendorf, Dept. of Urology, Martini Klinik, Hamburg, Germany

Testosterone replacement therapy prevents disease progression in men undergoing radical prostatectomy

By: Towe M.1, Huynh L.M.1, El-Khatib F.M.1, Yafi F.A.1, Ahlering T.1
University of California, Dept. of Urology, Irvine, Orange, United States of America

Evaluating the impact of lead-time bias on the observed efficacy of early salvage radiation therapy in prostate cancer: A post-hoc analysis of the RTOG 9601 trial

By: Abdollah F.1, Dalela D.1, Sood A.1, Arora S.1, Tang H.J.1, Keeley J.1, Alanee S.1, Rogers C.G.1, Peabody J.O.1, Menon M.1
Henry Ford Hospital, Vattikuti Urology Institute, Center for Outcomes Research, Analytics and Evaluation, Detroit, United States of America

What is the best definition of biochemical response to salvage radiation therapy in prostate cancer patients treated for PSA rising after radical prostatectomy? Results from a multi-institutional series

1IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, MN, United States of America, 3Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, 4IRCCS Ospedale San Raffaele, Dept. of...
Radiotherapy, Milan, Italy, 5 IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, URI, Milan, Italy, 6 University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 7 Charité University Hospital Berlin, Dept. of Radiation Oncology, Berlin, Germany, 8 Medical University of Vienna, Dept. of Urology, Vienna, Austria, 9 Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, 10 University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 11 University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, 12 Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

Aims and objectives of this presentation
648

Impact of primary Gleason pattern on results of early salvage radiotherapy after radical prostatectomy

By: Preisser F.1, Pompe R.S.2, Chun F.K-H.1, Graefen M.3, Huland H.3, Tilki D.3  
1 University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 2 University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3 University Hospital Hamburg-Eppendorf, Martini-Klinik, Hamburg, Germany

Aims and objectives of this presentation
649

Rates and patterns of metastases in patients with node-negative prostate cancer at radical prostatectomy that experience PSA failure: Post-hoc analysis of RTOG 9601 trial data

By: Sood A., Keeley J., Arora S., Dalela D., Jeong W., Rogers C., Peabody J., Menon M., Abdullah F.  
Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America

Aims and objectives of this presentation
650

There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy

1 IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2 Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3 Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, 4 IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, 5 IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, 6 IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, 7 University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 8 Charité University Hospital Berlin, Dept. of Radiation Oncology, Berlin,
Germany, 9Medical University of Vienna, Dept. of Urology, Vienna, Austria, 10Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, 11University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 12University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, 13Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

Aims and objectives of this presentation

651

652

Tumor control outcomes of salvage cryotherapy for radiorecurrent prostate cancer at median 12 years follow-up

By: Nair S.M. 1, Peters M. 2, Abed H. 1, Van Der Voort Van Zyp J. 2, Van Son M. 2, Chin J.L. 1
1London Health Sciences Centre, Dept. of Urology, London, Canada, 2University Medical Center Utrecht, Dept. of Radiotherapy, Utrecht, The Netherlands

Aims and objectives of this presentation

652

653

Long-term functional and oncological outcomes of salvage cryosurgery for locally recurrent prostate cancer following radiotherapy: A 12-year single center analysis

By: Exterkate L., Somford D.M., Vergunst H.
Canisius-Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands

Aims and objectives of this presentation

653

654

Salvage cryotherapy versus salvage radical prostatectomy for radiorecurrent prostate cancer: Long-term oncologic outcomes

By: Nair S.M. 1, Lyon T. 2, Dewar M. 1, Rangel L. 3, Abed H. 1, Hetou K. 1, Karnes R. 2, Chin J. 1, Boorjian S. 2
1London Health Sciences Centre, Division of Urology, London, Canada, 2Mayo Clinic, Division of Urology, Rochester, United States of America, 3Mayo Clinic, Dept. of Health Sciences Research, Rochester, United States of America

Aims and objectives of this presentation

654

655

Outcomes of the miltuximab first in human trial and proposed study design for a phase 1 trial 89zr/177lu theranostic trial

By: Campbell D. 1, Sabanathan D. 2, Gurney H. 2, Gillatt D. 2, Trifunovic M. 3, Poursoultan P. 4, Ho Shon K. 3, Mackay T. 1, Roach P. 5, Bailey D. 5, Walsh B. 1
1Minomic International Ltd, Macquarie Park, Australia, 2Macquarie University, Faculty of Medicine and Health Sciences, Macquarie Park, Australia, 3Macquarie Medical Imaging, Macquarie Park, Australia, 4Macquarie University, Faculty of Medicine and Health
Aims and objectives of this presentation
655

PSA persistence after radical prostatectomy and its impact on oncologic outcomes

By: Preisser F. 1, Pompe R.S. 2, Chun F. 1, Graefen M. 3, Huland H. 3, Tilki D. 3
1University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 2University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3University Hospital Hamburg-Eppendorf, Martini-Klinik, Hamburg, Germany

Aims and objectives of this presentation
656

15:19 - 15:30
State-of-the-art lecture What are the current indications for salvage radiotherapy
G. De Meerleer, Ghent (BE)
Evaluation for LUTS in clinical practice
Poster Session 47

Location: Green Area, Room 11
Chairs: W. Artibani, Verona (IT)  
B. Dybowski, Warsaw (PL)  
C. Gratzke, Munich (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

657 Malnutrition evaluated by the controlling nutritional status (CONUT) score is associated with severe nocturia in males
By: Ito M., Nakanishi Y., Madoka K., Sakamoto K., Takemura K., Suzuki H., Iida N., Tobisu K., Koga F.  
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation
657

658 Risk factors for the prevalence and cumulative incidence of urinary incontinence during pregnancy and the first year postpartum: A prospective cohort study
By: Chang S-R.  
National Taiwan University, College of Medicine, School of Nursing, Taipei, Taiwan

Aims and objectives of this presentation
658

659 Night shift workers have a higher overactive bladder score with an impairment of quality of life: A prospective cohort study
Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation
659

660 New uroflowmetry sensor for home-monitoring of male voiding dysfunction
By: Gruenwald, Massarwa O., Appel B.  
Rambam Medical Center, neuro-urology, Haifa, Israel

Aims and objectives of this presentation
660
Aims and objectives of this presentation
660

**661**

**Urodynamic study for distinguishing multiple system atrophy from Parkinson's disease**

By: Shin J.H. 1, Park K.W. 2, Lee J. 1, An D.H. 1, Lee S. 1, Choo M.S. 1
1 Asan Medical Center, Dept. of Urology, Seoul, South Korea, 2 Asan Medical Center, Dept. of Neurology, Seoul, South Korea

Aims and objectives of this presentation
661

**662**

**Detrusor underactivity: Are different diagnostic criteria often reliable in clinical practice?**

By: Rapisarda S. 1, Russo G.I. 1, Lombardo R. 2, De Nunzio C. 2, Scandura C. 1, Carbonaro B. 1, Sica A. 3, Vicentini C. 4, Cimino S. 1, Tubaro A. 1, Morgia G. 1
1 University of Catania, Dept. of Urology Section, Dept. of Surgery, Catania, Italy, 2 Sant’ Andrea Hospital, Sapienza University, Dept. of Urology, Rome, Italy, 3 Azienda Ospedaliera Sant’ Andrea, Dept. of Urology, Rome, Italy, 4 University of L’Aquila, Mazzini Hospital Teramo, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation
662

**663**

**Caesarean section versus vaginal delivery and the development of urinary incontinence and/or LUTS in premenopausal parous women**

By: Michailidou S. 1, Petridou M. 1, Tsapara V. 1, Moysidis K. 2, Apostolidis A. 2
1 Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece, 2 Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece

Aims and objectives of this presentation
663

**664**

**Categories for severity of the main symptom scores (ICIQ-MLUTS and IPSS) in male LUTS**

By: Ito H. 1, Young G. 2, Lewis A. 2, Blair P. 1, Cotterill N. 1, Abrams P. 1, Lane A. 2, Drake M. 1
1 Southmead Hospital, Bristol Urological Institute, Bristol, United Kingdom, 2 University of Bristol, Population Health Sciences, Bristol, United Kingdom

Aims and objectives of this presentation
664

**665**

**Impact of 6F dual channel urethral catheter on flow rate during video-urodynamic investigations**
Aims and objectives of this presentation

665

Development of a novel voided volume measuring device for automated recording of voiding diary

By: Takai S.1, Matsukawa Y.1, Hashizume N.2, Gotoh M.1
1Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan, 2Shimadzu Corporation, Technology Research Laboratory, Kyoto, Japan

Aims and objectives of this presentation

666

A score for screening severe obstructive sleep apnea syndrome in patients referred for nocturia

By: Misrai V.1, Peyronnet B.2, Pépin J.3, Charbonneau H.4, Pathak A.5, Attias D.6
1Clinique Pasteur, Dept. of Urology, Toulouse, France, 2Rennes University, Dept. of Urology, Rennes, France, 3Laboratoire HP2, INSERM U1042, Univ. Grenoble Alpes, Dept. of Pulmonology, Grenoble, France, 4Clinique Pasteur, Dept. of Anesthesiology and intensive care unit, Toulouse, France, 5Clinique Pasteur, Dept. of Cardiovascular Medicine, INSERM U1048, Toulouse, France, 6Clinique Pasteur, Dept. of Pulmonology, Toulouse, France

Aims and objectives of this presentation

668

Higher salt intake and non-dipping blood pressure are associated with nocturnal polyuria in patients with lower urinary tract symptoms

Iwate Medical University, Dept. of Urology, Morioka, Japan

Aims and objectives of this presentation

669

Relationship between lower urinary tract symptoms and visceral fat mass and psoas major muscle mass in women

By: Tomohiro M., Miyata Y., Yuno T., Araki K., Nakamura Y., Sagara Y., Ohba K., Sakai H.
Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan
Aims and objectives of this presentation

Prospective validation of a novel visual analogue uroflowmetry score (VAUS) in 1000 men with lower urinary tract symptoms (LUTS)

By: Tiwari R.V., Ng M.Y., Ho S.S.H.
Singapore General Hospital, Dept. of Urology, Singapore, Singapore

Aims and objectives of this presentation

Development of mathematical formulas for the prediction of outflow obstruction on an individual basis: A post-hoc analysis of the flow resistive forces index (QRF) study

By: Spyropoulos E.¹, Spyropoulos K.²
¹Private practice, Dept. of Urology, Paleo Faliro, Greece, ²University of Athens, School of Dentistry, Athens, Greece

Aims and objectives of this presentation
**Let’s have a closer look! Imaging of renal cancer**

**Poster Session 48**

**Sunday 17 March**
**14:00 - 15:30**

**Location:** Green Area, Room 12

**Chairs:** U. Capitanio, Milan (IT)  
A. Kotsar, Tartu (EE)  
A. Minervini, Florence (IT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**672**

**Differentiation of clear cell and non-clear cell renal cell carcinomas by radiomics features**

By: Liu G. ¹, Wu G. ², Li Z. ³  
¹Renji Hospital?School of Medicine?Shanghai Jiaotong University, Dept. of Radiology, Shanghai, China, ²Renji Hospital?School of Medicine?Shanghai Jiaotong University, Dept. of Radiology, Shanghai, China, ³Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Dept. of Biomedical and Health Engineering, Shenzhen, China

**Aims and objectives of this presentation**
672

---

**673**

**Differentiation of chromophobe renal cell carcinoma and renal oncocytoma with whole-lesion ADC analysis on diffusion-weighted MRI**

By: Uchida Y ¹, Yoshida S. ¹, Shimoda H. ¹, Tanaka H. ², Yamamoto K. ³, Sakamoto T. ⁴, Kaneko K. ¹, Kijima T. ¹, Yokoyama M. ¹, Ishioka J. ¹, Matsuoka Y. ¹, Saito K. ¹, Fujii Y. ¹  
¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan, ³Tokyo Medical and Dental University, Dept. of Pathology, Tokyo, Japan, ⁴PixSpace Ltd, Dept. of Radiology, Fukuoka, Japan

**Aims and objectives of this presentation**
673

---

**675**

**Contrast-enhanced ultrasonography (CEUS) and time/intensity curves for the characterization of small renal masses**

By: Pili A. ¹, Bertelli E. ², Sforza S. ³, Mari A. ³, Campi R. ³, Miele V. ², Minervini A. ³, Carini M. ³, Agostini S. ²  
¹AOUC Azienda Ospedaliero-Universitaria Careggi, Dept. of Urology, Florence, Italy,
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>675</td>
<td>Aims and objectives of this presentation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>676</td>
<td>Contrast-enhanced ultrasound in the diagnosis of renal mass and its concordance with the computerized tomography</td>
<td>Del Pozo Jiménez G., Castillón Vela I., Rengifo Abbad D., Fontanilla Echeveste T., Minaya Bernedo J., Turo Antona J., Carballido Rodríguez J.</td>
<td>H.U. Puerta de Hierro, Dept. of Urology, Majadahonda (Madrid), Spain, H.U. Puerta de Hierro, Radiodiagnostic Service, Majadahonda (Madrid), Spain</td>
</tr>
<tr>
<td>677</td>
<td>Aims and objectives of this presentation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>678</td>
<td>Ultrasound molecular imaging to predict response to sunitinib in a renal carcinoma patient derived xenograft model</td>
<td>Ingels A., Leguerney I., Cournede P-H., Irani J., Ferlicot S., Benatsou B., Sébrié C., Jourdain L., Guillot G., Patard J-J., Lassau N.</td>
<td>Henri Mondor Hospital, Dept. of Urology, Creteil, France, Univ. Paris-Sud, CNRS, Université Paris-Saclay, IR4M, Orsay, France, CentraleSupélec, Lab MICS, Gif-sur-Yvette, France, Hopital Bicêtre, Dept. of Urology, Kremlin-Bicêtre, France, Hopital Bicêtre, Dept. of Pathology, Kremlin-Bicêtre, France, Hopital de Mont de Marsan, Dept. of Urology, Mont de Marsan, France, Institut Gustave Roussy, Dept. of Radiology, Villejuif, France</td>
</tr>
<tr>
<td>679</td>
<td>Aims and objectives of this presentation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>680</td>
<td>The simplified PADUA RENAL (SPARE) nephrometry system predicts overall complication in patients who underwent partial nephrectomy for renal tumors</td>
<td>Blake P., Sathianathi N., Heller N., Rosenberg J., Rengel Z., Moore K., Kaluzniak H., Walczak E., Papanikolopoulos N., Weight C.</td>
<td>University of Minnesota, Medical School, Minneapolis, United States of America, University of Minnesota, Dept. of Urology, Minneapolis, United States of America, University of Minnesota, Dept. of Computer Science and Engineering, Minneapolis, United States of America, Carleton College, Dept. of Biology, Northfield, United States of America, University of North Dakota, Medical School, Grand Forks, United States of America</td>
</tr>
</tbody>
</table>

Scientific Programme - EAU19 Barcelona
Aims and objectives of this presentation

681

**Circularity analysis with three-dimensional reconstruction models as predictors of prognosis for clear cell renal cell carcinoma**

By: Zhao X.¹, Sun Z.¹, Jiang B.¹, Kan Y.¹, Zheng J.², Guo X.², Guo H.¹
¹Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical School, Dept. of Urology, Nanjing, China, ²Incol Medical Technology Co., Ltd., Dept. of technology, Hangzhou, China

Aims and objectives of this presentation

681

*682

**Great clinical diagnostic value of (68)Ga-PSMA PET/CT imaging for clear cell renal cell carcinoma**

By: Zhang C.¹, Zhao X.¹, Wang F.², Guo H.¹
¹Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, ²Nanjing First Hospital, Dept. of Nuclear Medicine, Nanjing, China

Aims and objectives of this presentation

682

683

**PSMA PET/CT for the primary evaluation of a localized renal mass**

By: Aviv T.¹, Prokocimer Y.¹, Bernstine H.², Nadu A.¹, Domachevsky L.², Groshar D.², Baniel J.¹, Golan S.¹
¹Rabin Medical Center - Beilinson Hospital, Dept. of Urology, Petah Tikva, Israel, ²Rabin Medical Center - Beilinson Hospital, Dept. of Nuclear Medicine, Petah Tikva, Israel

Aims and objectives of this presentation

683

684

**Expression of prostate-specific membrane antigen in clear cell renal cancer patients: A novel option for metastasis detection**

By: Thibaut A.¹, Hölters S.¹, Ohlmann C.¹, Janssen M.¹, Zimpfer A.², Bohle R.², Ezziddin S.³, Stöckle M.¹, Junker K.¹
¹Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany,
Aims and objectives of this presentation

99mTc-sestamibi SPECT/CT for the diagnosis of benign renal oncocytomas and hybrid oncocytic/chromophobe tumors: Combined data from prospective trials and real-world clinical experience

By: Meyer A.R. 1, Patel H.D. 1, Javadi M.S. 2, Pierorazio P. 1, Pavlovich C. 1, Han M. 1, Rowe S.P. 2, Allaf M.E. 1, Gorin M.A. 1

1Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, 2Johns Hopkins University School of Medicine, Dept. of Radiology, Baltimore, United States of America

Aims and objectives of this presentation

674
Paediatric urology: Bladder function and posterior urethral valves
Poster Session 49

Location: Green Area, Room 19
Chairs: To be confirmed
J.M. Nijman, Groningen (NL)
S. Tekgül, Ankara (TR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

685 Comparing open and pneumovesical approach for Politano-Leadbetter ureteric reimplantation; Single center, long term follow up study
By: Tae B.S. 1, Choi H. 1, Park J.Y. 1, Hong C. 2, Jeon B.J. 1, Bae J.H. 1
1Korea University Ansan Hospital, Dept. of Urology, Ansan, South Korea, 2 Konkuk University, School of Medicine, Dept. of Urology, Chung ju, South Korea

686 Analysis of factors influencing operative time of transvesicoscopic ureteral reimplantation
By: Kobayashi K., Johnin K., Tomita K., Murai R., Tsuru T., Yoshida T., Kageyama S., Narita M., Kawauchi A.
Shiga University of Medical Science, Dept. of Urology, Otsu, Japan

687 Medical history of nocturnal enuresis at school age is a risk factor for nocturia in adults: The Nagahama study
By: Negoro H. 1, Fukunaga A. 2, Kawaguchi T. 3, Funada S. 4, Yoshimura K. 5, Kanematsu A. 6, Matsuda F. 3, Nishiyama H. 1, Osamu O. 4
1University of Tsukuba Hospital, Dept. of Urology, Ibaraki, Japan, 2National Cancer Center Hospital, Dept. of Urology, Tokyo, Japan, 3Kyoto University Graduate School of Medicine, Center for Genomic Medicine, Kyoto, Japan, 4Kyoto University Graduate School of Medicine, Dept. of Urology, Kyoto, Japan, 5Shizuoka General Hospital, Dept. of Urology, Shizuoka, Japan, 6Hyogo Collage of Medicine, Dept. of Urology, Hyogo, Japan

688 Clinical utility of a grading scale of urinary incontinence (ENURI) in children with monosymptomatic enuresis
By: Romeu-Magraner G. 1, March-Villalba J.A. 1, Arlandis Guzmán S. 2, Sánchez González J.V. 1, Domínguez Hinarejos C. 1, Boronat Tormo F. 1
1University and Polytechnic Hospital La Fe Valencia, Dept. of Paediatric Urology, Valencia, Spain, 2University and Polytechnic Hospital La Fe Valencia, Dept. of Reconstructive and Functional Urology (SURF), Valencia, Spain
**Lower urinary tract dysfunction in children with hypermobility of joints**

By: Topuz B.¹, Pekbay Y.², Sarikaya S.¹, Acar Z.Z.², Irkilata H.C.³, Dayanc M.M.²

¹Gulhane Research and Training Hospital, Dept. of Urology, Ankara, Turkey, ²Prof. Dr. Murat Dayanc Private Pediatric Urology Clinic, Dept. of Pediatric Urology, Ankara, Turkey, ³Private Davraz Yasam Hospital, Dept. of Urology, Isparta, Turkey

**Usefulness of the BEARS sleep screening tool in the evaluation of sleep disorders in children with monosymptomatic enuresis**

By: Sánchez González J.V., March-Villalba J.A, Martínez-Cayuelas L., Conca Baenas M.A., Polo Rodrigo A., Serrano Durbá A., Domínguez Hinarejos C., Boronat Tormo F. University and Polytechnic Hospital La Fe, Dept. of Paediatric Urology, Valencia, Spain

**Relationship between 25-hydroxyvitamin D, vitamin B12, folate and primer nocturnal enuresis (PNE) in five to thirteen year old children: A single center cohort study**

By: Keles A.¹, Karakeci A.², Onur R.³

¹Istanbul Esenyurt State Hospital, Dept. of Urology, Istanbul, Turkey, ²Fırat University School of Medicine, Dept. of Urology, Elazığ, Turkey, ³Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey

**The effects of pelvic floor muscle rehabilitation (PFMR) on symptoms, voiding and pelvic floor muscle parameters in children with overactive bladder**

By: Pekbay Y.¹, Ergin O.², Topuz B.³, Sarikaya S.³, Acar Z.Z.⁴, Irkilata H.C.², Dayanc M.M.⁴

¹Prof. Dr. Murat Dayanc Pediatric Urology Clinic, Pediatric Urology, Ankara, Turkey, ²Private Davraz Yasam Hospital, Dept. of Urology, Isparta, Turkey, ³Gulhane Research and Training Hospital, Dept. of Urology, Ankara, Turkey, ⁴Prof. Dr. Murat Dayanc Pediatric Urology Clinic, Dept. of Pediatric Urology, Ankara, Turkey

**Influence of pediatric patient’s age in the remission of monosymptomatic enuresis when a therapeutic modality is applied**

By: Sánchez González J.V.¹, March-Villalba J.A.², Conca Baenas M.A.², Polo Rodrigo A.², Serrano Durbá A.², Domínguez Hinarejos C.², Boronat Tormo F.²

¹University and Polytechnic Hospital La Fe, Dept. of paediatric Urology, Valencia, Spain, ²University and Polytechnic Hospital La Fe, Dept. of paediatric Urology, Valencia, Spain

**Different kinds of posterior urethral valves in boys**

By: Sabirzyanova Z., Pavlov A., Simonyan G., Miphyakhetdinova O. Russian scientific center of roentgenradiology, Dept. of Urology, Moscow, Russia

**Posterior urethral valves in patients with a urethra appearing normally on VCUG: An approach to secondary radiologic signs**
Management of posterior urethral valve in infants: What is the role of vesicostomy?

By: El-Moghazy H.
Sohag University, Dept. of Urology, Sohag, Egypt

Surgical interventions in an adult population of posterior urethral valves: Long term urological outcomes

By: Namdarian B., Scrimgeour G., Wilby D., Dunford C., Connolly J., Wood D.N.
University College London Hospital, Paediatric Urology and Adolescent Reconstructive Urology, London, United Kingdom, University College London Hospital, Dept. of Nephrology, London, United Kingdom
Non-muscle invasive bladder cancer: Role of markers for diagnosis, prognosis and surveillance
Poster Session 50

Sunday 17 March
14:00 - 15:30

Location: Green Area, Room 20

Chairs: R. Campi, Florence (IT)
L.H. Klotz, Toronto (CA)
H. Mostafid, Surrey (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

700
Role of surgeon experience in the outcome of transurethral resection of bladder tumors

By: Ali M. H., Eltobgy A., Ismail I.Y., Ghobeish A.A.
Faculty of Medicine, Suez Canal University, Dept. of Urology, Ismailia, Egypt

Aims and objectives of this presentation
700

701
The impact of a past medical history of upper urinary tract urothelial carcinoma on failure cases of bacillus Calmette–Guérin intravesical instillation therapy

By: Iida K. 1, Naiki T. 1, Nagai T. 2, Nozaki S. 1, Etani T. 1, Ando R. 1, Akita H. 2, Okamura T. 2, Kubota H. 3, Kawai N. 1, Yasui T. 1
1Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, 2Anjo Kosei Hospital, Dept. of Urology, Aichi, Japan, 3Kanian Hospital, Dept. of Urology, Aichi, Japan

Aims and objectives of this presentation
701

702
Up-date of pathological outcome and subjective definition of failure for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: Result from Bladder Cancer Italian Active Surveillance (BIAS) project

Istituto Clinico Humanitas IRCCS Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy

Aims and objectives of this presentation
702
703  Systemic inflammatory markers and oncological outcomes in patients with high risk non-muscle invasive urothelial bladder cancer

By: Russo G.I. 1, Cantiello F. 2, Vartolomei M. 3, Lucarelli G. 4, Serretta V. 5, Morgia G. 1, Damiano R. 2, De Cobelli O. 3, Ferro M. 3
1University of Catania, Dept. of Urology, Catania, Italy, 2University of Catanzaro, Dept. of Urology, Catanzaro, Italy, 3Istituto Europeo di Oncologia (IEO), Dept. of Urology, Milan, Italy, 4University of Bari, Dept. of Urology, Bari, Italy, 5University of Palermo, Dept. of Urology, Palermo, Italy

Aims and objectives of this presentation
703

704  Tumor associated macrophages promote bladder tumor growth through PI3k/AKT signal induced by collagen

By: Shi Q., Jiakun L., Kun J., Lu Y., Qiang W.
West China Hospital, Dept. of Urology, Institute of Urology, Chengdu, China

Aims and objectives of this presentation
704

705  Evaluating the cost of surveillance for non-muscle invasive bladder cancer: An economic analysis based on risk categories

By: Mossanen M. 1, Wang Y. 2, Szymaniak J. 1, Tan W.S. 3, Huynh M.J. 1, Preston M.A. 1, Trinh Q-D. 1, Sonpavde G. 4, Schrag D. 4, Kibel A.S. 1, Chang S.L. 1
1Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America, 2Brigham and Women's Hospital, Center for Surgery and Public Health, Boston, United States of America, 3University College of London, Dept. of Urology, London, United Kingdom, 4Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

Aims and objectives of this presentation
705

706  Substratification of intermediate-risk non-muscle-invasive bladder cancer based on the prediction of high-risk recurrence: Impact of bladder neck involvement and positive urine cytology

Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation
706

707  Evaluation of non-muscle-invasive bladder cancer recurrence using a mRNA-based urine test (Xpert® Bladder Cancer Monitor) and cytology
By: Cancel-Tassin G. 1, Ciofu C. 2, Varinot J. 2, Audouin M. 2, Ondet V. 2, Gaffory C. 1, Roupret M. 3, Comperat E. 2, Cussenot O. 2
1CeRePP, CeRePP, Paris, France, 2Sorbonne Universite, GRC n°5, ONCOTYPE-URO, AP-HP, Tenon Hospital, Paris, France, 3Sorbonne Universite, GRC n°5, ONCOTYPE-URO, AP-HP, Pitie-Salpetriere Hospital, Paris, France

Aims and objectives of this presentation
707

708
Current European trends in endoscopic imaging and transurethral resection of bladder tumours

By: Waldbillig F. 1, Witte B. 1, Hein S. 2, Suarez-Ibarrola R. 2, Reiterer A. 3, Miernik A. 2, Kriegmair M.C. 1, Ritter M. 1
1University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany, 2University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, 3Fraunhofer Institute, Dept. of Physical Measurement Techniques, Freiburg, Germany

Aims and objectives of this presentation
708

709
Performance of bladder EpiCheck™ for NMIBC monitoring - updated results of a European multi-center study

By: Lozano Palacio F. 1, Morote J. 1, Leibovitch I. 2, Cornel E.B. 3, Joyce J. 4, Gakis G. 5, Alvarez-Maestro M. 6, Van Valenberg H. 7, Sternberg I. 2, Albers L.F. 4, Willemsen E. 3, Hegemann M.L. 8, Paitan Y. 9, Witjes J.A. 7
1Hospital Universitario Vall d’Hebron, Dept. of Urology, Barcelona, Spain, 2Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, 3ZGT Medical Center, Dept. of Male functional and Uro-oncology and Research, Hengelo, The Netherlands, 4Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, 5University Hospital of Würzburg, Dept. of Urology and Pediatric Urology, Würzburg, Germany, 6Hospital Universitario de La Paz, Dept. of Urology, Madrid, Spain, 7Radboud University Nijmegen Medical Center, Dept. of Urology, Nijmegen, The Netherlands, 8Sindelfingen-Böblingen Hospital, Dept. of Urology, Sindelfingen, Germany, 9Meir Medical Center, Clinical Microbiology Lab, Kfar Saba, Israel

Aims and objectives of this presentation
709

710
Treatment of high grade non-muscle invasive bladder carcinoma by standard number and dose of intravesical BCG instillations versus reduced number and dose of intravesical BCG instillations. An initial report of the phase III clinical trial ‘NIMBUS’

By: Grimm M-O. 1, Van Der Heijden A. 2, Colombel M. 3, Muijlwijk T. 4, Martinez-Piñeiro L. 5, Bjaartell A. 6, Caris C. 6, Schipper R. 6, Witjes W. 6, Babjuk M. 7, Türkeri L. 8, EAU Research Foundation NIMBUS Study Group
1University Hospital Jena, Dept. of Urology, Jena, Germany, 2Radboud UMC, Dept. of Urology, Nijmegen, The Netherlands, 3Hopital Edouard Herriot, Dept. of Urology, Lyon,
710
Risk-stratified surveillance and cost effectiveness of follow-up after trans-urethral resection of bladder tumor in patients with primary non-muscle-invasive bladder cancer


1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, 3Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

711
TERT promoter and FGFR3 mutations – a highly sensitive and non-invasive tool for bladder cancer recurrence detection


1CUF, Dept. of Urology, Coimbra, Portugal, 2i3S, Dept. of Cancer Signalling and Metabolism, Porto, Portugal, 3IPO Coimbra, Dept. of Urology, Coimbra, Portugal, 4Hospital de Braga, Urologia, Braga, Portugal, 5Hospital Fernando Pessoa, Dept. of Urology, Porto, Portugal, 6i3S, Dept. of Cancer Signalling and Metabolism, Porto, Portugal

712
Active surveillance in low risk bladder cancer. Is it a safe option?

By: Lozano Palacio F., Carles X. R., Albert A., Ropero J., Allue M., Catro L., Cocera R., Morote J.

Hospital Universitario Vall d'Hebron, Dept. of Urology, Barcelona, Spain

713
Aims and objectives of this presentation

710
Aims and objectives of this presentation

711
Aims and objectives of this presentation

712
Aims and objectives of this presentation

713
Aims and objectives of this session
One of the main goals of the EAU is to establish and introduce common standards for training and European urological practice in order to improve patient care. The E-BLUS exam certifies a basic level of laparoscopic urological skills. The exercises addresses bimanual dexterity, depth perception, suturing and cutting skills. Clinical application is found in such procedures as partial nephrectomy, total nephrectomy, pyeloplasty and radical prostatectomy. To aid in the training of these skills and to prepare for this E-BLUS exam the online theoretical course is mandatory http://uroweb.org/education/online-education/surgical-education/laparoscopy/theoretical-course/

The course will start with E-BLUS training to further develop your laparoscopic skills and to benefit from the knowledge and expertise of international laparoscopy experts. After the training your skill are tested in the E-BLUS exam. Make sure you are prepared for the exam because training time onsite will be limited and without previous training you will most likely not pass the exam. The exercises to be performed can be found in the instructional videos at http://uroweb.org/education/online-education/surgical-education/laparoscopy/
Aims and objectives of this session
Discuss available literature and practical management options and examples treatment of urolithiasis in 'non-index' patients, covering:
• Horse shoe kidney, caliceal diverticula, duplicate urinary system.
• Pregnancy, complex metabolic patients.
• After bladder substitution/ileal conduit/reimplantation.
• In transplant kidneys and spinal malformation.

14:30 - 17:30
Introduction
G.M. Kamphuis, Amsterdam (NL)

14:30 - 17:30
Urolithiasis in urinary system anomalies: Horse shoe kidneys
E. Emiliani, Barcelona (ES)

14:30 - 17:30
Urolithiasis in urinary system anomalies: Calyceal diverticula stones
S. Doizi, Paris (FR)

14:30 - 17:30
Urolithiasis in pregnancy
G.M. Kamphuis, Amsterdam (NL)

14:30 - 17:30
Urolithiasis in urinary system anomalies: After bladder substitution/ ileal conduit/ ureteral reimplantation
E. Emiliani, Barcelona (ES)

14:30 - 17:30
Medullary sponge kidneys
S. Doizi, Paris (FR)

14:30 - 17:30
Urolithiasis in transplant kidneys
G.M. Kamphuis, Amsterdam (NL)

14:30 - 17:30
Urolithiasis in urinary system anomalies: Duplicate urinary system and ectopic kidney
S. Doizi, Paris (FR)

14:30 - 17:30
Surgical treatment of complex metabolic patients: Brushite and cystine stones
E. Emiliani, Barcelona (ES)

14:30 - 17:30
Patients with relative contraindications: Spinal malformation / bleeding diathesis
G.M. Kamphuis, Amsterdam (NL)
Focal treatment in prostate cancer
ESU Course 36

Location: Green Area, Room 14
Chair: E. Barret, Paris (FR)

Aims and objectives of this session
Focal treatment (FT) is about eradicating the cancer lesion within the prostate while preserving genitourinary function. This interactive course offers delegates
• understanding of the rationale for focal treatment and patient selection criteria.
• update on principles, outcome and side effects of focal technologies.
• a thorough discussion of biopsy strategies and imaging in diagnostic work-up and follow-up
• information about existing registries.
As men with prostate cancer are getting younger the side effects of whole gland treatment are getting more important. With several new technologies available a significant development of focal treatment is expected in the coming years.

Selection criteria for FT

Rationale for FT
F. Sanguedolce, Barcelona (ES)

Role of imaging
E. Barret, Paris (FR)

Prostate biopsy modalities
A. Govorov, Moscow (RU)

Focal therapy modalities

Treatment modalities
F. Sanguedolce, Barcelona (ES)

Energy sources (technical aspects - videos)

Cryotherapy
A. Govorov, Moscow (RU)

HIFU
E. Barret, Paris (FR)

Brachytherapy
A. Govorov, Moscow (RU)

Others (laser ablation, irreversible electroporation, radiofrequency)
E. Barret, Paris (FR)

Follow up
Scientific Programme - EAU19 Barcelona

**Follow-up modalities**
F. Sanguedolce, Barcelona (ES)

**Oncological and functional outcomes**
A. Govorov, Moscow (RU)

**Definition of failure and failure management**
E. Barret, Paris (FR)

**Salvage FT**
F. Sanguedolce, Barcelona (ES)

**Clinical cases**
E. Barret, Paris (FR)
How will immunotherapy change the multidisciplinary management of urothelial bladder cancer?

ESU Course 35

Sunday 17 March 14:30 - 17:30

Location: Green Area, Room 15
Chair: A. Necchi, Milan (IT)

Voting will be available via the EAU19 App or via www.qna.at/eau

Aims and objectives of this session

Results obtained from large immunotherapy trials paved the way of a revolutionary road in the treatment of locally advanced and metastatic urothelial bladder cancer (UBC). For clear-cell renal cell carcinoma (RCC), use of immunotherapy combinations (with either other immune checkpoint inhibitors or targeted therapy/antiangiogenic drugs) resulted in a shifting paradigm for the first-line therapy of advanced disease. For both of these tumors, developments of immunotherapy trials in earlier disease stages are progressing at an impressively quick step. Therefore, as never before, there is a need for updates on the multidisciplinary management of these patients.

In brief, the aims of the course will be the following:
• To provide urologists with the state-of-the art on the use of immune-checkpoint inhibitors in UBC and RCC.
• To provide urologists with an overview of the ongoing clinical trials throughout the clinical stages, with a special focus on perioperative stages.
• To discuss the optimal clinical management of patients with UBC or RCC receiving immune checkpoint inhibitor treatment, including the management of side effects.

Background - State-of-the art and ongoing developments
A. Necchi, Milan (IT)

Clinical cases discussion
J. Bedke, Tübingen (DE)

Immune checkpoint inhibitors in the perioperative setting of urothelial cancer:

Immune checkpoint inhibitors and the multidisciplinary management of locally advanced bladder cancer:

Background
A. Necchi, Milan (IT)

Case discussion 1 – optimal approach for cisplatin - ineligible patients
J. Bedke, Tübingen (DE)

Case discussion 2 – therapeutic sequences for platinum - refractory patients
A. Necchi, Milan (IT)
| Case discussion 3 - Management of adverse events: What urologists should know |
| J. Bedke, Tübingen (DE) |

**Management of RCC in the perioperative setting:**

**Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy**
A. Bex, Amsterdam (NL)

**Neoadjuvant and adjuvant immunotherapy developments**
J. Bedke, Tübingen (DE)

**Immune checkpoint inhibitors and the multidisciplinary management of locally-advanced renal cell cancer:**

**Benchmark of immunotherapy - based results**
A. Necchi, Milan (IT)

**Case discussion 2 – role of tyrosine-kinase inhibitors in advanced RCC**
J. Bedke, Tübingen (DE)

**Case discussion 3 – development of first-line immune-oncology combinations**
A. Bex, Amsterdam (NL)

**Case discussion 1 – combination immunotherapy as first line therapy of advanced RCC**
A. Bex, Amsterdam (NL)

**Conclusion**
A. Necchi, Milan (IT)
Laparoscopic and robot-assisted laparoscopic radical cystectomy

ESU Course 34

Sunday 17 March
14:30 - 17:30

Location: Green Area, Room 16
Chair: N.P. Wiklund, Stockholm (SE)

Aims and objectives of this session
The course is video based. The steps in the surgical treatment of muscle invasive bladder cancer by conventional laparoscopy and robot-assisted technique will be described. The surgical technique to perform Male and female cystectomy, lymph node dissection, urinary diversion with extracorporeal and intracorporeal technique, conduits as well as orthotopic neobladders, will be shown. Indications, contraindications, outcomes and handling of complications will be discussed.

• The surgical steps in nerve sparing and non-nerve sparing male cystectomy.
• The surgical steps in female cystectomy with and without organ sparing technique.
• The surgical steps in lymph node dissection during cystectomy.
• The technique in urinary diversion, conduit and neobladder, with intra and extracorporeal technique.
• Indications, outcomes and complications after minimally invasive cystectomy.
• The handling of the most common complications after minimally invasive cystectomy.

Laparoscopic cystectomy in males (video-based teaching)

Conventional laparoscopy
J. Rassweiler, Heilbronn (DE)

Robot-assisted technique with nerve sparing technique
C.J. Wijburg, Arnhem (NL)

Laparoscopic cystectomy in Females (video based teaching)

Conventional cystectomy
J. Rassweiler, Heilbronn (DE)

Robot-assisted cystectomy with organ preservation
N.P. Wiklund, Stockholm (SE)

Laparoscopic lymph node dissection (video-based teaching)
J. Rassweiler, Heilbronn (DE)

Laparoscopic urinary diversion (video-based teaching)

Intracorporeal: Bricker
C.J. Wijburg, Arnhem (NL)

Intracorporeal: Neobladder
N.P. Wiklund, Stockholm (SE)
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Topic</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extracorporeal urinary diversion</td>
<td>J. Rassweiler, Heilbronn (DE)</td>
</tr>
<tr>
<td>Challenge the expert: Controversies in laparoscopic and robotic cystectomy</td>
<td></td>
</tr>
<tr>
<td>Oncological outcomes in laparoscopic cystectomy - Challenger</td>
<td>C.J. Wijburg, Arnhem (NL)</td>
</tr>
<tr>
<td>Oncological outcomes in laparoscopic cystectomy - Pro</td>
<td>N.P. Wiklund, Stockholm (SE)</td>
</tr>
<tr>
<td>Complications and functional outcomes in laparoscopic cystectomy - Challenger</td>
<td>J. Rassweiler, Heilbronn (DE)</td>
</tr>
<tr>
<td>Complications and functional outcomes in laparoscopic cystectomy - Pro</td>
<td>N.P. Wiklund, Stockholm (SE)</td>
</tr>
</tbody>
</table>
Management of BPO: From medical to surgical treatment, including setbacks and operative solutions (SOS)
ESU Course 38

<table>
<thead>
<tr>
<th>Sunday 17 March 14:30 - 17:30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location:</strong> Green Area, Room 21</td>
</tr>
<tr>
<td><strong>Chair:</strong> V.A.C. Ramani, Manchester (GB)</td>
</tr>
</tbody>
</table>

**Aims and objectives of this session**
- To help delegates understand the principles and evidence behind the assessment and medical management of a BPO patient.
- To summarise / review the evidence base for electro surgery and lasers for surgical management of BPO.
- To help delegates understand the factors that influence the patient's and surgeon's choice of treatment modalities.
- Setbacks and Operative Solutions (SOS): Tips and Tricks to improve outcomes and avoid complications.

**Introduction/scene setting BPO 2019**
V.A.C. Ramani, Manchester (GB)

**Assessment and medical management**
V.A.C. Ramani, Manchester (GB)

**Surgical management – Electrosurgery**
T.R.W. Herrmann, Frauenfeld (CH)

**Surgical management – Lasers and less invasive options**
S. Ahyai, Göttingen (DE)

**Setbacks and operative solutions / Case presentations**
S. Ahyai, Göttingen (DE)
T.R.W. Herrmann, Frauenfeld (CH)
V.A.C. Ramani, Manchester (GB)
Aims and objectives of this session
Recently new imaging technologies have been developed to improve the diagnosis and management of prostate cancer. These are multiparametric MRI, choline PET and new ultrasound based technologies. The course’s aim is to provide:
- An overview on the currently available imaging tools for prostate cancer.
- Practical information about their use.
- A critical assessment of their clinical performance and their limitations.

Introduction and objective of course
J. Walz, Marseille (FR)

Diagnosis of prostate cancer

Standarization, acquisition and reporting of multiparametric MRI
I.G. Schoots, Rotterdam (NL)

Reading of a prostate MRI and use of MRI for diagnosis of prostate cancer
I.G. Schoots, Rotterdam (NL)

MRI guided biopsy and image fusion (mp MRI and Ultrasound)
J. Walz, Marseille (FR)

What are possible alternatives to multiparametric MRI?
J. Walz, Marseille (FR)

Staging of prostate cancer

Staging with CT, MRI and bone scintigraphy
P.J.L. De Visschere, Ghent (BE)

MRI in local staging of prostate cancer
P.J.L. De Visschere, Ghent (BE)

Recurrent disease

Use of PET in the management of prostate cancer (initial staging and recurrence)
J. Walz, Marseille (FR)

MRI in detection of locally recurrent prostate cancer
P.J.L. De Visschere, Ghent (BE)
When to do imaging of the prostate? Case discussion and current practical questions
I.G. Schoots, Rotterdam (NL)
P.J.L. De Visschere, Ghent (BE)
J. Walz, Marseille (FR)

Closure and evaluation
Aims and objectives of this session
The advanced urethral stricture course will cover the assessment and surgical treatment of strictures of the penile, bulbar and posterior urethra. General principles of assessment and follow up, oral mucosa harvest and complications will be reviewed with evidence. Techniques of penile, bulbar and full length urethroplasty will be discussed and compared and cases reviewed with audience participation encouraged. Pelvic fracture urethral injuries will also be discussed together with management techniques. Female urethroplasty will also be discussed and assessed. Prior knowledge of relevant anatomy and basic endoscopic techniques will be helpful to those attending the course.

Introduction
R. Inman, Sheffield (GB)

General principles in urethral stricture surgery and cases
P. Nyirády, Budapest (HU)

Penile urethroplasty and cases
R. Inman, Sheffield (GB)

Bulbar and full length urethroplasty and cases
R. Inman, Sheffield (GB)

Posterior urethroplasty and cases
L. Martínez Piñeiro, Madrid (ES)

Female urethroplasty
R. Inman, Sheffield (GB)
E-BLUS Exam
Sponsored by KARL STORZ

Location: Green Area, Room 6

Tutors: S. Barmoshe, Brussels (BE)
A.S. Gözen, Heilbronn (DE)
J-T. Klein, Ulm (DE)
L. Osório, Porto (PT)
G. Pini, Milano (IT)
D. Rengifo Abbad, Majadahonda (ES)
C. Wagner, Gronau (DE)
To be confirmed

Aims and objectives of this session
One of the main goals of the EAU is to establish and introduce common standards for training and European urological practice in order to improve patient care. The E-BLUS exam certifies a basic level of laparoscopic urological skills. The exercises addresses bimanual dexterity, depth perception, suturing and cutting skills. Clinical application is found in such procedures as partial nephrectomy, total nephrectomy, pyeloplasty and radical prostatectomy. To aid in the training of these skills and to prepare for this E-BLUS exam the online theoretical course is mandatory http://uroweb.org/education/online-education/surgical-education/laparoscopy/theoretical-course/

The course will start with E-BLUS training to further develop your laparoscopic skills and to benefit from the knowledge and expertise of international laparoscopy experts. After the training your skill are tested in the E-BLUS exam. Make sure you are prepared for the exam because training time onsite will be limited and without previous training you will most likely not pass the exam. The exercises to be performed can be found in the instructional videos at http://uroweb.org/education/online-education/surgical-education/laparoscopy/
Treatment of upper urinary tract stone disease
Expert-Guided Poster Tour 10

Sunday 17 March
15:15 - 17:15

Location: Green Area, Room A
Chairs: P.J.S. Osther, Fredericia (DK)
C.M. Scoffone, Turin (IT)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

15:45 - 15:48
Introduction
P.J.S. Osther, Fredericia (DK)
C.M. Scoffone, Turin (IT)

PT247
Effect of payer status on perioperative outcomes and costs associated with elective therapy for nephroureterolithiasis
To be confirmed

PT248
Development and validation of the prediction nomogram for a stone episode
By: Hatakeyama S. 1, Imai A. 1, Hamano I. 1, Tanaka T. 1, Yoneyama T. 1, Yamamoto H. 1, Yoneyama T. 1, Hashimoto Y. 1, Nakaji S. 2, Ohyama C. 1
1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,
2Hirosaki University Graduate School of Medicine, Social Medicine, Hirosaki, Japan

PT249
Health related quality of life impact of renal and ureteric stones - do these differ?
By: Joshi H. 1, Pickles T. 2, Pietropaolo A. 3, Matanhelia M. 4, Somani B. 3, Phillip J. 4, Biyani S. 5
1University Hospital of Wales, Dept. of Urology, Cardiff, United Kingdom,
2Cardiff University, Dept. of Statistics, Cardiff, United Kingdom,
3Southampton University Hospital, Dept. of Urology, Southampton, United Kingdom,
4Southmead Hospital, Dept. of Urology, Bristol, United Kingdom,
5St. James’s University Hospital, Dept. of Urology, Leeds, United Kingdom

PT250
Acute stone admissions – should we have a lower threshold for treatment in female patients
By: Down C.J. 1, Malthouse T. 1, Lobo N. 2, Ali A. 2, Symes A. 1, Coker C. 1
1Brighton and Sussex University NHS Foundation Trust, Dept. of Urology, Brighton,
PT251

**Measuring Hounsfield units in cystinuria: Is it really so hard?**

By: Warren H.¹, Thomas K.¹, Poon D.², Srinivasan R.², Rottenberg G.², Bultitude M.¹, Thomas K.¹

¹Guy's and St. Thomas' NHS Foundation Trust, Urology Centre, London, United Kingdom, 
²Guy's and St. Thomas' NHS Foundation Trust, Dept. of Radiology, London, United Kingdom

---

PT252

**Budget impact analysis to support the decision between replacing reusable flexible ureteroscopes by single use devices and adopting a hybrid strategy for the urolithiasis treatment**

By: Pradere B.¹, Dubnitskiy-Robin S.², Faivre D'Arcier B.¹, Bruyère F.¹, Boutin J.M.¹, Watt S.³, Le Fol T.⁴, Rusch E.², Monmousseau F.², Brunet-Houdard S.²

¹CHRU Tours, Dept. of Urology, Tours, France, ²CHRU Tours, Dept. of Health-Economic Evaluation, Tours, France, ³CHRU Tours, Dept. of Pharmacy, Tours, France, ⁴CHRU Tours, Dept. of Biomedical, Tours, France

---

PT253

**Cost analysis on the use of disposable ureteroscopes (LithoVue- Boston Scientific) to decrease the number of reusable ureteroscopes repairs**


ACT Health, Dept. of Urology, Canberra, Australia

---

PT254

**In vitro and in vivo new evidence for flexor vue deflecting endoscopic system use: Optimization of the stone free rate (SFR) after RIRS**

By: Saita A.R.¹, Villa L.², Paciotti M.¹, Fasulo V.¹, Casale P.¹, Lughezzani G.¹, Buffi N.M.¹, Hurle R.¹, Domanico L.¹, Bevilacqua G.¹, Peschecchera R.¹, Lazzeri M.¹, Guazzoni G.¹

¹Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, ²San Raffaele Hospital, Dept. of Urology, Rozzano, Italy

---

PT255

**Protective effect of lead curtain on radiation exposure to the operator during ureteroscopy**

By: Denis E.¹, Abid N.²

¹CH St Joseph St Luc, Dept. of Urology, Lyon, France, ²Hôpital Edouard Herriot, Dept. of Urology, Lyon, France

---

PT256

**Post Ureteral Lithotripsy Sepsis Evaluation Score (CMUH-PULSE score) is a brand new tool to precise predict postoperative sepsis rate resulting from ureteroscopic lithotripsy (URSL)**

By: Laih C.Y.¹, Lai C.M.², Hsiao P.J.¹, Huang C.P.¹, Chen W.C.¹, Chou C.L.¹, Chang
<table>
<thead>
<tr>
<th>PT257</th>
<th>Significance of albumin to globulin ratio as a predictor of febrile urinary tract infection after ureteroscopic lithotripsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Choi S.H.¹, Ha Y.¹, Kim B.S.¹, Yoo E.S.¹, Chung S.K.¹, Min K.², Chung J-W.²</td>
</tr>
<tr>
<td></td>
<td>Lee J.N.², Kim H.T.², Kim T.², Kwon T.G.²</td>
</tr>
<tr>
<td>¹Kyungpook National University Hospital, Dept. of Urology, Daegu, South Korea, ²Kyungpook National University Chilgok Hospital, Dept. of Urology, Daegu, South Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT258</th>
<th>Role of cultural analysis in patients with indwelling ureteral stent submitted to ureteroscopy for stones</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Carobbio F.¹, Zamboni S.¹, Lattarulo M.¹, D’Aietti D.¹, Cristinelli L.¹, Van Hauwemeiren E.², Moroni A.¹, Antonelli A.¹, Simeone C.¹</td>
</tr>
<tr>
<td>¹Spedali Civili Hospital of Brescia, University of Brescia, Dept. of Urology, Brescia, Italy, ²Spedali Civili Hospital of Brescia, University of Brescia, Dept. of Infectious Diseases, Brescia, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT259</th>
<th>Prospective evaluation and classification of ureteroscopic findings of impacted calculi</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Hamamoto S.¹, Sugino T.¹, Taguchi K.¹, Ando R.¹, Inoue T.², Okada S.³, Okada A.¹, Matsuda T.², Yasui T.⁴, SMART Study Group</td>
</tr>
<tr>
<td>¹Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, ²Kansai Medical University Medical Center, Dept. of Urology, Osaka, Japan, ³Gyotoku general Hospital, Dept. of Urology, Chiba, Japan, ⁴Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Osaka, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT260</th>
<th>Withdrawn</th>
</tr>
</thead>
<tbody>
<tr>
<td>To be confirmed</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT261</th>
<th>Emergency versus elective ureteroscopy: Retrospective analysis of 4021 cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Malkhasyan V.A.¹, Semenyakin I.V.², Ivanov V.³, Dzhuraeva M.¹, Kasyan G.R.¹, Pushkar D.¹</td>
</tr>
<tr>
<td>¹A.I. Evdokimov Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, ²City clinical hospital named after S.I. Spasokukotsky, Dept. of Urology, Moscow, Russia, ³City Clinical Hospital named after S.I. Spasokukotsky, Dept. of Urology, Moscow, Russia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT262</th>
<th>Comparison of primary and delayed ureteroscopy for ureteric stones: Prospective non-randomised comparative study</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Aboumarzouk O.M.¹, Pietropaolo A.², Geraghty R.², Whitehurst L.², Kyriakides R.², Somani B.²</td>
</tr>
<tr>
<td>¹NHS Greater Glasgow and Clyde, Dept. of Urology, Glasgow, United Kingdom, ²Sci</td>
<td></td>
</tr>
<tr>
<td>PT263</td>
<td>Perioperative outcomes of flexible ureterorenoscopy for urolithiasis using the sheathless technique: A comparative study</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>By: Pradere B.¹, Peyronnet B.², Khene Z.E.², Freton L.², Alimi Q.², Mathieu R.², Manunta A.², Bensalah K.²</td>
<td></td>
</tr>
<tr>
<td>¹CHRU Tours, Dept. of Urology, Tours, France, ²CHU Rennes, Dept. of Urology, Rennes, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT264</th>
<th>Predicting ureteroscopic lithotripsy outcome by three-dimentional mean stone density</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Higuchi M., Yamashita S., Takashi I., Satoshi N., Kazurou K., Yasuo K., Isao H.</td>
<td></td>
</tr>
<tr>
<td>Wakayama medical University, Dept. of Urology, Wakayama, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT265</th>
<th>Rates of primary ureterorenoscopy access failure in a multi-ethnic Asian population</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Lu J.¹, Khor V.², Loke W.T²</td>
<td></td>
</tr>
<tr>
<td>¹National University Hospital, Dept. of Urology, Singapore, Singapore, ²Ng Teng Fong</td>
<td></td>
</tr>
<tr>
<td>General Hospital, Dept. of Urology, Singapore, Singapore</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT266</th>
<th>Role of general anesthesia versus general anesthesia with short intraoperative apnea for retrograde intrarenal surgery and for ureteroscopic laser lithotripsy for proximal ureteric stone: A single institution randomized control study</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Panackal A.¹, Singh M.², Krishana L.², Srinivas R.²</td>
<td></td>
</tr>
<tr>
<td>¹Kims Oman Hospital, Dept. of Urology, Muscat, Oman, ²Kims Oman Hospital, Dept. of Anesthesy, Muscat, Oman</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT267</th>
<th>The S.T.O.N.E. score: A new assessment tool to predict stone free rates in ureteroscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Chaker K., Bouzouita A., Gharbi M., Chakroune M., Saadi A., Ayed H., Cherif M., Ben Slama M.R., Derouiche A., Chebil M.</td>
<td></td>
</tr>
<tr>
<td>Charles Nicolle Hospital, University of Tunis El Manar, Dept. of Urology, Tunis, Tunisia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT268</th>
<th>When is the best time to assess the stone free rate after laser lithotripsy?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT269</th>
<th>Upper pole renal puncture in supine percutaneous nephrolithotomy – 9 year experience from a single tertiary stone unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>By: Moghul M., Withington J., Goyal A., Kucheria R., Allen D., Ajayi L.</td>
<td></td>
</tr>
<tr>
<td>Royal Free Hospital, Dept. of Urology, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
### PT270
**Evaluation of the surgical outcome SWL, mini-PCNL and RIRS for the management of lower pole stones with a size <2cm stones: A systematic review and meta-analysis**

By: **Kallidonis P.¹**, Kotsiris D.¹, Adamou C.¹, Ntasiotis P.¹, Somani B.², Tailly T.³, Oszoy M.⁴, Liatsikos E.¹

¹University Hospital of Patras, Dept. of Urology, Patras, Greece, ²University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ³Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria

### PT271
**Supine percutaneous nephrolithotomy in the obese patient**

By: **Moghul M.**, Withington J., Goyal A., Kucheria R., Allen D., Ajayi L.

Royal Free Hospital, Dept. of Urology, London, United Kingdom

### PT272
**Ureteroscopic assistance contributes to the safer renal puncture during endoscopic combined intrarenal surgery**

By: **Sugino T.¹**, Hamamoto S.¹, Tanaka Y.¹, Unno R.¹, Taguchi K.¹, Ando R.¹, Okada A.¹, Mogami T.², Kohri K.¹, Yasui T.¹

¹Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan, ²JA Mie Komono Kosei Hospital, Dept. of Urology, Komono, Japan

### PT273
**Should a miniature percutaneous nephrolithotomy be performed in obese patients?**

By: **Burns H.**, Ahmad N., Nalagatla S.K.

University Hospital Monklands, Dept. of Urology, Glasgow, United Kingdom

### PT274
**Withdrawn**

To be confirmed

### PT275
**Comparison of the treatment in patients with infectious risk factors: Laparoscopic pyelolithotomy, percutaneous nephrolithotomy or retrograde intrarenal surgery**

By: **Lu J.**, Xun Y., Li C., Wang S.

Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

### PT276
**Conservative treatment in small renal stones according to EAU recommendations: Long term results of a multicenter study, about 474 patients**

By: **Sallami S.¹**, Abou El Makarim S.¹, Ben Atta M.²

¹Mohamed Tahar Maamouri Teaching Hospital, Dept. of Urology, Nabeul, Tunisia, ²Oran Teaching Hospital, Dept. of Urology, Oran, Algeria
Radical prostatectomy
Expert-Guided Poster Tour 11

Sunday 17 March
15:15 - 17:15

Location: Green Area, Room B
Chairs: P. Albers, Düsseldorf (DE)
A. De La Taille, Créteil (FR)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

15:45 - 15:48
Introduction
P. Albers, Düsseldorf (DE)
A. De La Taille, Créteil (FR)

PT277
Prospective study of ambulatory radical prostatectomy: Results at 30 months

By: Dumonceau O. 1, Aldea R. 2, Beley S. 1, Benbouzid S. 1, Dominique S. 1, Lucaks B. 1, Messas A. 1, Peyrat L. 1, Haab F. 1
1Clinique Turin, Dept. of Urology, Paris, France, 2Clinique Turin, Dept. of Anesthesiology, Paris, France

Aims and objectives of this presentation
PT277

PT278
Castration-resistant prostate cancer-free survival in the multicentric prospective local treatment of metastatic prostate cancer (LoMP) trial

By: Buelens S. 1, Poelaert F. 1, De Bleser E. 1, Dhondt B. 1, Verla W. 1, Ost P. 2, Rappe B. 3, De Troyer B. 4, Verbaeys C. 5, Kimpe B. 6, Billiet I. 7, Plancke H. 8, Fransis K. 9, Willemen P. 10, Ameye F. 11, Decaestecker K. 1, Lumen N. 1
1Ghent University Hospital, Dept. of Urology, Ghent, Belgium, 2Ghent University Hospital, Dept. of Radiation Oncology, Ghent, Belgium, 3ASZ, Dept. of Urology, Aalst, Belgium, 4AZ Nikolaas, Dept. of Urology, Sint-Niklaas, Belgium, 5AZ Jan Palfijn, Dept. of Urology, Ghent, Belgium, 6Sint-Lucas Hospital, Dept. of Urology, Bruges, Belgium, 7AZ Groeninge, Dept. of Urology, Kortrijk, Belgium, 8Imelda Hospital, Dept. of Urology, Bonheiden, Belgium, 9University Hospital Antwerp, Dept. of Urology, Antwerp, Belgium, 10Jessa Hospital, Dept. of Urology, Hasselt, Belgium, 11AZ Maria Middelares, Dept. of Urology, Ghent, Belgium

Aims and objectives of this presentation
PT278
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT279</td>
<td>Association of local anaesthetic wounds infiltration and ultrasound transversus abdominal plane (US-TAP) block in patients undergoing robot-assisted radical prostatectomy: A double-blind randomized controlled trial</td>
<td>Cacciamani G.E.¹, Menestrina N.², Pirozzi M.¹, Corsi P.¹, De Marchi D.¹, Inverardi D.¹, Processali T.¹, Trabacchin N.¹, De Michele M.¹, Tafuri A.¹, Sebben M.¹, Cerruto M.A.¹, De Marco V.¹, Migliorini F.¹, Porcaro A.B.¹, Artibani W.¹</td>
<td>University of Verona, Dept. of Urology, Verona, Italy, University of Verona, Dept. of Anesthesiology, Verona, Italy</td>
<td>PT279</td>
</tr>
<tr>
<td>PT281</td>
<td>Sacrifice of accessory pudendal arteries during robot-assisted radical prostatectomy does not impact recovery of urinary continence</td>
<td>Matsushita K.¹, Sandhu J.S.², Narimoto K.³, Shimbo M.³, Endo F.³, Hattori K.³, Horie S.¹</td>
<td>Juntendo University, Graduate School of Medicine, Dept. of Urology, Tokyo, Japan, Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America, St. Lukes International Hospital, Dept. of Urology, Tokyo, Japan</td>
<td>PT281</td>
</tr>
<tr>
<td>PT282</td>
<td>Defining the indications for pelvic lymph node dissection (PLND) in prostate cancer (PCa) patients within a statewide quality improvement collaborative</td>
<td>Abdollah F.¹, Betrus G.², Cher M.³, Dalela D.¹, Keeley J.¹, Kim T.⁴, Lane B.⁵, Mansour S.⁶, Montie J.⁴, Schervish E.⁷, Sood A.¹, Swama K.⁴, Peabody J.¹, For The Michigan Urological Surgery Improvement Collaborative</td>
<td>Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, Urology Associates of Port Huron - McLaren, Dept. of Urology, Port Huron, United States of America, Wayne State University, Dept. of Urology, Detroit, United States of America, University of Michigan, Dept. of Urology, Ann Arbor, United States of America, Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, United States of America, Comprehensive Urology, Dept. of Urology, Lapeer, United States of America, Michigan Institute of Urology, Dept. of Urology, Utica, United States of America</td>
<td>PT282</td>
</tr>
<tr>
<td>PT283</td>
<td>Risk of inguinal hernia repair after radical prostatectomy</td>
<td>Ahtinen M.¹, Vironen J.², Murtola T.³</td>
<td>Tampere University Hospital, Dept. of Surgery, Tampere, Finland, Helsinki University Hospital, Abdominal Center, Helsinki, Finland, University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland</td>
<td>PT283</td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation
PT283

PT284

The impact of high initial PSA (≥50 ng/ml) at the time of radical prostatectomy for clinically localized prostate cancer on cancer specific survival

By: Mandel P.¹, Knipper S.², Chun F.¹, Steuber T.², Huland H.², Graefen M.², Tilki D.²
¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Aims and objectives of this presentation
PT284

PT285

Multivisceral surgery in men with locally advanced, symptomatic castration-resistant prostate cancer

By: Heidenreich A., Porres D., Karapanos L., Salem J., Pfister D.
University of Cologne, Dept. of Urology, Cologne, Germany

Aims and objectives of this presentation
PT285

PT286

Very early continence in patients undergoing radical prostatectomy and its influencing factors

By: Theissen L.T., Preisser F., Roos F., Becker A., Chun F., Mandel P.
University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany

Aims and objectives of this presentation
PT286

PT287

Long-term outcome following radical prostatectomy; Results from the Gothenburg screening trial

By: Arnsrud Godtman R.¹, Hellstrand A.², Månsson M.¹, Hugosson J.¹
¹Institute of clinical sciences, Sahlgrenska Academy, University of Göteborg, Dept. of Urology, Gothenburg, Sweden, ²Örebro University, Faculty of Medicine, Örebro, Sweden

Aims and objectives of this presentation
PT287

PT288

Total anatomical reconstruction during robot-assisted radical prostatectomy: Oncological and functional results up to 12 months of follow-up after over 1000 operations

AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy

Aims and objectives of this presentation
PT288
Aims and objectives of this presentation
PT288

<table>
<thead>
<tr>
<th>Presentation Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT289</td>
<td>Evaluation of periprostatic neurovascular bundles before and after RARP by means of diffusion tensor imaging (DTI): Initial experience</td>
<td>Siracusano S. 1, Porcaro A.B. 1, Pirozzi M. 1, Tafuri A. 1, Cacciarmami G. 1, Tiso L. 1, Odorizzi K. 1, Artibani W. 1, Cybulski A.J. 2, Talamini R. 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1AOUI Verona, Dept. of Urology, Verona, Italy, 2AOUI Verona, Dept. of Radiology, Verona, Italy, 3Unit CRO Aviano, Dept. of Epidemiology, Aviano, Italy</td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT289

<table>
<thead>
<tr>
<th>Presentation Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT290</td>
<td>Facility-level variation in pelvic lymph node dissection during radical prostatectomy and effect on overall survival in men with clinically localized high-risk prostate cancer</td>
<td>Krimphove M.J. 1, Friedlander D. 2, Cole A. 2, Lipsitz S. 3, Kluth L.A. 4, Trinh Q-D. 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1Universitätsklinikum Frankfurt, Dept. of Urology, Frankfurt, Germany, 2Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America, 3Center for Surgery and Public Health, Brigham and Women's Hospital, Dept. of Surgery, Boston, United States of America, 4University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany</td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT290

<table>
<thead>
<tr>
<th>Presentation Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT291</td>
<td>Does surgical approach have an impact on the development of symptomatic lymphoceles after radical prostatectomy and pelvic lymph node dissection?</td>
<td>Tsaur I., Ziewers S., Thomas A., Dotzauer R., Haferkamp A., Thomas C. University Medicine Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany</td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT291

<table>
<thead>
<tr>
<th>Presentation Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT292</td>
<td>The impact of prostate size on the outcomes of Retzius-sparing robotic radical prostatectomy</td>
<td>Kusuma V.R.M., Pavlakis P., Eden C. The Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom</td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT292

<table>
<thead>
<tr>
<th>Presentation Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT293</td>
<td>New approach to preserve male sexual function after nerve-sparing radical prostatectomy</td>
<td>Kyzlasov P., Plekhanova O.A., Volodin D.I., Sergeev V.P.</td>
</tr>
</tbody>
</table>

Aims and objectives of this presentation
PT293
<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT293</td>
<td>Intraoperative frozen section significantly reduces positive surgical</td>
<td>Preisser F. 1, Theissen L.T. 1, Wild P. 2, Köllermann J. 2, Chun F.K-H. 1, Mandel P. 1</td>
</tr>
<tr>
<td></td>
<td>margin rates and increases frequency of nerve-sparing at radical</td>
<td>1University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 2University Hospital Frankfurt, Dept. of Pathology, Frankfurt, Germany</td>
</tr>
<tr>
<td></td>
<td>prostatectomy</td>
<td></td>
</tr>
<tr>
<td>PT294</td>
<td>Oligometastatic prostate cancer: The importance of a multidisciplinary</td>
<td>Mistretta F.A. 1, Conti A. 1, Catellani M. 1, Serino A. 1, Delor M. 1, Luzzago S. 1, Cozzi G. 1, Ferro M. 1, Matei D.V. 1, Musi G. 1, Verre E. 2, Jereczek-Fossa B.A. 3, De Cobelli O. 1</td>
</tr>
<tr>
<td></td>
<td>approach in a high volume robotic center</td>
<td>1European Institute of Oncology - IEO, Dept. of Urology, Milan, Italy, 2European Institute of Oncology - IEO, Dept. of Oncology, Milan, Italy, 3European Institute of Oncology - IEO, Dept. of Radiotherapy, Milan, Italy</td>
</tr>
<tr>
<td>PT295</td>
<td>Clinical significance of P.R.O.S.T.A.T.E. score system for predicting</td>
<td>Seo W. 1, Lee C.H. 1, Kim W. 1, Park T.Y. 1, Min K. 1, Chung J.I. 1, Ku J.Y. 2, Ha H.K. 2</td>
</tr>
<tr>
<td></td>
<td>adverse pathologic results after radical prostatectomy in localized</td>
<td>1Inje University Busan Paik Hospital, Dept. of Urology, Busan, South Korea, 2Pusan National University Hospital, Dept. of Urology, Busan, South Korea</td>
</tr>
<tr>
<td></td>
<td>prostate cancer</td>
<td></td>
</tr>
<tr>
<td>PT297</td>
<td>Long-term functional outcomes after robotic vs. retropubic radical</td>
<td>Huber J. 1, Baunacke M. 1, Schmidt M-L. 1, Thomas C. 1, Groeben C. 1, Koch R. 2, Chun F. 3, Weissbach L. 4</td>
</tr>
<tr>
<td></td>
<td>prostatectomy in routine care: A 6-year follow-up of a large German</td>
<td>1TU Dresden, Dept. of Urology, Dresden, Germany, 2TU Dresden, Dept. of Medical Statistics and Biometry, Dresden, Germany, 3University of Frankfurt, Dept. of Urology, Frankfurt, Germany, 4Health Research for Men gGmbH, gfm, Berlin, Germany</td>
</tr>
<tr>
<td></td>
<td>health services research study</td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

PT299

Significance of time until PSA recurrence on clinical progression of surgically treated high-risk prostate cancer patients

By: Venclovas Z., Stanionis M., Matjosaitis A.J., Milonas D.
1Lithuanian University of Health Sciences, Dept. of Urology, Kaunas, Lithuania,
2Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania

Aims and objectives of this presentation

PT300

Early recovery of pre-RARP latency time in uroflow stop test with EMG may predict early erectile function restoration

By: Paladini A., Boni A., Del Zingaro M., Cochetti G., Turco M., Panciarola M., Mearini E.
University of Perugia, Urology Clinic, Dept. of Surgical and Biomedical Sciences, Perugia-Terni, Italy

Aims and objectives of this presentation

PT301

Experimental model of an artificial pneumoperitoneum to measure thermal spread during bipolar cauterizing

1University of Verona, Dept. of Urology, Verona, Italy,
2University of Verona, Dept. of Science, Verona, Italy,
3CRO Aviano, Dept. of Oncology, Aviano, Italy,
4University of Verona, Dept. of Patology, Verona, Italy

Aims and objectives of this presentation

PT302

Modern era robotic radical prostatectomy bias toward high volume accomplished surgeons in preeminent journals: Scientometrics

By: Moretti T.B.C., Magna L.A., Reis L.O.
1Institute of Urology of Piracicaba, Dept. of Urology, Piracicaba, Brazil,
2University of Campinas, Dept. of Genetics, Campinas, Brazil,
3University of Campinas, Dept. of Urology, Campinas, Brazil

Aims and objectives of this presentation

PT302
<table>
<thead>
<tr>
<th>PT303</th>
<th>Early and long-term continence is superior after early micturition on day two after robot-assisted radical prostatectomy: A randomized prospective trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Harke N.N. ¹, Wagner C. ², Addali M. ², Urbanova K. ², Witt J.H. ²</td>
</tr>
<tr>
<td>¹Essen University Hospital, Dept. of Urology, Essen, Germany, ²PZNW St. Antonius Hospital Gronau, Dept. of Urology, Gronau, Germany</td>
<td></td>
</tr>
<tr>
<td><strong>Aims and objectives of this presentation</strong></td>
<td>PT303</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT304</th>
<th>Reduction in membranous urethral volume and displacement of the urethra and anorectal junction following radical prostatectomy increases the risk of incontinence at 3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>To be confirmed</td>
<td><strong>Aims and objectives of this presentation</strong></td>
</tr>
<tr>
<td>PT304</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT305</th>
<th>Retzius-sparing robot-assisted radical prostatectomy in patients who already had major abdominal surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Galfano A., Secco S., Piccinelli M., Panarello D., Di Trapani D., Petralia G., Barbieri M., Strada E., Bocciardi A.M.</td>
</tr>
<tr>
<td>ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy</td>
<td><strong>Aims and objectives of this presentation</strong></td>
</tr>
<tr>
<td>PT305</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT306</th>
<th>Retzius-sparing vs. non-Retzius-sparing robotic-assisted radical prostatectomies: A comparative analysis of oncological outcomes of over 500 patients at a tertiary referral centre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom</td>
<td><strong>Aims and objectives of this presentation</strong></td>
</tr>
<tr>
<td>PT306</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT280</th>
<th>Impact of early dorsal venous complex ligation on early urinary continence recovery after robot-assisted radical prostatectomy: Results of a pre-specified interim analysis of a randomized clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Montorsi F. ¹, Bravi C.A. ², Fallara G. ¹, Rosiello G. ¹, Scarcella S. ¹, D’Ambrosio L. ¹, Gallina A. ¹, Scuderi S. ¹, Martini A. ¹, Mirone V. ³, Longo N. ³, Gandaglia G. ¹, Fossati N. ¹, Briganti A. ¹</td>
</tr>
<tr>
<td>¹IRCCS San Raffaele Hospital, Division of Oncology, Unit of Urology URI, Milan, Italy, ²IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology URI, Milan, Italy, ³University of Naples Federico II, Dept. of Urology, Naples, Italy</td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation
PT280
ESU/ESFFU Hands-on Training Course in Sacral Neuromodulation
Sponsored by MEDTRONIC

Location: Green Area, Room 7
Chair: H. Hashim, Bristol (GB)
Tutors: K. Everaert, Ghent (BE)
E. Chartier-Kastler, Paris (FR)
D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)
S. Musco, Florence (IT)
S. Arlandis Guzman, Valencia (ES)
L. Thomas, Bristol (GB)
P. Van Kerrebroeck, Maastricht (NL)

**Aims and objectives of this session**
A practical hands-on workshop that will allow the participants to practice on models the different steps of performing sacral neuromodulation including primary percutaneous nerve evaluation, tined lead and battery implantation and programming and also troubleshooting.

- Understand the indications for SNM
- Be able to perform the different steps of the procedure in a standardized format
- Be able to troubleshoot problems with SNM
New developments in robot-assisted prostatectomy

Video Session 09

Sunday 17 March
15:45 - 17:15

Location: Red Area, eURO Auditorium 1
Chairs: To be confirmed
F. Gómez Veiga, Salamanca (ES)
S. Nathan, London (GB)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V60

Salvage robot-assisted laparoscopic prostatectomy: Does primary treatment make a difference?

By: Önlö F.F. 1, Bhat S. 1, Rogers T. 1, Jenson C. 1, Roof S. 1, Rocco B.M.C. 2, Patel V. 1
1Florida Hospital Global Robotics Institute, Dept. of Urology, Celebration, United States of America,
2University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy

Aims and objectives of this presentation

V66

Innovations and techniques allowing surgical tailoring in patients with prostatic adenocarcinoma

By: Rocco B.M.C. 1, Puliatti S. 1, Eissa A. 2, Elsherbiny A. 2, Inzillo R. 1, Micali S. 1, De Carne C. 1, Patel V. 3, Bianchi G. 1, Sighinolfi M.C. 1
1University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy,
2Tanta University, Dept. of Urology, Faculty of Medicine, Tanta, Italy,
3Global Robotic Institute, Dept. of Urology, Orlando, United States of America

Aims and objectives of this presentation

V61

The Bollens’ stitch: A modified technique for robot-assisted radical prostatectomy

1Regina Elena Hospital, Dept. of Urology, Rome, Italy,
2Université Nord de France, St. Phillips Hospital, Dept. of Urology, Lille, France,
3Tor Vergata Hospital, Dept. of Urology, Rome, Italy,
4San Giovanni Hospital, Dept. of Urology, Rome, Italy,
5Umberto I Hospital, La Sapienza University, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation
<table>
<thead>
<tr>
<th>V63</th>
<th>Initial experience with da Vinci single port (SP) robot-assisted radical prostatectomies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Agarwal D.K., Sharma V., Viers B., Frank I., Tollefson M., Meskawi M., Gettman M.</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic, Dept. of Urology, Rochester, United States of America</td>
</tr>
<tr>
<td></td>
<td><strong>Aims and objectives of this presentation</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>V64</th>
<th>Standardized and simplified robot-assisted super-extended pelvic lymph node dissection for prostate cancer: The monoblock technique</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Würnschimmel C., Grande P., Hyseni A., Moschini M., Baumeister P., Mordasini L., Mattei A.</td>
</tr>
<tr>
<td></td>
<td>Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland</td>
</tr>
<tr>
<td></td>
<td><strong>Aims and objectives of this presentation</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>V65</th>
<th>Pure single-site trans-perineal robotic radical prostatectomy: First clinical report using the SP® surgical system</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td></td>
<td><strong>Aims and objectives of this presentation</strong></td>
</tr>
</tbody>
</table>

488
Dose-effect relationship for 1-year incontinence after post-prostatectomy intensity-modulated radiotherapy (MRT)

By: Gabriele P.¹, Cante D.², Sanguineti G.³, Munoz F.⁴, Avuzzi B.⁵, Garibaldi E.¹, Noris Chiorda B.⁵, Villa E.⁶, Saracino B.³, Girelli G.⁷, Waskiewicz J.M.⁸, Magli A.⁹, Valdagni R.¹⁰, Badenchini F.¹¹, Di Muzio N.¹², Rancati T.¹¹, Fiorino C.¹³, Tutolo M.¹⁴, Gandaglia G.¹⁴, Fossati N.¹⁴, Briganti A.¹⁴, Montorsi F.¹⁴, Cozzarini C.¹²

¹Istituto di Candiolo- Fondazione del Piemonte per l'Oncologia IRCCS, Dept. of Radiotherapy, Candiolo, Italy, ²Ospedale di Ivrea, A.S.L. TO4, Dept. of Radiotherapy, Ivrea, Italy, ³Istituto Nazionale dei Tumori Regina Elena, Dept. of Radiotherapy, Rome, Italy, ⁴Ospedale Regionale U.Parini-AUSL Valle d'Aosta, Dept. of Radiotherapy, Aosta, Italy, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy, ⁶Cliniche Gavazzeni-Humanitas GAV, Dept. of Radiotherapy, Bergamo, Italy, ⁷Ospedale degli Infermi, Dept. of Radiotherapy, Biella, Italy, ⁸Comprensorio Sanitario di Bolzano, Dept. of Radiotherapy, Bolzano, Italy, ⁹Azienda Ospedaliero Universitaria S. Maria della Misericordia, Dept. of Radiotherapy, Udine, Italy, ¹⁰University of Milan, Department of Oncology and Hemato-oncology - Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program - Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy, ¹¹Programma Prostata, Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy, ¹²IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ¹³IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy, ¹⁴IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation

Hyprofractionated vs conventionally fractionated radiotherapy for prostate cancer: 7-year outcome from the Dutch HYPRO trial

By: Wortel R.C.¹, De Vries K.², Pos F.J.³, Oomen-De Hoop E.², Heemsbergen W.D.², Incrocci L.²

¹UMC Utrecht, Dept. of Urology, Utrecht, The Netherlands, ²Erasmus MC, Dept. of Radiation Oncology, Rotterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of
Aims and objectives of this presentation

716

Comparison of self-reported acute urinary incontinence in patients treated with adjuvant or salvage post-prostatectomy intensity modulated-radiotherapy (IMRT)


1 Ospedale Regionale U.Parini, AUSL Valle d’Aosta, Dept. of Radiotherapy, Aosta, Italy, 2 Ospedale di Ivrea, A.S.L. TO4, Dept. of Radiotherapy, Ivrea, Italy, 3 Istituto di Candiolo-Fondazione del Piemonte per l’Oncologia IRCCS, Dept. of Radiotherapy, Turin, Italy, 4 Istituto Nazionale dei Tumori Regina Elena, Dept. of Radiotherapy, Rome, Italy, 5 Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy, 6 Cliniche Gavazzeni-Humanitas GAV, Dept. of Radiotherapy, Bergamo, Italy, 7 Ospedale degli Infermi, Dept. of Radiotherapy, Biella, Italy, 8 Comprensorio Sanitario di Bolzano, Dept. of Radiotherapy, Bolzano, Italy, 9 Azienda Ospedaliero Universitaria S. Maria della Misericordia, Dept. of Radiotherapy, Udine, Italy, 10 IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, 11 IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation

716

The efficacy and feasibility of radiation therapy to the primary tumor in patients with metastatic castration resistant prostate cancer


1 Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2 Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, 3 Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

Aims and objectives of this presentation

718

External beam radiotherapy (EBRT) compared with EBRT plus HDR brachytherapy boost (EBRT+BRACHY) dose escalation for intermediate- or high-risk prostate cancer: Higher disease control and survival with lower distant metastases and toxicity


IMOR Foundation, Medical Institute for Onco-Radiotherapy, Dept. of Radiation Oncology,
Aims and objectives of this presentation

Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

By: Mazzone E.¹, Fossati N.¹, Karnes R.J.², Boorjan S.A.², Luca B.², Bossi A.³, Di Muzio N.⁴, Cozzerini C.⁴, Noris Chiorda B.⁴, Gandaglia G.¹, Scuderri S.¹, Bartkowiak D.⁵, Böhmer D.⁶, Shariat S.⁷, Goldner G.⁷, Battaglia A.⁹, Joniau S.⁹, Haustermans K.¹⁰, De Meerleer G.¹⁰, Fonteyne V.¹¹, Ost P.¹¹, Van Poppel H.⁹, Montorsi F.¹, Wiegel T.⁵, Briganti A.¹
¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁶Charité University Hospital Berlin, Dept. of Radiation Oncology, Berlin, Germany, ⁷Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁸Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹¹Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

Aims and objectives of this presentation

Clinical result of helical tomotherapy for high-risk and very high-risk prostate cancer at single institution

By: Tsukuda F.¹, Horiguchi Y.², Ogata A.¹, Sakamoto N.², Koga S.¹, Hama Y.³ ¹Edogawa Hospital, Transplantation and Regenerative Medicine Center, Dept. of Urology, Tokyo, Japan, ²Edogawa Hospital, Dept. of Urology, Tokyo, Japan, ³Edogawa Hospital, Tokyo Edogawa Cancer Center, Dept. of Radiology, Tokyo, Japan

Aims and objectives of this presentation

Comparison of the oncologic outcomes of men with high risk prostate cancer treated with either I-125 or Pd-103 brachytherapy

By: Skouteris V.¹, Stock R.², Dounis A.¹, Koutsouveli E.¹, Katsochi D.¹, Kollias G.¹, Skouteris M.¹, Metsinis M.¹, Stone N.³ ¹Hygeia Brachytherapy Center, Dept. of Urology, Athens, Greece, ²The Icahn School of Medicine at Mount Sinai, Dept. of Radiation Oncology, New York, United States of America, ³The Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America
Aims and objectives of this presentation

722

**Persistently under-utilized adjuvant radiotherapy in patients with adverse pathological features at radical prostatectomy: A national cancer database (NCDB) analysis**

By: Rakic N.¹, Fotouhi A.², Baumgarten L.¹, Borchert A.¹, Dalela D.¹, Sood A.¹, Arora S.¹, Menon M.¹, Abdollah F.¹

¹Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America,
²Wayne State University, School of Medicine, Detroit, United States of America

Aims and objectives of this presentation

723

**Identification of differentially expressed genes to predict radioresistant prostate carcinomas**

By: Nestler T.¹, Wittersheim M.², Hellmich M.³, Pfister D.¹, Odenthal M.², Büttner R.², Schäfer S.², Heidenreich A.¹

¹University Hospital of Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany,
²University Hospital of Cologne, Institute of Pathology, Cologne, Germany,
³University of Cologne, Institute of Medical Statistics and Computational Biology, Cologne, Germany

Aims and objectives of this presentation

724

**Biochemical control of a combination of cyclooxygenase-2 inhibitor and 125I-brachytherapy in an open-labeled controlled randomized trial as a secondary endpoint**

By: Nakai Y.¹, Tanaka N.¹, Miyake M.¹, Anai S.¹, Asakawa I.², Yamaki K.², Hasegawa M.², Fujii T.³, Fujimoto K.¹

¹Nara Medical University, Dept. of Urology, Kashihara, Japan,
²Nara Medical University, Dept. of Radiation Oncology, Kashihara, Japan,
³Nara Medical University, Dept. of Pathology, Kashihara, Japan

Aims and objectives of this presentation

725

**Comparison of the morbidity in men with intermediate and high-risk prostate cancer treated with either I-125 or Pd-103 brachytherapy combined with external beam irradiation**

By: Stone N.¹, Skouteris V.², Dounis A.², Koutsouveli E.³, Katsochi D.³, Kollias G.³, Skouteris M.², Metsinis M.², Stock R.⁴

¹The Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America,
²Hygeia Brachytherapy Center, Dept. of Urology, Athens, Greece,
³Hygeia Brachytherapy Center, Dept. of Radiation Oncology, Athens, Greece,
⁴The Icahn School
Aims and objectives of this presentation

726

**High detection rate of colorectal cancer in scheduled serial total colonoscopy screening after radiation therapy for prostate cancer**

By: Nakamura Y., Kageyama Y., Soma T., Aoki Y., Fukui N., Sakai Y.
Saitama Cancer Center, Dept. of Urology, Saitama, Japan

Aims and objectives of this presentation

727

**Is external beam radiotherapy for prostate cancer a risk factor for bladder or rectal cancer?**


1Hadassah Hebrew University Medical Center, Dept. of Urology, Jerusalem, Israel,
2Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel

Aims and objectives of this presentation

728

**Prostate cancer as a risk factor for bladder carcinoma**

By: Rinott Mizrahi G., Friedman B., Boyarsky L., Rani Z., Orlin I., Yasinov F., Fares G., Stein A., Dekel Y.
Carmel Medical Center, Dept. of Urology, Haifa, Israel

Aims and objectives of this presentation

729
**Innovations in the diagnosis and management of upper tract urothelial carcinoma**

*Poster Session 52*

**Sunday 17 March**

**15:45 - 17:15**

**Location:** Green Area, Room 3

**Chairs:**
- F. Audenet, Paris (FR)
- P. Black, Vancouver (CA)
- A. Kolodziej, Wroclaw (PL)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**730**

**Single versus maintenance intravesical chemotherapy for the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: A randomized clinical trial**

By: Elshabrawy M., Harraz A. M., El-Nahas A.R., El-Kappany H., Osman Y.

Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt

**Aims and objectives of this presentation**

---

**731**

**Parallels between immunohistochemical classification of upper and lower tract urothelial carcinoma using markers of urothelial differentiation**


1Hiroshima University, Dept. of Urology, Hiroshima, Japan,
2Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan,
3Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada,
4University of Ottawa, Dept. of Urology, Ottawa, Canada

**Aims and objectives of this presentation**

---

**732**

**The relationship of expression of programmed cell death 1 ligand 1 (PD-L1) in cancer and extent of tumor infiltrating mononuclear cell (TIMC) to clinicopathological factors in upper tract urothelial carcinoma**


Dokkyo Medical University, Dept. of Urology, Mibu, Japan

**Aims and objectives of this presentation**
Can quantitative computed tomography texture analysis be used for evaluating stage and histologic grade of upper tract urothelial carcinoma?

By: Goujon A.¹, Khene Z.E¹, Thenault R.¹, El Akri M.¹, Bensalah K.¹, Shariat S.F², Acosta O.³, De Crevoisier R.⁴, Mathieu R.¹

¹CHU Pontchaillou, Dept. of Urology, Rennes, France, ²Vienna General Hospital, Dept. of Urology, Vienna, Austria, ³University of Rennes 1, Inserm U1099, Rennes, France, ⁴Centre Eugene Marquis, Radiotherapy, Rennes, France

Aims and objectives of this presentation

Selective cytology in detection of high grade upper urinary tract urothelial cancer: A systematic review and meta-analysis

By: Pones M.¹, Abufaraj M.¹, Förster B.¹, D'Andrea D.¹, Soria F.¹, Qteishat A.², Gandaglia G.³, Briganti A.³, Shariat S.¹

¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Princess Alexandra Hospital NHS Trust, Dept. of Urology, Harlow, United Kingdom, ³Urological Research Institute IRCCS, Unit of Urology, Division of Oncology, Milan, Italy

Aims and objectives of this presentation

Prognostic value of the systemic inflammation modified Glasgow Prognostic Score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration

By: Soria F.¹, D'Andrea D.², Karam J.A.³, Wood C.G.³, Rouprêt M.⁴, Margulis V.⁵, Karakiewicz P.I.⁶, Briganti A.⁷, Raman J.D.⁸, Bensalah K.⁹, Lotan Y.⁵, Gontero P.¹, Remzi M.², Gust K.², Shariat S.F.²

¹AOU Città della Salute e della Scienza di Torino, Presidio Molinette, Dept. of Urology, Turin, Italy, ²Medical University of Vienna, Vienna General Hospital, Dept. of Urology and Comprehensive Cancer Center, Vienna, Austria, ³The University of Texas M.D. Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁴Sorbonne Université, GRC n°5, Oncotype-uro, AP-HP, Hôpital Pitié-Salpêtrière, Dept. of Urology, Paris, France, ⁵University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁶University of Montreal, Dept. of Urology, Montreal, Canada, ⁷Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁸Penn State Milton S. Hershey Medical Center, Dept. of Urology, Hershey, United States of America, ⁹University of Rennes, Dept. of Urology, Rennes, France

Aims and objectives of this presentation

Lower urinary pH increases the risk of upper tract urothelial carcinoma development in patients with non-muscle invasive bladder cancer
Aims and objectives of this presentation

736

Diagnostic value of FDG-positron emission tomography (PET/CT) for lymph node staging in patients with upper tract urothelial carcinoma (UTUC)


1Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 2Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, 3UZ Leuven, Dept. of Urology, Leuven, Belgium, 4Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 5Moffitt Cancer Center, Dept. of Genitourinary Oncology, Tampa, United States of America, 6Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, 7UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, 8Aarhus University Hospital, Dept. of Nuclear Medicine and PET-Centre, Aarhus, Denmark, 9Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Biometrics, Amsterdam, The Netherlands, 10Medical University of Vienna, Dept. of Urology, Vienna, Austria, 11Bichat Hospital Paris Descartes University, Dept. of Urology, Paris, France, 12Bichat Hospital Paris Descartes University, Dept. of Urology, Roskilde, Denmark, 13Seoul National University Hospital, Dept. of Urology, Yongon Dong, South Korea, 14Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, The Netherlands

Aims and objectives of this presentation

737

Evaluation of sarcopenia in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A study from the Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology

By: Marcq G. 1, Roumiguié M. 2, Ouzaid I. 3, Roghmann F. 4, Aziz A. 5, Huillard O. 6, Sargos P. 7, Poyet C. 8, Moschini M. 9, Seiler R. 10, Necchi A. 11, Zerbib M. 12, Malavaud B. 2, Soulé M. 2, Shariat S. 13, Hendricksen K. 14, Xylinas E. 15

1CHRU Lille, Dept. of Urology, Lille, France, 2CHU Toulouse, Dept. of Urology, Toulouse, France, 3Bichat Claude Bernard Hospital, Paris Descartes University, Dept.of Urology, Paris, France, 4Ruhr-University Bochum, Marien Hospital, Dept.of Urology, Herne, Germany, 5University Medical Center Rostock, Dept.of Urology, Rostock, Germany, 6Cochin Hospital, Paris Descartes University, Dept.of Oncology, Paris, France, 7Institut Bergonie, Dept.of Radiation Therapy, Bordeaux, France, 8University Hospital Zürich, University of Zürich, Dept.of Urology, Zürich, Switzerland, 9Luzerner Kantonsspital, Dept.of Urology, Luzerne, Switzerland, 10University of Bern, Dept.of Urology, Bern, Switzerland, 11Fondazione IRCCS Istituto Nazionale dei Tumori, Dept.of Medical Oncology, Milan, Italy, 12Cochin Hospital, Paris Descartes University, Dept.of Urology,
Aims and objectives of this presentation
738

NBI versus white light digital flexible ureteroscopy in transitional renal cell carcinoma – an evidence-based, prospective, pathology-blinded comparison

By: Geavlete B., Multescu R., Georgescu D., Moldoveanu C., Ene C., Bulai C., Balan G., Ene A., Geavlete P.
Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania

Aims and objectives of this presentation
739

Algorithms predicting ≥pT2 and ≥pT3 upper tract urothelial cancer incorporating diffusion-weighted MRI

By: Koga F., Sakamoto K., Takemura K., Suzuki H., Kataoka M., Ito M., Nakanishi Y., Tobisu K.
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation
740

The American Joint Committee on Cancer prognostic groups for prediction of patients treated with surgery for invasive upper tract urothelial carcinoma

By: Li Z. ¹, Li X. ², Han H. ³, Zhou F. ³, Xiao K.F. ¹
¹Shenzhen People’s Hospital, Dept. of Urology, Shenzhen, China, ²The Seventh Affiliated Hospital, Sun Yat-sen University, Dept. of Oncology, Shenzhen, China, ³Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China

Aims and objectives of this presentation
741

Serum cytokeratin 19 fragments: A novel useful postoperative prognostic marker in patients with upper urinary tract urothelial carcinoma

By: Endo Y., Kimura G., Akatsuka A., Obayashi K., Sano M., Takeda H., Hayashi T., Kondo Y.
Nippon Medical School Hospital, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation
742
Adjuvant single-dose upper urinary tract instillation of mitomycin-C after therapeutic ureteroscopy for upper tract urothelial carcinoma: Preliminary results

Fundació Puigvert, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation

743
**Current surgical management of adrenals and retroperitoneal tumours**

**Poster Session 53**

**Sunday 17 March**

15:45 - 17:15

**Location:** Green Area, Room 4

**Chairs:** J.F. Busch, Berlin (DE)

To be confirmed

P. Tenke, Budapest (HU)

---

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

Associated video presentations are 4 minutes in length, followed by 2 minutes for discussion.

---

### 745 Validation of primary aldosteronism (PA) discrimination score for confirmatory tests of PA

**By:** Yamamoto H. ¹, Hatakeyama S. ¹, Okita K. ¹, Konishi S. ¹, Matsumoto T. ¹, Fujita N. ¹, Suzuki Y. ¹, Yoneyama T. ¹, Imai A. ¹, Yoneyama T. ¹, Hashimoto Y. ¹, Takayasu S. ², Nakaji S. ³, Ohyama C. ¹

¹Hirosaki University, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University, Endocrinology and Metabolism, Hirosaki, Japan, ³Hirosaki University, Social Medicine, Hirosaki, Japan

**Aims and objectives of this presentation**

745

---

### 746 The decline in estimated glomerular filtration rate over the course of surgical and medical treatments in patients with primary aldosteronism

**By:** Ujike T. ¹, Uemura M. ¹, Takezawa K. ¹, Kato T. ¹, Kawashima A. ¹, Abe T. ¹, Nagahara A. ¹, Fukuha S. ¹, Fujita K. ¹, Kiuchi H. ¹, Imamura R. ¹, Takao T. ², Miyagawa Y. ³, Saiki A. ⁴, Mukai K. ⁴, Ostuki M. ⁴, Nonomura N. ¹

¹Osaka University Graduate School of Medicine, Dept. of Urology, Osaka, Japan, ²Osaka General Medical Center, Dept. of Urology, Osaka, Japan, ³Sumitomo Hospital, Dept. of Urology, Osaka, Japan, ⁴Osaka University Graduate School of Medicine, Dept. of Metabolic Medicine, Osaka, Japan

**Aims and objectives of this presentation**

746

---

* 747 Prediction of adrenal pathology in patients with primary aldosteronism

To be confirmed
Aims and objectives of this presentation

V91
Associated video presentation Laparoscopic adrenalectomy: Surgical technique, tips and tricks

By: Del Pozo Jiménez G., Castillón Vela I., Rengifo Abbad D., Turo Antona J., Rodríguez Reina G., Rodríguez Monsalve M., Carballido Rodríguez J.
H.U.Puerta de Hierro, Dept. of Urology, Madrid, Spain

Aims and objectives of this presentation

V91

Permanent flank bulge after kidney surgery: Patient- and physician-reported outcomes of ten years

By: Kranz J.1, Wussow F.2, Grundl S.1, Schneidewind L.3, Steffens J.1
1St.-Antonius Hospital, Dept. of Urology, Eschweiler, Germany, 2Bethlehem Gesundheitszentrum, Dept. of Gynaecology, Stolber, Germany, 3Universitätsmedizin Greifswald, Clinic for Internal Medicine C, Haematology and Oncology, Greifswald, Germany

Aims and objectives of this presentation

749

Changes in circulating blood volume measured by pulse dye-densitometry during preoperative management with an α-blocker in patients with pheochromocytoma

By: Miyaji Y.1, Maeshima K.2, Kido E.2, Kawamoto Y.2, Tsukimori S.1, Kaifu M.1, Sanada J.3, Hara R.1, Fujii T.1, Nakatsuka H.2, Mune T.3, Nagai A.1
1Kawasaki Medical School, Dept. of Urology, Kurashiki, Japan, 2Kawasaki Medical School, Dept. of Anesthesiology, Kurashiki, Japan, 3Kawasaki Medical School, Division of Diabetes, Endocrinology and Metabolism, Kurashiki, Japan

Aims and objectives of this presentation

750

Pattern of treatment approaches and outcome of adrenocortical carcinoma: Analysis from the National Cancer Database

By: Eldefrawy A.H.1, Ryan S.1, Cotta B.1, Sarkar R.1, Bradshaw A.1, Meagher M.1, Hamilton Z.1, Murphy J.2, Derweesh I.1
1University of California San Diego, Dept. of Urology, San Diego, United States of America, 2University of California San Diego, Dept. of Radiation Oncology, San Diego, United States of America

Aims and objectives of this presentation

751
Impact of multimodal salvage therapy on survival in patients with recurrent adrenocortical carcinoma

Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

The safety and efficacy of anatomical retroperitoneoscopic approach vs intra-adipose capsule approach via adrenalectomy

The First Affiliated Hospital Of Dalian Medical University, Dept. of Urology, Dalian, China

Aims and objectives of this presentation

Comparison of robot-assisted adrenalectomy with traditional laparoscopic adrenalectomy: Perioperative and pathologic outcomes

By: Ji C., Lu Q., Guo H.
Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Nanjing, China

Aims and objectives of this presentation

Associated video presentation Robotic assisted adrenalectomy for a malignant adrenal tumor

By: Papadoukakis S. ¹, Nellas S. ¹, Frangou E. ², Horstmann M. ¹
¹MKH St. Josefshospital, Dept. of Urology, Krefeld, Germany, ²MKH St. Josefshospital, Dept. of Pathology, Krefeld, Germany

Aims and objectives of this presentation
Surgical aspects of kidney transplantation focusing on robotic laparoscopy

Poster Session 54

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 5

Chairs: A. Alcaraz, Barcelona (ES)
A.J. Figueiredo, Coimbra (PT)
J.D. Olsburgh, London (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

755
Increasing kidneys grafts for transplantation

By: Musquera M.¹, Sierra Del Rio A.¹, Peri L.¹, Paredes D.², Mercader Barrull C.¹, Pérez M.¹, Esforzado N.³, Sebastià M.C.⁴, Ribal M.J.¹, Revuelta N.³, Alcaraz Asensio A.¹

¹Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain, ²Hospital Clínic de Barcelona, Donation Unit, Barcelona, Spain, ³Hospital Clínic de Barcelona, Renal Transplant Unit, Barcelona, Spain, ⁴Hospital Clínic de Barcelona, Dept. of Radiology, Barcelona, Spain

Aims and objectives of this presentation

756
Effectiveness and harms of using kidneys with small renal tumors from deceased or living donors as a source of renal transplantation: A systematic review

By: Hevia Palacios V.¹, Hassan Zakri R.², Fraser Taylor C.³, Bruins H.M.⁴, Boissier R.⁵, Liedo E.⁶, Regele H.⁷, Budde K.⁸, Figueiredo A.⁹, Breda A.¹⁰, EAU Guideline on Renal Transplantation Panel

¹Hospital Universitario Ramón y Cajal, Dept. of Urology and Kidney Transplant, Madrid, Spain, ²Guy’s & St Thomas’ NHS Trust Hospitals, Dept. of Urology and Transplant, London, United Kingdom, ³St Georges NHS Trust Hospitals, Dept. of Urology and Transplant, London, United Kingdom, ⁴Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ⁵La Conception University Hospital, Aix-Marseille University, Dept. of Urology and Transplant, Marseille, France, ⁶Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ⁷Clinical Institute of Pathology, Medical University of Vienna, Dept. of Pathology, Vienna, Austria, ⁸Charité Medical University Berlin, Dept. of Nephrology, Berlin, Germany, ⁹Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, ¹⁰Fundacion Puigvert, Dept. of Urology, Barcelona, Spain
Aims and objectives of this presentation
756

Robotic assisted kidney transplantation: Update from the ERUS series

By: Musquera Felip M.¹, Peri L.¹, Ajami T.¹, Breda A.², Territo A.², Campi R.³, Semii S.³, Tugcu V.⁴, Decaestecker K.⁵, Janssen M.⁶, Stockle M.⁶, Fornara P.⁷, Doumerc N.⁸, Alcaraz A.¹
¹Hospital Clinic de Barcelona, Dept. of Urology, Barcelona, Spain, ²Fundación Puigvert, Dept. of Urology, Barcelona, Spain, ³Careggi Hospital, Dept. of Urology, Florence, Italy, ⁴Dr. Sadi Konuk Hospital, Dept. of Urology, Istanbul, Turkey, ⁵Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁶University Saarland, Dept. of Urology, Saar, Germany, ⁷University Hospital Halle, Dept. of Urology, Halle, Germany, ⁸University Hospital of Rangueil, Dept. of Urology, Toulouse, France

Aims and objectives of this presentation
757

Prospective propensity matched non-randomized comparison between open and robot-assisted kidney transplantation

By: Kumar A., Maheshwari R., Chaturvedi S., Desai P., Gaur P., Rakhul L.R., Qadri S., Banerjee K.
Max Healthcare, Dept. of Urology, Uro-Oncology, Robotics and Renal Transplantation, New Delhi, India

Aims and objectives of this presentation
758

Results of the 50 first cases of robotic assisted kidney transplantation compared to matched-pair open cases

By: Musquera Felip M.¹, Ajami Fardoun T.¹, Peri Cusi L.¹, D’Anna M.¹, Izquierdo Reyes L.¹, Diekmann F.², Alcaraz Asensio A.¹
¹Hospital Clinic de Barcelona, Dept. of Urology, Barcelona, Spain, ²Hospital Clinic de Barcelona, Dept. of Nephrology, Barcelona, Spain

Aims and objectives of this presentation
759

Robotic kidney transplant using renal grafts with multiple renal arteries has outcomes comparable to grafts with single artery

Medanta the Medicity, Dept. of Urology and Robotic Surgery, Gurgaon, India

Aims and objectives of this presentation
760
Robotic kidney transplantation from living and deceased donors in a referral academic centre: Technical nuances and preliminary results

By: Campi R.¹, Vignolini G.¹, Sessa F.¹, Greco I.¹, Larti A.², Sebastianelli A.¹, Giancane S.¹, Gacci M.¹, Peris A.³, Breda A.⁴, Siena G.¹, Li Marzi V.¹, Serni S.¹ ¹University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ²University of Florence, Careggi Hospital, Dept. of Nephrology, Florence, Italy, ³University of Florence, Careggi Hospital, Intensive Care Unit and Regional ECMO Referral Centre, Florence, Italy, ⁴Fundación Puigvert, University Autonoma of Barcelona, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation
761

Robot-assisted kidney transplantation in the obese: Result at 2 years of the first French series

By: Lesourd M.¹, Beauval J-B.¹, Sallusto F.¹, Kamar N.², Soulié M.¹, Gamé X.¹, Rischmann P.¹, Roumigué M.¹, Doumerc N.¹ ¹CHU Rangueil Toulouse, Dept. of Urology, Toulouse, France, ²CHU Rangueil Toulouse, Dept. of Nephrology, Toulouse, France

Aims and objectives of this presentation
762

Prospective comparative study on robot-assisted vs open kidney transplantation: Trend to less perioperative inflammatory response and similar functional results

By: Territo A.¹, Subiela J.D.¹, Theil G.², Gausa L.¹, Regis F.¹, Boissier R.³, Nasreldin M.², Formara P.², Gallioli A.¹, Guirado L.⁴, Breda A.¹ ¹Fundació Puigvert, Autonoma University of Barcelona, Dept. of Urology, Barcelona, Spain, ²University Hospital Halle, Dept. of Urology, Halle, Germany, ³Aix-Marseille Université, APHM, Nord Academic Hospital, Dept. of Urology, Marseille, France, ⁴Fundació Puigvert, Autonoma University of Barcelona, Dept. of Nephrology, Barcelona, Spain

Aims and objectives of this presentation
763

Sixteen years after the first laparoscopic living donor nephrectomy

By: Musquera M.¹, D'Anna M.¹, Peri L.¹, Ajami T.¹, Ribal M.J.¹, Álvarez-Vijande R.¹, Huguet J.², Izquierdo L.¹, Vilaseca A.¹, Martos R.¹, Diekmann F.³, Alcaraz A.¹ ¹Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³Hospital Clínic de Barcelona, Dept. of Nephrology, Barcelona, Spain

Aims and objectives of this presentation
764
Robot-assisted kidney autotransplantation (RAKAT): Update from the first series in Europe


1Ghent University Hospital, Dept. of Urology, Ghent, Belgium, 2University Hospital of Rangueil, Dept. of Urology and Renal Transplantation, Toulouse, France, 3Ghent University Hospital, Dept. of Vascular and Thoracic Surgery, Ghent, Belgium, 4AZ Damiaan, Dept. of Urology, Ostend, Belgium, 5Ghent University Hospital, Dept. of Nuclear Medicine, Ghent, Belgium

Aims and objectives of this presentation

Interest of intraoperative heparin therapy during renal transplantation after donor-living nephrectomy

By: Grevez T., Lavallée E., Broudeur L., Karam G., Rigaud J., Buschler M., Bruyère F., Branchereau J.

1Tours University Hospital, Dept. of Urology, Tours, France, 2University Hospital of Quebec, Dept. of Urology, Quebec, Canada, 3University Hospital of Nantes, Dept. of Urology, Nantes, France, 4Tours University Hospital, Dept. of Nephrology, Tours, France

Aims and objectives of this presentation

Magnetic Black-Star® double J stent in kidney transplantation: Is it worthy?


1Rangueil Universitary Hospital, Dept. of Urology, Kidney Transplantation and Andrology, Toulouse, France, 2Rangueil Universitary Hospital, Dept. of Pharmacology, Toulouse, France, 3Rangueil Universitary Hospital, Ambulatory Care Nurse Unit, Toulouse, France, 4Rangueil Universitary Hospital, Dept. of Nephrology, Multiorgan Transplantation and Dialysis, Toulouse, France

Aims and objectives of this presentation

Summary

A. Alcaraz, Barcelona (ES)
Imaging-guided approaches for the treatment of recurrent prostate cancer
Poster Session 55

**Location:** Green Area, Room 10

**Chairs:**
- T. Steuber, Hamburg (DE)
- J.P. Sweeney, Cork (IE)
- K. Touijer, New York (US)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion. Associated video presentations are 4 minutes in length, followed by 2 minutes for discussion.

* 769

**Long-term oncologic outcomes of patients treated with salvage lymph node dissection for nodal recurrence of prostate cancer: Results from a large, multi-institutional series**


1 IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, 2 Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3 University of Cologne, Dept. of Urology, Cologne, Germany, 4 Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 5 University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 6 University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Kiel, Germany, 7 Heinrich-Heine-University Medical Faculty, Dept. of Urology, Düsseldorf, Germany, 8 Medical University of Vienna, Dept. of Urology, Vienna, Austria, 9 University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 10 University of Southern California, USC Institute of Urology, Los Angeles, United States of America, 11 OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium

**Aims and objectives of this presentation**

769

770

**Mapping of site-specific relapse in patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 or 11C-Choline PET/CT: Impact of postoperative androgen deprivation therapy and radiotherapy**

By: Devos G., Witters M., Raskin Y., Everaerts W., Van Poppel H., Tosco L., De Meerleer G., Goffin K., Joniau S.

1 University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 2 Humanitas Gradenigo
Aims and objectives of this presentation

Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

By: De Bleser E. ¹, Jereczek-Fossa B.A. ², Pasquier D. ³, Zilli T. ⁴, Van As N. ⁵, Siva S. ⁶, Fodor A. ⁷, Dirix P. ⁸, Gomez De Iturriaga A. ⁹, Trippa F. ¹⁰, Detti B. ¹¹, Ingrosso G. ¹², Triggiani L. ¹³, Alessio B. ¹⁴, Alongi F. ¹⁵, Reynders D. ¹⁶, Fonteyne V. ¹⁷, Surgo A. ¹⁸, Loukili K. ³, Miralbell R. ⁴, Silva P. ⁵, Chander S. ⁶, Goetghebeur E. ¹⁹, Ost P. ²⁰
¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ²University of Milan, Dept. of Oncology and Hemato-oncology, Milan, Italy, ³Centre Oscar Lambret, Dept. of Radiation Oncology, Lille, France, ⁴University Hospital Geneva, Dept. of Radiation Oncology, Geneva, Switzerland, ⁵The Royal Marsden NHS Foundation Trust, Dept. of Radiation Oncology, London, United Kingdom, ⁶Peter MacCallum Cancer Centre, Dept. of Radiation Oncology, Melbourne, Australia, ⁷San Raffaele Scientific Institute, Dept. of Radiation Oncology, Milan, Italy, ⁸Iridium Cancer Network, Dept. of Radiation Oncology, Antwerp, Belgium, ⁹Hospital de Cruces, Dept. of Radiation Oncology, Barakaldo, Spain, ¹⁰Azienda Ospedaliera Santa Maria Di Terni, Dept. of Radiation Oncology, Terni, Italy, ¹¹Azienda Ospedaliera, Universitaria Careggi, Dept. of Radiation Oncology, Florence, Italy, ¹²Tor Vergata General Hospital, Dept. of Diagnostic imaging, Molecular imaging, Interventional radiology and Radiotherapy, Rome, Italy, ¹³University and Spedali Civili Hospital, Dept. of Radiation Oncology, Brescia, Italy, ¹⁴University Hospital of Modena, Dept. of Oncology and Hematology, Radiotherapy unit, Modena, Italy, ¹⁵Ospedale Cuore-Don calabria, Dept. of Radiation Oncology, Verona, Italy, ¹⁶University of Ghent, Dept. of Applied Mathematics, Computer Science and Statistics, Ghent, Belgium, ¹⁷Ghent University Hospital, Dept. of Radiotherapy and Experimental Cancer Research, Ghent, Belgium, ¹⁸European Institute of Oncology, Dept. of Radiation Oncology, Milan, Italy, ¹⁹University of Ghent, Applied Mathematics, Computer Science and Statistics, Ghent, Belgium, ²⁰Ghent University Hospital, Radiotherapy and Experimental Cancer Research, Ghent, Belgium

Aims and objectives of this presentation

Metastases-yield and PSA-kinetics following salvage lymph node dissection for prostate cancer: A comparison between conventional surgical approach and PSMA-radioguided surgery

By: Knipper S. ¹, Tilki D. ¹, Mansholt J. ¹, Berliner C. ², Bernreuther C. ², Steuber T. ¹, Maurer T. ¹, Graefen M. ¹
¹Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ²University Hospital Hamburg-Eppendorf, Dept. of Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg, Germany
Aims and objectives of this presentation

68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy at low PSA values ≤ 0.5 ng/ml

By: Kranzbühler B., Müller J., Becker A., Garcia Schüler H., Fankhauser C., Guckenberger M., Kaufmann P., Eberli D., Burger I.
1University Hospital Zürich, Dept. of Urology, Zurich, Switzerland, 2University Hospital Zürich, Dept. of Nuclear Medicine, Zurich, Switzerland, 3University Hospital Zürich, Dept. of Radiology, Zurich, Switzerland, 4University Hospital Zürich, Dept. of Radiation Oncology, Zurich, Switzerland

Aims and objectives of this presentation

Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3University of Cologne, Dept. of Urology, Cologne, Germany, 4Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 5University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 6University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Kiel, Germany, 7Medical University of Vienna, Dept. of Urology, Vienna, Austria, 8Heinrich-Heine-University Medical Faculty, Dept. of Urology, Düsseldorf, Germany, 9University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 10University of Southern California, USC Institute of Urology, Los Angeles, United States of America, 11OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium, 12University of Milan, Dept. of Oncology and Hemato-oncology, Milan, Italy, 13Centre Oscar Lambret, Dept. of Radiation Oncology, Lille, France, 14Geneva University Hospital Faculty of Medicine, Dept. of Radiation Oncology, Geneva, Switzerland, 15The Royal Marsden NHS Foundation Trust, Dept. of Radiation Oncology, London, United Kingdom, 16Peter MacCallum, Dept. of Radiation Oncology, Melbourne, Australia, 17IRCCS San Raffaele Hospital/ University Vita-Salute San Raffaele, Dept. of Radiation Oncology, Milan, Italy, 18Iridium Cancer Network, Dept. of Radiation Oncology, Antwerp, Belgium, 19Hospital de Cruces, Dept. of Radiation Oncology, Baracaldo, Spain, 20Azienda Ospedaliera Santa Maria di Terni, Dept. of Radiation Oncology, Terni, Italy, 21Azienda Ospedaliero-Universitaria Careggi, Dept. of Radiation Oncology, Florence, Italy, 22Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

Aims and objectives of this presentation

Scientific Programme - EAU19 Barcelona
Comparing the diagnostic accuracy of 68Ga-PSMA and 11C-Choline PET/CT scan according to PSA level: A large multi-institutional analysis with histological verification in patients treated with salvage lymph node dissection for recurrent prostate cancer


1IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3University of Cologne, Dept. of Urology, Cologne, Germany, 4Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, 5University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 6University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Kiel, Germany, 7Medical University of Vienna, Dept. of Urology, Vienna, Austria, 8Heinrich-Heine-University Medical Faculty, Dept. of Urology, Düsseldorf, Germany, 9University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 10University of Southern California, USC Institute of Urology, Los Angeles, United States of America, 11OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium

Aims and objectives of this presentation

Open and robotic salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: Morbidity and functional outcomes from a large multicenter series

By: Marra G. 1, Gontero P. 1, Alessio P. 1, Calleris G. 1, Filippini C. 2, Oderda M. 1, Sanchez-Salas R. 3, Goonewardene S. 4, Popert R. 4, Cahill D. 5, Persad R. 6, Palou J. 7, Joniau S. 8, Piechaud T. 9, De La Taille A. 10, Roupret M. 11, Van Velthoven R. 12, Morlacco A. 13, Mottrie A. 14, Fiscus G. 15, Berger A. 16, Van Der Poel H. 17, Murphy D.G. 18, Davis J. 19, Karnes R.J. 13

1San Giovanni Battista Hospital, Dept. of Surgical Sciences, Urology, Turin, Italy, 2University of Turin, Dept. of Statistics, Turin, Italy, 3Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, 4Guy’s Hospital, Dept. of Urology, London, United Kingdom, 5Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, 6Bristol NHS Foundation Trust, Dept. of Urology, Bristol, United Kingdom, 7Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 8Leuven University Hospitals, Dept. of Urology, Leuven, Belgium, 9Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, 10CHU Mondor, Dept. of Urology, Créteil, France, 11Sorbonne Université, Hôpital Pitié-Salpêtrière, GRC n°5, Oncotype-URO, AP-HP, Paris, France, 12Institut Jules Bordet, Université Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, 13Mayo Clinic, Dept. of Urology, Rochester, MN, United States of America, 14OLV Hospital, Dept. of Urology, Aalst, Belgium, 15Vanderbilt University, Medical Center North, Dept. of Urology, Nashville, TN, United States of America, 16USC Norris Comprehensive Cancer Center and Hospital, University of Southern California, Dept. of Urology, Los Angeles, CA, United States of America, 17University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg,
Aims and objectives of this presentation

776

Robotic assisted radical prostatectomy after focal therapy: Oncological and functional outcomes

By: Serra De Oliveira Marconi L.¹, Stonier T.², De Luyk N.¹, Tourinho-Barbosac R.³, Moore C.⁴, Ahmed H.U.⁵, Cathelineau X.³, Emberton M.⁶, Sanchez-Salas R.³, Cathcart P.¹

¹Guys and St Thomas NHS Foundation Trust, Urology Centre, London, United Kingdom, ²Kings College Hospital, Dept. of Urology, London, United Kingdom, ³Institut Mutualiste Montsouris, Université Paris-Descartes, Dept. of Urology, Paris, France, ⁴University College London Hospitals (UCLH), Dept. of Urology, London, United Kingdom, ⁵Imperial College London, Dept. of Urology, London, United Kingdom, ⁶Faculty of Medical Sciences, University College London, Dept. of Surgery and Interventional Science, London, United Kingdom

Aims and objectives of this presentation

777

Stereotactic reirradiation for local recurrence in the prostatic bed after prostatectomy: Preliminary results

By: Olivier J.¹, Basson L.², Puech P.³, Lacornerie T.⁴, Liem X.², Wallet J.⁵, Lartigau E.², Pasquier D.²

¹CHU Lille, Dept. of Urology, Lille, France, ²Oscar Lambret Center, Dept. of Radiotherapy, Lille, France, ³CHU Lille, Dept. of Radiology, Lille, France, ⁴Oscar Lambret Center, Medical Physics, Lille, France, ⁵Oscar Lambret Center, Dept. of Clinical Research and Innovation, Lille, France

Aims and objectives of this presentation

778

Salvage irreversible electroporation for locally recurrent prostate cancer after radiotherapy – oncologic and functional outcomes

By: Blazevski A.¹, Scheltema M.J.S.², Yuen B.¹, Cusick T.², Masand N.², Haynes A.², Stricker P.D.¹

¹St. Vincent's Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, ²Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Sydney, Australia

Aims and objectives of this presentation

779
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>487</td>
<td>Which patient with biochemical recurrence after primary treatment for prostate cancer would result in a positive 68Ga-PSMA PET/CT? A clinical tool to guide physicians before suggesting 68Ga-PSMA PET/CT</td>
<td>Bianchi L., Ceci F., Borghesi M., Polverari G., Mineo Bianchi F., Barbaresi U., Chessa F., Castellucci P., Schiavina R., Fanti S., Brunocilla E.</td>
<td></td>
</tr>
<tr>
<td>V60</td>
<td>Associated video presentation Salvage robot-assisted laparoscopic prostatectomy: Does primary treatment make a difference?</td>
<td>Önol F.F., Bhat S., Rogers T., Jenson C., Roof S., Rocco B.M.C., Patel V.</td>
<td></td>
</tr>
<tr>
<td>V93</td>
<td>Associated video presentation Laparoscopic salvage lymph node dissection after radical prostatectomy: A feasible technique</td>
<td>Gerolimetto C., Sampalmieri M., Proietti F., Molinaro E., Guidotti M., Franco G., Leonardo C.</td>
<td></td>
</tr>
</tbody>
</table>
Old and new slings and things for male incontinence
Poster Session 56

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 11
Chairs: V. Phé, Paris (FR)
N. Thiruchelvam, Cambridge (GB)
F. Van Der Aa, Leuven (BE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

780

The Virtue European trial for urinary incontinence after prostatectomy: 3-year outcomes


1Erasmie hospital, Dept. of Urology, Brussels, Belgium, 2Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, 3Caremeau University Hospital, Dept. of Urology, Nîmes, France, 4European Institute of Oncology, Dept. of Urology, Milan, Italy, 5Guy’s Hospital, Dept. of Urology, London, United Kingdom, 6Henri Mondor University Hospital, Dept. of Urology, Créteil, France, 7Puerta del Mar University Hospital, Dept. of Urology, Cádiz, Spain, 8Schleswig-Holstein University Hospital, Dept. of Urology, Kiel, Germany, 9Puigvert Foundation, Autonomous University Hospital of Barcelona, Dept. of Urology, Barcelona, Spain, 10Heilig Geist Hospital, Dept. of Urology, Cologne, Germany, 11University Hospital, Dept. of Urology, Ghent, Belgium, 12Pitié-Salpêtrière University Hospital, Dept. of Urology, Paris, France, 13Coloplast, Medical Affairs Office, Le Plessis-Robinson, France, 14Mater Private Hospital, Dept. of Urology, Dublin, Ireland

Aims and objectives of this presentation
780

782

High vs. low volume predicts outcome in males treated with AMS 800: Results from a large mid European cohort study (DOMINO, debates on male incontinence)


1University Hospital of Muenster, Dept. of Urology and Pediatric Urology, Münster, Germany, 2University Medical Center of Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, 3Ludwig-Maximilians University Hospital, Dept. of Urology, Munich, Germany, 4University Hospital of Bonn, Dept. of Urology, Pediatric Urology and Neurourology, Bonn, Germany, 5University Hospital of Bonn, Dept. of
Aims and objectives of this presentation
782

Robot-assisted bladder neck artificial urinary sphincter implantation in male patients with neurogenic stress urinary incontinence: A multicenter study

By: Encatassamy F., Hascoët J., Brierre T., Manunta A., Le Normand L., Gamé X., Peyronnet B., Perrouin-Verbe M-A.

1CHU de Nantes, Dept. of Urology, Nantes, France, 2CHU de Rennes, Dept. of Urology, Rennes, France, 3CHU de Toulouse, Dept. of Urology, Toulouse, France

Aims and objectives of this presentation
783

Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy

By: Ohba K., Ueda Y., Mukae Y., Nakamura Y., Sagara Y., Matsuo T., Miyata Y.

Nagasaki University Hospital, Urology and Renal Transplantation, Nagasaki, Japan

Aims and objectives of this presentation
784

Urinary male incontinence: Long term follow up with adjustable trans obturator male sling

By: Favro M., Marchioro G., Vidali M., Terrone C., Volpe A.

1Maggiore della Carità Hospital, Dept. of Urology, Novara, Italy, 2Maggiore della Carità Hospital, Clinical Chemistry Unit, Novara, Italy, 3Policlinico San Martino Hospital, Dept. of Urology, Genova, Italy

Aims and objectives of this presentation
785

Comparing fixed and adjustable male slings for treatment of male stress urinary incontinence

Aims and objectives of this presentation
786
Aims and objectives of this presentation

786

Artificial urinary sphincter implantation improves several storage and voiding symptoms in addition to urinary incontinence

By: Yokoyama M. 1, Masuda H. 2, Ito M. 3, Waseda Y. 4, Moriyama S. 1, Toide M. 1, Uehara S. 1, Yasuda Y. 1, Kijima T. 1, Yoshida S. 1, Ishioka J. 1, Matsuoka Y. 1, Saito K. 1, Fujii Y. 1

1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2National Cancer Center Hospital East, Dept. of Urology, Kashiwa-City, Japan, 3Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, 4Tokyo Metropolitan Ohtsuka Hospital, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

787

Prospective European registry for patients undergoing surgery for male stress urinary incontinence: An initial report of the registry ‘SATURN’

By: Van Der Aa F. 1, Heesakkers J. 2, Martens F. 2, Thiruchelvam N. 3, Bjartell A. 4, Caris C. 4, Schipper R. 4, Witjes W. 4, Hamid R. 5, EAU Research Foundation SATURN Study Group

Aims and objectives of this presentation

787
Scientific Programme - EAU19 Barcelona

1University Hospital Leuven, Dept. of Urology, Leuven, Belgium, 2Radboud UMC, Dept. of Urology, Nijmegen, The Netherlands, 3Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, 4EAU Research Foundation, Dept. of Clinical Research, Arnhem, The Netherlands, 5Royal National Orthopaedic Hospital, Dept. of Neurourology, London, United Kingdom

**Aims and objectives of this presentation**

788

<table>
<thead>
<tr>
<th>789</th>
<th>A new artificial urinary sphincter (VICTO) with conditional occlusion for male stress incontinence: Preliminary clinical results</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Ameli G., Weibl P., Rutkowski M., Huebner W.A.</td>
</tr>
<tr>
<td></td>
<td>Clinic of Korneuburg - Teaching Hospital, Dept. of Urology, Korneuburg, Austria</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

789

<table>
<thead>
<tr>
<th>790</th>
<th>The transobturator sub-urethral sling: A safe and effective option for all degrees of post prostatectomy urinary incontinence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>St. James's Hospital, Dept. of Urology, Dublin, Ireland</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

790

<table>
<thead>
<tr>
<th>791</th>
<th>Prospective analysis of continence and complication rates of AMS 800 AUS devices for patients with a history of neurological disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Ludwig T.A., Maurer V., Marks P., Rosenbaum C., Vetterlein M., Gild P., Engel O., Fisch M., Dahlem R.</td>
</tr>
<tr>
<td></td>
<td>University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

791

<table>
<thead>
<tr>
<th>792</th>
<th>Refillable artificial urinary sphincter ZSI 375 PF: Spanish multicentre experience</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1University Hospital of the Canary Islands, Dept. of Urology, San Cristóbal de La Laguna, Spain, 2Fundación Jiménez Díaz University Hospital, Dept. of Urology, Madrid, Spain, 3Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, 4University Hospital Puerta del Mar, Dept. of Urology, Cádiz, Spain, 5University Hospital of Salamanca, Dept. of Urology, Salamanca, Spain</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

792
Very early PFMT with indwelling catheter for post-prostatectomy incontinence, a randomized controlled trial

By: Filocamo M.T., Alladio F., Cordara G., Moiso A., Mondino P., Rossi R., Rosso D., Coppola P.
SS. Annunziata Hospital, Dept. of Urology, Savigliano, Italy

Aims and objectives of this presentation
New imaging in urology
Poster Session 57
Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 12
Chairs: M. Bertolotto, Trieste (IT)
J. Denstedt, London (CA)
M. Ritter, Bonn (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

794

Defining a national reference level for intra-operative radiation exposure in urological procedures: FLASH, a retrospective multi-centre UK study


1Guy's Hospital, Dept. of Urology, London, United Kingdom, 2Kings College Hospital, Dept. of Urology, London, United Kingdom, 3Luton & Dunstable Hospital, Dept. of Urology, Luton, United Kingdom, 4Worthing Hospital, Dept. of Urology, Worthing, United Kingdom, 5Charing Cross Hospital, Dept. of Radiology, London, United Kingdom, 6North Middlesex Hospital, Dept. of Urology, London, United Kingdom, 7Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, 8Derriford Hospital, Dept. of Urology, Derriford, United Kingdom, 9Northwick Park Hospital, Dept. of Urology, London, United Kingdom, 10West Middlesex Hospital, Dept. of Urology, London, United Kingdom, 11Bedford Hospital, Dept. of Urology, Bedford, United Kingdom, 12St George's Hospital, Dept. of Urology, London, United Kingdom, 13Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, 14Guy's and St Thomas', Dept. of Urology, London, United Kingdom, 15Glasgow Royal Infirmary, Dept. of Urology, Glasgow, United Kingdom, 16Princess Alexandra Hospital, Dept. of Urology, Harlow, United Kingdom, 17Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom

Aims and objectives of this presentation

795

Split renal function assessment by mathematical analysis of 3D rendering of CT scans

By: Proskura A., Alyaev Y.G., Khokhlachev S.B., Shpot E.V., Fiev D.N., Sorokin N.I. Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

Aims and objectives of this presentation

795
Comparison of computed tomography and contrast enhanced ultrasound for the management of complex renal cysts: A single-center experience

By: Angelini L.¹, Gioulis E.², Di Cristofano F.¹, Napoli R.¹, Petrucci F.¹, Salemi M.³, Piccoli G.², Valerio S.¹
¹Ospedale di Conegliano, Dept. of Urology, Conegliano, Italy, ²Ospedale di Conegliano, Dept. of Radiology, Conegliano, Italy, ³Ospedale di Conegliano, Directorate of Medical Services, Conegliano, Italy

Aims and objectives of this presentation

Impact of computerized tomography for upper tract imaging and potential role of renal ultrasound in patients presenting with asymptomatic microscopic hematuria

By: Fankhauser C.¹, Waisbrod S.¹, Fierz C.¹, Kranzbühler B.¹, Wettstein M.S.¹, Eberli D.¹, Sulser T.¹, Mostafid H.², Hermanns T.¹
¹University of Zurich, Dept. of Urology, Zurich, Switzerland, ²Royal Surrey County Hospital, Dept. of Urology, Surrey, United Kingdom

Aims and objectives of this presentation

The first real time imaging of hemorrhage after bladder overdistention by wireless capsule endoscope - hematuria after release from acute urinary retention

By: Mizuno H.¹, Yamamoto T.², Yoko Y.¹, Matsukawa Y.², Kamihira O.¹, Gotoh M.²
¹Komaki City Hospital, Dept. of Urology, Komaki, Japan, ²Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan

Aims and objectives of this presentation

Deep learning with a convolutional neural network algorithm for automated detection of urinary tract stones using abdominal X-ray image

By: Ishioka J.¹, Kobayashi M.², Fujiwara M.³, Kawamura N.³, Okuno T.³, Fukuda Y.², Kohno T.², Kawano K.², Morimoto S.², Uehara S.¹, Yasuda Y.¹, Kijima T.¹, Yoshida S.¹, Yokoyama M.¹, Matsuoka Y.¹, Saito K.¹, Saiki R.⁴, Kumazawa I.⁵, Fuji Y.¹
¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Tsuchiura Kyodo General Hospital, Dept. of Urology, Tsuchiura, Japan, ³JA Toride Medical Center, Dept. of Urology, Toride, Japan, ⁴Tokyo Institute of Technology, School of Engineering, Dept. of Information and Communications Engineering, Tokyo, Japan, ⁵Tokyo Institute of Technology, Institute of Innovative Research, Laboratory for Future Interdisciplinary Research of Science and Technology, Tokyo, Japan
Aims and objectives of this presentation
800

801

The efficacy of CT scan scout film in determining the urinary stones biochemical composition

By: Levi O. 1, Elias S. 2, Bass R. 1, Sidi A.A. 1, Tsivian A. 1, Tavdy 1

1The Edith Wolfson Medical Center, The Sackler faculty of Medicine, Dept. of Urologic Surgery, Holon, Israel, 2The Edith Wolfson Medical Center, The Sackler faculty of Medicine, Dept. of Diagnostics Imaging, Holon, Israel

Aims and objectives of this presentation
801

802

The use of dual energy computed tomograph in the identification of urinary stones in urolithiasis

By: Nazarov T., Komyakov B.K., Rychkov I.V., Lebedev D.G., Tursunov A.I., Trubnikova K.E., Lepekhina A.
North-Western State Medical University, Dept. of Urology, Saint-Petersburg, Russia

Aims and objectives of this presentation
802

803

The role of bladder wall thickness in the evaluation of detrusor underactivity: Development of a clinical nomogram

By: De Nunzio C. 1, Lombardo R. 1, Carter S. 2, Tema G. 1, Nacchia A. 1, Cancrini F. 1, Sica A. 1, Vicentini C. 3, Tubaro A. 1

1Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, 2London Clinic, Dept. of Urology, London, United Kingdom, 3University of L'Aquila, Dept. of Surgical Sciences, L'Aquila, Italy

Aims and objectives of this presentation
803

804

Predicting vital retroperitoneal residual tumors of metastatic testicular tumor patients after chemotherapy using radiomics

By: Nestler T. 1, Baeßler B. 2, Pinto Dos Santos D. 2, Paffenhöhl P. 1, Pfister D. 1, Maintz D. 2, Heidenreich A. 1

1University Hospital of Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany, 2University Hospital of Cologne, Institute of Diagnostic and Interventional Radiology, Cologne, Germany

Aims and objectives of this presentation
804

805

Leydig cell ultrasound features: A useful tool for a proper preoperative counselling
406

Clinical applications of magnetic resonance imaging in urethral strictures: Preliminary report with reference to 3D-volume rendering and 3D-printed models

By: Frankiewicz M.¹, Markiet K.², Belka M.³, Kozak O.², Krukowski J.¹, Szurowska E.², Matuszewski M.¹
¹Medical University of Gdansk, Dept. of Urology, Gdansk, Poland, ²Medical University of Gdansk, Dept. of Radiology, Gdansk, Poland, ³Medical University of Gdansk, Dept. of Pharmaceutical Chemistry, Gdansk, Poland

Aims and objectives of this presentation

806

807

Non-invasive evaluation of male urethra’s stenosis: The cine-urethro RM. Preliminary reports

By: Corongiu E.¹, Danti M.², Grande P.³, Squillacciotti S.¹, Pagliarella G.¹, Di Santo A.¹, Liberati E.¹, Forte F.¹
¹MG Vannini Hospital, Dept. of Urology, Rome, Italy, ²MG Vannini Hospital, Dept. of Radiology, Rome, Italy, ³Sapienza University of Rome, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation

807

17:04 - 17:08

Summary

M. Bertolotto, Trieste (IT)
Paediatric urology: The testis and specific problems
Poster Session 58

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 19
Chairs: Y. Farahat, Dubai (AE)
To be confirmed
D.N. Wood, London (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

808
Clinical usefulness of diagnostic tool to distinguish testicular torsion from torsion of the appendix testis
By: Kodama H. 1, Hatakeyama S. 1, Yamamoto H. 1, Imai A. 1, Yoneyama T. 1, Hashimoto Y. 1, Ito H. 2, Yoshikawa K. 3, Sasaki A. 4, Takahashi S. 5, Ohyama C. 1
1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,
2Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan,
3Mutsu General Hospital, Dept. of Urology, Mutsu, Japan,
4Tsugaru General Hospital, Dept. of Urology, Goshogawara, Japan,
5Aomori City Hospital, Dept. of Urology, Aomori, Japan

Aims and objectives of this presentation
808

809
Testicular migration through the inguinal canal: Analysis in 208 human fetuses
State University of Rio de Janeiro, Urogenital Research Unit, Rio de Janeiro, Brazil

Aims and objectives of this presentation
809

810
Shear wave elastography evaluation of the testis in Prader-Willi syndrome
By: Matsuyama S., Matsui F., Yazawa K., Matsumoto F.
Osaka Women's and Children's Hospital, Dept. of Urology, Osaka, Japan

Aims and objectives of this presentation
810

811
Testicular sparing surgery for testicular masses in the paediatric population: Current review of practice
By: Radford A. 1, Haid B. 2, Spinoit A. 3, Silay M.S. 4, Banuelos B. 5, Powis M. 6, Lakshminarayanan B. 6, EAU Young Academic Urologists
1Leeds Children's Hospital, EAU Young Academic Urologists Paediatric Urology Group,
Aims and objectives of this presentation

811 Is the Koff procedure with low spermatic vessel ligation the optimal choice for testes at the inner inguinal ring with long-looping vas?

By: Harms M., Haid B., Becker T., Oswald J.
Ordensklinikum Linz, Barmherzige Schwestern, Dept. of Pediatric Urology, Linz, Austria

Aims and objectives of this presentation

812 Indicators for outcomes in the last decade concerning laparoscopic Fowler-Stephens

Habib Thameur Hospital, Dept. of Pediatric Surgery, Tunis, Tunisia

Aims and objectives of this presentation

813 Novel technique for laparoscopic orchiopexy: New route production safely method to scrotum

By: Naito Y., Ajiki J., Yamada Y., Shiraishi T., Fujihara A., Matsubara H., Suzuki K., Hongo F., Ukimura O.
Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan

Aims and objectives of this presentation

814 Morphological evaluation of operated testes for cryptorchidism: New findings

By: Zampieri N., Caridha D., Patanè S., Bruno C., Bianchi F., Camoglio F.
1Azienda Ospedaliera Universitaria Integrata, University of Verona, Dept. of Pediatric Surgery, Pediatric Adolescent Fertility Lab, Verona, Italy, 2Azienda Ospedaliera Universitaria Integrata, Dept. of Radiology, Verona, Italy
Aims and objectives of this presentation

816

Testicular atrophy after orchiopexy for congenital undescended testis: Outcomes of testicular survival by different primary locations and ages at orchiopexy

By: Tseng C-S., Kuo M-C., Huang K-H., Huang C-Y., Pu Y-S., Chang H-C., Chiang I-N.
National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan

Aims and objectives of this presentation

816

817

Protective effect of liraglutide on experimental testicular ischemia reperfusion injury in rats

By: Degirmentepe R.B.¹, Bozkurt M.¹, Cekmen M.B.², Yildirim F.³, Sonmez K.³, Ada S.², Isman F.K.², Otuncemur A.¹, Altunrende F.¹
¹University of Health Science, Okmeydani Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ²Medeniyet University, Goztepe Training and Research Hospital, Dept. of Medical Biochemistry, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Faculty of Veterinary Medicine, Dept. of Pathology, Istanbul, Turkey

Aims and objectives of this presentation

817

818

Is the success rate of varicocelectomy different in adolescents with nutcracker syndrome (NCS)?

By: Hajiyev P.¹, Burgu B.¹, Akpinar C.², Esen B.², Karaburun M.², Ekberli G.¹, Fitoz S.³, Soygur T.¹
¹Ankara University School of Medicine, Dept. of Pediatric Urology, Ankara, Turkey, ²Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey, ³Ankara University School of Medicine, Dept. of Pediatric Radiology, Ankara, Turkey

Aims and objectives of this presentation

818

819

Intraoperative patients mobilization to evaluate collateral reflux during laparoscopic varicocelectomy

By: Zampieri N., Bianchi F., Peretti M., Scirè G., Patanè S., Camoglio F.
Azienda Ospedaliera Universitaria Integrata, University of Verona, Dept. of Pediatric Surgery, Pediatric Adolescent Fertility Laboratory, Verona, Italy

Aims and objectives of this presentation

819

820

Relationship between pneumoperitoneum and post-operative pain in pediatric varicocelectomy: Prospective study

Aims and objectives of this presentation

820
Aims and objectives of this presentation

**821**

**Robot-assisted extravesical ureteral reimplantation (REVUR) for bilateral vesicoureteral reflux in children: Results of a multicentric international survey**

By: Esposito C.¹, Masieri L.², Steyaert H.³, Escolino M.¹, Cerulo M.¹, Cini C.², Venturini S.², Lendvay T.S.⁴

¹University of Naples Federico II, Dept. of Pediatric Surgery, Naples, Italy, ²University of Florence, Meyer Children's Hospital, Dept. of Urology, Florence, Italy, ³Université Libre de Bruxelles(ULB), Dept. of Pediatric Surgery, Brussels, Belgium, ⁴Seattle Children's Hospital, Dept. of Pediatric Surgery, Seattle, United States of America

Aims and objectives of this presentation

821

**822**

**Low-dose antibiotic prophylaxis has no significant impact on the stability of the intestinal microbiome in children with urogenital tract malformations under 1 year of age**

By: Strasser C.¹, Spindelböck W.², Kashofer K.³, Oswald J.⁴, Haid B.⁴

¹Kepleruniversitätsklinikum, Dept. of Urology and Andrology, Linz, Austria, ²Medical University Graz, Dept. of Internal Medicine, Division of Gastroenterology and Hepatology, Graz, Austria, ³Medical University of Graz, Institute of Pathology, Graz, Austria, ⁴Hospital of the Sisters of Charity, Dept. of Paediatric Urology, Linz, Austria

Aims and objectives of this presentation

822
The impact of education and surgeon burnout on quality of care and service provision
Poster Session 59

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 20

Chairs: T. Bach, Hamburg (DE)
L.K. Bin, Singapore (SG)
K. Dimitropoulos, Aberdeen (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

823

To what extent statistical findings in randomized controlled trials are facts? The fragility index in urological oncology literature

By: Chertin L., Zisman A., Haifler M.
Shamir (Assaf Harofeh) Medical Center, Dept of Urology, Zerifin, Israel

824

The "EUREP hands-on training format": 4-years of hands-on training improvements from the European School of Urology (ESU)


1 Grande Ospedale Metropolitano, Dept. of Urology, Reggio Calabria, Italy, 2 University Hospital Gasthuisberg, Dept. of Urology, Leuven, Belgium, 3 SLK Klinikum, Dept. of Urology, Heilbronn, Germany, 4 Erasme Hospital, University Clinics of Brussels, Dept. of Urology, Brussels, Belgium, 5 St. James’s University Hospital Leeds, Dept. of Urology, Leeds, United Kingdom, 6 Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 7 The North West London Hospitals NHS Trust, Dept. of Urology, London, United Kingdom, 8 Ospedale San Raffaele–Turro, Dept. of Urology, Milan, Italy, 9 Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, 10 Charles University, Dept. of Urology, Prague, Czech Republic, 11 University of Athens, Dept. of Urology, Athens, Greece, 12 St. Antonius Hospital, Dept. of Urology and Oncology, Gronau, Germany, 13 University Hospital Pilsen, Dept. of Urology, Pilsen, Czech Republic, 14 Havenziekenhuis, Dept. of Urology, Rotterdam, The Netherlands, 15 Azienda Ospedaliero Universitaria di Careggi, Dept. of Urology, Florence, Italy, 16 University Hospital Motol, Dept. of Urology, Prague, Czech Republic, 17 St. John of God Hospital, Dept. of Urology, Vienna, Austria, 18 Charles University 2nd Faculty of Medicine and University Hospital Motol, Dept. of Urology, Prague, Czech Republic, 19 Athens Medical Centre, Dept. of Urology, Athens, Greece, 20 AMC University Hospital, Dept. of Urology, Amsterdam, The Netherlands, 21 General
Satisfaction with surgical training and confidence in performing surgical procedures among European urology residents

By: Carrion D.M.¹, Rodriguez Socarras M.², Mantica G.³, Esperto F.⁴, Duijvesz D.⁴, Vasquez J.L.⁵, Gozen A.⁶, Veneziano D.⁷, Palou J.⁸, Gomez Rivas J.¹

¹La Paz University Hospital, Dept. of Urology, Madrid, Spain, ²San Raffaele-Turro Hospital, San Raffaele University, Dept. of Urology, Milan, Italy, ³Humanitas Gavazzeni, Dept. of Urology, Bergamo, Italy, ⁴Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ⁵Herlev and Gentofte Hospital, Dept. of Urology, Herlev, Denmark, ⁶SLK-Kliniken, University of Heidelberg, Dept. of Urology, Heilbronn, Germany, ⁷Grande Ospedale Metropolitano, Dept. of Urology, Reggio Calabria, Italy, ⁸Fundacio Puigvert, University of Barcelona, Dept. of Urology, Barcelona, Spain

Simulation in urological training and education (SIMULATE): A randomised controlled clinical and educational trial to determine the effect of structured surgical simulation training

By: Aydin A.¹, Ahmed K.¹, Raison N.¹, Abe T.², Gözen A.S.³, Moltzahn F.⁴, Knoll T.⁵, Zhu W.⁶, Kunit T.⁷, Skolarikos A.⁸, Sfakianos J.⁹, Lantz A.¹⁰, Chew B.¹¹, Thalmann G.¹², Rassweiler J.³, Shinohara N.², Tewari A.⁹, Zeng G.⁶, Sarica K.¹², Van Hemelrijck M.¹³, Ahmed H.U.¹⁴, Khan M.S.¹, Dasgupta P.¹, SIMULATE

¹King’s College London, MRC Centre for Transplantation, London, United Kingdom, ²Hokkaido University Hospital, Dept. of Urology, Sapporo, Japan, ³SLK-Kliniken, University of Heidelberg, Dept. of Urology, Heilbronn, Germany, ⁴University of Bern, Dept. of Urology, Bern, Switzerland, ⁵Sindelfingen-Bo?blingen Medical Centre, University of Tübingen, Dept. of Urology, Sindelfingen, Germany, ⁶First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China, ⁷Paracelsus Medical Private University, Dept. of Urology, Salzburg, Austria, ⁸Sismanoglio Hospital, Athens Medical School, Dept. of Urology, Athens, Greece, ⁹Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ¹⁰Dalhousie University, Dept. of Urology, Halifax, Canada, ¹¹University of British Columbia, Dept. of Urology, Vancouver, Canada, ¹²Kafkas University, Dept. of Urology, Kars, Turkey, ¹³King’s College London, Division of Cancer Studies, London, United Kingdom, ¹⁴Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom

Academic and scientific activity of European urology residents during their training

By: Carrion D.M.¹, Rodriguez Socarras M.², Mantica G.³, Esperto F.⁴, Cebulla A.⁵, Vasquez J.L.⁶, Palou J.⁷, Gomez Rivas J.¹

¹La Paz University Hospital, Dept. of Urology, Madrid, Spain, ²San Raffaele-Turro Hospital, San Raffaele University, Dept. of Urology, Milan, Italy, ³San Raffaele-Turro Hospital, San Raffaele University, Dept. of Urology, Milan, Spain, ⁴Humanitas Gavazzeni, Dept. of Urology, Bergamo, Italy, ⁵Ulm University Medical Center, Dept. of Urology, Ulm, Germany, ⁶Herlev and Gentofte Hospital, Dept. of Urology, Herlev, Denmark, ⁷Fundacio Puigvert, University of Barcelona, Dept. of Urology, Barcelona, Spain
Outcomes of European basic laparoscopic urological skills (EBLUS) exams:
Results from European School of Urology (ESU) over 6 years (2013-2018)

By: Somani B.¹, Van Cleynenbreugel B.², Gozen A.³, Skolarikos A.⁴, Wagner C.⁵, Beatty J.⁶, Barmoshe S.⁷, Gaya J.M.⁸, Kalogeropoulos T.⁹, Oscar F.R.⁸, Salas R.¹⁰, Schmidt M.¹¹, Siena G.¹², Palou J.⁸, Geragthy R.¹, Veneziano D.¹⁴

¹University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ²University Hospital Gasthuisberg, Dept. of Urology, Leuven, Belgium, ³SLK Klinikum Heilbronn, Dept. of Urology, Heilbronn, Germany, ⁴University of Athens, Dept. of Urology, Athens, Greece, ⁵St.Antonius-Hospital, Dept. of Urology, Gronau, Germany, ⁶University Hospital Leicester, Dept. of Urology, Leicester, United Kingdom, ⁷Erasme Hospital, Dept. of Urology, Brussels, Belgium, ⁸Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁹AG Savvas Anticancer Hospital, Dept. of Urology, Athens, Greece, ¹⁰Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ¹¹University Hospital Motol, Dept. of Urology, Prague, Czech Republic, ¹²Azienda Ospedaliero-Universitaria di Careggi, Dept. of Urology, Florence, Italy, ¹³Ospedale San Raffaele–Turro, Dept. of Urology, Milan, Italy, ¹⁴Grande Ospedale Metropolitano, Dept. of Urology, Calabria, Italy

The impact of sleep-related impairment on burnout in urologists: Results from a national consortium study

By: Marchalik D.¹, Shaw N.¹, Padmore J.², Lu E.³, Rowe S.⁴, Trockel M.³

¹MedStar Georgetown University Hospital, Dept. of Urology, Washington, United States of America, ²MedStar Health, Dept. of Physician Wellbeing, Washington, United States of America, ³Stanford, Dept. Of Physician Wellness, Palo Alto, United States of America

Definition of a structured training curriculum for robot-assisted radical cystectomy:
A Delphi-consensus study led by the ERUS Educational Board


¹Onze Lieve Vrouw Hospital, Orsi Academy, Dept. of Urology, Aalst, Belgium, ²Azienda Ospedaliero, Universitaria Pisana, Dept. of Urology, Pisa, Italy, ³Urological Research Institute, IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ⁴Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium, ⁵Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ⁶Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ⁷Fundació Puigvert, Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, ⁸Royal Liverpool University Hospital, Dept. of Urology, Liverpool, United Kingdom, ⁹Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, ¹⁰Ankara Yildirim Beyazit University, Dept. of Urology, Ankara, Turkey, ¹¹Aarhus University Hospital, Dept. of Clinical Medicine, Dept. of Urology, Aarhus, Denmark, ¹²University of Southern California Institute of Urology & Catherine and Joseph Aresty, Dept. of Urology, Los Angeles, United States of America, ¹³Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, ¹⁴Azienda Ospedaliera Universitaria
Simulation-based teaching of prostate biopsies: Predictive validity of a prostate biopsy simulator

By: Fiard G.¹, Selmi S-Y.², Maigron M.³, Promayon E.², Descotes J-L.¹, Troccaz J.²

¹Grenoble University Hospital, Dept. of Urology and Kidney Transplant, Grenoble, France, ²TIMC-IMAG Laboratory, Dept. of GMCAO, Grenoble, France, ³Université Grenoble Alpes, Faculty of Medicine, Grenoble, France

Evaluation of the ESU E-BLUS teaching guide as a stand-alone educational tool for hands-on training sessions

By: Urzi D.¹, Morgia G.¹, Castelli T.¹, Cimino S.¹, Russo G.¹, Privitera S.¹, Gozen A.², Van Cleynenbreugel B.³, Somani B.K.⁴, Veneziano D.⁵, ESU Training Research group

¹Università degli Studi di Catania, Dept. of Urology, Catania, Italy, ²SLK Kliniken, Dept. of Urology, Heilbronn, Germany, ³University of Leuven, Dept. of Urology, Leuven, Belgium, ⁴University of Southampton, Dept. of Urology, Southampton, United Kingdom, ⁵Grande Ospedale Metropolitano, Dept. of Urology, Reggio Calabria, Italy

Informed consent: What risks are material to patients?

By: McCauley N., Manson-Bahr D., Lane T., Clark C.
Lister Hospital Stevenage, East and North Herts Trust, Dept. of Urology, Stevenage, United Kingdom

Trainee burnout in the United States and Europe: A multi-national comparative study

By: Marchalik D.¹, Talso M.², Goldman C.³, Carvalho F.¹, Esperto F.⁴, Pradere B.⁵, Van Besien J.⁶, Krasnow R.¹

¹MedStar Georgetown University Hospital, Dept. of Urology, Washington, United States of America, ²Petra Uro Group, Dept. of Urology, Milan, Italy, ³Georgetown University School of Medicine, Dept. of Urology, Washington, United States of America, ⁴Humanitas Medical Care, Dept. of Urology, Bergamo, Italy, ⁵Centre Hospitalier Universitaire de Tours, Dept. of Urology, Tours, France, ⁶Universitair Ziekenhuis Ghent, Dept. of Urology, Ghent, Belgium

16:58 - 17:05
State-of-the-art lecture How does burnout affect patient outcome?
T. Bach, Hamburg (DE)
Breaking news session
Plenary Session 5 BN

Monday 18 March
07:30 - 08:00

Location: Red Area, eURO Auditorium 1
Chairs: A. Briganti, Milan (IT)
        M. Wirth, Dresden (DE)

07:30 - 07:38
Breaking news Primary results from SAUL, a prospective multinational single-arm study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract
A.S. Merseburger, Lübeck (DE)

07:38 - 07:45
Discussant
J. Bedke, Tübingen (DE)

07:45 - 07:53
Breaking news ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by disease characteristics
A. Alcaraz, Barcelona (ES)

07:53 - 08:00
Discussant
N.W. Clarke, Manchester (GB)
**Prostate cancer**

**Plenary Session 5**

**Monday 18 March**

**08:00 - 10:30**

**Location:** Red Area, eURO Auditorium 1

**Chairs:**
A. Briganti, Milan (IT)
M. Wirth, Dresden (DE)

**Aims and objectives of this session**

This session aims to debate on some controversial topics in the field of prostate cancer in a novel, interactive way. Each speaker will expose his or her view on the subject and then will be challenged by a multi-disciplinary jury composed by key figures involved in the clinical decision-making process of prostate cancer. Finally, the role of mp-MRI as a possible triage test before first biopsy will be discussed in terms of utility and cost-effectiveness. The session also includes the AUA lecture on prostate cancer.

---

**08:00 - 09:45**

**Controversies in the management of prostate cancer: The jury is out**

**08:00 - 09:45**

**Jury member Urologist from YAU (Young Academic Urologists)**
R.C.N. Van Den Bergh, Nieuwegein (NL)

**08:00 - 09:45**

**Jury member Geriatrician**
A. Wagg, Edmonton (CA)

**08:00 - 09:45**

**Jury member Psychologist**
L. Bellardita, Milano (IT)

**08:00 - 09:45**

**Jury member Radiation oncologist**
A. Bossi, Villejuif (FR)

**08:00 - 09:45**

**Jury member Urologist**
C. Stief, Munich (DE)

**08:00 - 08:05**

**Case presentation** Screening in a 73-year old but fit man
M. Roobol, Rotterdam (NL)

**08:05 - 08:20**

**Questions/challenges from 3 members of the jury**
L. Bellardita, Milano (IT)
C. Stief, Munich (DE)
A. Wagg, Edmonton (CA)

**08:20 - 08:35**

**Rebuttal from presenter**
M. Roobol, Rotterdam (NL)

**08:35 - 08:40**

**Case presentation** Active surveillance in Gleason 3+4 but negative MRI
A. Rannikko, Helsinki (FI)

**08:40 - 08:55**

**Questions/challenges from 3 members of the jury**
L. Bellardita, Milano (IT)
R.C.N. Van Den Bergh, Nieuwegein (NL)
A. Wagg, Edmonton (CA)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:55 - 09:10</td>
<td>Rebuttal from presenter</td>
<td>A. Rannikko, Helsinki (FI)</td>
</tr>
<tr>
<td>09:10 - 09:15</td>
<td>Case presentation Local treatment in metastatic prostate cancer</td>
<td>M. Graefen, Hamburg (DE)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>Questions/challenges from 3 members of the jury</td>
<td>A. Bossi, Villejuif (FR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Stief, Munich (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R.C.N. Van Den Bergh, Nieuwegein (NL)</td>
</tr>
<tr>
<td>09:30 - 09:45</td>
<td>Rebuttal from presenter</td>
<td>M. Graefen, Hamburg (DE)</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td>Recent advances in prostate cancer: Real game changers?</td>
<td></td>
</tr>
<tr>
<td>09:45 - 09:55</td>
<td>Pre-biopsy MRI for all patients: Effective and sustainable?</td>
<td>M. Emberton, London (GB)</td>
</tr>
<tr>
<td>09:55 - 10:00</td>
<td>The EAU guidelines view</td>
<td>P. Cornford, Liverpool (GB)</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>American Urological Association (AUA) lecture Patient-reported outcomes after prostate cancer therapy: How good are we doing?</td>
<td>S. Chang, Nashville (US)</td>
</tr>
<tr>
<td>10:15 - 10:20</td>
<td>PIONEER – The European network of excellence for Big Data in prostate cancer</td>
<td>J. N'Dow, Aberdeen (GB)</td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>The EAU and European Health: The ERN eUROGEN programme</td>
<td>C.R. Chapple, Sheffield (GB)</td>
</tr>
</tbody>
</table>
Aims and objectives of this session
As more men achieve long-term survival after urogenital cancers, sexual dysfunction and infertility have increasingly been recognized as negative consequences that impact quality of life in cancer survivors. The surgeries we perform as urologists, including prostatectomy, retroperitoneal lymph node dissection and penile surgery can have profound and direct effects on sexual wellbeing and fertility. Furthermore, systemic therapies including chemotherapy and hormonal manipulation have been strongly associated to reductions in sexual function and sperm count. In this session, we will discuss these devastating side effects and provide guidance on how to deal with these issues in the daily practice.

08:00 - 08:30 Case-based debate Hypogonadal prostate cancer patient following treatment with curative intent
Moderator: E.C. Serefoglu, Istanbul (TR)

08:00 - 08:05 Case presentation
E.C. Serefoglu, Istanbul (TR)

08:05 - 08:15 Pro: Patient is definitely a candidate for TRT
J.P. Mulhall, New York (US)

08:15 - 08:25 Con: I would be reluctant to give this man TRT
B. Tombal, Brussels (BE)

08:25 - 08:30 Rebuttal and summary

08:30 - 08:45 Hypogonadism following childhood and testis cancer treatments: An underestimated issue?
A. Giwercman, Malmö (SE)

08:45 - 09:00 Pre- and postpubertal fertility preservation in men facing cancer?
C.F.S. Jensen, Herlev (DK)

09:00 - 09:15 Neglected sexual side-effects of radical prostatectomy and pelvic radiotherapy
P.A.S. Vendeira, Matosinhos (PT)

09:15 - 09:30 Has penile rehabilitation following prostatectomy proven useful?
G. Gandaglia, Milan (IT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 - 09:45</td>
<td>Guidelines snapshot Sexual function and organ preservation in penile cancer</td>
<td>B.E. Ayres, London (GB)</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td>Challenges in penile implant surgery following pelvic cancer treatment (fibrosis, reservoir placement)</td>
<td>I. Moncada Iribarren, Madrid (ES)</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Confederación Americana de Urología (CAU) lecture Sexual function preservation in robotic urology?</td>
<td>R. Coelho, Sao Paulo (BR)</td>
</tr>
</tbody>
</table>
Leadership and the EAU
Specialty Session

Monday 18 March
08:30 - 11:30

Location: Green Area, Room 19
Chair: J.P.M. Sedelaar, Nijmegen (NL)

Aims and objectives of this session
What is my role as a medical leader?
• Who are my stakeholders when it comes to leadership
• Leadership lessons

Managing peers and co-workers
• Preferences leadership styles

Analysis and diagnosis on your system

Reflection on my role as a leader
• What are the actual management challenges
• Reflection on my role

Enhancing engagement
• How does a climate of change occur
• What is my role within my team

Group work:
• Discuss how you can develop/implement medical leadership
• Consider potential challenges you might face in completing and how you may overcome them
• Distinguish technical challenges from adaptive challenges
• Observe your system
• Feedback on personal leadership

08:30 - 08:45
Welcome and introduction
J.P.M. Sedelaar, Nijmegen (NL)

08:45 - 09:45
Personal behaviour and leadership
H. Rijksen, Maarsbergen (NL)

09:45 - 10:45
Insights in your organisational patterns and symptoms
M. Evers, Maarsbergen (NL)

10:15 - 10:45
Ambidexterity
H. Rijksen, Maarsbergen (NL)

10:45 - 11:30
Adaptive challenges
M. Evers, Maarsbergen (NL)
Updated renal, bladder and prostate cancer guidelines 2019: What has changed?
ESU Course 45

**Monday 18 March**
**08:30 - 11:30**

**Location:** Green Area, Room 13

**Chair:** H.G. Van Der Poel, Amsterdam (NL)

**Aims and objectives of this session**
During the course recent practice changing alterations in the guidelines will be discussed. Based on the clinical recommendations the highlights of the guidelines one prostate, renal and bladder cancer as changed in the 2019 updates will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

**Introduction**
H.G. Van Der Poel, Amsterdam (NL)

**Update renal cancer: Localized**
A. Volpe, Novara (IT)

**Discussion**

**Update renal cancer: Metastasized**
A. Volpe, Novara (IT)

**Discussion**

**Update bladder cancer: Non-muscle invasive**
J.L. Domínguez Escrig, Valencia (ES)

**Discussion**

**Update bladder cancer: Muscle invasive**
J.L. Domínguez Escrig, Valencia (ES)

**Discussion**

**Update prostate cancer: Localized**
H.G. Van Der Poel, Amsterdam (NL)

**Discussion**
Update prostate cancer: Metastasized
H.G. Van Der Poel, Amsterdam (NL)

Discussion
Ultrasound in urology
ESU Course 43

Location: Green Area, Room 14
Chair: T. Loch, Flensburg (DE)

Aims and objectives of this session
Ultrasound is the basic imaging tool of the urologist and almost all urologists are using ultrasound in daily practice. Despite this, training and teaching of urological ultrasound is not provided in a satisfactory manner. The aim of the course is to provide the technical basics and standards for the use of ultrasound in urology. After the course the delegate should know the ideal settings for reliable and informative urological ultrasound as well as the normal and pathological findings.

• Covering urological organs: kidney, ureter, bladder, testis and penis.
• Standard patient positioning.
• Best choice of transducers and settings.
• Standard operating procedures (SOP).
• Normal, benign and malignant pathologic findings.
• Interventional and intraoperative ultrasound.

Technical basics and new technologies
T. Loch, Flensburg (DE)

Standardisation, tuning, acquisition and reporting of ultrasound exams
M. Ritter, Mannheim (DE)

Ultrasound of the kidney and ureter
M. Ritter, Mannheim (DE)

Ultrasound of the bladder
T. Loch, Flensburg (DE)

Ultrasound of the testis
T. Loch, Flensburg (DE)

Ultrasound of the penis
M. Ritter, Mannheim (DE)
# Prolapse management and female pelvic floor problems

**ESU Course 42**

**Location:** Green Area, Room 15

**Chair:** E. Kocjancic, Chicago (US)

## Aims and objectives of this session

This course gives practical information about prolapse management by urologists. From anatomy to mesh implant, the recent revival of native tissue repairs and the management of complications. Also laparoscopic and robotic approaches will be evaluated.

## Case 1: What can go wrong in the female pelvic floor support

**Evaluation of female pelvic floor and basic anatomical concepts**

E. Kocjancic, Chicago (US)

**Imaging**

G.R. Kasyan, Moscow (RU)

**POP classifications and its clinical usefulness**

H. Hashim, Bristol (GB)

## Case 2: Anterior prolapse

**Site specific repair**

G.R. Kasyan, Moscow (RU)

**Use of biological and synthetic meshes**

E. Kocjancic, Chicago (US)

**Use of pessaries**

H. Hashim, Bristol (GB)

## Case 3: Vaginal vault prolapse

**Vaginal approach**

E. Kocjancic, Chicago (US)

**Open colposacropexy**

H. Hashim, Bristol (GB)

**Laparoscopic and robotic colposacropexy**

G.R. Kasyan, Moscow (RU)

## Case 4: POP and urinary incontinence
<table>
<thead>
<tr>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Functional evaluation</td>
<td>H. Hashim, Bristol (GB)</td>
</tr>
<tr>
<td>Stress incontinence and POP</td>
<td>G.R. Kasyan, Moscow (RU)</td>
</tr>
<tr>
<td>Urgency incontinence and POP</td>
<td>E. Kocjancic, Chicago (US)</td>
</tr>
<tr>
<td>Case 5: Complications of POP surgery</td>
<td></td>
</tr>
<tr>
<td>Interactive discussion on different clinical scenarios</td>
<td>G.R. Kasyan, Moscow (RU)</td>
</tr>
<tr>
<td></td>
<td>E. Kocjancic, Chicago (US)</td>
</tr>
<tr>
<td></td>
<td>H. Hashim, Bristol (GB)</td>
</tr>
<tr>
<td>Questions and answers</td>
<td></td>
</tr>
</tbody>
</table>
The infertile couple - Urological aspects
ESU Course 41

Monday 18 March
08:30 - 11:30

**Location:** Green Area, Room 16

**Chair:** W. Aulitzky, Vienna (AT)

Aims and objectives of this session
This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility. In terms of therapy, this course will provide updated information on evidence based data and will discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation. We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

**Diagnostic work-up, medical treatment**
A. Salonia, Milan (IT)

**Pathophysiology, diagnosis and treatment of varicocele**
W. Aulitzky, Vienna (AT)

**Microsurgical refertilisation**
W. Aulitzky, Vienna (AT)

**Sperm retrieval techniques and genetic aspects of IVF/ICSI**
A. Salonia, Milan (IT)
Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips, tricks and indications
ESU Course 44

Location: Green Area, Room 21
Chair: O. Traxer, Paris (FR)

Aims and objectives of this session
The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions.
• To learn about equipment.
• To learn about technique and indications.
• To learn how to use an Holmium Laser.
• To learn tips and tricks for special circumstances.

Welcome message and introduction of the course
O. Traxer, Paris (FR)

Instrumentation: Endoscopes
O. Traxer, Paris (FR)

Instrumentation: Laser and lithotripsy devices
M. Grasso, Sleepy Hollow (US)

Instrumentation: Disposable (wires, retrieving devices, UAS, irrigation devices and others)
P.J.S. Oster, Fredericia (DK)

Technique: Stones
O. Traxer, Paris (FR)

Technique: Urothelial tumours and strictures
M. Grasso, Sleepy Hollow (US)

Tips and tricks and special circumstances
O. Traxer, Paris (FR)

Indications (guidelines) and clinical cases
P.J.S. Oster, Fredericia (DK)

Conclusions
O. Traxer, Paris (FR)
Aims and objectives of this session
This course has over many years dealt with the technique of urethra- and nerve-sparing cystectomy and subsequent orthotopic bladder substitution in male and female patients. It will deal with indications, technique, possible complications and their prevention. Urologists with a vast experience in cystectomy and urinary diversion will present technical tips using videoclips, results in the literature as well as own data.
• Technique of nerve-sparing cystectomy.
• Optimization of sphincter preservation for optimal continence results.
• Technical tips and tricks in orthotropic neobladder surgery.
• What to observe in male and female patients.

Preoperative investigations and selection of patients for orthotopic bladder substitution
J.E. Gschwend, Munich (DE)

Arguments for nerve-sparing cystectomy with orthotopic bladder substitution
A. Stenzl, Tübingen (DE)

How to do a nerve-sparing cystectomy in male patients
H. Abol-Enein, Mansoura (EG)

Surgical tricks to avoid complications with orthotopic bladder substitution
J.E. Gschwend, Munich (DE)

Video on how to obtain good functional results in female patients
A. Stenzl, Tübingen (DE)

Tips and Tricks: Male/female orthotopic urinary diversion
H. Abol-Enein, Mansoura (EG)

How to treat complications during follow-up
J.E. Gschwend, Munich (DE)

Tips and tricks for an orthotopic neobladder
A. Stenzl, Tübingen (DE)
Aims and objectives of this session
An effective communicator needs to be flexible, energetic and enthusiastic. Making a presentation puts you on public display. An audience not only listens to your ideas, it also responds to the way you use your voice and your body. You need more than a well written presentation to make an impact: you will also need to deliver it in a lively, flexible and interesting way. In this course we deliver tips and tricks for inspiring, invoking energy, confidence and safety in your presentation style. The course will be performed in TED format, with no podium available and itinerant talks in front of the slides.

At the end of this course, participants should be able to:
• Understand how Guidelines recommendations are formulated.
• Highlight the changes and the gaps of the different Guidelines discussed at the course.
• Be familiar with the strength of the evidence of the current Guidelines.
• Apply knowledge gained in this course to develop an evidence-based practice in the management of patients.

Introduction
D. Veneziano, Reggio Calabria (IT)
J. Gómez Rivas, Madrid (ES)

How to deliver an effective talk. Verbal language
J. Gómez Rivas, Madrid (ES)

Non-verbal language. Tips and tricks
J. Gómez Rivas, Madrid (ES)

TED talks: How to structure a successful presentation
D. Veneziano, Reggio Calabria (IT)

Optimizing your presentations with the latest software and hardware
D. Veneziano, Reggio Calabria (IT)

How to present the results of your research
G.E. Cacciamani, Verona (IT)

Mastering the stage. The expert opinion
M.J. Ribal Caparros, Barcelona (ES)

Closing remarks
### ESU/ESUT/ESUI Hands-on Training Course in Prostate MRI reading for urologists

**HOT 24**

**Monday 18 March 09:00 - 12:30**

**Location:** Green Area, Room 9

**Chair:** V. Kasivisvanathan, London (GB)

**Tutors:**
- I.G. Schoots, Rotterdam (NL)
- F. Giganti, London (GB)
- E. Barret, Paris (FR)

### Aims and objectives of this session

This course will provide interactive teaching from expert Faculty in prostate MRI reading and interpretation and help Urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS and Likert scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on their own laptops followed by a reference reading provided by expert radiologists and pathological verification.
Aims and objectives of this session

Course description
Minimally invasive surgery (MIS) is an emerging field for every subspecialty of Urology. However it requires more dedication and a careful approach when the urologists are dealing with children. Additionally the instruments used are also miniaturized and requires specific experience and knowledge.

Although not only paediatric urologists are performing MIS in children, but in majority of the UEMS countries the adult urologists have to deal with the problems on their own. When they try to approach the children in the same way they treat the adults, complications frequently occurs.

On the other hand in almost any of the congresses, this topic is touched only superficially and unfortunately the lack of information negatively effects the care of the children by MIS.

In this Hands-on Training all urologists (adult+ paediatric) will be enabled to find out the optimal instrumentation during performing laparoscopic surgery and robotic surgery in paediatric population. In addition they will be learning the tips and tricks to avoid complications and to increase the success.

Aims and objectives

At the end of this course you will be able to:
• Have learned practical information (positioning, insertion of trocars, setting the pressure, docking) about conventional laparoscopy and robotic surgery in children.
• Know about indications, tips and tricks for most common conventional laparoscopic surgeries
• Know about indications, tips and tricks for most common robotic paediatric surgeries.

Target audience: Urologists, interested in the field of Paediatric Laparoscopy
Aims and objectives of this session
Several new, potentially practice-changing data are released annually in the field of genito-urinary cancers. These studies involve not only Urologists but also Medical Oncologists and Radiation Therapists, highlighting the true multidisciplinary approach beyond the treatment of these tumours. This session aims to update the audience about the results of the new trials presented at the major international meetings in 2018 and early 2019 using a novel, multidisciplinary format.

10:30 - 12:00

Conclusions from recent oncology meetings regarding:

10:30 - 10:45
Hormone-naive prostate cancer
P.L. Nguyen, Boston (US)

10:45 - 11:00
Castration-resistant prostate cancer
C.P. Evans, Sacramento (US)

11:00 - 11:15
Urothelial cancer
T. Powles, London (GB)

11:15 - 11:30
Renal cell carcinoma
A.S. Merseburger, Lübeck (DE)

11:30 - 11:45
Testis and penile cancer
J. Oldenburg, Lørenskog (NO)

11:45 - 12:00
Society for Urologic Oncology (SUO) lecture Targeting the adaptive molecular landscape of advanced prostate cancer
M. Gleave, Vancouver (CA)
Semi-live surgery: Cystectomy and urinary diversion
Thematic Session 19

Monday 18 March
10:30 - 12:00
Location: Red Area, eURO Auditorium 2
Discussants: P. Albers, Düsseldorf (DE)
M. Gallucci, Rome (IT)
N.P. Wiklund, Stockholm (SE)

Aims and objectives of this session
Cystectomy and urinary diversion is one of the most difficult procedures in uro-oncological surgery. This session will present tips and tricks in robotic and open procedures including to deal with complications of the approaches. Videos will be presented and discussed by the surgeon and a distinguished panel.

10:30 - 10:45 Surgical video presentation Tips and tricks in robotic cystectomy
S. Siemer, Homburg (DE)

10:45 - 11:00 Questioned by discussants

11:00 - 11:15 Surgical video presentation Intra- versus extracorporal conduit (robotic)
A.E. Canda, Istanbul (TR)

11:15 - 11:30 Questioned by discussants

11:30 - 11:45 Surgical video presentation Different types of uretero-ileal anastomosis (open and robotic)
G. Niegisch, Düsseldorf (DE)

11:45 - 12:00 Questioned by discussants
### Aims and objectives of this session
Artificial mid-urethral sling is the most common surgery performed throughout the world to correct female stress urinary incontinence. Albeit considered a simple surgery, the failure to perform it adequately may cause complications and prevent the cure legitimated expected by patients. More recently, a movement against the use of artificial meshes for the treatment of pelvic organ prolapse invaded the field of stress urinary incontinence bewildering patients and caregivers. A clarification of these issues will constitute the main objective of the session.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Complications by sling type: Are all synthetic slings equal?</td>
<td>P. Toozs-Hobson, Birmingham (GB)</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Urethral and bladder erosion</td>
<td>M. Tutolo, Milan (IT)</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Pain after tape placement</td>
<td>F.M.J. Martens, Nijmegen (NL)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Voiding dysfunction: If and when to do a release?</td>
<td>A.K. Nambiar, Newcastle upon Tyne (GB)</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>The legal minefield of tape surgery</td>
<td>B. Leigh, London (GB)</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
Let's reduce the harm of surgery!
Thematic Session 13

Monday 18 March
10:30 - 12:00

Location: Green Area, Room 3

Chairs: F.C. Burkhard, Bern (CH)
J.W. Collins, Stockholm (SE)

Aims and objectives of this session
Enhanced recovery after surgery (ERAS) protocols aim to improve the outcome of the patients by optimizing patient management from diagnosis through to full recovery. The patient undergoing a surgical procedure following the concept of ERAS should have fewer side-effects from the surgery, a lower risk of complications, resulting in a faster, safer and more comfortable recovery with a shorter stay in the hospital and an earlier return to normal activity. In this session we consider how we can optimize the patient pre-operatively with ‘prehabilitation’, then standardize and optimize surgical and anaesthetic management and enhance recovery post-operatively.

10:30 - 10:45
The principles and the rationale of enhanced recovery 'around' surgery (ERAS)
J.W.F. Catto, Sheffield (GB)

10:45 - 10:50
Case presentation The ERAS patient case
To be confirmed

10:50 - 11:00
The evaluation by the geriatrician
S. O’Hanlon, Dublin (IE)

11:00 - 11:10
The need for prehabilitation
N. Fleshner, Toronto (CA)

11:10 - 11:20
What needs to be done by the urologist?
J.W. Collins, Stockholm (SE)

11:20 - 11:30
The role of the nursing staff/patient manager
B. Thoft Jensen, Aarhus (DK)

11:30 - 11:40
What would be the US approach?
C. Porter, Seattle (US)

11:40 - 12:00
Discussion Who is the target patient?
Panel: N. Fleshner, Toronto (CA)
B. Thoft Jensen, Aarhus (DK)
S. O’Hanlon, Dublin (IE)
C. Porter, Seattle (US)
From everyday clinical practice to curiosities - management of hot topics in infectious disease

Aims and objectives of this session
This session shows the broad scope of urogenital infections, every urologist is faced. From tuberculosis, which is a WHO high priority infection to antimicrobial resistance and antimicrobial stewardship strategies will be covered, highlighting the urgent Needs to cope with infectious Problems, are addressed in this session.

10:30 - 10:48
Case Treatment of urogenital tuberculosis - chemotherapy, surgery or a combined approach?
10:30 - 10:40
Case presentation
E. Kulchavenya, Novosibirsk (RU)
10:40 - 10:48
Discussion

10:48 - 11:03
Recurrent urinary tract infection - a standardised diagnostic work-up
B. Köves, Budapest (HU)

11:03 - 11:21
Case Kidney abscess - to drain, or not to drain?
11:03 - 11:13
Case presentation
V. Mouraviev, Davenport (US)
11:13 - 11:21
Discussion

11:21 - 11:39
Case Optimal antimicrobial use in endoscopic stone surgery
11:21 - 11:31
Case presentation
T. Perepanova, Moscow (RU)
11:31 - 11:39
Discussion

11:39 - 11:54
Antimicrobial treatment in the hospital setting - indication, route of administration, duration and choice of antimicrobials
S.E. Geerlings, Amsterdam (NL)

11:54 - 12:00
Concluding remarks
G. Bonkat, Basel (CH)
# Stone complications
Thematic Session 15

**Location:** Green Area, Room 5  
**Chairs:** T. Knoll, Sindelfingen (DE)  
C.M. Scoffone, Turin (IT)

### Aims and objectives of this session
Stone treatment today means minimally-invasive surgery. However, minimally-invasive doesn’t mean complication-free surgery. It is mandatory to select the right treatment modality for the right patient to avoid complications. If they occur, urologists should have a plan to deal with them.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Anticoagulation and stone treatment - what is possible?</td>
</tr>
<tr>
<td>K. Ghani, Ann Arbor (US)</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:10</td>
<td>Debate Ureteral access sheaths: Yes or no?</td>
</tr>
<tr>
<td>Moderator: G. Giusti, Milan (IT)</td>
<td></td>
</tr>
<tr>
<td>10:45 - 10:50</td>
<td>Introduction</td>
</tr>
<tr>
<td>G. Giusti, Milan (IT)</td>
<td></td>
</tr>
<tr>
<td>10:50 - 10:58</td>
<td>Yes</td>
</tr>
<tr>
<td>P. Kallidonis, Patras (GR)</td>
<td></td>
</tr>
<tr>
<td>10:58 - 11:06</td>
<td>No</td>
</tr>
<tr>
<td>V.M.J. De Coninck, Paris (FR)</td>
<td></td>
</tr>
<tr>
<td>11:06 - 11:10</td>
<td>Rebuttal</td>
</tr>
<tr>
<td>11:10 - 12:00</td>
<td>Case presentations Complication prevention in stone surgery</td>
</tr>
<tr>
<td>11:10 - 11:15</td>
<td>Case presentation</td>
</tr>
<tr>
<td>A. Hoznek, Creteil (FR)</td>
<td></td>
</tr>
<tr>
<td>11:15 - 12:00</td>
<td></td>
</tr>
</tbody>
</table>
**Aims and objectives of this session**
The audience will understand the arguments for and against of processing spermatozoa recovered from the ejaculate versus the epididymis or the testis for ICSI techniques in men with severe oligospermia. Differences in the ICSI-outcome will be discussed. Emphasis will be also given to the role of antioxidants in the management of male infertility. The contribution of genetic factors in the etiology of male infertility and surgical and laboratory techniques offering the possibility to men with testicular cancer to become fathers will be discussed.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:05</td>
<td>Case presentation and techniques: Severe oligospermia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-10:37</td>
<td>Case presentation</td>
<td>M.M. Fode, Herlev (DK)</td>
<td></td>
</tr>
<tr>
<td>10:37-10:44</td>
<td>Technique Ejaculated sperm: Don't touch the testis</td>
<td>Z. Kopa, Budapest (HU)</td>
<td></td>
</tr>
<tr>
<td>10:44-10:51</td>
<td>Technique Epididymal sperm is the way to go</td>
<td>T. Diemer, Giessen (DE)</td>
<td></td>
</tr>
<tr>
<td>10:51-10:58</td>
<td>Technique Testicular sperm is the best option</td>
<td>N. Sofikitis, Ioannina (GR)</td>
<td></td>
</tr>
<tr>
<td>10:58-11:05</td>
<td>Summary</td>
<td>M.M. Fode, Herlev (DK)</td>
<td></td>
</tr>
<tr>
<td>11:05-11:20</td>
<td>Fertility-sparing surgery in testis cancer</td>
<td>M. Dinkelman-Smit, Rotterdam (NL)</td>
<td></td>
</tr>
<tr>
<td>11:20-11:45</td>
<td>OAT case: Administration of antioxidants in men with oligoasthenospermia: Is it for the benefit of the male?</td>
<td>P. Capogrosso, Milan (IT)</td>
<td></td>
</tr>
<tr>
<td>11:20-11:25</td>
<td>Case presentation</td>
<td>P. Capogrosso, Milan (IT)</td>
<td></td>
</tr>
<tr>
<td>11:25-11:32</td>
<td>Pro If it doesn't help, it doesn't hurt</td>
<td>S.S. Minhas, London (GB)</td>
<td></td>
</tr>
<tr>
<td>11:32-11:39</td>
<td>Con Potentially dangerous for sperm-fertilising capacity</td>
<td>S. Çayan, Mersin (TR)</td>
<td></td>
</tr>
<tr>
<td>11:39-11:45</td>
<td>Discussion</td>
<td>P. Capogrosso, Milan (IT)</td>
<td></td>
</tr>
</tbody>
</table>
11:45 - 12:00  Genetic factors involved in male fertility: Are we testing enough?
S. Viville, Strasbourg (FR)
**Upper Tract Urothelial Cancer (UTUC)**

**Thematic Session 17**

**Monday 18 March**

**10:30 - 12:00**

**Location:** Green Area, Room 11

**Chairs:**
- P. Gontero, Turin (IT)
- J. Palou, Barcelona (ES)

**Aims and objectives of this session**

Radical nephro-ureterectomy (RNU) is still considered the standard treatment of patients with localised Upper Tract Urothelial Cancer (UTUC). However, RNU has a significant morbidity and alters renal function. Kidney-sparing procedures (KSP) have been proposed to preserve renal function while providing similar oncologic results in selected patients. The purpose of this session is to discuss all new findings in UTUC: Risk stratification, preoperative workup, lymphadenectomy template and the role for systemic treatment.

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Troubleshooting challenges in diagnostics</td>
<td>P. Black, Vancouver (CA)</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Radical nephro-ureterectomy: How radical to go?</td>
<td>T. Seisen, Boston (US)</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Technical video masterclass</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Robotic lower end</td>
<td>B.J. Challacombe, London (GB)</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Nephron-sparing approaches</td>
<td>A. Breda, Barcelona (ES)</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>A rational approach to systemic treatment of UTUC</td>
<td>S. Sridhar, Toronto (CA)</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Lynch syndrome: The tip of the iceberg</td>
<td>A.R. Zlotta, Toronto (CA)</td>
</tr>
</tbody>
</table>
Cancer in end-stage renal disease and after renal transplantation

Thematic Session 18

Monday 18 March

10:30 - 12:00

Location: Green Area, Room 12

Chairs: M-O. Grimm, Jena (DE)
E. Lledó García, Madrid (ES)

Aims and objectives of this session

Patients with end-stage renal disease and after transplantation are at increased risk to develop cancer. This has implications for the evaluation of recipients prior to and for follow-up after renal transplantation. Of note, treatment of frequent urologic cancers, such as bladder and prostate cancer, may be particularly challenging due to the presence of the transplant, immunosuppression and frequent comorbid disease of these patients. In this session distinguished experts summarize current knowledge regarding cancer in renal transplant patients.

10:30 - 10:45 Cancer risk in end-stage renal disease and after renal transplantation: What to consider?
O. Rodríguez Faba, Barcelona (ES)

10:45 - 11:00 Non-muscle invasive urothelial cancer after renal transplantation: Treatment, outcome and follow-up
R. Boissier, Marseille (FR)

11:00 - 11:15 How to deal with tumours in the transplant and native kidneys
M. Musquera Felip, Barcelona (ES)

11:15 - 11:50 Case-based debate Localised prostate cancer in kidney transplant recipients (1 low risk, 1 intermediate risk case)

11:15 - 11:20 Case presentation
E. Lledó García, Madrid (ES)

11:20 - 11:30 Radical prostatectomy
G. Salomon, Hamburg (DE)

11:30 - 11:40 External beam radiation
X. Maldonado, Barcelona (ES)

11:40 - 11:50 Focal therapy
M. Schostak, Magdeburg (DE)

11:50 - 12:00 Associated video presentation

V94 Laparoscopic partial nephrectomy in kidney transplantation
By: Garcia Alvarez C. ¹, Plata Bello A.C. ¹, González Álvarez R.J. ¹, Secaduras Arbelo T.M. ², Cabral Fernández A.V. ¹, Cereijo Tejedor D. ¹, Navarro Galmés M.A. ¹,
Fernández Cranz N. ¹, Concepción Masip T. ¹
¹Complejo Hospitalario Universitario de Canarias, Dept. of Urology, Tenerife, Spain,
²Hospital Nuestra Señora de la Candelaria, Intensive Care, Tenerife, Spain

Aims and objectives of this presentation
V94
How to successfully run a urology office in Europe
Thematic Session 20

Monday 18 March
10:30 - 12:00

Location: Green Area, Room 20

Chairs: H. Haas, Heppenheim (DE)
S.M. Haensel, Rotterdam (NL)
A. Zachariou, Volos (GR)

Aims and objectives of this session
Providing good medical care on the basis of scientific knowledge and making rational decisions are cornerstones of a successful urologic office, amended by a patient-centred approach and an appropriate organizational infrastructure of the office.

In this session different aspects of the optimal infrastructure are presented by office urologists: Established conjunctions to GPs, other specialties, and clinics are of core importance for a successful management of sick patients. Public communication to the patients, offering them the specialist’s help, and using new media, often misunderstood as merely a marketing tool, are important especially in unclear and complex situations. This communication has recently been regulated (and complicated) by the European Data Protection Law: the relevance in daily practice and how to implement it in our offices will be discussed. Science in office and scientific collaboration of offices and clinics are achieved in clinical studies, this will be discussed from an office urologist’s point of view.

The shape of office urology in Europe is not uniform and differs from country to country: office urologists will give you information about the characteristics in their country.

10:30 - 10:35 Welcome and introduction H. Haas, Heppenheim (DE)

10:35 - 10:50 The new European data protection law (GDPR): Practical implications in daily practice S.M. Haensel, Rotterdam (NL)

10:50 - 11:05 How to market your urology practice ethically and economically A. Zachariou, Volos (GR)

11:05 - 11:20 Social media in office urology S. Czarniecki, Warsaw (PL)

11:20 - 11:35 Networking in urologic office H. Brenneis, Pirmasens (DE)

11:35 - 11:50 Office urology in Europe H. Haas, Heppenheim (DE)

11:50 - 12:00 Future of office urology in Europe and closing remarks S.M. Haensel, Rotterdam (NL)
Advanced renal and bladder cancer: Risk, surgery and systemic therapies
Expert-Guided Poster Tour 12

Monday 18 March
11:30 - 13:30

Location: Green Area, Room A
Chairs: N. Shore, Myrtle Beach (US)
U. Vogl, Vienna (AT)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

12:00 - 12:03

Introduction
N. Shore, Myrtle Beach (US)
U. Vogl, Vienna (AT)

PT307

Essential research priorities in renal cancer: A modified Delphi consensus statement

By: Rossi S. ¹, Blick C. ², Handforth C. ³, Brown J. ³, Stewart G. ¹, Renal Gap Analysis Collaborative
¹University of Cambridge, Dept. of Urology, Cambridge, United Kingdom, ²Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, ³Weston Park Hospital and the University of Sheffield, Academic Unit of Clinical Oncology and Cancer Clinical Trials Unit, Sheffield, United Kingdom

Aims and objectives of this presentation
PT307

PT308

Development of modified IMDC model for metastatic renal cell carcinoma patients

By: Shirotake S. ¹, Kaneko G. ¹, Nishimoto K. ¹, Tanaka N. ², Ito K. ³, Kosaka T. ², Oya M. ², Oyama M. ¹
¹Saitama Medical University International Medical Center, Dept. of Uro-Oncology, Saitama, Japan, ²Keio University School of Medicine, Dept. of Urology, Tokyo, Japan, ³National Defense Medical College, Dept. of Urology, Saitama, Japan

Aims and objectives of this presentation
PT308

PT309

Prognostic value of metabolic conditions in patients with synchronous metastatic renal cell carcinoma

Aims and objectives of this presentation
PT309
<table>
<thead>
<tr>
<th>PT309</th>
<th>Early flare-response of C-reactive protein is associated with tumor shrinkage in patients with metastatic renal cell carcinoma treated with nivolumab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Fukuda S.(^1), Saito K.(^1), Yasuda Y.(^1), Soma T.(^2), Toide M.(^1), Fukushima H.(^1), Moriyama S.(^1), Uehara S.(^1), Fukui N.(^2), Kijima T.(^1), Yoshida S.(^1), Yokoyama M.(^1), Ishioka J.(^1), Matsuoka Y.(^1), Kageyama Y.(^2), Fujii Y.(^1)</td>
</tr>
<tr>
<td></td>
<td>(^1)Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, (^2)Saitama Cancer Center, Dept. of Urology, Saitama, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT310</th>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PT311</th>
<th>Overexpression of miR-15b promotes resistance to sunitinib in renal cell carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Feng C., Wen H.</td>
</tr>
<tr>
<td></td>
<td>Huashan Hospital, Dept. of Urology, Shanghai, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT312</th>
<th>Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Numakura K.(^1), Fujiyama N.(^2), Takahashi M.(^1), Igarashi R.(^1), Nara T.(^1), Chiba S.(^1), Kanda S.(^1), Saito M.(^1), Narita S.(^1), Inoue T.(^1), Habuchi T.(^1)</td>
</tr>
<tr>
<td></td>
<td>(^1)Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, (^2)Akita University Hospital, Center for Kidney Disease and Renal Transplantation, Akita, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT313</th>
<th>Influence of genetic polymorphisms of vascular endothelial related genes on clinical outcome of axitinib in patients with metastatic renal cell carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PT314</th>
<th>Cost analysis of different sequential treatment regimens for metastatic renal cell carcinoma in China</th>
</tr>
</thead>
</table>

---

564
Aims and objectives of this presentation
PT314

Clinicopathologic features of xp11.2 translocation renal cell carcinoma: Chinese multi-institutional analysis

By: Ning L., Weidong G.
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China

Aims and objectives of this presentation
PT315

Cytoreductive nephrectomy does not improve survival of metastatic renal cell carcinoma in the TKI era

By: Janisch F.¹, Fühner C.¹, Meyer C.P.¹, Hillemacher T.¹, Klotzbücher T.¹, Kienapfel C.¹, Vetterlein M.¹, Dahlem R.¹, Shariat S.F.², Fisch M.¹, Rink M.¹
¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany,
²Medical University of Vienna, Dept. of Urology, Vienna, Austria

Aims and objectives of this presentation
PT316

The peripheral blood inflammatory markers may predict response to nivolumab for advanced renal cell carcinoma

Iwate Medical University, Dept. of Urology, Iwate-Ken, Japan

Aims and objectives of this presentation
PT317

Impact of cytoreductive nephrectomy on overall survival outcomes in patients with metastatic renal cell carcinoma and brain and/or bone metastases
To be confirmed

Aims and objectives of this presentation
PT318

Comparison of efficacy and safety of checkpoint-inhibitors in patients with genitourinary cancers aged below and above 75 years

By: Schulz G.B.¹, Szabados B.², Spek A.¹, Staehler M.¹, Stief C.¹, Casuscelli J.¹
¹LMU Grosshadern, Dept. of Urology, Munich, Germany,
²Queen Mary University of London, Barts Cancer Institute, London, United Kingdom
Aims and objectives of this presentation
PT319

PT320
The impact of perioperative blood transfusion on oncologic outcomes in patients with non-metastatic renal cell carcinoma treated with surgery

By: Kim H.S. 1, Kim J.H. 1, Yoon H.S. 1, Lee H.W. 1, Lee J.W. 1, Bae J. 1, Kwak C. 2, Ku J.H. 2, Kim H.H. 2

1Dongguk University Ilsan Medical Center, Dept. of Urology, Goyang, South Korea,
2Seoul National University Hospital, Dept. of Urology, Seoul, South Korea

Aims and objectives of this presentation
PT320

PT321
Comprehensive molecular characterization of clear cell renal cell carcinoma with caval tumour thrombus

By: Liu C. 1, Gong X. 2, Zhang S. 2, Shi W. 2, Xie F. 2, Wang A. 2, Zhao Z. 2, Tan M. 2, Zhang P. 2, Du P. 2, Jia S. 2, Yu J. 2, Ma L. 1

1Peking University Third Hospital, Dept. of Urology, Beijing, China,
2Huidu Shanghai Medical Sciences Ltd, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation
PT321

PT322
The contribution of demographic, access and treatment-related factors on racial disparities in bladder cancer

By: Cole A.P. 1, Krimphove M.J. 1, Fletcher S.A. 1, Lipsitz S. 2, Gild P. 3, Preston M. 4, Menon M. 5, Kibel A. 1, Trinh Q-D. 1

1Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America,
2Brigham and Women's Hospital, Harvard Medical School, Division of Internal Medicine and Center for Surgery and Public Health, Boston, Massachusetts, United States of America,
3University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany,
4Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery, Boston, Massachusetts, United States of America,
5Vatikutti Urology Institute, Henry Ford Health System, Detroit, Michigan, United States of America

Aims and objectives of this presentation
PT322

PT323
Impact of frailty on treatment modality selection in patients with muscle-invasive bladder cancer

By: Hatakeyama S. 1, Yamamoto H. 1, Imai A. 1, Yoneyama T. 1, Hashimoto Y. 1, Koie T. 2, Ohyama C. 1

1Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan,
2Gifu University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
Aims and objectives of this presentation

PT323

Pathologic downstaging after neoadjuvant cisplatin-based combination chemotherapy in immunohistochemistry-defined molecular subtypes of bladder cancer

By: Sjodahl G., Abrahamsson J., Holmsten K., Eriksson P., Lövgren K., Lindh C., Ullén A., Liedberg F.

1Lund University, Division of Urological Research, Department of Translational Medicine, Malmö, Sweden, 2Karolinska Institutet, Theme Cancer, Patient Area Pelvic Cancer, Karolinska Hospital and Department of Oncology-Pathology, Stockholm, Sweden, 3Lund University, Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden, 4Karolinska University Hospital, Dept. of Pathology and Cytology, Stockholm, Sweden

Aims and objectives of this presentation

PT326

The impact of insurance status on outcomes for bladder cancer

By: Fletcher S.A., Cole A.P., Krimphove M.J., Lu C., Berg S., Lipsitz S.R., Trinh Q-D.

1Brigham and Women's Hospital, Harvard Medical School, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, 2Harvard TH Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America, 3Brigham and Women's Hospital, Harvard Medical School, Dept. of General Internal Medicine and Center for Surgery and Public Health, Boston, United States of America

Aims and objectives of this presentation

PT327

Concomitant carcinoma in situ at radical cystectomy: Survival, recurrence and follow-up implications


ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy

Aims and objectives of this presentation

PT328

Neutrophil to lymphocyte ratio (NLR) as a predictor of outcomes in patients with urothelial carcinoma (UC) treated with immune checkpoint inhibitors (ICI)

Aims and objectives of this presentation

PT328

Bladder-sparing radiotherapy with vinorelbine in localized muscle-invasive bladder cancer: A valid option for cisplatin-unfit patients?

By: Pichler R. 1, Lindner A.K. 1, Fritz J. 2, Arnold C. 3, Kavaïou O. 3, Schachtner G. 1, Tulchiner G. 1, Staudacher N. 1, Klinglmair G. 1, Skvortsov S. 3, Horninger W. 1, Heidegger I. 1

1Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, 2Medical University Innsbruck, Medical Statistics, Informatics and Health Economics, Innsbruck, Austria, 3Medical University Innsbruck, Therapeutic Radiology and Oncology, Innsbruck, Austria

Aims and objectives of this presentation

PT329

Response to vinflunine treatment correlates with survival outcomes in patients with advanced or metastatic urothelial carcinoma after platinum failure – analyses from the German, prospective, multicenter real-life study JONAS

By: Hegele A. 1, De Geeter P. 2, Goebell P.J. 3, Matz U. 4, Rosé C. 5, Villanova G. 6

1Philipps University, Dept. of Urology and Pediatric Urology, Marburg, Germany, 2Kassel Hospital, Dept. of Urology, Kassel, Germany, 3Friedrich-Alexander University, Dept. of Urology, Erlangen, Germany, 4Medical Urologic Practice, Doebeln, Germany, 5Pierre Fabre Pharma GmbH, Medical Department, Freiburg, Germany, 6Pierre Fabre Médicament, Medical Department, Boulogne-Billancourt, France

Aims and objectives of this presentation

PT330

Impact of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy (TMT) for muscle-invasive bladder cancer

By: Ajib K. A. 1, Tjong M. 1, Lunsky I. 1, Tan G.H 1, Nason G. 1, Erlich A. 2, Manjula M. 3, Sridhar S. 4, Fleshner N. 3, Zlotta A. 3, Berlin A. 4, Chung P. 4, Kulkarni G. 3

1University of Toronto, Dept. of Surgery, Toronto, Canada, 2Mount Sinai Hospital, Dept. of Urology, Toronto, Canada, 3University Health Network, Dept. of Urology, Toronto, Canada, 4University Health Network, Dept. of Radiology, Toronto, Canada

Aims and objectives of this presentation

PT331
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

### PT332

**Treatment of varicocele in children and adolescents: A systematic review and meta-analysis from European Association of Urology/European Society for Paediatric Urology Guidelines Panel**

By: Silay M.S.\(^1\), 't Hoen L.A.\(^2\), Quadackaers J.\(^3\), Undre S.\(^4\), Bogaert G.\(^5\), Dogan H.S.\(^6\), Kocvara R.\(^7\), Nijman R.J.M.\(^3\), Radmayr C.\(^8\), Tekgul S.\(^6\), Stein R.\(^9\)

1. Division of Pediatric Urology, Istanbul Medeniyet University, Dept. of Urology, Istanbul, Turkey,
2. Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands,
3. University Medical Centre Groningen, Dept. of Urology and Pediatric Urology, Groningen, The Netherlands,
4. East and North Herts NHS Trust, Dept. of Pediatric and Adult Urology, Stevenage, United Kingdom,
5. University of Leuven, Dept. of Urology, Leuven, Belgium,
6. Division of Pediatric Urology, Hacettepe University, Dept. of Urology, Ankara, Turkey,
7. General Teaching Hospital and Charles University 1st Faculty of Medicine in Praha, Dept. of Urology, Prague, Czech Republic,
8. Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria,
9. University of Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Dept. of Pediatric, Adolescent and Reconstructive Urology, Mannheim, Germany

### PT333

**EVOLVE: Designing a model of meaningful patient involvement in guideline development**

By: Björkqvist J.E.\(^1\), MacLennan S.\(^1\), Giles R.H.\(^2\), Comford P.\(^3\), MacLennan S.J.\(^4\)

1. Academic Urology Unit, University of Aberdeen, Aberdeen, United Kingdom,
2. Regenerative Medicine Centre Utrecht, University Medical Centre Utrecht, Dept. of Nephrology and Hypertension, Utrecht, The Netherlands,
3. Royal Liverpool University Hospitals Trust, Dept. of Urology, Liverpool, United Kingdom,
4. Urological Cancer Charity, Foresterhill Health Centre, Aberdeen, United Kingdom
PT334  Continent catheterisable tubes/stomas in adult neuro-urological patients: A systematic review


1Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Paris 6 University, Department of Urology, Paris, France, 2La Conception Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Department of Urology, Marseille, France, 3Erasmus Medical Center, Department of Urology, Rotterdam, The Netherlands, 4Careggi University Hospital, Department of Neuro-Urology, Florence, Italy, 5Hospital Universitario de Canario, Universidad de La Laguna, Department of Urology, Tenerife, Spain, 6London Spinal Injuries Centre, Department of Neuro-Urology, London, United Kingdom, 7Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, Department of Neuro-Urology, Zürich, Switzerland, 8University of Bern, Inselspital, Department of Urology, Bern, Switzerland, 9Swiss Paraplegic Center, Department of Neuro-Urology, Nottwil, Switzerland

PT335  Benefits and harms of electrical neuromodulation for chronic pelvic pain: A systematic review

By: Cottrell A.1, Schneider M.P.2, Goonewardene S.3, Baranowski A.P.4, Engeler D.E.5, Borovicka J.5, Dinis-Oliveira P.6, Elneil S.7, Yuan C.8, Hughes J.9, Messelink E.J.10, De C Williams A.C.11

1Royal Devon & Exeter Hospital, Department of Urology, Exeter, United Kingdom, 2University Hospital Berne, Department of Urology, Berne, Switzerland, 3The Royal Free and UCL, Department of Urology, London, United Kingdom, 4National Hospital for Neurology and Neurosurgery, UCL, Department of Neurology, London, United Kingdom, 5St. Gallen Hospital, Department of Urology, St. Gallen, Switzerland, 6University Institute of Health Sciences - CESPU/Faculty of Medicine, University of Porto, Department of Urology, Porto, Portugal, 7University College Hospital and the National Hospital for Neurology and Neurosurgery, Department of Gynaecology, London, United Kingdom, 8Health Science Centre, McMaster University, Hamilton, Department of Medicine, Ontario, Canada, 9James Cook University Hospital, Department of Anaesthesia, Middlesbrough, United Kingdom, 10University of Groningen Hospital, Department of Urology, Groningen, The Netherlands, 11Educational & Health Psychology UCL, Department of Psychology & Lang Sciences, London, United Kingdom

PT336  Diagnosis and management of paediatric urolithiasis: A contemporary review and update on behalf of the EAU Urolithiasis Guidelines Panel

By: Grivas N.1, Drake T.2, Neisius A.3, Petřík A.4, Seitz C.C.5, Skolarikos A.6, Türk C.7, Donaldson J.8, Ruhayel Y.9, Thomas K.10

1Cancer Institute-Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 2Southmead Hospital, Dept. of Urology, Bristol, United Kingdom, 3Hospital of the Brothers of Mercy, Johannes Gutenberg University Mainz, Dept. of Urology, Trier, Germany, 4First Faculty of Medicine, Charles University in Prague, Dept. of Urology, Prague, Czech Republic, 5Vienna General Hospital, Medical University of Vienna, Dept. of Urology, Vienna, Austria, 6Sismanoglio Hospital, National and Kapodistrian University of
Indication for a single postoperative instillation of chemotherapy in non-muscle-invasive bladder cancer: What factors should be considered?


¹Hospital Motol, Second Faculty of Medicine, Charles University, Dept. of Urology, Prague, Czech Republic, ²Caritas St. Josef Medical Centre, University of Regensburg, Dept. of Urology, Regensburg, Germany, ³Hôpital Tenon, AP-HP, Sorbonne University, Dept. of Pathology, Paris, France, ⁴San Giovanni Battista Hospital, Città della Salute e della Scienza, University of Turin, Dept. of Urology, Turin, Italy, ⁵Royal Surrey County Hospital, Dept. of Urology, Guilford, United Kingdom, ⁶Fundació Puigvert, Universidad Autónoma de Barcelona, Dept. of Urology, Barcelona, Spain, ⁷Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ⁸Hôpital La Pitié-Salpêtrière, AP-HP, Sorbonne University, Dept. of Urology, Paris, France, ⁹Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria, ¹⁰European Association of Urology, Guidelines Office, Brussels, Belgium, ¹¹Medical University of Graz, Dept. of Urology, Graz, Austria, ¹²General University Hospital, First Faculty of Medicine, Charles University, Dept. of Urology, Prague, Czech Republic, ¹³Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, ¹⁴Fundación Instituto Valenciano de Oncología, Servicio de Urología, Valencia, Spain, ¹⁵Hospital Universitario Fundación Alcorcón, Dept. of Urology, Madrid, Spain, ¹⁶CHU de Rennes, Service d’Urologie, Rennes, France

Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: Results from a European Multicentre Database (RECUR)

By: Dabestani S.¹, Beisland C.², Stewart G.D.³, Bensalah K.⁴, Gudmundsson E.⁵, Lam T.B.⁶, Gietzmann W.⁷, Zakikhani P.⁸, Marconi L.⁹, Fernández-Pello S.¹⁰, Monagas S.¹¹, Williams S.P.¹², Torbrand C.¹, Powles T.¹³, Van Werkhoven E.¹⁴, Meijer R.¹⁵, Volpe A.¹⁶, Staehler M.¹⁷, Ljungberg B.¹⁸, Bex A.¹⁹

¹Lund University, Skane University Hospital, Department of Clinical Sciences, Lund, Sweden, ²Haukeland University Hospital, Department of Urology, Department of Clinical Medicine, Bergen, Norway, ³University of Cambridge, Academic Urology Group, Department of Surgery, Cambridge, United Kingdom, ⁴University of Rennes, Department of Urology, Rennes, French Guiana, ⁵Landspitali University Hospital, Department of Urology, Reykjavik, Iceland, ⁶Aberdeen Royal Infirmary, University of Aberdeen, Academic Urology Unit, Department of Urology, Aberdeen, United Kingdom, ⁷University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁸Aberdeen Royal Infirmary, Department of Urology, Aberdeen, United Kingdom, ⁹Coimbra University
An international collaborative study from the EAU and ESMO to develop consensus statements for muscle invasive bladder cancer

1University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 2Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, 3European Association of Urology, Guidelines Office, Arnhem, The Netherlands, 41st Faculty of Medicine, Charles University and General University Hospital, Dept. of Urology, Prague, Czech Republic, 5Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; MIM-Hospital del Mar Medical Research Institute, Dept. of Oncology, Barcelona, Spain, 6Division of Cancer Medicine, University of Manchester and Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust, University of Manchester and The Christie Hospital, Manchester, United Kingdom, 7University Hospitals Birmingham NHS Foundation Trust, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, 8Hospital Clinic, Dept. of Urology, Barcelona, Spain, 9Charité University Hospital, Dept. of Oncology, Berlin, Germany, 10Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria, 11Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, 12The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, Dept. of Oncology, London, United Kingdom, 13Erasmus Medical Centre, Dept. of Pathology, Rotterdam, The Netherlands, 14Amsterdam UMC, University of Amsterdam, location AMC, Dept. of Urology, Amsterdam, The Netherlands, 15Bichat-Claude Bernard Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 16University Hospitals KU Leuven, Dept. of Urology, Leuven, Belgium, 17Academic Urology Unit, University of Aberdeen, Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, 18The Institute of Cancer Research, Dept. of Oncology, London, United Kingdom

An international collaborative study to develop consensus statements for deferred treatment with curative intent for localised prostate cancer

By: MacLennan S. 1, Lam T.B. 1, Irani J. 2, Plass K. 3, Willemse P.M. 4, Mason M. 5, Cornford P. 6, NDow J. 1, Van Poppel H.P.A.M. 7, Mottet N. 8, DETECTIVE Study group
PT341

**Management of localised prostate cancer in kidney transplant patients: A systematic review from the EAU Guidelines on renal transplantation panel**

By: Hevia Palacios V.\(^1\), Boissier R.\(^2\), Rodríguez-Faba O.\(^3\), Fraser-Taylor C.\(^4\), Hassan-Zakri R.\(^5\), Lledó García E.\(^6\), Regele H.\(^7\), Budde K.\(^8\), Figueiredo A.\(^9\), Olsburgh J.\(^5\), Breda A.\(^3\)

\(^1\)Hospital Universitario Ramón y Cajal, Alcalá University Madrid, Urology and Kidney Transplant Department, Madrid, Spain, \(^2\)La Conception University Hospital, Assistance-Publique Marseille, Aix-Marseille University, Department of Urology and Kidney Transplantation, Marseille, France, \(^3\)Fundacion Puigvert, University Autonoma of Barcelona, Department of Urology, Barcelona, Spain, \(^4\)St Georges NHS Trust Hospitals, Department of Urology and Transplant, London, United Kingdom, \(^5\)Guy's & St Thomas' NHS Trust Hospitals, Department of Transplant and Urology, London, United Kingdom, \(^6\)Hospital General Universitario Gregorio Marañón, Department of Urology, Madrid, Spain, \(^7\)Medical University of Vienna, Clinical Institute of Pathology, Vienna, Austria, \(^8\)Charité Medical University Berlin, Department of Nephrology, Berlin, Germany, \(^9\)Coimbra University Hospital, Department of Urology and renal Transplantation, Coimbra, Portugal

PT342

**PIONEER’s update and integration of a localised prostate cancer core outcome set for effectiveness trials and a standard set for clinical practice**

By: Beyer K.\(^1\), Maclellan S.\(^2\), Lardas M.\(^3\), Morris L.\(^4\), Omar M.I.\(^2\), Flaherty S.\(^5\), Antunes-Lopes T.\(^6\), Pacheco-Figueiredo L.\(^6\), Monagas S.\(^7\), Esperto F.\(^8\), Briganti A.\(^9\), Van Hemelrijck M.\(^1\)

\(^1\)Kings College London, Translational and Oncology Research (TOUR), London, United Kingdom, \(^2\)University of Aberdeen, Academic Urology Unit, Health Services Research Unit, Aberdeen, United Kingdom, \(^3\)Leto Hospital, Department of Urology, Athens, Greece, \(^4\)University Hospitals Leuven, Department of Urology, Leuven, Belgium, \(^5\)International Consortium for Health Outcomes Measurement, ICHOM, Cambridge, United States of America, \(^6\)Hospital de São João, Department of Urology, Porto, Portugal, \(^7\)Leon University Hospital, Department of Urology, Leon, Spain, \(^8\)Humanitas Gavazzeni, Department of Urology, Bergamo, Italy, \(^9\)University Vita e Salute-San Raffaele, Department of Urology, Milan, Italy

PT343

**Effectiveness and harms of using kidneys with small renal tumors from deceased or living donors as a source of renal transplantation: A systematic review**

By: Hevia Palacios V.\(^1\), Hassan Zakri R.\(^2\), Fraser-Taylor C.\(^3\), Bruins M.H.\(^4\), Boissier R.\(^5\), Lledó García E.\(^6\), Regele H.\(^7\), Budde K.\(^8\), Figueiredo A.\(^9\), Breda A.\(^10\), Yuan C.
PT344

A quality assessment of patient-reported outcome measures for sexual function in neurologic patients using the consensus-based standards for the selection of health measurement instruments checklist: A systematic review

By: 't Hoen L.A. 1, Groen J. 1, Scheepe J.R. 1, Reuvers S. 1, Castro Diaz D. 2, Padilla Fernández B. 2, Hamid R. 3, Ecclestone H. 3, Karsenty G. 4, Phé V. 5, Boissier R. 4, Kessler T. 6, Gross T. 7, Schneider M.P. 6, Del Popolo G. 8, Musco S. 8, Pannek J. 9, Blok B.F.M. 1

1Erasmus Medical Center, Department of Urology, Rotterdam, The Netherlands, 2University Hospital of the Canary Islands, Department of Urology, Tenerife, Spain, 3London Spinal Injuries Centre, Department of Neuro-Urology, Stanmore, United Kingdom, 4Aix Marseille University, Department of Urology, Marseille, France, 5National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, Department of Uro-Neurology, London, United Kingdom, 6Spinal Cord Injury Center and Research, University of Zürich, Balgrist University Hospital, Neuro-Urology, Zürich, Switzerland, 7University of Bern, Department of Urology, Bern, Switzerland, 8Careggi University Hospital, Department of Neuro-Urology, Florence, Italy, 9Swiss Paraplegic Center, Neuro-Urology, Nottwil, Switzerland

PT345

Long-term effectiveness and complication rates of bladder augmentation in patients with neurogenic bladder dysfunction: A systematic review

By: 't Hoen L.A. 1, Ecclestone H. 2, Blok B.F.M. 1, Karsenty G. 3, Phé V. 4, Boissier R. 3, Castro-Diaz D. 5, Padilla Fernández B. 5, Del Popolo G. 6, Musco S. 6, Pannek J. 7, Kessler T.M. 8, Gross T. 9, Schneider M. 8, Groen J. 1, Rizwan H. 2

1Erasmus Medical Center, Department of Urology, Rotterdam, The Netherlands, 2London Spinal Injuries Centre, Department of Urology, Stanmore, United Kingdom, 3Aix Marseille University, Department of Urology, Marseille, France, 4Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Paris 6 University, Department of Urology, Paris, France, 5Hospital Universitario de Canarias, Universidad de La Laguna, Department of Urology, Tenerife, Spain, 6Careggi University Hospital, Department of Neuro-Urology, Florence, Italy, 7Swiss Paraplegic Center, Neuro-Urology, Nottwil,
**PT346**

**The role of care pathways in urology: Vision of the European Association of Urology Guidelines Office**

By: Dimitropoulos K., Ribal Caparros M.J., van der Velden A., Plass K., Shepherd R., N'Dow J., Omar M.I.

1University of Aberdeen, Academic Urology Unit, Dept. of Urology, Aberdeen, United Kingdom, 2Hospital Clinic, Dept. of Urology, Barcelona, Spain, 3European Association of Urology, Guidelines Office, Arnhem, The Netherlands

**PT347**

**What are the benefits of empiric nutritional and medical therapy on the semen parameters, pregnancy rates and live birth rates in couples with idiopathic infertility? A systematic review and meta-analysis**


1European Association of Urology, Guidelines Office, Arnhem, The Netherlands, 2Nottingham Hospital, Dept. of Urology, Nottingham, United Kingdom, 3University Hospital Birmingham, Dept. of Urology, Birmingham, United Kingdom, 4Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, 5Health Sciences Centre, McMaster University, Division of Gastroenterology and Cochrane UGPD Group, Department of Medicine, Hamilton, Canada, 6University Hospital Giessen and Marburg GmbH, Campus Giessen, Justus-Liebig-University, Dept. of Urology, Paediatric Urology and Andrology, Giessen, Germany, 7University of Florence, Dept. of Experimental and Clinical Biomedical Sciences “Mario Serio”, Florence, Italy, 8Free University of Brussels, Centre for Reproductive Medicine, Brussels, Belgium, 9Semmelweis University, Andrology Centre, Dept. of Urology, Budapest, Hungary, 10EMCO Private Clinic, Urology and Andrology Unit, Bad Dürrnberg, Austria, 11Imperial College Health Care, Dept. of Mens Health and Andrology, London, United Kingdom

**PT348**

**Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A systematic review**


1Laboratory of Molecular Endocrinology, University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 2Antonius Hospital, Utrecht, Dept. of Urology, Utrecht, The Netherlands, 3Hospital Saint Luc Saint Joseph, Dept. of Urology, Lyon, France, 4University of Bern, Inselspital, Bern, Dept. of Urology, Bern, Switzerland, 5Hasselt, Belgium, 6University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, 7Charité University Hospital, Section for Interdisciplinary Genito-Urinary Cancer Medicine, Berlin, Germany, 8University
PT349

Treatment of bladder stones in adults: A systematic review and meta-analysis on behalf of the EAU Urolithiasis Guideline panel

By: Donaldson J.1, Ruhayel Y.2, MacLennan S.3, Yuan C.4, Shepherd R.5, Thomas K.6, Skolarikos A.7, Seitz C.8, Petrik A.9, Türk C.10, Neisius A.11

1Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, 2Skåne University Hospital, Dept. of Urology, Malmö, Sweden, 3University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 4McMaster University, Division of Gastroenterology & Cochrane UGPD Group, Department of Medicine, Health Sciences Centre, Hamilton, Canada, 5European Association of Urology, Guidelines Office, Arnhem, The Netherlands, 6Guy’s Hospital, Dept. of Urology, London, United Kingdom, 7Sismanoglio Hospital, Athens Medical School, Second Dept. of Urology, Athens, Greece, 8Medical University of Vienna, General Hospital of Vienna, Dept. of Urology, Vienna, Austria, 9Region Hospital, Dept. of Urology, České Budějovice, Czech Republic, 10Hospital of the Sisters of Charity, Dept. of Urology, Vienna, Austria, 11Hospital of the Brothers of Mercy Trier, Johannes Gutenberg University Mainz, Dept. of Urology, Trier, Germany

PT350

Practical recommendations of the EAU-ESPU guidelines for monosymptomatic nocturnal enuresis – bedwetting

By: Bogaert G.1, Undre S.2, Stein R.3, Nijman J.M.4, Quaedackers J.4, ’t Hoen L.A.5, Kočvara R.6, Silay M.S.7, Tekgül S.8, Radmayr C.9, Dogan H.S.8

1University of Leuven, Dept. of Urology, Leuven, Belgium, 2East and North Herts NHS Trust, Dept. of Pediatric and Adult Urology, Stevenage, United Kingdom, 3Heidelberg
Online professionalism - 2018 update of European Association of Urology (@Uroweb) commendations on the appropriate use of social media


1University of Medicine Johannes Gutenberg-University Mainz, Dept. of Urology, Mainz, Germany,
2University of California, San Francisco, Dept. of Urology, San Francisco, United States of America,
3Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia,
4New York University, Dept. of Urology and Population Health, New York, United States of America,
5University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom,
6University of Barcelona, Dept. of Urology, Hospital Clinic, Barcelona, Spain,
7University of Sydney, Sydney Adventist Hospital Clinical School, Sydney, Australia,
8La Pitié-Salpêtrière Hospital, Assistance-Publique Hôpitaux de Paris, Dept. of Urology, Paris, France,
9Fight Bladder Cancer, Oxfordshire, United Kingdom,
10Rijnstate Hospital, Arnhem, Dept. of Urology, Robotic Surgery, Arnhem, The Netherlands,
11University Hospital Carl Gustav Carus, Technische Universität Dresden, Dept. of Urology, Dresden, Germany,
12University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom,
13Temple University Health System, Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, United States of America
Aims and objectives of this session
This novel course will give a state of the art update on the variety of penile diseases that urologists will encounter in everyday clinical practice. The faculty consists of a group of internationally renowned experts in this field. A spectrum of pathologies can affect the penis including benign disorders to cancers. There will be particular focus on interactive case based discussions highlighting the pitfalls and controversies in management of penile diseases;

• The aetiology, diagnosis and medical management of the common penile diseases including inflammatory conditions of the penis.
• The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis.
• The medical and surgical management of Peyronie's disease.
• The course will also deal with the surgical management of these diseases including the surgical indications and surgical techniques used in penile reconstructive surgery.
• The management of penile carcinoma including the aetiology, techniques/outcome of organ sparing surgery and surgical management of advanced disease including lymphadenectomy will be discussed.
### Percutaneous nephrolithotripsy (PCNL)

**ESU Course 50**

**Monday 18 March**

**12:00 - 15:00**

**Location:** Green Area, Room 14

**Chair:** E. Liatsikos, Patras (GR)

#### Aims and objectives of this session

Aim of this course is to describe in detail the surgical techniques of all available treatment options in percutaneous surgery of renal stones. In addition, to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on their prevention and proper management.

#### Objectives

- Describe the basic percutaneous nephrolithotripsy techniques.
- Provide tips to improve the efficacy of the operation.
- Provide evidence on the comparison of percutaneous with ureteroscopic and extracorporeal treatment options; Which approach for which stone.
- Describe associate complications including their management.

#### Guidelines on stone treatment

T. Knoll, Sindelfingen (DE)

#### PCNL instrumentation – Suite organisation, wires, dilators and lithotriptors

C.M. Scoffone, Turin (IT)

#### From Skin to Stone: Step-by-Step access using only fluoroscopy (Prone position)

E. Liatsikos, Patras (GR)

#### From Skin to Stone: Step-by-Step access using US and fluoroscopy (Supine position)

C.M. Scoffone, Turin (IT)

#### MiniPerc- Indications, equipment and technique

T. Knoll, Sindelfingen (DE)

#### Tips and tricks in PCNL

E. Liatsikos, Patras (GR)

#### Round table: Complications of PCNL: Diagnosis, management, prevention

E. Liatsikos, Patras (GR)
T. Knoll, Sindelfingen (DE)
C.M. Scoffone, Turin (IT)
Aims and objectives of this session
This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained on a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well. Don’t miss this course, a must for all robotic surgeons!:
  • Video based step-by-step approach.
  • Standard techniques.
  • Complex cases.
  • Troubleshooting and complication management.
  • Technical innovations: What’s new in robotics?

Introduction
A. Mottrie, Aalst (BE)

Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery
B.J. Challacombe, London (GB)

Robotic pyeloplasty: Multichannel or single technique
N. Buffi, Milan (IT)

Renal surgery: Nephrectomy and nephroureterectomy: How I do it
B.J. Challacombe, London (GB)

Partial nephrectomy I: Step 1: Isolation of renal hilum; Step 2: Mobilisation of the kidney; Step 3: Clamping of renal pedicle: Different techniques
N. Buffi, Milan (IT)

Partial nephrectomy II: Step 4: Different tumour resection techniques
A. Mottrie, Aalst (BE)

Partial nephrectomy III: Step 5: Different renorraphy techniques
B.J. Challacombe, London (GB)

Partial nephrectomy IV: Special & difficult indications
A. Mottrie, Aalst (BE)

Partial nephrectomy V: Complication management and new tools
A. Mottrie, Aalst (BE)
Wrap up and conclusions
B.J. Challacombe, London (GB)
**Male urinary incontinence management**
ESU Course 48

**Location:** Green Area, Room 16
**Chair:** E. Chartier-Kastler, Paris (FR)

**Aims and objectives of this session**
- To review:
  - mechanisms of continence in men.
  - mechanisms of post-surgical incontinence in men.
- To analyse symptoms and to indicate conservative treatment.
- To be able to select one surgical treatment, referring to literature and guidelines.
- To learn about long term follow-up of each surgical technique and to be able to deliver the best and objective information to patients.

**Introduction: Focus on SUI**
E. Chartier-Kastler, Paris (FR)

**Prevalence/Aetiology/anatomy**
F. Van Der Aa, Leuven (BE)

**Workout of post-surgical incontinence**
E. Chartier-Kastler, Paris (FR)

**Conservative treatment for post-surgical incontinence**
F. Van Der Aa, Leuven (BE)

**Surgical treatment for post-surgical incontinence**

**Alternatives to artificial urinary sphincter (AUS)**
S. Arlandis Guzman, Valencia (ES)

**Artificial urinary sphincter (AUS)**
E. Chartier-Kastler, Paris (FR)

**Pelvic floor radiotherapy and SUI**
S. Arlandis Guzman, Valencia (ES)

**Clinical cases**

**Open questions**

**Conclusion: Key points**
F. Van Der Aa, Leuven (BE)
Aims and objectives of this session
Having attended the course, the attendee should:
• Understand the basic physical principles referable to urodynamics.
• Be able to assess the quality of a urodynamic trace.
• Recognise common artefacts and know how to correct them.
• Know the indications for urodynamic studies in men, women and neurological patients.

Urodynamics: Philosophy, scientific basis and technique
P. Abrams, Bristol (GB)

Urodynamics in neurourology
J.L.H.R. Bosch, Utrecht (NL)

Urodynamics in female urology
P. Abrams, Bristol (GB)

Urodynamics in men
J.L.H.R. Bosch, Utrecht (NL)
### Advanced course on upper tract laparoscopy: Kidney, UPJ, ureter and stones
#### ESU Course 53

**Location:** Green Area, Room 22  
**Chair:** G. Janetschek, Salzburg (AT)

**Monday 18 March**  
**12:00 - 15:00**

#### Aims and objectives of this session
Surgery of the kidney by means of laparoscopy is standard of care, and has replaced open surgery to a great extent.  
**Approach:** Transperitoneal, retroperitoneoscopy, posterior, direct through the mesentery of the colon. Each approach has specific advantages also depending on the procedure to be performed.  
**Procedures:** Ablative, reconstruction, stone surgery.  
**Presentation:** Power-point, interactive, videos, tips and tricks, complications.

- For surgery of the kidney, the daVinci robot is often an overkill. Also it is not available everywhere. Therefore standard laparoscopy is still of importance and should be mastered by every endoscopic surgeon.  
- Choice of the perfect approach makes the respective surgery easier and safer.  
- Standard laparoscopy is greatly facilitated by 3D vision.  
- When mastering both laparoscopic surgical skills as well as the surgical concept of the respective procedure complications can either be avoided or managed appropriately.

**Approach: Transperitoneal, retroperitoneoscopy**  
G. Janetschek, Salzburg (AT)

**Kidney: Nephrectomy, management of cysts**  
A. Alcaraz, Barcelona (ES)

**Ureter: Nephroureterectomy, end-to-end anastomosis, replacement**  
H. Baumert, Paris (FR)

**Pyeloplasty: Indication – techniques – problems**  
H. Baumert, Paris (FR)

**Stone surgery**  
A. Alcaraz, Barcelona (ES)

**Complication management**  
G. Janetschek, Salzburg (AT)

**Questions, tips and tricks**  
A. Alcaraz, Barcelona (ES)  
H. Baumert, Paris (FR)  
G. Janetschek, Salzburg (AT)
Office management of male sexual dysfunction
ESU Course 54

Location: Green Area, Room 23
Chair: C. Stief, Munich (DE)

Aims and objectives of this session
The course is aimed at providing practical advice on how to diagnose and treat a patient with
Premature ejaculation or ED. It will allow
• An up-to-date understanding of the aetiology of ED and EP,
• An adequate work up enabling an individually adopted regimen.
• Currently available treatment options as topical and oral drugs, testosterone and devices.
• Post-prostatectomy ED with various approaches.

Introduction
C. Stief, Munich (DE)

Diagnostics - What is necessary?
I. Eardley, Leeds (GB)

Testosterone replacement
C. Stief, Munich (DE)

Oral therapy for ED
I. Eardley, Leeds (GB)

Therapy of ED when pills fail
D.J. Ralph, London (GB)

Medical therapy for premature ejaculation
I. Eardley, Leeds (GB)

Surgical topics: Penile implants, priapism, Peyronie's
D.J. Ralph, London (GB)

What to do after radical prostatectomy?
C. Stief, Munich (DE)
Advancements in benign prostatic hyperplasia treatment and prostate biopsy

Video Session 10

Monday 18 March 12:15 - 13:45

Location: Red Area, eURO Auditorium 1

Chairs: J-N.L. Cornu, Rouen (FR)
F. Gomez Sancha, Madrid (ES)
To be confirmed

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V67

First 3D holmium laser enucleation of the prostate (3D-HoLEP)

By: Sanchez Macias J. ¹, Franco M. ¹, Pardo A. ², Camacho Rovira D. ¹, Calaf O. ³, Mercader C. ¹, Alcaraz A. ¹

¹Hospital Clinic, Dept. of Urology, Barcelona, Spain, ²Laseralia, C.E.O., Barcelona, Spain, ³hospital Germans Trias, Dept. of Urology, Badalona, Spain

Aims and objectives of this presentation

V68

Urethra and ejaculation preserving robot-assisted simple prostatectomy: Near infrared fluorescence imaging-guided Madigan technique

By: Simone G., Misuraca L., Anceschi U., Minisola F., Ferriero M., Guaglianone S., Tuderti G., Gallucci M.

Regina Elena National Cancer Institute, Dept.of Urology, Rome, Italy

Aims and objectives of this presentation

V69

Transurethral bipolar-plasmakinetic endoscopic enucleation of prostate exceeding 200g: Tips ans tricks with 24 cases results

By: Zou Z., Liang C.

The First Affiliated Hospital of Anhui Medical University, Dept. of Urology, Heifei, China

Aims and objectives of this presentation

V70

Holmium laser enucleation of the prostate: Tips and tricks to reduce incontinence

By: Maheshwari P. ¹, Chaurasia A. ¹, Okwi N. ², Mukasa N.V. ³

¹Fortis Hospital Mulund, Dept. of Urology, Mumbai, India, ²Busitema University, Dept. of Surgery, Faculty of Health Sciences , Busetima, Uganda, ³Mulago National Hospital,
Aims and objectives of this presentation

Endoscopic enucleation of the prostate: A step by step approach

By: Enikeev D., Rapoport L., Taratkin M., Glybochko P.
Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia

Freehand MRI/US cognitive fusion transperineal biopsy of the prostate in local anesthesia: A video demonstration

By: Shahin O., Kwiatkowski M., Wyler S.
1Uromerian.ch, Praxis an der Merian Iselin Klinik, Basel, Switzerland, 2Kantonsspital Aarau, Dept. of Urology, Aarau, Switzerland

Local anaesthetic transperineal prostate (LATP) biopsy using the precision point access system: A step-by-step video

By: Campbell A., Omer A., Popert R., Lamb A.
1University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, 2Guys Hospital, Dept. of Urology, London, United Kingdom
Minimising the risk of treatment in candidates for cystectomy
Poster Session 60

Monday 18 March
12:15 - 13:45

Location: Red Area, eURO Auditorium 2

Chairs: P. Black, Vancouver (CA)
J. Cresswell, Middlesbrough (GB)
P. Zehnder, Sursee (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

835

The role of cutaneous ureterostomy diversion: A multicenter analysis

By: Laura I. ¹, Lombardo R. ², Tema G. ², Cancrini F. ², Lotrecchiano G. ³, Minervini A. ⁴, Simone G. ⁵, Cindolo L. ⁶, D’Orta C. ⁶, Ajami T. ¹, Antonelli A. ⁷, Castellani D. ⁸, Alcaraz A. ¹, De Nunzio C. ²

¹Hospital Clinic of Barcelona, Urology, Dept. of Urology, Barcelona, Spain, ²Sapienza University of Rome, Sant'Andrea, Dept. of Urology, Rome, Italy, ³AORN “Rummo” Hospital, Dept. of Urology, Benevento, Italy, ⁴University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ⁵IFO, Istituto Nazionale Tumori Regina Elena Hospital, Dept. of Urology, Rome, Italy, ⁶San Pio da Pietralcina Hospital, Dept. of Urology, Vasto, Italy, ⁷Spedali Civili di Brescia Hospital, Dept. of Urology, Brescia, Italy, ⁸INRCA Hospital, Dept. of Urology, Ancona, Italy

836

Utility of serum markers in the assessment of perioperative and postoperative morbidity and mortality after radical cystectomy for muscle invasive bladder cancer

By: Claps F., Pavan N., Rizzo M., Boltri M., Migliozzi F., Liguori G., Trombetta C.
Urology Clinic, Dept. of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy

837

Impact of the number of radical cystectomies per hospital on 90-day mortality in Spain

By: Guijarro Cascales A. ¹, Llorente C. ¹, Hernandez V. ¹, Pérez-Fernández E. ², Fernández-Conejo G. ¹, De La Peña E. ¹

¹Hospital Universitario Fundación Alcorcón, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Fundación Alcorcón, Research, Madrid, Spain

838

Relative importance of the components of an eras protocol after radical cystectomy based on a multicenter prospective study (PRORAC)

By: Llorente C. ¹, Guijarro A. ¹, Passas J. ², Aguilar L. ², Hernandez C. ³, Moralejo M. ³, Gonzalez Enguita C. ⁴, Husillos A. ⁴, Ortiz F. ⁵, Sanchez Chapado M. ⁵, Carballido J. ⁶, Castillón I. ⁶, Mateo E. ⁷, Romero I. ⁷, Fernández Del Álamo J. ⁸, Llanes L. ⁸,
839 Long term survival after radical cystectomy with respect to centralisation: Outcomes from 1110 patients treated at a single high-volume centre
By: Pang K.H.¹, Novara G.H.², Din O.S.³, Morgan S.L.⁴, Noon A.P.⁵, Catto J.W.F.¹
¹University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, ²University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ³Sheffield Teaching Hospitals NHS Foundation Trust, Cancer Research Centre, Sheffield, United Kingdom, ⁴Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Histopathology, Sheffield, United Kingdom, ⁵Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Sheffield, United Kingdom

840 Tetra-modality bladder sparing therapy can be a viable treatment option for muscle-invasive bladder cancer patients with sarcopenia
Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

841 Association of super extended lymphadenectomy at radical cystectomy with perioperative complications
By: D’Andrea D., Soria F., Gust K., Seitz K., Fajkovic H., Remzi M., Shariat S.
Medical University of Vienna, Dept. of Urology, Vienna, Austria

842 Association between antiplatelet or anticoagulant therapy and perioperative morbidity in patients undergoing radical cystectomy for urinary bladder cancer
By: Vetterlein M.W., Gild P., Bradtke M., Klemm J., Janisch F., Soave A., Dahlem R., Fisch M., Rink M.
University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

843 Comparative effectiveness of robotic assisted and open radical cystectomy in contemporary cohorts of bladder cancer patients: An international multicenter collaboration
1Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 2Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria, 3Bichat Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 4Division of Surgery and Intervention Science, University College London, University College London Hospital, Dept. of Urology, London, United Kingdom, 5IRCCS, Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 6Hartford Healthcare Medical Group, Urology Division, Hartford, United States of America, 7University of Minnesota, Dept. of Urology, Minneapolis, United States of America, 8Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, 9Urological Research Institute, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, 10University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 11University Medical Center Rostock, Dept. of Urology, Rostock, Germany, 12University of Montreal Health Centre, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 13Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Dept. of Urology, Paris, France, 14Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA, Dept. of Urology, New York, United States of America, 15La Croix du Sud, Dept. of Urology, Toulouse, France, 16University College London Hospital NHS Foundation Trust, Dept. of Uro-Oncology, London, United Kingdom, 17Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

844 Optimizing outcomes reporting after robot-assisted radical cystectomy: External validation of the USC-Pentafecta


Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

845 Clinical recurrence after radical cystectomy for bladder cancer, defining optimal surveillance after surgery


Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, Mayo Clinic, Dept. of Urology, Rochester, United States of America, Urological Research Institute, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, European Institute of Oncology, Dept. of Urology, Milan, Italy, Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy
847  The impact of acute kidney injury on renal impairment and cardiovascular disease in patients with muscle invasive bladder cancer treated with radical cystectomy

By: Fujita N.¹, Momota M.¹, Tobisawa Y.¹, Yoneyama T.¹, Yamamoto H.¹, Imai A.¹, Hatakeyama S.¹, Ito H.², Yoneyama T.¹, Hashimoto Y.¹, Yoshikawa K.³, Ohyama C.¹

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, ³Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

848  ERAS concepts in the perioperative management of patients undergoing radical cystectomy for bladder cancer: Long-term-follow up and oncological outcome of a prospective randomized study

GROSSHADERN CLINICS, LMU, DEPT. OF UROLOGY, MUNICH, GERMANY

849  Feasibility of endoluminal partial cystectomy for urothelial cancer: First results from an animal hybrid model

By: Aufderklamm S.¹, Kruck S.², Hoffmans T.¹, Aicher W.K.¹, Hennenlotter J.¹, Scharpf M.³, Stenzl A.¹, Amend B.¹

¹Eberhard Karls University, Dept. of Urology, Tübingen, Germany, ²Helios Klinikum Pforzheim, Dept. of Urology, Pforzheim, Germany, ³Eberhard Karls University, Dept. of Pathology, Tübingen, Germany
**Novel compounds in prostate cancer therapies**

**Poster Session 61**

**Monday 18 March**

**Location:** Green Area, Room 1

**Chairs:** To be confirmed

C.P. Evans, Sacramento (US)
C. Thomas, Dresden (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**850**

**Novel mechanism of bone metastasis mediated by exosomes derived from metastatic prostate cancer**

By: Urabe F. 1, Kosaka N. 1, Yamamoto Y. 1, Kimura T. 2, Egawa S. 2, Ochiya T. 1

1National Cancer Center Research Institute, Division of Molecular and Cellular Medicine, Tokyo, Japan
2The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan

---

**851**

**KIFC1 inhibitor CW069 induces apoptosis and reverses resistance to docetaxel in prostate cancer**

By: Sekino Y. 1, Koike Y. 2, Sakamoto N. 2, Shiota M. 3, Shigematsu Y. 1, Sentani K. 2, Oue N. 2, Teishima J. 1, Yasui W. 2, Matsubara A. 1

1Hiroshima University Graduate School of Biomedical and Health Sciences, Dept. of Urology, Hiroshima, Japan
2Hiroshima University Graduate School of Biomedical and Health Sciences, Dept. of Molecular Pathology, Hiroshima, Japan
3Kyushu University, Dept. of Urology, Fukuoka, Japan

---

**852**

**Iron induces ferroptosis and synergizes with anti-androgen therapy in prostate cancer pre-clinical models**

By: Campanella A. 1, Bordini J. 1, Morisi F. 2, Elia A.R. 3, Cucchiara V. 4, Bellone M. 3, Camaschella C. 2, Brigantti A. 4

1Vita-Salute San Raffaele University, Dept. of Experimental Oncology, Milan, Italy
2IRCCS Ospedale San Raffaele, Dept. of Genetics and Cell Biology, Milan, Italy
3IRCCS Ospedale San Raffaele, Dept. of Immunology, Transplantation and Infectious Diseases, Milan, Italy
4IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Dept. of Experimental Oncology/Unit of Urology, URI, Milan, Italy

---

**853**

**A novel three-dimensional cell culture model based on the composite dacron/collagen scaffold for prostate cancer**

By: Hu M. 1, Liu X. 2, Li C. 2, Ding Q. 1, Wang L. 2, Jiang H. 1

1Huashan Hospital, Fudan University, Dept. of Urology, Shanghai, China
2Donghua
Establishment of an androgen-sensitive patient derived xenograft model of prostate cancer

By: Karkampouna S.1, Grosjean J.1, Klima I.1, Genitsch V.2, Sboner A.3, K. Y. Ng C.4, De Filippo M.R.5, Piscuoglio S.5, Spahn M.6, Rubin M.A.1, Thalmann G.N.7, Kruithof-De Julio M.1

1University of Bern, Dept. of BioMedical Research, Bern, Switzerland, 2University of Bern, Institute of Pathology, Bern, Switzerland, 3Institute for Computational Biomedicine, Dept. of Pathology and Laboratory Medicine, Bern, Switzerland, 4University of Basel, Dept. of Biomedicine, Basel, Switzerland, 5University of Basel, Institute of Pathology, Basel, Switzerland, 6Centre for Urology Hirslanden Clinic, Dept. of Urology, Zurich, Switzerland, 7University Hospital of Bern, Dept. of Urology, Bern, Switzerland

Prostate cancer-derived anti-GRP78 autoantibodies compromise the blood-brain barrier and accelerate atherosclerosis progression in vivo

By: Al-Hashimi A.1, Won K.2, Austin R.2, Shayegan B.3

1McMaster University, Dept. of Surgery - Division of Urology, Hamilton, Canada, 2McMaster University, Dept. of Medicine, Hamilton, Canada, 3McMaster University, Dept. of Surgery - Division of Urology, Hamilton, Canada

Cripto blockade reduces prostate cancer reactivity to microenvironment and metastatic potential

By: La Manna F.1, Staender L.1, Gray P.C.2, Zoni E.1, Karkampouna S.1, Thalmann G.N.3, Kruithof-De Julio M.1

1University of Bern, Dept. of BioMedical Research, Bern, Switzerland, 2The Salk Institute for Biological Studies, Clayton Foundation Laboratories for Peptide Biology, San Diego, United States of America, 3University Hospital of Bern, Dept. of Urology, Bern, Switzerland

Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells

By: Iwamoto H., Izumi K., Kadono Y., Mizokami A.
Kanazawa University Graduate School of Medical Science, Dept. of Integrative Cancer Therapy and Urology, Kanazawa, Japan

Anti-tumor effect of oncolytic reovirus in castration resistance prostate cancer: In vitro and in vivo analysis

By: Han J.H., Kim Y., Kim B.M., Choi S.Y., Lim B., Kyung Y.S., You D., Kim C-S.
Asan Medical Center, Dept. of Urology, Seoul, South Korea

Niclosamide exerts anticancer activity via inhibition of FOXM1-mediated DNA damage response in castration resistant prostate cancer
Overcoming ABCB1-mediated olaparib resistance in advanced prostate cancer

By: Gao A., Lombard A., Liu C., Lou W., Armstrong C., Dall M., Evans C.
University of California Davis, Dept. of Urology, Sacramento, United States of America

Impact of CT guided high-dose prostate irradiation on rodent gland regeneration

By: Zahalka A.H., Brodin P., Maryanovich M., Watts K.L., Guha C., Frenette P.S.
1Albert Einstein College of Medicine, Dept. of Cell Biology, New York City, United States of America, 2Albert Einstein College of Medicine, Dept. of Radiation Oncology, New York City, United States of America, 3Montefiore Medical Center, Dept. of Urology, New York City, United States of America, 4Albert Einstein College of Medicine, Dept. of Stem Cell and Regenerative Medicine, New York City, United States of America

Conclusion
**Indications and oncological outcomes of the use of neoadjuvant targeted therapy in patients with localized kidney cancer**

By: Voylenko O., Stakhovskyi O., Kononenko O., Pikul M., Semko S., Vitruk I., Stakhovsky E.
National Cancer Institute, Dept. of Plastic and Reconstructive OncoUrology, Kiev, Ukraine

**Aims and objectives of this presentation**

**Three dimensional volumetrics of inferior vena cava tumor thrombus predicts surgical outcomes**

1University of Southern California, USC Institute of Urology, Los Angeles, United States of America, 2University of Southern California, USC Institute of Radiology, Los Angeles, United States of America, 3University of Verona, Dept. of Urology, Verona, Italy

**Aims and objectives of this presentation**

**Who is dying after nephrectomy for cancer? Study of risk factors and causes of death after analyzing morbidity and mortality reviews (UroCCR-33 study)**

By: Fontenil A., Bigot P., Bensalah K., Mejean A., Soulié M., Bernhard J.C., Salomon L., Charles T., Azzouzi R., Larre S.
1CHU Angers, Dept. of Urology, Angers, France, 2CHU Rennes, Dept. of Urology, Rennes, France, 3Hôpital Georges Pompidou, Dept. of Urology, Paris, France, 4CHU Toulouse, Dept. of Urology, Toulouse, France, 5CHU Bordeaux, Dept. of Urology, Bordeaux, France, 6CHU Henri Mondor, Dept. of Urology, Paris, France, 7CHU Poitiers, Dept. of Urology, Poitiers, France, 8CHU Reims, Dept. of Urology, Reims, France
866

Aims and objectives of this presentation

867

A retrospective national database review analysing post-operative mortality of renal surgery in Australia

By: Brien SM ¹, Maddern G.J. ², Catterwell R. ², Herath M. ³
¹The Queen Elizabeth Hospital, Dept. of Surgery, Adelaide, Australia, ²The Queen Elizabeth Hospital, Dept. of Urology, Adelaide, Australia, ³Walkerville, Australia

Aims and objectives of this presentation

868

Should stage III renal cell carcinoma with pN1 be classified as stage IV of the American Joint Committee on Cancer classification? A RECUR external validation

¹Lund University, Dept. of Clinical Sciences Lund, Lund, Sweden, ²Haukeland University Hospital and University of Bergen, Dept. of Urology and Dept. of Clinical Medicine, Bergen, Norway, ³University of Cambridge, Dept. of Surgery, Academic Urology Group, Cambridge, United Kingdom, ⁴San Raffaele Scientific Institute and IRCCS San Raffaele Hospital, Dept. of Urology and Division of Experimental Oncology/Unit of Urology, IR, Milan, Italy, ⁵Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁶University of Rennes, Dept. of Urology, Rennes, France, ⁷Landspitali University Hospital, Dept. of Urology, Reykjavik, Iceland, ⁸University of Aberdeen and Aberdeen Royal Infirmary, Academic Urology Unit and Dept. of Urology, Aberdeen, United Kingdom, ⁹Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, ¹⁰Cabueñes University Hospital, Dept. of Urology, Gijón, Spain, ¹¹San Agustin University Hospital, Dept. of Urology, Aviles, Spain, ¹²Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, ¹³University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ¹⁴University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ¹⁵Ludwig Maximilians University of Munich, Dept. of Urology, Clinic Grosshadern, Munich, Germany, ¹⁶Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ¹⁷The Netherlands Cancer Institute, Division of Surgical Oncology, Dept. of Urology, Amsterdam, The Netherlands

Aims and objectives of this presentation

869

Can components of full blood count (FBC) predict survival in patients with renal cell carcinoma (RCC)? A large cohort analysis of red cell distribution width (RDW)

St George's University Hospitals, Dept. of Urology, London, United Kingdom
**Impact of sex on prognosis of non-metastatic clear cell renal cell carcinoma patients undergoing curative surgery: An inverse probability of treatment weighting analysis**

By: Fukushima H.¹, Saito K.¹, Yasuda Y.¹, Tanabe K.¹, Toide M.¹, Fukuda S.¹, Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Patil D.², Cotta B.³, Patel S.³, Master V.², Derweesh I.³, Fujii Y.¹

¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ³University of California San Diego, Dept. of Urology, San Diego, United States of America

**The critical role of lymph node dissection in selecting high-risk non-metastatic renal cancer candidates for adjuvant therapy after nephrectomy**

By: Capogrosso P.¹, Larcher A.¹, Bravi C.A.¹, Nini A.², Dell'Oglio P.¹, Muttin F.¹, Cianflone F.¹, Baiamonte G.¹, Trevisani F.¹, Salonia A.¹, Bertini R.¹, Montorsi F.¹, Capitanio U.¹

¹Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Experimental Oncology, Milan, Italy, ²Universitätsklinikum Düsseldorf, Dept. of Urology, Düsseldorf, Italy

**External validation of the updated Leibovich prognostic models for prediction of oncologic outcomes in clear cell and papillary renal cell carcinoma**


Singapore General Hospital, Dept. of Urology, Singapore, Singapore

**Testing the external validity of CARMENA trial comparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma**

By: Arora S.¹, Sood A.¹, Dalela D.¹, Patel A.¹, Keeley J.¹, Trinh Q-D.², Audrey F.³, Prokopiv U.³, Rakic N.³, Rogers C.¹, Menon M.¹, Abdollah F.¹

¹Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, ²Brigham and Women's hospital, Dept. of Urological Surgery and Center for Surgery and Public Health, Boston, United States of America, ³Wayne State University School of Medicine, Medical School, Detroit, United States of America
Aims and objectives of this presentation

874

Does presence of bone metastases portend worsened prognosis in metastatic renal cell carcinoma? Analysis of the REMARCC (REgistry of MetAstatic RCC) database

By: Bradshaw A. 1, Mir M.C. 2, Autorino R. 3, Minervini A. 4, Kriegmair M. 5, Maurer T. 6, Porpiglia F. 7, Van Bruwaene S. 8, Linares E. 9, Hevia V. 10, Musquera M. 11, Rousel E. 12, Pavan N. 13, Antonelli A. 14, Zhang S. 15, Meagher M. 1, Rubio J. 16, Garuli G. 3, Tracy A. 3, Campi R. 4, Albertson M. 12, Furlan M. 14, Eldefrawy A. 1, Derweesh I. 1

1UC San Diego Health, Dept. of Urology, La Jolla, United States of America, 2Fundacion Instituto Valenciano Oncologia, Dept. of Urology, Valencia, Spain, 3VCU Medical Center, Dept. of Urology, Richmond, United States of America, 4University of Florence, Careggi Hospital, Florence, Italy, 5University Medical Centre Mannheim, Dept. of Urology, Mannheim, Germany, 6Technical University of Munich, Dept. of Urology, Munich, Germany, 7University of Turin San-Luigi, Gonzaga Hospital, Turin, Italy, 8AZ Groeninge, Dept. of Urology, Kortrijk, Belgium, 9Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain, 10Hospital Ramon y Cajal, Dept. of Urology, Madrid, Spain, 11Hospital Clinic, Dept. of Urology, Barcelona, Spain, 12KULeuven, Dept. of Urology, Leuven, Belgium, 13University of Trieste, Dept. of Urology, Trieste, Italy, 14University of Brescia, Spedali Civili Hospital, Brescia, Italy, 15Peking University, Third Hospital, Beijing, China, 16Fundacion Instituto Valenciano Oncologia, Urologia, Valencia, Spain

Aims and objectives of this presentation

875

Trends in the treatment of renal cell carcinoma metastases in the era of targeted therapies – a population based analysis in Germany

By: Meyer C.P. 1, Groeben C. 2, Koch R. 2, Rink M. 1, Huber J. 2

1University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2Medical Faculty Carl Gustav Carus, Technical University Dresden, Dept. of Urology, Dresden, Germany

Aims and objectives of this presentation

876

Systematic review of the role of pancreatic metastatectomy in metastatic renal cell carcinoma (mRCC)

By: Rodger F. 1, Nair R. 2, Holroyd D. 1

1Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, 2Guys and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation

877
ICS educational module: Cough stress test in the evaluation of female urinary incontinence: Introducing the ICS-Uniform cough stress test

By: Guralnick M.L.¹, Fritel X.², Tarcan T.³, Espuna-Pons M.⁴, Rosier P.F.W.⁵
¹Medical College of Wisconsin, Dept. of Urology, Milwaukee, United States of America, ²Universite de Poitiers, Dept. of Medicine and Pharmacy, Poitiers, France, ³Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ⁴University of Barcelona, ICGON, Barcelona, Spain, ⁵University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands

Comparison of longitudinal health-related quality of life outcomes between the anterior and posterior surgical approach to robot-assisted radical prostatectomy

Okayama University Graduate School of Medicine, Dept. of Urology, Okayama, Japan

Urinary incontinence with no obvious reason at 1 month after robot-assisted radical prostatectomy strongly predicts delayed continence recovery: The longitudinal survey of questionnaires

By: Kamei J.¹, Fujimura T.¹, Igawa Y.², Fukuhara H.³, Shinoda Y.⁴, Aizawa N.², Niimi A.⁵, Matsunaga A.⁴, Yoshida M.⁶, Yamada Y.⁵, Sugihara T.¹, Sato Y.⁵, Nakagawa T.⁷, Homma Y.⁸, Kume H.⁵
¹Jichi Medical University, Dept. of Urology, Tochigi, Japan, ²The University of Tokyo, Graduate School of Medicine, Dept. of Urology, Tokyo, Japan, ³Kyorin University, Dept. of Urology, Tokyo, Japan, ⁴The University of Tokyo, Graduate School of Medicine, Dept. of Rehabilitation, Tokyo, Japan, ⁵The University of Tokyo, Graduate School of Medicine, Dept. of Urology, Tokyo, Japan, ⁶The University of Tokyo, Graduate School of Medicine, Dept. of Gerontological Nursing/ Wound Care Management, Tokyo, Japan, ⁷Teikyo University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁸Japan Red Cross Hospital, Dept. of Urology, Tokyo, Japan
A prospective analysis of the effects of nerve-sparing robot-assisted radical prostatectomy on lower urinary tract symptoms

Tottori University Faculty of Medicine, Dept. of Urology, Yonago, Japan

Risk of prolapse and urinary complications in adult spina bifida patients with neurogenic acontractile detrusor using clean intermittent catheterization versus Valsalva voiding

By: El Akri M.1, Brochard C.2, Hascoet J.1, Jezequel M.2, Alimi Q.1, Khene Z.1, Richard C.1, Bonan I.2, Kerdraon J.2, Gamé X.3, Manunta A.1, Siproudhis L.2, Peyronnet B.1
1CHU Pontchaillou, Dept. of Urology, Rennes, France, 2CHU Pontchaillou, Spina Bifida Reference Center, Rennes, France, 3CHU Rangueil, Dept. of Urology, Toulouse, France

Does sacral neuromodulation have an effect on bladder sensations in patients with non-obstructive retention?

Maastricht University Medical Center +, Dept. of Urology, Maastricht, The Netherlands

Sarcopenia patients are clinically dissatisfied with postoperative urinary function compared with non-sarcopenia patients in robot-assisted radical prostatectomy

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan

Predictive factors for post-prostatectomy incontinence based on urodynamic evaluation

By: Majima T., Takai S., Oowaki T., Fujita T., Yasuhito F., Yoshihisa M., Masashi K., Tokunori Y., Momokazu G.
Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan

Nocturnal polyuria in males with LUTS: Prevalence and association with nocturia, IPSS and uroflowmetry

By: Rubilotta E.1, Balzarro M.1, Bassi S.1, Trabacchin N.1, Righetti R.2, Curti P.2, D'Amico A.1, Cerruto M.A.1, Artibani W.1
1A.O.U.I. Verona, Dept. of Urology, Verona, Italy, 2AULSS 9 Mater Salutis Hospital, Dept. of Urology, Legnago, Italy

Prospective comparative investigation of telephone follow-up in female urology

By: Balzarro M.1, Rubilotta E.1, Trabacchin N.1, Bassi S.1, Mancini V.2, Cerruto
**888**

**Pubis-rectum length and early recovery of continence after robot-assisted laparoscopic prostatectomy**

By:Kiuchi H., Sekii Y., Inagaki Y., Ueda N., Takezawa K., Fukuhara S., Fujita K., Uemura M., Imamura R., Nonomura N.

Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan

**889**

**Preoperative functional ultrasound imaging of the pelvic floor: Correlation with early continence outcomes post radical prostatectomy**

By: van Diepen D.C., Chan L., Thanigasalam R., Leslie S., Andre L., Sved P., Vasilaras A., Tse V., Mitterdorfer A.

1Institute of Academic Surgery - Royal Prince Alfred & Concord Repatriation General Hospital, Dept. of Urology, Sydney, Australia,

2Concord Repatriation General Hospital, Dept. of Urology, Sydney, Australia,

3Royal Prince Alfred Hospital, Dept. of Urology, Sydney, Australia

**890**

**Comparing pad use per day versus ICIQ-SF for the assessment of continence following radical prostatectomy**


1Clinica Universidad de Navarra & Hospital Universitari Son Espases, Dept. of Urology, Pamplona & Palma de Mallorca, Spain,

2Macquarie University, Dept. of Mathematics and Statistics, Sidney, Australia,

3Clinica Universidad de Navarra, Dept. of Urology, Pamplona, Spain,

4The University of Sydney, Westmead Hospital, Dept. of Urology, Sydney, Australia,

5University of Melbourne & Clinical Research Institute, Westmead Private Physiotherapy Services, Dept. of Physiotherapy, Sidney, Australia

**891**

**The relationship between predominant symptom in mixed urinary incontinence and video-urodynamic findings in women – are the proposed updated NICE 2018 guidelines reasonable?**


University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

**892**

**Is there a place for the assessment of bladder sensations to determine success of test stimulation in sacral neuromodulation in patients with overactive bladder?**


Maastricht University Medical Center+, Dept. of Urology, Maastricht, The Netherlands
**Advances and challenges in the treatment of castration resistant prostate cancer**

**Poster Session 64**

**Monday 18 March**
**12:15 - 13:45**

**Location:** Green Area, Room 4

**Chairs:** R. Azhar, Jeddah (SA)
R.J. Van Soest, Rotterdam (NL)
A. Zarkar, Birmingham (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**Risk of dementia following androgen deprivation therapy for treatment of prostate cancer**

By: Tully K.¹, Krasnova A.², Epstein M.³, Marchese M.¹, Dickerman B.⁴, Cole A.P.¹, Lipsitz S.⁵, Nguyen P.⁶, Kibel A.¹, Choueiri T.⁷, Basaria S.⁸, Mucci L.⁴, Sun M.⁷, Trinh Q-D.¹

¹Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America,
²Columbia Mailman School of Public Health, Columbia Mailman School of Public Health, New York, United States of America,
³SUNY Downstate Medical Center, SUNY Downstate Medical Center, Boston, United States of America,
⁴Harvard TH Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America,
⁵Brigham and Women's Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, United States of America,
⁶Brigham and Women's Hospital, Harvard Medical School, Dept. of Radiation Oncology, Boston, United States of America,
⁷Dana Farber Cancer Institute, Harvard Medical School, Lank Center for Genitourinary Oncology, Boston, United States of America,
⁸Brigham and Women's Hospital, Harvard Medical School, Research Program in Men's Health: Aging and Metabolism, Boston, United States of America

**Aims and objectives of this presentation**

---

**Radium 223 therapy in symptomatic metastatic castrate resistant prostate cancer - quality of life matters: Real-world outcomes from a single UK centre**

By: Jiang X.Y.¹, Atkinson S.², Cumming S.¹, Burns A.³, Pearson R.A.¹, Frew J.¹, Azzabi A.¹, McMenemy R.¹, Pedley ¹

¹Northern Centre for Cancer Care, Dept. of Clinical Oncology, Newcastle upon Tyne, United Kingdom,
²Northern Centre for Cancer Care, Dept. of Nuclear Medicine, Newcastle upon Tyne, United Kingdom,
³Northern Centre for Cancer Care, Dept. of Radiotherapy Information Technology, Newcastle upon Tyne, United Kingdom
<table>
<thead>
<tr>
<th>894</th>
<th><strong>Withdrawn</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

894

<table>
<thead>
<tr>
<th>895</th>
<th><strong>Disease burden and bone health in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO non-interventional study</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Poeppel T.D. ¹, Möllers M. ², Assa E. ³, Kalinovsky J. ⁴, Benson A. ⁵, Selkinski I. ³</td>
</tr>
<tr>
<td></td>
<td>¹University of Duisburg-Essen and German Cancer Consortium (DKTK), partner site University Hospital Essen, Dept. of Nuclear Medicine, Essen, Germany, ²Knappschaftskrankenhaus Dortmund, Dept. of Nuclear Medicine, Dortmund, Germany, ³Helios Dr. Horst-Schmidt-Kliniken, Institute of Nuclear Medicine, Wiesbaden, Germany, ⁴Bayer Consumer Care AG, Medical Affairs – Oncology, Basel, Switzerland, ⁵Bayer HealthCare, Medical Affairs – Statistics, Whippany, United States of America</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

895

<table>
<thead>
<tr>
<th>896</th>
<th><strong>Overall adverse events in patients treated with radium223 for metastatic castration resistant prostate cancer: Registry study and analysis of real life data from EudraVigilance</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

896

<table>
<thead>
<tr>
<th>897</th>
<th><strong>Circulating tumour cells in patients with metastatic castration resistant prostate cancer under treatment with cabazitaxel - a prospective biomarker study from the Hellenic Oncology Research Group</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hellenic Oncology Research Group, Dept. of Medical Oncology, Athens, Greece</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

897

<table>
<thead>
<tr>
<th>898</th>
<th><strong>Next generation sequencing (NGS) in metastatic castration resistant prostate cancer (mCRPC) to identify targets for individualized treatment – is it feasible in daily routine?</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Heidenreich A. ¹, Nestler T. ¹, Paffenholz P. ¹, Büttner R. ¹, Karapanos L. ², Pfister D. ¹</td>
</tr>
</tbody>
</table>

* 898
Aims and objectives of this presentation

### 898

**Comparison of docetaxel and androgen receptor axis-targeted (ARAT) agents for metastatic castration-resistant prostate cancer patients with intraductal carcinoma of the prostate (IDC-P)**

By: Kato M.\(^1\), Yamamoto A.\(^2\), Tochigi K.\(^1\), Ohwaki T.\(^1\), Ishida S.\(^3\), Fujita T.\(^1\), Sassa N.\(^1\), Gotoh M.\(^1\), Tsuzuki T.\(^3\)

\(^1\)Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan,
\(^2\)Toyohashi Municipal Hospital, Dept. of Urology, Toyohashi, Japan,
\(^3\)Aichi Medical University, School of Medicine, Dept. of Surgical Pathology, Nagakute, Japan

Aims and objectives of this presentation

### 899

**Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Long-term overall survival and safety analyses of the phase 3 PREVAIL study**

By: Armstrong A.\(^1\), Tombal B.\(^2\), Saad F.\(^3\), Parli T.\(^4\), Phung D.\(^5\), Beer T.M.\(^6\)

\(^1\)Duke University, Dept. of Medicine and Surgery, Durham, United States of America,
\(^2\)Clinique Universitaires Saint-Luc, Dept. of Urology, Brussels, Belgium,
\(^3\)University of Montreal Hospital Center, Dept. of Urologic Oncology, Montreal, Canada,
\(^4\)Pfizer Inc., Clinical Development, San Francisco, United States of America,
\(^5\)Astellas Pharma Inc., Dept. of Biostatistics, Leiden, The Netherlands,
\(^6\)OHSU Knight Cancer Institute, Oregon Health & Science University, Dept. of Hematology-Medical Oncology, Portland, United States of America

Aims and objectives of this presentation

### 900

**Performance of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer men: A head to head comparison based on a 2014-2017 French population-based study**

By: Scailteux L.M.\(^1\), Campillo-Gimenez B.\(^2\), Kerbrat S.\(^3\), Despas F.\(^4\), Mathieu R.\(^5\), Vincendeau S.\(^5\), Balusson F.\(^3\), Happe A.\(^3\), Nowak E.\(^6\), Oger E.\(^3\)

\(^1\)CHU Rennes, Dept. of Pharmacovigilance and pharmacoepidemiology, Rennes, France,
\(^2\)INSERM, U1099, Centre Eugène Marquis, Promotion of Clinical Trials, Rennes, France,
\(^3\)Université de Rennes, Dept. of Pharmacoeconomics and Health Services Research, Rennes, France,
\(^4\)University Hospital of Rangueil Toulouse, Inserm U1048, Toulouse, France,
\(^5\)CHU Rennes, Dept. of Urology, Rennes, France,
\(^6\)Université de Bretagne Loire, Université de Brest, CHRU de Brest, INSERM CIC 1412, Brest, France
Aims and objectives of this presentation
901

Open-label, phase I, dose escalation study to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E (GEN0101) in castration-resistant prostate cancer patients

By: Fujita K.¹, Nakai Y.¹, Kato D.¹, Kawashima A.¹, Ujike T.¹, Nagahara A.¹, Uemura M.¹, Imamura R.¹, Okihara K.², Ukimura O.², Kaneda Y.³, Nonomura N.¹
¹Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan, ²Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, ³Osaka University Graduate School of Medicine, Division of Gene Therapy Science, Suita, Japan

Aims and objectives of this presentation
902

Age influence on adverse events in patients treated with abiraterone plus prednisone, enzalutamide and radium-223 for metastatic castration resistant prostate cancer: Analysis of real life data from Eudra Vigilance database.

Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation
903

Late administration of luteinizing hormone-releasing hormone agonists, the impact on testosterone (T) suppression, and frequency of T and PSA testing in prostate cancer in the real-world

By: Crawford E.D.¹, Boldt-Houle D.², Concepcion R.³, Atkinson S.²
¹University of Colorado, Dept. of Urology, Aurora, United States of America, ²Tolmar Pharmaceuticals, Inc., Dept. of Medical Affairs, Lincolnshire, United States of America, ³Integra Connect, Dept. of Urologic Clinical, West Palm Beach, United States of America

Aims and objectives of this presentation
904

Switching from GnRH agonists to antagonists for castration-resistant prostate cancer as a second-line hormonal therapy: A multicenter prospective study

By: Sugimura R.¹, Kawahara T.¹, Yokomizo Y.², Ohtake S.², Kuroda S.¹, Taku M.¹, Ito H.¹, Izumi K.¹, Miyoshi Y.¹, Yao M.², Miyamoto H.³, Uemura H.¹
¹Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Dept. of Urology, Yokohama, Japan, ³University of Rochester, Dept. of Surgical Pathology and Laboratory Medicine, Rochester, United States of America

Aims and objectives of this presentation
905
13:38 - 13:45  **State-of-the-art lecture** The advances in the treatment of CRPC  
R.J. Van Soest, Rotterdam (NL)
A novel trifecta to simplify the assessment of perioperative outcomes after robot assisted partial nephrectomy for cT1 renal masses: Results of a multicenter series

By: Brassetti A., Anceschi U., Tuderti G., Anceschi S., Ferriero M.C., Brassetti A., Mastroianni R., Flamia R.S., Gallucci M., Simone G.
Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation

Strict trifecta and pentafecta rates in laparoscopic partial nephrectomy: A single centre retrospective study

Hospital Universitario Virgen de la Victoria, Dept. of Urology, Malaga, Spain

Aims and objectives of this presentation

Mid-term oncologic and functional outcomes of endoscopic robot-assisted simple enucleation for renal tumors: Results from a tertiary referral centre

University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy

Aims and objectives of this presentation

Pre- or peri-ablative biopsies: A comparison of different diagnostic strategies in small renal masses treated with ablation
Aims and objectives of this presentation

Patterns of renal mass biopsy across the MUSIC-KIDNEY statewide QI collaborative

By: Patel A.¹, Perkins S.¹, Bazzi M.², Arcot R.², Johnson A.³, Qi J.³, Kim T.³, Ghani K.³, Schervish E.⁴, Lane B.⁵, Rogers C.¹, Michigan Urological Surgery Improvement Collaborative (MUSIC)
¹Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ²Wayne State University, Dept. of Urology, Detroit, United States of America, ³University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ⁴Michigan Institute of Urology, Dept. of Urology, Troy, United States of America, ⁵Spectrum Health Group, Dept. of Urology, Grand Rapids, United States of America

Aims and objectives of this presentation

Active surveillance for small renal masses ≤2cm: Results from an Italian multi-institutional prospective protocol

By: Cazzaniga W.¹, Castiglione F.¹, Larcher A.¹, Nini A.², Carenzi C.¹, Matloob R.S.E.¹, Villa L.¹, Conti G.³, Maccagnano C.³, Simeone C.⁴, Antonelli A.⁴, Montanari E.⁵, Albo G.⁵, Salvioni R.⁶, Stagni S.⁶, Catanzaro M.⁶, Montorsí F.¹, Capitanio U.¹, Bertini R.¹
¹Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Experimental Oncology, Milan, Italy, ²Universitätshklinikum Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ³Azienda Ospedaliera Sant'Anna di Como, Dept. of Urology, Como, Italy, ⁴Spedali Civili Hospital, University of Brescia, Urology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Brescia, Italy, ⁵IRCCS Fondazione Ca'Granda- Ospedale Maggiore Policlinico University of Milan, Dept. of Urology, Milan, Italy, ⁶Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation

Active surveillance vs. nephron sparing surgery for small renal mass in very elderly patients: A competing risk analysis

By: Mir Maresma M.C.¹, Marchioni M.², Pavan N.³, Antonelli A.⁴, Capitanio U.⁵, Takagi T.⁶, Derweesh I.⁷, Linares E.⁸, Rha K.⁹, Maurer T.¹⁰, Mottrie A.¹¹, Long J.A.¹², Furlan M.⁴, Larcher A.⁵, Breda A.¹³, Porpiglia F.¹⁴, Cheaib J.¹⁵, Garisto J.
Aims and objectives of this presentation

912

Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A retrospective cohort study

By: Tan W.S. 1, Trinh Q-D. 2, Hayn M. 3, Marchese M. 2, Lipsitz S. 4, Nabi J. 2, Kilbridge K. 5, Kibel A. 2, Sun M. 5, Chang S. 2, Sammon J. 3
1 Imperial College Healthcare, Dept. of Urology, London, United Kingdom, 2 Brigham and Women’s Hospital, Dept. of Urology, Boston, United States of America, 3 Maine Medical Center, Dept. of Urology, Portland, United States of America, 4 Brigham and Women’s Hospital, Center for Surgery and Public Health, Boston, United States of America, 5 Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, United States of America

Aims and objectives of this presentation

913

Long term trifecta outcomes of partial nephrectomy versus percutaneous ablation in cT1a renal masses

By: Covin B. 1, Benoit T. 1, Delchier M.C. 2, Lagarde S. 2, Roumi guié M. 1, Doumerc N. 1, Thoulouzan M. 1, Huyghe E. 1, Gamé X. 1, Soulié M. 1, Beauval J.B. 1
1 CHU Toulouse Rangueil, Dept. of Urology, Toulouse, France, 2 CHU Toulouse Rangueil, Dept. of Radiology, Toulouse, France

Aims and objectives of this presentation

914
Cryoablation vs partial nephrectomy for T1a renal cell carcinoma: A comparison of survival benefit stratified by tumour size

By: Liao X., Qiu S., Bao Y., Yang L., Wei Q.
West China Hospital, Sichuan University, Dept. of Urology, Institute of Urology, Chengdu, China

Aims and objectives of this presentation
915

Comparison of perioperative and oncologic outcomes between cryoablation and partial nephrectomy for small renal masses: A propensity-score matching analysis

1S. Orsola-Malpighi University Hospital, Dept. of Urology, Bologna, Italy, 2San Bassiano Hospital, Dept. of Urology, Bassano del Grappa, Italy

Aims and objectives of this presentation
916

Is cryoablation an effective treatment for trifecta outcomes in small renal masses? Long-term results from a multicenter cryotherapy registry

1Azienda Sanitaria Universitaria Integrata di Trieste, Dept. of Urology, Trieste, Italy, 2University of Trieste, Biostatistics Unit, Dept. of Medical Sciences, Trieste, Italy, 3University of Padua, Dept. of Statistical Sciences, Padua, Italy, 4San Bassiano Hospital, Urology Unit, Bassano del Grappa, Italy, 5San Bassiano Hospital, Radiology Unit, Bassano del Grappa, Italy, 6Azienda Sanitaria Universitaria Integrata di Trieste, Dept. of Radiology, Trieste, Italy

Aims and objectives of this presentation
917

Cryoablation versus partial nephrectomy for clinical T1b renal cell carcinoma: Comparison of survival outcomes in a matched cohort

By: Zheng X.N., Yang L., Wei Q.
West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China

Aims and objectives of this presentation
918

13:38 - 13:45

Summary
A. Bex, Amsterdam (NL)
Transcriptome-wide analysis of Peyronie’s disease plaques using RNA sequencing uncovers targetable signalling pathways for medical therapy

By: Milenkovic U.1, Janky R.2, Hatzichristodoulou G.3, Van Renterghem K.4, Cellek S.5, Bivalacqua T.J6, De Ridder D.1, Albersen M.1
1KU Leuven, Dept. of Development and Regeneration, Faculty of Medicine, Leuven, Belgium, 2KU Leuven, VIB Nucleomics Core, Leuven, Belgium, 3Julius-Maximilians-University of Würzburg, Dept. of Urology and Pediatric Urology, Wurzburg, Germany, 4University of Hasselt, Faculty of Medicine, Hasselt, Belgium, 5Anglia Ruskin University, Faculty of Health, Education, Medicine and Social Care, Chelmsford, United Kingdom, 6Johns Hopkins School of Medicine, James Buchanan Brady Urological Institute and Dept. of Urology, Baltimore, United States of America

Aims and objectives of this presentation

The impact of liraglutide treatment on the erectile function of the diabetic rats

To be confirmed

Aims and objectives of this presentation

Low intensity shockwave therapy (LiST) may promote angiogenesis and alter α1/α2 adrenergic receptors ratio with decrease in sympathetic activity in the erectile tissue of naturally aged rats

By: Sokolakis I.1, Dimitriadis F.2, Psalla D.3, Kalyvianakis D.2, Hatzichristou D.2
1Julius-Maximillan University Medical Centre of Wuerzbrug, Dept. of Urology and Paediatric Urology, Wuerzburg, Germany, 2Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, 3Aristotle University of Thessaloniki, Faculty of Veterinary Medicine, Laboratory of Pathology, Thessaloniki, Greece

Aims and objectives of this presentation
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>923</td>
<td>Contribution of Orai channels to contraction of rat and human corpus cavernosum increases with aging</td>
<td>By: Garcia Rojo E. 1, Angulo J. 2, García-Gómez B. 1, Justo Quintas J. 1, Santos- Pérez De La Blanca R. 1, Medina-Polo J. 3, Romero Otero J. 1</td>
<td>1Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, 2Hospital Universitario Ramón y Cajal, Dept. of Histology and Histopathology Research, Madrid, Spain, 3al Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain</td>
</tr>
<tr>
<td>924</td>
<td>Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie’s disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation</td>
<td>By: Milenkovic U. 1, Ilg M.M. 2, Zuccato C. 3, Ramazani Y. 4, De Ridder D. 1, Albersen M. 1</td>
<td>1KU Leuven, Dept. of Development and Regeneration, Faculty of Medicine, Leuven, Belgium, 2Anglia Ruskin University, Faculty of Medical Sciences, Chelmsford, United Kingdom, 3University of Padua, Faculty of Medicine and Surgery, Padua, Italy, 4KU Leuven, Dept. of Pediatric Nephrology and Growth and Regeneration, Leuven, Belgium</td>
</tr>
<tr>
<td>925</td>
<td>Cavernous branched nerve regeneration using non-tubular artificial nerve sheets without sutures using freeze-dried alginate gel in a rat model</td>
<td>By: Narita N.S. 1, Suzuki Y. 2, Obara T. 3, Habuchi T. 1</td>
<td>1Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, 2Kitano Hospital, Dept. of Plastic and Reconstructive Surgery, Osaka, Japan, 3Akita Red Cross Hospital, Dept. of Urology, Akita, Japan</td>
</tr>
<tr>
<td>926</td>
<td>Local electrostimulation of injured cavernosal nerve improves erectile function recovery in a rat model of neurogenic erectile dysfunction</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>927</td>
<td>Receptors and sensory nerve pathways of the penis: A three dimensional computer assisted anatomical dissection (3DCAAD)</td>
<td>By: Flochlay M. 1, Diallo D. 2, Bessede T. 2, Prudhomme M. 3, Costa P. 1, Kharlamov E. 4, Mitrokhin V. 5, Aleksandrov B. 6, Droupy S. 1</td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation
927

**Adipose-derived stem cells (ASCs) combined with control-released DF-PEG/GCS hydrogel scaffold restore the erectile function in a diabetes rat model**

By: Lu M., Xiao D.D., Ti Y.R., Zou L., Yan H., Lu M.
Shanghai Renji Hospital, Dept. of Urology and Andrology, Shanghai, China

Aims and objectives of this presentation
928

**Effects of exosomes from adipose-derived stem cells on recovery of erectile function in a bilateral cavernous nerve injury rat model**

Seoul St. Mary's Hospital, The Catholic University of Korea, Dept. of Urology, Seoul, South Korea

Aims and objectives of this presentation
929

**Human induced pluripotent stem cell-derived testosterone-producing Leydig cells ameliorate serum testosterone level in rats**

By: Takaki I., Masato F., Takashi A.
1Kobe University, Dept. of Urology, Kobe, Japan, 2Kobe University, Dept. of iPS cell Applications, Kobe, Japan

Aims and objectives of this presentation
930

**Testosterone associated relaxation of human corpus cavernosum of patients with erectile dysfunction: Are non genomic pathways involved?**

By: Soebadi M.A., Van Den Broeck T., Raets L., Brone B., Van Renterghem K.
1Laboratory of Experimental Urology, Dept. of Development and Regeneration, Leuven, Belgium, 2Jessa Hospital, Dept. of Urology, Hasselt, Belgium, 3University of Hasselt, Dept. of Urology, Hasselt, Belgium, 4University of Hasselt, Dept. of Biomedical Research Institute, Hasselt, Belgium

Aims and objectives of this presentation
931
Loss-of-function mutation in FGFR1 gene as a cause of idiopathic hypogonadotropic hypogonadism

By: Wang D., Niu Y., Chen Y., Liu J.
Tongji Hospital, Dept. of Urology, Wuhan, China

Aims and objectives of this presentation

State-of-the-art lecture Can we cure erectile dysfunction?
F. Castiglione, London (GB)
Reconstructive aspects of the upper urinary tract and bladder
Poster Session 67

Monday 18 March
12:15 - 13:45

Location: Green Area, Room 11
Chairs: Y. Abu-Ghanem, Ramat Gan (IL)
        E.L. Koldewijn, Eindhoven (NL)
        A. Vaze, Mumbai (IN)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

933
The long-term effect of bladder augmentation on renal function
University College London Hospitals NHS Foundation Trust, Dept. of Reconstructive Urology, London, United Kingdom

Aims and objectives of this presentation
933

934
Extraperitoneal robotic YV-plasty for recurrent bladder neck contracture
By: Brachlow J.F., John H., Padievit C., Horton K.
Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

Aims and objectives of this presentation
934

935
Mitrofanoff continent urinary diversion: Better life comfort in spite of surgical complications
Habib Bourguiba Hospital, Dept. of Urology, Sfax, Tunisia

Aims and objectives of this presentation
935

936
Long-term outcomes of Mitrofanoff channel formation in adults
By: O'Connor E.¹, Malde S.², Raja L.¹, Foley C.L.³, Taylor C.J.², Wood D.N.¹, Ockrim J.L.¹, Greenwell T.J.¹
¹University College Hospital at Westmoreland Street, Dept. of Urology, London, United Kingdom,
²Guy's and St Thomas's Hospital Trust, Dept. of Urology, London, United Kingdom,
³Lister Hospital, Dept. of Urology, Stevenage, United Kingdom
Aims and objectives of this presentation

936

Refluxing versus non-refluxing ureteric implantation in continent cutaneous urinary diversion: A propensity-scored comparison regarding long-term renal, metabolic and functional outcomes

By: Kalogirou C.¹, Sokolakis I.¹, Schwinger M.¹, Krebs M.¹, Herzog A.L², Gakis G.¹, Hatzichristodoulou G.¹, Riedmiller H.¹, Kübler H.¹, Kocot A.¹
¹University Medical Centre of the University of Würzburg, Dept. of Urology and Paediatric Urology, Wurzburg, Germany, ²University Medical Centre of the University of Würzburg, Dept. of Nephrology, Wurzburg, Germany

Aims and objectives of this presentation

937

Withdrawn
To be confirmed

Aims and objectives of this presentation

938

Retrosigmoid ileal conduit with no transposition of the left ureter reduces the risk of ureteroileal anastomotic strictures after radical cystectomy: Mid-term follow-up results of a prospective study

By: Ficarra V.¹, Crestani A.², Rossanese M.¹, Subba E.¹, Calandriello M.², Valotto C.², Inferrera A.¹, Giannarini G.²
¹University of Messina, Urology Section, Dept. of Human and Paediatric Pathology Gaetano Barresi, Messina, Italy, ²Academic Medical Centre Santa Maria della Misericordia, Urology Unit, Udine, Italy

Aims and objectives of this presentation

939

The long-term results of ureteral reimplantation by different antireflux techniques: Analysis of the trifecta, functional, anatomic, and surgical outcomes

By: Tseng C-S., Wong S-M., Kuo M-C., Chow P-M., Huang C-Y., Pu Y-S., Chang H-C. National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan

Aims and objectives of this presentation

940

Autophagy is needed during the differentiation of adipose derived stem cells to functional smooth muscle cells for use in bladder engineering

By: Salemi S., Haralampieva-Mohr D., Kranzbühler B., Mortezavi A., Sulser T., Eberli D.
University Hospital Zürich, Dept. of Urology, Zürich, Switzerland

Aims and objectives of this presentation
941

944 Image based 3D reconstruction of the bladder using structure-from-motion – proof of principle in a phantom model

By: Ujwala P. ¹, Pentek Q. ¹, Hein S. ², Miernik A. ², Reiterer A. ¹
¹INATECH, University of Freiburg, Dept. of Sustainable Systems Engineering, Freiburg, Germany, ²Medical Center, University of Freiburg, Dept. of Urology, Division of Urotechnology, Freiburg, Germany

Aims and objectives of this presentation
944

945 Genitourinary fistulas: Changing patterns of causation and evolution in management

By: Lal M. , Hussain M. , Abidi S. , Sultan G. , Hashmi A. , Hussain Z. , Naqvi A. , Rizvi A.
Sindh Institute of Urology and Transplantation, Dept. of Urology, Karachi, Pakistan

Aims and objectives of this presentation
945

946 Patient reported outcomes after ileocystoplasty in spinal cord injury (SCI) population

By: Sakalis V. ¹, Guy P. ², Oliver R. ², Melissa D. ²
¹Agios Pavlos General Hospital of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, ²Salisbury NHS Trust, Dept. of Urology, Salisbury, United Kingdom

Aims and objectives of this presentation
946

947 Long-term outcomes of non-continent cutaneous urinary diversion in patients with multiple sclerosis

By: Akakpo W. ¹, Chartier-Kastler E. ¹, Joussain C. ², Denys P. ², Lubetzki C. ³, Phé V. ¹
¹Pitie Salpetriere Hospital, Sorbonne Universite, Dept. of Urology, Paris, France, ²Raymond-Poincaré AP-HP Hospital, Dept. of Physical Medicine and Rehabilitation, Garches , France, ³Pitie Salpetriere Hospital, Sorbonne Universite, Dept. of Neurology, Paris, France

Aims and objectives of this presentation
947
History of urology
Poster Session 68

Monday 18 March
12:15 - 13:45

Location: Green Area, Room 12
Chairs: L.A. Fariña-Pérez, Vigo (ES)
        D. Schultheiss, Giessen (DE)
        P. Van Kerrebroeck, Maastricht (NL)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

956
Urology in modern/contemporary music, literature and art

By: Månsson K.G.W.
Skånes Universitetssjukhus, Dept. of Urology, Malmö, Sweden

Aims and objectives of this presentation
956

948
Joaquin María Albarran: A sad farewell that proves the birth of a urological LatAm urological conscience

By: Angulo Cuesta J., 1 Fredotovich N., 2 Fariña L., 3 Gomiz J.J., 3 Otero I., 3 Pérez-Albacete M., 3 Fernández-Arias M. 4
1 Universidad Europea de Madrid, Dept. of Urology, Madrid, Spain, 2 Confederación Americana de Urología, Oficina de Historia, Buenos Aires, Argentina, 3 Asociación Española de Urología, Oficina de Historia, Madrid, Spain, 4 Universidad de Ciencias Médicas de la Habana, Oficina del Historiador, Habana, Cuba

Aims and objectives of this presentation
948

949
Urological disease as a basis for miracles in the canonization process of the Roman Catholic church

By: Touma N., 1 Duffin J. 2
1 Queen's University, Dept. of Urology, Kingston, Canada, 2 Queen's University, Dept. of History and Medicine, Kingston, Canada

Aims and objectives of this presentation
949

950
Hypersexuality: An important urological problem and cause of death in the French Valois kings

By: Van Kerrebroeck P.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
</table>
| 950     | Medical illustration in the work 'urogenital' pathology and 'morphology and function of vesico-prostato-urethral musculature' by the Spanish urologist Salvador Gil Vernet | Gil-Vernet Sedo J.M.  
Teknon Medical Center, Dept. of Urology, Barcelona, Spain | Maastricht University Medical Center, Dept. of Urology, Maastricht, The Netherlands |
Leicester General Hospital, Dept. of Urology, Leicester, United Kingdom | Francis Seymour Kidd (1878–1934): Urologist and co-founder of British Journal of Urology (BJU) |
| 952     | Ruy Gómez de Silva (1516-1573), private to King Philip II of Spain, treated for "carnosities" of the urethra by Dr Francisco Díaz: Diagnosis, evolution to chronic urinary retention and end-stage renal disease due to chronic pyelonephritis. Autopsy study | Fariña-Pérez L.A.  
Hospital Povisa, Dept. of Urology, Vigo, Spain | Ruy Gómez de Silva (1516-1573), private to King Philip II of Spain, treated for "carnosities" of the urethra by Dr Francisco Díaz: Diagnosis, evolution to chronic urinary retention and end-stage renal disease due to chronic pyelonephritis. Autopsy study |
| 953     | Gonorrhoea! What the Dickens?                                        | Goddard J.C.  
University of Leicester Hospitals NHS Trust, Dept. of Urology, Leicester, United Kingdom  
University of Buckingham, Humanities and Medical History, Buckingham, United Kingdom | Gonorrhoea! What the Dickens? |
| 954     | Urology in Persia: From Avicenna’s canon of medicine to modern urology in today’s Iran | Rahnama'i M.S., Hajebrahimi S., Tavakoli F., Van Kerrebroeck Ph.E.V., Kajbafzadeh A. | Urology in Persia: From Avicenna’s canon of medicine to modern urology in today’s Iran |
Aims and objectives of this presentation

955

1. Male genitalia votives to Gods giving specific disease information during Ancient Ages
   
   By: Guner E., Seker K.G., Sam E.
   
   University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Dept. of Urology, Istanbul, Turkey

957

2. Giorgio Nicolich, father of urology in Trieste
   
   By: Boschian R., Ponte E., Pavan N., Rizzo M., Rebez G., Liguori G., Trombetta C.
   
   1. University of Trieste, Dept. of Urology, Trieste, Italy
   2. University of Trieste, Dept. of Medical History, Trieste, Italy

958

   
   By: Fandella A.
   
   Casa di Cura Rizzola, Dept. of Urology, San Donà di Piave Ve, Italy

959

4. From cult worship to cure: The history of human castration
   
   By: Oliver R., Almushatat A.
   
   The Royal London Hospital, Dept. of Urology, London, United Kingdom

960

5. The double lithotome caché
   
   By: Álvarez-Vijande R., D'Anna M., Costa-Grau M.
   
   Hospital Clinic of Barcelona, Dept. of Urology, Barcelona, Spain
Aims and objectives of this presentation
961
## Ablative surgery for BPO relief: Lasers on prime time

**Poster Session 69**

**Monday 18 March**

| 12:15 - 13:45 |

**Location:** Green Area, Room 20  
**Chairs:** H.S.S. Ho, Singapore (SG)  
M. Rieken, Zürich (CH)  
G.Y. Robert, Bordeaux (FR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

<table>
<thead>
<tr>
<th>962</th>
<th>Photoselective vaporization of the prostate: Evaluation of conflicts of interest and industrial sponsorship stratified by favorability of the study outcome</th>
</tr>
</thead>
</table>

By: **Wettstein M.S.**<sup>1</sup>, Pazhepurackel C.<sup>1</sup>, Neumann A.S.<sup>1</sup>, Woon D.T.S.<sup>2</sup>, Herrera-Caceres J.O.<sup>2</sup>, Poyet C.<sup>1</sup>, Sulser T.<sup>1</sup>, Kulkarni G.S.<sup>2</sup>, Hermanns T.<sup>1</sup>

<sup>1</sup>University Hospital of Zurich, Dept. of Urology, Zurich, Switzerland, <sup>2</sup>Princess Margaret Cancer Centre, University Health Network, Division of Urology, Dept. of Surgery, Toronto, Canada

**Aims and objectives of this presentation**

962

<table>
<thead>
<tr>
<th>963</th>
<th>Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate: Results of the UNBLOCS randomized controlled trial</th>
</tr>
</thead>
</table>

By: **Hashim H.**<sup>1</sup>, Lane A.<sup>2</sup>, Worthington J.<sup>2</sup>, Noble S.<sup>2</sup>, Brooks S.<sup>2</sup>, Cotterill N.<sup>3</sup>, Page T.<sup>4</sup>, Swami S.<sup>5</sup>, Abrams P.<sup>1</sup>, UNBLOCS trial

<sup>1</sup>North Bristol NHS Trust, Bristol Urological Institute, Bristol, United Kingdom, <sup>2</sup>University of Bristol, School of Social and Community Medicine, Bristol, United Kingdom, <sup>3</sup>Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, <sup>4</sup>The Newcastle upon Tyne Hospitals NHS Foundation Trust, Dept. of Urology, Newcastle, United Kingdom, <sup>5</sup>NHS Grampian, Academic Urology Unit, Aberdeen, United Kingdom

**Aims and objectives of this presentation**

963

<table>
<thead>
<tr>
<th>964</th>
<th>Postoperative complications after holmium laser enucleation of the prostate in a high volume center with more than 15 years of experience</th>
</tr>
</thead>
</table>

By: **Capogrosso P.**<sup>1</sup>, Pozzi E.<sup>2</sup>, Abbate C.<sup>1</sup>, Chierigo F.<sup>2</sup>, Schifano N.<sup>1</sup>, Zuabi R.<sup>2</sup>, Belladelli F.<sup>2</sup>, Cazzaniga W.<sup>1</sup>, Ventimiglia E.<sup>1</sup>, Matloob R.<sup>1</sup>, Scattoni V.<sup>1</sup>, Dehò F.<sup>1</sup>, Mirone V.<sup>3</sup>, Gaboardi F.<sup>4</sup>, Salonia A.<sup>1</sup>, Montorsi F.<sup>1</sup>

<sup>1</sup>IRCCS Ospedale San Raffaele, Unit of Urology, URI, Milan, Italy, <sup>2</sup>Università Vita-Salute San Raffaele, Unit of Urology, URI, Milan, Italy, <sup>3</sup>Department of Neurosciences, Sciences
Aims and objectives of this presentation

964

**Major acute cardiovascular events after transurethral prostate surgery: A population-based analysis**

By: Marchioni M.¹, Cindolo L.², Di Nicola M.¹, Schips L.³, De Sio M.⁴, Lima E.⁵, Mirone V.⁶, Cormio L.⁷, Liatsikos E.⁸, Porpiglia F.⁹, Autorino R.¹⁰, EAU Section of Uro-Technology (ESUT) Research Group

¹G. D'Annunzio University of Chieti, Dept. of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, Chieti, Italy,
²ASL Abruzzo 2, Dept. of Urology, Chieti, Italy,
³G. D'Annunzio University of Chieti, Dept. of Medical, Oral and Biotechnological Sciences, Chieti, Italy, ⁴Luigi Vanvitelli University of Naples, Dept. of Urology, Naples, Italy,
⁵Hospital of Braga, Dept. of Urology, Braga, Portugal, ⁶Federico II University, Dept. of Urology, Naples, Italy, ⁷University of Foggia, Dept. of Urology and Kidney Transplantation, Foggia, Italy, ⁸University of Patras, Dept. of Urology, Patras, Greece, ⁹San Luigi Gonzaga Hospital, Dept. of Oncology, Division of Urology, Orbassano, Italy, ¹⁰VCU Health, Dept. of Oncology, Division of Urology, Richmond, United States of America

Aims and objectives of this presentation

965

**Complications after surgery for benign prostatic enlargement and medication use: A population-based cohort study in Ontario, Canada**

By: Matta R.¹, Labossiere J.R.H.², Wallis C.J.D.¹, Hird A.E.¹, Kulkarni G.S.¹, Kodama R.T.¹, Carr L.K.¹, Radomski S.B.¹, Herschorn S.¹, Nam R.K.¹

¹University of Toronto, Dept. of Urology, Toronto, Canada, ²University of Alberta, Dept. of Urology, Edmonton, Canada

Aims and objectives of this presentation

966

**Relationship between recovery of urinary continence after holmium laser enucleation of the prostate (HoLEP) and preoperative membranous urethral length on magnetic resonance imaging**

By: Zhang F., Liu K., Xiao C., Ma L.
Peking University, Dept. of Urology, Beijing, China

Aims and objectives of this presentation

967

**Outcomes of holmium laser enucleation of the prostate in acute-on-chronic urinary retention with high residual volumes**
By: Guest K., Whiting D., Penev B., Smith T., Cynk M.
Maidstone Hospital, Dept. of Urology, Maidstone, United Kingdom

**Aims and objectives of this presentation**

968

---

**Influence of the median lobe on the results at 4 years of the prostate vaporization by GreenLight laser®**

By: Vanalderwerelt V., Grevez T., Pradère B., Faiivre D’Arcier B., Bruyère F.
CHRU of Tours, Dept. of Urology, Tours, France

**Aims and objectives of this presentation**

969

---

**Perioperative outcomes of transurethral resection, open prostatectomy and laser therapy in the surgical treatment of benign prostatic obstruction: A “real world” data analysis of the German D.V.P.Z. from 2005-2017 with 10,420 patients**


1Prostatecenter Cologne, Cologne, Germany, 2Prostatecenter Metropolregion Nuremberg, Fuert, Germany, 3Prostatecenter Freiburg, Freiburg, Germany, 4Prostatecenter Berlin, Berlin, Germany, 5Prostatecenter Leverkusen, Leverkusen, Germany, 6Prostatecenter Marl, Marl, Germany, 7Prostatecenter Hochfranken-Fichtelgebirge, Marktredwitz, Germany, 8Urology Center Munich, Planegg, Germany, 9Prostatecenter Niederrhein, Wesel, Germany, 10Prostatecenter Nuremberg-Middle Franconia, Nuremberg, Germany, 11Prostatecenter Nymphenburg, Munich, Germany, 12Prostatecenter Bocholt, Bocholt, Germany, 13Prostatecenter Moers, Moers, Germany, 14Prostatecenter Speyer, Speyer, Germany, 15Prostatecenter Rhine-Ruhr, Oberhausen, Germany, 16Prostatecenter Elbe-Weser, Stade, Germany, 17Prostatecenter Emscher-Lippe, Gladbeck, Germany, 18Prostatecenter Muensterland, Muenster, Germany, 19Prostatecenter Mainspitze, Ruesselsheim, Germany, 20Prostatecenter Alfred Krupp-Hospital, Essen, Germany, 21Prostatecenter Hohauatus, Bad Homburg, Germany, 22Dachverband der Prostatazentren Deutschlands, Berlin, Germany, 23Prostatecenter Siegen-Wetzlar, Siegen, Germany

**Aims and objectives of this presentation**

970

---

**Comparing transurethral endoscopic enucleation of the prostate using 980nm diode laser vs. bipolar-plasmakinetic: Dual-centre, noninferiority, randomized controlled trial with 2-year follow-up results**

By: Zou Z. 1, Xu A. 2, Chen B. 2, Chen J. 3, Duan C. 4, Gao Y. 2, Wang Y. 5, Zheng S. 2, Liu C. 2, Liang C. 1
Aims and objectives of this presentation

971

Effect of preoperative urethral dilatation during HoLEP on preventing urethral stricture: Randomized controlled study

By: Shin Y.S., Park J.K.
Chonbuk National University Medical School, Dept. of Urology, Jeonju, South Korea

972

Withdrawn

To be confirmed

973

Comparison of perioperative course and short term outcome of aquablation, laser enucleation, greenlight vaporisation and TUR-P

By: Bach T., Wuelfing C., Anheuser P., Tauber S., Brunken C., Gross A.J.
1Asklepios Hospital Harburg, Dept. of Urology, Hamburg, Germany, 2Asklepios Hospital Altona, Dept. of Urology, Hamburg, Germany, 3Asklepios Hospital Wandsbek, Dept. of Urology, Hamburg, Germany, 4Asklepios Westklinikum, Dept. of Urology, Hamburg, Germany, 5Asklepios Hospital Barmbek, Dept. of Urology, Hamburg, Germany

974

Thulium vapoenucleation of the prostate versus holmium laser enucleation of the prostate: A prospective randomized trial with 24-month follow-up

By: Netsch C., Becker B., Gross A.
Asklepios Klinik Barmbek, Dept. of Urology, Hamburg, Germany

975

Impact of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: A lesson from five-year serial follow-up data

976
Aims and objectives of this presentation

976

13:43 - 13:43 Conclusion
Mini invasive approaches for upper tract urothelial cancer treatment

Expert-Guided Poster Tour 14

Monday 18 March
13:30 - 15:30

Location: Green Area, Room A
Chairs: M.J. Ribal Caparros, Barcelona (ES)
        S. Shariat, Vienna (AT)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

14:00 - 14:03
Introduction
M.J. Ribal Caparros, Barcelona (ES)
S. Shariat, Vienna (AT)

PT352
MECA79 positive high endothelial venule density (HEV) correlates with clinical outcomes in upper tract urothelial carcinoma patients treated with radical nephroureterectomy

By: Yasuhiro H., Yamamoto H., Hatakeyama S., Yoneyama T., Ohyama C.
Hirosaki University, Dept. of Urology, Hirosaki, Japan

PT353
Upper tract urothelial carcinoma and paired intravesical recurrences: Are they clonally related?

By: van Doeveren T.\(^1\), Van Leenders A.G.J.L.H.\(^2\), Dinjens W.N.M.\(^2\), Van De Werken H.J.G.\(^3\), Van Leeuwen P.J.\(^4\), Van Riet J.\(^3\), Boormans J.L.\(^1\)
\(^1\)Erasmus MC, University Medical Center Rotterdam, Dept. of Urology, Rotterdam, The Netherlands,
\(^2\)Erasmus MC, University Medical Center, Dept. of Pathology, Rotterdam, The Netherlands,
\(^3\)Erasmus MC, University Medical Center, Cancer Computational Biology Center, Rotterdam, The Netherlands,
\(^4\)Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands

PT355
Comparison of oncological and perioperative outcomes of open, laparoscopic, and robotic nephroureterectomy approaches in patients with non-metastatic upper-tract urothelial carcinoma

By: Kim H.J.\(^1\), Kim T.\(^2\), Song S.H.\(^1\), Lee H.M.\(^1\), Kwon O.S.\(^2\), Oh J.J.\(^1\), Lee S.E.\(^1\), Hong S.K.\(^1\), Byun S.S.\(^1\)
\(^1\)Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea,
\(^2\)Hallym University Kangnam Sacred Heart Hospital, Dept. of Urology, Seoul, South Korea
PT356

Do laparoscopic or open approach for bladder cuff during RNU impact oncological outcomes?

By: Pizzighella M.¹, Pradere B.¹, Vanaldenwerelt V.¹, Peyronnet B.², Alimi Q.², Graffeille V.², Bensalah K.², Brichart N.³, Jeannot P.¹, Amar S.¹, Fosse A.¹, Laine P.¹, Chaumel M.¹, Monléon L.¹, Léonard G.¹, Atme R.¹, Boutin J.M.¹, Faivre D'Arcier B.¹, Bruyere F.¹

¹CHU Tours, Dept. of Urology, Tours, France, ²CHU Rennes, Dept. of Urology, Rennes, France, ³CH Orléans, Dept. of Urology, Orléans, France

PT357

Lymph node dissection for patients with invasive upper tract urothelial carcinoma managed by radical nephroureterectomy

By: Li Z.¹, Li X.², Zhou F.³, Xiao K.¹, Han H.³, Zhang X.¹, Fang J.¹, Guo J.¹

¹Shenzhen People’s Hospital, Dept. of Urology, Shenzhen, China, ²The Seventh Affiliated Hospital?Sun Yat-sen University, Dept. of Oncology, Shenzhen, China, ³Sun Yat-sen University Cancer Cente, Dept. of Urology, GuangZhou, China

PT358

The impact of histological variants on survival in in upper urinary tract urothelial carcinoma patients treated with nephroureterectomy: A multicenter collaboration

By: Zamboni S.¹, Foerster B.², Abufaraj M.², Seisen T.³, Roupret M.³, De La Taille A.⁴, Peyronnet B.⁵, Bensalah K.⁶, Wirth M.P.⁷, Novotny V.⁷, Soria F.⁸, Chlostà P.⁹, Antonelli A.¹⁰, Simeone C.¹⁰, Baumeister P.¹, Mattei A.¹, Montorsi F.¹¹, Simone G.¹², Gallucci M.¹², Matsumoto K.¹³, Karakiewicz P.I.¹⁴, Briganti A.¹¹, Xylinas E.¹⁵, Shariat S.F.², Moschini M.², On behalf of the EAU Research Foundation

¹Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ²Vienna General Hospital, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³Pitié-Salpêtrière Hospital, Assistance-Publique Hôpitaux de Paris; Pierre et Marie Curie Medical School, University Paris 6, Academic Dept. of Urology, Paris, France, ⁴Centre Hospitalier Universitaire Mondor Assistance Publique des Hôpitaux de Paris, INSERM U955Eq07, Dept. of Urology, Paris, France, ⁵Hôpital Pontchaillou, CHU Rennes, Dept. of Urology, Rennes, France, ⁶Rennes University Hospital (France), 2 rue Henri Le Guillou, Rennes, France, 35000, Dept. of Urology, Rennes, France, ⁷University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, ⁸Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria, Dept. of Urology and Andrology, Vienna, Austria, ⁹Jagiellonian University, Dept. of Urology, Krakow, Poland, ¹⁰Spedali Civili Hospital of Brescia, University of Brescia, Dept. of Urology, Brescia, Italy, ¹¹Urological Research Institute, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ¹²Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹³Kitasato University School of Medicine, Dept. of Urology, Kanagawa, Japan, ¹⁴University of Montreal, Dept. of Urology, Montreal, Canada, ¹⁵Bichat Hospital, Paris Descartes University, Dept. of Urology, Paris, France

PT359

Psoas major muscle volume predicts the prognosis of patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy

By: Yuzuriha S.¹, Hasegawa M.¹, Nakajima N.¹, Shimizu Y.¹, Oda K.¹, Uchida T.¹, Kano T.¹, Ootaki T.¹, Umemoto T.¹, Kawakami M.¹, Kim H.¹, Nitta M.¹, Hanai K.¹, Kawamura Y.¹
PT360

**The crucial role of ureteroscopy in the diagnostic/therapeutic pathway of upper tract urothelial carcinoma**

By: Gallioli A. 1, Breda A. 1, Boissier R. 1, Territo A. 1, Gaya J.M. 1, Martínez M.J. 2, Gavrilov P. 1, Mercadé A. 1, Regis F. 1, Palou Redorta J. 1

1Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 2Fundació Puigvert, Dept. of Radiology, Barcelona, Spain

PT362

**Are urine cytology, retrograde pyelography, and ureteroscopy still routinely required for all patients with upper tract urothelial cancer in the modern era of cross-sectional imaging?**

By: Elawdy M. 1, Osman Y. 1, Taha D.E. 1, Abd El-Hamid M. 2, Abouelkheir R. 3, Elsaeed E. 1

1Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt, 2Urology and Nephrology Center, Mansoura University, Dept. of Pathology, Mansoura, Egypt, 3Urology and Nephrology Center, Mansoura University, Dept. of Radiology, Mansoura, Egypt

PT363

**Laparoscopic/robotic nephroureterectomy comparing intra-corporeal versus open extra-vesical bladder cuff excision**

By: Kuo W-T., Lin J., Yu C., Tsai C.M.

Kaohsiung Veteran General Hospital, Dept. of Urology, Kaohsiung, Taiwan

PT365

**Developing a prediction model for disease-free survival from upper urinary tract urothelial carcinoma in the Korean population: A retrospective multicenter study**

By: Kim S.H. 1, Song M.K. 2, Hong B. 3, Kang S.H. 4, Jeong B.C. 5, Ku J.H. 6, Seo H.K. 7

1Center for Prostate Cancer, National Cancer Center, Dept. of Urology, Goyang, South Korea, 2Research institute and National Cancer Center, Biometrics Research Branch, Goyang, South Korea, 3Asan Medical Center, Dept. of Urology, Seoul, South Korea, 4Korea University Anam Hospital, Korea University College of Medicine, Dept. of Urology, Seoul, South Korea, 5Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea, 6Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, 7Center for Prostate Cancer, Hospital Biomarker Branch, Research Institute, National Cancer Center, Dept. of Urology, Goyang, South Korea

PT366

**The impact of preoperative blood-based inflammation markers and tumor size on oncologic outcomes in patients with upper tract urothelial carcinoma**

By: Jan H.-C., Hu C-Y., Yang W-H., Ou C-H.

National Cheng-Kung University Hospital, Dept. of Urology, Tainan, Taiwan
Accurate clinical T3 staging by a computed tomography scoring system is an independent preoperative predictor of survival in patients with urothelial carcinoma of the ureter

By: Hayashi T.1, Goto K.1, Honda Y.2, Hsi R.S.3, Sentani K.4, Ikeda K.5, Kohada Y.1, Shinmei S.1, Inoue S.1, Teishima J.1, Yasui W.4, Awai K.2, Matsubara A.1
1Hiroshima University, Dept. of Urology, Hiroshima, Japan, 2Hiroshima University, Dept. of Diagnostic Radiology, Hiroshima, Japan, 3Vanderbilt University Medical Center, Dept. of Urology, Nashville, United States of America, 4Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, 5Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

Obesity-specific effect of sex on prognosis of upper tract urothelial carcinoma patients undergoing radical nephroureterectomy: A Japanese multicenter study

By: Fukushima H.1, Saito K.1, Yasuda Y.1, Uehara S.1, Kijima T.1, Yoshida S.1, Yokoyama M.1, Ishioka J.1, Matsuoka Y.1, Kihara K.1, Koga F.2, Okuno T.3, Arisawa C.4, Kamata S.5, Nagahama K.6, Masuda H.7, Yonese J.8, Kogeyama Y.9, Noro A.10, Tsuji T.11, Morimoto S.12, Fuji Y.1
1Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, 2Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, 3Toride Medical Center, Dept. of Urology, Ibaraki, Japan, 4Tobu Chiki Hospital, Dept. of Urology, Tokyo, Japan, 5Soka Municipal Hospital, Dept. of Urology, Soka, Japan, 6National Center for Global Health and Medicine, Konodai Hospital, Dept. of Urology, Chiba, Japan, 7National Cancer Center Hospital East, Dept. of Urology, Chiba, Japan, 8Canter Institute Hospital of Japanese Foundation for Cancer Research, Dept. of Urology, Tokyo, Japan, 9Saitama Cancer Center, Dept. of Urology, Saitama, Japan, 10Saitama Red Cross Hospital, Dept. of Urology, Saitama, Japan, 11Tokyo Metropolitan Otsuka Hospital, Dept. of Urology, Tokyo, Japan, 12Tsuchiura Kyodo General Hospital, Dept. of Urology, Ibaraki, Japan

Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma

By: D’Andrea D.1, Resch I.1, Chlostia P.2, Soria F.1, Abufaraj M.1, Kimura S.1, Jay Nash F.1, Margulis V.3, Karakiewicz P.I.4, Roupret M.5, Rink M.6, Briganti A.7, Lotan Y.3, Shariat S.F.1
1Medical University of Vienna, Dept. of Urology, Vienna, Austria, 2Jagiellonian University, Dept. of Urology, Cracow, Poland, 3University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, 4University of Montreal, Dept. of Urology, Montreal, Canada, 5Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris Sorbonne Université, Dept. of Urology, Paris, France, 6University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 7Vita-Salute University, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

Can we predict the histopathologic grade of upper tract urothelial carcinoma based on the ureteroscopic appearance?

By: Freund J.E.1, Legemate J.D.1, Baard J.1, Saeb-Parsy K.2, Wiseman O.2, Doizi
PT371  Volumetric imaging for staging upper tract urothelial carcinoma - a pilot study

By: Brehmer M.¹, Grahn A.², Tanaka N.³, Uhlén P.⁴
¹Karolinska Institutet, Danderyd Hospital (KI DS), Dept. of Clinical Sciences, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Oncology and Pathology, Stockholm, Sweden, ³Keio University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁴Karolinska Institutet, Dept. of Medical Biochemistry and Biophysics, Stockholm, Sweden

PT372  Retrograde pyelography before radical nephroureterectomy for upper urinary tract urothelial carcinoma aggravates intravesical tumor recurrence

By: Ko Y.H., Choi J.Y., Song P.H., Moon K.H., Jung H.C.
Yeungnam University, Dept. of Urology, Daegu, South Korea
The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

**14:00 - 14:03**

**Introduction**
A. Lamb, Oxford (GB)
D. Tilki, Hamburg (DE)

**PT373**

**The effect of US Preventive Services Task Force’s screening recommendation on trifecta and pentafecta outcomes in robot-assisted laparoscopic prostatectomy based on analysis of a single-surgeon series**

By: Bhat K.R.S, Onol F., Rogers T., Jenson C., Rocco B.M.C., Patel V.

Global Robotic Institute, Dept. of Urology, Celebration, United States of America,
University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy

**Aims and objectives of this presentation**
PT373

**PT374**

**The changing face of surgically treated low-risk prostate cancer (PCa): A national cancer database (NCDB) analysis**


Wayne State University, School of Medicine, Detroit, United States of America,
Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America,
Harvard Medical School, Dept. of Surgery, Boston, United States of America

**Aims and objectives of this presentation**
PT374

**PT375**

**Relationship between socioeconomic factors and non-prostate cancer mortality after radical prostatectomy**

By: Fröhner M., Farahzadi S., Koch R., Hübler M., Wirth M.P.
PT375

The EORTC quality of life questionnaire predicts long-term overall survival in patients treated with robotic assisted radical prostatectomy: Analysis of a large single center cohort

By: De Nunzio C.¹, Pastore A.L.², Lombardo R.¹, Nacchia A.¹, Carbone A.², Fuschi A.², Dutto L.³, Witt J.H.³
¹Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ²Sapienza University of Rome, ICOT Latina Hospital, Dept. of Urology, Latina, Italy, ³St. Antonius Hospital, Dept. of Urology, Paediatric Urology and Urological Oncology, Gronau, Germany

PT376

Long-term survival rates of localized prostate cancer patients treated by radical prostatectomy are significantly better than predicted life expectancy of the general population

By: Sakai Y.S.ª, Soma T.ª, Nakamura Y.ª, Aoki Y.ª, Fukui N.ª, Kageyama Y.ª
Saitama Cancer Center, Dept. of Urology, Ina, Japan

PT377

Identification of multi-stakeholder value in prostate cancer treatment by application of Multi-Criteria Decision Making (MCDM)

By: Jorissen P.¹, Moons K.¹, Pintelon L.¹, De Ridder D.², Everaerts W.²
¹KU Leuven, Dept. of Mechanical Engineering, Leuven, Belgium, ²KU Leuven, Dept. of Development and Regeneration, Leuven, Belgium

PT378

Gleason grade grouping: The significance of primary Gleason 5 in patients with Gleason grade group 5

By: Tilki D.¹, Preisser F.², Huland H.¹, Graefen M.¹, Chun F.², Mandel P.²
¹University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ²University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany
<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT380</td>
<td>Development of a procedure-specific classification system for reporting postoperative complications in prostate cancer patients undergoing robot-assisted radical prostatectomy</td>
<td>Gandaglia G., Barletta F., Robesti D., Pellegrino A., Cannoletta D., Stabile A., Martini A., Cucchiara V., Galos A.B., Bertini R., Colombo R., Suardi N., Gallina A., Fossati N., Montorsi F., Briganti A.</td>
<td>IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, University Hospital “Ospedali Riuniti”, Unit of Urology, Milan, Italy</td>
<td>Aims and objectives of this presentation</td>
</tr>
<tr>
<td>PT381</td>
<td>Opioid use before and after radical prostatectomy: Nationwide population-based study</td>
<td>Cazzaniga W., Loeb S., Garmo H., Robinson D., Stattin P.</td>
<td>IRCCS Ospedale San Raffaele, Uppsala University, Division of Experimental Oncology, Unit of Urology URI, Milan, Italy, New York University and Manhattan Veterans Affairs Medical Center, Dept. of Urology and Population Health, New York, United States of America, Regional Cancer Centre Uppsala Orebro, Uppsala University Hospital, Regional Cancer Centre, Uppsala, Sweden, Ryhov Hospital, Dept. of Urology, Jonköping, Sweden, Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden</td>
<td>Aims and objectives of this presentation</td>
</tr>
<tr>
<td>PT382</td>
<td>Fewer days of workplace absenteeism with robotic radical prostatectomy compared to open radical prostatectomy</td>
<td>Pucheril D.T., Chen X., Krimphove M.J., Tully K.H., Fletcher S.A., Dasgupta P., Trinh Q-D.</td>
<td>Brigham and Women’s Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, King’s College London, Faculty of Life Sciences and Medicine, London, United Kingdom</td>
<td>Aims and objectives of this presentation</td>
</tr>
<tr>
<td>PT383</td>
<td>Hot or cold: No difference in long-term potency between touch-cautery and athermic suture-ligation in control of pedicle during robot-assisted radical prostatectomy</td>
<td>Hofmann M., Huynh L., Skarecky D., Ahlering T.</td>
<td>University of California, Irvine, Dept. of Urology, Orange, United States of America</td>
<td>Aims and objectives of this presentation</td>
</tr>
</tbody>
</table>
A novel nomogram to predict lymph node invasion among patients with clinically localized prostate cancer based on clinical and mpMRI parameters: The importance of ECE score. Results from a single center series

By: Di Trapani E.¹, Catellani M.¹, Musi G.¹, Ferro M.¹, Bianchi R.¹, Cozzi G.¹, Alessi S.², Luzzago S.¹, Cordima G.¹, Mistretta F.A.¹, Conti A.¹, Matei D.V.¹, Petralia G.², De Cobelli O.¹
¹IEO, European Institute of Oncology IRCCS, Dept. of Urology, Milan, Italy, ²IEO, European Institute of Oncology IRCCS, Dept. of Radiology, Milan, Italy

Aims and objectives of this presentation
PT384

Prostate capsule extension: Can we plan surgical treatment based on MRI findings? An analysis of predictive factors to better identify T3a before surgery

By: Regis L.¹, Cuadras M.¹, Miret E.¹, Salazar A.¹, Planas J.¹, Celma A.¹, Lorente D.¹, Maast R.², Roche S.², Semidey M.E.³, De Torres M.I.³, Trilla E.¹, Morote J.¹
¹Vall d'Hebron Hospital, Dept. of Urology, Barcelona, Spain, ²Vall d'Hebron Hospital, Dept. of Radiology, Barcelona, Spain, ³Vall d'Hebron Hospital, Dept. of Pathology, Barcelona, Spain

Aims and objectives of this presentation
PT385

Impact of focal versus whole-gland therapy for prostate cancer in sexual function and urinary continence

By: Borges R.C.¹, Tourinho-Barbosa R.R.¹, Collura-Merlier S.¹, Muttin F.¹, Constantin D.S.¹, Bakavicius A.¹, Barret E.¹, Rozet F.¹, Carneiro A.², Cathala N.¹, Prapotnich D.¹, Mombet A.¹, Sanchez-Salas R.¹, Cathelineau X.¹
¹Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ²Hospital Israelita Albert Einstein, Dept. of Urology, São Paulo, Brazil

Aims and objectives of this presentation
PT386

Higher free testosterone predicts faster potency recovery after robot assisted radical prostatectomy

By: El-Khatib F.M., Huynh L., Towe M., Yafi F., Ahlering T.
University of California, Irvine, Dept. of Urology, Orange, United States of America

Aims and objectives of this presentation
PT387

Long-term outcomes and patterns of recurrence in patients with clinical lymphadenopathies undergoing radical prostatectomy as part of a multimodal treatment

Aims and objectives of this presentation
PT388
### Aims and objectives of this presentation

#### PT388

**Extended lymph node dissection is associated with improved overall survival in patients with very high-risk prostate cancer: A national cancer database analysis**

By: Sood A., Keeley J., Arora S., Dalela D., Jeong W., Rogers C., Peabody J., Menon M., Abdollah F.

Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America

#### PT389

**TRoMbone: Testing radical prostatectomy in men with oligo metastatic prostate cancer that has spread to the bone - a randomized controlled feasibility trial**


1 University College London Hospital, Dept. of Uro-Oncology, London, United Kingdom, 2 Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, 3 Oxford University Hospital, Dept. of Urology, Oxford, United Kingdom, 4 Guy's Hospital, Dept. of Urology, London, United Kingdom, 5 Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, 6 Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom

#### PT390

**Impact of timing on radiation therapy adverse events following radical prostatectomy, an analysis of the RTOG 9601 cohort**


1 Henry Ford Hospital, Health System, Dept. of Urology, Detroit, United States of America, 2 Harvard Medical School, Dept. of Urology, Boston, United States of America

#### PT391

**Barriers to selective referral of genitourinary cancers to high- vs. low-volume hospitals**


1 IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, URI, Milan, Italy, 2 Mayo Clinic, Dept. of Urology, Rochester, MN, United States of America, 3 University Hospitals Leuven, Dept. of Urology, Leuven, Belgium
Scientific Programme - EAU19 Barcelona

By: Berg S.1, Pucheril D.T.1, Sahraoui A.1, Tan W.S.2, Krimphove M.J.1, Marchese M.1, Lipsitz S.R.3, Noldus J.4, Kibel A.S.1, Trinh Q-D.1
1Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 2University College London, Division of Surgery and Interventional Science, Dept. of Urology, London, United Kingdom, 3Brigham and Women's Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, 4Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and NeuroUrology, Herne, Germany

Aims and objectives of this presentation
PT392

PT393

Retzius sparing robotic assisted radical prostatectomy: Beyond the learning curve - “Warts 'n all”

Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom

Aims and objectives of this presentation
PT393

PT394

Does combined anterior and posterior reconstruction improve early continence in robotic assisted radical prostatectomy?

By: Stanowski M., Lobo N., Petrides N., Kommu S., Eddy B.
Kent and Canterbury Hospital, East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom

Aims and objectives of this presentation
PT394

PT395

Hormone therapy for prostate cancer increases the risk of new-onset hypertension: A nationwide propensity score-matched four-year longitudinal cohort study

By: Tseng S., Shiao-Jin S., Wen-Jeng W., Ching-Chia C., Jhen-Hao J.
Kaohsiung Medical University Hospital, Dept. of Urology, Kaohsiung City, Taiwan

Aims and objectives of this presentation
PT395

PT396

The impact of initial PSA <100 ng/mL on prognosis in patients with metastatic hormone naïve prostate cancer (mHNPC)

By: Suzuki Y.1, Hatakeyama S.1, Yamamoto H.1, Imai A.1, Yoneyama T.1, Hashimoto Y.1, Koie T.2, Ohyama C.1
1Hirosaki University, Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Gifu University, Graduate School of Medicine, Dept. of Urology, Gifu, Japan
Androgen deprivation treatment (ADT) in the contemporary management of prostate cancer: Real life practice patterns vs. guidelines

By: Mitropoulos D.¹, Chlosta P.², Häggman M.³, Ström T.⁴, Markussis V.⁵
¹National and Kapodistrian University of Athens Medical School, Dept. of Urology, Athens, Greece, ²Jagiellonian University, Dept. of Urology, Krakow, Poland, ³Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden, ⁴Ipsen Sweden, Medical Department, Stockholm, Sweden, ⁵Ipsen Greece, Medical Department, Athens, Greece
Management of complex urethral strictures

Video Session 11

Monday 18 March
14:00 - 15:30

Location: Red Area, eURO Auditorium 1

Chairs: To be confirmed
S. Kulkarni, Pune (IN)
L. Martínez Piñeiro, Madrid (ES)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

Withdrawn

V74

Aims and objectives of this presentation

V75

Oral grafts for urethral augmentation. Step-by-step harvesting technique from inner cheek and sublingual area

Marques de Valdecilla University Hospital, Dept. of Urology, Santander, Spain

Aims and objectives of this presentation

V76

Bulbo-membranous urethroplasty with "BAES-flap": A description of the surgical technique

By: Gil-Vernet Sedo A. 1, Céspedes M. 1, Ropero J. 2, Diaz F. 1
1Parc Sanitari Sant Joan de Déu, Dept. of Urology, Barcelona, Spain, 2Hospital Universitari Vall d’Hebron, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation

V77

Anastomotic urethroplasty in first year of life

By: Kulkarni S. 1, Joshi P.M.J 2
1Kulkarni Reconstructive Urology Center, Dept. of Reconstructive Urology, Pune, India, 2Kulkarni Reconstructive Urology Center, Dept. of Reconstructive Urology, Pune, India

Aims and objectives of this presentation
<table>
<thead>
<tr>
<th>V78</th>
<th>Penile skin flap neourethra after radical penile amputation</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Kulkarni S., Bhadranwar S., Rawal A., Mousa A., Joshi P.M.</td>
</tr>
<tr>
<td></td>
<td>Kulkarni Reconstructive Urology Center, Reconstructive Urology, Pune, India</td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>V78</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>V79</th>
<th>Augmented non-transected anastomotic urethroplasty (Kodama’s operation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Kotov S.V.</td>
</tr>
<tr>
<td></td>
<td>Pirogov Russian National Research Medical University, Dept. of Urology and Andrology, Moscow, Russia</td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>V79</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>V80</th>
<th>Transperineal prerectal approach for the treatment of posterior urethral stricture after radical prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Vitarelli A., Divenuto L., Vulpi M., Ditonno P.</td>
</tr>
<tr>
<td></td>
<td>1University of Bari &quot;Aldo Moro&quot;, Urology and Andrology Unit, Department of Emergency and Organ Transplantation, Bari, Italy, 2University of Bari, Urology and Andrology Unit, Department of Emergency and Organ Transplantation, Bari, Italy</td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>V80</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>V81</th>
<th>Ventral inlay and dorsal onlay buccal grating for long segment nearly obliterative to obliterative bulbar urethral strictures</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Chawla A.K., Kapadia A., Odougar A., Hegde P., Binmohammed Z.</td>
</tr>
<tr>
<td></td>
<td>Kasturba Medical College, Manipal University, Dept. of Urology and Renal Transplant, Manipal, India</td>
</tr>
<tr>
<td>Aims and objectives of this presentation</td>
<td>V81</td>
</tr>
</tbody>
</table>
Reducing complications and improving outcomes in cystectomy

Poster Session 70

Monday 18 March
14:00 - 15:30

Location: Red Area, eURO Auditorium 2
Chairs: B. Ali-El-Dein, Mansoura (EG)
A. Noon, Sheffield (GB)
G.N. Thalmann, Bern (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

977
Understanding risk factors associated with early unplanned reoperation after radical cystectomy and urinary diversion
By: Laymon M., Ghobrial F.K., Hashem A., Abol-Enein H., Shaaban A., Mosbah A.
Urology and Neprology Center, Dept. of Urology, Mansoura, Egypt

Aims and objectives of this presentation
977

978
Modified Wallace anastomosis reduces ureteroenteric stricture rates – prospective randomised study of ureteroenteric stricture rates after ileal conduit urinary diversion
By: Vukovic M., Kavaric P., Magdelinic A., Pratljacic D., Sabovic E., Radovic N.
Clinical centre of Montenegro, Dept. of Urology, Podgorica, Montenegro

Aims and objectives of this presentation
978

979
The impending need of a new disease specific comorbidity index for bladder cancer patients candidate to robot-assisted radical cystectomy
By: Lambert E.1, Dell’Oglio P.2, Vollemaere J.1, Uvin P.1, Goossens M.1, Van Der Jeugt J.1, Devos G.1, De Groote R.1, Turri F.1, Larcher A.3, Collins J.4, Schatteman P.1, De Naeyer G.1, D’Hondt F.1, Mottrie A.2
1Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium, 2Onze Lieve Vrouw Hospital, Orsi Academy, Dept. of Urology, Aalst, Belgium, 3Urological Research Institute, IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 4Orsi Academy, Dept. of Urology, Aalst, Belgium

Aims and objectives of this presentation
979

980
Socioeconomic parameters as predictors of competing (non-bladder cancer) mortality after radical cystectomy
Aims and objectives of this presentation

980

Predicting post-operative complications in radical cystectomy patients using pre-operative CT-measured adipose tissue indices

1 Queen Elizabeth University Hospital, Dept of Urology, Glasgow, United Kingdom, 2 University of Toronto, Dept of Surgery and Surgical Oncology, Division of Urology, Toronto, Canada

Aims and objectives of this presentation

981

Impact of neoadjuvant pembrolizumab on intra and peri-operative complications after radical cystectomy: A comparison with both standard chemotherapy and no adjuvant treatment

By: Zaffuto E. 1, Moschini M. 2, Burgio G. 1, Scuderi S. 1, Barletta F. 1, Nocera L. 1, Mirone V. 3, Salonia A. 1, Colombo R. 1, Montorsi F. 1, Briganti A. 1, Necchi A. 4, Gallina A. 1
1 IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 2 Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 3 University Federico II, Dept. of Urology, Naples, Italy, 4 Fondazione IRCCS Istituto Nazionale Tumori, Division of Oncology, Unit of Urology, Milan, Italy

Aims and objectives of this presentation

982

Phase 1 clinical trial to evaluate the use of a tissue engineered neo-urinary conduit using adipose derived smooth muscle cells after radical cystectomy

By: Bivalacqua T. 1, Steinberg G. 2, Smith N. 2, Joice G. 1, Sopko N. 1, Lerner S. 3, Bochner B. 4, Lee C. 5, Rivera E. 6, Jain D. 6, Bertram T. 6, Schoenberg M. 7
1 Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, 2 University of Chicago, Dept. of Urology, Chicago, United States of America, 3 Baylor College of Medicine, Dept. of Urology, Houston, United States of America, 4 Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 5 Ohio State University, Dept. of Urology, Columbus, United States of America, 6 Tengion Regenerative Medicine, Dept. of Urology, Winston-Salem, United States of America, 7 Albert Einstein School of Medicine, Dept. of Urology, Bronx, United States of America
Aims and objectives of this presentation

983

Comprehensive assessment of time-to-event data of perioperative short-term complications following radical cystectomy

University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

Aims and objectives of this presentation

984

Does indocyanine green reduce ureteroileal anastomotic strictures after robotic radical cystectomy?

University of Southern California, USC Institute of Urology, Los Angeles, United States of America

Aims and objectives of this presentation

985

Randomized controlled trial to compare the length of stay, perioperative outcomes and complications in patients undergoing radical cystectomy with and without the enhanced recovery after surgery (ERAS) protocol in a tertiary care centre in India

By: Nayak B., Bansal D., Singh P., Seth A., Nayyar R., Ramachandran R.
1 All India Institute of Medical Sciences, New Delhi, Dept. of Urology, New Delhi, India, 2 All India Institute of Medical Sciences, New Delhi, Dept. of Anaesthesia, New Delhi, India

Aims and objectives of this presentation

986

Prospective randomized comparison of quality of life and sexual function between ileal neobladder versus sigmoid neobladder reconstruction following nerve sparing, vas sparing, seminal vesicle sparing and partial prostate sparing radical cystectomy

By: Singh V., Sinha R.J., Aggarwal A.J., Pandey S.
King George’s Medical University, Dept. of Urology, Lucknow, India

Aims and objectives of this presentation

987

Patients with perioperative complications presented a higher risk of cancer specific mortality after radical cystectomy: A two year multicentre Italian real-life analysis

By: De Nunzio C., Cindolo L., Simone G., Lombardo R., Tema G., Leonardo C.
Aims and objectives of this presentation

Period-specific mean annual hospital volume of radical cystectomy is associated with outcome and perioperative quality of care in Sweden – a nation-wide population based study


1Institution of Translational Medicine, Lund University, Dept. of Urology, Malmö, Sweden, 2Institution of Translational Medicine, Lund University, Dept. of Urology, Lund, Sweden, 3Linköping University, Dept. of Clinical and Experimental Medicine, Linköping, Sweden, 4Karolinska Institute, Danderyd Hospital, Dept. of Clinical Sciences, Stockholm, Sweden, 5Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, 6Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, 7Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, 8Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Gothenburg, Sweden

Aims and objectives of this presentation

A competing risk analysis of survival after radical cystectomy for bladder cancer patients: The impact of age at the time of surgery


1IRCCS Ospedale San Raffaele; URI, Dept. of Urology, Division of Oncology, Milan, Italy, 2Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 3Medical University of Vienna, Dept. of Urology, Vienna, Austria
Aims and objectives of this presentation

990

991

Timing, patterns and predictors of 90-days readmission rate after robotic radical cystectomy with totally intracorporeal urinary diversion

University of Southern California, USC institute of Urology, Los Angeles, United States of America

Aims and objectives of this presentation

991
An intratumoural cytotoxic immunotherapy approach to target prostate cancer in a syngeneic murine model

By: Papaevangelou E.¹, Smolarek D.¹, Elhage O.¹, Smith R.A.², Dasgupta P.¹, Galustian C.¹
¹King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom, ²King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom

Aims and objectives of this presentation

Development and characterization of novel AKR1C3 inhibitors: Therapeutic potential for castration-resistant prostate cancer

By: Fujimoto N.¹, Endo S.², Oguri H.², Toyooka N.³, Matsunaga T.², Ikari A.², Tomisaki I.¹, Nakayama T.⁴
¹University of Occupational and Environmental Health, Dept. of Urology, Kitakyushu, Japan, ²Gifu Pharmaceutical University, Laboratory of Biochemistry, Gifu, Japan, ³University of Toyama, Graduate School of Innovative Life Science, Toyama, Japan, ⁴University of Occupational and Environmental Health, Dept. of Pathology, Kitakyushu, Japan

Aims and objectives of this presentation

Investigating a novel recombinant antibody to attenuate prostate cancer progression by targeting cell surface GRP78

By: Al-Hashimi A.¹, Won K.², Pham E.³, Mariano N.⁴, Bailis J.⁴, Austin R.⁵, Shayegan B.⁶
¹McMaster University, Dept. of Surgery - Division of Urology, Hamilton, Canada,
Aims and objectives of this presentation
994

**Stat5 mediates enzalutamide-resistant prostate cancer growth**

By: Nevalainen M.1, Udhane V.1, Maranto C.1, Hoang D.2, Gu L.2, Erickson A.3, Devi S.1, Talati P.2, Jacobsohn K.4, Iczkowski K.5, See W.4, Kilari D.6, Mirtti T.3

1Medical College of Wisconsin, Dept. of Pathology, Pharmacology and Toxicology, Milwaukee, United States of America, 2Thomas Jefferson University, Dept. of Cancer Biology, Philadelphia, United States of America, 3University of Helsinki, Dept. of Pathology, Helsinki, Finland, 4Medical College of Wisconsin, Dept. of Urology, Milwaukee, United States of America, 5Medical College of Wisconsin, Dept. of Pathology, Milwaukee, United States of America, 6Medical College of Wisconsin, Dept. of Medicine, Milwaukee, United States of America

Aims and objectives of this presentation
995

**Novel selective lysine specific demethylase 1 inhibitors effectively impair castration resistant prostate cancer growth**

By: Etani T.1, Naiki T.1, Nagai T.1, Nozaki S.1, Iida K.1, Ando R.1, Kawai N.1, Tozawa K.1, Suzuki T.2, Yasui T.1

1Nagoya city university, Dept. of Nephro-urology, Nagoya, Japan, 2Kyoto Prefectural University of Medicine, Dept. of Chemistry, Kyoto, Japan

Aims and objectives of this presentation
996

**SQLE, a miR-205 dependent cholesterol biosynthesis regulator, is a druggable target in prostate cancer**

By: Kalogirou C.1, Hartmann E.2, Rosenfeldt M.2, Röhrig F.3, Krebs M.1, Rosenwald A.2, Kübler H.1, Schmitz W.3, Kneitz B.1, Schulze A.3

1University Medical Centre of the University of Würzburg, Dept. of Urology and Paediatric Urology, Würzburg, Germany, 2University Medical Centre of the University of Würzburg, Dept. of Pathology, Würzburg, Germany, 3Theodor-Boveri Institute of the University of Würzburg, Dept. of Biochemistry and Molecular Biology, Würzburg, Germany

Aims and objectives of this presentation
997

**Potential therapeutic role of the combination of biguanides and statins in prostate cancer: Association with alterations in key genes and miRNAs levels**

Aims and objectives of this presentation
998
Aims and objectives of this presentation
998

Identification of a novel therapeutic target for castration-resistant prostate cancer by proteomic analysis of serum extracellular vesicles

Graduate School of Medicine, Osaka University, Dept. of Urology, Osaka, Japan

Aims and objectives of this presentation
999

Carboxylesterase - TRAIL expressing human adipose stem cells inhibit tumor growth in castration resistant prostate cancer bearing mice with less toxicity

By: Song Y.S. , Oh E.J. , Lee S.H. , Song E.S. , Kim J.H. , Doo S.W. , Yang W.J. , Yun J.H. , Lee S.J.
1Soonchunhyang University College of Medicine, Dept. of Urology, Seoul, South Korea,
2Soonchunhyang University College of Medicine, Medical Research Institute, Seoul, South Korea,
3Gwangjin-Gu Health Center, Medical Treatment Division, Seoul, South Korea,
4Soonchunhyang University College of Medicine, Dept. of Urology, Gumi, South Korea,
5Kyunghhee University Hospital, Dept. of Urology, Seoul, South Korea

Aims and objectives of this presentation
1000

Investigation of gene therapy for prostate cancer by the JC virus-like particles delivering a PSA promoter driven-suicide gene

By: Shen C-H. , Jou Y-C. , Lai W-H. , Lin M-C. , Chang D.
1Chiayi Christian Hospital, Dept. of Urology, Chiayi, Taiwan,
2National Chung Cheng University, Institute of Molecular Biology, Chiayi, Taiwan

Aims and objectives of this presentation
1001
1002  Overcoming enzalutamide-resistance by inhibition of the transcription factor Stat5b in prostate cancer

By: Erb H. 1, Bodenbender J. 2, Diehl T. 2, Tsauer I. 2, Jüngel E. 2, Gleave M. 3, Haferkamp A. 2, Culig Z. 4, Thomas C. 1

1 University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, 2 University of Mainz, Dept. of Urology, Mainz, Germany, 3 University of British Columbia, The Vancouver Prostate Centre, Vancouver, Canada, 4 University of Innsbruck, Dept. of Urology, Innsbruck, Austria

Aims and objectives of this presentation

1002

1003  Combining local ablative therapy with immunotherapy using bifunctional nanoparticle in treating prostate cancer

To be confirmed

Aims and objectives of this presentation

1003

1004  CDK8/CDK19 inhibition as a new therapeutic option for advanced prostate cancer

By: Hupe M.C. 1, Offermann A. 2, Becker F. 2, Joerg V. 2, Vogel W. 2, Braegelmann J. 3, Perner S. 2, Merseburger A. 1

1 University Hospital Schleswig-Holstein, Campus Luebeck, Dept. of Urology, Luebeck, Germany, 2 University Hospital Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Leibniz Center for Medicine and Biosciences, Dept. of Pathology, Luebeck, Germany, 3 Center of Integrated Oncology Cologne–Bonn, Medical Faculty, University of Cologne, Molecular Pathology, Institute for Pathology, Medical Faculty and Department of Translational Genomics, Bonn, Germany

Aims and objectives of this presentation

1004

1005  VERU-111, a novel oral inhibitor of α and β tubulin, inhibits tumor growth in the human castration-resistant AR variant prostate cancer (PCa) model 22Rv1

By: Getzenberg R. 1, Markowski M.M. 2, Eisenberger M.A. 2, Steiner M.S. 3, Antonarakis E.S. 2

1 Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, United States of America, 2 Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States of America, 3 Veru Inc, Veru, Miami, United States of America

Aims and objectives of this presentation

1005
<table>
<thead>
<tr>
<th><strong>1006</strong></th>
<th><strong>Evaluation of enhanced mobilisation with individual goal-setting and self-monitoring after abdominal surgery due to cancer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>By: <a href="#">Porserud A.</a>, Aly M. [2], Nygren-Bonnier M. [3], Hagströmer M. [3]</td>
<td></td>
</tr>
<tr>
<td><strong>Aims and objectives of this presentation</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>1007</strong></th>
<th><strong>Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aims and objectives of this presentation</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>1008</strong></th>
<th><strong>Effects of enhanced recovery after surgery protocols of postoperative ileus and bowel obstruction in patients undergoing radical cystectomy</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Institute Hospital, Japanese Foundation for Cancer Research, Dept. of Genitourinary Oncology, Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td><strong>Aims and objectives of this presentation</strong></td>
<td></td>
</tr>
</tbody>
</table>
1009 Alvimopan is associated with a reduction in length of stay and hospital costs for patients undergoing radical cystectomy

By: Huang T.H.¹, Mossanen M.¹, Preston M.¹, Chung B.I.², Huang W.J.³, Chang S.L.¹
¹Brigham and Women’s Hospital, Dept. of Surgery, Boston, United States of America,
²Stanford University Medical Center, Dept. of Urology, Stanford, United States of America,
³Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan

Aims and objectives of this presentation
1009

1010 Evaluation of patient satisfaction managed in a enhanced recovery after surgery program (ERAS) using the validated questionnaire EVAN-G

By: Fakhfakh S.¹, Pouliquen C.², Walz J.¹, Brun C.², Tourret M.², Fauchard M.², Mokart D.³, Cini E.⁴, Boulant S.⁵, Massacrier S.⁵, Pignot G.¹
¹Institut Paoli Calmettes, Dept. of Onco Urology, Marseille, France,
²Institut Paoli Calmettes, Dept. of Anesthesiology, Marseille, France,
³Institut Paoli Calmettes, Dept. of Anesthesiology, Marseille, France,
⁴Institut Paoli Calmettes, Dept. of Onco Urology ERAS, Marseille, France,
⁵Institut Paoli Calmettes, Dept. of Onco Urology ERAS Nurse, Marseille, France

Aims and objectives of this presentation
1010

1011 Patient blood management applied to radical cystectomy in "enhanced recovery after surgery" era: Preliminary results

By: De Lorenzis E.¹, Rocchini L.², Botticelli F.², Fontana M.², Piccoli M.², Morelli M.², Gallioli A.², Lorusso V.², Boeri L.², Sampogna G.², Zanetti S.P.², Longo F.², Albo G.², Cappellini M.D.³, Montanari E.²
¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Dept. of Urology, Milan, Italy,
²Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico Department of Clinical Sciences and Community Health, University of Milan, Dept. of Urology, Milan, Italy,
³Rare Diseases Center, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico Department of Clinical Sciences and Community Health, University of Milan, Dept. of Medicine, Milan, Italy

Aims and objectives of this presentation
1011

1012 Intensified and standardized digital communication with your cystectomy patients potentially is a simple and effective way to decrease readmission rates

By: Zehnder P., Moltzahn F., Zehnder J-L., Hasler D., Flückiger D., Birkhäuser F.D. Hirslanden Klinik St. Anna, Dept. of Urology, Lucerne, Switzerland
Aims and objectives of this presentation

1012

Comorbidities and complications in relation to radical cystectomy due to cancer - a randomized control trial

By: Andersen C.S., Jensen B.T., Kingo P.S., Bjerggaard Jensen J.
Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark

Aims and objectives of this presentation

1013

Outcomes of “Chennai” enhanced recovery protocol after major urological surgery

By: Ragavan N., Dholakia K., Karthik V.C., Ramesh M., Baskaran J.
Apollo Hospital, Dept. of Urology, Chennai, India

Aims and objectives of this presentation

1014

ERAS® protocol improves cancer-specific and overall survival after elective radical cystectomy: A retrospective cohort study

By: Crettenand F. 1, M’Baya O. 1, Jichlinski P. 1, Martel P. 1, Dartiguenave F. 1, Blanc C. 2, Rouvé J.D. 2, Valerio M. 1, Cerantola Y. 1, Lucca I. 1
1 University Hospital-CHUV, Dept. of Urology, Lausanne, Switzerland, 2 University Hospital-CHUV, Dept. of Anesthesiology, Lausanne, Switzerland

Aims and objectives of this presentation

1015

Enhanced recovery after nephrectomy: Conception, implementation and outcomes in a high volume specialist centre

By: Withington J. 1, Yuminaga Y. 1, Gulamhusein A. 1, Lyness C. 2, Cullen D. 1, Barod R. 1
1 Royal Free London, Specialist Centre for Kidney Cancer, London, United Kingdom, 2 Royal Free London, Dept. of Anaesthetics, London, United Kingdom

Aims and objectives of this presentation

1016

Pain control after laparoscopic partial nephrectomy (LPN): Comparison of transversus abdominis plane block (TAP block) versus wound infiltration

By: Taha T. 1, Sionov B.V. 1, Tiberiu E. 2, Rosenberg P. 2, Stein A. 2, Sidi A.A. 1, Tsivian A. 1
1 The E. Wolfson Medical Center, Dept. of Urologic Surgery, Holon, Israel, 2 The E. Wolfson Medical Center, Dept. of Anesthesiology, Holon, Israel

Aims and objectives of this presentation

1017
<table>
<thead>
<tr>
<th>Session</th>
<th>Presentation Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1018</td>
<td>The impact of Enhanced Recovery After Surgery protocol on postoperative pain management in the era of opioid crisis: The post-chemotherapy open RPLND paradigm</td>
<td>Dimitropoulos K., Pisters L.L., Karatzas A., Vaiopoulos C., Papandreou C., Daliani D., Zachos I., Gravas S., Tzortzis V.</td>
<td>Aberdeen Royal Infirmary, NHS Grampian, Dept. of Urology, Aberdeen, United Kingdom, MD Anderson Cancer Centre, Dept. of Urology, Houston, United States of America, University Hospital of Larissa, Dept. of Urology, Larissa, Greece, Papageorgiou Hospital, Dept. of Medical Oncology, Thessaloniki, Greece, Euroclinic, Dept. of Medical Oncology, Athens, Greece</td>
</tr>
<tr>
<td>1018</td>
<td>Identifying factors which prolong length of stay following open retroperitoneal lymph node dissection</td>
<td>Pearce A.K., Whibley J., Walker S., Mayer E.K., Nicol D.</td>
<td>The Royal Marsden Hospital, Dept. of Urology, London, United Kingdom</td>
</tr>
<tr>
<td>15:19 - 15:24</td>
<td>Summary</td>
<td>S. Daneshmand, Los Angeles (US)</td>
<td></td>
</tr>
</tbody>
</table>
Pelvic floor muscle training improves sexual distress in women with stress urinary incontinence

By: Zachariou A.1, Papakosta S. 2, Filiponi M. 2, Dimitriadis F. 3, Skouros S. 1, Tsounapi P. 4, Takenaka A. 4, Sofikitis N. 1
1University of Ioannina, Dept. of Urology, Ioannina, Greece, 2Rehabilitation Centre EF PRATTEIN, Dept. of Physical Medicine and Rehabilitation, Volos, Greece, 3Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, 4Tottori University, Dept. of Urology, Yonago, Japan

Aims and objectives of this presentation
1020

A prospective parallel cohort, multi-center study of the Solyx™ single incision sling system vs. the Obtryx™ II sling system for the treatment of women with stress urinary incontinence: Patient-reported outcomes at 3 years

By: White A.B. 1, Eilber K.S. 2, Anger J.T. 2, Kahn B.S. 3, Schaffer J.I. 4
1University of Texas, Dell Medical School, Dept. of Women's Health, Austin, United States of America, 2Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America, 3Scripps Clinic, Dept. of Obstetrics and Gynecology, San Diego, United States of America, 4University of Texas Southwestern Medical Center, Dept. of Obstetrics and Gynecology, Dallas, United States of America

Aims and objectives of this presentation
1021

Effects of the REMEEX system® in female patients with intrinsic sphincteric deficiency and recurrent urinary incontinence: 10-year outcomes

By: Song P.H. 1, Min G.E. 2, Choi J.Y. 1, Ko Y.H. 1, Moon K.H. 1, Jung H.C. 1
1College of Medicine, Yeungnam University, Dept. of Urology, Daegu, South Korea, 2Kyung Hee University College of Medicine, Kyung Hee University Hospital at Gangdong,
Dept. of Urology, Seoul, South Korea

Aims and objectives of this presentation

1022

Comparison of open and robot-assisted artificial urinary sphincter implantation in female patients with stress urinary incontinence: A multicenter study


1University of Rennes, Dept. of Urology, Rennes, France, 2Strasbourg University Hospital, Dept. of Urology, Strasbourg, France, 3Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, 4Pole Sante Sud, Dept. of Urology, Le Mans, France, 5Rennes University Hospital, Dept. of Urology, Rennes, France, 6Brest University Hospital, Dept. of Urology, Brest, France, 7Pitié Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, 8Foch Hospital, Dept. of Urology, Suresnes, France, 9Saint Grégoire Private Hospital, Dept. of Urology, Rennes, France, 10Groupe hospitalier Diaconesses Croix Saint Simon, Dept. of Urology, Paris, France, 11Tenon University Hospital, Dept. of Urology, Paris, France, 12Rouen University Hospital, Dept. of Urology, Rouen, France, 13Limoges University Hospital, Dept. of Urology, Limoges, France, 14Brest University Hospital, Dept. of Urology, Brest, France

Aims and objectives of this presentation

1023

Associated video presentation Robot-assisted implantation of artificial urinary sphincter in women: A standardized surgical technique


1Rennes University Hospital, Dept. of Urology, Rennes, France, 2Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, 3Pole Sante Sud, Dept. of Urology, Le Mans, France, 4Pitié Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, 5Saint Grégoire Private Hospital, Dept. of Urology, Rennes, France, 6Foch Hospital, Dept. of Urology, Suresnes, France, 7Toulouse University Hospital, Dept. of Urology, Toulouse, France, 8Limoges University Hospital, Dept. of Urology, Limoges, France, 9Brest University Hospital, Dept. of Urology, Brest, France

Aims and objectives of this presentation

V05

Long-term outcomes of female stress incontinence surgery: A real-world study

By: Ravindra P., Henry M., Bazo A., Parkinson R.

Nottingham University Hospitals NHS Trust, Dept. of Urology, Nottingham, United Kingdom

Aims and objectives of this presentation

V05
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>1024</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1025</strong> Efficacy and safety of minislings for the treatment of female stress urinary incontinence in a cohort with a median follow-up of 10 years</td>
<td></td>
</tr>
<tr>
<td>By: Manso M., Botelho F., Silva C., Cruz F. Centro Hospitalar São João, Dept. of Urology, Porto, Portugal</td>
<td></td>
</tr>
<tr>
<td><strong>1026</strong> Outcomes of open artificial urinary sphincter in female patients with stress urinary incontinence after a follow-up of 10 years</td>
<td></td>
</tr>
<tr>
<td>By: Tricard T., Jochum F., Saussine C. Nouvel Hôpital Civil - Hôpitaux Universitaire de Strasbourg, Dept. of Urology, Strasbourg, France</td>
<td></td>
</tr>
<tr>
<td><strong>1027</strong> Tension-free vaginal tape: Over 10 years follow-up</td>
<td></td>
</tr>
<tr>
<td>By: Illiano E., Natale F., Marchesi A., Costantini E. 1 1Andrological and Urogynecological Clinic, Santa Maria Hospital Terni, University of Perugia, Dept. of Surgery and Biomedical Sciences, Terni, Italy, 2San Carlo di Nancy hospital, Dept. of Urology, Rome, Italy, 3Andrological and Urogynecological Clinic, Santa Maria Hospital Terni, University of Perugia, Dept. of surgery and biomedical sciences, Terni, Italy</td>
<td></td>
</tr>
<tr>
<td><strong>1028</strong> Success and satisfaction of tension-free vaginal tape surgery in females with stress urinary incontinence: Results at 17 years of follow-up</td>
<td></td>
</tr>
<tr>
<td>By: Kim H.W., shin D.G., Yoon C.S., Choi S., Cho W.Y., Min K.S., Oh T.H., Lee W., Kang B., Lee J.Z. 1 1Pusan National University Hospital, Dept. of Urology, Busan, South Korea, 2BHS Hansseo Hospital, Dept. of Urology, Busan, South Korea, 3Kosin University College of Medicine, Dept. of Urology, Busan, South Korea, 4Dong-A University Hospital, Dept. of Urology, Busan, South Korea, 5Inje University Busan Paik Hospital, Dept. of Urology, Busan, South Korea, 6Samsung Changwon Hospital, Dept. of Urology, Changwon, South Korea, 7Ulsan-Jeil Hospital, Dept. of Urology, Ulsan, South Korea</td>
<td></td>
</tr>
</tbody>
</table>
A multicenter randomized trial comparing robot-assisted versus pure laparoscopic sacrocolpopexy for pelvic organ prolapse


Aims and objectives of this presentation

Surgical and long-term postoperative outcomes of minimally invasive mesh sacrocolpopexy: A high-volume center experience


Aims and objectives of this presentation

Transvaginal mesh repair for pelvic organ prolapse surgery improve patient’s quality of life at long term follow up


Aims and objectives of this presentation

Management of urethrocutaneous fistulae complicating sacral and perineal pressure ulcer in neuro-urological patients: A national multicenter study from the French-speaking Neurourology Study Group (GENULF)


Aims and objectives of this presentation
Nantes, France, 4 Kerpape Hospital, Dept. of Physical Medicine and Rehabilitation, Ploemeur, France, 5 Rehabilitation Centre of L’Arche, Dept. of Physical Medicine and Rehabilitation, Saint-Saturnin, France, 6 Raymond Poincaré Academic Hospital, Dept. of Physical Medicine and Rehabilitation, Garches, France, 7 CHU Rangueil, Dept. of Physical Medicine and Rehabilitation, Toulouse, France, 8 CHU Rangueil, Dept. of Urology, Toulouse, France, 9 Lyon Sud Hospital, Lyon University Hospital, Dept. of Urology, Lyon, France, 10 CHU Rennes, Dept. of Urology, Rennes, France, 11 Raymond Poincaré Academic Hospital, Dept. of Orthopaedic Surgery, Garches, France, 12 APHM, Hôpital de la Conception, Aix Marseille Université, Dept. of Urology, Marseille, France

**Aims and objectives of this presentation**

1032
The evolving field of hormone-sensitive prostate cancer

Poster Session 74

Monday 18 March
14:00 - 15:30

Location: Green Area, Room 4
Chairs: G.P. Haas, Syracuse (US)
A. Morgans, Chicago (US)
B. Ralla, Berlin (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1033

The role of abiraterone acetate plus prednisone/prednisolone in high- and low-risk metastatic hormone sensitive prostate cancer


1 The Christie GenitoUrinary Research Group, Dept. of Surgery, The Christie Hospital, Manchester, United Kingdom, 2 Institute of Cancer and Genomic Studies, Dept. of Oncology, Birmingham, United Kingdom, 3 Academic Urology Unit, Dept. of Medical Oncology, London, United Kingdom, 4 Medical Research Council, Clinical Trials Unit, London, United Kingdom, 5 University College London Cancer Institute, Dept. of Oncology, London, United Kingdom, 6 Guys and St Thomas NHS Foundation trust, Dept. of Medical Oncology, London, United Kingdom, 7 St James University Hospital, Dept. of Urology, Leeds, United Kingdom, 8 Beatson West of Scotland Cancer Centre, Dept. of Medical Oncology, Glasgow, United Kingdom, 9 University of Wolverhampton, Faculty of Education, Health and Wellbeing, Wolverhampton, United Kingdom, 10 Cardiff University, Division of Cancer and Genetics, Cardiff, United Kingdom, 11 University Hospital Birmingham NHS Foundation Trust, Dept. of Radiology, Birmingham, United Kingdom

Aims and objectives of this presentation
1033

1034

Survival in men with de novo metastatic prostate cancer before and after the introduction of chemotherapy for advanced prostate cancer: A nationwide, population-based study

By: Westerberg M. 1, Franck Lissbrant I. 2, Damber J.E. 2, Robinson D. 3, Garmo H. 4, Stattn P. 4

1 Uppsala University, Dept. of Mathematics, Uppsala, Sweden, 2 Institute of Clinical Sciences, Sahlgrenska Academy at University of Göteborg, Dept. of Oncology, Gothenburg, Sweden, 3 Ryhov Hospital, Dept. of Urology, Jönköping, Sweden, 4 Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden
Aims and objectives of this presentation
1034

*Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)*


1Malteser Hospital Bonn, Dept. of Urology, Bonn, Germany, 2Praxis für Urologie Pankow, Dept. of Urology, Berlin, Germany, 3Praxisgemeinschaft für Urologie, Dept. of Urology, Borken, Germany, 4Urologicum Duisburg, Dept. of Urology, Duisburg, Germany, 5Urologikum Hamburg, Dept. of Urology, Hamburg, Germany, 6Saarland University Medical Center, Dept. of Urology, Homburg, Germany, 7Praxis für Urologie, Dept. of Urology, Kempen, Germany, 8Zentrum für Onkologie und Urologie Rostock, Dept. of Urology, Rostock, Germany, 9PANDAMED Wuppertal, Dept. of Urology, Wuppertal, Germany, 10DGU Wuppertal, Dept. of Urology, Wuppertal, Germany, 11Urologische Gemeinschaftspraxis, Dept. of Urology, Zwickau, Germany, 12Studienpraxis Urologie, Dept. of Urology, Nürtingen, Germany, 13Urologische Praxisgemeinschaft, Dept. of Urology, Wolfsburg, Germany, 14Urologische Partnerschaft Köln, Dept. of Urology, Cologne, Germany

Aims and objectives of this presentation
1035

*1036

Inpatient morbidity and cost of cytoreductive radical prostatectomy in the United States

By: Arora S. 1, Sood A. 1, Dalela D. 1, Keeley J. 1, Rakic N. 2, Prokopiv U. 2, Fotouhi A. 2, Peabody J.O. 1, Mani M. 1, Abdollah F. 1

1Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, 2Wayne State University School of Medicine, Medical School, Detroit, United States of America

Aims and objectives of this presentation
1036

*1037

Neoadjuvant apalutamide (arn-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) – initial results of a phase II trial

By: Aslim E.J. 1, Yang X. 1, Ngo N-T. 2, Khor L.Y. 2, Chen K. 1, Chong T.W. 1, Yuen J.S.P. 1, Tay K.J. 1, Ho H.S.S. 1, Lee L.S. 1

1Singapore General Hospital, Dept. of Urology, Singapore, Singapore, 2Singapore General Hospital, Dept. of Pathology, Singapore, Singapore

Aims and objectives of this presentation
1037
Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis


1Studienpraxis Urologie, Dept. of Urologic, Oncology, Nürtingen, Germany, 2Centre Hospitalier de l'Université de Montréal/CRCHUM, Dept. of Urologic, Oncology, Montréal, Canada, 3Janssen, Dept. of Health Economics & Market Access EMEA, High Wycombe, United Kingdom, 4Janssen, Dept. of Health Economics & Market Access EMEA, Beerse, Belgium, 5Janssen, Dept. of Research & Development, Clinical Oncology, Beerse, Belgium, 6Evidera, Dept. of Modelling and Simulation, London, United Kingdom, 7Evidera, Dept. of Meta Research, London, United Kingdom, 8University of Paris Sud, Gustave Roussy, Villejuif, France

Aims and objectives of this presentation

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study


1University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland, 2Finnish Cancer Registry, Dept. of Cancer Statistics, Helsinki, Finland, 3Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 4Tampere University Hospital, Dept. of Urology, Tampere, Finland, 5University of Tampere, Faculty of Social Sciences, Tampere, Finland

Aims and objectives of this presentation

Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin-releasing hormone (GnRH) agonist for prostate cancer: Final analysis of the EQUINOXE study

By: Droupy S., Colson M., Pello-Leprince-Ringuet N., Perrot V., Descazeaud A.

1CHU de Nimes, Dept. of Urology, Nimes, France, 2CHU de Marseille, Dept. of Sexology, Marseille, France, 3Ipsen Pharma, Dept. of Urology, Boulogne-Billancourt, France, 4CHU de Limoges, Dept. of Urology, Limoges, France

Aims and objectives of this presentation

Initial patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial

By: Yang X.Y., Aslim E.J., Chen K., Chong T.W., Yuen J.S.P., Tay K.J., Ho H.S.S.
Lee L.S.
Singapore General Hospital, Dept. of Urology, Singapore, Singapore

Aims and objectives of this presentation
1043

Identifying the optimal postoperative strategies for clinically node positive patients treated with radical prostatectomy and extended pelvic lymph node dissection: Is androgen deprivation therapy always mandatory?

By: Gandaglia G.\textsuperscript{1}, Karnes R.J.\textsuperscript{2}, Devos G.\textsuperscript{3}, Battaglia A.\textsuperscript{3}, Mulwijk T.\textsuperscript{3}, Soligo M.\textsuperscript{2}, Evaraerts W.\textsuperscript{3}, Boeri L.\textsuperscript{2}, Robesti D.\textsuperscript{1}, Cannoletta D.\textsuperscript{1}, Zaffuto E.\textsuperscript{1}, Scuderi S.\textsuperscript{1}, Barletta F.\textsuperscript{1}, Karakiewicz P.I.\textsuperscript{4}, Fossati N.\textsuperscript{1}, Moschini M.\textsuperscript{2}, Joniau S.\textsuperscript{3}, Montorsi F.\textsuperscript{1}, Briganti A.\textsuperscript{1}

\textsuperscript{1}IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology URI, Milan, Italy, \textsuperscript{2}Mayo Clinic, Dept. of Urology, Rochester (MN), United States of America, \textsuperscript{3}University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, \textsuperscript{4}University of Montreal Health Center, Montreal, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada

Aims and objectives of this presentation
1044

15:17 - 15:24
State-of-the-art lecture Contemporary management of hormone sensitive prostate cancer
A. Morgans, Chicago (US)
Outcomes of partial nephrectomy: Kidney function and beyond
Poster Session 75

Location: Green Area, Room 5
Chairs: A. Antonelli, Brescia (IT)
P.L. Chlosta, Cracow (PL)
M. Oya, Tokyo (JP)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1045
Trends in the practice of renal surgery for cancer in France after the introduction of robotic surgery: Data from the National Health Care System Registry
By: Ouzaid I. ¹, Bernhard J. ², Bigot P. ³, Nouhoud F. ⁴, Long J. ⁵, Boissier R. ⁶, Gimel P. ⁷, Bodin T. ⁸, Hetet J. ⁹, Bensalah K. ¹⁰
¹Bichat Claude Bernard Hospital, Dept. of Urology, Paris, France, ²CHU Bordeaux, Dept. of Urology, Bordeaux, France, ³CHU, Dept. of Urology, Paris, France, ⁴CHU Rouen, Dept. of Urology, Rouen, France, ⁵CHU Grenoble, Dept. of Urology, Grenoble, France, ⁶CHU Conception, Dept. of Urology, Marseille, France, ⁷Centre d’urologie, Site Médipôle, Dept. of Urology, Cabestany, France, ⁸Centre d’urologie Prado-Louvain, Dept. of Urology, Marseille, France, ⁹Clinique Jules Verne, Dept. of Urology, Nantes, France, ¹⁰CHU Rennes, Dept. of Urology, Rennes, France

* 1046
Acute kidney injury after partial nephrectomy: Epidemiology, predictive factors and implications for clinical practice
Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Experimental Oncology, Milan, Italy

1047
Elevated C-reactive protein is associated with functional decline following surgery for renal cell carcinoma: Results of an international cohort study
By: Cotta B. ¹, Saito K. ², Meagher M. ¹, Patil D. ³, Eldefrawy A. ¹, Yosuda Y. ², Bradshaw A. ¹, Ryan S. ¹, Anyakora D. ¹, Yee A. ¹, Alksne J. ¹, Wan F. ¹, Master V. ³, Fujii Y. ⁴, Derweesh I. ¹
¹University of California San Diego, Dept. of Urology, San Diego, United States of America, ²Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ³Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ⁴Tokyo Medical and Dental University, Dept. of Urology, Tokyo, United States of America
CT measurement of intraparenchymal tumor volume as predictor of renal function after robotic partial nephrectomy

By: Palumbo C., Antonelli A., Furlan M., Veccia A., Tellini R., Ferrari F., Simeone C. Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy

Development and validation of a novel scoring index CART (C-reactive protein, age, race, tumor size) to predict renal functional decline post partial nephrectomy


1UC San Diego Health, Dept. of Urology, La Jolla, United States of America, 2Emory University School of Medicine, Dept. of Urology, Emory, United States of America, 3Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

Impact of intraoperative bleeding on the risk of chronic kidney disease after elective nephron sparing surgery in patients with T1b kidney cancer


1Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Dept. of Urology, Division of Experimental Oncology, Milan, Italy, 2Maggiore della Carità Hospital, Dept. of Urology, Novara, Italy, 3Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, 4Clinica Urologica I, Azienda Ospedaliera Universitaria Careggi, Università degli studi di Firenze, Dept. of Urology, Florence, Italy, 5San Luigi Gonzaga Hospital, Università degli studi di Torino, Dept. of Oncology, Division of Urology, Turin, Italy

Robotic partial nephrectomy in solitary kidneys: Impact of ischemia on trifecta outcomes


1Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2Glickman Urological and Kidney Institute, Cleveland Clinic, Dept. of Urology, Cleveland, United States of America

Biomarkers in express-diagnosing of acute kidney injury among patients with the localized kidney cancer after partial nephrectomy under warm ischemia

To be confirmed

Robot-assisted partial nephrectomy is associated with early recovery of renal function: Comparison of open, laparoscopic, and robot-assisted partial nephrectomy using diethylene triamine penta-acetic acid (DTPA) renal scintigraphy

1054

**Renal function assessment during follow-up after surgical treatment for renal cell carcinoma**

By: Capogrosso P.¹, Larcher A.¹, Cianflone F.¹, Muttin F.¹, Trevisani F.¹, Nini A.², Ripa F.¹, Zaffuto E.¹, Briganti A.¹, Salonìa A.¹, Montorsi F.¹, Bertini R.¹, Capitanio U.¹

¹Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Urology, Division of Experimental Oncology, Milan, Italy,
²Universitätsklinikum Düsseldorf, Dept. of Urology, Düsseldorf, Germany

1055

**Comparison of overall survival between the life expectancy and the estimated outcome in patients who underwent radical nephrectomy or partial nephrectomy for renal cell carcinoma**

By: Tanaka N., Nakai Y., Miyake M., Inoue T., Anai S., Fujimoto K.
Nara Medical University, Dept. of Urology, Kashihara, Japan

1056

**Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals**

By: Tan W.S.¹, Berg S.², Cole A.², Krimphove M.², Marchese M.², Lipsitz S.³, Nabi J.², Sammon J.⁴, Choueiri T.⁵, Kibel A.², Sun M.⁵, Chang S.², Trinh Q-D.²

¹Imperial College Healthcare, Dept. of Urology, London, United Kingdom,
²Brigham and Women’s Hospital, Dept. of Urology, Boston, United States of America,
³Brigham and Women’s Hospital, Center for Surgery and Public Health, Boston, United States of America,
⁴Maine Medical Center, Dept. of Urology, Boston, United States of America,
⁵Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, United States of America

1057

**Comparison of long-term functional outcomes after radical nephrectomy and nephron-sparing surgery**

By: Semko S., Pikul M., Voylenko O., Stakhovskyi O., Kononenko O., Vitruk I., Stakhovsky E.
National Cancer Institute, Dept. of Plastic and Reconstructive Oncology, Kiev, Ukraine

1058

**The influence of robot-assisted nephron sparing surgery on blood pressure of patients with hypertension: The preliminary results**

By: Wang X., Zhao X., Guo H.
Drum Tower Hospital, Dept. of Urology, Nanjing, China
* 1059

**A double-blind, placebo-controlled parallel group study to evaluate the effect of a single oral dose of GSK958108 on ejaculation latency time in male patients suffering from premature ejaculation**

By: Marcer A.¹, Migliorini F.¹, Bettica P.², Ziviani L.², Jesper L.², Poggesi I.², Artibani W.¹, Mileri S.²

¹Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Urology, Verona, Italy, ²GlaxoSmithKline, Dept. of Clinical Pharmacology & Discovery Medicine, Verona, Italy

**Aims and objectives of this presentation**

1059

1061

**A new method of quantitatively measuring penile erection hardness in erectile dysfunction patients: Real-time ultrasonic shear wave elastography**

By: Yang L.¹, Ruan L.², He D.¹

¹The First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xian, China, ²The First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Ultrasonography, Xian, China

**Aims and objectives of this presentation**

1061

1062

**Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus silodosin 4 mg on demand in patients with lifelong premature ejaculation: A prospective, randomized study**

To be confirmed

**Aims and objectives of this presentation**

1062
<table>
<thead>
<tr>
<th>Presentation Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1063</td>
<td>The impact of aortic calcification on severe erectile dysfunction in patients with end stage renal disease</td>
<td>By: Fujita N. 1, Momota M. 1, Tobisawa Y. 1, Yoneyama T. 1, Yamamoto H. 1, Imai A. 1, Hatakeyama S. 1, Yoneyama T. 1, Hashimoto Y. 1, Yoshikawa K. 2, Ohyama C. 1</td>
<td>1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Mutsu General Hospital, Dept. of Urology, Mutsu, Japan</td>
<td>1063</td>
</tr>
<tr>
<td>1064</td>
<td>Differences in provider-led sexual health counseling practices for male versus female radical cystectomy patients</td>
<td>By: Gupta N. 1, Kucirka L. 2, Semerjian A. 3, Bivalacqua T. 1</td>
<td>1Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, 2Johns Hopkins University School of Medicine, Dept. of Gynecology and Obstetrics, Baltimore, United States of America, 3St. Joseph Mercy Hospital, Dept. of Urology, Ypsilanti, United States of America</td>
<td>1064</td>
</tr>
<tr>
<td>1065</td>
<td>Pelvic muscle floor rehabilitation in lifelong premature ejaculation: 48 months follow-up outcomes</td>
<td>By: Pastore A.L. 1, Maruccia S. 2, Casellato S. 2, Al Salhi Y. 1, Fuschi A. 1, Martoccia A. 1, Capone L. 1, Illiano E. 3, Velotti G. 1, Costantini E. 3, Carbone A. 1</td>
<td>1Sapienza University of Rome, Faculty of Pharmacy and Medicine, Dept. of Urology, Latina, Italy, 2Zucchi Istituti Clinici, Dept. of Urology, Monza, Italy, 3University of Perugia, Dept. of Urology, Terni, Italy</td>
<td>1065</td>
</tr>
<tr>
<td>1066</td>
<td>Current step-wise EAU recommendations for hypogonadism screening in erectile dysfunction are not cost-effective</td>
<td>By: Ribeiro Morgado L.A. 1, Moura M.L. 2, Dinis P. 1, Silva C. 1</td>
<td>1Centro Hospitalar Sao Joao, Dept. of Urology, Porto, Portugal, 2Faculdade de Medicina da Universidade do Porto, Dept. of Urology, Porto, Portugal</td>
<td>1066</td>
</tr>
<tr>
<td>1067</td>
<td>Testosterone replacement therapy improves potency recovery following robot assisted radical prostatectomy</td>
<td>By: El-Khatib F.M. 1, Huynh L. 2, Towe M. 2, Yafi F. 2, Ahlering T. 2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

1067

The association between structural brain alterations and serum testosterone levels in patients with type 2 diabetes mellitus

By: Atalay H.A.¹, Canat L.¹, Akarsu M.²
¹Okmeydanı Training and Research Hospital, Dept. of Urology, Istanbul, Turkey,
²Okmeydanı Training and Research Hospital, Dept. of Internal Medicine, Istanbul, Turkey

Aims and objectives of this presentation

1068

The effect of testosterone replacement therapy on sexual dysfunction and quality of life in adult men with opioid-induced androgen dysfunction: A systematic review

By: Birch B., Kunitsyna M.
University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

Aims and objectives of this presentation

1069

Comparison for subgroups of patients with LOH symptoms based on endocrinological findings - normal vs compensated normal, and primary hypogonadism vs secondary hypogonadism

By: Ishikawa K.¹, Soejima M.¹, Yoshiyama A.¹, Nagashima Y.¹, Hiramatsu I.¹, Uesaka Y.¹, Nozaki T.¹, Ogishima T.¹, Shirai M.¹, Kobayashi K.², Horie S.³, Tsujimura A.¹
¹Juntendo University Urayasu Hospital, Dept. of Urology, Chiba, Japan,
²Men’s Health Clinic Tokyo, Dept. of Urology, Tokyo, Japan,
³Juntendo University, Graduate School of Medicine, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

1070

Serum PSA as a predictor of symptomatic hypogonadism particularly in relation to psychological symptoms

By: Matsushita K., Tsujimura A., Horie S.
Juntendo University, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

1071
The relationship between depressive symptoms and erectile dysfunction across different ages: Which patients deserve more clinical attention?

By: Capogrosso P. 1, Ventimiglia E. 1, Boeri L. 2, Pozzi E. 3, Schifano N. 1, Cazzaniga W. 1, Chierigo F. 4, Belladelli F. 4, Zuabi R. 4, Abbate C. 1, Dehò F. 1, Mirone V. 5, Gaboardi F. 6, Montorsi F. 1, Salonia A. 1

1IRCCS Ospedale San Raffaele, Dept. Urology, Urological research institute (URI), Milan, Italy, 2IRCCS Fondazione Ca’ Granda – Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, 3Università Vita-Salute San Raffaele, Dept. Urology, Urological research institute (URI), Milan, Italy, 4Università Vita-Salute San Raffaele, Dept. Urology, Urological research institute (URI), Milan, Italy, 5Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples “Federico II”, Dept. of Urology, Naples, Italy, 6IRCCS Ospedale San Raffaele Turro, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation

1072

15:23 - 15:23

Conclusion
Molecular classification of urothelial tumours and implications for clinical practice
Poster Session 77

Monday 18 March
14:00 - 15:30

Location: Green Area, Room 11
Chairs: To be confirmed
T.W. Todenhöfer, Tübingen (DE)
A. Vlahou, Athens (GR)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1073

Molecular decoding of sarcomatoid variant of muscle-invasive bladder cancer might reveal treatment strategies

1University of Bern, Institute of Pathology, Bern, Switzerland, 2University Hospital Bern, Dept. of Oncology, Bern, Switzerland, 3University Hospital Bern, Dept. of Urology, Bern, Switzerland, 4University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 5GenomeDX Biosciences, R&D, Vancouver, Canada

Aims and objectives of this presentation

* 1074

FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?

1Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept of Surgical Oncology, Urology, Amsterdam, The Netherlands, 2Caritas St Joseph Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, 3University of Turku, Dept. of Urology, Turku, Finland, 4CNIO, Dept. of Genetic Molecular Epidemiology and Cancer Biology, Madrid, Spain, 5Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, 6Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 7Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Medical Oncology, Amsterdam, The Netherlands, 8University of Erlangen, Dept. of Pathology, Erlangen, Germany, 9University Health Network, Dept. of Urology, Toronto, Canada, 10Institut Curie,
Aims and objectives of this presentation

**1074** Comprehensive genomic analysis of upper urinary tract urothelial carcinoma

By: Fujii Y.¹, Sato Y.¹, Suzuki H.², Tetsuichi Y.², Yoshida K.³, Shiraishi Y.³, Kawai T.¹, Nakagawa T.¹, Nishimatsu H.⁴, Okaneya T.⁵, Sanada M.⁶, Makishima H.², Miyano S.³, Ogawa S.², Kume H.¹

¹The University of Tokyo Hospital, Dept. of Urology, Tokyo, Japan, ²Graduate School of Medicine, Kyoto University, Dept. of Pathology and Tumor Biology, Kyoto, Japan, ³Institute of Medical Science The University of Tokyo, Laboratory of DNA information Analysis, Human Genome Center, Tokyo, Japan, ⁴The Fraternity Memorial Hospital, Dept. of Urology, Tokyo, Japan, ⁵Toranomon Hospital, Dept. of Urology, Tokyo, Japan, ⁶Clinical Research Center, Nagoya Medical Center, Dept. of Advanced Diagnosis, Nagoya, Japan

Aims and objectives of this presentation

**1075** Assessment of TERT mutations in urinary sediment DNA by NGS and ddPCR for bladder cancer detection – a comparison

By: Stoeckel F.¹, Salomo K.¹, Stasik S.², Thiede C.², Menschikowski M.³, Heberling U.¹, Wirth M.P.¹, Füssel S.¹

¹University Hospital, Technische Universität Dresden, Dept. of Urology, Dresden, Germany, ²University Hospital, Technische Universität Dresden, Medical Department I, Dresden, Germany, ³University Hospital, Technische Universität Dresden, Institute of Clinical Chemistry and Laboratory Medicine, Dresden, Germany

Aims and objectives of this presentation

**1076** Circulating tumor cells are a strong predictor of cancer specific survival in high risk non-muscle invasive bladder cancer: Final analysis of a prospective observational study

By: Busetto G.M.¹, Raimondi C.², Gazzaniga P.², Del Giudice F.¹, De Berardinis E.¹

¹Sapienza Rome University Policlinico Umberto I, Dept. of Urology, Rome, Italy, ²Sapienza Rome University Policlinico Umberto I, Molecular Medicine, Rome, Italy

Aims and objectives of this presentation

**1077** Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes

By: Strissel P.¹, Pfannstiel C.², Chiappinelli K.³, Sikic D.⁴, Wach S.⁴, Wirtz R.⁵, 

¹Sapienza Rome University Policlinico Umberto I, Dept. of Urology, Rome, Italy, ²University Hospital, Tubingen, Germany, ³University Hospital, Tubingen, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, New York, ⁵National Cancer Institute, Bethesda, Maryland

Aims and objectives of this presentation

**1078**

1University Hospital, Friedrich-Alexander Universität Erlangen-Nürnberg, Dept. of Gynaecology and Obstetrics, Erlangen, Germany, 2University Hospital, Friedrich-Alexander Universität Erlangen-Nürnberg, Institute of Pathology, Erlangen, Germany, 3The George Washington University School of Medicine and Health Sciences, Dept. of Microbiology, Immunology and Tropical Medicine, Washington, DC, United States of America, 4University Hospital, Friedrich-Alexander Universität Erlangen-Nürnberg, Dept. of Urology and Paediatric Urology, Erlangen, Germany, 5Stratifyer Molecular Pathology, Cologne, Germany, 6University Hospital, University of Regensburg, Dept. of Urology, Regensburg, Germany, 7Ruprecht-Karls-Universität Heidelberg, Dept. of Urology, Medical Faculty, Mannheim, Germany, 8University Hospital, University of Ulm, Dept. of Urology, Ulm, Germany, 9TU Munich, Institute of Pathology, Munich, Germany

Aims and objectives of this presentation

1078

1079

10-immune related gene expression panel to predict the overall survival and tumor recurrence in patient with muscle-invasive bladder cancer

By: Zhu Y., Zhang J., Gu C., Zhu Y., Ye D.
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation

1079

1080

High levels of heat-shock factor 1 (HSF1) are associated with poor prognosis in muscle-invasive bladder cancer patients treated with chemoradiation-based bladder sparing protocol

Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

1080

1081

Impact of RAGE gene polymorphisms on urothelial cell carcinoma clinicopathologic characteristics and long term survival

By: Sheng-Chun H.  1 , Wang S-S.  1 , Li J-R.  1 , Chen C-S.  1 , Chang L-W.  1 , Yang C-K.  1 , Chiu K-Y.  1 , Cheng C-L.  1 , Ou Y-C.  2 , Ho H-C.  1 , Yang S-F.  3

1Taichung Veteran General Hospital, Dept. of Surgery, Taichung, Taiwan, 2Tung's Taichung MetroHarbor Hospital, Dept. of Urology, Taichung, Taiwan, 3Chung Shan Medical University, Institute of Medicine, Taichung, Taiwan
Aims and objectives of this presentation

1082

Urinary microbiota — a potential biomarker and therapeutic target for bladder cancer

By: Bi H.¹, Tian Y.², Huang Y.¹, Zhang Y.²
¹Peking University Third Hospital, Dept. of Urology, Beijing, China, ²Beijing Ditan Hospital, Institute of Infectious Diseases, Beijing, China

Aims and objectives of this presentation

1082

EGFR cell expression during adjuvant treatment after transurethral resection for non-muscle invasive bladder cancer

By: Di Maida F.¹, Mari A.¹, Scalici Gesolfo C.², Cangemi A.³, Allegro R.⁴, Tellini R.¹, Russo A.³, Carini M.¹, Minervini A.¹, Serretta V.²
¹University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ²University of Palermo, Dept. of Urology, Palermo, Italy, ³University of Palermo, Dept. of Oncology, Palermo, Italy, ⁴University of Palermo, Dept. of Statistics, Palermo, Italy

Aims and objectives of this presentation

1083

Long noncoding RNA LNMAT2 promotes bladder cancer metastasis by CCL5-dependent macrophage recruitment

By: Chen C.¹, Jian H.¹, Wang H.¹, Xu C.¹, Yue Z.², Tianxin L.¹
¹Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China, ²Sun Yat-Sen University, Dept. of Tumor Intervention, Guangzhou, China

Aims and objectives of this presentation

1084

15:19 - 15:26

Summary

A. Vlahou, Athens (GR)
Scientific Programme - EAU19 Barcelona

Understanding approaches to ureteric obstruction
Poster Session 78

Monday 18 March
14:00 - 15:30

Location: Green Area, Room 12
Chairs: A. Basiri, Tehran (IR)
M. Bultitude, London (GB)
S.K. Lildal, Arhus N (DK)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1085

Surgical approaches for treatment of ureteropelvic junction obstruction – a systematic review and network meta-analysis

By: Uhlig A.1, Uhlig J.2, Trojan L.1, Hinterthaner M.3, Emmert A.4, Strauss A.1
1University Medical Center Goettingen, Dept. of Urology, Goettingen, Germany,
2University Medical Center Goettingen, Dept. of Diagnostic and Interventional Radiology, Goettingen, Germany,
3University Medical Center Goettingen, Dept. of Thoracic and Cardiovascular Surgery, Goettingen, Germany,
4University Medical Center Goettingen, Thoracic and Cardiovascular Surgery, Goettingen, Germany

Aims and objectives of this presentation
1085

1086

siRNA-silencing of CD40 attenuates unilateral ureteral obstruction-induced kidney injury in mice

By: Narváez Barros M.A.1, Guteras R.2, Sola A.2, Manonelles A.3, Morote J.1, Torras J.3, Grinyó J.M.3, Cruzado J.M.3
1Vall d'Hebron Hospital, Dept. of Urology, Barcelona, Spain,
2Bellvitge Biomedical Research Institute, Experimental Nephrology and Transplantation, Barcelona, Spain,
3Bellvitge University Hospital, Dept. of Nephrology, Barcelona, Spain

Aims and objectives of this presentation
1086

1087

Reversal unilateral ureteral obstruction: A mice experimental model

By: Narváez Barros M.A.1, Guteras R.2, Sola A.2, Manonelles A.3, Morote J.1, Cruzado J.M.3
1Vall d'Hebron Hospital, Dept. of Urology, Barcelona, Spain,
2Bellvitge Biomedical Research Institute (IDIBELL), Experimental and Translational Laboratory of Nephrology, Clinic Sciences, University of Barcelona, Barcelona, Spain,
3Bellvitge University Hospital, Dept. of Nephrology, Barcelona, Spain
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1087</td>
</tr>
<tr>
<td><strong>1088</strong></td>
</tr>
<tr>
<td>Is the ureteral length associated with the patient's size?</td>
</tr>
<tr>
<td>By: Mansouri A., Thanwerdas J., Malavaud B.</td>
</tr>
<tr>
<td>¹Hôpital Jean Rougier, Dept. of Urology, Cahors, France, ²CHU Rangueil, Dept. of Urology, Toulouse, France</td>
</tr>
<tr>
<td><strong>1089</strong></td>
</tr>
<tr>
<td>Management of complex ureteral strictures with self-expanding metallic ureteral stents and subcutaneous extra-anatomic ureteral bypasses: Long-term results after two decades of experience</td>
</tr>
<tr>
<td>By: Lorca Alvaro J., Laso García I.M., Arias Fúnez F., Duque Ruiz G.I., Santiago González M., Brasero Burgos J., Gómez Dos Santos V., Burgos Revilla F.J. Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Dept. of Urology, Madrid, Spain</td>
</tr>
<tr>
<td><strong>1090</strong></td>
</tr>
<tr>
<td>Long term outcome of balloon dilatation of benign ureteric strictures</td>
</tr>
<tr>
<td>By: Yam W.L., Ng K.S., Teo J.K., Ng F.C.</td>
</tr>
<tr>
<td>¹Changi General Hospital, Dept. of Urology, Singapore, Singapore, ²Changi General Hospital, Dept. of Radiology, Singapore, Singapore</td>
</tr>
<tr>
<td><strong>1091</strong></td>
</tr>
<tr>
<td>Endourological management of benign ureteral stricture: Less is more?</td>
</tr>
<tr>
<td>By: Colicchia M., Beltrami P., Soligo M., Bettin L., Zattoni F., Iafrate M., Dal Moro F., Zattoni F. University of Padua, Dept. of Urology, Padua, Italy</td>
</tr>
<tr>
<td><strong>1092</strong></td>
</tr>
<tr>
<td>Management of long ureteral stenosis: Alternatives to indwelling ureteral stents</td>
</tr>
<tr>
<td>By: Roux S., Pettenati C., Dariane C., Sbizzera M., Dominique I., Matillon X., Toinet T., Neuzillet Y., Bessède T., Drouin S., Nouaille A., Champy C., Timsit M.O., Méjean A.</td>
</tr>
<tr>
<td>¹Hôpital Européen Georges-Pompidoul, AP-HP, University of Paris Descartes, Dept. of Urology, Paris, France, ²Hôpital Européen Georges-Pompidoul, AP-HP, University of Paris Descartes, Dept. of Urology, Paris, France, ³Hospices Civils de Lyon, HCL,</td>
</tr>
</tbody>
</table>
University of Lyon 1, Dept. of Urology, Lyon, France, Hospices Civils de Lyon, HCL, University of Lyon 1, Dept. of Urology, Lyon, France, Hospices civils de Lyon, HCL, University of Lyon 1, Dept. of Urology, Lyon, France, Hôpital Foch, University of Versailles-Saint-Quentin-En-Yvelynes, Dept. of Urology, Suresnes, France, Hôpital Foch, University of Versailles-Saint-Quentin-En-Yvelynes, Dept. of Urology, Suresnes, France, Hôpital Kremlin-Bicêtre, AP-HP, University of Paris Sud, Dept. of Urology, Le Kremlin-Bicêtre, France, Hôpital de la Pitié-Salpêtrière, AP-HP, University of Pierre et Marie Curie, Dept. of Urology, Paris, France, Hôpital Saint-Louis, AP-HP, University of Paris Diderot, Dept. of Urology, Paris, France, Hôpital Henri Mondor, AP-HP, University of Paris-Est Créteil, Dept. of Urology, Créteil, France

Aims and objectives of this presentation

1092

Interest of the pigtail suture stent in preventing the irritative signs of the lower urinary tract

By: Mrabti M., Tetou M., El Harech Y., Bouaiti E., Ameur A., Alami M.
Military Hospital Mohammed V, Dept. of Urology, Rabat, Morocco, Military Hospital Mohammed V, Dept. of Epidemiology, Rabat, Morocco

Aims and objectives of this presentation

1093

Intraureteroplasty – a new way of ureter modeling in ureterocystostomy

By: Kononenko O., Vukalovych P., Voylenko O., Stakhovskyi O., Semko S., Vitruk I., Pikul M., Stakhovsky E.
National Cancer Institute, Dept. of Plastic and Reconstructive Onco-Urology, Kiev, Ukraine

Aims and objectives of this presentation

1094

Rational renographic approach for the evaluation of uretero-ileal stenosis

By: Recupero S.M., Ragonese M., Pinto F., Racioppi M., Sacco E., Palermo G., Tartaglione G., Bassi P., Foschi N.
Catholic University Medical School and Academic Hospital Fondazione A.Gemelli - IRCSS, Dept. of Urology, Nephrology and Kidney Transplantation, Rome, Italy, Cristo Re Hospital, Dept. of Nuclear medicine, Rome, Italy

Aims and objectives of this presentation

1095

Minimally invasive treatment for complex urinary tract endometriosis. Results from a high-volume referral center at a median follow up of 47 months

By: Mari A., Di Maida F., Tellini R., Sforza S., Campi R., Rivetti A., Mattei A.
Aims and objectives of this presentation

1097

Extranatomical urinary diversion with the Detour™ for the treatment of complex ureteric stenosis: Preliminary experience with 19 cases

By: Kartalas-Goumas I., Tondelli E., Talso M., Zanetti G.
Vimercate Hospital, Dept. of Urology, Vimercate, Italy

Aims and objectives of this presentation

1098

Comparative assessment of laparoendoscopic single-site surgery to conventional laparoscopy in management of upper urinary tract pathologies

By: Ghaith A.F., Abdel-Karim A., Abdel Raheem A., Hgrass A., El-Tatawy H., Micali S., Elashry O.
1Tanta University Hospital, Dept. of Urology, Tanta, Egypt, 2Alexandria University Hospital, Dept. of Urology, Alexandria, Egypt, 3University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy

Aims and objectives of this presentation

1099
Minimally-invasive surgical therapies for BPO: Results and indications
Poster Session 79

Monday 18 March
14:00 - 15:30

Location: Green Area, Room 20
Chairs: P.A. Geavlete, Bucharest (RO)
        S. Madersbacher, Vienna (AT)
        M. Speakman, Taunton (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1100
Rezūm steam ablation therapy for benign prostatic hyperplasia: Initial results from the United Kingdom

By: Johnston M. 1, Shah T. 2, Emara A. 1, Gehring T. 1, Farmer T. 1, Nedas T.G. 1, Rajkumar G. 1, McFarlane A. 2, Winkler M. 2, El-Husseiny T. 2, Ahmed H.U. 2, Hindley R.G. 1

1Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke, United Kingdom, 2Imperial College London, Dept. of Urology, London, United Kingdom

Aims and objectives of this presentation
1100

1101
Evaluation of outcome of transurethral needle ablation (TUNA) for treating symptomatic BPH: A 10-year experience

By: Haroun H., El-Tatawy H., Soliman M.G., Ragab M., Tawfik A., Sabaa M.
Tanta University, Faculty of Medicine, Dept. of Urology, Tanta, Egypt

Aims and objectives of this presentation
1101

1102
The prostatic urethral lift (Urolift) versus the convection water vapor ablation (Rezūm) for minimally invasive treatment of BPH: A comparison of improvements and durability in 3-year clinical outcomes

By: Shepherd S. 1, Saadat S.H. 1, Chuhtai B. 2, Bojani N. 3, Zorn K. 3, Elterman D. 1

1Toronto Western Hospital - University Health Network, Dept. of Surgery, Division of Urology, Toronto, Canada, 2Weill Cornell Medicine, Dept. of Urology, New York City, United States of America, 3University of Montreal, Montreal, Canada

Aims and objectives of this presentation
1102

1103
Is prostate artery embolization (PAE) the future for the treatment of lower urinary tract symptoms secondary to benign prostatic hypertrophy?
Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: 12 month results of a clinical trial


Aims and objectives of this presentation

Four year results of water vapor thermal therapy for treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH): What minimal important difference (MID) in symptom relief benefits patient quality of life?


Aims and objectives of this presentation

Retrograde ejaculation after holmium laser enucleation of the prostate (HOLEP) – evaluation of patient bother and impact on sexual function using validated questionnaires


Aims and objectives of this presentation
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1107</td>
<td>Aquablation for BPH in large prostates (80-150cc): 6-month results from the WATERII multicenter trial</td>
<td>By: Desai M.M., WATERII Study Investigators University of Southern California, Dept. of Urology, Los Angeles, United States of America</td>
</tr>
<tr>
<td>1108</td>
<td>Predictors of index bladder outlet obstruction procedure care setting and its impact on perioperative outcomes and costs</td>
<td>By: Tully K.¹, Friedlander D. ², Krimphove M. ³, Noldus J. ⁴, Trinh Q-D. ² ¹Marien Hospital Herne, Dept. of Urology, Herne, Germany, ²Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America, ³University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany, ⁴Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany</td>
</tr>
<tr>
<td>1109</td>
<td>Relief of lower urinary tract symptoms after MRI-guided transurethral ultrasound ablation (TULSA): Subgroup analyses in patients with symptoms of benign prostatic hyperplasia</td>
<td>By: Elterman D. ¹, Hatiboglu G. ², Hetou K. ³, Staruch R. ⁴, Burtnyk M. ⁴, Relle J. ⁵, Shepherd S. ¹, Chin J. ³ ¹Toronto Western Hospital - University Health Network, Dept. of Surgery, Division of Urology, Toronto, Canada, ²University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ³Western University, London Health Sciences Centre, Division of Urology, London, Canada, ⁴Profound Medical, Medical Affairs, Mississauga, Canada, ⁵Beaumont Health System, Dept. of Urology, Royal Oak, United States of America</td>
</tr>
<tr>
<td>1110</td>
<td>Novel technique in ejaculation preserving trans urethral bipolar prostatectomy: Enucleation and resection modalities</td>
<td>By: Abou Taleb A.A. ¹, Fathy A. ², Ahmed S. ², Saber W. ², Sebaey A. ², Shaer W. ², Noah K. ¹, Noureldin Y. ² ¹Benha University, Upro medical center, Dept. of Urology, Cairo, Egypt, ²Benha University, Dept. of Urology, Cairo, Egypt</td>
</tr>
<tr>
<td>1111</td>
<td>Ejaculatory hood sparing vs. standard GreenLight™ laser photoselective vaporization of the prostate: Sexual and urodynamic assessment through randomized controlled trial</td>
<td></td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

1111

ProstaCare: Water electrolysis system for the treatment of benign prostate hyperplasia

By: Lim Y.W., Tiong H.Y., Chua W.J., Sim S.P.A., Ho S.S.H.

1 Singapore General Hospital, Dept. of Urology, Singapore, Singapore, 2 National University Hospital, Dept. of Urology, Singapore, Singapore

Aims and objectives of this presentation

1112

Pulling the Foley: Can the prostatic urethral lift be used in men with catheter dependent urinary retention?


1 Rowan University, Dept. of Urology, Stratford, United States of America, 2 New Jersey Urology, Dept. of Urology, Voorhees, United States of America

Aims and objectives of this presentation

1113

Summary

S. Madersbacher, Vienna (AT)
How to proceed with hematuria
ESU Course 55

Monday 18 March
14:15 - 16:15

Location: Green Area, Room 13
Chair: S. Boorjian, Rochester (US)

Aims and objectives of this session
Hematuria is one of the most common indications for urologic evaluation, and is recognized as a sign of potentially important illness. Therefore, knowledge of the differential diagnosis, principles of evaluation, and strategies for management of hematuria is critical. This course is designed for the practicing urologist, to provide a guidelines-based and case-oriented approach to the evaluation and management of hematuria.

After attending the course, participants will:
- Understand guideline recommendations for initial evaluation of asymptomatic microscopic hematuria.
- Describe existing data regarding hematuria screening.
- Recognize intravesical treatment regimens and associated side effect profiles for hemorrhagic cystitis.
- Create strategies for treating refractory hemorrhagic cystitis, upper urinary tract, and prostate-related bleeding.

Course introduction and background to hematuria
S. Boorjian, Rochester (US)

Review of microscopic hematuria
H. Mostafid, Surrey (GB)

AUA guidelines (and beyond) on microscopic hematuria
S. Boorjian, Rochester (US)

Cases and questions focusing on microhematuria
S. Boorjian, Rochester (US)
H. Mostafid, Surrey (GB)

Evaluation and management of gross hematuria and hemorrhagic cystitis
S. Boorjian, Rochester (US)
H. Mostafid, Surrey (GB)

Prostate/Urethral/Upper urinary tract bleeding
H. Mostafid, Surrey (GB)

Cases and questions focusing on gross hematuria
S. Boorjian, Rochester (US)
H. Mostafid, Surrey (GB)
Alternative approaches to complex genital surgery

Video Session 12

Monday 18 March
15:45 - 17:15

Location: Red Area, eURO Auditorium 1
Chairs: S. Beley, Paris (FR)
I. Moncada Iribarren, Madrid (ES)
T. Rashid, London (GB)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

V82

How to improve your Xiapex results in Peyronie’s disease: The percutaneous needle tunnelling (PNT) technique. Step-by-step surgical video

By: Fernandez Pascual E.\(^1\), González-García F.J.\(^2\), García-Criado E.\(^1\), Souto A.D.\(^1\), Marcos D.\(^1\), Angulo J.\(^3\), Carballido J.\(^1\), Martínez-Salamanca J.I.\(^1\)

\(^1\) University Hospital Puerta de Hierro-Majadahonda, Dept. of Urology, Madrid, Spain,
\(^2\) Lyx Institute of Urology, Dept. of Urology, Madrid, Spain,
\(^3\) Institute Ramón y Cajal of Health Research (IRYCIS), Dept. of Histology, Madrid, Spain

Aims and objectives of this presentation

V82

V83

Surgical treatment of Peyronie’s disease with buccal mucosa graft

By: Kotov S.V., Usufov A.G.
Pirogov Russian National Research Medical University, Dept. of Urology and Andrology, Moscow, Russia

Aims and objectives of this presentation

V83

V84

Robotic sigmoid vaginoplasty: A feasible single stage minimally invasive alternative

By: Khandekar A., Pandey S., Abraham B., Mohammad A.I.
Kokilaben Dhirubhai Ambani Hospital, Dept. of Urology, Mumbai, India

Aims and objectives of this presentation

V84

V85

From pubis to phallus: A complete demonstration of the three stages of radial artery forearm phalloplasty formation

By: Chiriacò G., Blecher G.A., Christopher A.N., Ralph D.J.
University College London Hospital (UCLH), Dept. of Andrology, London, United Kingdom
<table>
<thead>
<tr>
<th>V86</th>
<th>Gender affirming surgery: Vaginoplasty and clitoroplasty with modified peno-scrotal flap technique</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Trombetta C., Migliozzi F., Rizzo M., Bucci S., Perin C., Boltri M., Claps F., Liguori G.</td>
</tr>
<tr>
<td></td>
<td>ASUITS, Faculty of Medicine and Surgery, Dept. of Urology, Trieste, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>V87</th>
<th>Revision of inflatable penile prosthesis in a patient with prosthetic malfunction and glans ischemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Kocjancic E., Acar O., Morgantini L.A., Halgrimson W.</td>
</tr>
<tr>
<td></td>
<td>University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>V88</th>
<th>Video-endoscopic inguinal lymphadenectomy: 48 cases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hospital of Leon, Dept. of Urology, Leon, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>V89</th>
<th>Laparoscopic (robot-assisted) VEIL - a single centre experience</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Srivathsan R., Yuvaraja T.</td>
</tr>
<tr>
<td></td>
<td>Kokilaben Dhirubhai Ambani Hospital, Dept. of Robotic Urooncology, Mumbai, India</td>
</tr>
</tbody>
</table>
Advancing the outcome of advanced and metastatic bladder cancer
Poster Session 80

Monday 18 March
15:45 - 17:15

Location: Red Area, eURO Auditorium 2
Chairs: C. Beisland, Bergen (NO)
Y. Loriot, Villejuif (FR)
P. Patel, Birmingham (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

16:08 - 16:13

State-of-the-art lecture The role of surgery and peri-operative systemic therapy
P. Patel, Birmingham (GB)

1114

Do urologists take the better slice of cake in muscle-invasive bladder cancer (MIBC)?

By: Dosanjh A. 1, Mintz H.P. 2, Mytton J.L. 1, Gallier S. 1, James N.D. 3, Patel P. 3
1University Hospitals Birmingham NHS Foundation Trust, Dept. of Health Informatics, Birmingham, United Kingdom, 2University of Warwick, Warwick Medical School, Coventry, United Kingdom, 3University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom

1115

Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histological subtype matter?

By: Berg S. 1, D'Andrea D. 2, Vetterlein M.W. 3, Cole A.P. 1, Fletcher S.A. 1, Krimphove M.J. 1, Marchese M. 1, Lipsitz S.R. 4, Sonpavde G. 5, Noldus J. 6, Shariat S.F. 2, Kibel A.S. 1, Trinh Q-D. 1, Mossanen M. 1
1Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, 2Medical University of Vienna, Dept. of Urology, Vienna, Austria, 3University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 4Brigham and Women's Hospital, Harvard Medical School, Division of Internal Medicine and Center for Surgery and Public Health, Boston, United States of America, 5Dana Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America, 6Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and NeuroUrology, Herne, Germany

1116

Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup
Combining DNA-repair gene mutations and molecular subtyping for more accurate prediction of outcome after neoadjuvant chemotherapy for bladder cancer

By: Batista Da Costa J. 1, Seiler R. 2, Ikeda K. 1, Zhou J. 1, Winters B. 3, Gibb E. 4, Volik S. 1, Wright J. 3, Sommerland M. 5, Douglas J. 5, Collins C. 1, Black P. 1

1 University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 2 University of Bern, Dept. of Urology, Bern, Switzerland, 3 University of Washington School of Medicine, Dept. of Urology, Seattle, United States of America, 4 GenomeDX Biosciences, Dept. of R&D, Vancouver, Canada, 5 University Hospital of Southampton, Dept. of Urology, Southampton, United Kingdom
Validation of the COBRA nomogram for the prediction of cancer specific survival in patients with bladder cancer treated with radical cystectomy


1Sant'Andrea Hospital- "Sapienza" University, Dept. of Urology, Rome, Italy, 2Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 3University of Southern California, Dept. of Urology, Los Angeles, United States of America, 4Mansoura University, Dept. of Urology, Mansoura, Egypt, 5Sant'Andrea Hospital-, Dept. of Urology, Rome, Italy, 6Umberto I- "Sapienza" University, Dept. of Urology, Rome, Italy

Surgical outcome of pre-operative atezolizumab before radical cystectomy for muscle-invasive urothelial carcinoma of the bladder


1Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, 2Hospital Universitario Marqués de Valdecilla, Dept. of Medical Oncology, Santander, Spain, 3University of Southampton, Southampton Clinical Trials Unit, Southampton, United Kingdom, 4Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, The Netherlands, 5Hospital Universitari Germans Trias i Pujol (HUGTIP), Institut Català d’Oncologia, Badalona, Spain, 6Institut Paoli-Calmettes, Dept. of Medical Oncology, Marseille, France, 7Hospital Clínico Universitario, Dept. of Medical Oncology, Santiago De Compostela, Spain, 8Churchill Hospital, Dept. of Medical Oncology, Oxford, United Kingdom, 9Hôpital Saint-André, Dept. of Medical Oncology, Bordeaux, France, 10Hosp Lyon SUD, Dept. of Medical Oncology, Lyon, France, 11Reina Sofía University Hospital, Dept. of Medical Oncology, Cordoba, Spain, 12Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain, 13Royal Marsden Hospital, Dept. of Medical Oncology, London, United Kingdom, 14Hospital Universitario , Dept. of Medical Oncology, Madrid, Spain, 15Hospital Del Mar, Dept. of Medical Oncology, Barcelona, Spain

First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (Pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC)
By: **Necchi A.**¹, Bandini M.², Gallina A.², Bianchi M.², Raggi D.¹, Fare’ E.¹, Messina A.¹, Chung J.³, Ali S.³, Ross J.³, Anichini A.¹, Colecchia M.¹, Gandaglia G.², Fossati N.², Scuderi S.², Pederzoli F.², Salonia A.², Colomb R.², Briganti A.², Montorsi F.²

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Urological Research Institute (URI), IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ³Foundation Medicine, Cambridge, United States of America

1123

**Antihypertensive drugs and risk of bladder cancer death in Finland**

By: **Santala E.E.**¹, Kotsar A.², Tammela T.L.J.¹, **Murtola T.**¹

¹University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland, ²Tartu university Hospital, Dept. of Urology, Tartu, Estonia

1124

**Identification of stromal macrophage infiltration predict overall survival and recurrence-free survival in patients with muscle invasive bladder cancer**

By: **Zhu Y.**, Zhang J., Gu C., Zhu Y., **Ye D.**

Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

17:01 - 17:08

**State-of-the-art lecture Current role of systemic therapy**

Y. Loriot, Villejuif (FR)
PSA and prostate cancer screening: What is new in 2019?

Poster Session 81

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 1

Chairs: F. Abdollah, West Bloomfield (US)
S. Carlsson, New York (US)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1125

Prostate cancer risk after stop-age in men participating in a long-term screening program: Results from the Gothenburg randomized population-based prostate-cancer screening trial

By: Frånlund M.¹, Månsson M.¹, Arnsrud Godtman R.¹, Grenabo Bergdahl A.¹, Stranne J.¹, Lilja H.², Hugosson J.¹

¹Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ²Memorial Sloan-Kettering Cancer Center, Dept. of Surgery (Urology Service) and Dept. of Epidemiology and Biostatistics, New York, United States of America

1126

Prostate-specific antigen (PSA) levels in men 60 to 70 years of age predict aggressive prostate cancer in the PLCO cancer screening trial: Implications for risk-stratified screening

By: Berger A.¹, Aden-Buie G.², Kibel A.S.¹, Mucci L.A.³, Penney K.³, Wilson K.³, Gerke T.², Preston M.¹

¹Brigham and Women's Hospital/Harvard University, Dept. of Surgery, Urology, Boston, United States of America, ²Moffit Cancer Center, Dept. of Surgery, Urology, Tampa, United States of America, ³Harvard Channing School of Public Health, Dept. of Epidemiology, Boston, United States of America

1127

Inappropriate PSA testing - can it be stopped?

To be confirmed

1128

Socioeconomic patterns of first-time PSA testing in general practice

By: Benzon Larsen S.¹, Lerche C.S.¹, Andersen I.², Thygesen L.C.³, Andersen K.K.⁴, Duun-Henriksen A.K.⁵, Johansen C.⁶, Røder M.A.¹, Dalton S.O.⁶, Brasso K.¹

¹Copenhagen University Hospital, Copenhagen Prostate Cancer Center, Copenhagen, Denmark, ²Copenhagen University, Dept. of Public Health, Copenhagen, Denmark, ³University of Southern Denmark, National Institute of Public Health, Copenhagen, Denmark, ⁴Danish Cancer Society Research Center, Statistics and Pharmaco-Epidemiology, Copenhagen, Denmark, ⁵Danish Cancer Society Research Center,
1129

**The relation between baseline PSA, cancer detection and PC death, long-term data from ERSPC**

By: Roobol M.¹, Remmers S.¹, Hugosson J.², Carlsson S.V.³, Auvinen A.⁴, Tammela T.L.J.⁵, Denis L.J.⁶, Nelen V.⁷, Villers A.⁸, Rebillard X.⁹, Kwiatkowski M.¹⁰, Recker F.¹⁰, Zappa M.¹¹, Puliti D.¹¹, Paez A.¹², Lujan M.¹³, Bangma C.H.¹

¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands,
²Sahlgrenska Academy at Goteborg University, Dept. of Urology, Gothenburg, Sweden,
³Sahlgrenska Academy at Goteborg University, MSKCC, Dept. of Urology, Gothenburg, Sweden,
⁴University of Tampere, School of Health Sciences, Tampere, Finland,
⁵University of Tampere, Dept. of Urology, Tampere, Finland,
⁶Oncology Center Antwerp, Dept. of Urology, Antwerp, Belgium,
⁷Provinciaal Instituut voor Hygiene, Dept. of Urology, Antwerp, Belgium,
⁸Universite Lille Nord de France, Dept. of Urology, Lille, France,
⁹Clinique Beau Soleil, Dept. of Urology, Montpellier, France,
¹⁰Kantonsspital Aarau, Dept. of Urology, Aarau, Switzerland,
¹¹ISPO, Dept. of Clinical and Descriptive Epidemiology, Florence, Italy,
¹²Universitario de Fuenlabrada, Dept. of Urology, Madrid, Spain,
¹³Hospital Infanta Cristina, Dept. of Urology, Madrid, Spain

1130

**PSA-testing as a part of mandated health check-ups and risk of prostate cancer: Nationwide, population-based case control study of firefighters**

By: Cazzaniga W.¹, Gauffin O.², Johansson E.², Robinson D.³, Stattin P.⁴

¹University Vita-Salute San Raffaele, Dept. of Urology, Milan, Italy,
²Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden,
³Ryhov Hospital, Dept. of Urology, Jönköping, Sweden,
⁴Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

1131

**Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau)**

By: Gstrein L.¹, Mortezaí A.¹, Millan C.¹, Wyler S.², Grobholz R.³, Huber A.⁴, Manka L.⁵, Sulter T.¹, Recker F.², Eberli D.¹, Kwiatkowski M.²

¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland,
²Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland,
³Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland,
⁴Cantonal Hospital Aarau, Laboratory Medicine, Aarau, Switzerland,
⁵Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany

1132

**The effect of common diabetes medications on PSA levels in men without prostate cancer**

By: Binti Abd Jalal N.¹, Garmo H.¹, Nordstrom T.², Aly M.², Eklund M.², Aldofsson J.³, Van Hemelrijck M.¹, Beckmann K.¹

¹Kings College London, School of Cancer and Pharmaceutical Studies, London, United Kingdom,
²Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden,
³Karolinska Institute, CLINTEC-Department, Stockholm, Sweden
Effects of antihypertensive drug use on prostate cancer-specific survival in Finnish men

By: Siltari A. 1, Murtola T. 2, Talakka K. 3, Taari K. 4, Tammela T. 1, Auvinen A. 5
1University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland,
2University of Tampere, Tampere University Hospital, Faculty of Medicine and Life Sciences, Department of Urology, Tampere, Finland, 3Finnish Cancer Registry, Helsinki, Finland, 4University of Helsinki, Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 5University of Tampere, School of Health Sciences, Tampere, Finland

Association of common medication with prostate-specific antigen level in 45-year-old German men: Results of the PROBASE trial

By: Meissner V.H. 1, Ertlav Z. 1, Kron M. 2, Schulwitz H. 1, Albers P. 3, Arsov C. 3, Kuczyk M. 4, Imkamp F. 4, Hohenfellner M. 5, Hadaschik B. 5, Gschwend J.E. 1, Herkommer K. 1
1Klinikum Rechts der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, 2University of Ulm, Institute of Epidemiology and Medical Biometry, Ulm, Germany, 3Universitätsklinikum Dusseldorf, Heinrich-Heine-University, Dept. of Urology, Dusseldorf, Germany, 4Hanover Medical School, Clinic for Urology and Urologic Oncology, Hanover, Germany, 5Universitätsklinikum Heidelberg, Ruprecht-Karls-University, Dept. of Urology, Heidelberg, Germany

A population-based randomized trial of early detection of clinically significant prostate cancer (ProScreen): Pilot phase results

By: Rannikko A. 1, Kilpeläinen T. 1, Matikainen M. 1, Kenttämies A. 2, Petas A. 1, Santti H. 1, Mirtti T. 3, Rinta-Kiikka I. 4, Kujala P. 5, Taari K. 1, Natunen K. 6, Lilja H. 7, Tammela T. 8, Auvinen A. 6
1University of Helsinki and HUS Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 2University of Helsinki and HUS Helsinki University Hospital, Dept. of Radiology, Helsinki, Finland, 3University of Helsinki and HUS Helsinki University Hospital, Dept. of Pathology, Helsinki, Finland, 4Tampere University Hospital and University of Tampere, Dept. of Radiology, Tampere, Finland, 5Tampere University Hospital and University of Tampere, Finlab laboratories, Dept. of Pathology, Tampere, Finland, 6University of Tampere, Faculty of Social Sciences, Tampere, Finland, 7Memorial Sloan Kettering Cancer Center, Dept. of Laboratory Medicine and Medicine, New York, United States of America, 8Tampere University Hospital and University of Tampere, Dept. of Urology, Tampere, Finland

Impact of a changing population structure and clustering of cancer in prostate cancer patients depending on a first-degree family-history

By: Herkommer K. 1, Bittner R. 1, Meissner V.H. 1, Kron M. 2, Schiele S. 1, Schulwitz H. 1, Gschwend J.E. 1
1Klinikum rechts der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, 2University of Ulm, Institute of Epidemiology and Medical Biometry, Ulm, Germany
Multi-parametric prostate MRI as a screening test among male BRCA carriers

By: Margel D.¹, Sela S.¹, Tamir S.², Kedar I.³, Ber Y.¹, Kedar D.¹, Nadu A.¹, Baniel J.¹

¹Rabin Medical Center, Dept. of Urology, Peath-Tikva, Israel,
²Rabin Medical Center, Dept. of Imaging, Peath-Tikva, Israel,
³Rabin Medical Center, The Rafael Recanati Genetic Institute, Peath-Tikva, Israel
Improving management and outcomes of urological emergencies

Poster Session 82

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 2
Chairs: N. Kitrey, Ramat Gan (IL)
        L. Martínez Piñeiro, Madrid (ES)
        S.V. Yrastorza, Quezon City (PH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1140

Validation of the TWIST score for diagnosis of testicular torsion in adults

By: Barbosa J.A., Botelho Y. S., Srougi M., Nahas W.C., Arap M.A.
University of Sao Paulo Medical School, Dept. of Urology, Sao Paulo, Brazil

Aims and objectives of this presentation

1140

1141

Testicular torsion and atmospheric temperature: Is there any relationship?

By: Mokadem S., Chakroun M., Essid M.A., Bouzouita A., Ayed H., Cherif M., Ben Slama R., Derouiche A., Chebil M.
Hôpital Charles Nicolle, Dept. of Urology, Tunis, Tunisia

Aims and objectives of this presentation

1141

1142

Neutrophil-lymphocyte ratio predicts organ salvage in testicular torsion with marginal diagnostic delay

By: Ko Y.H., Choi J.Y., Song P.H., Hyun J.S., Jung H.C.
1Yeungnam University, Dept. of Urology, Daegu, South Korea, 2Gyeongsang National University, Dept. of Urology, Jinju, South Korea

Aims and objectives of this presentation

1142

1143

Orchidopexy for testicular torsion: A systematic review of surgical technique


1143
Aims and objectives of this presentation

Protective effect of hydrogen sulphite on experimental testicular ischemia reperfusion in rats

By: Bozkurt M.¹, Değirmentepe R.B.¹, Polat E.C.¹, Yıldırım F.², Sönmez K.², Çekmen M.³, Eraldemir C.³, Ötünçtemur A.¹
¹University of Health Sciences, Okmeydani Training And Research Hospital, Dept. of Urology, Istanbul, Turkey, ²Istanbul University- Cerrahpasa, Faculty of Veterinary Medicine, Dept. of Pathology, Istanbul, Turkey, ³Kocaeli University, Faculty of Medicine, Dept. of Biochemistry, Kocaeli, Turkey

Aims and objectives of this presentation

Ameliorative effect of ozone therapy on testicular ischemia-reperfusion injury in rats

By: Sancak E.B.¹, Demirci E.D ²
¹Canakkale Onsekiz Mart University , Dept. of Urology, Faculty of Medicine, Canakkale, Turkey, ²Yozgat City Hospital, Dept. of Urology, Yozgat, Turkey

Aims and objectives of this presentation

Long-term outcomes of urethral catheterisation injuries: A prospective multi-institutional study

By: Davis N.D.¹, Bhatt N.², MacCraith E.³, Mooney R.M.⁴, Leonard G.L.⁵, Flood H.F.⁵, Walsh M.W.⁵
¹The Austin Hospital, Dept. of Urology, Melbourne, Australia, ²Tallaght Hospital, Dept. of Urology, Dublin, Ireland, ³St Vincent's University Hospital, Dept. of Urology, Dublin,
Aims and objectives of this presentation

1146

Assessment of acute male urethral catheterisation problems in a tertiary centre and usefulness of a new catheterisation protocol using portable flexible cystoscopy with disposable sterile sheets

Hospital Marqués de Valdecillía, Dept. of Urology, Santander, Spain

Aims and objectives of this presentation

1147

Results of surgical treatment of radiation induced hemorrhagic cystitis

By: Oliveira Marinho A.C., Simões P., Figueiredo A.
Hospital and University Center of Coimbra, Urology and Renal Transplantation, Coimbra, Portugal

Aims and objectives of this presentation

1148

Incidence and predictive factors of pseudo-aneurysms after renal trauma: Results of TRAUMAFUF, a national multicentric study

1CHRU Tours, Dept. of Urology, Tours, France, 2CHU Rennes, Dept. of Urology, Rennes, France, 3CHU Strasbourg, Dept. of Urology, Strasbourg, France, 4CHRU Lille, Dept. of Urology, Lille, France, 5CHU Lyon, Dept. of Urology, Lyon, France, 6CHU Angers, Dept. of Urology, Angers, France, 7Hôpital Kremlin Bicêtre, Dept. of Urology, Paris, France, 8CHU Rouen, Dept. of Urology, Rouen, France, 9CHRU Lille, Dept. of Urology, Lille, France, 10CHU Caen, Dept. of Urology, Caen, France, 11CHU Clermont Ferrand, Dept. of Urology, Clermont Ferrand, France, 12CHU Amiens, Dept. of Urology, Amiens, France, 13CHU Nantes, Dept. of Urology, Nantes, France, 14CHU Toulouse, Dept. of Urology, Toulouse, France, 15Hôpital Pompidou, Dept. of Urology, Paris, France, 16CHU Grenoble, Dept. of Urology, Grenoble, France

Aims and objectives of this presentation

1149

A 15 year retrospective analysis of renal trauma in a tertiary South Australian hospital

1150
Aims and objectives of this presentation

Risk factors for death after renal trauma: Results of the French multicenter study TRAUMAFUF

By: Lebacle C.¹, Ruggiero M.¹, Hutin M.², Freton L.³, Olivier J.⁴, Dominique I.⁵, Millet C.⁶, Bergerat S.⁷, Panayotopoulos P.⁸, Betari R.⁹, Matillon X.⁵, Chebbi A.¹⁰, Patard P-M.¹¹, Szabla N.¹², Brichart N.¹³, Boehm A.¹⁴, Rizk J.⁴, Gryn A.¹¹, Dariane C.¹⁵, Madec F-X.¹⁶, Nouhaud F-X.¹⁰, Pradere B.¹⁴, Fiard G.¹⁷, Peyronnet B.³, T. Caes, L. Sabourin, K. Guleryuz, X. Rod, for the TRAUMAFUF collaborative group

¹University hospital of Bicêtre, AP-HP, Paris-Saclay University, Dept. of Urology, Le Kremlin Bicêtre, France, ²University of Montpellier, Dept. of Urology, Montpellier, France, ³University of Rennes, Dept. of Urology, Rennes, France, ⁴University of Lille, Dept. of Urology, Lille, France, ⁵University of Lyon, Dept. of Urology, Lyon, France, ⁶University of Clermont-Ferrand, Dept. of Urology, Clermont-Ferrand, France, ⁷University of Strasbourg, Dept. of Urology, Strasbourg, France, ⁸University of Angers, Dept. of Urology, Angers, France, ⁹University of Amiens, Dept. of Urology, Amiens, France, ¹⁰University of Rouen, Dept. of Urology, Rouen, France, ¹¹University of Toulouse, Dept. of Urology, Toulouse, France, ¹²University of Caen, Dept. of Urology, Caen, France, ¹³University of Orleans, Dept. of Urology, Orleans, France, ¹⁴University of Tours, Dept. of Urology, Tours, France, ¹⁵University Hospital of Georges Pompidou European Hospital, Ap-Hp, Paris Descartes University, Dept. of Urology, Paris, France, ¹⁶University of Nantes, Dept. of Urology, Nantes, France, ¹⁷University of Grenoble, Dept. of Urology, Grenoble, France

The role of magnetic resonance imaging for the diagnosis of penile fracture in real life emergency settings – comparative analysis with intraoperative findings

By: Sokolakis I.¹, Schubert T.¹, Oelschlaeger M.¹, Krebs M.¹, Gschwend J.², Holzapfel K.³, Kuebler H.¹, Gakis G.¹, Hatzichristodoulou G.¹

¹Julius-Maximillian University Medical Centre of Wuerzbrug, Dept. of Urology and Paediatric Urology, Würzburg, Germany, ²Technical University of Munich, Klinikum rechts der Isar, Dept. of Urology, Munich, Germany, ³Landshut-Achdorf Hospital, Institute of Radiology, Landshut, Germany
Urology in the elderly
Poster Session 83

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 3
Chairs: T. Antunes Lopes, Porto (PT)
S. Arlandis Guzman, Valencia (ES)
D. Bratuš, Maribor (SI)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1153

The impact of frailty gap on prognosis in patients with urological cancers: A comparison of community-dwelling population

By: Soma O. 1, Hatakeyama S. 1, Yamamoto H. 1, Imai A. 1, Yoneyama T. 1, Hashimoto Y. 1, Koie T. 2, Ohyama C. 1
1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan,
2Gifu University School of Medicine, Dept. of Urology, Gifu, Japan

1154

Pre-operative risk assessment by ASA score and modified Frailty Index (mFI) in oncological and non oncological urological surgery

By: Serretta V. 1, Muffoletto F. 1, Tulone G. 1, Dioguardi S. 1, Guzzardo C. 1, Billeci S. 1, Baiamonte D. 1, Giannone S. 1, Sanfilippo C. 2, Scalici Gesolfo C. 3, Simonato A. 1
1University of Palermo, Section of Urology, Dept. of Surgical, Oncological and Oral Sciences, Palermo, Italy,
2GSTU Foundation, Statistics, Palermo, Italy,
3Paolo Borsellino Hospital, Dept. of Urology, Marsala, Italy

1155

Improved prognosis for old-aged patients with metastatic renal cell carcinoma after targeted therapy

By: Teishima J. 1, Mita K. 2, Shigeta M. 3, Hasegawa Y. 4, Kadonishi Y. 5, Inoue S. 1, Hayashi T. 1, Matsubara A. 1
1Hiroshima University, Dept. of Urology, Hiroshima, Japan,
2Hiroshima City Asa Citizens Hospital, Dept. of Urology, Hiroshima, Japan,
3Kure Medical Center and Chugoku Cancer Center, Dept. of Urology, Kure, Japan,
4Fukuyama Medical Center, Dept. of Urology, Fukuyama, Japan,
5Onomichi General Hospital, Dept. of Urology, Onomichi, Japan

1156

Non-muscle invasive urothelial bladder cancer (NMIBC) in very elderly patients: What does affect overall survival (OS)? Clinical outcomes in a retrospective analysis

By: Di Cosmo G., Verzotti E., Pavan N., Silvestri T., Boschian R., Liguori G.
1157

**Comparison of outcomes between standard and palliative management for high grade non-muscle invasive bladder cancer in patients older than 85 years**

By: Carrión Puig A., Diaz F., Raventos C., Lozano F., Miret E., Cuadras M., Morote J.
Hospital Vall Hebron, Dept. of Urology, Barcelona, Spain

1158

**Too old for a prostate biopsy?**

Coimbra University Hospital Center, Dept. of Urology and Renal Transplantation, Coimbra, Portugal, Coimbra University Hospital Center, Dept. of Pathology, Coimbra, Portugal

1159

**Perioperative parameters and prognosis analysis of patients aged 80 years old or older treated with radical prostatectomy for prostate cancer**

By: Zhang F., Huang Y., Ma L.
Peking University Third Hospital, Dept. of Urology, Beijing, China

1160

**The role of G8 screening tool in the assessment of surgical outcome of elderly patients (≥75 y.o.) with high-risk prostate cancer: A pilot study**

By: Matsushita K., Sandhu J.S., Horie S., Endo F., Shimbo M., Narimoto K., Hattori K.
1Juntendo University, Dept. of Urology, Tokyo, Japan, 2Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America, 3St. Lukes International Hospital, Dept. of Urology, Tokyo, Japan

1162

**The impact of fall on nocturia and frailty in community-dwelling individuals**

By: Hatakeyama S., Imai A., Yamamoto H., Matsumoto T., Soma O., Yoneyama T., Hashimoto Y., Nakaji S., Ohyama C.
1Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 2Hirosaki University School of Medicine, Social Medicine, Hirosaki, Japan

1163

**Benign prostatic hyperplasia increases the risk of Parkinson’s disease: A population-based study**

By: Chan J.K-S., Shih H.J., Huang C.J.
1Wan Fang Hospital, Dept. of Urology, Taipei, Taiwan, 2Wan Fang Hospital, Dept. of Anesthesiology, Taipei, Taiwan

1165

**Effect of mirabegron on cognitive function in elderly patients with overactive bladder: Results from a phase 4 placebo-controlled study (PILLAR)**
Strategies to safely treat OAB in the elderly based on comorbidity, comedication and risks of serious adverse events

By: Martens F.M.J., De Wall L.L., Heesakkers J.F.A.
Radboudumc, Dept. of Urology, Nijmegen, The Netherlands
Survivorship in prostate cancer: It is all about patients
Poster Session 84

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 4
Chairs: C. Porter, Seattle (US)
G. Salomon, Hamburg (DE)
B. Tombal, Brussels (BE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1167
Quality of life of partners of patients treated with gonadotropin-releasing hormone (GnRH) agonist for prostate cancer: Final analysis of the EQUINOXE study, focusing on relation between quality of life and dyadic adjustment

By: Descazeaud A. 1 , Colson M.H. 2 , Pello-Leprince-Ringuet N. 3 , Perrot V. 3 , Droupy S. 4
1University Hospital, Dept. of Urology, Limoges, France, 2CISIH, Ste Marguerite hospital, Dept. of Immunology Hematology, Marseille, France, 3Ipsen Pharma, Dept. of Research, Boulogne Billancourt, France, 4CHU Caremaeau, Dept. of Urology, Nimes, France

Aims and objectives of this presentation

1168
Utilization of psychiatric resources prior to genitourinary (GU) cancer diagnosis: Implications for survival outcomes

By: Klaassen Z. 1 , Wallis C. 2 , Goldberg H. 2 , Chandrasekar T. 3 , Sayyid R. 1 , Williams S. 4 , Moses K. 5 , Terris M. 1 , Nam R. 6 , Kurdyak P. 7 , Kulkarni G. 2
1Medical College of Georgia at Augusta University; Georgia Cancer Center, Surgery, Division of Urology, Augusta, United States of America, 2University of Toronto, Princess Margaret Cancer Centre, Surgery, Division of Urology, Toronto, Canada, 3Thomas Jefferson University Hospital, Dept. of Urology, Philadelphia, United States of America, 4University of Texas Medical Branch, Surgery, Division of Urology, Galveston, United States of America, 5Vanderbilt University, Dept. of Urology, Nashville, United States of America, 6Sunnybrook Hospital, Surgery, Division of Urology, Toronto, Canada, 7Centre for Addiction and Mental Health, Dept. of Psychiatry, Toronto, Canada

Aims and objectives of this presentation

1169
Evaluating the prognostic value of radical prostatectomy and radiation therapy on survival of patients with neuroendocrine prostate cancer: A retrospective study based on SEER database

By: Yang B. , Cao X. , Yang G. , Guo Y. , Mao S. , Yao X.
Aims and objectives of this presentation

1169

Psychological and functional impact of different primary treatments for prostate cancer: A comparative prospective analysis

By: Maggi M., Salciccia S., Gentilucci A., Sciarra A.
University Sapienza, Dept. of Urological Sciences, Rome, Italy

Aims and objectives of this presentation

1170

The hazard of depression after radical prostatectomy – a nationwide registry-based study

By: Friberg A.S.1, Brasso K.2, Andersen E.W.3, Helgstrand J.T.2, Röder M.A.2, Johansen C.1, Dalton S.O.4
1Rigshospitalet, Copenhagen University Hospital, Dept. of Oncology, Copenhagen, Denmark, 2Rigshospitalet, Copenhagen University Hospital, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, 3Danish Cancer Society Research Center, Dept. of Statistics and Pharmaco-epidemiology, Copenhagen, Denmark, 4Danish Cancer Society Research Center, Survivorship, Copenhagen, Denmark

Aims and objectives of this presentation

1171

Adverse effects after radical prostatectomy are strongly associated with the personality trait of neuroticism

By: Axcrona E.J.K.1, Nilsson R.2, Brennhovd B.3, Fossà S.4, Dahl A.4
1Akershus University Hospital, Dept. of Urology, Lørenskog, Norway, 2Telemark Hospital, Dept. of Urology, Skien, Norway, 3Oslo University Hospital, Dept. of Urology, Oslo, Norway, 4Oslo University Hospital, National Advisory Unit for Late Effects after Cancer Therapy, Oslo, Norway

Aims and objectives of this presentation

1172

Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study

By: Knipper S.1, Preisser F.2, Mazzone E.3, Mistretta F.A.3, Palumbo C.3, Tian Z.3, Briganti A.4, Shariat S.F.5, Saad F.3, Tilki D.1, Graefen M.1, Karakiewicz P.3
1Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, 2University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 3University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, 4IRCCS San
Aims and objectives of this presentation

1174

Self-reported functional assessment by patients receiving different prostate cancer strategies: Five-year results from the VICAN large prospective cohort

By: Pignot G.¹, Touzani R.², Bouhnik A-D.², Marino P.², Walz J.¹, Rybikowski S.¹, Maubon T.¹, Salem N.³, Dermeche S.⁴, Fakhfakh S.¹, Gravis G.⁴, Bendiane M-K.²

¹Institut Paoli-Calmettes, Dept. of Urology, Oncologic Surgery 2, Marseille, France, ²Institut Paoli-Calmettes, SESSTIM, Marseille, France, ³Institut Paoli-Calmettes, Dept. of Radiotherapy, Marseille, France, ⁴Institut Paoli-Calmettes, Dept. of Oncology, Marseille, France

Aims and objectives of this presentation

1174

Impact of putative chemopreventative agents on prostate cancer diagnosis

By: Goldberg H.¹, Mohsin F.², Klaassen Z.¹, Chandrasekar T.¹, Wallis C.J.D.¹, Herrera Caceres J.O.¹, Ahmed A.¹, Woon D.¹, Alibhai S.³, Berlin A.⁴, Saskin R.⁵, Hamilton R.J.¹, Kulkarni G.S.¹, Fleshner N.¹

¹University Health Network, University of Toronto, Dept. of Surgical Oncology, Urology Division, Toronto, Canada, ²University of Toronto, Dalla Lana School of Public Health, Toronto, Canada, ³Princess Margaret Cancer Center, University of Toronto, Dept. of Geriatric Oncology, Toronto, Canada, ⁴University Health Network, University of Toronto, Dept. of Radiation Oncology, Toronto, Canada, ⁵Institute for Clinical Evaluative Sciences, ICES Central - Cancer Research Program, Toronto, Canada

Aims and objectives of this presentation

1175

Decision regret after radical prostatectomy is no matter of surgical approach: A 6-year follow-up of a large German collective from routine care

By: Baunacke M.¹, Schmidt M.-L.¹, Groeben C.¹, Thomas C.¹, Koch R.², Chun F.³, Weissbach L.⁴, Huber J.¹

¹TU Dresden, Dept. of Urology, Dresden, Germany, ²TU Dresden, Dept. of Medical Statistics and Biometry, Dresden, Germany, ³Goethe-University Hospital, Dept. of Urology, Frankfurt/Main, Germany, ⁴Health Research for Men GmbH, gfm, Berlin, Germany

Aims and objectives of this presentation

1176

Body image issues and attitudes towards exercise in men diagnosed with prostate cancer undergoing androgen deprivation therapy

Aims and objectives of this presentation

1177
### Aims and objectives of this presentation

#### Impact of preoperative pelvic floor muscles strength and endurance on urinary incontinence after radical prostatectomy

By: Milonas D. ¹, Venclovas Z. ¹, Siupsinskas L. ², Zachovajevas P. ³, Zachovajevas P. ³, Zachovajiene B. ⁴

¹Lithuanian University of Health Sciences, Medical Academy, Dept. of Urology, Kaunas, Lithuania, ²Lithuanian University of Health Sciences, Medical Academy, Institute of Sport, Kaunas, Lithuania, ³Lithuanian Sport University, Dept. of Rehabilitation and Applied Biology, Kaunas, Lithuania, ⁴Lithuanian university of Health Sciences, Institute of Sport, Kaunas, Lithuania

#### 5 and 10-years follow up of radical prostatectomy with pelvic lymphadenectomy: A cancer-specific survival analysis on a 1274 prostate cancer cohort

By: Sighinolfi M.C. ¹, Eissa A. ², Sandri M. ³, Puliatte S. ⁴, Vitale M.G. ⁴, Bruni A. ⁴, Romano A. ⁵, Peracchia G. ⁵, Grisanti R. ⁶, Reggiani Bonetti L. ⁷, Bagni I. ⁷, Morini E. ¹, Zoeir A. ², Micali S. ¹, Bianchi G. ¹, Patel V. ⁸, Rocco B. ¹

¹University of Modena & Reggio Emilia, Dept. of Urology, Modena, Italy, ²Faculty of Medicine, Tanta University, Dept. of Urology, Tanta, Egypt, ³University of Brescia, Data Methods and Systems Statistical Laboratory, Brescia, Italy, ⁴Azienda Ospedaliera Universitaria di Modena, Dept. of Oncology, Modena, Italy, ⁵AUSL, Dept. of Urology, Carpi, Italy, ⁶Ospedale di Sassuolo, Dept. of Urology, Modena, Italy, ⁷University of Modena & Reggio Emilia, Dept. of Pathology, Modena, Italy, ⁸Global Robotic Institute, Dept. of Urology, Orlando, United States of America

#### Longitudinal QoL in patients with high versus low-intermediate risk prostate cancer treated by RALP: A multicentre study

By: Devlies W. ¹, De Coster G. ², Van Damme N. ², Roumeguère T. ³, Quackels T. ³, Van Cleynenreugel B. ¹, Dekuyper P. ⁴, Ameye F. ⁴, Everaerts W. ¹, Joniau S. ¹

RALP: the Belgian RALP consortium
Aims and objectives of this presentation

1181
Tips and tricks in partial nephrectomy
Poster Session 85

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 5
Chairs: V. Matveev, Moscow (RU)
F. Porpiglia, Turin (IT)
To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1182

Robot-assisted laparoscopic partial nephrectomy in selective ischemia versus conventional laparoscopic partial nephrectomy in total ischemia: Functional and surgical outcomes of a prospective randomised controlled trial

By: Würnschimmel C. ¹, Di Pierro G.B. ¹, Grande P. ¹, Baumeister P. ¹, Roth M. ², Moschini M. ¹, Mattei A. ¹
¹Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ²Luzerner Kantonsspital, Dept. of Radiology, Lucerne, Switzerland

Aims and objectives of this presentation

1183

Off-clamp laparoscopic partial nephrectomy in a hybrid room after tumor embolization versus conventional laparoscopic approach: A propensity-matched analysis

By: Ouzaid I. ¹, Capogrosso P. ², Bertolo R. ³, Bouvier A. ⁴, Capitanio U. ², Bigot P. ⁵
¹Bichat Claude Bernard Hospital, Dept. of Urology, Paris, France, ²San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ³Glickman Urological Institute, Dept. of Urology, Cleveland, United States of America, ⁴CHU Angers, Dept. of Radiology, Angers, France, ⁵CHU Angers, Dept. of Urology, Angers, France

Aims and objectives of this presentation

1184

Trifecta outcomes of off-clamp versus on-clamp robot assisted partial nephrectomy: Nephrometry adjusted analysis from ROSULA database

By: Brassetti A. ¹, Bertolo R. ², Tuderti G. ¹, Bindayi A. ³, Garisto J. ², Anceschi U. ¹, Guaglianone S. ¹, Ferriero M. ¹, Simone G. ¹
¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ³UC San Diego Health System, Dept. of Urology, La Jolla, United States of America
<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>1184</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Near-infrared fluorescence imaging with indocyanine green in robot-assisted partial nephrectomy: Pooled analysis of comparative studies</strong></td>
<td></td>
</tr>
<tr>
<td>By: Veccia A. 1, Antonelli A. 2, Anele U.A. 1, Hampton L.J. 1, Porpiglia F. 3, Derweesh I. 4, Autorino R. 1</td>
<td></td>
</tr>
<tr>
<td>1 VCU Health, Dept. of Urology, Richmond, United States of America, 2 ASST Spedali Civili Hospital, Dept. of Urology, Brescia, Italy, 3 San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, 4 UC San Diego Moores Cancer Center, Dept. of Urology, San Diego, United States of America</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>1185</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Super-selective robot-assisted partial nephrectomy using near-infrared fluorescence versus early-unclamping of the renal artery</strong></td>
<td></td>
</tr>
<tr>
<td>Grenoble University Hospital, Dept. of Urology, Grenoble, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>1186</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical outcome and characteristics of 41 patients underwent selective artery embolization for postoperative bleeding following partial nephrectomy</strong></td>
<td></td>
</tr>
<tr>
<td>By: Chung D.Y 1, Almujalhem A. 1, Raheem A. 2, Kim J. 1, Jongsoo L. 3, Kang D.H. 4, Jung Hae D. 5, Chang K. 6, Kim J.H. 1, Chung B.H. 7, Choi Y.D. 1, Rha K.H. 1</td>
<td></td>
</tr>
<tr>
<td>1 Yonsei University College of Medicine, Urological Science Institute, Dept. of Urology, Seoul, South Korea, 2 Tanta University College of Medicine, Dept. of Urology, Tanta, Egypt, 3 Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, South Korea, 4 Inha University School of Medicine, Dept. of Urology, Incheon, South Korea, 5 Yongin Severance Hospital, Yonsei University Health System, Dept. of Urology, Yongin, South Korea, 6 Yonsei University Wonju College of Medicine, Dept. of Urology, Wonju, South Korea, 7 Gangnam Severance Hospital, Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aims and objectives of this presentation</th>
<th>1187</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Impact of learning curve on perioperative outcomes of off-clamp minimally invasive partial nephrectomy: Propensity score matched comparison of outcomes between training versus expert series</strong></td>
<td></td>
</tr>
<tr>
<td>By: Tuderti G., Ferriero M., Anceschi U., Mastroianni R., Flammia R.S., Brasseti A.</td>
<td></td>
</tr>
</tbody>
</table>

| Aims and objectives of this presentation | 1188 |
Minisola F., Costantini M., Misuraca L., Guaglianone S., Gallucci M., Simone G. 
Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

**Aims and objectives of this presentation**

1188

**Learning curves of 500 robot-assisted partial nephrectomies: The bed-side assistant counts**

By: Zeuschner P.¹, Saar M.¹, Meyer I.¹, Wagenpfeil G.², Stöckle M.¹, Siemer S.¹, Janssen M.¹

¹Saarland University, Dept. of Urology and Pediatric Urology, Hamburg, Germany,
²Saarland University, Dept. of Medical Biometry, Epidemiology and Informatics, Hamburg, Germany

**Aims and objectives of this presentation**

1189

**Virtual planning of organ-preserving laparoscopic surgery in patients with localized kidney cancer**

By: Sirota E., Alyaev Y.G., Rapoport L.M., Bezrukov E.A.
Institute for urology and reproductive health, Sechenov University, Dept. of Urology, Moscow, Russia

**Aims and objectives of this presentation**

1190

**The volume of the functional renal parenchyma as objective indicator for the resection of RCC: Results from high volume center**

By: Voylenko O., Semko S., Vitruk I., Stakhovskyi O., Kononenko O., Pikul M., Stakhovsky E.
National Cancer Institute, Dept. of Plastic and Reconstructive Oncourology, Kyiv, Ukraine

**Aims and objectives of this presentation**

1191

**Impact of resection techniques on perioperative and early functional outcomes after partial nephrectomy for localized renal masses: Results from a prospective, multicentre study (SIB Project)**

By: Minervini A.¹, Campi R.², Lane B.R.³, De Cobelli O.⁴, Sanguedolce F.⁵, Hatzichristodoulou G.⁶, Antonelli A.⁷, Mari A.¹, Rodriguez-Faba O.⁸, Keeley F.X.⁵, Langenhuijsen J.⁹, Klatte T.¹⁰, Roscigno M.¹¹, Akdogan B.¹², Furlan M.⁷, Karakoyunlu N.¹³, Marszalek M.¹⁴, Capitanio U.¹⁵, Volpe A.¹⁶, Brookman-May S.¹⁷, Smaldone M.C.¹⁸, Uzzo R.G.¹⁸, Carini M.¹, Kutikov A.¹⁸

¹Careggi Hospital, University of Florence, Dept. of Urology, Florence, Italy, ²University of Florence, Dept. of Urology, Florence, Italy, ³Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, Michigan, United States of America, ⁴European Institute of
Aims and objectives of this presentation

1192

Withdrawn

To be confirmed

Aims and objectives of this presentation

1193

Feasibility of omitting outer (cortical) renorrhaphy during robotic partial nephrectomy - a multi-institutional analysis

By: Arora S.1, Bronkema C.2, Porter J.R.3, Mottrie A.4, Menon M.1, Rogers C.G.1, Jeong W.1, Dasgupta P.5, Rha K.H.6, Ahlawat R.K.7, Capitanio U.8, Yuvaraja T.B.9, Rawal S.10, Moon D.A.11, Sivaramakrishnan A.12, Maes K.K13, Porpiglia F.14, Gautam G.15, Turkeri L.16, Bhandari M.1, Abdollah F.1

1Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, 2Wayne State University School of Medicine, Medical School, Detroit, United States of America, 3Swedish Medical Center, Dept. of Urology, Seattle, United States of America, 4OLV Vattikuti Robotic Surgery Institute, Dept. of Urology, Melle, Belgium, 5MRC Centre for Transplantation, King's College, Dept. of Urology, London, United Kingdom, 6Yonsei University Health System, Dept. of Urology, Seoul, South Korea, 7Medanta Kidney and Urology Institute, Dept. of Urology, Gurgaon, India, 8San Raffaele Hospital, Urology Clinic, Milan, Italy, 9Kokilaben Dhirubhai Ambani Hospital, Dept. of Urology, Mumbai, India, 10Rajiv Gandhi Cancer Institute and Research Center, Dept. of Urology, Delhi, India, 11Peter MacCallum Cancer Center, Dept. of Urology, Melbourne, Australia, 12Apollo Hospital, Dept. of Urology, Chennai, India, 13Hospital Da Luz, Center for Robotic and Minimally Invasive Surgery, Luz Saude, Portugal, 14San Luigi Gonzaga University Hospital, Dept. of Urology, Turin, Italy, 15Max Institute of Cancer Care, Dept. of Surgical Oncology, New Delhi, India, 16Acibadem Hospitals Group, Dept. of Urology, Istanbul, Turkey
### 1195

**Cellular analysis of the intra-cystic fluid after partial or radical nephrectomy for Bosniak III-IV cystic renal lesions**

By: Anract J.¹, Dariane C.¹, Soutif A.¹, Verkarre V², Pettenati C.¹, Wiedemann L.¹, Rembeyo G.¹, Le Guilchet T.¹, Hurel S.¹, Mandron E.¹, Fontaine E.¹, Correas J.M.³, Mejean A.¹, Timsit M.O.¹

¹Hopital Europeen Georges Pompidou, Dept. of Urology, Paris, France, ²Hopital Europeen Georges Pompidou, Dept. of Pathology, Paris, France, ³Hopital Necker, Dept. of Radiology, Paris, France

### 1196

**Multi-photon microscopy for characterization of renal cell carcinoma pseudocapsule: Implications for tumour enucleation**

By: Tan Y.Q.¹, Tay W.K.¹, Ooi L.Y.², Teo Z.C.R.³, Tiong H.Y.¹

¹National University Health System, Dept. of Urology, Singapore, Singapore, ²National University Health System, Dept. of Pathology, Singapore, Singapore, ³National University Health System, Division of Nephrology, Dept. of Medicine, Singapore, Singapore
Peyronie's disease, priapism and shockwave therapy in andrology
Poster Session 86

**Monday 18 March 15:45 - 17:15**

**Location:** Green Area, Room 10

**Chairs:** Gruenwald, Haifa (IL)
V.G. Mirone, Naples (IT)
A. Muneer, London (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

1201

**Home-modeling after penile prosthesis implantation is a viable option for management of residual curvature in Peyronie's disease**

By: Moncada Iribarren I.¹, Krishnappa P.²
¹Hospital Universitario La Zarzuela, Dept. of Urology, Madrid, Spain, ²NU Hospitals, Dept. of Urology, Bangalore, India

**Aims and objectives of this presentation**

1201

---

*1197

**Vacuum device in acute inflammatory phase of Peyronie's disease: A prospective randomized controlled trial**

By: Terribile M., Arcaniolo D., Quattrone C., Stizzo M., Toro F., Manfredi C., De Sio M. University of Campania Luigi Vanvitelli, Dept. of Woman, of Child, and of General and Specialized Surgery, Naples, Italy

**Aims and objectives of this presentation**

1197

---

1198

**Clinical efficacy and safety of clostridium histolyticum collagenase treatment in Peyronies's disease: A single center prospective analysis**

By: Schlager D., Suarez-Ibarrola R., Leiber C.
University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany

**Aims and objectives of this presentation**

1198

---

1199

**Treatment related outcomes for patients with atypical Peyronie's disease**

By: El-Khatib F.M., Osman M.M., Towe M., Huynh L.M., Yafi F.
University of California, Irvine, Dept. of Urology, Orange, United States of America
Aims and objectives of this presentation

1200

How uncommon penile curvatures influence clinical outcomes in patients with Peyronie's disease receiving collagenase clostridium hystolyticum therapy?

By: Cocci A. 1, Russo G.I. 2, Cito G. 1, Minervini A. 1, Gacci M. 1, Serni S. 1, Verrienti P. 1, Giammusso B. 2, Mondaini N. 1

1 AOU Careggi, Dept. of Urology, Florence, Italy, 2 University of Catania, Dept. of Urology, Catania, Italy

Aims and objectives of this presentation

1202

The repair of abnormalities in the penile suspensory ligament

By: Ralph O. 1, Shroff N. 1, Blecher G. 1, Anfonso M. 1, Christopher N. 1, Ralph D.J. 1, Chiriacò G. 2

1 UCLH, Dept. of Urology, Chesham, United Kingdom, 2 Azienda Ospedaliero Universitaria di Trieste, Dept. of Urology, Trieste, Italy

Aims and objectives of this presentation

1203

Penile implant surgery does not reduce penile size; A prospective study of 122 patients followed up for two years

By: Habous M.E. 1, Giona S. 2, Abdelwahab O. 3, Binsaleh S. 4, Mulhall J. 5, Muir G. 6, Ralph D. 7

1 Elaj Medical Center, Dept. of Urology, Jedda, Saudi Arabia, 2 Frimley Park Hospital, Dept. of Urology, Camberley, United Kingdom, 3 Benha University, Dept. of Urology, Benha, Egypt, 4 King Saud University, Dept. of Urology, Riyadh, Saudi Arabia, 5 MSKCC, Dept. of Sexual medicine and Infertility, New York, United States of America, 6 King's College Hospital, Dept. of Urology, London, United Kingdom, 7 St Peter institute, UCLH, Dept. of Andrology, London, United Kingdom

Aims and objectives of this presentation

1204

Satisfaction with inflatable penile prosthesis in patients with history of ischemic priapism

By: Hawksworth D.J., Koomson A.B., Burnett A.L.

Johns Hopkins University School of Medicine, Brady Urological Institute, Baltimore, United States of America

Aims and objectives of this presentation

1204
1205

**The findings of polysomnographic and nocturnal penile tumescence testing in men with stuttering priapism**

By: Johnson M. 1, Chiriaco G. 1, Johnson T.F. 1, McNeillis V. 2, Ralph D.J. 1

1 University College London Hospital, Dept. of Andrology, London, United Kingdom,

2 Royal National Throat Nose and Ear Hospital, Sleep Unit, London, United Kingdom

**Aims and objectives of this presentation**

1205

---

1206

**oMtFSFI: Operated male to female sexual function index. Development and validation of the first questionnaire to assess sexual function after male to female gender reassignment surgery**

By: Vedovo F. 1, Di Blas L. 2, Perin C. 1, Pavan N. 1, Zatta M. 3, Bucci S. 1, Morelli G. 4, Cocci A. 5, Delle Rose A. 5, Caroassi Grisanti S. 5, Gentile G. 6, Colombo F. 6, Rolle L. 7, Timpano M. 7, Verze P. 8, Spirito L. 8, Schiralli F. 9, Bettocchi C. 9, Palmieri A. 8, Mirone V. 8, Trombetta C. 1

1 Azienda Sanitaria Universitaria Integrata di Trieste, Dept. of Urology, Trieste, Italy,

2 University of Trieste, Life Sciences, Trieste, Italy,

3 Azienda Sanitaria Universitaria Integrata di Trieste, Infectious Diseases, Trieste, Italy,

4 University of Pisa, Dept. of Urology, Pisa, Italy,

5 University of Florence, Dept. of Urology, Florence, Italy,

6 University Hospital S.Orsola-Malpighi, Dept. of Gynecology and Urology, Andrology, Bologna, Italy,

7 AO Città della Salute e della Scienza, University of Turin, Dept. of Urology, Turin, Italy,

8 University of Naples, Federico II, Dept. of Urology, Naples, Italy,

9 University of Bari, Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, Bari, Italy

**Aims and objectives of this presentation**

1206

---

1207

**Percutaneous angioplasty of internal pudendal arteries for the treatment of erectile dysfunction not responsive to pharmacological therapy. Initial experience in six patients**

By: Marcer A. 1, Migliorini F. 1, Sebben M. 1, Bassi S. 1, Mariotto A. 1, Rubilotta E. 1, Balzarro M. 1, Ribichini F. 2, Artibani W. 1

1 Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Urology, Verona, Italy,

2 Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Cardiology, Verona, Italy

**Aims and objectives of this presentation**

1207

---

* 1208

**Effectiveness and safety of Platelet rich Plasma (PrP) cavernosal injections plus external shock wave treatment for penile erectile dysfunction: First results from a prospective, randomized, controlled, interventional study**

By: Ruffo A. 1, Franco M. 2, Illiano E. 3, Stanojevic N. 4

1 Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Urology, Verona, Italy,

2 Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Cardiology, Verona, Italy,

3 University of Naples, Federico II, Dept. of Urology, Naples, Italy,

4 University of Bari, Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, Bari, Italy
Aims and objectives of this presentation

1208

Linear focus low-intensity extracorporeal shockwave therapy in the treatment of erectile dysfunction: A multi-center, double-blinded, prospective, randomized, placebo-controlled study

By: Yang L., Chen X., He D.
The First Affiliated Hospital of Xian Jiaotong University, Dept. of Urology, Xian, China

Aims and objectives of this presentation

1209

Extracorporeal shock wave therapy for chronic prostatitis/chronic pelvic pain syndrome

By: Kulchavenya E., Shevchenko S., Baranchukova A.
Novosibirsk Research TB Institute, Novosibirsk Medical University, Dept. of Urogenital, Novosibirsk, Russia

Aims and objectives of this presentation

1210

State-of-the-art lecture Can we treat all Peyronie's disease without surgery?
A. Muneer, London (GB)
Understanding the origins of urothelial tumours
Poster Session 87

Monday 18 March
15:45 - 17:15

Location: Green Area, Room 11
Chairs: To be confirmed
M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)
R. Seiler, Bern (CH)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

1211 Long noncoding RNA DANCR facilitates metastasis and proliferation in bladder cancer cells by activating IL-11-STAT3 signaling

By: Xu C., Ziyue C., Ruihui X., Ming H., Jingtong Z., Qianghua Z., Jian H., Tianxin L., Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

Aims and objectives of this presentation

1213 Tumor microenvironment enhances autologous mesenchymal stem cells carrying telomerase-dependent adenoviruses for metastatic cancers

By: Hu C-Y., Shiau A-L., Wu C-L., Shieh G-S.
1National Cheng-Kung University Hospital, Dept. of Urology, Tainan, Taiwan, 2National Cheng Kung University Medical College, Dept. of Microbiology and Immunology, Tainan, Taiwan, 3National Cheng Kung University Medical College, Dept. of Biochemistry and Molecular Biology, Tainan, Taiwan, 4Tainan Hospital, Dept. of Urology, Tainan, Taiwan

Aims and objectives of this presentation

1214 Immunological microenvironment of FGFR3 altered muscle-invasive bladder cancer

By: Weyerer V., Stoehr R., Bolenz C., Hartmann A., Erben P., Eckstein M.
1University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Dept. of Pathology, Erlangen, Germany, 2University of Ulm, Dept. of Urology, Ulm, Germany, 3Medical Faculty Mannheim, Heidelberg University, Dept. of Urology, Mannheim, Germany

Aims and objectives of this presentation
1215  
**Molecular characterization of N-methyl-N-nitrosourea-induced bladder urothelial tumor in rats**


1Hyogo Prefectural Nishinomiya Hospital, Dept. of Urology, Nishinomiya, Japan, 2The Johns Hopkins University School of Medicine, Dept. of Pathology, Baltimore, United States of America, 3The Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America

**Aims and objectives of this presentation**

1215

1216  
**Silibinin induced parallel activation of macroautophagy and inhibition of chaperone-mediated autophagy in bladder cancer**

By: **Zeng J., Fan Y., Hou T., Wu K., Chen Y., He D., Li L.**

The First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China

**Aims and objectives of this presentation**

1216

1217  
**Identification of neoantigen candidates in bladder cancer reveals negative correlation between antigen-specific immunoreactivity and inflammation**


1Xinhua hospital, Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China, 2Shanghai Institute, Shanghai Jiaotong University School of Medicine, Dept. of Immunology and Microbiology, Shanghai, China, 3Tongji University, Faculty of Life Science, Shanghai, China, 4Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine, Dept. of Immunology and Microbiology, Shanghai, China, 5Ruijin hospital, Shanghai Jiaotong University School of Medicine, Dept. of Neurology, Shanghai, China

**Aims and objectives of this presentation**

1217

* 1218  
**The expression of ANGPTL2 on tumor vessels predicts outcome in invasive bladder cancer after radical cystectomy**

By: **Poyet C., Buser L., Wild P., Saba K., Sulser T., Detmar M., Roudnicky F.**

1University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, 2University Hospital Zurich, Dept. of Pathology, Zurich, Switzerland, 3ETH Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland

**Aims and objectives of this presentation**

1218
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Aims and objectives of this presentation</strong></td>
<td>1219</td>
</tr>
<tr>
<td>1221</td>
<td>Loss of CHEK2 is associated with risk of progression and worse progression-free survival in pT1 urothelial carcinoma of the bladder</td>
<td>Spachmann P.J. 1, Azzolina V. 1, Weber F. 2, Evert M. 2, Denzinger S. 1, Burger M. 1, Otto W. 1, Breyer J. 1</td>
</tr>
<tr>
<td></td>
<td><strong>Aims and objectives of this presentation</strong></td>
<td>1221</td>
</tr>
<tr>
<td>*1222</td>
<td>Beta-arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer</td>
<td>Hennig M.J.P. 1, Kallifatidis G. 2, Smith D. 2, Morera D. 2, Kuczyk M. 3, Kramer M. 1, Merseburger A. 1, Lokeshwar B. 2, Lokeshwar V. 2</td>
</tr>
<tr>
<td></td>
<td><strong>Aims and objectives of this presentation</strong></td>
<td>1222</td>
</tr>
<tr>
<td>1223</td>
<td>Potential new treatment for patients with bladder cancer with a high risk of progression to invasive disease</td>
<td>Van Der Pluijm G. 1, Van Der Horst G. 1, Van De Merbel A. 1, Ruigrok E. 1, Van Der Mark M.H. 1, Ploeg E. 1, Jäätela M. 2, Kruithof-De Julio M. 3, Uhm J. 1, Pelger R.C.M. 1, Bangma C.H. 4, Boormans J. 4, Zwarthoff E.C. 5</td>
</tr>
<tr>
<td></td>
<td><strong>Aims and objectives of this presentation</strong></td>
<td>1223</td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

1223

1224

New biomarkers of bladder cancer in liquid biopsies

By: Do Rosário Fernandes F.J. ¹, Flores J. ², Horvatovich P. ³, Lodeiro C. ², Martinez J.L. ², Santos H. ², Calais F. ¹, Pinheiro L. ¹

¹Centro Hospitalar de Lisboa Central, Dept. of Urology, Lisbon, Portugal, ²Faculty of Sciences and Technology, BIOSCOPE Research Group, Lisbon, Portugal, ³Faculty of Science and Engineering, Dept. of Analytical Biochemistry Group, Groningen, The Netherlands

Aims and objectives of this presentation

1224

17:05 - 17:05

Conclusion
Improving outcomes of renal transplantation
Poster Session 88

Location: Green Area, Room 12
Chairs: O. Hakenberg, Rostock (DE)
J.D. Olsburgh, London (GB)
C. Terrone, Turin (IT)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

1225
Evaluation of the delayed renal function after controlled donor cardiac death using hypothermic machine perfusion compared with cold storage: Looking for a precise diagnosis

By: Etcheverry Giadrosich B.R. 1, Riera Canals L. 1, Fiol Riera M. 1, Suarez Novo J. 1, Melilli Melilli E. 2, Bestard Matamoros O. 2, De Lama Salvador E. 3, Romero Martinez N. 3, Mora Salvado J. 4, Bajen Lazaro M. 4, Vígues Julia F. 1

1Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, 2Hospital Universitari de Bellvitge, Dept. of Nephrology, Barcelona, Spain, 3Hospital Universitari de Bellvitge, Dept. of Radiology, Barcelona, Spain, 4Hospital Universitari de Bellvitge, Dept. of Nuclear Medicine, Barcelona, Spain

Aims and objectives of this presentation
1225

1226
Donation after controlled circulatory death, type III. Experience and results over 4 years in a single institution, HUGTIP

By: Castillo C. 1, Areal Calama J. 1, Perez Mir M. 2, Buisan Rueda O. 1, Gonzalez Satue C. 1

1Hospital Universitari Germans Trias i Pujol, Dept. of Urology, Badalona, Spain, 2Hospital Universitari Germans Trias i Pujol, Dept. of Nephrology, Badalona, Spain

Aims and objectives of this presentation
1226

1227
Maastricht III kidneys: Does donor age influence DGF or graft survival?

By: Fernandez-Concha Schwalb J. 1, Etcheverry B. 1, Riera L. 1, Fiol M. 1, Bonet X. 1, Suarez J.F. 1, Bestard O. 2, Vigués F. 1

1Bellvitge University Hospital, Dept. of Urology, Barcelona, Spain, 2Bellvitge University Hospital, Dept. of Nephrology, Barcelona, Spain

Aims and objectives of this presentation
1227
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1228</td>
<td>Kidneys received from living donors over 70 years of age: Are those feasible as the grafts?</td>
<td>Saito M., Inoue T., Narita S., Numakura K., Kanda S., Chiba S., Nara T., Satoh S., Habuchi T.</td>
<td>Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan</td>
</tr>
<tr>
<td>1229</td>
<td>Management of end-stage renal disease patients diagnosed with active surveillance-eligible prostate cancer during pre-transplantation work-up: A decision analysis</td>
<td>Bieri U., Hübel K., Seeger H., Kulkarni G.S., Sulser T., Hermanns T., Wettstein M.S.</td>
<td>University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, University Hospital Zurich, Dept. of Nephrology, Zurich, Switzerland, Princess Margaret Cancer Centre, University Health Network, Division of Urology, Dept. of Surgery, Toronto, Canada</td>
</tr>
<tr>
<td>1231</td>
<td>Body fat area as a predictive marker of new-onset diabetes mellitus after kidney transplantation</td>
<td>Taoka R., Abe Y., Naito H., Miyauchi Y., Matsuoka Y., Tajima M., Kato T., Tsunemori H., Ueda N., Sugimoto M., Kakehi Y.</td>
<td>Kagawa University, Dept. of Urology, Kagawa, Japan</td>
</tr>
<tr>
<td>1232</td>
<td>The level of QOL improves slower in preemptive kidney transplantation than the one in non-preemptive kidney transplantation</td>
<td>Mitsui Y., Araki M., Aiyoshi Y., Maruyama Y., Sadahira T., Wada K., Edamura K., Kobayashi Y., Watanabe M., Watanabe T., Nasu Y.</td>
<td>Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan</td>
</tr>
</tbody>
</table>
**Aims and objectives of this presentation**

1232

**1233**

**A novel, specific RIPK1 inhibitor reduces necroptosis and provides significant benefit in ischemic kidney injury in mice**

By: Gallagher K.M. ¹, Beal A. ², Finger J. ², Hughes J. ¹, Ross J. ¹, Marson L ¹, Berlin J. ², Ferenbach D. ¹, Boulter L. ³, Laird A. ⁴, Leung S. ⁴, Wigmore S. ¹, Harrison E. ⁵

¹University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom, ²GlaxoSmithKline, Pattern Recognition Receptor DPU, Collegeville, United States of America, ³University of Edinburgh, MRC Institute of genetics and molecular medicine, Edinburgh, United Kingdom, ⁴Western General Hospital Edinburgh, Dept. of Urology, Edinburgh, United Kingdom, ⁵University of Edinburgh, Centre for Medical Informatics, Usher Institute, Edinburgh, United Kingdom

**Aims and objectives of this presentation**

1233

**1234**

**Tissue-resident memory CD8+ T cells in the kidney – implications for renal transplantation**

By: Friedersdorff F. ¹, Dornieden T. ¹, Sattler A. ², Bergmann Y. ², Ruhm A. ², Schlomm T. ¹, Kotsch K. ²

¹Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Dept. of Surgery, Berlin, Germany

**Aims and objectives of this presentation**

1234

**1235**

**Genetic predisposition with regards to the role of MMPs in allograft rejections following renal transplantation**

By: Srivastava A. ¹, Prasad N. ², Bhatt M. ¹

¹SGPGIMS, Dept. of Urology and Renal Transplantation, Lucknow, India, ²SGPGIMS, Dept. of Nephrology, Lucknow, India

**Aims and objectives of this presentation**

1235

**1236**

**Early application of mTOR inhibitors reduce vascular inflammatory response after ischemia-reperfusion injury**

By: Wenzel M. ¹, Haffer H. ², Werner I. ³, Richter M. ⁴, Chun F. ¹, Beiras-Fernandez A. ⁵

¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²Charité Berlin, Dept. of Trauma Surgery, Berlin, Germany, ³University Hospital Frankfurt, Dept. of Cardiothoracic Surgery, Frankfurt, Germany, ⁴Kerkhoff Klinik, Dept. of Cardiothoracic Surgery, Bad Nauheim, Germany, ⁵University Hospital Mainz, Dept. of Cardiothoracic Surgery, Mainz, Germany
Aims and objectives of this presentation

1236

Longitudinal serum N-glycan profiling predict biopsy-proven graft rejection after a living donor kidney transplantation

By: Soma O.¹, Hatakeyama S.¹, Yoneyama T.¹, Noro D.¹, Tobisawa Y.¹, Hashimoto Y.¹, Koie T.², Sasaki H.³, Saito M.⁴, Harada H.⁵, Chikaraishi T.³, Ishida H.⁶, Tanabe K.⁶, Satoh S.⁴, Ohyama C.¹

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Gifu University School of Medicine, Dept. of Urology, Gifu, Japan, ³St. Marianna University of Medicine, Dept. of Urology, Kawasaki, Japan, ⁴Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁵Sapporo City General Hospital, Dept. of Kidney Transplant Surgery, Sapporo, Japan, ⁶Tokyo-Woman’s Medical University, Dept. of Urology, Tokyo, Japan

Aims and objectives of this presentation

1237

Thymoglobulin seems to increase hemorrhagic risk in sensitized kidney recipients


Hospital del Mar, Dept. of Urology, Barcelona, Spain

Aims and objectives of this presentation

1238

17:04 - 17:11

Summary

J.D. Olsburgh, London (GB)
Aims and objectives of this session
There is a wide variety of options for treatment of male LUTS. In this session game changing studies will be presented and discussed. In addition various new interventional techniques will be compared to established ones with the help of ease based discussions.

The second part of this sessions is reserved for a summing up of the entire meeting: top experts will give an overview of the best contributions of the 2019 meeting and their impact in the upcoming years.
### Scientific Programme - EAU19 Barcelona

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:35 - 09:40</td>
<td><strong>2. Vaporisation</strong>&lt;br&gt;A. Elshal, Mansoura (EG)</td>
</tr>
<tr>
<td>09:40 - 09:45</td>
<td><strong>3. Enucleation</strong>&lt;br&gt;G.Y. Robert, Bordeaux (FR)</td>
</tr>
<tr>
<td>09:45 - 09:50</td>
<td><strong>4. Aquablation</strong>&lt;br&gt;T. Bach, Hamburg (DE)</td>
</tr>
<tr>
<td>09:50 - 10:15</td>
<td><strong>Case 2</strong>&lt;br&gt;<em>Same patient with strong wish to preserve ejaculation</em></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em>&lt;br&gt;J-N.L. Cornu, Rouen (FR)&lt;br&gt;J.P.F.A. Heesakkers, Nijmegen (NL)</td>
</tr>
<tr>
<td>09:50 - 09:51</td>
<td><strong>Welcome</strong>&lt;br&gt;J.P.F.A. Heesakkers, Nijmegen (NL)</td>
</tr>
<tr>
<td>09:51 - 09:55</td>
<td><strong>Case presentation</strong>&lt;br&gt;J.P.F.A. Heesakkers, Nijmegen (NL)</td>
</tr>
<tr>
<td>09:55 - 10:00</td>
<td><strong>1. Apex-sparing surgery (TUR, GLL)</strong>&lt;br&gt;S. Madersbacher, Vienna (AT)</td>
</tr>
<tr>
<td>10:00 - 10:05</td>
<td><strong>2. Rezūm</strong>&lt;br&gt;K-D. Sievert, Detmold (DE)</td>
</tr>
<tr>
<td>10:05 - 10:10</td>
<td><strong>3. Urolift / TIND</strong>&lt;br&gt;C. Gratzke, ()</td>
</tr>
<tr>
<td>10:10 - 10:15</td>
<td><strong>4. PAE</strong>&lt;br&gt;D. Abt, St. Gallen (CH)</td>
</tr>
<tr>
<td>10:15 - 10:35</td>
<td><strong>Case 3</strong>&lt;br&gt;<em>Big prostate 150 gram</em></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em>&lt;br&gt;J-N.L. Cornu, Rouen (FR)&lt;br&gt;J.P.F.A. Heesakkers, Nijmegen (NL)</td>
</tr>
<tr>
<td>10:15 - 10:20</td>
<td><strong>Case presentation</strong>&lt;br&gt;J-N.L. Cornu, Rouen (FR)</td>
</tr>
<tr>
<td>10:20 - 10:25</td>
<td><strong>1. Holep</strong>&lt;br&gt;C.M. Scoffone, Turin (IT)</td>
</tr>
<tr>
<td>10:25 - 10:30</td>
<td><strong>2. Laparoscopic or robotic adenomectomy</strong>&lt;br&gt;H. John, Winterthur (CH)</td>
</tr>
<tr>
<td>10:30 - 10:35</td>
<td><strong>3. Open simple prostatectomy</strong>&lt;br&gt;A. Elshal, Mansoura (EG)</td>
</tr>
<tr>
<td>10:35 - 11:00</td>
<td><strong>Case 4</strong>&lt;br&gt;<em>75 years old, 4 stents on clopidogrel, cannot stop. Prostate 70 gram, retention</em></td>
</tr>
<tr>
<td></td>
<td><em>Moderators:</em>&lt;br&gt;J-N.L. Cornu, Rouen (FR)&lt;br&gt;J.P.F.A. Heesakkers, Nijmegen (NL)</td>
</tr>
<tr>
<td>10:35 - 10:40</td>
<td><strong>Case presentation</strong>&lt;br&gt;J.P.F.A. Heesakkers, Nijmegen (NL)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>10:40 - 10:45</td>
<td>1. Turp?</td>
</tr>
<tr>
<td></td>
<td>S. Madersbacher, Vienna (AT)</td>
</tr>
<tr>
<td>10:45 - 10:50</td>
<td>2. Laserablation</td>
</tr>
<tr>
<td></td>
<td>C. Llorente, Madrid (ES)</td>
</tr>
<tr>
<td>10:50 - 10:55</td>
<td>3. PAE</td>
</tr>
<tr>
<td></td>
<td>D. Abt, St. Gallen (CH)</td>
</tr>
<tr>
<td>10:55 - 11:00</td>
<td>4. Rezūm</td>
</tr>
<tr>
<td></td>
<td>K-D. Sievert, Detmold (DE)</td>
</tr>
<tr>
<td>11:00 - 11:10</td>
<td>Lessons learned</td>
</tr>
<tr>
<td></td>
<td>C.R. Chapple, Sheffield (GB)</td>
</tr>
<tr>
<td>11:10 - 13:10</td>
<td>Souvenir sessions</td>
</tr>
<tr>
<td>11:10 - 11:20</td>
<td>Benign prostatic disease</td>
</tr>
<tr>
<td></td>
<td>J-N.L. Cornu, Rouen (FR)</td>
</tr>
<tr>
<td>11:20 - 11:30</td>
<td>Urolithiasis and endourology</td>
</tr>
<tr>
<td></td>
<td>T. Knoll, Sindelfingen (DE)</td>
</tr>
<tr>
<td>11:30 - 11:40</td>
<td>Renal cancer and transplantation</td>
</tr>
<tr>
<td></td>
<td>M-O. Grimm, Jena (DE)</td>
</tr>
<tr>
<td>11:40 - 11:50</td>
<td>Prostate cancer: Early detection and screening</td>
</tr>
<tr>
<td></td>
<td>C.H. Bangma, Rotterdam (NL)</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>Prostate cancer: Localised and advanced disease</td>
</tr>
<tr>
<td></td>
<td>A. Briganti, Milan (IT)</td>
</tr>
<tr>
<td>12:00 - 12:10</td>
<td>Systemic therapy in Genitourinary (GU) cancer</td>
</tr>
<tr>
<td></td>
<td>M. De Santis, Berlin (DE)</td>
</tr>
<tr>
<td>12:10 - 12:20</td>
<td>Urothelial cancer</td>
</tr>
<tr>
<td></td>
<td>M. Rouprêt, Paris (FR)</td>
</tr>
<tr>
<td>12:20 - 12:30</td>
<td>Functional urology</td>
</tr>
<tr>
<td></td>
<td>J.P.F.A. Heesakkers, Nijmegen (NL)</td>
</tr>
<tr>
<td>12:30 - 12:40</td>
<td>Imaging in urology</td>
</tr>
<tr>
<td></td>
<td>A. Villers, Lille (FR)</td>
</tr>
<tr>
<td>12:40 - 12:50</td>
<td>Basic science</td>
</tr>
<tr>
<td></td>
<td>Z. Culig, Innsbruck (AT)</td>
</tr>
<tr>
<td>12:50 - 13:00</td>
<td>Paediatric urology and rare diseases</td>
</tr>
<tr>
<td></td>
<td>W.F.J. Feitz, Nijmegen (NL)</td>
</tr>
<tr>
<td>13:00 - 13:10</td>
<td>Andrology</td>
</tr>
<tr>
<td></td>
<td>M. Albersen, Leuven (BE)</td>
</tr>
</tbody>
</table>